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FOREWORD
Technological advances have quickly propelled hematology forward; for
example: microarray expression analyses; single-nucleotide polymorphism (SNP)
chips (platforms to look at genomic changes); sophisticated fluorescent in situ
hybridization; newly identified cell surface antigens associated with various dis-
eases and cell types; understanding of transcription factors (engines of prolifera-
tion and differentiation of hematopoietic cells); and more complete knowledge of
chromosomal changes, mutations and amplifications associated with various
hematological malignancies. These advances have been the engines for better
diagnosis and classification of hematopoietic disorders. Furthermore, a variety of
new therapeutic approaches have come to the forefront, such as targeted therapies
(thyrosine kinase inhibitors) for myeloproliferative disorders; lenalidomide for
myelodysplastic syndrome (MDS) and multiple myeloma; demethylating agents
for MDS and myeloid leukemia, as well as, humanized monoclonal antibodies for
lymphomas. Many of these advancements have occurred since the first edition of
Modern Hematology: Biology and Clinical Management by Dr. Rienhold Munker
and colleagues was published 6 years ago.
This new edition, edited by Drs. Reinhold Munker, Erhard Hiller, Jonathan
Glass, and Ronald Paquette, provides in clear terms an understanding of the
cellular physiology, immunology, and molecular biology of hematopoietic dis-
orders. It gives new diagnostic methodologies and guides the health care worker
to practical approaches to the diagnoses and management of these blood disor-
ders. The book covers all of the major hematopoietic diseases and a number of
the rare diseases as they interface with new scientific knowledge. It has excellent
“how to” tables providing dosage and time schedules of different chemothera-
peutic agents, as well as clearly defined tables to aid in diagnosis and prognosis.
Modern Hematology: Biology and Clinical Management, Second Edition is a
fine montage of applied research and practical approaches to diagnosis and
management of our patients. The book is ideal for the house officers, fellows in
training, interested scientists, as well as the practicing hematologist.
H. Phillip Koeffler, MD
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PREFACE
In the 6 years since the publication of Modern Hematology: Biology and
Clinical Management, major advances in the understanding, diagnosis, and  treat-
ment of blood disorders have again been made. Molecular studies are now used
on a daily basis to diagnose a variety of hematological disorders and to guide
their treatment. Targeted therapies, such as kinase inhibitors in myeloprolifera-
tive disorders and humanized monoclonal antibodies for lymphomas, have trans-
formed the treatment approach to these diseases. Peripheral blood and even
umbilical cord blood are now routinely used as sources of stem cells for trans-
plantation. The growing use of nonmyeloablative transplantation emphasizes
immunotherapy over cytotoxic chemotherapy. These advances motivated us to
update Modern Hematology: Biology and Clinical Management with the latest
clinical and scientific developments in hematology. We welcome the contribu-
tions of new authors. The growing use of databases prompted us to add an
overview of printed and electronic resources for hematologists.
Modern Hematology: Biology and Clinical Management, Second Edition
brings together facts, concepts, and protocols important for the practice of hema-
tology. In 23 concise chapters, all major blood diseases are covered; rarer dis-
eases are discussed if they are of scientific interest. The first two chapters
introduce the reader to the scientific basis of blood disorders. As in the previous
edition, each chapter is illustrated by tables, figures, and a selection of color
plates. Our text is ideal for residents or fellows in training. However, students,
physicians in other specialties, and even pure scientists may take advantage of
our book both as a reference and a study guide. We hope that ultimately, all
patients with benign and malignant blood disorders will benefit from the publi-
cation of Modern Hematology: Biology and Clinical Management, Second
Edition.
Reinhold Munker, MD
Erhard Hiller, MD
Jonathan Glass, MD
Ronald Paquette, MD
vii
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1. INTRODUCTION
The formation of blood cells (hemopoiesis) is determined by the interaction
of multiple genes and involves cytokines and other protein factors. The relative
ease with which hematopoietic cells can be studied and the development of new
techniques in cell biology have enabled us to understand many of the factors
determining cell renewal and differentiation. Based on this knowledge, major
progress has been made in the last 15 yr in the treatment and diagnosis of many
hematological disorders. In this chapter, we describe the cell types involved in
normal hematopoiesis and their interactions with one another. Furthermore, the
basic techniques necessary for the study of hematopoietic cells in the normal and
pathological state are outlined.
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2. COMPONENTS OF BLOOD AND BONE MARROW
2.1. Sites of Hematopoiesis
During the first few weeks of embryonic life, the formation of blood cells takes
place in the yolk sac. Later, until the sixth or seventh month of fetal development,
the liver and spleen are the major hematopoietic organs. By the time of birth,
more than 90% of all new blood cells are formed in the bone marrow. Here, the
progenitor cells are found, in various stages of development, situated in anatomi-
cal niches in the bone marrow from where they are then released into the marrow
sinuses, the marrow circulation, and further on into the systemic circulation.
During infancy and childhood, the marrow of all bones contributes to hemato-
poiesis. During adult life, hematopoietic marrow is restricted to certain bones
(e.g., pelvic bones, vertebral column, proximal ends of the femur, skull, ribs, and
sternum). Even in these areas, a proportion of the marrow cavity consists of fat.
During periods of hematopoietic stress (e.g., in severe hemolytic anemias and in
some myeloproliferative disorders), the fatty marrow as well as the spleen and
liver can resume the production of blood cells. This situation is called extramed-
ullary hematopoiesis.
2.2. Stromal Cells
Growth and differentiation of hematopoietic cells in the bone marrow is regu-
lated by the extracellular matrix and microenvironment provided by stromal cells.
These cells, including macrophages, fibroblasts in various stages of differentia-
tion, endothelial cells, fat cells, and reticulum cells, nurture hematopoietic stem
cells and progenitor cells by producing growth factors like granulocyte/
macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulat-
ing factor (G-CSF), interleukin (IL)-6, or stem cell factor. Other cytokines secreted
by stromal cells regulate the adhesion molecules present on hematopoietic cells,
allowing them to remain in the bone marrow or migrate to an area where the
respective cell type is needed.
2.3. Hematopoietic Stem Cells
All hematopoietic cells of the organism derive from pluripotent stem cells that
are capable of both self-renewal and differentiation into all hematopoietic lin-
eages. As Fig. 1.l shows, one stem cell provides progenitor cells for myelo- and
monopoiesis, erythropoiesis, megakaryopoiesis, and lymphopoiesis. Other cell
types such as stromal cells or dendritic cells also derive from the pluripotent
hematopoietic stem cell. It has been estimated that one stem cell gives rise to at
least 106 mature hematopoietic cells. Under normal conditions, the stem cells
provide hematopoietic cells for the entire life span. Each day, a healthy adult
organism produces more than 1012 hematopoietic cells. Many blood disorders
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Fig. 1.1. Scheme of hematopoietic differentiation (for abbreviations, see text).
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(e.g., leukemias, aplastic anemias, or myelodysplastic syndromes) are disorders
of stem cells.
Stem cells are very rare, representing less than 0.01% of all nucleated cells in
the normal bone marrow. Based on animal experiments, the morphology of stem
cells is thought to be similar to that of small lymphoid cells. In recent years, the
marker expression of human stem cells has been studied. Human stem cells
express the surface proteins CD34 and c-kit and are negative for CD38 and
lineage-specific markers. In animal systems, stem cells can be assayed as spleen
colony-forming units (CFU) in irradiated hosts. Only the more differentiated
progenitors of human hematopoietic cells can be tested for their ability to form
colonies in soft agar or methylcellulose. One of the earliest progenitor cells in
such systems is CFUGEMM, which contains granulocytes, monocytes, erythroid
cells, and platelet progenitors. From this pluripotent progenitor, more special-
ized progenitors are formed (see Fig. 1.1). Under normal conditions, the majority
of stem cells is dormant (G0 phase of the cell cycle). A stem cell divides only to
maintain the steady state of hematopoiesis or to meet the body’s demand for
progenitor cells (stochastic model of hematopoiesis). The daughter cells then
either differentiate into determined progenitor cells (e.g., lymphohematopoietic
cells) or return to dormancy by reentering the stem cell pool. Stem cells can be
enriched and transplanted (stem cell or bone marrow transplantation). The stem
cell donor does not experience a detectable loss of stem cells.
There are several hierarchical levels of stem and progenitor cells. In general,
the hematopoietic growth factors do not act on true stem cells, but support the
survival and the differentiation of committed cells. Although “early-acting”
cytokines such as stem cell factor, FLT3-ligand, G-CSF, or IL-6 regulate the
earliest progenitor cells, “late-acting” cytokines such as erythropoietin for eryth-
ropoiesis or thrombopoietin for megakaryopoiesis support the growth and differ-
entiation of progenitor cells that are already committed to their respective lineage.
Many other cytokines play a positive or negative role in the differentiation of
hematopoietic cells. A list of the known cytokines is given in Chapter 2.
The gene expression in early stem cells is complex and involves the co-expres-
sion of multiple transcription factors. For example, the combination of C/EBP α
and Pu 1 directs the expression of the receptor for G-CSF, which is critical for
early myelopoiesis. Pu 1 binds to and regulates the promotors of several myeloid
growth-factor receptor genes. The Notch family of transmembrane receptors was
described in Drosophila as a ligand-dependent suppressor of cell differentiation.
Similar receptors have recently been found on human stem cells, suggesting that
they may also be involved in maintaining an undifferentiated state.
The significance of telomeres present in human stem cells and the activity of
telomerase in these cells is currently of interest. Telomeres are specialized struc-
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tures at the end of chromosomes that change with cell division. Shortening of
telomeres is associated with cellular aging. Telomerase is an enzyme capable of
extending the length of telomeres. It has now been found that adult stem cells
have shorter telomeres than fetal stem cells and that the length of telomeres
shortens further after transplantation. The activity of telomerase is generally low
in stem cells (which corresponds to their quiescent state), but can be upregulated
on entry into the cell cycle. The implications of these findings are not yet clear,
but they may indicate that not all stem cells are immortal.
3. ERYTHROPOIESIS
Red blood cells are specialized cells that deliver oxygen to tissues and remove
carbon dioxide from the human body. Erythropoiesis, the “making of red cells,”
involves many different genes and gene products that lead to the production of
the mature cell. Erythropoiesis begins at the level of the multipotent stem cell,
which then undergoes commitment and differentiation. Listed as follows are the
stages of erythroid differentiation:
1. Stem cell.
2. BFU-E (burst-forming unit, erythroid; immature erythroid progenitor).
3. CFU-E (colony-forming unit, erythroid; more mature erythroid progenitor).
4. Proerythroblasts, erythroblasts, normoblasts (morphologically recognizable red
cell precursors, they still have a nucleus, multiply by cell division, and progres-
sively decrease in size as hemoglobin content increases).
5. Reticulocytes; mature red blood cells (erythrocyte).
Remnants of ribosomal RNA can be visualized in reticulocytes; no nucleus is
present in the mature red cell. The vast majority of nucleated red-cell precursors
are confined to the bone marrow.
One proerythroblast gives rise to 12–16 mature red blood cells within 5–10 d.
The erythropoietic differentiation is modulated by several cytokines (stem cell
factor, IL-3, GM-CSF, and erythropoietin). Erythropoietin is the major cytokine
that adapts the production of red cells to the needs of the organism. Both the
proliferation and differentiation of CFU-E and late BFU-E are accelerated as a
response to erythropoietin. In response to low hemoglobin levels in the blood and
tissue hypoxia, the production of erythropoietin by the kidneys is increased.
When the serum levels of erythropoietin are increased, both the rate and the speed
of erythropoiesis increase. Erythropoietin binds to specific receptors on red cell
precursors, consequently activating the Janus 2 kinase  (JAK2) by tyrosine phos-
phorylation. This in turn activates the STAT pathway and Ras signal transduc-
tion. A number of transcription factors are involved in the activation of
erythroid-specific genes including GATA1, GATA2, NFE2, SCL, EKLF, and
myb. During early erythropoiesis, the downregulation of the SCL gene precedes
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the downregulation of the GATA 2 and GATA 1 genes. In bone marrow, eryth-
ropoiesis occurs in distinct anatomic locations called erythroblastic islands, in
which a central macrophage is surrounded by a ring of developing erythroblasts.
Important mediators of the cell–cell contact in the erythroid islands include the
integrins, the immunoglobulin (Ig) superfamily, and cadherins. In states of
chronic tissue hypoxia (e.g., in hemolytic anemias) the proportion of the marrow
devoted to erythropoiesis expands and sometimes transforms a large portion of
the fatty marrow into active hematopoietic marrow.
3.1. Hemoglobin
Hemoglobin is the molecule responsible for the transport of oxygen. Under
physiological conditions, three types of hemoglobins exist:
• Hemoglobin A (α2β2): major adult hemoglobin (96–98%).
• Hemoglobin F (α2γ2): predominant during fetal development, 60–80% at birth,
0.5–0.8% during adult life.
• Hemoglobin A2(α2δ2): normally 1.5–3%.
The hemoglobin molecule has a molecular weight of 64,500 and consists of
four polypeptide chains, each carrying a heme group. The heme synthesis starts
with the amino acid glycine. Later, porphobilinogen, uroporphyrinogen,
coproporphyrinogen, and protoporphyrin are formed as intermediate steps. Iron
(Fe2+) is supplied from serum transferrin and combines with protoporphyrin to
form heme. One heme molecule then binds with one globin chain to form the
hemoglobin molecule that avidly binds oxygen.
The release of oxygen from red cells into tissue is strictly regulated. Under
normal conditions, arterial blood enters tissues with an oxygen tension of 90
mmHg and a hemoglobin saturation close to 97%. Venous blood returning from
tissues is deoxygenated. The oxygen tension is about 40 mmHg, the hemoglobin
saturation is 70–80%. The oxyhemoglobin dissociation curve describes the rela-
tion between the oxygen saturation or content of hemoglobin and the oxygen
tension at equilibrium. The oxygen dissociation curve has a sigmoid shape (see
Fig. 1.2). Under normal conditions, only the upper part of this curve is used. The
affinity of hemoglobin for oxygen and the deoxygenation in tissues is influenced
by temperature, by CO2 concentration, and by the level of 2,3-diphosphoglycerate
in the red cells. In the case of tissue or systemic acidosis, the oxygen dissociation
curve is shifted to the right and more oxygen is released. The same effect results
from the uptake of carbon dioxide, which raises the oxygen tension of carbon
dioxide. This facilitates the unloading of oxygen. As the body temperature
increases, the affinity of hemoglobin for oxygen decreases, thereby facilitating
oxygen release.
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The oxygen supply to peripheral tissues is influenced by three mechanisms:
1. The blood flow, which is controlled by the heart beat volume and the constriction
or dilatation of peripheral vessels.
2. The oxygen transport capacity, which depends on the number of red blood cells
and the hemoglobin concentration.
3. The oxygen affinity of hemoglobin.
In anemic patients, the stroke volume of the heart is increased, the heart beats
faster (tachycardia), and, in addition, the 2,3-diphosphoglycerate concentration
in red blood cells can increase to facilitate the oxygen dissociation in tissues. A
compensation mechanism that takes several days or weeks is the increased syn-
thesis of red blood cells.
3.2. Iron Metabolism
With a normal Western diet, 10–15 mg of iron is ingested daily. Under normal
circumstances, only 5–10% of this dietary iron is absorbed as Fe2+ in the duode-
num or, to a lesser degree, in the jejunum. In severe iron deficiency, the propor-
tion of resorbed iron may increase up to 30%. Iron is lost from the body via sweat,
urine, and feces. Iron resorption is improved under the normal acidic and reduc-
ing conditions of the gastrointestinal mucosa. The mucosal cells of the duode-
num are also capable of resorbing dietary heme iron that later dissociates. Iron
resorption can increase severalfold according to the body’s demand (e.g., during
pregnancy, after an acute blood loss, or in menstruating women). Iron absorption
proceeds under the influence of the HFE protein (mutated in hereditary hemo-
chromatosis). Under normal conditions, the HFE protein binds to the transferrin
Fig. 1.2. Hemoglobin oxygen dissociation curve.
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receptor at the cell membrane surface. Both proteins (bound to iron and transfer-
rin) are then imported into the cell. Excess iron can be shed from the mucosal villi
of the gut, but if the iron supply continues to exceed iron requirements, iron
overload will develop. The most common form is the genetic disorder hemochro-
matosis, but iron overload can also occur in patients with blood disorders who
depend on transfusions. In such patients, iron is deposited in the liver, pancreas,
heart muscle, and other organs.
Iron is an essential component of hemoglobin. Most of the iron needed for
erythropoiesis does not derive from dietary iron, but is liberated from senescent
red blood cells phagocytized by macrophages in the reticuloendothelial system.
Iron enters the plasma as Fe3+, where it binds to transferrin and can be used again
in erythropoiesis. About 30% of the total body iron is stored in the reticuloendot-
helial system either as transferrin, ferritin, or hemosiderin. The β-globulin trans-
ferrin is synthesized in the liver and can bind two atoms of iron reversibly.
Normally, transferrin is only one-third saturated. The progenitor cells of eryth-
ropoiesis have specific transferrin receptors, thereby enabling the transfer of iron
into these developing erythroid cells.
3.3. The Red Blood Cell
The normal erythrocyte has a diameter of about 8 µm and a biconcave disc
form that provides the red cell with a maximum surface-for-gas exchange as well
as optimal deformability. The bipolar lipid layer of the red cell membrane is
stabilized on the inner side by the attachment of the structural proteins actin and
spectrin. Defects of these proteins lead to hemolytic anemia. The outer layer is
covered with mucopolysaccharides that form part of the structure of blood group
antigens. The N-acetylneuraminic acid found in these glycoproteins results in a
negative charge of the cell surface.
Because red cells have lost their nuclei, they are no longer capable of synthe-
sizing proteins, including enzymes. Red cells remain viable and functional for an
average of 120 d. The necessary energy for red cell metabolism is supplied by the
Embden-Meyerhof pathway, which generates adenosine triphosphate by metabo-
lizing glucose to lactate. This anerobic process also results in the formation of
nicotinamide-adenine dinucleotide, which is essential for the reduction of meth-
emoglobin to functionnally active hemoglobin.
Hemoglobin is split into globin and heme in the reticuloendothelial system.
Both components can be recycled. The globin chains are metabolized into amino
acids consequently used for the synthesis of new proteins, and iron is used for
further heme synthesis. The remaining protoporphyrin is metabolized to biliru-
bin. The bilirubin is conjugated in the liver and excreted via bile secretions into
the intestine. Intestinal bacteria metabolize bilirubin into stercobilinogen and
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stercobilin, which are excreted via feces. Part of these hemoglobin degradation
products are reabsorbed and excreted via urine as urobilin and urobiliogen.
4. MYELOPOIESIS
Under the influence of cytokines such as G-CSF, a myeloid progenitor cell,
CFU-G, is formed. This cell then differentiates into the morphologically recognizable
myeloid precursors: myeloblasts, promyelocytes, myelocytes, and metamyelocytes.
Normally these cells do not appear in peripheral blood. Myeloblasts are rather
large cells (12–20 µm in diameter) and have a large nucleus with fine chromatin
and several nucleoli. No cytoplasmic granules are present. The normal marrow
contains up to 5% of myeloblasts. Cell division of myeloblasts results in the
formation of promyelocytes, slightly larger neutrophilic precursors with granules
in their cytoplasm. These cells in turn give rise by cell division to myelocytes,
which have smaller granules (secondary or specific granules). At this stage, a
differentiation of the myelocytes into the neutrophil, eosinophil, and basophil series
can be recognized. Further cell division produces metamyelocytes. These cells can
no longer divide and have a somewhat indented nucleus and numerous granules
in their cytoplasm.
Between the mature neutrophil and the metamyelocyte, so-called “juvenile,”
“stab,” or “band” forms are observed in which the nucleus is not yet fully seg-
mented. Such cells occur normally in the peripheral blood (less than 8% of circu-
lating neutrophils) and are increased under hematopoietic stress, such as during
infections.
The normal number of neutrophilic granulocytes in the peripheral blood is
about 2500–7500/µL. Neutrophilic granulocytes have a dense nucleus split into
two to five lobes and a pale cytoplasm. The cytoplasm contains numerous pink-
blue or gray-blue granules. Two types of granules can be distinguished morpho-
logically: primary or azurophilic granules, which appear at the promyelocyte
stage, and secondary granules, which appear later. The primary granules contain
myeloperoxidase, acid phosphatase, and acid hydrolases, whereas lysozyme,
lactoferrin, and collagenase are found in the secondary granules. All granules are
of lysosomal origin.
According to cytokinetic studies, the time required for the division and matu-
ration of a myeloblast to a mature granulocyte is 6–12 d. It has been estimated
that 1.5 × 109 granulocytes/kg are produced daily in the healthy organism. Most
of these cells stay at various stages of maturation in the bone marrow, from where
they can be mobilized in case of hematopoietic stress. Following their release from
the bone marrow, granulocytes circulate for no longer than 12 h in the blood.
Approximately half of the granulocytes present in the bloodstream are found in
the circulating pool, whereas the other half is kept in a marginated pool attached
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to blood vessel walls. After granulocytes move from the circulation into tissues,
they survive for about 5 d before they die while fighting infections or as a result
of senescence.
The major function of granulocytes (neutrophils) is the uptake and killing of
bacterial pathogens. The first step involves the process of chemotaxis, by which
the granulocyte is attracted to the pathogen. Chemotaxis is initiated by chemotac-
tic factors released from damaged tissues or complementary components. The next
step is phagocytosis or the actual ingestion of the bacteria, fungi, or other particles
by the granulocyte. The recognition and uptake of a foreign particle is made easier
if the particle is opsonized, which is done by coating them with an antibody or
complement. The coated particles then bind to Fc or C3b receptors on the granu-
locytes. Opsonization is also involved in the phagocytosis of bacteria or other
pathogens by monocytes. During phagocytosis a vesicle is formed in the phago-
cytic cell into which enzymes are released. These enzymes, including collagena-
ses, aminopeptidase, and lysozyme, derive from the secondary granules of the
granulocyte. The final step in the phagocytic process is the killing and digestion
of the pathogen. This is achieved by both oxygen-dependent and -independent
pathways. In the oxygen-dependent reactions, superoxide, hydrogen peroxide,
and OH radicals are generated from oxygen and NADPH. The reactive oxygen
species are toxic not only to the bacteria, but also to surrounding tissue, causing the
damage observed during infections and inflammation.
4.1. Eosinophils
Eosinophils, which make up 1–4% of the peripheral blood leukocytes, are
similar to neutrophils but with somewhat more intensely stained reddish gran-
ules. In absolute terms, eosinophils number up to 400/µL. Eosinophilic cells can
first be recognized at the myelocyte stage. Eosinophils have a role in allergic
reactions, in the response to parasites, and in the defense against certain tumors.
4.2. Basophils
Basophils are seen less frequently than eosinophils; under normal conditions,
fewer than 100 cells/µL are found in the peripheral blood. Basophils have recep-
tors for irnmunoglobulin (Ig)E and, in the cytoplasm, characteristic dark gran-
ules overlie the nucleus. Degranulation of basophils results from the binding of
IgE and allergic or anaphylactic reactions are associated with the release of
histamine and heparin.
4.3. Mast Cells
Similarly to basophils, mast cells derive from bone marrow CD34+ progeni-
tors, have receptors for IgE, and store histamine. Mast cells typically migrate into
and mature in connective tissues. Mast cells participate in allergic and immuno-
logical reactions.
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4.4. Monocytes
As already mentioned, monocytes derive from the myeloid progenitor cell
(CFU-GM), which replicates and differentiates into monocytes and, later, mac-
rophages under the influence of certain growth factors. After commitment to the
monocytic lineage has been made, the cell goes through distinct monoblast and
promonocyte stages before developing into a mature monocyte. Circulating
monocytes make up 2–6% of all leukocytes (in absolute numbers 200–800/µL).
Monocytes are larger than most other cells of the blood (diameter 15–20 pm).
The cytoplasm is abundant and stains blue, with many fine vacuoles. Fine gran-
ules are often present. The nucleus is large and often indented with clumped
chromatin. Monocytes and macrophages (see “Macrophages”) can phagocytose
pathogens, present antigens, and secrete many cytokines.
4.5. Macrophages
After several hours of transit in the blood, the monocytes migrate into different
tissues, where they differentiate into macrophages. Macrophages are larger than
monocytes, and have an oval nucleus, prominent nucleoli, a blue cytoplasm, and
phagocytic vesicles. The different types of macrophages (e.g., Kupfer cells in the
liver, alveolar macrophages in the lung, osteoclasts in the bone, macrophages in
the bone marrow, peritoneal macrophages) are known as components of the
reticulo-endothelial system. Macrophages are long-lived (life span at least 10 d
or much longer) and secrete numerous cytokines, enzymes, and enzyme inhibi-
tors. The major cytokines secreted by macrophages are tumor necrosis factor
(TNF)-α, IL-1α, and IL-1β (monokines). Macrophages avidly phagocytose and
kill bacteria and other pathogens. In addition, macrophages have immunological
functions (antigen presentation) and can kill tumor cells. An important function
of macrophages is to remove debris (scavenger function) and to regulate the
proliferation of stromal cells.
4.6. Dendritic Cells
The existence and function of dendritic cells (D.C. in Fig. 1.1) has only recently
been recognized. Dendritic cells are present in many tissues, including in the skin
(where they are known as Langerhans cells), in the airways, in lymphoid tissues,
in solid organs, and in blood and bone marrow. Morphologically, they appear as
large mononuclear cells with stellate processes. The major function of dendritic
cells is to present antigens. Most types of dendritic cells derive from hematopoietic
progenitor cells. Some, like follicular dendritic cells, derive from lymphoid or
stromal cells. Methods for culturing and expanding human dendritic cells have
recently been developed. Dendritic cells can be grown from CD34+ bone marrow
progenitor cells or from CD14+ blood monocytes. The cytokines GM-CSF and IL-
4 are needed at the beginning of the culture and further maturation of the cells is
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reached under the influence of monocyte-derived factors. Mature dendritic cells
have a characteristic marker profile: they strongly express class II human leuko-
cyte antigens (HLAs) as well as co-stimulatory and adhesion molecules. In vivo,
dendritic cells capture and process antigens, migrate to lymphoid organs, and
secrete numerous cytokines to initiate immune responses. Dendritic cells stimu-
late quiescent B- and T-lymphocytes. They are very potent stimulators of T-cell
responses: small numbers of dendritic cells and low levels of antigen induce a
strong T-cell immunity. Under certain circumstances, dendritic cells can also
tolerize the organism to self-antigens, thereby preventing autoimmune reactions.
A new approach aimed at overcoming the deficient antitumor immunity of cancer
patients has recently been described in which dendritic cells are primed with tumor
antigens in vitro and then reinfused into the patient.
5. MEGAKARYOPOIESIS
Platelets are small cell fragments (average size 3–4 µm) that are important for
hemostasis and coagulation. The normal platelet count is between 150,000 and
450,000/µL. Platelets derive from megakaryocytes, which are very large cells
with a large, multilobulated nucleus. The mean DNA content of megakaryocytes
is at least eight times that of other somatic cells. One megakaryocyte can produce
at least several thousand platelets. The formation and release of platelets is
related to a preformed structure in the cytoplasm of megakaryocytes, the so-called
“demarcation membrane system.” Megakaryocytes derive from megakaryocyte
progenitors (CFU-Mega, see Fig. 1.1), which in turn originate in the hematopoi-
etic stem cell. Megakaryocytes are mainly found in the bone marrow but can
transit to many organs, including the lung, where part of the platelet release
occurs. The maturation of megakaryocytes and the production of platelets occurs
under the influence of thrombopoietin (TPO; for details see Chapter 2). TPO acts,
together with certain other cytokines like IL-6 and IL-11, on early megakaryo-
cyte progenitors as well as mature megakaryocytes. Under physiological condi-
tions, the serum levels of TPO are low at normal or elevated platelet counts and
high in individuals with low platelet counts. Details on the physiology of plate-
lets are described in Chapter 19.
6. LYMPHATIC TISSUES AND IMMUNE RESPONSE
6.1. Development and Organs of the Lymphoid System
The common or pluripotent hematopoietic stem cell differentiates at an early
stage into lymphoid and myeloid progenitor cells. From these lymphoid stem
cells, the two main classes of lymphocytes, B- and T-cells, develop. The lympho-
cytes populate the major lymphatic organs, but can also be found circulating in
the peripheral blood. Two types of lymphoid organs can be distinguished: the
Chapter 1 / Basic Biology of Hemopoiesis 13
central lymphoid organs (bone marrow, thymus) and the peripheral lymphoid
organs (lymph nodes, tonsils, spleen, mucosa-associated lymphoid tissue). The
central lymphoid organs are the original site of lymphopoiesis and lymphoid
maturation, whereas the peripheral lymphoid organs specialize in trapping anti-
gen and initiating adaptive immune responses. In the peripheral blood, 80–85%
of the lymphoid cells belong to the T-cell lineage, whereas in the peripheral
lymphoid tissues most lymphoid cells belong to the B-cell lineage.
6.2. B-Lymphocytes
The major task of B-lymphocytes is the production of antibodies (humoral
immunity). The first steps of B-cell differentiation take place in the bone marrow,
where lymphoid progenitors differentiate into pro-B- and pre-B-cells. A surface
marker that is expressed very early in B-cell ontogeny is CD19. The initial stages
of B-cell development depend on the interaction between cell surface molecules
and secreted products of stromal cells with their receptor–ligand partners on
lymphoid progenitors. Numerous cytokines and growth factors (e.g., TNF, IL-1,
IL-2, IL-6, IL-7, IL-10, interferon [IFN]-γ) direct the growth and differentiation of
B-cells. In the peripheral blood, where they make up 4–6% of all mononuclear
cells, B-cells bear additional surface markers (e.g., CD20, CD22). The specific-
ity of B-cell immunity is reached via surface receptors for antigen (in most cases
IgD or IgM). After leaving the bone marrow and circulating in the blood, the
mature B-cells migrate into the follicles of the secondary lymphoid organs (e.g.,
spleen, lymph nodes, and other tissues). Following the contact with an antigen,
B-cells differentiate into antibody-secreting plasma cells or into B-memory cells.
B-memory cells are long-lived and reside for the most part in lymph nodes.
Without antigen stimulation, B-cells have a short life span.
The lymphoid follicles provide the necessary environment for B-cells to
maintain their existence as mature recirculating antigen-specific cells. The an-
tigen-specific repertoire of B-cells is generated by the sequential rearrangement
of Ig gene segments. This developmental program involves changes in the
expression of other cellular proteins and is directed by transcription factors. If
an intact Ig chain is generated, then this type of rearrangement is terminated, and
the next step in the rearrangement cascade can begin. If successive rearrange-
ments fail to generate first a heavy chain (pre-B-cell receptor) and then a light
chain, which can be assembled into a complete immunoglobulin molecule, the
B-cell ceases to develop further and goes into apoptosis (programmed cell death).
The end result of the successive rearrangements of immunoglobulin genes is a
B-cell with a surface Ig of a single specificity.
An efficient antibody response and immune defense can only be achieved in
cooperation with T-lymphocytes. However, before the T-cells can recognize the
antigen and induce the proliferation of B-cells and their differentiation into
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plasma cells or memory cells, certain criteria must be met. First, antigen-presenting
cells must process the antigen (which may be bound to the receptors of B-cells).
Next, the processed antigen must be associated with the molecules of the major
histocompatibility complex.
6.3. T-Lymphocytes
T-lymphocytes also derive from stem cells located in the bone marrow. How-
ever, before becoming functional cells, the precursor cells migrate to the thymus
where they proliferate, differentiate into mature cells, and are finally released
into the blood. At the same time autoreactive T-cells are eliminated. The earliest
stage of T-cell development is the prothymocyte. Immature T-cells co-express-
ing the surface markers CD4 and CD8 are located primarily in the cortex of the
thymus. During maturation, the T-cell precursors lose either CD4 or CD8 and
migrate to the medulla. A large majority of thymocytes is eliminated during this
process. During differentiation, antigen-specific surface receptors are formed.
These antigen-receptors recognize either bacterial antigens on antigen-present-
ing cells or new antigens on tumor cells, transplanted cells, or virally infected
cells. Taken together, T-lymphocytes specialize in cell-mediated immunity. They
do not react with intact antigens but with antigen fragments presented in associa-
tion with molecules of the major histocompatibility complex. There are two main
classes of T-lymphocytes circulating in the peripheral blood: CD4-positive cells
(helper cells) and CD8-positive cells (suppressor or cytotoxic T-lymphocytes),
explained as follows.
• CD4-positive T-lymphocytes recognize foreign antigens in association with
HLA class II molecules and have, for the most part, helper or inducer functions.
CD4-positive cells secrete lymphokines after the presentation of the antigen by
macrophages has taken place. These cytokines activate macrophages but can
also stimulate the proliferation of B-cells and induce the production of antibod-
ies by plasma cells. The secretion of IL-2 also contributes to the development of
cytotoxic T-lymphocytes.
• CD8-positive T-lymphocytes react with foreign antigens in association with
class I molecules and are the specific effector or killer cells of cell-mediated
immunity. CD8-positive lymphocytes also have suppressor functions and con-
trol the proliferation of other T-cell subsets as well as the function of B-cells.
6.4. Natural Killer Cells
Natural killer (NK) cells belong to the lymphoid lineage, although some have
markers of the monocyte/myeloid lineage. Morphologically, NK cells are char-
acterized as large granular lymphocytes. NK cells are defined by their ability to
kill some tumor cells by antigen-independent mechanisms (natural immunity).
The physiological function of NK cells is still being debated and includes the
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removal of certain tumor cells or of virally infected cells. NK cells can be
expanded and cultured in the presence of IL-2. Such expanded NK cells
(lymphokine-activated killer cells) have been used in the experimental treatment
of tumors. Recently, a family of inhibitory receptors on natural killer cells was
described. These molecules are specific for some members of the major histo-
compatibility complex and inhibit the activation of NK cells.
7. PLASMA COMPONENTS
The blood plasma contains all proteins and factors necessary for the integrity
of the organism. Some of these factors are involved in coagulation, and others
function as transport proteins, hormones, or immunoglobulins. Most of the
plasma proteins are synthesized and secreted in the liver. By means of electro-
phoresis, the major proteins of the serum or plasma can be resolved into five
bands, designated albumin,αl, α2, β, and γ fractions. Specialized proteins can be
further analyzed with antisera (immunoelectrophoresis).
The major protein of plasma or serum is albumin. Albumin maintains the
colloidal osmotic pressure of human serum and is a transport protein for many
hormones, ions, vitamins, and other factors.
Next in the order of electrophoretic mobility are the α-l-globulins. Among
them are acid-α-l-glycoprotein, α-l-lipoprotein, and α-l-antitrypsin.
The β-2-globulin fraction contains β-2-macroglobulin, β-2-haptoglobulin
(important as a binder of free hemoglobin), ceruloplasmin, β-2-lipoprotein, and
transcobalamin as well as many other proteins.
The γ-globulin fraction contains transferrin (an iron-binding protein) and many
other proteins.
The γ-globulin fraction contains most, but not all, normal immunoglobulins
(e.g., IgG, IgA, IgM, IgD, and IgE). A global deficiency of the normal immuno-
globulin fraction can be recognized by a low or absent γ fraction in the serum
electrophoresis.
8. DIAGNOSTIC PROCEDURES IN HEMATOLOGY
8.1. Bone Marrow Aspiration
Because the bone marrow is the main site of hematopoiesis as well as of many
hematological disorders, a bone marrow aspiration is essential for the evaluation of
the clinical situation. Leukemias, autoimmune thrombocytopenias, myelodysplastic
syndromes, and most lymphoproliferative disorders especially cannot be diag-
nosed without a bone marrow aspiration. Other hematological disorders, such as
an obvious iron deficiency anemia or a pernicious anemia caused by vitamin B12
deficiency, do not need a bone marrow aspiration performed routinely.
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A bone marrow aspiration is usually performed at the posterior iliac crest. If
special precautions are taken, the bone marrow can also be aspirated at other
locations (e.g., the sternum or anterior iliac crest). The skin over the posterior
iliac crest is carefully disinfected and the surrounding area is covered with sterile
drapes. The skin and the periosteum are infiltrated with a local anesthetic. For
anxious patients, a short-acting intravenous narcotic or sedative (e.g., mepridine,
benzodiazepine) may be helpful. For the aspiration, a special needle is advanced
5–10 mm through the periosteum before the trocar is removed. A syringe is then
connected with the needle and small portions of marrow (0.5–3 mL) are gently
aspirated.
A bone marrow aspiration yields samples for cytomorphology, cytogenetics,
surface markers, and molecular studies. In some chronic infections, bone mar-
row cultures are also indicated. For the optimal morphological evaluation, eth-
ylenediamine tetraacetic acid (EDTA) is used as an anticoagulant; for other
studies like cytogenetics or surface markers, heparin is used.
A bone marrow aspiration provides information about the state of matura-
tion and the proliferation of the three hematopoietic lineages (erythropoiesis,
myelopoiesis, and thrombopoiesis). If bone marrow spicules are present, the
overall cellularity and the relative contribution of the three lineages can be evalu-
ated. Special morphological features (e.g., dysplasia or nuclear asynchrony) can
be assessed. Atypical cells (leukemic cells and lymphoma or carcinoma cells)
can be recognized and further classified by cytochemistry. The iron stores of the
bone marrow can be examined with special stains.
8.1.1. FLOW CYTOMETRY
Flow cytometry discriminates leukemic or other cells according to their marker
expression. For flow cytometry, the cells are incubated with fluorescent antibod-
ies. The immunophenotyping can be performed with heparinized blood or bone
marrow or EDTA-anticoagulated samples. Flow cytometry also gives informa-
tion about the granularity of cells (forward and sideward scatter) and can be
performed with antibodies labeled with different fluorescent compounds (mul-
tiparameter analysis). An example for immunophenotyping is given in Chapter
10. A list of the currently described CD markers is found in Appendix 2.
8.1.2. IMMUNOCYTOCHEMISTRY
Immunocytochemistry combines the morphology of blood or bone marrow
cells with antibody staining. For this method, antibodies labeled with peroxidase
(brown staining) or alkaline phosphatase (blue staining) are used.
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8.2. Bone Marrow Biopsy
In contrast to bone marrow aspiration, a bone marrow biopsy provides infor-
mation about the histology of the bone marrow. A bone marrow biopsy is per-
formed at the posterior iliac crest with a larger biopsy needle (trephine biopsy,
Jamshidi, or similar type of needle). For a bone marrow biopsy, a small cutaneous
incision must be made. When the biopsy needle has penetrated the cortical layer
and the trocar has been removed, the needle is rotated and advanced with firm
movements for about 2 or 3 cm. After this, the needle is rotated without further
advancing and then removed. The biopsy core (10–20 mm long and 2–3 mm
wide) is then placed in a fixative. If a hypoplastic leukemia is suspected, a touch
imprint can be made by gently rolling the biopsy cylinder on a slide. A bone
marrow biopsy has a superior diagnostic value in the staging of malignant lym-
phomas, the assessment of the cellularity in aplastic anemias, and the evaluation
of the infiltration by a multiple myeloma. Generally, a bone marrow biopsy
provides more information about the architecture and the topographic relation-
ship of normal and malignant cells than does a bone marrow aspiration. A bone
marrow biopsy provides less information about cytological details. A bone
marrow biopsy is also indicated when an aspiration yields a dry tap. In many
cases, a bone marrow fibrosis prevents the aspiration of nucleated cells. In such
cases, a biopsy demonstrates the degree of fibrosis and, if present, the infiltration
with abnormal cells.
Possible side effects of a bone marrow biopsy or aspiration are bleeding or
infection. To prevent bleeding, a local pressure should be applied for several
Fig. 1.3. Needles used for bone marrow aspiration and biopsy.
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hours. Two commonly used needles for bone marrow aspiration and biopsy are
shown in Fig. 1.3.
8.3. Peripheral Blood Film
The differential count of white cells can be done automatically, and this is
reliable in most cases. However, the visual inspection of the peripheral blood yields
valuable information. The morphology of the red cells can be examined (for details
of common red cell abnormalities, see Chapter 5.). The presence and morphology
of abnormal or uncommon cells, like circulating leukemia and lymphoma cells,
myeloma cells, or activated lymphoid cells can be assessed. The number of plate-
lets can be estimated semiquantitatively. Cases of pseudothrombocytopenia (see
Chapter 20), for example, can be diagnosed by inspecting the blood film.
SUGGESTED READING
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245–252.
Burrows PD, Cooper MD. B cell development and differentiation. Curr Opin Immunol 1997;9:
239–244.
Cross MA. Enver T. The lineage commitment of haemopoietic progenitor cells. Curr Opin Gen
Dev 1997;7:609–613.
Gewirtz AM. Megakaryocytopoiesis: the state of the art. Thromb Haemost 1995; 74:204–209.
Hsia CCW. Respiratory function of hemoglobin. N Engl J Med 1998;338:239–247.
Janeway CA, Travers P. Immunobiology. In: The Immune System in Health and Disease, 3rd ed.
New York and London: Garland, 1997.
Migliaccio AR, Migliaccio G. The making of an erythroid cell. Molecular control of erythropoiesis.
Biotherapy 1998;10:251–268.
Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993; 81:2844–2853.
Chapter 2 / Molecular Biology and Cytokines 19
19
From: Contemporary Hematology: Modern Hematology, Second Edition
Edited by: R. Munker, E. Hiller, J. Glass, and R. Paquette  © Humana Press Inc., Totowa, NJ
2 Molecular Biology and Cytokines
Reinhold Munker, MD
and Amanda Sun, MD, PhD
CONTENTS
INTRODUCTION
RECOMBINANT DNA TECHNOLOGY
CLONALITY OF TUMORS
DIAGNOSTIC APPLICATIONS OF MOLECULAR BIOLOGY
AND GENE THERAPY
CYTOKINES
SUGGESTED READING
1. INTRODUCTION
The proliferation and differentiation of hematopoietic cells is regulated by the
interaction of multiple genes, transcription factors, and proteins.
The genetic information is encrypted in DNA. The cell synthesizes messenger
RNA (mRNA) via transcription. The corresponding proteins are synthesized (trans-
lation) in the cytoplasm. Molecular biology is of special importance to the clinical
hematologist, as leukemias and lymphomas are clonal neoplasms and can be de-
tected by DNA analysis if a genetic marker lesion is known. The discovery of DNA
sequences in normal cells that are homologous to RNA viruses led to the descrip-
tion of oncogenes. These genes, also called proto-oncogenes, are responsible for
cell growth and differentiation in normal cells. In several neoplasms, a mutation or
abnormal expression of oncogenes is present. The loss of antioncogenes also con-
tributes to the initiation and progression of tumors. Other genes that permit the
survival of malignant cells are the group of antiapoptotic genes. There is reasonable
hope that the elucidation of the molecular pathogenesis of leukemias and lympho-
mas will lead to new treatment possibilities.
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Cytokines are proteins involved in cell-to-cell communication. They are pro-
duced and secreted by both normal and malignant cells. Some cytokines have
growth-stimulatory properties; others inhibit cell growth or induce cell death.
Most cytokines bind to specific receptors on the cell surface. The number of
known cytokines and related molecules has expanded enormously in recent years.
Some cytokines, like the family of interferons (IFNs), the family of colony-
stimulating factors (CSFs), and interleukin (IL)-2 have entered into clinical prac-
tice. It can be foreseen that in the next years, even more cytokines and cytokine
antagonists will become important in clinical hematology.
2. RECOMBINANT DNA TECHNOLOGY
Recombinant DNA technology has made possible the isolation and character-
ization of genes from the human genome. This method involves the use of enzymes
(restriction endonucleases) that recognize and cleave double-stranded DNA at
certain points. In addition, other nucleic acid-modifying enzymes and plasmids
(extrachromosomal DNA from bacteria) enable further re-engineering of DNA.
This can be done, for example, by inserting the desired DNA sequences into these
plasmids, expanding them in vitro, and then retrieving large quantities of recom-
binant proteins in eukaryotic cells. Any tissue can be examined for the presence
of certain genes by Southern blotting. Minute amounts of DNA can be amplified
with PCR and then visualized on gels. In Northern blots, RNA is separated on
gels and then specific mRNA is detected after hybridization with cloned DNA
fragments. In Western blots, the presence and molecular weight of proteins in
cell extracts or body fluids is examined by immunological methods.
3. CLONALITY OF TUMORS
The clonality of human tumors is one of the major principles underlying
malignant transformation. Clonality means that a tumor is derived from a single
transformed cell (and retains some characteristics of this cell). Usually, it takes
several years until a tumor has grown from a single cell to the stage where it can
be diagnosed clinically. Virtually all hematological neoplasms (leukemias, lym-
phomas, and myeloproliferative and myelodysplastic syndromes) are clonal.
One of the few exceptions is the lymphoproliferative disorder associated with the
Epstein-Barr virus (EBV), which is clinically malignant, yet polyclonal in many
cases. In some elderly persons, or in the immediate period after bone marrow
transplantation, monoclonal or oligoclonal cells can be demonstrated in the absence
of a malignancy.
The criteria for malignant growth are abnormal morphology, clinical aggres-
siveness, genetic changes, and clonality. The general rule is that all or most of
these criteria should be present in order to diagnose a malignant tumor. There are
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several methods to establish clonality in hematological disorders. Some of these
methods are used only in research laboratories, whereas other methods have
entered clinical routine.
3.1. Cytogenetics
The study of chromosomes, or cytogenetics, aids in the diagnosis of many
human tumors and is a common method used to establish the clonality of abnor-
mal cells found in the bone marrow, the peripheral blood, or any other tissue. The
normal human somatic cell is diploid, meaning that each of the 22 chromosomes
is present in two copies. In addition, the sex chromosomes, XX in females and
XY in males, are present in all somatic cells. The cells of sperm or oocytes that
have 23 single chromosomes are haploid. The normal human chromosomes are
numbered 1–22 in decreasing order of size. Each chromosome has two arms, the
shorter “p” arm and the longer “q” arm, which meet at the centromere. Chromo-
somes are usually visible only during metaphase. In order to study chromosomes,
the cells are cultured in media and then arrested in metaphase with colchicine.
Special stains are used to identify regions and bands of chromosomes. Common
changes in chromosomes are gains and losses of chromosomes, translocations,
deletions, and inversions. The genetic changes of pathogenetic or diagnostic
relevance are not random, but involve all or most chromosomes studied; this
establishes clonality. In a translocation, part of one chromosome is moved to
another chromosome. A well-known translocation is t(9;22), where part of chro-
mosome 9 is moved to chromosome 22 and vice versa. This translocation is also
known as the Philadelphia chromosome and is diagnostic of chronic myelog-
enous leukemia (see Fig. 8.1). One refers to a deletion when part of a chromo-
some is missing. The deletion of part of a chromosome and its reattachment to
the breakpoint in the opposite direction is called an inversion (denoted as inv).
Sensitive cytogenetic methods can detect chromosomal changes in most leuke-
mias and lymphomas. When even more sensitive molecular methods are used
(see “Molecular Cytogenetics”), changes in the DNA of tumor cells can be
demonstrated in virtually all hematological neoplasms. Some cytogenetic
changes have prognostic relevance. Examples are t(15;17) and inv(16), which
are markers for a better-than-average prognosis in acute myelogenous leukemia,
and t(9;22), which is associated with an unfavorable prognosis in acute lymphoid
leukemia. New cytogenetic aberrations often appear when a leukemia or lym-
phoma undergoes progression, as in the case of chronic myelogenous leukemias
that acquire new cytogenetic abnormalities when entering the accelerated phase
and then the blast crisis. The acquisition of new cytogenetic aberrations is called
“clonal progression” or “clonal evolution” and is a poor prognostic sign. The
analysis of chromosomes (“karyotyping”) is usually done only with a limited
number of cells (in routine cytogenetic analysis 15–25 metaphases are exam-
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ined). Minor clones of aberrant cells can therefore be missed. Some cytogenetic
aberrations are frequent in hematological neoplasms but not specific for a par-
ticular disease. For example, t(3;21) can occur in acute myelogenous leukemia
as well as in the blast crisis of chronic myelogenous leukemia.
3.2. Molecular Cytogenetics
A further refinement in the area of cytogenetics has been achieved through the
ability to clone the breakpoints for most translocations and other genetic changes
in tumor cells. So-called fusion genes encoding novel RNAs and proteins are
occasionally created by the genetic changes in tumor cells. An example is the
BCR-ABL fusion gene resulting from the translocation t(9;22). The analysis of
fusion genes can clarify certain mechanisms of transformation, as in the case of
lymphoma cells with the translocation t(14;18), which express a protein inhib-
iting apoptosis. The most sensitive method to assay fusion genes is the PCR. PCR
can be used for the study of minimal residual disease after intensive treatment or
bone marrow transplantation, but PCR is not quantitative in routine use. With the
same methods, point mutations or the expression of oncogenes can be assayed.
The analysis of protein (Western blot), RNA (Northern blot), and DNA (South-
ern blot) is not as sensitive as PCR but permits an approximate quantification.
The fraction of malignant cells that can be recognized by Western, Northern, or
Southern blot is in the range of 1–5%. PCR can recognize one malignant cell in
105normal cells if a specific molecular marker for the tumor cell is known. A new
method known as fluorescence in situ hybridization (FISH) can also analyze
nondividing interphase cells, allowing determination of the type of cell with a
particular mutation or translocation. A disadvantage of FISH is that the currently
available probes yield a rather high background. Molecular genetic methods
such as PCR and FISH are intended as complements, not substitutes for, the
classical cytogenetic methods. In order to perform PCR or FISH, the type of
mutation must first be known.
3.3. Rearrangement of Immunoglobulin Genes
or of the T-Cell Receptor
During the ontogeny of normal B-cells, the genes for the heavy and light
chains of the different immunoglobulin molecules are rearranged sequentially.
Similarly, the genes encoding the α, β, γ, and δ chains of the T-cell antigen
receptor are rearranged in normal T-cells. In malignant B- or T-cells, the immu-
noglobulin genes or the T-cell receptor genes have clonal rearrangements. Again,
these rearrangements can be studied by Southern blot (which is semiquantitative)
or by PCR (which is the most sensitive method). The study of immunoglobulin
gene rearrangements also detects cells at an early stage of B-cell development,
but is not specific for the B-cell lineage, as acute myeloid leukemias occasionally
have rearranged immunoglobulin genes.
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3.4. Light-Chain Restriction
The analysis of light chains using flow cytometry or immunocytochemistry is
a simple tool to detect clonality in neoplasms that express light chains (κ or λ)
on their surface or in their cytoplasm. Mature lymphoid neoplasms (e.g., chronic
lymphocytic leukemia or follicular lymphomas) express surface light chains,
whereas tumor cells of multiple myeloma or some acute lymphoblastic leuke-
mias express only cytoplasmic light chains. The normal ratio of κ to λ expressing
B-cells in humans is about 2:1. If a significant imbalance of light-chain expres-
sion is found, clonality is likely.
3.5. Loss of Heterozygosity
Loss of heterozygosity (LOH) refers to the loss of genetic material from one
allele at a specific gene locus. LOH is tested with PCR amplification of polymor-
phic microsatellite markers for a particular gene or locus. LOH is specific for the
detection of clonally derived cells, but is not sensitive enough for the study of
minimal residual disease. In addition, some normal persons have clonally de-
rived cells that can be detected with LOH; therefore, control tissues should be
studied. LOH studies as well as the study of the inactivation of genes on the X
chromosome are only performed in specialized research laboratories.
3.6. X-Inactivation Assays
These studies are performed with genes located on the normal X chromosome.
An example for such a gene is glucose-6-phosphate dehydrogenase (G6PD),
which has two allelic forms, A and B. Normal females have two X chromosomes
and may be homozygous for A or B or heterozygous (AB) in all somatic cells.
Normal cells in heterozygote females are approx 50% of the A-type and 50% of
the B-type. Using a simple enzyme assay for G6PD, it has been shown that
myeloproliferative syndromes are clonal disorders involving myeloid, mono-
cytic, and other cell types. These studies can only be performed in heterozygotes.
More recently, the inactivation of other genes located on the X chromosome was
studied by DNA- or RNA-based methods. An example is the gene encoding the
human androgen receptor locus. Again, these studies can only be performed in
females. The inactivation of the gene of interest on the X chromosome is studied
by the analysis of methylation or transcription. An advantage of X-inactivation
assays is that no prior knowledge of mutations or gene rearrangements is neces-
sary. A caveat for these assays is that adequate controls are required because
some individuals have a more or less than 50% likelihood of gene silencing on
the X chromosome. Clonal cells can also be detected by this method in some
older individuals without a malignancy being present.
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3.7. Small RNA Molecules in Hematology
Recently, two types of small RNA molecules, microRNA (miRNA) and small
interfering RNA (siRNA), have emerged as sequence-specific posttranscrip-
tional regulators of both prokaryotic and eukaryotic gene expression.  Below, a
brief overview of miRNA and siRNA and their implications in hematological
research is given.
3.7.1. miRNA
MiRNAs are a family of about 22 nucleotide small, functional, noncoding
RNAs that have been shown to play important roles in various biological pro-
cesses, including developmental timing, apoptosis, cell proliferation, fat me-
tabolism and hematopoietic differentiation.
Hundreds of miRNA genes have recently been found in both animals and
plants.  In animals, miRNAs are transcribed by RNA polymerase II through
sequential processing in the nucleus and cytoplasm. MiRNAs are initially tran-
scribed as long transcripts (pri-miRNAs), which are cleaved by the nuclear en-
donuclease Drosha to generate the intermediate short, 60-70 nt hairpin structures
(pre-miRNAs).  Pre-miRNA is subsequently transported to the cytoplasm by
exportin-5 and cleaved by RNase III Dicer to about 22 nt RNA duplex. One
strand of the duplex is the mature miRNA, and miRNA regulates gene expression
at the transcriptional and/or translational level.
One group reported the identification of more than 100 miRNAs from mouse
bone marrow.  Among them, three (miR-181, miR-223, and miR-142s) were spe-
cifically expressed in hematopoietic tissues. MiR-181 was preferentially expressed
in B lineage cells. Overexpression of miR-181 by a retrovirus vector in hemato-
poietic stem cells led to an increase of cells in the B lymphoid compartment. The
results indicate the potential role of miRNA in hematopoietic differentiation.
miRNA profiling in human B cell chronic lymphocytic leukemia (CLL) was
performed by another research group.  Significant difference in the expression
pattern was observed between normal and CLL patient samples. More recently,
it was discovered that the expression of miR-155 is increased in human B cell
lymphomas. This observation has linked miRNA to the pathogenesis of human
lymphatic malignancies.
In an in vivo model, “antagomirs” were created ablating endogenously
overexpressed miRNAs. As a secondary phenomenon, multiple other genes were
repressed in mice treated with “antagomirs.” Ultimately, “antagomirs” or similar
molecules might be useful for treating human diseases including leukemia and
cancer.
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3.7.2. SiRNA
RNA interference is an evolutionarily conserved process of posttranscriptional
gene silencing through siRNAs that mediate mRNA degradation. This phenomena
was first described in C. elegans, and was found in different organisms such as
plants, fungi, flies and mammals. DsRNAs are processed by the highly conserved
RNase III Dicer and cleaved into 21-23 nt small interfering RNAs (siRNAs).
siRNAs are then packaged into RNA-induced silencing complexes (RISC).  The
RISC directs the base pairing and cleavage of the target mRNA.  In mammalian
cells, dsRNA larger than 30 bp can also trigger interferon/antiviral response, lead-
ing to nonspecific silencing of cellular genes.  The success of the direct introduc-
tion of chemically synthesized small duplex RNA into mammalian cells without
triggering interferon response has allowed the development of many strategies to
introduce siRNA.  RNAi has been rapidly growing as an effective tool for study
of gene function and for therapeutic applications.
Many hematopoietic genes have been targeted by siRNA, including BCR-
ABL, AML1/MTG8, CD4 and CD8. Using a cell line bearing the BCR-ABL
rearrangement, RNAi can achieve sequence-specific silencing of the BCR-ABL
oncogene.  Transfection of a 19 nt dsRNA specific for the BCR/ABL fusion
mRNA into K562 leukemic cells depleted the corresponding mRNA and
oncoprotein, and induced apoptosis.  Reduction of BCR-ABL mRNA levels was
also observed in primary CML cells upon introduction of anti BCR-ABL siRNA
by electroporation.  RNAi shows promise as a technology for future therapeutic
development.
4. DIAGNOSTIC APPLICATIONS OF MOLECULAR BIOLOGY
AND GENE THERAPY
A number of hematological diseases (e.g., thalassemias, sickle cell ane-
mias, leukemias, and lymphomas) have a genetic basis, and the introduction
of molecular methods has allowed for a more refined diagnosis of these disor-
ders. For example, certain cases of chronic myelogenous leukemia were recog-
nized that do not have the classical Philadelphia chromosome yet were shown by
molecular analysis to harbor the BCR-ABL fusion gene. The classification of
non-Hodgkin’s lymphomas has been made more reproducible, as molecular and
immunological methods have been employed for diagnostic purposes. The defec-
tive genes in hematological disorders may be inherited (germ-line defects) or
acquired (somatic mutations). Because many of the molecular defects were defined,
the replacement of defective genes by gene therapy is a logical treatment. For gene
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transfer, human DNA sequences are introduced into a packaging system or vec-
tor (discussed in the following paragraphs) and transferred into the cell of inter-
est. The vectors also often carry genes for antibiotic resistance, which allows
later selection of transduced cells. The transduced cells synthesize proteins
according to the DNA sequences transferred. Gene transfer can replace miss-
ing or defective genes or introduce genes usually not found in the target cells.
At present, human somatic gene therapy is at a turning point. It was shown for
the first time that gene replacement could actually have major clinical benefit
(normalizing the immune defect of children with X-linked severe combined
immunodeficiency [SCID]). Almost at same time, the first major or serious
complications were observed after gene therapy. A patient died from an infection
or inflammatory response related to the adenoviral vector used for gene transfer.
Out of 11 patients cured by gene therapy of X-linked SCID, two developed acute
leukemia by insertional mutagenesis (see Chapter 10). These tragic events have
tempered the enthusiasm that surrounded gene therapy and have led to additional
safeguards for clinical protocols. However, basic research continues to make
progress and new protocols are currently under development. Gene therapy can
also promote an effective immunotherapy by making tumor cells immunogenic.
The types of vectors used, some of the problems involved, and the first clinical
applications of gene therapy are discussed in this chapter.
4.1. Viral Vectors and Gene Delivery Systems
4.1.1. RETROVIRAL VECTORS
This widely used modality of gene transfer has permitted the transfer of genes
into cell lines, experimental animals, and patients. Retroviral vectors are based
on the Moloney murine leukemia virus and can integrate only into dividing cells.
The retroviruses used for gene transfer are made replication incompetent. Unfor-
tunately, the efficiency of gene transfer is generally low and only 8–9 kb of
foreign DNA can be transferred using these vectors. Furthermore, retroviruses
integrate randomly into the host genome, which can theoretically cause inser-
tional mutagenesis.
4.1.2. ADENOVIRAL VECTORS
Adenoviral vectors can also infect nonproliferating cells. These viruses are
generally stable and can be purified. The uptake of adenoviral vectors is episo-
mal; therefore, no long-term expression is achieved. Adenoviruses usually
mediate a strong expression of the integrated genes. Up to 15 kb of foreign
DNA can be transferred. The induction of antibodies that decrease the efficacy
of repeated administration can cause a problem when using adenoviral vectors.
Adeno-associated virus is a defective parvovirus and can also be used in gene
transfer experiments. This virus is nontoxic but difficult to prepare on a large
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scale. Adeno-associated virus integrates into the host genome and potentially
infects a wide range of target cells.
Foamy viruses are retroviruses that belong to the spumavirus family of non-
pathogenic viruses. Recent studies showed that foamy viruses transduce hemato-
poietic stem cells more effectively than oncoretroviral vectors.
4.1.3. FOAMY VIRUSES
Foamy viruses are retroviruses that belong to the spumavirus family of non-
pathogenic viruses. Recent studies showed that foamy viruses transduce hemato-
poietic stem cells more effectively than oncoretroviral vectors.
4.2. Nonviral Vector Systems
Liposomes are a simple, nontoxic, and noninfectious modality of gene trans-
fer. The efficiency of gene transfer, however, is rather low, as liposomes compete
with serum in vitro and the DNA transferred in liposomes is degraded in the cell.
At present, further vectors based on viruses (e.g., herpesviruses and
lentiviruses) are being developed. A common problem of all the currently used
gene transfer systems has been that only a minority of cells can be infected and
the expression of the transferred gene is lost after some time.
4.3. Clinical Gene Therapy Protocols
Gene therapy is an attractive idea for hematological disorders, in which stem
cells can be treated, and for cancer in general, in which patients have limited
options after relapse.
The first group of studies aims at the replacement of missing genes. A small
group of children with adenosine-deaminase (ADA) deficiency has been treated
by gene transfer. These patients have severely defective T- and B-cells (SCID).
As a consequence of the deficient enzyme, adenosine and desoxy-adenosine
triphosphate accumulate in cells, thus interfering with DNA synthesis. T-cells
from children with ADA deficiency were infected in vitro with ADA-expressing
retroviruses, then re-infused into the children after in vitro culture. The first
children in which the ADA gene was transferred obtained about 25% of the
normal ADA levels and had fewer infections than before. The administration of
transfected lymphocytes has to be repeated every 3–6 mo. More recently, some
patients underwent nonmyeloablative conditioning with busulphan prior to trans-
plantation with oncoretrovirally transduced CD34+ cells. As expected, a tran-
sient myelosuppression was observed, but otherwise the procedure was well
tolerated. The transduction efficiency of clonogenic progenitors was between 21
and 25%. At preliminary analysis, the peripheral blood B-, T-, and natural killer
(NK) cells showed levels of gene marking between 70 and 100%. The transfer
of other genes is also under investigation. As mentioned, SCID could be success-
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fully corrected by gene therapy. X-linked SCID is due to a defect in the common
γ c-chain of the IL-2 cytokine receptor family. Without specific treatment, SCID
is fatal within the first year of life. Two groups (one in France, one in Great
Britain) treated children with SCID by gene therapy.
In Gaucher’s disease, several groups have transferred the gene coding for
glucocerebrosidase into stem cells from bone marrow or blood. In Hurler syn-
drome, a storage disease, the first clinical trials with gene transfer into hematopoi-
etic stem cells are being performed. In hemophilia, attempts are being made to
replace the gene coding for factor VIII or IX by transducing skin or other tissues.
Hemophilias are attractive disorders for gene therapy because a low level of
transgene expression (1–5%) might offer major clinical benefit. Currently, the
results of 6 phase I/II clinical trials are under evaluation. It appears that the
vectors used had little toxicity but did not lead to any lasting transgene expres-
sion. More recently, gene therapy trials for hemophilia B were initiated using
recombinant adeno-associated virus, which has not been associated with human
diseases. Chronic granulomatous disease is another disease in which the genetic
defects have been characterized and gene replacement has entered phase I clini-
cal studies. Gene replacement studies also aim at replacing mutated genes in
tumor cells, for example, by the replacement of the missing or mutated p53 gene
in solid tumors and the alteration of abnormal growth in leukemic cells that have
a leukemia-specific translocation. The goal of reversing malignant growth can
theoretically also be accomplished by downregulating the expression of
oncogenes and certain growth factor genes with antisense oligonucleotides or
small interfering RNAs.
The second group of clinical protocols are gene-marking studies. The aim of
these studies is not to cure a disease but to follow the fate of transplanted or
transduced cells in vivo. Small amounts of blood or other tissues are taken and
the presence or absence of the marker gene is demonstrated with PCR. From
these marker gene experiments, it was shown that relapse of acute leukemias after
autologous bone marrow transplantation derives both from the host (residual leu-
kemic cells surviving the conditioning) and from the graft (autologous stem cells
contaminated with leukemic progenitor cells).
The third group of studies aims at stimulating a local or systemic antitumor
immunity by transducing tumor cells with cytokine genes (e.g., the genes for
granulocyte/macrophage colony stimulating factor [GM-CSF], IL-2, or tumor
necrosis factor [TNF]). The transduced tumor cells are irradiated and then rein-
jected into the host.
In some animal models, “bystander effects” are observed whereby only a
fraction of the tumor cells is transduced, but the subsequent immune reaction also
eliminates or attacks nontransduced tumor cells. A similar approach is also taken
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with tumor-infiltrating lymphocytes. These cells are genetically modified, irra-
diated, and then re-injected into the patient. A new development involves trans-
ducing tumor cells with peptide transcription units. The proteins synthesized by
the transduced cells bind to class I human leukocyte antigen molecules and
thereby can stimulate a T-cell-dependent immune response against the tumor.
The modification of dendritic cells may also promote a potent cellular immune
response directed against tumors. Many groups are focusing on the generation of
antitumor vaccines aimed at making the immune system recognize hitherto poorly
immunogenic tumor cells. Many tumor cells fail to express the co-stimulatory
molecule B-7. If B-7 is transferred, the tumor cells can become immunogenic and
can be eliminated by the immune system. In patients with AIDS, several groups
are trying to restore cellular immunity either by immunizing asymptomatic
patients with transduced cells or enhancing the degradation of HIV-mRNA by
ribozymes, small interfering RNAs, or other mechanisms.
Finally, a diverse group of studies aims at modifying the general behavior of
normal or malignant cells. An example is the transfer of a multidrug resistance
gene to hematopoietic stem cells, thereby making them resistant to chemothera-
peutic drugs. This procedure could permit the use of higher doses of drugs for the
treatment of a malignant tumor, at least theoretically. The transfer of suicide
genes can also be used to eliminate tumor cells. The first clinical application of
a suicide gene was in patients with glioblastomas. Vectors coding for thymidine
kinase were injected into these brain tumors. After integration, a drug
(gancyclovir) then activated the suicide program of the transduced tumor cells.
A similar approach has also been used in the adoptive transfer of T-lymphocytes.
These cells are transduced with a suicide gene and then transfused into a recipient
to induce a graft-vs-leukemia reaction. Once a significant graft-vs-host reaction
has developed, the suicide program of the transduced cells is activated, thereby
stopping any noxious effects.
5. CYTOKINES
5.1. Colony-Stimulating Factors
CSFs were originally defined as substances that stimulate the colony growth
of blood cells in soft agar or methylcellulose. The first hematopoietic growth
factors described were granulocyte colony-stimulating factor (G-CSF), GM-CSF,
macrophage colony-stimulating factor (M-CSF), and IL-3. Accordingly, G-CSF
supports the in vitro growth of granulocyte colonies, GM-CSF supports the
growth of mixed colonies with both granulocytes and monocytes/macrophages,
and M-CSF stimulates the growth of pure macrophage colonies. IL-3 promotes
the growth of mixed colonies that may also contain red cell precursors and
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megakaryocytes. In the meantime, additional cytokines or ILs have been described
that also influence the differentiation of hematopoietic cells in vitro and in vivo.
In this section, we discuss the basic biology of CSFs and their clinical appli-
cations in hematological disorders.
5.1.1. BASIC BIOLOGY
G-CSF is a glycoprotein with a molecular weight (MW) of 18 kDa, which can
be synthesized by numerous cells, including monocytes, fibroblasts, and epithe-
lial and endothelial cells, but not T-lymphocytes. Substances that induce the
secretion of G-CSF are bacterial products or other cytokines.
GM-CSF is a glycoprotein with an MW of about 14–35 kDa, which is synthe-
sized by mast cells, T-lymphocytes, endothelial cells, fibroblasts, and thymic
epithelial cells. In vitro, bacterial products, other cytokines, and phorbol esters
can induce the synthesis of GM-CSF.
M-CSF is also a glycoprotein, has an MW of about 45–70 kDa, and is synthe-
sized by monocytes, macrophages, fibroblasts, epithelial and endothelial cells,
and osteoblasts. M-CSF is also induced by other cytokines.
IL-3 has an MW between 14 and 28 kDa and is produced by T-lymphocytes
and mast cells in response to mitogens, phorbol esters, calcium ionophores, and
an immunoglobulin (Ig)E receptor activation.
The genes for most human CSFs are located on chromosome 5, with the
exception of the G-CSF gene, which is found on chromosome 17.
The action of cytokines is mediated via high- and low-affinity receptors on the
cell surface. These receptors are specific for each CSF; however, cross-modula-
tions occur, for example, between IL-3 and GM-CSF. Most factors (G-CSF, M-CSF,
and GM-CSF) not only support the proliferation and differentiation of progenitor
cells, but also increase the functional capacity of mature cells (granulocytes and
monocytes).
5.1.2. CSFS LICENSED FOR CLINICAL USE
GM-CSF is available in the United States as a recombinant cytokine expressed
in yeast (sargramostim). In other countries, GM-CSF is also available as a recom-
binant protein expressed in Escherichia coli (molgramostim). The recommended
dose of sargramostim is 250 µg/m2 (given by intravenous or subcutaneous injec-
tion). The indications for sargramostim approved by the Food and Drug Admin-
istration (FDA) are: promote recovery of myelopoiesis in patients with acute
myelogenous leukemia (AML) older than 55 yr who received induction chemo-
therapy; mobilize autologous stem cells; promote myeloid recovery after autolo-
gous or allogeneic stem cell (bone marrow) transplantation; and improve
myelopoiesis in patients with delayed engraftment after autologous (allogeneic)
engraftment.
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G-CSF is available in the United States as a recombinant protein expressed in
E. coli (filgrastim). In other countries, G-CSF is also available as a recombinant
protein expressed in a mammalian cell line (lenograstim). The recommended
dose of filgrastim is 5 µg/kg (administered by subcutaneous or intravenous
injection). The FDA has approved these indications for filgrastim: support
myeloid recovery after chemotherapy for AML; mobilize peripheral blood stem
cells; accelerate myeloid recovery after myelosuppressive chemotherapy or bone
marrow or stem cell transplantation and severe chronic neutropenia. Because
CSFs are expensive and in many instances shorten neutropenia but do not
improve the ultimate prognosis of the underlying malignancy, the American
Society for Clinical Oncology (ASCO) has developed guidelines for the use of
CSFs after myelosuppressive chemotherapy. A primary prophylaxis is only rec-
ommended if the risk of febrile neutropenia is 40% per cycle of chemotherapy.
If a patient has experienced febrile neutropenia during a previous cycle of chemo-
therapy, the use of myeloid growth factors appears justified to maintain dose-
intensity in curable malignancies (testicular cancer, Hodgkin’s and non-Hodgkin’s
lymphoma).
5.1.3. USE OF CSFS IN PATIENTS WITH HEMATOLOGICAL DISORDERS
The cloning of the genes for CSFs and the production of recombinant proteins
has made large-scale clinical use of these cytokines possible. In contrast to other
cytokines such as TNF and IL-2, the CSFs are generally well tolerated. Some
patients treated with G-CSF experience bone pain, and have a slight enlargement
of the spleen as side effects. Lethargy, bone pain, and slight fever are symptoms
observed in some patients treated with GM-CSF and, especially at higher dos-
ages, cases of phlebitis, generalized edema, and pericarditis were encountered
(capillary leakage syndrome).
In vivo, the plasma half-life of the CSFs is in the range of minutes to hours.
Subcutaneous administration results in a more sustained plasma level and pos-
sibly in a better clinical efficacy than intravenous bolus injections. The doses of
CSFs tested in various studies until now have ranged between 1 and 30 µg/kg/
d. G-CSF stimulates a dose-dependent leukocytosis (increase of neutrophils) in
patients and in normal individuals, whereas GM-CSF also increases the number
of eosinophils and monocytes. The action of the hematopoietic growth factors is
reversible within days after discontinuing their administration.
The hemopoietic growth factors G-CSF and GM-CSF are widely used in
patients with acquired neutropenia. G-CSF is especially well tolerated. Accord-
ing to most studies, the period of neutropenia can be shortened by several days
in high-risk patients who have undergone autologous or allogeneic stem cell
transplants or other high-dose chemotherapy, thus reducing the likelihood of
infection. The general use of these factors in all patients who undergo high-dose
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therapy is not recommended because of the high cost involved. Only patients
who have a high likelihood of serious infections should be treated prophylacti-
cally. The increase in the dose of cytostatic drugs is limited not only by neutro-
penia, but also by other toxicities that cannot be ameliorated by the CSFs. The
use of CSFs in patients with a high likelihood of infection also applies to other
situations such as severe aplastic anemia. In summary, the use of CSFs in patients
with acquired neutropenia is mainly supportive, but may improve the prognosis
in high-risk situations.
A clear indication for the use CSFs is idiopathic neutropenia. In congenital
neutropenia (Kostmann syndrome), for example, the patients suffer from
septicemias, pneumonias, and other infections from early infancy. After treat-
ment with G-CSF, the number of neutrophils normalizes and chronic ulcerations
and infections heal. Several patients have now been treated for more than 15 yr
with few side effects. GM-CSF is less effective in patients with Kostmann syn-
drome and increases more eosinophils than neutrophils. In cyclic neutropenia,
G-CSF does not eliminate the cyclic variations of neutrophils, but greatly
reduces infectious complications. Other acquired neutropenias (autoimmune or
idiopathic) also benefit from hematopoietic growth factors.
5.2. Pegfilgrastim
Pegfilgrastim is filgrastim (G-CSF) bound to polyethylene glycol, which
significantly increases the in vivo half-life compared with native recombinant
G-CSF. Therefore, one injection of pegylated G-CSF per cycle of chemotherapy
is sufficient to stimulate neutrophil recovery. The side effect profile is compa-
rable to G-CSF. The indication of pegfilgrastim as approved by the FDA is to
reduce the risk of neutropenia following myelosuppressive chemotherapy. The
recommended dose of pegfilgrastim is 6 mg given by subcutaneous injection.
5.3. Thrombopoietin
Thrombopoietin (TPO) or megakaryocyte growth and development factor
(MGDF) is the major physiological regulator of megakaryocytes and platelet
production. The gene for human TPO is located on chromosome 3q27. The
mature protein has 332 amino acids. TPO is heavily glycosylated and has an MW
of around 70 kDa. TPO is the ligand for the c-MPL receptor, which is present on
early hemopoietic progenitor cells, megakaryocytes, and platelets. The m-RNA
for TPO is expressed in the liver, kidney, and to a lesser extent in stromal cells
of spleen and bone marrow. Signaling via c-MPL involves activation of the
JAK[Janus kinase]/STAT and Ras signaling pathways. The serum levels of TPO
are high in thrombocytopenic patients and low in normal individuals. TPO stimu-
lates both the proliferation and maturation of cells committed to megakaryocyte
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production. Recombinant TPO has been given to patients who were thrombocy-
topenic following chemotherapy. In these patients, platelets increased with a
latency of 8–12 d. The dose of TPO administered was in the range of 0.1–1 µg/
kg daily. Platelets produced or stimulated by TPO are functionally normal. The
yield of platelets obtained by platelet pheresis from healthy donors treated with
TPO is increased two- to threefold, however, in such individuals, the risk of
thrombosis with high platelet counts must be considered. According to some
studies, TPO is synergistic with other growth factors in mobilizing progenitor
cells. Potential clinical applications of recombinant TPO are as prophylaxis for
thrombocytopenia following chemotherapy and delayed platelet recovery fol-
lowing autologous transplantation. Recombinant TPO continues to be used in
clinical trials for the treatment and prophylaxis of thrombocytopenia. The clini-
cal trials of a pegylated form of TPO were stopped after a subset of patients
developed neutralizing antibodies to TPO (with severe thrombocytopenia in a
few patients). Currently, a small-molecule agonist of the TPO receptor is under-
going clinical trials for thrombocytopenia.
5.4. Erythropoietin
Erythropoietin (EPO) is produced by kidney cells (in embryonic life also in
the liver) and is stimulated by tissue hypoxia. EPO is encoded by a gene on
chromosome 7 and has an MW of 1.8 kDa (34–39 kDa in its glycosylated form).
It promotes the proliferation and differentiation of erythropoietic cells from
progenitor cells. Recombinant EPO is widely used for the treatment of renal
anemia (see Chapter 5). Subcutaneously injected EPO is also used for other
indications such as aplastic anemias, myelodysplastic syndromes, anemias fol-
lowing chemotherapy, and anemias of chronic disease; however, in these indi-
cations, the effect of EPO is less predictable. The normal EPO serum levels are
between 4 and 26 mU/mL. Recombinant EPO can be expected to improve
hematopoiesis if the endogenous EPO level is normal or moderately increased.
The recommended dose of recombinant EPO is 100–150 U/kg three times
weekly. In patients with renal disease, the recommended dose is lower (50 U/kg
three times weekly). Side effects of recombinant EPO include hypertension or
hyperviscosity and are mainly observed in patients with renal anemia treated
with a high dose of EPO. The improvement in hematocrit may take up to 12 wk
after beginning treatment with EPO. EPO is also effective in many cases of HIV-
associated anemia (see Chapter 17). A new indication for EPO is the anemia
observed in preterm infants. At doses of 200 U/kg, most preterm infants improve
their hematocrit and many avoid blood transfusions. Another indication of EPO
is the treatment and prophylaxis of anemia in Jehova’s witnesses who refuse
blood transfusions for religious reasons.
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5.5. Darbepoietin-α
Darbepoietin is a modified form of EPO (five amino acids were modified to
permit the attachment of two additional carbohydrate side chains). This modifi-
cation leads to a more than threefold longer in vivo half-life. The indications for
darbepoietin approved by the FDA are anemia of chronic renal insufficiency and
anemia secondary to chemotherapy. The effects and side effects of darbepoietin
are comparable to EPO. The advantage for patients is less-frequent dosing. The
recommended initial dose in patients with chronic kidney failure is 30–50 µg/kg
given intravenously or subcutaneously. The target hemoglobin in kidney failure
is 11–12 g/dL. In patients who receive chemotherapy, one injection of
darbepoietin per cycle was found effective to prevent anemia.
Table 1
Currently Known Interleukins and Interferons and Their Characteristics
Interleukins
Interleukin (IL)-1 Originally described as endogenous pyrogen or lymphocyte-
activating factor, it exists in two forms (IL-lα and IL-1β) and is
pleiotropic and a mediator of many inflammatory and
immunological reactions. IL-1 is secreted by activated monocytes
and endothelial cells, cleaved from a precursor peptide (molecular
weight [MW] 33 kDa) to a mature protein (MW 17 kDa) by the
enzyme IL-1-converting enzyme. IL-1 receptor antagonist occurs
as a natural inhibitor of IL-1.
IL-2 Previously known as T-cell growth factor, it has an MW of about
15 kDa and is encoded by a gene on chromosome 4. IL-2 plays a
central role in the expansion and activation of antigen-reactive T-
lymphocytes. IL-2 has autocrine and paracrine effects on T-cells,
but also activates natural killer (NK) cells and other cell types. IL-2 is
used in the experimental tumor therapy with lymphocyte-activated
killer (LAK) cells and tumor-infiltrating lymphocyte (TIL) cells.
LAK cells can be expanded in the presence of 1L-2 and show some
activity in patients with melanomas and other cancers. TIL cells
have been isolated from tumors and similarly expanded with IL-2.
IL-3 See Subheading 5.1.
IL-4 Secreted by activated T-lymphocytes (especially TH2 cells), MW
of about 18 kDa, acts both on B- and T-lymphocytes. IL-4 activates
quiescent B-lymphocytes and inhibits the action of
proinflammatory cytokines on monocytes and macrophages.
(continued)
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Table 1 (Continued)
Interleukins
IL-5 Homodimeric protein with an MW of about 50 kDa, secreted by
activated T-cells and mast cells, major biological function is to
promote the growth and differentiation of eosinophils. Increased
serum levels of IL-5 have been found in hypereosinophilic
syndromes.
IL-6 Pleiotropic cytokine (MW 26 kDa), produced by activated
monocytes, macrophages, endothelial cells, fibroblasts, and some
tumor cells. Major stimulators of IL-6 production are other
cytokines like tumor necrosis factor (TNF)-α or IL-1, mediator of
acute phase and inflammatory reactions, stimulating the growth
of differentiated B-cells and the generation of cytotoxic T-cells.
IL-6 acts on hematopoietic progenitor cells together with colony-
stimulating factors and promotes the growth of myeloid and
megakaryopoietic colonies. IL-6 acts as an autocrine growth factor
in multiple myeloma and other malignancies.
IL-7 Glycoprotein, with an MW of 25 kDa, stimulates early B- and T-
cells, is expressed in the stromal cells of thymus, spleen, bone
marrow, and other tissues, and is recognized as a growth factor for
mature T-cell lymphomas such as Sezary syndrome.
IL-8 Small molecule secreted by monocytes and stromal cells
(chemokine), recruits granulocytes, is involved in the
pathogenesis of adult respiratory distress syndrome, and has
pyrogenic activities.
IL-9 Pleiotropic cytokine secreted by activated CD4 cells, has an MW
of 30–40 kDa. IL-9 acts on T-cells and mast cells, has a synergistic
activity with IL-3 on early erythropoietic cells. m-RNA for IL-9
is found in tumor cells of Hodgkin’s disease and anaplastic large-
cell lymphomas.
IL-l0 Anti-inflammatory properties, MW 18 kDa, produced by activated
T-cells, B-cells, and macrophages. IL-10 inhibits the secretion of
proinflammatory cytokines like TNF-α, IL-I, IL-6, IL-11, and
interferon (IFN)-γ. The apoptosis of B-cells is inhibited in the
presence of IL-10.
IL-11 Cloned from stromal cells, is considered as an additional
hemopoietic growth factor. IL-11 stimulates the development of
megakaryocytes (together with other cytokines), promotes the
hematopoietic reconstitution after chemotherapy, and has
immunomodulatory effects. IL-11 has an MW of approx 20 kDa.
Recombinant IL-11 (oprelvekin) was approved by the Food and
Drug Administration for the prevention of severe thrombocyto-
(continued)
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Table 1 (Continued)
Interleukins
penia and patients with nonmyeloid malignancies after
myelosuppressive chemotherapy. The recommended dose
 of oprelvekin is 50 µg/kg once daily (given subcutaneously).
IL-12 Exists as a heterodimer, has an MW of 75 kDa, is secreted by
 monocytes or macrophages after stimulation by endotoxin
 or by activated B-lymphocytes. IL-12  strongly induces the
secretion of IFN-γ  by T-cells and NK cells  and augments the
 cytotoxicity of NK cells. IL-12 also induces the proliferation
 of activated T- and NK cells.
IL-13 Structural homology with IL-4 is produced by a subpopulation
of activated T-lymphocytes. IL-13 activates B-lymphocytes
(e.g., IL-4).
IL-15 Produced by epithelial cells and monocytes,
stimulates the proliferation of activated
T-lymphocytes. IL-15 has a functional similarity to IL-2
and binds with the β and γ  chain of the IL-2 receptor.
IL-16 IL-16 monomer has an MW of 14 kDa, is produced by CD8-
positive T-cells, serves as a chemoattractant for CD4-positive
lymphocytes, eosinophils, and monocytes. IL-16 binds to the CD4
molecule and is considered to be immunomodulatory and
proinflammatory.
IL-17 Produced by activated T-cells, proinflammatory activities. IL-17
induces the production of other cytokines (e.g., IL-6 and IL-8)
from stromal cells.
IL-18 Previously described as IFN-γ-inducing factor, related to the IL-1
family. IL-18 is pleiotropic, but generally has proinflammatory
activities. Similar to IL-10, IL-18 requires the IL-1β-converting
enzyme for cleavage to its active form. Most activities of
interleukin-18 are due to a receptor complex that recruits the IL- l
receptor-activating kinase and the consequent translocation of
nuclear factor (NF)-κB.
IL-19 Homolog of IL-10, activity at present not well described.
IL-20 Homolog of IL-10, activates keratinocytes.
IL-21 Pleiotropic cytokine, influences proliferation, effector function,
and differentiation of B-, T-, NK, and dendritic cells. Has a private
receptor (IL-21 receptor) which activates the JAK/signal
transducers and activators of transcription pathway upon ligand
binding).
IL-22 Induces inflammatory responses.
IL-23 Induces IFN-γ production and proliferation in T-cells.
(continued)
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5.6. Stem Cell Factor
Stem cell factor (SCF) is the ligand for the c-kit proto-oncogene. SCF has an
essential role in embryonic development and serves as a growth factor of early
hematopoiesis. In vitro, SCF acts synergistically together with G-CSF, EPO, and
IL-3 in stimulating hematopoietic colonies. SCF also plays a critical role in mast
cell production and function, melanocyte production, germ cell function, and
gastrointestinal motility. The gene for human SCF is localized on chromosome
12. When administered to experimental animals, SCF leads to an increase in red
blood cells, neutrophils, lymphocytes, eosinophils, and basophils. The receptor
for SCF (c-kit) is expressed in acute myelogenous leukemias and certain lym-
phomas. Human SCF is available in Australia, New Zealand, and Canada as a
recombinant protein (ancestim) and was found to increase the mobilization of
peripheral blood stem cells in patients who failed a previous mobilization with
chemotherapy and/or G-CSF. The recommended dose is 20 µg/kg/d subcutane-
ously. Because some patients developed anaphylactoid reactions due to mast cell
activation, a premedication with inhaled β-mimetics and antihistamines is rec-
ommended.
5.7. FLT3 Ligand
FLT3 ligand is a cytokine widely expressed in human tissues. A transmembrane
form can be cleaved to generate a soluble form that also has biological activity. The
FLT3 receptor is a tyrosine kinase and has a restricted expression (early myeloid and
early lymphoid progenitor cells, myeloid leukemias, and certain lymphomas). Based
on studies of its expression and function, FLT3-ligand is categorized together with
SCF as an early hematopoietic cytokine. Both cytokines require the interaction with
other early acting or lineage-specific cytokines. In contrast to SCF, FLT3-ligand does
not act on early erythroid cells. A potential clinical application of FLT3-ligand is the
expansion of stem cell grafts. FLT3-ligand also stimulates lymphoid progenitors,
dendritic cells, and NK cells. Activating mutations of the FLT3 receptor are observed
in about 30% of acute myelogenous leukemias (see Chapter 9).
Table 1 (Continued)
Interleukins
IL-24 Member of IL-10 family, produced by activated monocytes and
T-helper cells, can function through receptors or intracellularly as
cytotoxic agent.
IL-25 Member of IL-17 family, induces production of IL-4, IL-5, and IL-13.
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5.8. Tumor Necrosis Factor-α
TNF-α is a protein with an MW of 17 kDa, produced mainly by activated
monocytes and encoded by a gene on chromosome 6. TNF was originally char-
acterized by its action on certain murine tumors. The physiological relevance of
TNF is cell-to-cell interaction and immunoregulation. Lymphotoxin is a related
cytokine produced mainly by lymphoid cells. Circulating TNF can be measured
in septic shock (endotoxemia) and during acute graft-vs-host reactions. The
systemic treatment with TNF in human cancer has showed considerable toxicity
and has had only sporadic antitumor effects.
5.9. Fas Ligand
Fas ligand, like TNF, is a type II transmembrane protein with an MW of 38–
40 kDa. Fas ligand is produced by activated T- and NK cells, for example, in areas
of immune privilege like the testis or the anterior eye chamber. An ectopic
expression of fas ligand is found in tumor cells such as colon cancer and mela-
noma, Fas ligand is cleaved by metalloproteinases and interacts with a receptor
present on activated cells and other cell types (Fas, CD95). The physiological
function of fas ligand is the transmission of death signals to sensitive cells.
5.10. TNF-Related Apoptosis-Inducing Ligand
TNF-related apoptosis-inducing ligand (TRAIL) is a type II membrane-bound
TNF family ligand that is homologous to Fas ligand. TRAIL has the unique
property of selectively killing tumor cells and sparing most normal cells. The
main function of TRAIL is to induce apoptosis in sensitive cells and activate the
transcription factor nuclear factor (NF)-κB. TRAIL has five receptors: DR4 and
DR5 transmit death signals, DcR1 and DcR2 act as decoy receptors, and a soluble
receptor (osteoprotegerin). The tumor specificity of TRAIL is unclear, but may
be related to its intracellular signal transduction.
5.11. Transforming Growth Factor-β
TGF-β is a 14-kDa molecule that is synthesized as a 25–28 kDa homodimeric
polypeptide. Three different isoforms of TGF-β are expressed in many tissues,
especially in lymphoid cells, monocytes, megakaryocytes, and platelets. The
dominant activity of TGF-β is suppression of cell growth, which is illustrated by
its ability to inhibit the T-cell response to mitogens. By indirect mechanisms,
TGF-β also stimulates some cells, thus promoting angiogenesis and wound heal-
ing, for example. TGF-β is expressed in a number of tumor cells including
Hodgkin’s lymphoma with nodular sclerosis.
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5.12. Interleukins
A list of the currently known interleukins (abbreviated as IL-1 through IL-25)
and their characteristics are briefly described in Table 1.
5.13. Interferons
IFN-α is widely used for the treatment of hematological diseases (hairy cell
leukemia and chronic myelogenous leukemia). IFN-α and IFN-β belong to the
group of type I IFNs, whereas IFN-γ is a type II (immune) IFN. Originally, the
IFNs were characterized as antiviral substances. However, it was later found that
their main activity is immunomodulation. The type I interferons, for example,
stimulate the activity of NK cells and modulate the synthesis of immunoglobu-
lins. Moreover, IFN-α has direct effects on tumor cells, such as increasing the
expression of cell surface antigens, including class I histocompatibility antigens.
This cytokine also has a direct antiproliferative action, possibly through the
induction of 2',5'-oligo-adenylate synthetase and inhibits several cell growth-
associated proteins. The dose of IFN-α used for the treatment of blood diseases
is administered subcutaneously in the range of 3 × 106 U given three times a week
to 5 × 106 U given daily. This dose often must be modified, however, as a result
of such side effects as fever, chills, myalgias, lethargy, and, less frequently,
cardiovascular and metabolic disturbances, interstitial nephritis, confusion, and
neuropathies. The pyrogenic side effects subside spontaneously in most cases,
and can be controlled with antipyretics. For other side effects, the dose of IFN
needs to be altered or the treatment discontinued. About 3–5% of patients de-
velop neutralizing antibodies that render the treatment ineffective. Common
hematological side effects of IFN-α are neutropenia and thrombocytopenia.
IFN-β. IFN-β has been found to be less effective than IFN-α against hairy cell
leukemia and chronic myelogenous leukemia. A positive response to IFN-β
treatment has recently been observed in patients with multiple sclerosis.
IFN-γ. IFN-γ is produced by activated T-lymphocytes. The immunological
and antiviral effects of IFN-γ are different from those of the type I IFNs. IFN-γ
activates monocytes and macrophages, leads to an increase in the expression of
Fc receptors, augments the production of superoxide, and enhances phagocytosis
and bactericidal capacity. It increases the cytotoxicity of NK cells and the immu-
noglobulin synthesis of B-lymphocytes. Like IFN-α, IFN-γ inhibits the growth
of some tumor cells in vitro and enhances the cell surface expression of numerous
antigens including class I and class II histocompatibility antigens. Clinically,
IFN-γ is less active than IFN-α in the treatment of hematological disorders. More
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recently, it was shown that children with the granulocyte defect chronic granu-
lomatous disease have fewer infections when treated with subcutaneous IFN-γ.
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1. INTRODUCTION
Patients with hematological malignancies such as leukemias and lymphomas
are predisposed to a wide spectrum of infections that need special attention.
These patients are immunosuppressed not only as a result of the immune defects
associated with the underlying disease, but also because of the treatment regi-
mens that generally further decrease the patient’s resistance to infections. An
intensive transfusion support with platelets, red cell concentrates, immuno-
globulins, cytokines, and other drugs is necessary. Many patients also need
antiemetic agents, nutritional support, pain medication, and, very often, venous
catheters. All of these measures are considered supportive care and apply in a
similar fashion to the high-dose treatment of solid tumors. Supportive care
measures, along with the treatment and prophylaxis of infections, are discussed
in this chapter. Transfusion support is discussed in Chapter 22.
42 Hiemenz and Munker
2. DIAGNOSING SUSPECTED INFECTION
IN NEUTROPENIC PATIENTS
The immune system can be compromised by the underlying disease, the treat-
ment of the disease, or many procedures and devices utilized in support of treat-
ment of the underlying disease (e.g., central venous catheters). Neutropenia has
been recognized as the major risk factor for development of opportunistic infec-
tion in patients with hematological malignancy or undergoing cancer chemo-
therapy. Bodey and colleagues studied the relationship between the neutrophil
count and the development of severe infection in 52 patients treated for acute
leukemia at the National Institutes of Health from 1959 to 1963 (1). In the presence
of severe neutropenia, defined as less than 100 cells/mm3, there were 43 episodes
per 1000 d with a marked drop in infection rate as the neutrophil count rose. In
addition, the risk of infection increased with increasing duration of neutropenia.
This relationship between neutropenia and life-threatening infection has been
reported by numerous investigators since the initial publication by Bodey et al.
in 1966 (2,3). The Infectious Diseases Society of America (IDSA) defines neu-
tropenia as an absolute neutrophil count of less than 500 cells/mm3, or <1000
cells/mm3 with a predicted decrease to less than 500 cells/mm3 (4). Although the
risk of neutropenia has been recognized for more than 40 yr, other qualitative
defects in humoral and/or cellular immunity may also increase the risk of infec-
tion with a variety of pathogens including bacterial, fungal, and viral pathogens.
Examples include infections with encapsulated bacteria in patients with
dysgammaglobulinemia due to underlying myeloma or infections due to cellular
immune deficiency such as Pneumocystis carinii pneumonia or cryptococcal
meningitis in the patient with Hodgkin’s lymphoma, and invasive aspergillosis
or cytomegalovirus (CMV) pneumonia in the leukemic patient with chronic
graft-vs-host disease (GVHD) on immunosuppressive therapy (5). All of these
patients may have a normal or elevated neutrophil count.
When faced with fever in the neutropenic patient, defined by the IDSA as a
single oral temperature of 38.3°C (101.0°F) or 38.0°C (100.4°F) for 1 h or
longer, the diagnosis of severe infection must be considered. This situation is
consider an emergency and should lead to prompt evaluation and initiation of
empirical antimicrobial treatment. Evaluation includes a thorough history and
physical examination (4). The history should include the nature and status of the
underlying disease, chemotherapy received, other immunosuppressive drugs
such as steroids, use of cytokines, and past and recent infections as well as
previous procedures. Initial examination should assess all sites of possible infec-
tion. The profoundly neutropenic patient may have minimal signs or symptoms
of inflammation with 50 to 75% of cases having no definable source of infection
when fever develops. The clinician should carefully inspect the eyes, orophar-
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ynx, and skin (with particular attention to vascular catheter tunnel and exit sites,
bone marrow aspirate sites, nails, and nailbeds) (2). The perineal and perirectal
areas are frequently missed but are critical areas to inspect initially and on a
regular basis when fever persists. Evidence of perirectal or perianal infection in
the neutropenic patient may require modification of initial empirical antimicro-
bial treatment. Surgical intervention may be warranted for drainage of develop-
ing abscess(es) (6). It is also important to carefully inspect the scalp, as hair may
hide evidence of infection.
In addition to a thorough physical examination, laboratory evaluation of the
febrile neutropenic patient includes a hemogram, electrolytes, renal, and liver
function tests. Cultures of blood and urine should be obtained, as these are the
most common sites of microbiologically documented infection. A minimum
total of two sets (aerobic and anaerobic) of blood cultures should be obtained for
the initial evaluation. It has been recommended that, in addition to drawing one
set of cultures from a peripheral venipuncture, one set of blood cultures should
be obtained from each lumen in patients with central venous catheters. In this
group of patients, it is often difficult to obtain peripheral venous access even for
simple blood sampling. The need to routinely obtain cultures from the peripheral
vein in cancer patients with central venous catheters, therefore, has often been
questioned. In a recent retrospective review, DeJardin et al. found a high predic-
tive value of negative blood cultures drawn from central venous catheters of
febrile cancer patients (7). These authors have suggested that peripheral veni-
puncture was thus not routinely required unless blood cultures from the central
venous catheter were found to be positive. A routine chest radiograph should be
performed to exclude or diagnose pneumonia. Performance of the chest radio-
graph, however, should not delay initiation of empirical antibacterial therapy
immediately after cultures are obtained.
Further diagnostic steps should be taken if clinically indicated. In addition to
blood and urine, cultures should be obtained from any other site(s) found on
exam to be suspicious for possible focus of infection. If skin lesions are present,
biopsy or aspiration should be performed. Biopsy specimens should then be sent
for cytology and/or histopathology with special stains for microorganisms as
well as culture for bacteria, fungi, and viruses (e.g., Herpes simplex and Varicella
zoster). In the setting of diarrhea, stool culture for bacterial pathogens, screening
for the presence of Clostridium difficile toxin, as well as evaluation for ova and
parasites should be considered. Cerebrospinal fluid (CSF) should be obtained
from a lumbar puncture (or Ommaya reservoir when present) in patients who
have neurological symptoms or a change in mental status to diagnose meningitis.
Bacterial surveillance cultures from the oropharynx, urine, and stool have been
performed on a regular basis in neutropenic patients at a number of institutions.
Although information obtained from these cultures may be valuable for epide-
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miological purposes, they are not recommended for the management of the in-
dividual patient. In the absence of specific signs or symptoms of infection, bac-
terial surveillance cultures have little value in predicting infection, rarely change
antibiotic therapy, and are costly (2).
High-resolution computed tomography (CT) of the chest should be consid-
ered in any patient with abnormalities on routine chest radiograph to better define
possible pulmonary infection. CT scan should also be considered despite nega-
tive routine radiograph of the chest if symptoms or signs of pulmonary infection
exist such as cough, shortness of breath, or hypoxemia, or if there is persistent
or recurrent fever after a week of broad spectrum empirical antibacterial therapy
(8). Bronchoscopy with bronchoalveolar lavage (BAL) should be performed in
patients with abnormal radiograph or CT scan to obtain specimens for cytology,
culture, and stains for bacteria, fungal, and viral pathogens. If viral pneumonia
is suspected, specimens may be examined for viral DNA by PCR.
Tests for inflammatory cytokines such as C-reactive protein, procalcitonin,
interleukin-6, and interleukin-8 may correlate with the presence of an infection
in neutropenic patients, but none are specific or reliable and they cannot be used
for treatment decisions in the acute situation. The presence of galactomannan in
blood has been utilized for a number of years in Europe as a surrogate marker of
invasive aspergillosis and was recently approved for use in the United States by
the Food and Drug Administration for a similar indication. The sensitivity and
specificity of this test may vary in different populations of patients (i.e., children
versus adults, neutropenic versus non-neutropenic hosts) and therefore results
must be taken in context with the clinical situation. β-glucan is another surrogate
marker for invasive fungal infection and may apply to a broad group of pathogens
that possess a high concentration of β-glucan in their cell wall (9–11).
3. TREATING INFECTIONS IN NEUTROPENIC PATIENTS
A large array of pathogens is responsible for infections in immunosuppressed
and/or neutropenic patients with hematological disorder. The source of infection
may be from the normal endogenous flora or may result from nosocomial acquisi-
tion from the exogenous environment. Gram-negative rods (Escherichia coli,
Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter spp., and oth-
ers) usually arise from the gastrointestinal tract and may cause serious infections
in compromised patients. Antimicrobial developments in the 1980s and 1990s
led to an increase in the armamentarium of antimicrobial agents available to treat
these common Gram-negative pathogens (e.g., extended-spectrum β-lactams,
carbapenems, quinolones) (2,4). Unfortunately, increased exposure to these
agents empirically and prophylactically has led to the selection of Gram-negative
pathogens with broad-spectrum antimicrobial resistance. Organisms with broad
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antibacterial resistance such as Acinetobacter anitratis and Stenotrophomonas
maltophilia are usually acquired from the hospital environment (3,12,13). The
incidence of infection with Gram-positive cocci (Coagulase-negative staphylo-
cocci, Staphyloccocus aeurus, α-hemolytic such as Streptococcus mitis, and
Enterococcus spp.) has increased over the last decade, and now accounts for the
majority of microbiologically documented bacterial infections in the neutro-
penic host in many institutions (3,12,13). Although the increased use of indwell-
ing central venous silastic catheters has been considered to be the cause of the
increase in Gram-positive bacteria infections, the oropharnynx and gastrointes-
tinal tract are also considered sources of infection. Severe mucositis after inten-
sive chemotherapy and the use of quinolone prophylaxis have been found to be
independent risk factors that can increase the risk of α-hemolytic streptococcal
sepsis. Bacteremia with α-streptococcus can lead to septic shock accompanied
by adult respiratory distress syndrome (ARDS), more commonly seen with Gram-
negative rod bacteremia (14). Approximately 10–20% of neutropenic patients
with microbiologically documented bacterial infections are infected with
anerobic bacteria (anaerobic streptococci, Clostridia spp., Bacteroides spp.) or
mixed (Gram-positive, Gram-negative, aerobic, and/or anaerobic) infections.
All neutropenic and febrile patients are at risk of fungal infections. Patients
with T-cell dysfunction caused by an underlying hematological disorder or its
treatment may also be at increased risk for fungal infection. GVHD after alloge-
neic blood or marrow transplantation is a well-known risk factor for invasive
mycosis that may last for months or years (15–17). The use of monoclonal
antibodies with anti-T-cell activity for treatment of lymphoproliferative malig-
nancies or GVHD has been recognized as a risk factor for development of inva-
sive fungal infections (18). Candida albicans and Aspergillus spp. have
accounted for the majority of invasive fungal infections in patients with hema-
tological disorders. However, a shift toward the non-albicans Candida spp. and
an increase of Aspergillus spp. as the major cause of fungal-related morbidity and
mortality has been seen in many institutions (19). In addition, infection with a
wide variety of previously uncommon opportunistic fungal pathogens has been
noted over the last two decades. These emerging pathogens include a number of
septate filamentous fungi such as Fusarium spp. and Scedosporium spp. that may
mimic Aspergillus spp. on microscopic inspection of tissues. Nonseptate fila-
mentous fungal infections with Zygomycetes, previously considered a complica-
tion of uncontrolled diabetes, has been increasing reported in patients with
hematological malignancies or after hematopoietic stem cell transplantation.
Invasive infections with the dematiaceous molds, as well as a variety of yeast
including the Trichosporon spp. have also been reported. It is important to be
familiar with these potential pathogens, as they may have variable sensitivities
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or be frankly resistant to amphotericin B, the newer triazoles, and/or the
echinocandins (20).
Viral infections in patients with hematological disorders are most commonly
the consequence of reactivation of members of the herpesviruses (H. simplex, V.
zoster, CMV, HHV-6, etc.) and will be discussed in a later chapter. Community
respiratory viruses such as influenza, parainfluenza, adenovirus, respiratory
syncytial virus (RSV), and rhinovirus have been reported to cause outbreaks of
infection in highly susceptible patients and must be taken into account when
considering antiviral therapy and infection control practices for a hematology
and/or transplant clinic or ward (21–23). Adenovirus and polyoma type BK virus
have been associated with hemorrhagic cystitis, particularly after hematopoietic
stem cell transplantation. Less common viral pathogens include echovirus,
cocksackie virus, rotavirus, polyoma type JC virus, and parvovirus B19 and
should be considered in the appropriate setting.
3.1. Empirical Treatment
In patients with neutropenia (<500 neutrophils/mm3) and unexplained fever
(38.3°C), broad-spectrum antibiotic treatment should be started without delay.
Although recent studies suggest that patients with fever and neutropenia classi-
fied as “low risk” may be treated with ciprofloxacin and amoxicillin-clavulanate
through the oral route (24,25), most would consider patients with hematological
disorder at “high risk” requiring hospitalization and intravenous antimicrobial
therapy. Historically, the classic therapy to begin with was a combination of an
aminoglycoside with an extended-spectrum penicillin. Extensive clinical trials
and more recent IDSA guidelines, however, suggest the following options:
• Monotherapy with either an extended-spectrum cephalosporin with activity
against P. aeruginosa such as cefepime or ceftazidime.
• Another option for monotherapy is to use a broad-spectrum carbapenem, with
activity against P. aeruginosa , such as imipenem/cilistatin or meropenem.
• Combination therapy may still be used as initial therapy for the febrile neutro-
penic patient. The IDSA recommends the routine addition of an aminoglycoside
when treating with an antipseudomonal penicillin, although there have been
recent data that support the use of piperacillin/tazobactam as a single agent
(4,27). When combination therapy is felt to be indicated, an aminoglycoside plus
either an antipseudomonal penicillin, cephalosporin (cefepime or ceftazidime),
or carbapenem (imipenem/cilistatin or meropenem) is recommended. In pa-
tients with suspected- or proven-resistant Gram-positive bacterial infections,
vancomycin should be combined with any one of cefepime, ceftazidime,
imipenem/cilistatin, meropenem (with or without an aminoglycoside), or an
aminoglycoside plus an antipseudomonal penicillin (Table 1).
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Examples of patients at risk of having resistant Gram-positive infection include
those suspected of catheter infection based on clinical findings, those colonized
with methicillin-resistant S. aureus (MRSA) or penicillin- or cephalosporin-
resistant pneumococci, and those with documented Gram-positive bacteremia
before antimicrobial susceptibility has been defined. Vancomycin should also be
considered as part of early empirical antibacterial therapy in patients with hypo-
tension or cardiovascular instability. Fever and neutropenia should be considered
a dynamic process with continued and ongoing evaluation of the patient. Anti-
microbial therapy should be adjusted based on culture results, the clinical course
of the patient, and persistence of fever.
With persistent or recurrent fever in the neutropenic patient after 3 to 5 d of
broad-spectrum antibacterial coverage without a documented source of infec-
tion, the empirical addition of broad-spectrum antifungal coverage is considered
the standard of care to reduce the risk of morbidity and mortality caused by
invasive mycosis (28). Although overall survival was not improved in the studies
performed at the National Cancer Institute and by the European Organisation for
Research and Treatment of Cancer (EORTC) more than two decades ago, the
incidence of documented invasive fungal infections was significantly reduced
when amphotericin B deoxycholate was empirically added to ongoing antibac-
terial therapy (28,29). Over the last 10 yr, a number of alternative antifungal
agents have been shown to be equally effective yet less toxic as compared with
amphotericin B for empirical therapy of the persistently febrile neutropenic
patient. These include members of the class of lipid formulations of amphotericin
B, extended spectrum triazoles, and the echinocandins (30–34) (Table 2). At-
tempts to make a definitive diagnosis of infection should continue with thorough
examination, cultures, and chest radiography including CT of the lungs with
Table 1
Empirical Treatment of Fever of Unknown Origin in a Neutropenic Patient
A. Single-agent treatment
Extended-spectrum cephalosporin (cefepime or ceftazidime)
Carbapenem (imipenem/cilistatin or meropenem)
B. Combination treatment
Extended-spectrum penicillin + aminoglycoside
Extended-spectrum cephalosporin (cefepime or ceftazidime) + aminoglycoside
Carbapenem (imipenem/cilistatin or meropenem) + aminoglycoside
Extended-spectrum penicillin + aminoglycoides + vancomycin
Extended-spectrum cephalosporin (cefepime or ceftazidime) or carbapenem
(imipenem/cilistatin or meropenem) + vancomycin
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bronchoscopy and BAL if abnormal (8). Serological tests for evidence of inva-
sive fungal infection using galactomannan and β-glucan may be helpful; how-
ever, false-positive and false-negative tests have been noted (9–11).
3.2. Documented Bacterial Infections
Bacterial infections should be treated according to the antibiotic spectrum and
the clinical pattern of sensitivity. A marked increase in antibiotic resistance has
occurred over the last decade. The most common resistant bacteria encountered
in patients with hematological disorders include MRSA, methicillin-resistant
S. epidermidis, vancomycin-resistant enterococcus (VRE), and β-lactamase
producing Gram-negative bacilli (12,13). The National Nosocomial Infections
Surveillance System (NNIS) noted a steady increase in MRSA to more than 50%
of isolates from 300 hospitals reported to the database in 1999 and over 55%
MRSA in 2000 (35,36). Although viridans streptococci are found as part of the
normal microbial flora, they have been isolated as pathogens with increasing
frequency in patients with hematological disorders. Risk factors include severe
neutropenia, mucositis, treatment with high-dose cytosine arabinoside, and
antimicrobial prophylaxis with either a fluoroquinolone or trimethoprim-
sulfamethoxazole. Although most patients respond to therapy, a toxic shock-like
syndrome with hypotension, a maculopapular rash, palmar desquamation, and
ARDS has been reported in as many as 25% of cases (15,37).
The increased use of vancomycin for the treatment of proven or probable
MRSA, viridans streptococci, or for empirical therapy of febrile neutropenic
patients is considered to be one of the major risk factors for the increasing
incidence of VRE seen in the 1990s. Other risk factors noted have been the use
of oral vancomycin for the treatment of C. difficile-related enteritis, use of drugs
with anaerobic activity, gastrointestinal procedures, mucositis, acute renal fail-
Table 2
Empirical Antifungal Therapy for Patients With Persistent Fever and Neutropenia
A. Polyenes
Amphotericin B deoxycholate
Lipid formulations of amphotericin B
Liposomal amphotericin (AmBisome)a, amphotericin B complex (Abelcet)
B. Azoles
Itraconazole (intravenous formulation with cyclodextran)a
Voriconazole (intravenous and oral formulation)
C. Echinocandins
Caspofungina
aApproved for this indication by the Food and Drug Administration.
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ure, glucose intolerance, or diabetes (38–40). Compared with the mean rate of
growth of vancomycin-resistant isolates of enterococci reported to the NNIS
database over the prior 5 yr, the rate of growth between 1998 and 2000 appeared
to be decreasing (35,36,41). It is hoped that this trend will continue as a result of
both better infection control practices and more judicious use of vancomycin.
Newer antimicrobials such as linezolid and quinupristin/dalfopristin have been
developed for the treatment of VRE (42,43). Although the initial experience had
suggested that linezolid might have more hematological side effects (especially
thrombocytopenia) compared with the other antimicrobial agents, recent reports
in both children and adults suggest that the toxicity profile is not worse than that
of vancomycin (44,45). Even with these newer agents, however, resistant organ-
isms have already been reported (46).
Most Gram-negative bacterial isolates from patients with hematological dis-
orders remain sensitive to standard antibacterial agents. Patients will usually
respond to appropriate therapy if there is eventual recovery from immune
dysfunction. As with the Gram-positive bacteria, however, there has been a
gradual increase in isolation of multi-drug resistant Gram-negative organisms
like S. maltophilia (12). These infections usually occur in the most complicated
patients with uncontrolled malignancy, prolonged hospitalization, prolonged
immune suppression, and multiple courses of prior antibiotic therapy.
3.3. Documented Fungal Infections
Oropharyngeal candidiasis is often diagnosed clinically with classical signs of
erythema, white plaques, and ulcers. Presumptive diagnosis of infection with
Candida spp. by inspection only, without examination of wet mount or Gram stain
of exudate material, may not be accurate. Infection with H. simplex, bacterial
infections, and noninfectious causes of mucositis in patients with underlying he-
matological disorders may mimic oral lesions due to Candida spp. Local treatment
can be attempted with nonresorbable antifungal agents (nystatin or clotrimazole),
but if this fails, or if the patient is severely neutropenic, systemic treatment may
be indicated. For patients not already receiving azole prophylaxis, fluconazole is
the most commonly used antifungal agent for the systemic treatment of oropharyn-
geal candidiais. Typically, this infection is due to C. albicans, which is usually
highly susceptible to treatment with fluconazole. In the unusual setting of oropha-
ryngeal infection refractory to systemic therapy with fluconazole, documentation
of persistent or recurrent fungal infection should be attempted. Treatment with a
broader-spectrum antifungal agent that covers the non-albicans species of Can-
dida would then be recommended. Broader-spectrum antifungal drugs would in-
clude amphotericin B, one of its lipid formulations, or an echinocandin. Although
alternative triazole such as itraconazole or voriconazole could be considered, cross
resistance between azoles has been seen among the non-albicans Candida spp.
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Most experts would therefore recommend using either an echinocandin or ampho-
tericin B product in this setting. Esophageal candidiasis is common in patients with
AIDS and hematological neoplasms undergoing chemotherapy. A typical symp-
tom is a burning pain on swallowing. Esophageal candidiasis can also be treated
with local or systemic antifungal therapy. If the patient has already been on
fluconazole prophylaxis, or has failed systemic therapy with fluconazole, the same
attempts to document persistent fungal infection and switch to alternative therapy
with an echinocandin or amphotericin product are recommended.
Deep-seated or invasive candidiasis is a spectrum of infections. It may present
as isolated candidemia, infection of a single organ (endocarditis or endophtalmitis),
orwide-spread disseminated infection involving the liver and spleen (hepatosplenic
candidiasis), kidneys, and/or other organs. Some clinicians will differentiate dis-
seminated candidiasis into acute and chronic forms. Acute disseminated candidi-
asis is a syndrome of acute, life-threatening infection presenting as persistent
fungemia, hypotension, and multi-organ failure in the neutropenic patient. Cu-
taneous and skeletal muscle involvement frequently occurs in the acute form of
invasive candidiasis. In contrast, chronic disseminated candidiasis is established
by hematogenous spread of infection during neutropenia. It is not accompanied
by hypotension and frequently previous blood cultures failed to document
fungemia prior to the patient manifesting signs and symptoms of infection. As
marrow function recovers and neutropenia resolves, radiological manifestations
of chronic infection are seen in the liver and spleen on ultrasound, CT, or most
reliably on magnetic resonance imaging (MRI). The patient may have presented
with persistent or new fevers, but may also have had minimal temperature eleva-
tions with anorexia, weight loss, or failure to thrive along with an isolated increase
in alkaline phosphatase. This clinical presentation warrants further evaluation to
rule out chronic disseminated fungal infection. Although frequently referred to as
“hepatosplenic candidiasis” because of the radiological manifestations in the
liver and spleen, this infection may be widely disseminated involving many other
organs. Confirmation of the diagnosis of fungal infection with biopsy and culture
of liver and/or other accessible lesions should be attempted in order to direct
appropriate therapy. Although most of these infections are caused by Candida
spp. disseminated infection with other bacterial, fungal, or protozoal pathogens
may have similar clinical presentations (47,48).
Disseminated candidiasis requires prompt and aggressive therapy. Sources
for Candida fungemia include not only indwelling central venous catheters, but
also the gastrointestinal tract. The need for routine removal of central venous
silastic catheters (Hickman® and Broviac® [C.R. Bard, Inc.], etc.) for successful
treatment of candidemia has therefore been controversial. Fungemia with certain
species of Candida (e.g., C. parapsilosis) however is clearly felt to be line-
related, necessitating removal of the indwelling catheter. If the catheter is left in
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place and fungemia does not rapidly clear with appropriate antifungal therapy,
the central line will need to be removed promptly. All patients with positive
blood cultures for Candida spp. should be treated with an appropriate course of
antifungal therapy regardless of immune status and whether or not the central line
was removed (49,50).
Isolated candidemia can be successfully treated with 10–14 d of antifungal
therapy after clearing of fungemia. Historically, however, appropriate treatment
for disseminated candidiasis consisted of prolonged treatment with amphotericin
B, possibly combined with flucytosine. Fluconazole is much better tolerated for
longer courses of therapy. The use of this azole has usually been reserved for the
non-neutropenic patient and as follow-up therapy for patients responding to induc-
tion treatment with amphotericin B. Lipid formulations of amphotericin have been
shown to be useful in patients with disseminated disease refractory to treatment
with conventional amphotericin B and fluconazole (47). A recent randomized trial
comparing caspofungin with amphotericin B deoxycholate in the treatment of
invasive candidiasis has shown the echinocandin to be equally efficacious and less
toxic than the polyene in both neutropenic and nonneutropenic hosts (51).
Infection with Aspergillus spp., once the second most-common fungal infec-
tion in immunocompromised hosts, is now the most common cause of mortality
related to invasive fungal infections in the United States (19). More than two
decades ago, Gerson et al. showed that a prolonged severe neutropenia (>2 wk)
led to an exponential rise in risk of invasive pulmonary aspergillosis in a group
of patients with leukemia (52). More recent studies have focused on the risk of
invasive fungal infections in the allogeneic transplant recipient on immunosup-
pressive therapy for GVHD after marrow recovery (15,53). The most common
site of invasive Aspergillus infection is the lungs. Infections can also involve the
sinuses and other organs and expand in a locally destructive fashion. Pulmonary
disease has a characteristic radiological appearance (round mass overlaid by a
crescent of air) (8) and may result in catastrophic bleeding. On CT, a nodular
lesion is typical and has a surrounding “halo” due to bleeding into the tissues.
These lesions will frequently evolve as neutropenia resolves with contraction of
tissue surrounded by a crescent of air (“air  crescent” sign) (see Fig. 3.1A,B).
Although amphotericin B deoxycholate had been the drug of choice for invasive
Aspergillus infections for four decades, overall response to treatment was poor
in patients with underlying hematological disorders with most neutropenic pa-
tients dying of fungal disease (48,53,54). Over the last decade, lipid formulations
of amphotericin B have become available, allowing higher doses of drug to be
delivered safely for longer periods of time (55). Caspofungin was also found to
be active in a retrospective trial of the treatment of invasive aspergillosis in
patients refractory or intolerant to other standard antifungal therapy (mainly
amphotericin B or its lipid formulations). A recent large, multinational, multi-
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Fig. 3.1. Invasive pulmonary aspergillosis (IPA) in a neutropenic patient with acute
myelogenous leukemia. Above, a typical “air halo” can be seen on CT imaging with
surrounding ground glass opacity. The patient was starting on antifungal therapy, recov-
ered his blood counts, and developed an “air crescent” sign (see lower image) 10 d later.
The diagnosis of IPA was confirmed after surgical resection. (Reproduced from ref. 8,
with permission).
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institutional randomized clinical trial has led to a major change in the recom-
mended standard therapy for invasive aspergillosis. In this trial, amphotericin B
deoxycholate was compared prospectively to the newer triazole voriconazole in
patients with proven or probable invasive aspergillosis. This study showed su-
perior response rates and overall outcome in patients who began therapy with
voriconazole as compared with those whose treatment was initiated with ampho-
tericin B deoxycholate. This superior outcome was seen even when taking in to
account a change to other licensed antifungal therapy, which in the case of
amphotericin B deoxycholate, was most commonly a switch to a lipid formula-
tion of amphotericin B because of toxicity. Moreover, the survival benefit with
voriconazole was seen even in the neutropenic patient population and those who
had received a hematopoietic stem cell transplantation (56). Although one must
take into account the increased risk of drug–drug interactions, visual hallucina-
tions, and photosensitivity of the skin not seen with the more narrow-spectrum
agent fluconazole, voriconazole now appears to be the drug of choice for the
treatment of invasive aspergillosis in the immunocompromised host with a he-
matological disorder. Unfortunately, a large proportion of these patients were
still considered nonresponders and no doubt died from complications of invasive
aspergillosis. Although difficult to study in a randomized trial, most experts feel
that surgical debridement, when possible, is beneficial in improving overall
outcome in patients with invasive filamentous fungal infections like Aspergillus
(54,57).
The availability of newer agents with activity against Aspergillus spp. has led
to the consideration of combination therapy for treatment of invasive disease in
the immunocompromised host. A number of in vitro studies, in vivo animal
models, and retrospective clinical reports have suggested the potential benefit of
combination therapy, particularly utilizing a cell wall-active agent such as an
echinocandin with a cell membrane-active drug, either voriconazole or a polyene
(58–64). Marr et al. suggested an improved outcome with the routine addition of
caspofungin to voriconazole in a group of bone marrow transplant recipients
treated for invasive aspergillosis at the Fred Hutchinson Cancer Research Center
in Seattle. Unfortunately, this was not a randomized trial and long-term follow
up of these patients is unknown (65). The continued and increasing importance
of infections with Aspergillus spp. warrant further prospectively controlled trials
of combination therapy.
C. albicans and Aspergillus spp. have accounted for the majority of opportu-
nistic invasive fungal infections in patients with hematological disorders. In
addition to a shift toward the non-albicans Candida spp. and an increase of
Aspergillus spp. as a major cause of morbidity and mortality in many centers, a
wide variety of previously uncommon opportunistic fungal pathogens have been
encountered over the last two decades (19). These emerging pathogens include
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septate filamentous fungi such as Fusarium spp. that may be difficult to distin-
guish from Aspergillus spp. on microscopic inspection of tissues, along with an
expanding group nonseptate Zygomycetes, the dematiaceous molds, as well as a
variety of yeasts including the Trichosporon spp.. The increasing recognition of
these isolates as causes of life-threatening invasive fungal infections in patients
with hematological disorders mandates knowledge of the microbiology, epide-
miology, and options for the prevention and treatment of these previous uncom-
mon opportunistic pathogens (20).
In neutropenic patients with pulmonary infiltrates, the antibiotic treatment
should include other antibiotics in addition to the broad-spectrum coverage
outlined in Table 1. If a Legionella pneumonia is suspected, erythromycin should
be added. The addition of trimethoprim-sulfamethoxazole is indicated if an
infection with P. carinii (see Chapter 18) is suspected. Most patients who
develop pulmonary infiltrates should also receive empirical antifungal treat-
ment. Patients with hematological neoplasms are also at risk of infection with
Mycobacterium tuberculosis and atypical mycobacteriae.
Certain viral pathogens are also responsible for infections in patients with
leukemia, lymphoma, and/or neutropenia. Details about herpesvirus infections
are given in Chapter 18.
4. PROPHYLAXIS OF INFECTIONS
IN NEUTROPENIC PATIENTS
A high standard of personal hygiene is essential for the neutropenic patient.
If prolonged neutropenia (longer than 3–5 d) is expected, the patient should be
housed in private rooms and strict hand washing should be observed. Potential
sources of pathogens (e.g., fresh flowers) should be removed from the patient’s
room. Contact with infected patients should be avoided under all circumstances.
For patients with more prolonged neutropenia, such as recipients of bone marrow
grafts, special measures such as isolation in rooms with positive pressure and
high-efficiency particulate air (HEPA) filtration may reduce the risk of acquisi-
tion of aspergillus spores and the development of subsequent invasive aspergillo-
sis (66). The use of a total protective environment (TPE) with isolation of patients
in a “sterile” room with HEPA filters and laminar air flow, a low-bacteria diet,
topical antiseptics and washings, and the administration of oral nonresorbable
antibiotics (colistin, neomycin, norfloxacin) and antifungal agents (amphoteri-
cin B, nystatin) in these high-risk patients led to the reduction in documented
infections in some prospective randomized clinical trials. Unfortunately, the lack
of a survival advantage has led to the decline in use of TPE in most centers,
although many centers continue to use positive pressure and HEPA filtration.
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Specific antimicrobial prophylaxis has been found to be beneficial in some
settings. Numerous studies have focused on the use of oral absorbable antibiotics
(e.g., trimethoprim-sulfamethoxazole, erythromycin, fluoroquinolones, and oth-
ers). The most commonly used agents utilized for antibacterial prophylaxis are
the extended-spectrum fluoroquinolones. Although they may reduce the fre-
quency of Gram-negative infections, they do not have significant enough activity
to prevent breakthrough infections with Gram-positive organisms and may also
lead to the development of resistant Gram-negative organisms. Oral antibiotics,
therefore, should be reserved for certain high-risk situations. Antifungal prophy-
laxis with fluconazole was shown to be highly effective in prevention of infec-
tions with Candida (mainly albicans species) in bone marrow transplant
recipients in several randomized trials in the 1990s. Recent studies are focusing
on the utility of newer broader-spectrum agents such as voriconazole and
posaconazole in this high-risk group of patients. Unfortunately, like antibacterial
therapy, when an effective therapy for one infection is found (e.g., Aspergillus),
increased or “breakthrough” infection with resistant organisms may be seen
(e.g., Zygomycetes).
Although previously considered a protozoa, P. carinii (also designated as
P. jarvoii), is now classified as a fungus. Trimethoprim-sulfamethoxazole is
active as a prophylaxis of infections with P. carinii. (see Chapter 18). Although
aerosolized treatment with pentamidine and oral dapsone has been used, break-
through infections have been seen. Trimethoprim-sulfamethoxazole therefore
remains the prophylactic agent of choice. Such a prophylaxis is indicated in high-
risk situations (e.g., bone marrow transplants, patients with acute lymphoblastic
leukemia under high-dose steroids).
Antiviral prophylaxis with acyclovir was shown to be extremely effective
in reduction of the morbidity due to mucositis exacerbated by infection with
H. simplex after bone marrow transplant over two decades ago. Although many
centers use acyclovir, valcyclovir, or famciclovir for prophylaxis against infec-
tion with V. zoster virus, the dose of drug needed is higher and the period of time
required for adequate protection is much longer (e.g., 6–12 mo after a hemato-
poietic stem cell transplant) than that needed for prophylaxis against H. simplex.
Many clinicians will, therefore, educate their patients, family members, and
other caregivers regarding the early signs and symptoms of viral infection.
Antiviral treatment for Varicella is then withheld until the earliest signs of infec-
tion are evident. This approach is only effective if therapy is begun within 48–
72 h of the first sign of infection and may serve to reduce the risk of visceral
dissemination, reducing the need for prolonged prophylaxis in high-risk patients.
For CMV infections (see Chapter 18), several drugs are active for prophylaxis
(e.g., ganciclovir, foscarnet, cidofovir), but because of their toxicity profile,
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routine prophylactic use is not indicated. Prospective monitoring of blood for a
positive signal for CMV antigen or by quantitative PCR is now standard of care
for patients at high risk (i.e., allogeneic blood or marrow transplant recipients,
patients receiving therapy with anti-CD52 antibody, etc.) for development of
CMV-related disease (e.g., pneumonitis, hepatitis, cerebritis). Pre-emptive
therapy with either ganciclovir or foscarnet is given in the presence of a positive
signal for CMV to reduce the risk of progression to CMV disease and withheld
in patients with a negative signal in attempt to avoid unwarranted drug toxicity.
Recent and ongoing prophylactic studies of newer oral formulations of antiviral
agents with activity against CMV (e.g., valganciclovir) are promising. The rou-
tine use of hyperimmuneglobulins as a means of antiviral prophylaxis, more
common in past years, has fallen in to disfavor because of costs, toxicities, and
the improvements in the use of pre-emptive antiviral therapy.
Many treatment protocols for hematological malignancies include the use of
hematopoietic growth factors. These factors (granulocyte colony-stimulating
factor [G-CSF], granulocyte/macrophage colony-stimulating factor [GM-CSF],
and others) generally shorten neutropenia by several days. The rationale, dosage,
and side effects of hematopoietic growth factors are discussed in Chapter 2.
5. VENOUS ACCESS
Patients who undergo intensive treatment for hematological malignancies
need multiple transfusions, often parenteral nutrition, antibiotics, cytostatic
drugs, and multiple other drugs. In these patients, a large lumen venous catheter
is indicated. For patients who undergo multiple cycles of chemotherapy (e.g.,
patients with lymphomas) or who will have prolonged cytopenias (e.g., in bone
marrow or stem cell transplantation) or who need prolonged parenteral nutrition,
an implanted catheter system is useful (portacath systems, Hickman or Broviac
multiple lumen systems, and other catheters). These systems are implanted sur-
gically and can stay for several months if necessary. Portacath-type systems need
special needles for access and are recommended for patients who experience
shorter cytopenias or who need long-term parenteral nutrition. Hickman-type
catheters are suited for patients with acute leukemia or who undergo marrow
transplantation. The implanted catheter systems are not free from complications
(total rate 2–5%) including bleeding or pneumothorax at the time of implantation
and thromboses or infections later on.
If a central venous catheter is the source of bacteremia, an attempt can be made
to treat the infection by appropriate antibiotics including vancomycin. If the
fever or the local signs of infection do not regress within 24 h, the catheter should
be replaced. The catheter should be drawn immediately if signs of a tunnel
infection are evident.
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A local thrombus in a central venous catheter can often be reopened by inject-
ing 1–3 mL of a solution containing 3000–5000 U/mL of streptokinase or uroki-
nase. The extravasation of cytostatic drugs through a central venous catheter that
has been correctly positioned is almost impossible. However, if this occurs as a
result of leakage of the catheter, the affected tissue should be infiltrated with 5–
15 mL of isotonic saline solution and the catheter should he removed. Necrotic
tissue should be excised surgically.
6. FURTHER CONSIDERATIONS
All patients with hematological malignancies need an intensive emotional sup-
port. Many patients suffer from anxiety, whereas others develop major depressions
or other affective disorders requiring treatment.
Many patients need analgesia. The side effects of commonly used analgesic
drugs (e.g., respiratory depression with morphine) and drug interactions must be
considered.
Nausea and vomiting are common side effects of many cytostatic drugs and
can be prevented or ameliorated by modern antiemetic therapy. Examples of
effective regimens are given in Table 3; however, they must be modified indi-
vidually. The choice of antiemetic agent depends on the emetogenic potential of
the chemotherapy. Several other emetic drugs have a similar mechanism of
action. The side effects of these antiemetic drugs should be considered.
Ondansetron belongs to the class of 5-hydroxytryptamine antagonists and has
only minor side effects (headaches, slight elevation of transaminases). Palonosetron
(recommended dose 0.25 mg i.v.) is a longer acting 5-hydroxytryptamine antago-
Table 3
Antiemetic Regimen for Chemotherapy in Leukemias and Lymphomas
Regimen Dose
A. Ondansetron + 2 × 8 mg i.v.a
Dexamethasone 10 mg i.v.
B. Ondansetron + 2 × 8 mg i.v.a
Dexamethasone + 5 mg i.v.
Aprepitant 125 mg p.o. d 1, 80 mg d 2, 3
C. Ondansetron 2 × 8 mg i.v.a
D. Metoclopramide ± 3 × 1–2 mg/kgb
Dexamethasone 10 mg i.v.
aFirst dose 1 h before chemotherapy, second and third dose after 4 and 8 h,
intravenously (i.v.) or orally.
bFirst dose 1 h before chemotherapy, second and third dose after 2 and 4 h i.v.
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nist and should be considered in cases of delayed nausea and vomiting. Combi-
nations using aprepitant (a neurokinin-1-receptor antagonist) should be consid-
ered in high-emetogenic chemotherapy; however, the dose of dexamethasone (if
part of the regimen) should be reduced by half (because dexamethasone is elimi-
nated by CYP3A4).
Metoclopramide is an effective antiemetic agent but has troublesome side
effects in 5–20% of patients (extrapyramidal reactions, dystonic reactions, seda-
tion, diarrhea). Steroids are effective in combination regimens of antiemetic
drugs and have few side effects if used on a short-term basis. Other drugs (ben-
zodiazepines, cannabinoids) are also useful and effective in antiemetic combi-
nation treatments.
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1. DEFINITIONS AND INTRODUCTION
Hematopoietic stem cells have two important functions: they give rise to all
blood cell lineages and they also recapitulate themselves. These processes are
thought to occur through asymmetric division, in which one daughter cell is
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identical to the parent and the other daughter is committed to further differentia-
tion into mature blood cells. True hematopoietic stem cells occur rarely in the
bone marrow, they divide infrequently, and the forces that regulate their prolif-
eration and differentiation are incompletely understood. Stem cells are identified
in clinical practice by their expression of the CD34 antigen, which functions as
an adhesion protein to the bone marrow stroma. Although hematopoietic stem
cells express CD34, only a small fraction of CD34+ cells are capable of giving
rise to all peripheral blood cell lineages (pluripotent). The majority of CD34+
cells have limited proliferative capacity, and they have been committed to pro-
duce a restricted spectrum of cells types.
Stem cell transplantation (SCT) is the infusion of hematopoietic progenitor
cells, in numbers adequate to engraft the bone marrow of the recipient, after the
administration of conditioning therapy. The stem cells may be obtained from the
patient (autologous), an identical twin (syngeneic), or an individual of a different
genetic background who has a compatible tissue type (allogeneic). The suitabil-
ity of an allogeneic donor, whether related or unrelated to the patient, is deter-
mined by typing the tissue antigens of the patient and prospective donor. It is
desirable that the tissue antigens, or human leukocyte antigens (HLA), of the
donor and recipient are identical. Donor stem cells can be procured from the bone
marrow, the peripheral blood, or from umbilical cord blood. Currently, stem cells
used to transplant patients with malignant diseases are most frequently procured
from the peripheral blood, whereas those used in patients with bone marrow
failure states and immunodeficiency disorders usually are collected from the
bone marrow. The basic principles of SCT are shown in Fig. 4.1.
2. INDICATIONS FOR SCT
SCT is performed for congenital immunodeficiency and metabolic disorders
(lysosomal storage diseases); bone marrow failure states (aplastic anemia,
myelodysplastic syndrome); sickle cell anemia; hematological malignancies
(leukemias, lymphomas, multiple myeloma); and solid tumors (testicular cancer,
neuroblastoma), for which dose-intensive chemotherapy has greater effective-
ness than standard-dose chemotherapy. Because of the potentially severe toxic-
ity associated with SCT, it is only applied to patients with adequate pulmonary,
renal, hepatic, and cardiac function and performance status. Transplantation
should be delayed in patients with active uncontrolled infection. Patients with a
malignancy are more likely to be cured by SCT if their disease is in remission or
has responded to conventional therapy. The potential for SCT to cure a patient
is low when chemotherapy-refractory malignant disease is present.
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3. SELECTION OF A TRANSPLANT TYPE
The decision regarding the type of transplant for a specific individual is based
on the disease and its remission status, stem cell donor availability, and the age
of the recipient. There are benefits and risks that are unique to the use of autolo-
gous or allogeneic stem cells. Autologous transplants are typically performed
when there is a steep dose–response of the chemotherapy against the malignancy.
In this setting, autologous transplantation is simply a way to rescue the patient
from treatment-related bone marrow toxicity; the stem cell infusion does not
otherwise have therapeutic benefit. The chance of cure following an autologous
transplant is more likely when the patient has had a favorable response to preced-
ing chemotherapy. Patients with treatment-resistant disease are unlikely to be
cured. Autologous transplants are associated with a low risk of treatment-related
mortality (<5%) but a high relapse risk. Because autologous stem cells can be
contaminated by malignant cells, the bone marrow must be adequately free of
disease prior to stem cell collection in order for this approach to be feasible. In
addition, patients who have received extensive prior chemotherapy, especially
alkylating agents, may have reduced stem cell numbers that prevent the collec-
tion of adequate numbers of cells for transplantation. Allogeneic stem cells are
free of disease and have not been adversely affected by prior cytotoxic chemo-
therapy. However, allogeneic transplantation is associated with the risk of graft-
vs-host disease (GVHD), a complication that increases the mortality rate of this
approach. Acute GVHD occurs when the T-lymphocytes present in the stem cell
graft initiate an immune response against host antigens, causing injury to the
Fig. 4.1. The basic principles of stem cell transplantation.
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skin, liver, and/or gastrointestinal tract. Because the risk of GVHD increases
progressively with age, standard allogeneic transplantation is typically limited to
patients who are less than 50 yr of age. Although T-lymphocytes can cause
GVHD, they also can mediate an immune response against the recipient’s malig-
nancy. This phenomenon has been most clearly established as occurring in patients
with myeloid leukemias, especially chronic myelogenous leukemia, and there-
fore it is termed the graft-vs-leukemia (GVL) effect. When allogeneic stem cells
are used, the risk of excess early mortality from acute GVHD may exceed or be
less than the benefit of the GVL effect depending on the patient’s age, disease,
and remission status. Therefore, the choice of allogeneic vs autologous stem cells
for transplantation in any individual is based partly on the expected risk of acute
GVHD vs the potential benefit of a graft-vs-malignancy effect. In addition,
allogeneic stem cells must be used for inherited disorders, immunodefiency
states, bone marrow failure states, and malignant disorders in which autologous
stem cells cannot be harvested or rendered adequately tumor-free.
4. STEM CELL DONOR SELECTION AND EVALUATION
The most important criterion for stem cell donor selection is tissue-type com-
patibility with the recipient. This is evaluated by performing serological testing
of HLA on peripheral blood leukocytes. HLA compatibility between related
individuals typically is determined using antisera against the HLA-A, -B, and -DR
loci. Because each individual has two alleles at each HLA locus, a total of six
antigens are evaluated. Each sibling has a one in four chance of being HLA-
identical with the patient. Parents are unlikely to be more than haplo-identical
with the child. If there is no related donor available, an unrelated donor search
is initiated. The use of unrelated donor stem cells conveys a higher risk of GVHD
and is associated with increased early mortality compared to related donor stem
cells. This increased risk of mortality is approximately an absolute 10% differ-
ence. In evaluating unrelated donors, serological testing is initially used as a
screening test. The antibodies used in the serological assays do not discriminate
perfectly between different HLA antigens at the molecular level. Amino acid
differences can exist between HLA antigens that are found to be the same by
serological testing. Therefore, molecular DNA analyses using PCR are used to
evaluate potential unrelated stem cell donors who are found to be HLA-compat-
ible with the patient by initial serological screening. Ideally, a 10/10 matched
donor is ultimately identified using PCR analysis of HLA-A, -B, -C, -DRB1, and
-DQB1 loci. Of these antigens, the DQB1 locus is least important.
Once a compatible donor is identified, a decision must be made regarding the
type of stem cells that will be collected. For most transplants, stem cells collected
from the peripheral blood are preferred over those collected from the bone mar-
Chapter 4 / Transplantation of Stem Cells 67
row. This is because the collection of peripheral blood stem cells (PBSCs) is
better tolerated by the donor (see “Stem Cell Collection” below) than bone
marrow collection. In addition, PBSCs produce survival superior to that of bone
marrow in the allogeneic transplant setting. This is because PBSCs engraft 3–5
d sooner than bone marrow (reducing the risk of serious infection), and they
decrease the risk of disease relapse. PBSCs contain, on average, 10-fold more T-
lymphocytes than bone marrow, which are capable of mediating a GVL effect.
Bone marrow collection may be necessary when young children are donors
because their blood volume is too small to permit the use of the apheresis ma-
chine to collect PBSCs.
All stem cell donors are screened to ensure that they will tolerate the collection
procedure and that they are not at risk for transmitting disease to the recipient.
Laboratory tests are performed to exclude infection by hepatitis viruses, human
T-cell leukemia virus type 1 or 2, or HIV. Bone marrow donors usually donate
1–2 units of blood prior to the procedure, depending on the volume of marrow
that will be collected, for reinfusion following the harvest if required for anemia.
This is not required prior to PBSC donation.
In the United States, the National Marrow Donor Program (NMDP) maintains
a registry of approx 5 million volunteer donors. The NMDP also facilitates
international and cord blood bank searches. The NMDP has data on the ethnicity
of stem cell donors, and performs outcomes analysis. The success rates of finding
a matched donor depend on ethnicity of a patient, being at present highest in
Caucasians and Asian-Americans.
5. UMBILICAL CORD BLOOD STEM CELLS
Blood obtained from the umbilical cord at the time of delivery contains a high
concentration of hematopoietic stem cells, and it can be used for transplantation.
A number of umbilical cord blood (UCB) banks have been established that
provide cord blood units for transplantation to unrelated recipients. UCB stem
cells are more primitive than those from bone marrow and peripheral blood and
the total numbers of cells that can be obtained is low. Therefore, engraftment
following transplantation of UCB cells typically is slower than when another
source of stem cells is used. The minimum number of UCB stem cells required
for engraftment is approx 10% of the number of PBSCs. Nevertheless, the prin-
cipal limitation of the use of UCB is the low number of stem cells available from
a typical collection, and therefore UCB transplants are predominantly performed
in children. One potential advantage of UCB is that the T-lymphocytes in the
graft are relatively naive. This appears to lessen the risk of GVHD and permits
the use of UCB stem cells in patients with a greater degree of HLA disparity than
is tolerated using bone marrow or peripheral blood as a source of stem cells. Up
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to two antigen mismatches are acceptable when selecting an UCB unit for
transplantation, although the survival of recipients of 4/6 HLA-matched units is
inferior to that of recipients of 5/6 or 6/6 matched units. Additional advantages of
this cell source are its ready availability and lack of inconvenience to the donor.
Disadvantages include the limited stem cell dose causing delayed hematopoietic
recovery, and inability to obtain additional cells from the donor in the event of
graft failure or disease relapse. Retrospective studies have demonstrated similar
survival results for recipients of unrelated bone marrow and UCB. Therefore, a
number of variables including UCB cell dose, degree of HLA disparity between
donor and recipient, and the disease to be transplanted, all may play a role in
deciding between UCB, peripheral blood, and bone marrow as a stem cell source.
6. STEM CELL COLLECTION
Hematopoietic stem cells normally reside in the bone marrow. As a result,
bone marrow harvesting has been a reliable method to obtain stem cells for
transplantation. The bone marrow donor receives spinal, epidural, or general
anesthesia in the operating room and is positioned in the prone position. The skin
over the iliac crests is cleansed with betadine and iodophor, then covered with
sterile drapes. The bone marrow is withdrawn by repeatedly inserting a trochar
into the marrow space of the iliac crest, aspirating 3–5 mL of bone marrow into
a heparinized syringe, removing the trochar and ejecting the marrow into a bag
containing heparinized media. The adequacy of the collection is usually checked
approximately midway though the procedure by performing a mononuclear cell
(MNC) count. An adequate bone marrow collection should contain at least 3 ×
108 MNCs/kg of recipient weight. Bone marrow collection continues until the
target MNC count is reached. Once the collection is completed, the bone marrow
is filtered to remove bone fragments and clots.
Stem cells occur infrequently in the peripheral blood but, following recovery
from chemotherapy or after adminstration of several hematopoietic growth fac-
tors, they can be induced to enter the circulation. Stem cell mobilization in
normal donors is usually performed by administering granulocyte colony-stimu-
lating factor (G-CSF) 10 µg/kg by subcutaneous injection daily until collection
is complete. PBSCs also can be mobilized using granulocyte/macrophage colony-
stimulating factor (GM-CSF). In patients with malignant conditions chemo-
therapy is often given, followed by the daily administration of growth factors, to
mobilize PBSCs as the neutrophil count recovers. PBSC collection usually be-
gins 5 d after the start of hematopoietic growth factor administration when growth
factors alone are used. In patients who have stem cells mobilized with growth
factors following chemotherapy, collections may be initiated when the number
of CD34+ cells in the peripheral blood reaches the threshold established at each
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institution. Harvesting of the stem cells is performed using apheresis, a proce-
dure in which a machine continuously withdraws blood from one vein of the
donor, removes the MNC fraction by centrifugation, and returns the remainder
of the blood through another venous access. The blood is anticoagulated during
this procedure with the use of sodium citrate. The cell product obtained in this
manner contains predominantly immature granulocytes, lymphocytes, and mono-
cytes; immature hematopoietic progenitor cells including stem cells usually
comprise less than 1% of the total cells. The adequacy of stem cell collection
can be assessed by analyzing the percentage of cells expressing the CD34
antigen. The number of CD34+ cells administered following myeloablative
therapy correlates with the time to engraftment of neutrophils and platelets. The
minimum threshold of CD34+ cells required for stable engraftment is approx 106
cells/kg. The number of stem cells collected for transplantation usually ranges
within 2–5 × 106 CD34+ cells/kg.
UCB is collected after the baby is delivered and the cord has been clamped.
If the placenta has been delivered, it is held up by a clamp with the umbilical cord
hanging down. The cord is cleaned with alcohol and the umbilical vein is can-
nulated with a large needle connected to a bag containing anticoagulant. The
blood is collected by gravity drainage. The volume of the cord blood is measured
and a MNC count is performed to ensure that a minimum threshold of acceptabil-
ity is reached. If so, samples are removed for infectious disease and sterility
testing, CD34 cell quantitation, HLA typing, and if appropriate, hemoglobinopa-
thy testing. Approximately 1.8 × 108 MNCs/kg or 1.7 × 105 CD34+ cells/kg is
considered adequate for transplantation.
7. CONDITIONING THERAPY
The conditioning therapy administered prior to SCT can be used for two
potential purposes: in patients with a malignant disorder, it reduces the tumor
burden to the minimum possible level, and in patients who are receiving stem
cells from a related or unrelated donor, it also suppresses the host immune system
and allows engraftment to occur. Conditioning therapy may consist of radia-
tion and chemotherapy or chemotherapy alone. The chemotherapeutic agents
employed to condition patients with malignancies may be disease-specific. The
drugs are selected to avoid agents used earlier in the course of treatment, to which
the malignancy may have developed resistance. In addition, the conditioning
therapies are chosen such that their primary toxicities are hematological and their
nonhematological toxicities do not overlap, in order to prevent injury to organs
other than the bone marrow.
Recently, nonmyeloablative conditioning regimens, using immunosuppressive
chemotherapies such as cyclophosphamide and fludarabine, have been investi-
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gated as an approach to SCT. Because the GVL effect is critical to the cure of
several malignancies following allogeneic BMT, the nonmyeloablative approach
uses less-toxic doses of chemotherapy to permit engraftment of the donor
immune system. The efficacy of this approach relies on the potential ability of
the transplanted immune system to eradicate the recipient’s malignancy. The
reduced intensity of the conditioning regimen reduces the incidence and severity
of acute GVHD. Therefore, nonmyeloablative transplants have been favored in
patients with advanced age (>50 yr), those who had undergone a prior autologous
transplant with full intensity conditioning, and those with slow-growing tumors
for whom dose-intense chemotherapy is not curative (low-grade lymphomas).
Although the risk of acute GVHD is diminished, chronic GVHD remains a
significant cause of mortality for patients undergoing nonmyeloablative trans-
plantation. Although the results are encouraging in some settings, clinical indi-
cations for this approach have not been firmly established.
8. BLOOD PRODUCT ADMINISTRATION
Several unique precautions must be taken when transfusing blood products
into SCT recipients (see Table 1). These precautions include prophylactic trans-
fusion of blood products, irradiation of all blood products, administration of
cytomegalovirus (CMV)-seronegative blood products to seronegative allogeneic
transplant recipients, and avoidance of allosensitization.
Patients with SCT experience pancytopenia following conditioning therapy
and before marrow recovery. During this time period, transfusion support is
required to prevent symptomatic anemia and life-threatening thrombocytopenia.
Packed red blood cells typically are transfused prophylactically when the hemo-
globin falls below 9 g/dL. Platelet transfusions are administered when the plate-
let count is below 10,000/µL in stable patients, or below 20,000/µL in febrile
patients. Platelet transfusion is indicated for platelet count <50,000/µL in the
setting of active bleeding or head trauma. A single donor platelet unit (one apheresis
pack) is preferred over the use of random donor platelets (10 units) for transplant
patients to minimize the risk of allosensitization (discussed later).
Because SCT recipients are profoundly immunosuppressed by the condition-
ing therapy, they are at risk for the development of GVHD (see Subheading 11)
from lymphocytes present in blood products. Irradiation prevents the lympho-
cytes from proliferating in response to host antigens and eliminates the risk of
transfusion-related GVHD.
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CMV can produce life-threatening pneumonia, hepatitis, or colitis in allo-
geneic transplant recipients (see “Prevention and Treatment of Posttransplant
Infections”). Patients who have not been exposed to CMV should receive blood
products only from donors who are seronegative for CMV. Leukocyte reduction
of blood products using a filter has been shown to reduce the risk of transmitting
CMV. Whether or not leukocyte-reduced blood products can substitute for CMV-
negative ones is controversial.
Allosensitization, the development of immunity to HLA, must be avoided for
two reasons: it can cause patients to become refractory to platelet transfusions
and it can increase the risk of graft rejection in patients receiving allogeneic
transplants. Because HLA are expressed on platelets, the development of
humoral immunity to a wide variety of HLA can lead to rapid clearance of
transfused platelets and difficulty in maintaining adequate platelet levels
posttransplant. Reduction of leukocytes (which also express HLA) from blood
products has been shown to reduce the risk of allosensitization. Therefore, recipi-
ents of SCT should all receive leukocyte-reduced blood products. In addition,
whenever possible, platelet products should be obtained from a single donor by
apheresis, rather than by pooling platelet products from several different donors.
Platelet-refractory patients may require transfusions of platelets from HLA-
matched donors. Allosensitization that occurs prior to transplant conditioning
also can increase the risk of graft rejection, particularly in patients who receive
less-aggressive conditioning regimens for nonmalignant diseases. Candidates
for allogeneic SCT should never receive blood product transfusions from family
Table 1
Guidelines for Blood Product Transfusion in Stem Cell Transplant Patients
Prophylactically transfuse platelets for platelet count less than 10,000/µL in stable
patients or less than 20,000/µL in febrile patients.
Use single-donor platelets rather than random donor platelets.
Irradiate all blood products.
Leukocyte reduce all blood products.
Use only cytomegalovirus (CMV)-negative blood products for CMV seronegative
allogeneic stem cell transplant patients.
Do not transfuse prospective allogeneic stem cell transplant recipients with blood
products from family members prior to transplantation.
Minimize all transfusions in aplastic anemia patients prior to transplantation.
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members prior to transplantation in order to minimize the risk of graft rejection.
In addition, every effort should be made to minimize blood product transfusions
prior to transplantation in aplastic anemia patients, who typically receive rela-
tively mild conditioning therapy.
9. PREVENTION AND TREATMENT
OF POSTTRANSPLANT INFECTIONS
The profound neutropenia that occurs following the administration of
myeloablative therapy subjects transplant recipients to a risk of developing
serious bacterial or fungal infections. (Neutropenia is defined here as an absolute
neutrophil count of less than 500/µL.) Because many infections that occur during
the neutropenic period originate from the gastrointestinal tract, prophylactic “gut
sterilizers” have traditionally been used in an attempt to reduce this problem. A
poorly absorbed antibiotic such as norfloxacin (400 mg by mouth twice daily),
and the oral antifungal agents nystatin (1 million units orally four times daily)
and clotrimazole (10 mg troche dissolved in mouth four times daily) are used in
many centers to prevent infections. In recipients of allogeneic transplants,
itraconazole has been demonstrated to significantly reduce the risk of invasive
fungal infections compared with fluconazole. The dose of itraconazole is 200 mg
i.v. every 12 h for 2 d followed by 200 mg every 24 h from d 1 to d 100
posttransplant. Itraconazole suspension 200 mg p.o. every 12 h can be substituted
for the injection if there is no malabsorption due to GVHD, but the capsule
formulation is too poorly absorbed to be effective. Continuation of itraconazole
should be considered if steroids are continued beyond 100 d posttransplant.
Itraconazole affects cyclophosphamide metabolism, so these drugs should not be
given concurrently.
The initial neutropenic fever that occurs in a transplant patient must be treated
rapidly and empirically. In the absence of an obvious source, after appropriate
cultures are obtained, intravenous antibiotics that have activity against a broad
spectrum of Gram-negative bacilli, Gram-positive cocci, and anaerobic organ-
isms should be administered as quickly as possible. Potential regimens are listed
in Table 2. Antimicrobial therapy subsequently can be modified if cultures dem-
onstrate the etiology of the infection. If fevers persist in spite of antibiotics and
without a source, empiric antifungal therapy may be initiated, especially if a
prolonged period of neutropenia is anticipated. In allogeneic transplant patients,
an azole antifungal agent with activity against Aspergillus is appropriate, includ-
ing itraconazole or voriconazole (Table 3). Alternatively, amphotericin B may
be initiated empirically at a dose of 0.5 mg/kg/d, but full treatment doses (1 mg/
kg/d) are required if fungal infection is documented. Patients usually are not at
high risk for Aspergillus infection and therefore can be treated with empiric
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Table 2
Empiric Antibiotic Regimens for Treatment of Febrile Neutropenia
in Adult Transplant Patients
1. Imipenem 500 mg i.v. every 6 h
2. Ceftazidime 1 g i.v. every 8 h, alone or with Vancomycin 1 g i.v. every 12 h
3. Aminoglycoside (with activity against local Pseudomonas), and Ceftazidime 1 g
i.v. every 8 h, or Piperacillin 3 g i.v. every 4 h
4.* Ciprofloxacin 400 mg i.v. every 12 h, or Aztreonam 2 g every 6–8 h, and Vanco-
mycin 1 g i.v. every 12 h
*Acceptable for use in most patients with demonstrated penicillin allergy.
Table 3
Empiric Antifungal Agents for Treatment of Febrile Neutropenia
in Adult Transplant Patients
Allogeneic Transplant Patients
1. Voriconazole 6 mg/kg i.v. every 12 h 24 h, then 4 mg/kg every 12 h
2. Itraconazole 200 mg i.v. every 12 h 48 h, then 200 mg every 24 h
3. Amphotericin B
Empiric therapy: 0.5 mg/kg i.v. qd
Treatment of documented infection: 1 mg/kg i.v. qd
Autologous Transplant Patients
1. Fluconazole 400 mg i.v. qd
fluconazole. Antimicrobial coverage usually can be discontinued after neutro-
penia resolves (absolute neutrophil count >500/µL) when it is applied empiri-
cally, but a full treatment course is required if a source of infection is identified.
Pneumocystis pneumonia was a major problem following allogeneic bone
marrow transplantation (BMT) prior to the routine use of prophylactic measures.
Patients now are given trimethoprim/sulfamethoxazole (TMP/SMX; 160 mg/
800 mg) three times daily for approx 7 d prior to transplantation, stopping 2 d
before stem cell infusion. Following marrow recovery, TMP/SMX is adminis-
tered three times daily with leucovorin 5 mg daily on 2 d per week. Pneumocystis
prophylaxis is continued until the patient has discontinued all immunosuppres-
sive therapy. Dapsone (100 mg daily) can be substituted for TMP/SMX in sulfa
allergic patients.
Patients who are seropositive for CMV are at risk for reactivation of this virus
and development of hepatitis, colitis, or a highly fatal interstitial pneumonitis
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following allogeneic BMT. Prophylactic therapy has markedly reduced the
incidence of CMV infection. Patients seropositive for CMV can be treated pro-
phylactically with ganciclovir 5 mg/kg/d for approx 1 wk prior to transplantation,
stopping 2 d before stem cell infusion. After the neutrophil count rises above
1000/µL, ganciclovir may be resumed at a dose of 6 mg/kg/d on the 5 d of the
week that the TMP/SMX is not given, and it is continued until 100 d posttrans-
plant. Because ganciclovir is myelosuppressive, blood counts must be monitored
in order to reduce or temporarily discontinue drug therapy if neutropenia devel-
ops. Dose adjustment is also required for renal insufficiency (creatinine clear-
ance <80 mL/min). An alternative strategy is to monitor the blood weekly for
CMV reactivation using a quantitative assay, and treat only patients who develop
viremia. Patients who are CMV seronegative do not require ganciclovir but
should be given blood products only from CMV-seronegative donors. It is con-
troversial whether the use of leukocyte-reduced blood products can replace CMV-
negative products for these patients. Seronegative patients who receive stem
cells from a seropositive donor rarely develop CMV infection and therefore do
not benefit from prophylactic ganciclovir.
Varicella zoster and Herpes simplex viruses (HSV) also are commonly reac-
tivated following SCT. Patients with a history of recurrent oral or genital HSV
lesions prior to transplantation may benefit from the prophylactic administration
of acyclovir (400 mg orally twice daily) during the posttransplant period. Oral
mucosal herpetic lesions occur commonly after high-dose chemotherapy and the
resultant mucositis can cause substantial morbidity. Direct fluorescent antigen
testing for HSV permits rapid identification of this infection. Treatment consists
of acyclovir 5 mg/kg i.v. every 8 h. Patients who undergo allogeneic or unrelated
SCT and who develop cutaneous zoster lesions are at risk for secondary dissemi-
nation. Pulmonary involvement that develops in this setting can be fatal. There-
fore, patients with zoster limited to a single dermatome should be treated with
intravenous acyclovir 10 mg/kg every 8 h, to prevent secondary spread, until
crusting of the lesions has occurred, then the acyclovir can be given orally. More
prolonged intravenous treatment is required in the setting of disseminated zoster.
10. GRAFT FAILURE
Graft failure is defined as pancytopenia and a severely hypocellular bone
marrow that persists beyond approx 21 d following PBSC transplant or 28 d after
a BMT. Risk factors for graft failure in patients receiving autografts include the
administration of inadequate numbers of stem cells, poor graft quality due to
extensive prior treatment of the patient with alkylating agents, or extensively
manipulation of the graft (i.e., if it has been treated with cytotoxic agents for the
purpose of purging tumor cells). Patients receiving allografts are at increased risk
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of graft failure if they have had extensive prior allosensitization from blood
products, if the conditioning therapy was inadequate to eliminate the recipient
immune system, if they have HLA incompatibility with the donor, if the graft has
been depleted of T-lymphocytes, or if the stem cell dose is inadequate. Admin-
istration of myelosuppressive medications (e.g., methotrexate) to the patient
after stem cell infusion can delay engraftment and increase the risk of graft
failure. Persistent or recurrent malignancy in the bone marrow also can cause
prolonged pancytopenia posttransplant. The diagnosis of graft failure is made by
performing a bone marrow biopsy, and in the setting of allogeneic transplanta-
tion, testing the bone marrow for the presence of donor cells by performing
restriction fragment length polymorphism (RFLP) analysis. Cytogenetic analy-
sis on the bone marrow is performed if the patient had a malignancy with a known
chromosomal abnormality. Treatment with myeloid growth factors such as G-
CSF (5–10 µg/kg/d) or GM-CSF (250 µg/m2/d) may be useful in this setting. In
addition, every effort should be made to obtain additional stem cells from the
donor for treatment of graft failure in allotransplant patients. Additional immu-
nosuppressive therapy usually is given prior to a second stem cell infusion in
these patients to minimize the risk of repeat graft rejection.
11. GRAFT-VS-HOST DISEASE
Patients who receive allogeneic or unrelated stem cells can develop GVHD.
Risk factors for this complication include older age of the recipient, HLA mis-
match between the donor and recipient, use of an unrelated donor, use of a parous
female donor, and increased numbers of T-lymphocytes in the graft.
The syndrome of GVHD is divided into an acute phase that is defined to occur
within the first 100 d posttransplant, and the subsequent chronic phase. This
acute disease may involve the skin, gastrointestinal tract, and liver. Skin involve-
ment usually develops first and is manifested as palmar, plantar, and auricular
erythema. Acute skin GVHD may evolve into a diffuse erythematous maculo-
papular rash. When skin involvement is severe, bullae and desquamation develop.
Acute liver involvement is initially manifested as an asymptomatic rise in the
conjugated bilirubin level, with more minor elevations of the serum alkaline
phosphatase and transaminase levels. Synthetic function of the liver is initially
preserved, but severe disease may progress to liver failure and hepatic encepha-
lopathy. Gastrointestinal GVHD is characterized by diarrhea that may become
voluminous. Severe enteric involvement is characterized by shedding of the
colonic mucosa, bleeding, ileus with bowel distension, and potential perforation.
Involvement of the upper gastrointestinal tract is manifested by oral mucositis,
esophagitis, or gastritis. Patients may experience protracted anorexia, nausea,
and vomiting. The grading of acute GVHD is shown in Table 4
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Chronic GVHD is defined to begin at least 100 d after transplantation, but it
usually evolves gradually from acute GVHD. Risk factors include previous acute
GVHD, older age of the recipient, use of an unrelated or mismatched donor, and
infusion of high numbers of T-lymphocytes with the graft. Skin involvement is
characterized by a thin epidermis that ulcerates easily, or by lichenified plaques.
In contrast, the dermis becomes firm, and joint contractures may develop. Hyper-
pigmentation usually is present, but vitiligo also may occur. Dermal structures
including hair, sweat glands, and nails may be lost. Xerophthalmia causes a gritty
sensation in the eyes, and xerostomia may cause dysphagia. Chronic GVHD of
the gastrointestinal tract may manifest as oral mucositis, esophageal webs, or
malabsorption. White plaques or reticulations may be present on the buccal
mucosa. When chronic liver GHVD occurs, the alkaline phosphatase typically
is the most elevated laboratory test, the transaminases are affected to an interme-
diate degree, and bilirubin is the least abnormal. Pulmonary involvement can
present as bronchiolitis obliterans. Patients with chronic GVHD have impaired
immunological reconstitution and are at increased risk of developing opportunis-
tic infections.
The diagnosis of acute skin GVHD can usually by made clinically, but liver
or gut involvement is best established by biopsy because other posttransplant
complications, especially infections, can mimic these conditions. Histopathol-
ogy of the skin reveals vacuolization of the dermal–epidermal junction, and
lymphocytic infiltration into the epidermis and perivascular region. Liver involve-
ment is manifested by destruction of epithelial cells lining the interlobular bile
ducts and portal lymphocytic infiltration. Colonic or rectal biopsy characteristi-
cally reveals vacuolization of single crypt cells (“exploding crypt cells”).
Prophylaxis against acute GVHD is tailored to patient risk factors. Patients at
high risk for acute GVHD, such as patients older than 40 yr and those receiving
mismatched or unrelated grafts may receive methotrexate. Patients with chronic
myelogenous leukemia may also receive this drug because of data demonstrating
Table 4
Staging of Acute GVHD
Stage Skin Liver (bilirubin) Gut (diarrhea)
I Rash <25% BSA 2–3.5 mg/dL 0.5–1.0 L/d
II Rash 25–50% BSA 3.5–8 mg/dL 1.0–1.5 L/d
III Erythroderma 8–15 mg/dL 1.5–2.5 L/d
IV Desquamation  >15 mg/dL  >2.5 L/d
BSA, body surface area
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that it improves survival. A common regimen is to administer methotrexate 15
mg/m2 on day 1, and 10 mg/m2 on days 3 and 6 following the transplant. Meth-
otrexate acts by killing T-lymphocytes from the graft that are proliferating in
response to recipient antigens. Most patients receive cyclosporine or tacrolimus
prophylactically. These drugs inhibit T-lymphocyte activation by interfering
with interleukin-2 production. Cyclosporine or tacrolimus are typically contin-
ued for at least 6 mo posttransplant, during which time blood levels and renal and
hepatic function are monitored to avoid drug toxicity. Mycophenolate mofetil may
be combined with cyclosporine in high-risk patients. It is converted to
mycophenolic acid, which blocks inosine monophosphate dehydrogenase-medi-
ated guanosine nucleoside synthesis, thus inhibiting the proliferation of B- and
T-lymphocytes. Intravenous immunoglobulin can be used to prevent CMV in-
fection but it also decreases the risk of GVHD. It usually is infused weekly at
doses of 0.5 g/kg until 100 d posttransplant. Glucocorticoids may be used to
prevent GVHD in high-risk patients but this treatment does not improve survival.
Depletion of T-lymphocytes from the graft effectively diminishes the risk of
death due to acute GVHD, but this benefit is offset by an increased risk of death
from disease relapse, as a result of a loss of the GVL effect, and from a higher
incidence of graft rejection.
Treatment of acute GVHD consists primarily of glucocorticoid administra-
tion. Initially, 1–2 mg/kg/d of methylprednisolone, or its equivalent, is given
intravenously. If there is no response or the acute GVHD is severe, much higher
methylprednisolone doses, up to 1 gm/d for 3 d, may be administered. When gut
GVHD is present, cyclosporine should be given intravenously because absorp-
tion is unreliable when given by mouth. Other immunosuppressive drugs with
complementary mechanisms of action such as mycophenolate mofetil or
sirolimus can be added to the immunsuppressive regimen. Antithymocyte globu-
lin can be used (15–20 mg/kg/d for 4–5 d) for severe acute GVHD, but its impact
on outcome has not been studied in a randomized, controlled trial. Symptomatic
treatment for severe diarrhea should be instituted only after potential infectious
etiologies (enteric pathogens, parasites, or Clostridium difficile) have been
excluded. Thereafter, tincture of opium frequently is useful in reducing the
volume of diarrhea. The somatostatin analog, octreotide acetate, beginning at
200 µg/d i.v. in two to four divided doses may be useful in some patients. Limited
clinical data suggest that ursodeoxycholic acid 10–15 mg/kg/d may be useful in
treating GVHD involving the liver. Isolated severe skin GVHD can be treated
with topical steroids.
Chronic GVHD is generally less responsive to immunosuppressive medica-
tions than the acute form of the disease. The value of glucocorticoids for the
treatment of chronic GVHD is unproven and they increase the risk of infection
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in this susceptible population. Many treatments have been tried, but none are
consistently effective.
12. POSTTRANSPLANT PNEUMONIA
The profound immunosuppression of patients undergoing SCT, especially
recipients of allogeneic and unrelated stem cells, places them at risk of develop-
ing pneumonia as a result of a wide variety of pathogens. Many of these organ-
isms usually cause self-limited or mild disease in immunocompetent individuals.
The large number of potential pathogens makes the choice of empiric therapy
difficult, and rapid disease progression can occur when inadequate treatment is
rendered. Therefore, establishment of a specific etiological diagnosis often is
critical in the management of posttransplant pneumonia.
The approach to a patient with a posttransplant pneumonia depends on the
clinical setting. Patients who are noted to have a localized pneumonia prior to
receiving antibiotics may be adequately treated with empiric broad-spectrum
antibiotics (Table 2) after appropriate sputum and blood cultures have been
obtained. However, patients who develop a diffuse or interstitial pneumonia, or
those who develop pneumonia while receiving broad-spectrum antibiotics should
be evaluated by bronchoscopy. Bronchoalveolar lavage and transbronchial biopsy
should be performed. Specimens should be sent for appropriate diagnostic stud-
ies, some of which are listed in Table 5. While awaiting the test results, consid-
eration should be given to treating patients empirically for all possible infectious
entities. Rapid clinical deterioration often can occur in the absence of appropriate
therapy. Once the results of the diagnostic studies are available, the antimicrobial
regimen can be simplified. If the bronchoscopic studies are nondiagnostic and
the pneumonia is progressing in spite of empiric therapy, thoracoscopic or open
lung biopsy should be considered.
Prophylaxis against P. carinii should be administered to all recipients of allo-
geneic or unrelated stem cell transplants, as outlined in “Prevention and Treatment
of Posttransplant Infections.” This infection rarely occurs in patients who receive
appropriate prophylaxis. Treatment of P. pneumonia consists of TMP/SMX at
15–20 mg/kg/d i.v. (of TMP) divided into three to four doses. Patients allergic
to sulfa drugs can receive pentamidine 4 mg/kg/d i.v.
Aspergillus spp. are the most common fungal cause of invasive pulmonary
infections. Voriconazole and amphotericin B are equally effective at treating
pulmonary aspergillosis, but voriconazole does not cause renal insufficiency and
is better tolerated. Voriconazole is administered intravenously as a loading dose
of 6 mg/kg every 12 h for the first 24 h, then 4 mg/kg every 12 h. Amphotericin
B is given intravenously at a dose of 1 mg/kg/d i.v. for adults and 2 mg/kg/d for
children. Liposomal amphotericin B can be considered for patients who develop
renal insufficiency. Caspofungin can effectively treat some cases of refractory
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Table 5
Causes of Pneumonia After Stem Cell Transplantation
Etiological agents Diagnostic tests
Bacterial
Legionella species DFA, urine RIA, culture
Mycobacteria species Acid fast stain, culture
Nocardia species Acid fast stain, culture
Routine bacterial pathogens Gram stain, bacterial culture
Fungal
Pneumocystis carinii DFA
Aspergillus spp. Fungal stain, culture
Candida spp. Fungal stain, culture
Coccidioides immitis Fungal stain, culture
Histoplasma capsulatum Fungal stain, culture
Cryptococcus neoformans Fungal stain, culture
Mucor, Rhizopus, or Fusarium spp. Fungal stain, culture
Viral
Cytomegalovirus Q-PCR, culture, histopathology
Herpes simplex virus DFA, culture
Varicella zoster virus DFA, culture
Adenovirus IFA, culture
Respiratory syncytial virus DFA, culture
Influenza viruses IFA, culture
Parainfluenza IFA, culture
Other organisms
Mycoplasma pneumoniae PCR, culture, serologies
Chlamydia pneumoniae DFA, culture
Diffuse alveolar hemorrhage
Therapy-related toxicity
Conditioning chemotherapy Diagnoses of exclusion
Carmustine
Cyclophosphamide
Melphalan
Radiation therapy
Recurrent malignancy (lymphangitic) Histopathology
RIA, radioimmunoassay; DFA, direct fluorescent antibody; IFA, indirect fluorescent assay;
Q-PCR, quantitative PCR.
aspergillosis infection, but it has not been compared with voriconazole or am-
photericin B as initial therapy. It is administered intravenously as a 70 mg dose
on the first day, followed by 50 mg daily.
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CMV pneumonia can be effectively prevented in seropositive allogeneic and
unrelated SCT patients with prophylactic gancyclovir, as described in “Preven-
tion and Treatment of Posttransplant Infections.” Seronegative patients should
receive only CMV-negative blood products to prevent infection. CMV pneumo-
nia rarely occurs in recipients of autologous SCT. Treatment requires the admin-
istration of gancyclovir 2.5 mg/kg every 8 h for 20 d and intravenous
immunoglobulin 0.5 g/kg every other day for 10 doses.
HSV or V. zoster pneumonia is treated with acyclovir 10–12 mg/kg every 8 h.
Dose reduction may be required if renal insufficiency is present.
Pneumonia caused by common viral pathogens including adenovirus, influ-
enza, parainfluenza, and respiratory syncytial virus (RSV) can be fatal in recipi-
ents of SCT. Therefore, family members or health care workers who have any
viral illness should not be permitted in the rooms of patients undergoing SCT. No
therapy appears to be effective against these viruses once pneumonia is diag-
nosed. The value of surveillance cultures or prophylactic antiviral therapy have
not been adequately studied in the transplant population. Recently, RSV infec-
tion of the upper respiratory tract detected by surveillance culture was effectively
treated with aerosolized ribavirin 20 mg/mL administered 18 h/d with intrave-
nous immunoglobulin 0.5 g/kg every other day. Established RSV pneumonia
was not successfully treated with this regimen. Ribavirin is teratogenic, an irri-
tant, and is difficult to administer safely. Therefore, aerosolized ribavirin should
only be used in hospitals that have established adequate safety practices to pro-
tect health care workers from toxicity of the drug. A new intravenous formulation
of ribavirin may improve its safety profile.
Pneumonia due to therapy-related toxicity typically responds to glucocorti-
coid administration. Diffuse alveolar hemorrhage that occurs following autolo-
gous SCT also may be therapy-related and requires prompt treatment with
glucocorticoids. An infectious etiology should be carefully excluded prior to
initiating treatment for either of these problems.
13. HEPATIC VENO-OCCLUSIVE DISEASE
Hepatic veno-occlusive disease (VOD) is a disorder characterized by hyper-
bilirubinemia, hepatomegaly, and ascites that results from blockage of hepatic
venules. It is caused by vascular endothelial injury from conditioning chemo-
therapy and/or radiation. The best-established risk factor is antecedent liver
disease or hepatitis. Specific conditioning regimens have not been associated
with increased risk of VOD but prior treatment with high-dose chemotherapy
does predispose to the development of VOD. The clinical criteria used to diag-
nose this disorder include the presence of two of the following within 30 d of
transplant: jaundice (directed bilirubin >2 mg/dL), tender hepatomegaly, and
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ascites or unexplained weight gain of more than 5%. Unfortunately, these criteria
are not specific and there are no clinical characteristics of VOD that readily
distinguish it from other causes of posttransplant jaundice. The differential diag-
nosis of VOD includes congestive heart failure, cholestasis from drugs or biliary
tract disease, hepatitis from infection or drugs, and in allogeneic transplant
patients, GVHD.
Evaluation of suspected VOD includes a review of the medications that the
patient is receiving to identify any that cause cholestasis or hepatitis. Physical
examination is performed to exclude congestive heart failure as an etiology.
Blood is drawn for hepatitis serologies if clinically indicated. Ultrasonography
is used to exclude obstruction of the biliary tree and to evaluate venous flow in
the liver. Transjugular liver biopsy may be required to exclude GVHD. The
histopathology of VOD may reveal subintimal thickening of the hepatic venules
with lumenal occlusion by reticulum or collagen, but not by thrombus.
Centrilobular hepatocyte necrosis also may be present in VOD.
Prophylaxis against VOD with heparin has not been demonstrated conclu-
sively to reduce the risk of this complication, and has been associated with
significant risk of bleeding. No treatment has been clearly proven to improve the
outcome of patients with established VOD. Recombinant human tissue plasmi-
nogen activator has been reported to reverse the course of VOD in some patients,
but controlled, randomized clinical trials have not been performed. Supportive
care measures remain the standard of care including the management of fluid
overload, coagulopathy, and encephalopathy. Patients with advanced liver fail-
ure occasionally may be candidates for orthotopic liver transplantation.
14. THROMBOTIC MICROANGIOPATHY
Thrombotic microangiopathy (TM; thrombotic thrombocytopenic purpura or
hemolytic uremic syndrome) can occur following either autologous or alloge-
neic SCT. A number of factors may be important in the pathogenesis of the
microvascular injury underlying this disorder including the toxicities of the
conditioning regimen and the immunosuppressive drugs administered posttrans-
plant. The use of cyclosporine is associated with the development of this disor-
der, and GVHD prophylaxis with a combination of cyclosporine, methotrexate,
and glucocorticoids may convey a higher risk. TM typically presents as a pro-
gressive decline in the hemoglobin and platelet count between 1 and 6 mo
posttransplant. Renal insufficiency, neurological symptoms, or fever also may
be present. The diagnosis is supported by the presence of intrascular hemolysis
(elevated reticulocyte count, serum lactate dehydrogenase, and indirect bilirubin
levels; decreased haptoglobin; positive urine hemosiderin) and the presence of
fragmented erythrocytes on the peripheral smear. In patients who present with
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diarrhea and TM, stool should be studied for the presence of Escherichia coli
strain O157:H7
Discontinuing or markedly reducing the cyclosporine dose may lead to
improvement in some recipients of allogeneic transplant. Substitution of
other immunosuppressive agents for cyclosporine may be useful, but this
approach has not been adequately evaluated. Therapeutic plasma exchange
or passage of patient serum through a staphylococcal protein A column using an
apheresis machine has been reported to benefit some patients, but these measures
are infrequently effective. Inexorable progression of renal failure, refractory
thrombocytopenia, and multi-organ system failure are common sequelae.
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1. INTRODUCTION
Anemias can be secondary to a primary blood disorder (e.g., stem cell failure
in aplastic anemia, malignant transformation of stem cells in acute leukemias),
but more often, anemias are secondary to other diseases or conditions (e.g., acute
blood loss after trauma, chronic blood loss in menstruating women, inadequate
nutrition, chronic autoimmune conditions, chronic infections, and many other
disorders). An anemia is normally defined as a decrease of hemoglobin below
13.5 g/dL in males and 11.5 g/dL in females. Between the age of 6 mo and
puberty, the normal hemoglobin concentration is somewhat lower (between 11
and 15 g/dL). A reduction of the hemoglobin value is often accompanied by
changes in other red cell parameters (e.g., microcytic and hypochromic in iron
deficiency anemia, macrocytic in vitamin B12 deficiency and other conditions).
The normal red cell values in adults are shown in Table 1.
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Anemias are frequently associated with an abnormal red cell morphology. A
glossary of the commonly encountered changes in red cell morphology is given
in Table 2. Some of these changes are shown in Fig. 5.l . The major categories
of anemias and their clinical manifestations are described in Table 3. In this
chapter, the major categories of microcytic, megaloblastic, and other common
types of anemias are described, whereas in Chapter 6, the inherited and acquired
hemolytic anemias are discussed.
2. ANEMIAS DUE TO ACUTE BLEEDING
Any major bleeding, internal or external, leads to an anemia. First, the patient
is hypovolemic and develops tachycardia, then, after several hours, the internal
plasma pool or the volume substitution leads to a dilution of the red cell concen-
tration. Acute blood loss is seen in many surgical conditions: trauma, bleeding
esophageal varices, perforated ulcers, or aneurysmal ruptures. The treatment of
these conditions is urgent (e.g., surgical or endoscopic stoppage of the bleeding,
volume substitution, treatment, and prevention of shock). The indication for
blood transfusion should be individualized. A commonly accepted threshold
below which red cell transfusions are given is a hemoglobin concentration of
8 g/dL. Patients who are adapted to low hemoglobin concentrations may need a
transfusion only at a lower hemoglobin value; patients who have had an acute
blood loss and are in a critical cardiovascular condition may already need trans-
fusions at hemoglobin values of 9 or 10 g/dL.
3. ANEMIAS DUE TO CHRONIC BLOOD LOSS
Minor but chronic blood loss in the gastrointestinal tract often leads to anemia.
Reasons for the blood loss may be cancer in the gastrointestinal tract or benign
conditions like hiatal hernias, hemorrhoids, angiodysplasia, or peptic ulcer dis-
ease. Hereditary conditions like telangiectasia or a coagulation factor deficiency
Table 1
Normal Adult Red Cell Values
Males Females
Hemoglobin concentration 13.5–17.5 g/dL 11.5–15.5 g/dL
Hematocrit (%)  40–52 36–48
Red cell number 4.5–6.5 (× 1012/L) 3.9–5.6 (× 1012/L)
Mean cell hemoglobin (pg) 27–34
Mean cell volume (fL) 80–95
Mean cell hemoglobin 30–35
concentration (MCHC)
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Table 2
Abnormalities in Red Cell Morphology and Their Associated Clinical Manifestations
Term Abnormality Associated conditions
Acanthocytosis Irregular membrane A-β-lipoproteinemia, liver cirrhosis,
pancreatitis
Anisocytosis Frequent variations in size Nonspecific, iron deficiency, and
other anemias
Burr cells Cells with many short, Renal failure, liver disease,
spiked projections hemolytic-uremic syndrome
(HUS), or thrombotic
thrombocytopenic purpura (TTP)
Dimorphic red Distinct population of Mixed iron and vitamin B12
blood cells small and larger cell
deficiency, following transfusion
Elliptocytosis Elliptoid form Hereditary elliptocytosis, other
conditions
Heinz bodies Hemoglobin precipitates G6PD deficiency hemoglobin-
due to oxidation (seen pathies, thalassemias
with methylene blue
stain)
Hypochromasia Poorly hemoglobinized Iron deficiency anemia,
thalassemias, other conditions
Macrocytosis Cells larger than usual Liver disease, MDS, compensated
hemolysis, vitamin B12 or folate
deficiency, other conditions
Microcytosis Cells smaller than usual Iron deficiency, thalassemias, other
conditions
Poikilocytosis Increased variability in Severe iron deficiency, other
cell shape conditions
Schistocytes Fragmented red cells Trauma, burns, HUS, or TTP
Target cells Target-like cells Iron deficiency, liver disease,
thalassemias, and other
hemoglobin disorders
MDS, myelodysplastic syndrome.
may also be responsible. At a certain point, chronic blood loss results in iron
deficiency and an iron deficiency anemia results (see “Iron Deficiency Anemia”).
It is imperative to identify the source of blood loss in all patients with iron
deficiency. The treatment depends on the cause (e.g., resecting a colon cancer,
treating a hemorrhagic gastritis, treating hemorrhoids). An iron substitution may
help to compensate the iron deficiency and thereby hasten the recovery of eryth-
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Fig. 5.1. Common changes in red cell morphology.
Table 3
Major Types of Anemias and Their Laboratory Findingsa
Type of anemia Laboratory findings
Acute bleeding anemia Initially, the hemoglobin does not reflect the
amount of blood lost
Iron deficiency anemia Low serum iron with increased total iron-binding
capacity, low ferritin.
Anemias of chronic disease Low serum iron and total iron-binding capacity,
ferritin usually not reduced.
Anemias of other diseases: Serum erythropoietin is inappropriately low in
renal insufficiency, hepatic renal insufficiency, TSH is elevated in
cirrhosis, and hypothyroidism, hypothyroidism.
malnutrition, and others
Megaloblastic anemias Low serum vitamin B12, increased urinary
methylmalonic acid and serum homocysteine
levels in vitamin B12 deficiency; low serum
folic acid level in folate deficiency.
Hemolytic anemias (acute, chronic, Increased reticulocyte count, unconjugated
congenital, and acquired forms) bilirubin, LDH
aAnemias associated with other hematological disease entities are not considered here.
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ropoiesis. Blood transfusions are rarely necessary in anemias of chronic blood
loss. The major causes of chronic blood loss are described in Table 4. In order
to investigate an iron deficiency anemia in an adult, a colonoscopy and, if that is
negative, a gastroduodenoscopy should be performed.
4. IRON DEFICIENCY ANEMIA
Iron deficiency is the end result of an iron loss in excess of iron absorption.
There are three stages of iron deficiency:
1. The iron stores are reduced but are still sufficient for erythropoiesis.
2. The iron stores are depleted; erythropoiesis is reduced.
3. Manifest iron deficiency anemia has developed (erythropoiesis reduced; hemo-
globin has decreased to less than normal).
On a worldwide basis, iron deficiency is among the most frequent causes of
anemia. Persons with an increased iron demand, such as pregnant or menstruat-
ing women, or children in the stages of growth and development, are the first to
develop an iron deficiency anemia. Children fed with cow’s milk often develop
an iron deficiency because of the low iron content of this milk. In adults, iron
deficiency is most often due to blood loss from the gastrointestinal or urogenital tract.
4.1. Pathophysiology
The normal body iron content is 3–5 g. This quantity is contained in hemo-
globin, myoglobin, iron stores, and in the reticuloendothelial system (RES); a
Table 4
Etiology of Chronic Blood Loss
Gastrointestinal bleeding Esophageal varices
Hiatal hernia
Erosive gastritis (spontaneous, secondary to aspirin)
Duodenal ulcer, gastric ulcer
Colon cancer, gastric cancer
Ulcerative colitis, Crohn’s disease, Coeliac disease,
hemorrhoids, angiodysplasia
Hookworm infestation
Hereditary hemorrhagic telangiectasia
Urogenital bleeding Renal cell cancer, bladder cancer
Gynecological tumors
Kidney stones
Increased menstrual blood loss
Other causes Frequent blood donations
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small amount is contained in serum as ferritin. Iron absorption and iron loss are
normally kept constant during adult life. The daily iron demand is 1.3 mg for men
and 1.8 mg for women (during the years of menstruation). Adolescents and
pregnant women need more iron. Generally, the Western diet contains sufficient
iron to compensate for the daily iron losses. Iron resorption takes place mainly
in the duodenum and, to some extent, in the jejunum. The mucosal cells regulate
intestinal iron absorption. Iron is either directly absorbed and transferred into the
circulating blood or stored in the mucosal cells as ferritin. If serum iron is low,
iron uptake from the gastrointestinal tract is rapid; if serum iron is elevated or
normal, more iron is retained in the mucosal cells. The iron transport from blood
to different sites of iron utilization or storage is then performed by transferrin, a
specialized transport protein of the β-globulin fraction of human serum. One
molecule of transferrin can bind two iron atoms. Normally, about 30% of the total
iron-binding capacity is saturated with iron. In the next step, the transferring iron
complex is bound to transferrin receptors on the surface of erythroblasts and
other cells. Nonutilized iron is then either transported to different storage tissues
and accumulated as ferritin or hemosiderin, or excreted via the kidneys. The total
iron storage pool is about 800 mg in men and 400 mg in women.
When a negative iron balance occurs, iron resorption first increases from the
normal value of 5–10% to a maximum of 20%. If the iron stores are completely
exhausted, as can be recognized by a decrease of the serum iron and ferritin and
an increase in transferrin, then the erythropoiesis becomes defective. Abnor-
mally small, poorly hemoglobinized (hypochromic) red blood cells are synthe-
sized. After a few weeks, the total hemoglobin concentration decreases (manifest
iron deficiency anemia). If the iron deficiency is more severe, the synthesis of
other iron-dependent proteins (e.g., cytochromes, myoglobin, flavoproteins) is
also impaired.
4.2. Clinical Signs and Diagnosis
The symptoms of iron deficiency anemia depend on its severity. Patients are
easily fatigued, may have dyspnea on exertion and have pale skin and pale
mucous membranes. An atrophic glossitis, spoon nails (koilonychia), or an
angular stomatitis develop. In very severe cases, the patients have dysphagia
due to esophageal webs (Plummer-Vinson syndrome). Some patients also develop
atrophic gastritis.
An early event in iron deficiency is a decrease in serum ferritin, the major
iron storage protein. Normal serum concentration of ferritin is 40–350 ng/mL
in men and 20–150 ng/mL in women. The serum values reflect the body iron
stores in the reticuloendothelial system. The next laboratory sign of iron defi-
ciency to develop is a decrease in the hemoglobin concentration. At this point,
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the number of red blood cells can still be normal. If the iron deficiency persists,
abnormalities of red cell morphology can be recognized (e.g., poikilocytosis,
anisocytosis, hypochromasia). The reticulocytes are generally decreased and the
red cell indices (e.g., mean corpuscular volume [MCV], mean corpuscular
hemoglobin [MCH], mean corpuscular hemoglobin concentration [MCHC])
are below normal. The bone marrow morphology shows nonspecific changes.
The stainable iron, usually seen in bone marrow macrophages after staining with
Prussian blue, is decreased or absent. In iron deficiency, the transport protein
transferrin is usually increased. The serum iron concentration is generally low,
but is not a reliable indicator of the degree of iron deficiency. The transferrin
saturation (serum/total iron-binding capacity) is typically less than 10%.
A new parameter for estimating iron deficiency is the measurement of the
serum transferrin receptors. In contrast to ferritin, the levels of serum transferrin
receptors are usually not influenced by acute or chronic infections. The normal
values (as measured by ELISA) are 4–9 µg/L. In iron deficiency, the levels of
serum transferrin receptors increase proportionally to the degree of iron defi-
ciency. Increased values, however, are also seen in some myeloproliferative
syndromes and anemias with proliferation of the erythroid series.
Early iron deficiency can also be diagnosed by measuring the red blood cell
protoporphyrin. The normal value is approx 30 µg/dL of red cells. In iron defi-
ciency, the value increases to greater than 100 µg/dL. Increased levels are also
found in lead poisoning and some sideroblastic anemias and porphyrias.
4.3. Treatment
The first step is to identify and treat the underlying cause of the iron defi-
ciency. It is especially important that an underlying malignancy is not over-
looked. The standard treatment of iron deficiency is oral ferrous sulfate. One
tablet (100 mg, containing 67 mg as ferrous iron) is given before meals and
should be continued until the iron deficiency is corrected and the iron stores are
replenished (3–4 mo in severe iron deficiency). In severe cases, two or three
tablets daily can be given. Ferrous fumarate and ferrous gluconate is equivalent
to ferrous sulfate. Most iron preparations are also available as elixir. An increase
in reticulocytes should be seen 7–10 d after the iron substitution is begun if the
iron is being adequately absorbed. If gastrointestinal side effects occur (e.g.,
vomiting, abdominal cramps, nausea), iron can be given together with meals or
a different formulation can he used, but this decreases the resorption and slows
the effect of treatment. A prophylactic iron treatment should he given during
pregnancy or for premature newborns. Parenteral iron should only be given when
oral iron is not effective or cannot be tolerated. Parenteral iron can be given as
bolus injections, as an intravenous infusion, or as an intramuscular injection. For
90 Munker
the parenteral substitution, ferric iron (iron-dextran or iron-sorbitol citrate) is
used. The amount of iron dextran required can be calculated as follows: iron
needed (mg) = [(15–hematocrit [HCT]) × wt lbs)] + 100. The dose range for one
injection or infusion is 500–1500 mg. When given by intravenous infusion, the
iron preparation should be diluted in 250 mL of 0.9% sodium chloride. A test
dose of 0.5 mL should be infused over 1 min; then, if no reaction occurs, the
remainder should be given over 30–60 min. Parenteral iron is preferable when
gastritis or a duodenal ulcer leads to pronounced side effects or if a severe mal-
absorption precludes the resorption. Parenteral iron always carries the risk of a
hypersensitivity reaction and therefore should be given under close medical
supervision. Most cases can and should be managed with oral iron.
5. ANEMIAS OF CHRONIC DISEASES
AND OTHER TYPES OF ANEMIAS
5.1. Anemias of Chronic Diseases
A slight anemia (hemoglobin around 9–11 g/dL) is found associated with
many chronic infections, rheumatoid disorders, disseminated tumors, lympho-
mas, hepatitis C, malaria, and other disorders. For the most part, anemias of
chronic diseases are not due to iron deficiency, but to iron sequestered in the RES.
Inflammatory cytokines like interferon-β and tumor necrosis factor (TNF)-α
upregulate the expression of DMT1 with an increased uptake of iron into acti-
vated macrophages. The iron sequestration was explained in the past by the
increased production of lactoferrin by neutrophils, which then competes with
transferrin for iron binding. Iron bound to lactoferrin cannot be utilized by red
cell precursors and is instead taken up by the RES. More recently, it was discov-
ered that hepcidin is the mediator of the anemia of chronic diseases. Hepcidin is
an acute phase protein induced in liver cells by lipopolysaccharide and
interleukin-6 but downregulated by TNF-α. Hepcidin diverts iron traffic through
decreased duodenal absorption of iron and the blocking of iron release from
macrophages. Further pathomechanisms of the anemias of chronic disease (which
are also termed anemias of inflammation) are the impaired proliferation of eryth-
roid progenitor cells and a blunted response to erythropoietin. The anemia of
chronic disorders is in general only slowly progressive. The red cell indices are
normochromic or slightly hypochromic. If the degree of anemia is severe, a
search for other causes should be made. The anemia of chronic disorders has a
low serum iron and a normal or elevated (in active inflammation) ferritin. The
serum transferrin receptors are normal. Erythropoietin levels tend to be low (if
the baseline of the patient’s hemoglobin is less than 10 g/dL). The anemia of
chronic diseases is best treated by treating the underlying disease. In severe or
symptomatic anemia, a blood transfusion is indicated. If the serum ferritin is less
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than 30 ng/mL, a search for the possible causes of iron deficiency, including
screening for blood loss, should be made. More recent studies showed that a cau-
tious treatment of the anemia of chronic diseases with erythropoietin improves the
patient’s performance status similarly to the anemia of kidney diseases. An
overcorrection (hemoglobin >11–12 g/dL) should be avoided. An iron supple-
mentation should be given if a true iron deficiency is documented or if an insuf-
ficient response to erythropoietin is observed. In the future, hepcidin antagonists
will be developed to overcome the retention of iron within the RES.
5.2. Anemias Due to Malnutrition
Malnourished children or adults in different parts of the world are often ane-
mic. Severe protein malnourishment (kwashiorkor) is always associated with
anemia. This anemia is multifactorial (iron, folic acid, protein, dilutional ane-
mia). Treatment of severe malnutrition should be started parenterally with the
substitution of protein, electrolytes, iron, and vitamins.
5.3. Anemias Due to Liver Diseases
Chronic liver disease often causes a macrocytic anemia. Biological factors are
folate deficiency, chronic blood loss, alcohol-induced changes, hemolysis, and
hypersplenism. The red cells sometimes have the morphology of target cells
(because of increased cholesterol in the cell membrane). A rare complication of
alcoholic liver disease is Zieve’s syndrome, in which acute hemolysis is associ-
ated with hyperlipidemia and alcoholic hepatitis. Morphologically, acanthocytes
are found in the blood smear.
5.4. Anemia of Pregnancy
Starting with the sixth week of pregnancy, a woman’s plasma volume increases
and reaches a maximum around the 24th week. The red cell mass does not increase
proportionally. The end result in many pregnant women is a dilutional anemia.
The hemoglobin stabilizes at around 11 g/dL, the hematocrit between 32 and
34%, and the red cells are normochromic. If the hemoglobin is lower, further
causes of anemia are most likely present (e.g., a manifest iron deficiency).
5.5. Anemia of Renal Failure
Virtually all patients with chronic renal failure develop an anemia. The ane-
mia is particularly severe in some renal disorders (e.g., analgesic kidney disease).
The anemia of renal failure is normochromic and normocytic with low reticulo-
cytes. The major cause of renal anemias is an inadequate production of erythro-
poietin by the kidneys (see Chapter 2). Additional factors that also contribute to
the anemia are a reduced red cell survival, direct toxic effects on erythropoiesis,
blood losses during dialysis, infections, and increased aluminum levels in some
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patients. Patients with chronic renal failure who are not treated with erythropoi-
etin have hematocrit values between 20 and 35%.
Severe or symptomatic cases of renal anemia should be treated with recom-
binant erythropoietin. Erythropoietin can be given intravenously (after dialysis,
three times weekly) or by subcutaneous injection. The recommended doses are
between 50 and 150 U/kg. The aim of the erythropoietin treatment is to keep the
hemoglobin level above 8 g/dL and to avoid transfusions. The optimum hemo-
globin concentration is between 10 and 12 g/dL. Erythropoietin is contraindi-
cated if the patient has uncontrolled hypertension, seizures, and problems of
vascular access. Potential side effects of erythropoietin are an increase in blood
pressure, a thrombotic tendency, and flu-like symptoms. An alternative to recom-
binant erythropoietin is pegylated erythropoietin, which needs less frequent dosing
(see Chapter 2).
5.6. Anemia of Endocrine Disorders
Many endocrine disorders are associated with a certain degree of anemia.
Examples are hypopituitarism, Addison’s syndrome, and thyroid disease. The
anemias of endocrine disorders are, in general, normochromic and normocytic.
5.7. Thalassemia Minor
Individuals with thalassemia minor are asymptomatic and their anemia usu-
ally is detected by a routine blood count. The red cells are microcytic, often
leading to a misdiagnosis of iron deficiency. However, iron studies typically are
normal. Thalassemias result from either a mutation of one β-globin gene or
deletion of two α-globin genes. The diagnosis of the thalassemias is discussed
in Chapter 6.
5.8. Sideroblastic Anemia
Idiopathic sideroblastic anemia can present with a microcytic, hvpochromic
anemia. The bone marrow biopsy is diagnostic: it reveals erythroid dysplasia and
hyperplasia. Ringed sideroblasts comprise more than 20% of the erythroid series.
It was recently recognized that a common pathogenetic mechanism in sideroblastic
anemias is the abnormal iron deposition in mitochondria. Two major types of
sideroblastic anemias can be distinguished: the rare hereditary sideroblastic
anemias and the more common acquired forms, which may be secondary to drugs
and toxins (ethanol, zinc, isoniazid, cycloserine) and can also be observed as part
of some myelodysplastic syndromes (see Chapter 11). As causes of X-linked
hereditary sideroblastic anemias, mutations of the ALAS-2 and hABC7 gene
were identified. In other forms of hereditary sideroblastic anemias, deletions of
mitochondrial DNA and mutations of the WFS1/wolframin gene were found. In
some cases of acquired sideroblastic anemias (as part of myelodysplastic syn-
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dromes), point mutations of mitochondrial DNA could be identified. As for
treatment, any potential toxin should be withdrawn. Some cases of congenital
(and acquired) sideroblastic anemia respond to pyridoxine, which should be
given (in responsive patients) at a dose of 50–200 mg daily.
5.9. Lead Poisoning
This disorder is usually seen in children who have eaten paint chips tainted
with lead, but it also can be seen in adults who have occupational exposure. The
clinical manifestations of lead poisoning may include abdominal pain, encepha-
lopathy, peripheral neuropathy, gout, or a proximal renal tubular acidosis. The
anemia or lead poisoning is more hypochromic than microcytic, with basophilic
stippling of the red cells. There is frequently an element of hemolysis with
reticulocytosis. Diagnosis is best made by finding increased free-erythrocyte-
protoporphyrin levels, and elevated urinary coproporphyrin III and δ-amino-
levulinic acid levels. Serum lead levels are a less sensitive indicator of tissue lead
stores.
5.10. Pure Red Cell Aplasia
Pure red cell aplasia is characterized by an absence of erythroid precursors in
the bone marrow. This condition can be congenital (Diamond-Blackfan anemia)
or acquired. As pathogenesis, defects of progenitor cells and/or an autoimmune
or toxic injury to erythroid progenitors have been proposed. In congenital cases
of pure red anemia, some patients have mutations in hematopoietic stem cells. In
other patients, abnormalities of apoptosis in the red cell precursors were described.
Patients with Diamond-Blackfan anemia are treated symptomatically with blood
transfusion. Some patients with Diamond-Blackfan anemia respond to steroids
or other immunosuppressive agents and enter remission. In refractory patients,
a bone marrow or stem cell transplantation may be indicated. An acquired form
of pure red cell aplasia is caused by an infection with parvovirus B19 and is seen
in advanced HIV infection or chronic hemolytic anemias (see Chapter 18). The
chronic autoimmune form of pure red cell aplasia is often associated with auto-
immune disorders or a T-cell lymphoma or thymoma. It is postulated that these
cases are initiated by a T-cell response or antibodies against erythroid progenitor
cells. A fraction of such patients respond to immunosuppression, chemotherapy,
plasmapheresis, or thymectomy (in cases of thymoma). Pure red cell aplasia is
a rare disease. More recently, in Europe an increased number of cases were
observed in patients treated with a certain formulation of erythropoietin-α
(serum-free, injected subcutaneously). This formulation of erythropoietin was
subsequently withdrawn from the market. In most instances, neutralizing anti-
bodies against erythropoietin could be demonstrated. It is thought the formula-
tion used made erythropoietin more immunogenic.
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6. MEGALOBLASTIC ANEMIAS
The megaloblastic anemias are caused by a deficiency of vitamin B12 or folates,
or by related conditions that lead to impaired DNA synthesis. Characteristically,
the maturation of the nucleus in erythroblasts in the bone marrow is delayed as
a result of defective DNA synthesis. This discordant maturation is generally
termed “megaloblastic.” The chromatin of megaloblasts is basophilic and appears
lacy and irregular. Sometimes the chromatin is clumped and takes on a bizarre
appearance. The proportion of erythropoiesis in the bone marrow is increased.
Figure 5.2 demonstrates megaloblastic erythroblasts (see also Color Plate 1).
The maturation defect in megaloblastic anemias can also be observed in
myelopoiesis and megakaryocytes. The megakaryoctes and granulocytes are
hypersegmented and the metamyelocytes and band forms are abnormally large.
In addition to the anemia, defective maturation of hematopoietic precursor cells
leads to leuko- and thrombocytopenia.
6.1. Physiology of Vitamin B12
This vitamin consists of a corrin ring with a cobalt atom in its center attached
to a nucleotide portion. Such compounds are termed cobalamins. The pharma-
cological preparations of vitamin B12 (cyanocobalamin and hydroxocobalamin)
Fig. 5.2. Pernicious anemia (bone marrow aspirate with megaloblastic erythropoiesis,
large erythroblasts with immature nuclei).
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are biologically inactive. The active forms that are generated by enzymatic syn-
thesis are adenosylcobalamin and methylcobalamin. Adenosyl-cobalamin is the
tissue form of vitamin B12, whereas methylcobalamin circulates in blood. The
daily requirement for vitamin B12, is about 1–2 µg in adults. A normal diet
provides a large excess of vitamin B12. The molecule is liberated in the stomach
where it binds to the glycoprotein “intrinsic factor” which is derived from the gastric
mucosa. The complex intrinsic factor-vitamin B12 is then resorbed in the distal
ileum. After resorption, the vitamin dissociates again and then binds to the trans-
port protein transcobalamin (TC) II before entering the enterohepatic circula-
tion. Another transport protein, TCI, is produced by granulocytes. The main
storage site of vitamin B12 is the liver (2–3 mg, a 1000-fold excess of the daily
requirement). Vitamin B12 is essential for several enzyme systems:
1. Adenosylcobalamin is a coenzyme involved in the conversion of methyl-malo-
nyl-coenzyme A (CoA) to succinyl CoA,
2. The synthesis of methionine from homocysteine, and
3. The synthesis of S-adenosyl methionine
6.2. Physiology of Folate (Pteroyl Glutamic Acid)
Folic acid is the parent compound of folates that consists of pteridine, p-amino
benzoic acid, and glutamic acid. Biologically, tetrahydrofolic acid is the most
important compound. The major intracellular compounds are folate poly-
glutamates, which have additional glutamate moieties attached. Folates are
needed in many biochemical reactions (e.g., synthesis of DNA, purines, and
thymine) and are essential for all proliferating cells, including hematopoietic
cells. Folates are present as polyglutamates in many foods, especially greens,
yeast, and liver, but are easily destroyed by cooking. The daily requirement of
folates is about 150 µg. Folates are resorbed in the upper jejunum as mono-
glutamates. The body stores of folates are sufficient for several months.
6.3. Pernicious Anemia
Pernicious anemia is an autoimmune disorder in which antibodies against
parietal cells and/or intrinsic factors can be demonstrated. Pernicious anemia is
more common in males than in females and has an age peak around 60 yr.
Pernicious anemia is often associated with other autoimmune disorders. The
gastric mucosa is atrophic and the secretion of intrinsic factor is defective. The
earliest gastric lesion in patients with pernicious anemia is an inflammatory
infiltrate in the submucosa. Typically, patients with autoimmune pernicious
anemia have a type A gastritis, which involves the fundus but spares the antrum.
Autoantibodies to parietal cells and to intrinsic factor are present in the serum
and in gastric secretions. The molecular target of the parietal cell antibodies is
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the H+/K+- ATPase in parietal cells that causes gastric atrophy and achlorhydria.
Parietal cell antibodies can he found in the serum of approx 90% of patients with
pernicious anemia. About 30% of first-degree relatives (who do not have perni-
cious anemia) also have parietal cell antibodies, whereas low titers of these
antibodies are found in only 2–8% of the normal population. Antibodies to intrin-
sic factor are found in 50–60% of patients with pernicious anemia. Type I auto-
antibodies block the binding of vitamin B12 to intrinsic factor, whereas type II
autoantibodies (present in 35–40% of the patients) bind to a different epitope of
intrinsic factor.
The pathogenesis of autoimmune pernicious anemia is a selective malabsorp-
tion of vitamin B12. Development of pernicious anemia is described in schematic
form in Fig. 5.3. The vitamin deficiency leads to an ineffective erythropoiesis
with megaloblastic features. Lack of vitamin B12 is also the cause of disturbances
in myelopoiesis, megakaryocyte maturation, and further neurological and muco-
cutaneous symptoms. It is generally easy to diagnose pernicious anemia. The
anemia is macrocytic and the reticulocyte count is low in relation to the degree
of anemia. The bone marrow is usually hypercellular, with a decrease of the
myeloid/erythroid cell ratio due to a marked increase in cells of the erythroid
series. The erythropoiesis shows prominent megaloblastic features. Because of
the defective erythropoiesis, laboratory findings of hemolysis are observed (e.g.,
raised LDH, raised unconjugated bilirubin). Serum levels of vitamin B12 are low
Fig. 5.3. Pernicious anemia due to vitamin B12 deficiency; pathophysiology.
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or very low. Because vitamin B12 is required for the conversion of methylmalonyl
CoA to succinyl CoA, deficiency of this coenzyme results in increased urinary
excretion of methylmalonic acid. Similarly, the conversion of homocysteine to
methionine requires vitamin B12; serum homocysteine levels are elevated in
vitamin B12 deficiency. Both of’ these tests may be more sensitive indicators of
vitamin B12 deficiency than measurement of serum vitamin B12 levels. An absorp-
tion test (Schilling test) is performed with radioactively labeled vitamin B12. An
unlabeled dose is given first by intramuscular injection to saturate the vitamin
B12-binding sites, and then a radioactively labeled dose is given by mouth. The
urine is collected for 24 h to determine if the oral vitamin B12 was absorbed. If
the absorption is normal, 10–20% of the ingested vitamin B12 can be found in the
urine. A pathological Schilling test (<3% of tracer found) can be normalized
when intrinsic factor is given orally together with vitamin B12. A pathological
Schilling test should normalize when it is repeated with the simultaneous oral
administration of a purified intrinsic factor.
The onset of pernicious anemia is insidious in most cases. Patients experience
fatigue and shortness of breath on exertion and are pale and mildly icteric.
The tongue is often beefy red and painful (Hunter’s glossitis). Many patients
have angular stomatitis, some have an esophagitis with dysphagia. Today, in
many cases, an early diagnosis of vitamin B12 deficiency is made when asymp-
tomatic patients have a blood count and their vitamin B12 levels are determined
for unrelated reasons.
Severe vitamin B12 deficiency may cause a progressive neuropathy with dam-
age to the peripheral sensory nerves and the posterior and lateral columns (sub-
acute combined degeneration of the cord). If the disease is not treated, the lesions
will progress from demyelination to axonal degeneration and eventually neu-
ronal death. Common symptoms are an impaired sense of vibration, paresthesias,
and numbness. The patients experience difficulty in walking (positive Romberg’s
sign). Neuropathologically, the lesions involve both the posterior column and the
lateral column. The lesion of the lateral column manifests as limb weakness,
spasticity, and extensor plantar responses. Many patients develop mild person-
ality defects or memory loss, and some patients develop frank psychosis. Occa-
sionally the neurological symptoms of vitamin B12 deficiency occur with only
minor hematological abnormalities.
Blood transfusions are necessary only in rare cases for the treatment of per-
nicious anemia. The causal treatment is the substitution of vitamin B12, which is
given by the intramuscular route (hydroxocobalamin, 1000 µg). After 5–6 d, a
strong increase in reticulocytes can be found in the blood and the signs of hemoly-
sis regress. During the first 2–3 wk, six injections should be given. Because
erythropoiesis shows a maximum increase, the iron stores may become exhausted
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and many patients need iron supplements. During the initial treatment of perni-
cious anemia, the serum K+ levels may decrease steeply and should be moni-
tored. If a patient with vitamin B12-deficiency anemia is inadvertently treated
with folate, the anemia may improve, but irreversible neurological damage may
occur (due to a subacute combined degeneration of the cord). Therefore, all
megaloblastic anemias need a thorough investigation. Patients with autoimmune
pernicious anemia need a lifelong substitution. Maintenance injections (1000
µg) should be given every 3 mo. Prophylactically, vitamin B12 should also be
given to patients who had a total gastrectomy or ileal resection. For patients with
neuropathy, a higher-dose substitution is recommended in the initial treatment
phase.
In the older population, a subclinical vitamin B12 deficiency is common. Clini-
cally, these patients often have a subtle neurological dysfunction. The secretion
of intrinsic factor and the Schilling test is normal in this population. It is thought
that this deficiency of vitamin B12 is due to reduced gastric secretions, leading
to a delayed release of the vitamin from binding substances in food. Further
causes are bacterial infections and drugs that suppress gastric acid. A subclinical
vitamin B12 deficiency may rapidly become symptomatic when anesthesia with
nitric oxide (which oxidizes cobalamin) is performed or when folates are given.
6.4. Other Causes of Vitamin B12 Deficiencies
Several other conditions besides pernicious anemia may lead to a symptom-
atic vitamin B12 deficiency, including malabsorption of tropical sprue, blind
loops syndrome (bacterial overgrowth), fish tapeworms, gastric or ileal resec-
tions, and a strict vegetarian diet. Rare causes of megaloblastic anemia are the
congenital deficiency of the binding protein TCII and congenital defects in the
secretion of intrinsic factor.
6.5. Megaloblastic Anemias Due to Folate Deficiency
Folates may be deficient in malnourished persons and alcoholics. In patients
with intestinal disorders, folates may not be resorbed in the small intestine. The
causes of folate deficiency are outlined in Table 5. The symptoms of severe folate
deficiency are similar to those in severe vitamin B12 deficiency. However, there
are no neurological signs and symptoms. Serum folate levels are decreased (nor-
mal values 3–15 µg/L), and vitamin B12 levels are normal. Serum folates rapidly
normalize after substitution; therefore, the measurement of red cell folates may
be necessary to recognize folate deficiency as cause of a megaloblastic anemia.
Folate deficiency during pregnancy is a risk factor for neural tube defects. In
recent years, folate deficiency and subsequent elevations of homocysteine were
recognized as cause of premature cardiovascular disease. To treat folate defi-
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ciency, 5 mg daily are given orally for several months. If possible, the underlying
disorder, like ileitis, should be treated. For example, many patients with chronic
hemolytic anemias need a lifelong maintenance treatment. During pregnancy, a
substitution of at least 400 µg daily is recommended.
SUGGESTED READING
Alcindor T, Bridges KR. Review: sideroblastic anemias. Br J Haematol 2002;116:733–743.
Baynes RD, Cook JD. Current issues in iron deficiency. Curr Opin Hematol 1996;3:145–149.
Durand P, Prost M, Blanche D. Folate deficiencies and cardiovascular pathologies. Clin Chem Lab
Med 1998;36:419–429.
Hoffbrand V, Provan D. ABC of clinical haematology: macrocytic anaemias. Br Med J
1997;314:430–433.
Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med 1997;337:1441–1448.
Weiss G, Goodnough LW. Anemia of chronic disease. N Engl J Med 2005;352:1011–1023.
Table 5
Causes of Folate Deficiency
Reduced alimentary intake Malnutrition, alcoholism, synthetic diets
Malabsorption Tropical sprue, gluten-induced enteropathy, smoking
Increased demand Pregnancy, chronic hemolytic anemias, malignancies
Genetic causes Mutations of genes responsible for folate absorption or
metabolism (MTHFR and other genes)
Drugs Inhibitors of dihydrofolate reductase (methotrexate),
sulfasalazine, oral contraceptives, phenytoin
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1. INTRODUCTION
The different forms of hemolytic anemias are a severe, worldwide health
problem. The hemolytic anemias can be classified into acquired and inherited
types. The acquired forms are usually caused by the development of autoantibod-
ies against red cells, whereas the latter forms are possibly due to red cell mem-
brane defects, red cell enzyme defects, or abnormalities of the hemoglobin (Hb)
molecule. The normal composition of Hb is described in Chapter 1.
All hemolytic anemias have several common clinical features as a result of
both increased destruction and an increased compensatory production of red
cells. The increased destruction of red cells leads to symptoms of anemia,
enlargement of the spleen, the formation of gallstones, and laboratory findings
showing hemolysis (raised unconjugated bilirubin and other features). The
increased production of red cells is reflected by an elevated reticulocyte count
in the blood as well as an increase of erythropoiesis in the bone marrow and leads
to bone abnormalities, especially in children with chronic hemolytic anemias.
The major features of inherited hemolytic anemias are described in Table 1.
102 Munker et al.
2. INHERITED MEMBRANE DEFECTS
2.1. Hereditary Spherocytosis
Hereditary spherocytosis (HS) is the most common hereditary hemolytic
anemia in persons of northern European descent (incidence 0.02%). The inher-
itance is autosomal dominant in most cases. A defect in a major structural protein
of the red cell membrane (spectrin, ankyrin, band 3, and/ or protein 4.2) leads to
a loss of membrane lipids with decreased osmotic resistance. The defective genes
causing spherocytosis were cloned (ANK1, EPB3, ELB42, SPTA1, and SPTB).
The cells of abnormal morphology (e.g., decreased surface area, micro-
spherocytes) can no longer pass through the splenic microvasculature and are
phagocytosed.
The severity of the disease is variable. Patients may have a chronic anemia or
may be hematologically normal. Some patients show symptoms only during
infections or other stressful conditions. Anemic patients have chronic fatigue and
many have icteric episodes. Others have colics in the right upper abdomen if they
have gallstones. The spleen is always enlarged in HS. Some patients have aplas-
tic crises (due to an infection with parvovirus B19). During such a crisis, the
production of red cells is abruptly stopped and a severe anemia follows. Some
individuals with HS have a neonatal icterus that later normalizes.
The diagnosis of HS can be made when typical spherocytes are detected on the
blood film (diameter <7 µm) and the osmotic resistance is decreased. As an
alternative to the osmotic fragility test, the acidified glycerol lysis test can be
used. In most patients, the family history is positive. The direct antiglobulin test
Table 1
Major Characteristics of Inherited Hemolytic Anemias
Hereditary spherocytosis Dominant inheritance (in most cases), defect of red cell
membrane, splenectomy if symptomatic.
G6PD deficiency Defect of red cell enzyme, hemolytic episodes
triggered by certain drugs and other conditions.
Sickle cell anemia Single-gene disease (HbS), symptoms in homozygotes,
severe hemolysis with painful crises, reduced life
expectancy, intensive supportive treatment needed.
Thalassemias α-Thalassemia: α-chain of globin molecule reduced or
absent (deletion of three genes: moderately severe
hemolytic anemia).
β-Thalassemia: β-chain reduced or absent (homozygous
form: severe hemolytic anemia with reduced life
expectancy, chronic transfusions required, iron
overload).
Chapter 6 / Hemolytic Anemias 103
(Coombs’ test) is always negative. As in other hemolytic anemias, the lactate
dehydrogenase (LDH) and unconjugated bilirubin are increased and the serum
haptoglobin is decreased. The proportion of reticulocytes is normal or increased.
Most patients have an enlarged spleen.
Splenectomy normalizes or improves the hemolytic anemia and is indicated
in all symptomatic cases. An exception exists, however, in the case of children
less than 5-yr-old, because of the considerable risk of postsplenectomy infec-
tions (mainly pneumococcal septicemias). Patients undergoing splenectomy for
HS should be vaccinated against pneumococci and Hemophilus influenzae and
should be advised to take 250 mg penicillin twice daily for an indefinite period.
A revaccination against pneumococci is recommended every 6 yr. Recently, a
partial splenectomy was proposed to reduce the risk of postsplenectomy infections.
Patients who have a partial splenectomy or who have an accessory spleen that
enlarges may need a second operation if a symptomatic anemia recurs. In aplastic
crisis, patients with HS may need blood transfusions and other supportive mea-
sures. Intravenous immunoglobulin (IVIg) has been used to prevent aplastic
crisis in patients with HS by administering it early in the course of the disease.
The substitution of folic acid may improve the anemia to some extent.
Cholecystectomy is required in some patients, especially those with intact
spleen due to hemolysis leading to unconjugated hyperbilirubinemia, increased
pigment stone formation, and cholecystitis. The major features of HS and its
management are summarized in Table 2.
2.2. Hereditary Elliptocytosis
Hereditary elliptocytosis (HE), a familial hemolytic anemia, can be recog-
nized by the presence of a sizable proportion of oval or elliptical red cells on
peripheral blood films. As with spherocytosis, the inheritance of HE is autosomal
dominant. The molecular defects involved are heterogeneous, including muta-
tions of spectrin, protein 4.1, or glycophorin C. Most cases have a mild clinical
presentation without evidence of anemia. HE is symptomatic in rare cases of
homozygosity, in which infections have been associated with exacerbations of
the disease. Patients who are heterozygous for two different mutations (double
heterozygosity, hereditary pyropoikilocytosis) may have a severe hemolytic
anemia. Symptomatic patients with HE benefit from splenectomy, similarly to
patients with spherocytosis.
2.3. Hereditary Pyropoikilocytosis
Hereditary pyropoikilocytosis is a rare form of elliptocytosis with recessive
inheritance. The red cells are characterized as micropoikilospherocytes and are
thermally unstable. Most patients have a severe hemolytic anemia.
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3. INHERITED ENZYME DEFECTS
The glucose metabolism of red blood cells is regulated by a large number of
enzymes. In clinical practice, only two types of enzyme defects are important: the
deficiency of glucose-6-phosphate dehydrogenase (G6PD) and the deficiency of
pyruvate kinase (PK).
3.1. G6PD Deficiency
Deficiencies of the red cell enzyme G6PD comprise the most common human
enzymopathy. It has been estimated that in some Mediterranean countries, as
well as in Asia and Africa, 5–20% of the population (in some countries even
60%) have a deficiency of G6PD. The degree of G6PD deficiency is variable,
often being found to be more severe in Mediterranean patients than in patients
from Africa. In Asia, the incidence varies between 0.1 and 14%. At least 200
million people suffer from G6PD deficiency on a worldwide basis.
G6PD catalyzes the first step of the pentose phosphate pathway (Embden-
Meyerhof reaction, conversion of glucose-6-phosphate to 6-phosphogluconate).
The G6PD-deficient red cells have a limited capacity to generate nicotinamide
adenine dinucleotide phosphate (NADP) and NADPH (reduced form). The lack
of reducing potential makes them vulnerable to oxidative stress. Certain drugs,
vegetables, and stress conditions (see Table 3) induce an acute intravascular
hemolysis. It has been speculated that these drugs or conditions induce the for-
mation of free radicals.
G6PD deficiency is a hereditary recessive disorder linked to the X chromo-
some. The disease is therefore manifested most severely in males, whereas
female heterozygotes generally only act as carriers. Females may be affected in
cases of extreme lyonization, Turner’s syndrome (XO), and 50% of females are
affected when both parents are carriers. Because female carriers have the advan-
tage of being protected against malaria, the disease is often prevalent in areas
where malaria is endemic. At least 400 different mutations of G6PD are known.
Based on the degree of enzyme deficiency, five classes of G6PD deficiency can
be distinguished.
Table 3
Factors Causing Hemolysis in Patients With G6PD Deficiency
1. Infections (pneumonias, hepatitis, sepsis), severe illnesses, diabetic ketoacidosis
2. Drugs (acetanilide, nalidixic acid, naphthalene, nitrofurantoin, pamaquine,
phenazopyridine, phenylhydrazine, primaquine, sulfacetamide, sulfamethoxazole,
sulfanilamide, sulfapyridine, toluidine blue, dapsone, and other compounds)
3. Fava beans (most common in Mediterranean variant)
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• Class I variants: severe enzyme deficiency (rare, chronic active hemolysis)
• Class II variants: severe enzyme deficiency (only intermittent severe hemolysis,
frequent in Mediterranean patients)
• Class III variants: moderate enzyme deficiency (10–60% of normal, only inter-
mittent hemolysis, frequent in African-American patients, hemolysis usually
associated with infections or drugs)
• Class IV variants: no enzyme deficiency or hemolysis (of limited clinical rel-
evance)
• Class V variants: increased enzyme activity (of limited clinical relevance)
Between hemolytic episodes, patients are hematologically normal. After ingest-
ing fava beans or certain drugs, they rapidly develop severe intravascular hemo-
lysis. Patients develop hemoglobinuria, fever, back pain, and icterus.
The diagnosis of G6PD deficiency can be made by measuring the enzyme
activity in red cells. The enzyme measurement should not be made during a
hemolytic episode or after transfusion because this will give a falsely elevated
enzyme activity. For male patients, a screening test with a fluorescent substrate
can give rapid information. During the hemolytic episode the blood film shows
numerous fragmented cells and Heinz bodies. Heinz bodies consist of oxidized
and denatured Hb and can be visualized as an intracellular inclusion with supravital
staining.
The treatment of a hemolytic episode consists of supportive measures. Removal
of potential stress factors is obviously necessary and blood transfusions should be
given if needed. As a prophylactic measure, all potentially dangerous agents
should be avoided in patients with G6PD deficiency. Babies with G6PD defi-
ciency may develop neonatal jaundice and may need an exchange transfusion
and/or phototherapy.
3.2. Pyruvate Kinase Deficiency
The inheritance of the red cell enzyme PK deficiency is autosomal recessive.
In this deficiency, an impaired nicotinamide adenine dinucleotide (NAD) syn-
thesis and the depletion of adenosine triphosphate (ATP) enhance the hemolysis
of erythrocytes. Heterozygotes are usually asymptomatic, whereas homozygotes
have a hemolytic anemia of variable severity. By mutation analysis, it was shown
that most homozygote patients are actually compound heterozygotes for the two
most common mutant forms of the enzyme. In the peripheral blood smear,
acanthocytes, echinocytes (sea urchin-like cells), and spherocytes are promi-
nent. Splenomegaly, gallstones, and icterus are commonly observed in symp-
tomatic patients. The diagnosis of PK deficiency can be made by screening tests
or by measuring the enzyme activity in the red cells. As in other chronic hemolytic
anemias, infections may lead to an exacerbation of the hemolysis. Splenectomy
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may be beneficial for symptomatic patients who need frequent transfusions. At
birth, PK-deficient infants may be severely anemic and often require an exchange
transfusion.
3.3. Other Red Cell Enzyme Deficiencies Associated With Hemolytic
Anemia
Less common than G6PD and PK deficiency is the deficiency of glucose
phosphate isomerase, which may manifest itself by hemolytic crises.
4. HEMOGLOBINOPATHIES
The genetic abnormalities of the Hb molecule are mainly divided into two
categories: the structural abnormalities and abnormalities due to the reduced
synthesis of normal α- or β-chains of the globin molecule. Sickle cell anemia is
the prototype of a structural abnormality, whereas in the thalassemias, a reduced
synthesis of the globin chains is encountered. Other structural abnormalities of
the Hb molecule cause HbC, HbE disease, and other disorders. Each hemoglo-
binopathy occurs in homozygous and heterozygous forms. Clinical manifesta-
tions are usually only present in the homozygous state. Heterozygotes are referred
to as having a trait of the hemoglobinopathy.
4.1. Sickle Cell Anemia
Sickle cell anemia or sickle cell disease (SCD) is an inherited hemolytic
disorder that is the result of a mutation in the β-globin gene. The mutated Hb is
called HbS. In heterozygotes (sickle cell trait), HbS does not cause major clinical
problems. In fact, it gives the carriers a certain advantage vis-à-vis plasmodium
falciparum malaria. In contrast, most homozygotes for HbS go through life with
major health problems affecting every organ system. Patients with sickle cell
anemia have until now a shorter life span than the average. Fortunately, however,
advances in the care of these patients, such as early diagnosis, better antibiotics
treatment, and better pain control, have contributed to a significant improvement
in their life expectancy. In 1973, Diggs reported a mean survival of about 14 yr
for homozygous patients whereas in 1994, Platt et al. reported a markedly im-
proved life expectancy of 42 yr for males and 48 yr for females, which was mainly
related to prophylactic penicillin, vaccination, and parental education about
splenic sequestration. The cure of SCD is still elusive despite major advances in
the understanding of its pathophysiology.
4.1.1. PATHOPHYSIOLOGY
A single substitution in the β-globin gene results in the substitution of the sixth
amino acid in the β-globin subunit from glutamic acid to valine with hydrophobic
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properties. This substitution results in a fundamental change in the properties of
HbS in the deoxygenated state. In the absence of oxygen and at a critical concen-
tration of HbS there are many intramolecular interactions that form molecular
rods, which continue to grow and deform the cell. The sickling phenomenon in
turn damages the cell membrane and shortens red cell survival (hemolysis). In
addition, there are other factors, such as white cells, endothelial cells, coagula-
tion, and cytokine/inflammation pathways, that affect the sickling phenomenon.
Chronic and intermittent tissue hypoxia, and possibly inflammation, eventually
leads to tissue damage and organ malfunction. Intravascular hemolysis results in
Hb release, which leads to an intense local and systemic inflammatory and
cytokine response causing endothelial damage and sludging resulting in ischemia.
The systemic component is probably responsible for multifocal cascade of events
leading to generalized and/or multifocal symptoms seen in acute attacks. Repeated
episodes lead to subintimal proliferation of fibroblasts and smooth muscle, and
narrowing and eventual obliteration of endarterioles. These findings first mani-
fest in those organs of body that have maximum acidosis and hypoxia, such as
splenic sinusoids and the hyperosmolar environment of renal medulla. Hence,
homozygous patients with SCD have usually autoinfarcted their spleen by 5 yr
of age and have polyuria, a telltale symptom of poor concentration of urine due
to infarction of renal medulla, by 10 yr of age. In milder phenotypes of SCD,
splenic function (as inferred from presence of red cell “pits” and absence of
Howell-Jolly bodies on peripheral smear or by a radionuclide uptake spleen
scan) can remain near normal even beyond the teenage years.
The narrowing and eventual obliteration of endarterioles and even major ar-
teries is classically seen in the internal jugular and middle cerebral arterial dis-
tribution in the brain. Poor collateral circulation (from inadequate vessel
proliferation leading to “moyamoya”-[Japanese for “puff of smoke”]-type vas-
cular appearance on angiogram) in response to vascular narrowing and ischemia,
anemia (hence lower total cerebral oxygen “reserve” capacity and supply), and
damage due to inflammation are all responsible for intellectual deficits seen in
almost half of older patients with SCD. Acute ischemia or microemboli are the
final stress for the already precarious vascular supply that manifests itself as
stroke in about 10% of patients with SCD (and as silent infarcts as an incidental
finding on computed tomography [CT] or magnetic resonance imaging [MRI] in
approx 30%). Ischemic cerebral events manifest mainly between 5 and 10 yr of
age. Rupture of the friable overburdened collateral vessels possibly lead to cata-
strophic and sometimes fatal intracranial hemorrhage that is usually seen in
adults with SCD.
The various pathological processes that take place during multiple episodes
of intravascular sickling lead to the clinical symptoms. The symptoms are either
acute as a result of an ongoing sickling process or chronic as a result of organ
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dysfunction or failure. The clinical symptoms vary significantly in severity in
various sickle genotypes. Many other genes interact with the sickle cell gene and
alter the severity of SCD. These genes are referred to as epistatic genes. HbS in
a critical concentration can also interact in a heterozygote state with other Hb
such as HbC, D, E, as well as with the α- and β-thalassemias. However, all these
phenotypes except hemoglobin sickle disease and HbS with β°-thalassemia
(when the only β-gene present is nonfunctional and does not produce any β-
chains) and HbSD phenotype generally manifest a clinical course that is some-
what milder than homozygous (HbSS) disease. HbS with β-+ thalassemia (when
the only β-gene present produces variable amounts of β-chains) and HbS het-
erozygous with hereditary persistence of fetal Hb (also called HPFH), are the
mildest phenotypes of SCD. Various phenotypes of SCD have milder disease
when present with a concomitant α-thalassemia trait as a result of a decrease in
the mean corpuscular hemoglobin concentration (MCHC). A decrease in MCHC
by 3 g/dL lowers the HbS polymer formation threefold.
4.1.2. DIAGNOSIS
The clinical presentation and family history show a number of common fea-
tures in most cases. Because of the chronic nature of the disease, the Hb is
generally low compared to the symptoms of anemia. The blood smear shows
sickle cells and target cells. Screening tests for sickling are positive (incubation
of red cells under low oxygen conditions, e.g., with dithionate). The definitive
diagnosis of SCD is made by means of a hemoglobin electrophoresis or by PCR.
In homozygous SCD, the hemoglobin electrophoresis shows the typical band of
HbS, whereas the band of normal HbA is absent. Figure 6.1 shows the hemoglo-
bin electrophoresis of a normal individual and of a person with sickle cell anemia.
For patients with sickle cell trait, the proportion of HbA and HbS is almost  equal
however HbA is always greater than HbS. Homozygotes for HbS may have a
variable proportion of HbF. Cases of SCD with a larger proportion of HbF (20–
30%), especially those with pancellular distribution, are associated with an
extremely mild clinical course because it delays and decreases the HbS polymer
formation significantly.
4.1.3. CLINICAL PROBLEMS
Table 4 shows various clinical problems associated with sickle cell anemia.
We will describe some of the most common problems seen in the sickle cell
clinic.
4.1.4. ACUTE SICKLE CELL PAIN CRISIS AND CHRONIC PAIN
Some patients with sickle cell anemia often have chronic aches and pains and
use multiple analgesics continuously or intermittently. The chronic pain is often
interspersed by episodes of acute pain “crises.” Although many factors are
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Fig. 6.1. Hemoglobin electrophoresis (normal [1,4], sickle cell anemia [2], and sickle cell
trait [3]).
Table 4
Problems Related to Sickle Cell Disease
• Anemia due to ineffective hematopoiesis and chronic hemolysis
• Pain crises due to tissue hypoxia and infarction (caused by red cell sludging) and
inflammatory reactions
• Chronic joint disease caused by bone necrosis and inflammation (seen classically in
hip joint due to avascular necrosis of femoral neck)
• Acute chest syndrome with gradual development of pulmonary hypertension after
multiple such episodes
• Severe infections such as pneumonias and osteomyelitis due to a defective immune
system coupled with ischemia
• Chronic vascular disease (stroke, etc.)
• Acute hemolytic crises
• Acute and subacute splenic sequestration
• Aplastic crises
• Priapism
• Chronic organ failure
responsible for these pain episodes, the major problem is tissue hypoxia with or
without infarction or inflammation. The painful crises are the most common
manifestations of SCD and they often worsen with age. The pain crises appear
in an unpredictable fashion or are initiated by stressful factors such as infection,
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physical or psychological trauma, menstruation, cold weather, and others. The
severity and the frequency of the painful episodes also have prognostic signifi-
cance, which should be factored into the long-term therapeutic management.
Although pain control is a challenge for the physician, in most instances, pain can
be managed in an outpatient setting with reassurance, hydration, and short- and
long-acting narcotics. It is important nevertheless to eliminate all possible pre-
cipitating factors if any are identified.
Patient education about healthy living (i.e., good hydration, nutrition, non-
competitive exercise, adequate rest, avoiding exposure to cold [wearing gloves
and stockings], and periodic follow-ups) is important. Warm soaks may cause
symptom relief, but cold compresses or ice must be avoided. More recently,
inflammation has been identified as a cause of sickling and pain. Therefore, the
use of anti-inflammatory drugs should be kept in mind. It is always important to
treat pain adequately because chronic pain can affect the patient’s outlook on life
and lower the quality of life. In addition, it is especially important to treat acute
severe pain promptly, adequately, empathically, and with frequent monitoring
(for prompt control and to avoid oversedation) in the emergency and inpatient
setting. This approach promptly breaks the pain cycle, improves patient self-
confidence and compliance, and ensures quicker resolution.
4.1.5. ACUTE CHEST SYNDROME AND PULMONARY HYPERTENSION
Second to pain crises, pulmonary complications are the most common and
most feared, being the leading cause of death in the acute and chronic setting. The
two main acute problems are infectious pneumonia and acute chest syndrome.
Both these problems have similar clinical manifestations: fever, chest pain, and
shortness of breath, leukocytosis and pulmonary infiltrate on chest X-ray. How-
ever, it is important to make the correct diagnosis because the treatment is dif-
ferent. If the two problems cannot be differentiated from one another, which
commonly occurs, the patient should be treated for both. All patients with acute
pulmonary problems should be cared for as inpatients with hydration, pain con-
trol, oxygen, and antibiotics as well as red cell transfusion or red cell exchange
ifnecessary. Transfusions should be leukocyte-depleted to avoid alloimmunization.
One-third of the patients eventually develop pulmonary hypertension.
4.1.6. ACUTE AND CHRONIC BONE AND JOINT PAIN
Patients with sickle cell anemia are predisposed to develop bone infarction.
These infarctions result, over a long period of time, in bone and joint dysfunction
at the large joints, especially the hip. These lesions cause significant pain and
joint malfunction. The bone and joint problems, if severe and repetitive, should
be treated with anti-inflammatory and analgesic drugs and physiotherapy. If the
joint function cannot be restored the patients should be referred to an orthopedist
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for further evaluation and treatment. Joint replacement is an option if the less
invasive treatments are not helpful.
4.1.7. VASCULAR DISEASE AND STROKE
Vascular disease, especially in the brain, is more common in patients with
SCD and manifests far earlier than the population at large. Central nervous
vascular accident is the most catastrophic complication of SCD. In more recent
years stroke prevention has become possible by using transcranial ultrasonogra-
phy for early diagnosis and preventive treatment of selected patients as shown by
the  Stroke Prevention Trial in Sickle Cell Anemia (STOP).
In a series of studies, children at high risk of stroke could be identified with
certainty (relative risk = 44, 95% confidence interval 5.5–346) and the impend-
ing stroke prevented with chronic blood transfusion or red cell exchange trans-
fusion. Recent data suggests that these patients at “high risk” of stroke need
indefinite chronic transfusion after reports of stroke on its discontinuation after
years of being on a chronic transfusion program. Stroke in the adult population
is not as common as it is in children but it is higher than in the general population
in patients with multiple risk factors. The specific risk factors in SCD for stroke
are “a previous stroke and silent cerebral infarcts.” Familial predisposition has
also been mentioned as a risk factor. It should also be noted that now that many
patients reach middle age, all other usual risk factors for stroke such as hyperten-
sion, hypercholesterolemia, and smoking should be identified and treated.
Patients with sickle cell anemia are in particular sensitive to the deleterious
effects of high blood pressure. The treatment of strokes is chronic partial exchange
red cell transfusion to emergently lower the HbS concentration below 30%. Other
treatments (see “New Treatments”) should be offered as an adjunctive treatment
or when transfusion program is not practical because of poor compliance, reli-
gious beliefs, multiple alloantibodies, severe iron overload, or other reasons. The
exchange red cell transfusion has been used to slow and even prevent iron over-
load, but at the cost of increased donor exposure, and if started, should be con-
tinued probably beyond childhood.
4.1.8. IRON OVERLOAD
Iron accumulates at a different rate in different individuals, and in different
organs. Every organ also has a different susceptibility toward the toxic effects of
elemental iron.
If they receive repeated blood transfusions, patients with sickle cell anemia
are especially prone to iron overload, at an approximate rate of 200 mg of iron
per red cell unit. We start treating iron overload when the serum ferritin exceeds
1000 ng/mL. Serum ferritin, however, is not an accurate assessment of iron
deposits. The hepatic iron concentration obtained by liver biopsy is more reliable
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but also more invasive. An alternative noninvasive technique would be to esti-
mate the hepatic iron by a superconducting quantum interface density measure-
ment. However, this is rarely available. MRI is an easier alternative with
acceptable results.
The use of iron chelators in β-thalassemia major has shown that it brings
significant health improvement and prolongs survival. Iron chelation should also
be offered to patients with SCD who have iron overload and has a beneficial
effect. However, parenteral iron chelation (Desferroxamine, Desferal®) is costly
and cumbersome. In addition, the patient compliance is poor because of its side
effects and its complex and restrictive nature related to daily and prolonged slow
subcutaneous infusions. Extremely small, lighter infusion pumps may improve
compliance. Yet, it is clear that the availability of oral chelators is a great advan-
tage and welcomed by the patients. Although deferiprone (an oral iron chelator,
also called L1) has been approved and is used in Europe, it is not approved for
use in the United States. In the United States, deferasirox was recently licensed
for the treatment of transfusion-associated iron overload (see Chapter 23 for
details).
4.1.9. ALLOANTIBODY AND AUTOANTIBODY FORMATION
In the United States, 10 to 30% of patients with transfused SCD develop
allosensitization leading to alloantibody (mainly C, E, K, and S) and autoanti-
body formation. The main reason is the discrepancy in minor blood groups in the
donor population (predominantly white), and the recipients (most likely African-
American). Allosensitization possibly activates the immune system into a hyper-
active state leading to further, earlier, multiple, and simultaneous alloantibody
and autoantibody formation making it extremely difficult to find compatible
blood for transfusion. The formation of auto- and alloantibodies can be decreased
by consistently using C, E, and K antigen-matched blood.
4.1.10. SPLENIC AND LIVER SEQUESTRATION
About 25% of patients with SCD develop a sudden massive pooling of blood
in spleen that may rarely be asymptomatic. Of these cases, 80% occur before the
second birthday. The patients commonly present with pallor, prostration, decreased
activity, abdominal pain, massive splenic enlargement frequently associated with
an upper respiratory infection or acute chest syndrome, and positive blood cul-
ture in 16% of patients. If untreated, 20% die and 50% of survivors will experi-
ence a repeat attack. Parental education directed to teaching splenic palpation
and seeking immediate help on above symptoms can increase the incidence
threefold and decrease mortality 10-fold. Resuscitation, hydration, cautious small
transfusion (as the pooled blood is released after transfusion, causing hypervis-
cosity and stroke), should be followed in some cases by chronic transfusion
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program until child is more than 2-yr-old. At this time a splenectomy is per-
formed and the patient urged to take penicillin daily for an indefinite period.
Liver sequestrations are mild and less sudden because liver is not as distensible
as the spleen.
4.1.11. PRIAPISM
Priapism is described as unwanted, often excruciatingly painful, sustained or
intermittent (stuttering) erection that is not the result of sexual stimulation and
is detrimental to the sexual organ structure and function. Priapism is not uncom-
mon in SCD.
The mechanism of priapism is probably a gradual hypoxemia during the stasis
of the blood in the corpora cavernosa and red cell sickling. When priapism takes
place in sleep, it also results from sickling of the red cells in the corpora. The
glans and corpus spongiosa are often not involved because the latter tumescence
is often caused by erection associated with sexual desire. The treatment of pri-
apism is aimed at rapid pain relief and the detumescence of the penis in order to
preserve function and prevent complications. The treatment is generally hydra-
tion, pain control, and exchange red cell transfusions, if necessary. Partial
exchange transfusion must be instituted if the priapism lasts longer than 12 h.
If these measures are not effective, irrigation of the corpora can be effective.
Surgical creation of shunts is reserved for patients who are resistant to all treat-
ments. On a case report basis, a response was observed to β-agonists. Other drugs
such as hydroxyurea or bicalutamide and α-adrenergic agonists have been used
with inconsistent results.
Finally, patient education to maintain good hydration, exercise, avoidance of
constipation, and sexual counseling are important elements in the treatment plan.
4.1.12. OTHER COMPLICATIONS
There are many other complications associated with SCD, such as dermatopa-
thy, retinopathy, nephropathy, endocrinopathy, and neuropsychiatric problems.
It is preferable that the patients are directly referred to experts for these issues.
4.1.13. NEW TREATMENTS
Hydroxyurea was shown to reduce the frequency of pain crises, acute chest
syndrome, and the need for blood transfusions. The mechanisms of action of
hydroxyurea include increased production of HbF and an alteration of the adhe-
sive properties of leukocytes. Not all patients respond to hydroxyurea; most need
regular blood counts and may have side effects. Contraception is necessary for
patients who can conceive or become pregnant. Other agents that induce HbF are
under investigation. Further future treatments include agents that block endothe-
lia–leukocyte interaction, ion-channel blockers to improve red cell hydration,
inhalation of nitric oxide, and gene therapy. Hematopoietic stem cell transplan-
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tation (SCT) is the only treatment at present that can cure SCD. In children with
severe SCD who had a matched-related donor, a transplant-related mortality of
5% or less and a long-term survival of 90% were reported. At present, few
children with SCD have undergone an allogeneic transplantation. Transplants
for adults using reduced intensity conditioning, using cord blood or matched-
unrelated donors are currently under development.
4.2. Thalassemias
In adults, the predominant Hb molecule has four chains: two α- and two β-chains
(HbA). In thalassemias, the synthesis of either the α- or the β-chains is reduced or
absent, thus preventing the formation of a normal Hb molecule. In α-thalassemias
the α-chain is reduced or absent, whereas in β-thalassemias the β-chain is reduced
or absent. The excess globin chains denature in the red cell precursors and cause
premature cell death. The two forms of thalassemias (α or β) differ in their
clinical presentation and severity. The α-thalassemias are more frequent in per-
sons of African, Mediterranean, or Asian descent, whereas the β-thalassemias
are more frequent in persons from Southeast Asia.
4.2.1. β-THALASSEMIAS
Two main variants of β-thalassemias exist: in the β0-form, no β-chains are
produced, and in the β+-form, a reduced amount of β-chains is produced (10–
20%). The molecular pathogenesis of β-thalassemias is heterogeneous. More
than 150 different mutations in the β-globin gene have been described. Most
lesions are point mutations, and some involve small deletions.
In the β0-type, the levels of HbF are raised, HbA is absent, and HbA2 has a
variable concentration. The β+-type is associated with raised HbF, a variable
amount of HbA, and normal HbA2. The most severe disease develops in homozy-
gous patients (thalassemia major, Cooley’s disease). The clinical symptoms
begin about 4–6 mo after birth when HbF is normally replaced by HbA. In
patients with β-thalassemia, HbF persists. In addition, the free α-chains have
toxic effects and lead to an ineffective erythropoiesis. Clinically, homozygous
patients with β-thalassemia have a severe hemolytic anemia and are icteric. A
hepatosplenomegaly develops. Bone changes develop, as a result of the erythroid
hyperplasia in the hematopoietic marrow. These changes are obvious in children
with frontal bossing. The bones are prone to fractures as a result of a thinning of
the cortex. As a pathogenic cofactor, increased endogenous erythropoietin levels
are observed. Furthermore, the iron reabsorption is increased because of anemia.
As a result, and also because of repeated transfusions, children with β-thalas-
semia develop iron overload. They have a pigmented skin and may develop the
symptoms of heart failure (hemosiderosis). Bacterial, viral, and fungal infections
are common, especially after splenectomy.
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4.2.1.1. Laboratory Diagnosis. Patients with β-thalassemia have a hypo-
chromic microcytic anemia, increased reticulocytes with normoblasts, and target
cells in the peripheral blood. An iron overload is indicated by elevated iron and
ferritin levels in the serum and an increased saturation of the serum iron-binding
capacity. Hb electrophoresis reveals the absence or only a faint band of HbA,
whereas HbF is increased. HbA2 (2α2γ-chains) may also be increased. The
molecular defect can be identified by Southern blotting or PCR.
4.2.1.2. Treatment. Patients with homozygous β-thalassemia need regular
transfusions to maintain the hemoglobin concentration above 9.5 or 10 g/dL.
Chronic transfusions lead to an iron overload; therefore, an iron chelation therapy
with desferoxamine should be given to these patients. Details of the chelation
treatment with desferoxamine and oral iron chelaters are given in Chapter 23.
The substitution of folic acid is beneficial for many patients with β-thalassemia.
Patients requiring very frequent transfusions (>220 mL/kg/yr) may benefit from
splenectomy. Splenectomy should be deferred until a child has reached the age
of 6 yr. All infections should be treated promptly. Splenectomized patients should
receive a lifelong penicillin prophylaxis. Patients with β-thalassemia have suc-
cessfully undergone bone marrow or SCT from human leukocyte antigen (HLA)-
identical siblings.
4.2.2. α-THALASSEMIAS
The most severe form (deletion of all four α-genes) is not compatible with life
beyond the fetal stage and leads to hydrops fetalis. When only three chains are
deleted, a moderately severe hypochromic microcytic anemia results (HbH dis-
ease). This hereditary condition is usually caused by deletions removing all but
one single α-globin gene (deletional HbH disease). A small number of patients
have deletions removing two α-globin genes plus a nondeletional mutation af-
fecting a third α-globin gene (nondeletional HbH disease, generally with a more
severe clinical course). HbH disease has a wide phenotypic variability from
asymptomatic to severe anemia with hepatosplenomegaly. In a proportion of
patients, growth retardation is observed during childhood and iron overload in
adults regardless of the number of blood transfusions. This can lead to heart,
liver, and endocrine dysfunction. In contrast to α-chains, the free β-chains do not
form precipitates but aggregate to tetramers, which are relatively unstable. Red
cells with such aggregates have a shortened life span and are sequestered and
hemolyzed in the spleen. If only one or two α-chain genes are deleted, the hemoly-
sis is generally well compensated. The hemoglobin concentration is normal in most
cases, yet the red cells are hypochromic and microcytic (α-thalassemia trait).
4.2.3. THALASSEMIA INTERMEDIA AND OTHER HEMOGLOBINOPATHIES
Milder forms of thalassemia that do not need transfusions are termed thalas-
semia intermedia. Patients with this form sometimes have skeletal abnormalities,
delayed development, or leg ulcers. The cause of thalassemia intermedia is het-
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erogeneous: some patients have a homozygous β-thalassemia with high levels of
HbF and others have heterozygous β-thalassemia with other globin defects.
Genetic screening for hemoglobinopathies is recommended for all women
belonging to a high-risk population. The first step is to determine if the mother
is heterozygous for the major hemoglobinopathies (e.g., by hemoglobin electro-
phoresis). If this is the case, the father should also be screened. If he has the same
abnormality, there is a 25% chance that the fetus is homozygous and has signifi-
cant disease. These cases should be referred to a center specializing in the treat-
ment of hemoglobinopathies and offering prenatal counseling. In most cases of
hemoglobinopathy, a prenatal diagnosis by DNA analysis and PCR amplifica-
tion is possible. If the diagnosis of thalassemia major is made early, the option
of abortion can be offered to the parents.
4.3. HbC Disease
HbC alleles are common in patients from West Africa. Worldwide, homozy-
gosity for HbC (HbC disease) is the third most common hemoglobinopathy
involving a mutated gene (after SCD and HbE). Clinically, HbC disease is gen-
erally benign, associated with a mild hemolytic anemia and slight splenomegaly.
On blood smears, target cells, microspherocytes, anisocytosis, poikilocytosis,
and rod-shaped cells (containing HbC crystals) are found. HbC disease generally
requires no treatment, although in severe cases folic acid should be supple-
mented. Symptomatic disease is observed when HbC alleles are co-inherited
with other hemoglobinopathies (e.g., a sickle cell gene).
4.4. HbE Syndromes
HbE alleles are common in patients from Southeast Asia. In the homozygous
state, a mild anemia, microcytosis, and target cells are observed.
4.5. Methemoglobinemia
Methemoglobinemia is a condition in which excess methemoglobin (oxidized
Hb, unable to carry oxygen) is found in the blood. Normally, the level of meth-
emoglobin is maintained at less than 1% in red cells by NADH diaphorase.
Methemoglobinemia may be congenital, resulting from enzyme defects or abnor-
mal Hb, or acquired as a result of toxins or drugs (among others, local anesthetics,
sulfonamides, nitrates, and nitroprusside). Clinically, patients with acquired
methemoglobinemia are cyanotic and have an altered mental status, especially
if the methemoglobin concentration is greater than 20–30%. The cyanosis does
not respond to oxygen inhalation. In severe cases (methemoglobin >30–40%), a
treatment with the reducing agent methylene blue should be considered. Meth-
ylene blue should be avoided in patients who are G6PD-deficient, as it is inef-
fective and may precipitate hemolysis. For such patients, an exchange transfusion
is indicated.
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5. ACQUIRED HEMOLYTIC ANEMIAS
5.1. Autoimmune Hemolytic Anemias
These anemias are caused by the development of autoantibodies against red
cells and the subsequent destruction of the antibody-coated red cells. There are
two types: the autoimmune hemolytic anemias (AIHA) of the warm type with the
antibody reacting best at 37°C and AIHA of the cold type with the antibody
reacting best at 4°C. Both forms have a positive direct antiglobulin test (Direct
Antiglobulin Test [DAT], Coombs’ test) demonstrating the presence of antibod-
ies (IgG, IgA, or IgM immunoglobins) or complement (C3, C3d) on the surface
of red cells. A negative DAT does not exclude the diagnosis of AIHA, as the
antibody may be of weak affinity. Inversely, a positive DAT is not in all cases
associated with an overt hemolytic anemia. The principle of the antiglobulin or
Coombs’ test is outlined in Fig. 22.2. Both forms of AIHA can present as an acute
or chronic disorder and can be idiopathic or secondary to other disorders. The
hemolysis in AIHA is of the delayed type: the antibody-coated red cells undergo
hemolysis in the spleen’s reticuloendothelial system. Drug-induced autoimmune
hemolytic anemia often is induced by a drug or a metabolite binding tightly to red
cells or exposing a neoantigen on red blood cells after drug. In many instances,
AIHA is a sign of an acquired immune imbalance.
5.1.1. AIHA OF THE WARM TYPE
The disease is often idiopathic but may also be associated with autoimmune
disorders such as systemic lupus erythematosus, certain lymphomas, chronic
lymphocytic leukemia; certain drugs such as methyldopa, procainamide,
diclofenac, some antibiotics; and cytostatic drugs, as well as with other diseases.
5.1.1.1. Clinical Presentation. AIHA can occur at any age. The hemolytic
anemia is of variable severity. Patients experience fatigue, dyspnea, and jaun-
dice, and the spleen may be enlarged. During an acute hemolytic crisis, patients
may be febrile. In rare cases, AIHA is associated with an autoimmune
thrombopenic purpura (Evan’s syndrome).
5.1.1.2. Laboratory Features. The laboratory findings are typical of a
hemolytic anemia. Microspherocytes can be seen in the blood film. The DAT is
positive, most often as a result of IgG ± complement on the red cells. In rare cases,
hemolysis is due to IgA antibodies, which are not detected with commercial IgG/
C3 antisera. If the autoantibody is produced at high concentrations, free antibody
can also be found with the indirect antiglobulin test. The autoantibodies often
have blood group specificity (e.g., recognizing rhesus [Rh], Kidd, or Landsteiner-
Wiener [LW] antigens on red cells).
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5.1.1.3. Treatment.
1. Blood transfusions may be necessary for severe, symptomatic anemia and should
be given according to the same standards used for other anemic patients. If the
specificity of the autoantibody is known, red cell concentrates negative for this
antigen should be transfused if possible. The presence of alloantibodies result-
ing from previous transfusions or pregnancy has to be excluded. Because of the
presence of autoantibodies, it is often difficult to find compatible red cell concen-
trates. Hence, the least incompatible blood is transfused with informed consent
and adequate monitoring (to recognize an acute hemolytic transfusion reaction).
2. Any underlying cause of AIHA should be treated and any offending drug (e.g.,
methyldopa) should be withdrawn.
3. Corticosteroids are the standard treatment for AIHA. The starting dose is 1–2
mg/kg prednisone per day, which should be reduced according to the clinical
response. Some patients need a maintenance dose for many months. Some criti-
cally ill patients may need a higher dose of steroids initially (intravenous methyl
prednisone).
4. Splenectomy is indicated for patients who are refractory to corticosteroids, or
who need a high-maintenance dose. A preoperative study with radioactively
labeled red cells may be helpful to predict the efficacy of splenectomy.
5. An immunosuppressive treatment (e.g., with cyclophosphamide, cyclosporine,
or azathioprine) may improve the hemolysis in patients who do not respond well
to corticosteroids.
6. High-dose immunoglobulins (similar to the treatment of idiopathic thrombo-
cytopenic purpura, see Chapter 20) may be effective in some cases of AIHA.
7. Rituximab (a humanized monoclonal antibody against CD20) has shown effi-
cacy in some cases of refractory AIHA.
8. Plasmapheresis can be used as the last resort; however, the IgG antibody can be
present in very high concentration in tissues, so is not cleared by plasmapheresis.
5.1.2. AIHA OF THE COLD TYPE
This disorder may also be idiopathic or associated with infections (e.g., myco-
plasma pneumonias, infectious mononucleosis), with lymphomas or as part of the
cold agglutinin syndrome. The antibody is almost always IgM and has a binding
optimum at lower temperatures. After an exposure to cold temperatures, the
antibody binds to the red cells, activates the complement, and initiates hemolysis.
As in warm-type AIHA, the red cells are phagocytosed by the reticuloendothelial
system, most often in the liver. In contrast to the warm type, intravascular hemoly-
sis is also seen.
5.1.2.1. Clinical Features. Hemolytic crises and other clinical signs are
aggravated in the cold. Many patients develop acrocyanosis when exposed to
cold temperatures. Jaundice and splenomegaly may also be present.
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5.1.2.2. Laboratory Features. The laboratory features are similar to those for
warm-type AIHA, except that the red cells tend to agglutinate in the cold. The
DAT is usually positive and shows the presence of complement on red cells.
Serum antibodies, if present, are IgM. The specificity of the antibody is often
anti-I (anti-i in newborns). In some cases, the antibody has specificity within the
ABO, MNS, or LW systems. The cold autoantibodies may be polyclonal (in
cases associated with infections or low-grade lymphomas) or monoclonal (in the
case of the cold agglutinin syndrome). In the cold agglutinin syndrome, very high
titers of the autoantibody may be observed.
5.1.2.3. Treatment. The principal mode of treatment is to avoid exposure to
the cold. If an underlying cause of the AIHA can be identified, this cause should
be treated. Corticosteroids and splenectomy are rarely effective, because of the
intravascular nature of hemolysis. In very severe acute cases, plasmapheresis
may be helpful in stopping the hemolysis especially because IgM, being a large
molecule, remains in vascular space and can be easily removed. In chronic cases,
immunosuppressive agents (e.g., chlorambucil or cyclophosphamide) may be
effective. In severe symptomatic anemia, washed red cell concentrates must be
transfused to avoid the infusion of additional complement. The transfusion should
be made with a blood warmer. In refractory cases, rituximab was found to be
effective.
Paroxysmal cold hemoglobinuria is due to a biphasic IgG antibody (reacting
both at warm and cold temperatures, Donath Landsteiner antibody). This syn-
drome is observed in tertiary syphilis and in children after a viral illness. Parox-
ysmal cold hemoglobinuria is usually self-limited, but may cause significant
intravascular hemolysis
5.2. Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal stem cell
disorder. In PNH, the phosphatidyl-inositol-glycan (PIG) anchor molecules are
defective. As the molecular basis of PNH, the mutation of the PIG-A gene on the
short arm of the X chromosome has been found. Until now, more than 100
different mutations of the PIG-A gene have been described, including missense
and frameshift mutations, splice defects, and other mutations. The defect of the
anchor molecules can be present in all or only some hematopoietic lineages. This
glycolipid anchor attaches several proteins to the cell membrane that are impor-
tant for the regulation of complement molecules (among them CD59 [membrane
inhibitor of reactive lysis], CD55 [decay accelerating factor], and C8 binding
protein). A defect in these molecules leads to a higher sensitivity to complement-
mediated lysis and a tendency for thrombosis. Other surface molecules, CD14,
CD24, and CD66, are also missing on PNH cells. PNH is a rare disorder that
manifests as a chronic hemolytic anemia or as pancytopenia. Some patients have
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hemolytic crises during the night and become aware of red urine (hemoglobin-
uria) in the morning. The major complications include recurring thromboses,
such as portal vein thromboses and thromboses of the cerebral vessels or of the
cutaneous veins. Sudden severe headaches or abdominal pain should always
alert the clinician to the possibility of a thrombosis in any patient with PNH. A
chronic iron loss often leads to an iron deficiency anemia.
A common finding is a normochromic, normocytic anemia. Some patients are
granulocytopenic and thrombocytopenic. The laboratory signs are consistent
with a chronic hemolytic anemia. Increased hemolysis is observed during infec-
tions. The diagnosis of PNH was classically made with the acid hemolysis or the
sucrose test (the addition of sucrose or acidified serum leads to enhanced in vitro
hemolysis). However, it is more convenient and reproducible to measure the
expression of anchor molecules in different cell compartments by flow cytometry.
A screening test for PNH is to measure different blood cells for the expression
of CD55 or CD59. In most patients, three types of PNH cells can be distin-
guished: type III cells, which totally lack GPI-anchored molecules; type II cells
with a severely reduced expression; and type I cells, which have retained an
approximately normal surface expression.
PNH can evolve into other entities (e.g., aplastic anemia, myelodysplasia,
and, rarely, acute leukemia) and, vice versa, PNH clones can be recognized in a
proportion of patients with aplastic anemia.
The treatment of PNH is mainly supportive. If frequent thromboses occur, the
patients should be anticoagulated. A major thrombosis should be treated with
thrombolysis and heparin. Iron and folic acid should be substituted. A pulse of
corticosteroids may be indicated during a hemolytic crisis. Danazol (an androgen
derivative) can also be considered in the treatment of PNH. Blood transfusions
should be given if a symptomatic anemia develops. The prognosis of PNH depends
on disease severity. Uncomplicated cases may survive with the disease for more
than 10 or 15 yr. If PNH leads to progressive complications, a bone marrow or
SCT from an HLA-identical sibling may be worth considering and may offer a
chance for cure.
5.3. Hemolytic Disease of the Newborn
Among the conditions causing hemolytic disease of the newborn (HDN), the
maternal alloimmunization due to blood group incompatibility between the mother
and the fetus is the most common. HDN due to ABO antibodies is the most frequent
type, whereas Rh antibodies may cause the most severe type of disease.
5.3.1. HDN DUE TO ABO ANTIBODIES
About two-thirds of HDN are due to ABO incompatibility. The HDN pre-
dominantly occurs in an infant with the blood group A or B of an O mother. The
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disease shows a broad spectrum of severity, with mild to moderate symptoms in
Caucasians and severe disease in African and Chinese neonates; about one-third
of the cases occur in India. The diagnosis of ABO HDN is difficult, as the indirect
antiglobulin test is usually negative or only weakly positive and the estimation
of IgG anti-A or anti-B is complicated by the presence of a large amount of
naturally occurring IgM ABO antibodies. It is necessary to neutralize maternal
serum with secretor saliva or to treat it with 2-mercaptoethanol or dithiothreitol
prior to the estimation of anti-A or anti-B IgG. Some cases of ABO HDN are
associated with microspherocytosis and increased osmotic fragility. The hemo-
globin of the infant is generally normal, and reticulocytosis or normoblastosis is
present only in severe cases. Mild to moderate ABO HDN can be treated by
phototherapy, whereas severely affected infants need an exchange transfusion.
5.3.2. HDN DUE TO RH ANTIBODIES
Because anti-D immunoglobulins have become available for prophylaxis, the
Rh HDN has almost been completely eradicated. Because the Rh antigen exists
only on human red cells, the entry of Rh (D)-positive erythrocytes into the
maternal circulation is a prerequisite for Rh immunization. In some cases, a
fetomaternal hemorrhage before delivery is the cause of sensitization. However,
even before the anti-D-prophylaxis was available, not all Rh-negative women
who were exposed to Rh-positive erythrocytes became sensitized.
The diagnosis of Rh HDN is easily established when Rh (D) antibodies are
detected in the human serum and the antiglobulin test is positive on the fetal
erythrocytes. Maternal IgG antibody can cross the placental barrier and coat Rh
(D) positive red cells, thus reducing their life span. The disease occurs in intrau-
terine life and hydrops fetalis is the most severe clinical manifestation. Antenatal
assessment is therefore essential to identify a severely affected fetus and rescue
it by intrauterine transfusion (IUT). The noninvasive parameters that can predict
severity include periodic measurements of Rh antibody levels and periodic
ultrasound examinations. A spectroscopic analysis of the amniotic fluid is
helpful although it involves amniocentesis (relatively safe under ultrasound
guidance). It is also possible to obtain fetal blood to confirm the diagnosis of Rh
HDN and to assess the degree of anemia by determining hemoglobin and hema-
tocrit. However, considering the risk involved with this procedure, it should be
carried out only when the fetus is suspected to be critically ill and requiring an IUT.
The IUT is usually planned when the mother has high titers of anti-D antibod-
ies, the amniotic fluid shows increasing bilirubin (Liley’s zone II or III), and/or
ultrasound reveals ascites. If the hemoglobin concentration is more than 2 g/dL
lower than the normal value at the same age of gestation, then an IUT is per-
formed. An IUT can be given as early as 18 wk gestation and must be repeated
at 1- to 3-wk intervals. Fetuses who had multiple IUTs generally do not need
exchange transfusion but may need a simple transfusion at birth. In alloimmu-
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nization due to Rh HDN, the delivery is induced after 32 or 34 wk depending on
the facilities available in the intensive care unit. Infants who did not require an
IUT may require a preventive exchange transfusion immediately after birth. All
cases of Rh HDN usually receive phototherapy to convert bilirubin into a non-
toxic form. If hyperbilirubinemia is present at birth, an exchange transfusion
should always be performed to prevent the possible risk of permanent neurologi-
cal damage (kernicterus). Other antibodies, such as anti-Kell antibodies, may
also cause HDN, although usually of a less severe form than Rh HDN. The
management of these cases depends on the degree of severity.
5.4. Special Forms of Acquired Hemolytic Anemias
Vascular changes and a toxic alteration of the endothelium can also cause a
shortened survival and premature hemolysis of red cells. In many of these con-
ditions, an abnormal red cell morphology is found (e.g., fragmentocytes,
schistocytes in blood smear). Several infections, for example, malaria and babe-
siosis, may cause a massive hemolytic anemia. In meningococcal sepsis, toxins
damage the endothelium and lead to a microangiopathic hemolytic anemia.
5.4.1. HEMOLYSIS DUE TO PARASITIC INFECTIONS
Although malaria is rarely seen in the West, it remains a major health problem
elsewhere in much of the world. Individuals visiting or inhabiting sub-Saharan
Africa, Central or South America, the Middle East, Southern Asia, or Polynesia
are at risk for this infectious cause of hemolytic anemia. Malaria is caused by four
protozoan species of the genus Plasmodium: P. vivax, P. falciparum, P. malariae,
and P. ovale. These protozoans are transmitted into the blood of the host by the
saliva of the Anopheles mosquito. The parasites enter the blood as sporozoites
and initially infect hepatocytes, where they proliferate and develop into merozoi-
tes. The merozoites reenter the blood, where they infect red blood cells, repro-
duce asexually, and emerge to infect additional erythrocytes. It is important to
note that P. vivax and P. ovale can persist as dormant forms in the liver, which
can be reactivated at a later time. The symptoms of malaria include fevers, chills,
fatigue, and headache. In addition to these symptoms, patients infected with
P. falciparum may present with altered mental status, acute renal failure,
respiratory distress, or gastroenteritis. These clinical manifestations are due to
the tendency of red cells infected with P. falciparum to adhere to endothelial cells
of the vasculature and cause diffuse microvascular occlusions. Physical exami-
nation may reveal splenomegaly, particularly in patients who are chronically
infected or in those with P. falciparum. Laboratory tests are remarkable for
evidence of an extravascular hemolytic anemia. Diagnosis is made by examining
a thick peripheral blood smear for the presence of the parasites. Identification of
the Plasmodium species is determined by examining the morphology of the
organisms on the slide. Treatment of malaria depends on the species of the
124 Munker et al.
infecting parasite, the severity of the illness, and the likelihood that the organism
is chloroquine resistant. Chloroquine-sensitive malaria may persist in Central
America, the Middle East, and the Caribbean. Guidelines for the treatment of
malaria and prophylactic measures for travelers are given in Table 5.
Babesiosis is a hemolytic anemia due to infection of erythrocytes by piriform
(pear-shaped) protozoans. In Europe, the disease is caused by Babesia divergens
and B. bovis, which usually are bovine parasites. On the east coast of the United
States, B. microti, a rodent parasite, is the etiological organism. On the west
coast, a recently identified piroplasm called WA1 has been found in several
cases. All of these organisms are transmitted by ticks of the genus Ixodes. Babe-
siosis can also be transmitted by blood transfusions. Babesiosis is usually a mild,
self-limited disease, but immunosuppressed patients, and especially individuals
who have undergone splenectomy, may have severe and life-threatening disease
manifestations. These patients can experience fevers, chills, headache, fatigue,
myalgias, and arthralgias at presentation, but respiratory and renal failure may
subsequently ensue. Physical examination may reveal icterus and mild splenom-
egaly. Laboratory results demonstrate an extravascular hemolytic anemia, and
frequently thrombocytopenia. A thick smear of the peripheral blood reveals
intraerythrocytic parasites, and an intracellular tetrad of merozoites is pathogno-
monic for babesiosis. Babesia may be overlooked, because parasitemia is often
sparse, infecting less than 1% of erythrocytes early in the course of illness.
Serological testing can confirm the diagnosis. Treatment consists of quinine
sulfate 650 mg po TID and clindamycin 600 mg po three times daily (1200 mg
i.v. twice daily) for 7–10 d. As an alternative, the combination of azithromycin
and atovaquone was found effective. A chronic carrier state may be established
if the treatment is not completed. In severe cases, an exchange transfusion may
be life-saving.
Bartonellosis (Carrion’s disease or Oroya fever) is endemic in parts of South
America and is caused by Bartonella bacilliformis. Bartonellosis causes an acute
hemolytic anemia and a chronic granulomatous reaction. The infectious agent is
transmitted by the bite of sand flies. Untreated, bartonellosis has a high mortality.
On peripheral blood smears, the intraerythrocytic bacilli can easily be recog-
nized. Several antibiotics (ciprofloxacin, penicillin, streptomycin) have been
found effective for bartonellosis.
5.4.2. MICROANGIOPATHIC ANEMIAS
In these conditions (hemolytic-uremic syndrome, thrombotic thrombo-
cytopenic purpura, see Chapter 20) toxins damage the endothelium and the red
cells or platelets that come into contact with the endothelium are destroyed.
Fragmentocytes may be present in the peripheral blood smear. Similar condi-
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Table 5
Treatment and Prophylaxis of Malaria
Treatment of malaria due Inpatient therapy of chloroquine-sensitive
to Plasmodium vivax, P. malariae, disease:
or P. ovale chloroquine phosphate 10 mg base/kg i.v. over
8 h, then 15 mg base/kg i.v. over 24 h.
Outpatient therapy of chloroquine-sensitive
disease:
chloroquine phosphate l0 mg base/kg orally
(p.o.), then 5 mg base/kg p.o. after 12, 24, and 36 h.
Concurrent therapy for patients with P. vivax or
P. ovale: primaquine 0.25 mg base/kg p.o. daily
×14 d (avoid in pregnant women and newborns)
Therapy of chloroquine-resistant disease:
halofantrine 8 mg/kg p.o., then 8 mg/kg p.o. after
6 h, 12 h, and 7 d with primaquine 0.5 mg base/
kg p.o. daily ×28 d (avoid primaquine in pregnant
women and newborns).
Treatment of malaria due Quinidine gluconate 10 mg/kg IV over 1 h, then 0.02
to P. falciparum mg/kg/min with electrocardiogram monitoring
until patient is able to take oral medications, then
quinine sulfate 10 mg salt/kg p.o. every 8 h with
doxycycline 100 mg p.o. twice daily for 7 d.
Substitute pyrimethamine-sulfadoxine
(pyrimethamine 20 mg/kg and sulfadoxine 1 mg/
kg) for doxycycline in children and pregnant
women.
Prophylaxis in areas free Chloroquine 8.3 mg salt/kg, up to 500 mg, p.o.
of chloroquine resistance weekly beginning 1–2 wk before travel and
continuing until 4 wk after travel.
Prophylaxis in areas Mefloquine 250 mg salt p.o. weekly in adults
with chloroquine resistance beginning 1 wk before travel and continuing until
4 wk after travel, or doxycycline 100 mg p.o.
daily beginning on the first day of exposure and
continuing until 4 wk after travel. Both
are contraindicated in pregnancy and
doxycycline is contraindicated in children.
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tions occur after bone marrow transplantation or after the administration of cer-
tain drugs (e.g., cyclosporine, cisplatin, mitomycin C).
5.4.3. DISSEMINATED INTRAVASCULAR COAGULATION
Disseminated intravascular coagulation (DIC) results from a number of con-
ditions in which the systemic activation of the coagulation cascades occurs,
resulting in the deposition of fibrin thrombi within the microvasculature. The
causes of DIC and treatment strategies are described in Chapter 20.
5.4.4. OTHER CAUSES OF RED BLOOD CELL HEMOLYSIS
Various forms of trauma can induce red cell fragmentation and intravascular
hemolysis. Intravascular red cell injury can be caused by mechanical heart valves
or prosthetic vascular devices. External trauma from prolonged marching or
running, or playing bongo drums, also can induce red cell fragmentation with
hemolysis. Severe burns can directly damage red blood cells. Lead poisoning
causes chronic hemolysis in addition to sideroblastic anemia. Copper toxicity
due to industrial exposure or Wilson’s disease also is associated with red cell
hemolysis. Hypophosphatemia, for example, during parenteral nutrition, can
shorten red cell survival. Exposure to hypotonic fluid, as in near-drowning, can
induce hemolysis. Enzymes produced by clostridial organisms can cause mas-
sive intravascular hemolysis. Envenomation by some spiders and snakes also can
disrupt red blood cell membranes.
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1. DEFINITIONS AND PATHOPHYSIOLOGY
Most changes in the white blood cell count are reactive and due to an increase
or decrease of cells of the myeloid series. By definition, a leukocytosis is present
if leukocytes are increased to more than 10,000/µL; in leukopenia leukocytes are
below 4000/µL. Infants and small children have slightly different normal values
(for the normal values of blood counts, see Appendix 3). A neutropenia is present
if granulocytes are below 2000/µL, agranulocytosis if granulocytes are below
500/µL. By definition, granulocytes are increased if they are greater than 8000/
µL. In leukemoid reactions, leukocytes are increased to more than 30,000/µL. A
left shift in the differential count means that the number of band forms (and other
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precursors such as metamyelocytes) is increased to more than 5%. In a pathologi-
cal left shift, more immature precursors such as promyelocytes can be seen in the
peripheral blood; this is almost always a sign of a hematological disorder.
The granulocytes of the peripheral blood derive from the bone marrow. The
earliest cell is the pluripotent stem cell, which is capable of self-renewal (see
Chapter 1). Several steps of division and differentiation lead to mature cells
(granulocytes), which are capable of fighting infections. The intermediate cells,
which can be recognized morphologically, are myeloblasts, promyelocytes,
myelocytes, and metamyelocytes. Cells of the myeloid series are produced under
the control of interacting cytokines according to the needs of the organism.
Approximately 40% of the cells in the peripheral blood are in a reserve pool on
the endothelium (marginated pool) and can be mobilized rapidly in case of infec-
tion or other stress conditions.
2. DIFFERENTIAL DIAGNOSIS OF LEUKOCYTOSIS
(NEUTROPHILIC LEUKOCYTOSIS)
A leukocytosis is a sign of any number of bacterial or other infections. Most
cases of infectious leukocytosis are associated with a left shift and neutrophils
often show a toxic granulation. The bilobed granulocytes seen in Pelger-Huët
anomaly resemble band forms, but this rare condition with autosomal dominant
inheritance does not have pathological value (Fig. 7.1, see also Color Plate 2).
Similar granulocytes are occasionally seen in patients with acute myelogenous
leukemia (pseudo-Pelger cells). In severe infections, the granulocytes may de-
velop cytoplasmic inclusions or Döhle bodies (Fig. 7.2; see also Color Plate 3).
A massive leukocytosis (leukemoid reaction) most often indicates a severe
complication (gall bladder empyema, perforated appendicitis, or bacterial sep-
sis). Stress reactions with a leukocytosis of 10,000–15,000/µL are common after
epileptic seizures, renal colics, or myocardial infarctions. Nicotine and a treat-
ment with steroids or lithium often lead to a leukocytosis. Severe hemolytic
anemias and the regeneration from aplasia stimulate hemopoiesis in general and
are followed by a leukocytosis. Rare cases of lung cancer and bladder cancer
have a paraneoplastic leukocytosis. In these cases, it was shown that the tumor
cells produce cytokines such as granulocyte colony-stimulating factor (G-CSF)
or granulocyte/macrophage colony-stimulating factor (GM-CSF). Some per-
sons also have an idiopathic or familiar increase in leukocytes.
The major differential diagnosis of a neutrophil leukocytosis discovered in a
person without symptoms is an early stage of a chronic myelogenous leukemia
(CML) or other myeloproliferative syndrome (see Chapter 8). In CML, generally
the Philadelphia chromosome or the BCR-ABL oncogene can be found, whereas
a reactive leukocytosis harbors no cytogenetic aberrations.
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Fig. 7.1. Granulocyte of a patient with Pelger-Hu’t abnormality (two round nuclear lobes
are connected by a very thin strand and have the appearance of spectacles).
Fig. 7.2. Döhle bodies. Cytoplasmic inclusion in granulocytes, observed in severe infec-
tions.
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Children with Down syndrome sometimes have a leukemoid reaction in the
first few months of life which later subsides spontaneously. A leukoerythroblastic
reaction is defined by the appearance of myeloid and erythroid progenitors in the
peripheral blood. This is seen in osteomyelosclerosis and when the bone marrow
is infiltrated with tumor cells (bone marrow carcinosis).
3. DIFFERENTIAL DIAGNOSIS OF LEUKOPENIA
(GRANULOCYTOPENIA)
A slight neutropenia with granulocytes between 1000 and 2000/µL of idio-
pathic origin or that commonly found in certain ethnic groups does not normally
lead to an increased incidence of infections. The risk of serious infectious is
increased if the granulocytes are below 1000 and especially if they are below 500/
µL. Neutropenia or agranulocytosis can be a side effect of a number of drugs (see
“Agranulocytosis”). A dose-dependent leukopenia can also occur if large areas
of the bone marrow are irradiated. Postinfectious neutropenias are seen after
hepatitis, infectious mononucleosis, measles, varicella, and other viral infec-
tions. A moderate leukopenia is classic in typhoid fever, but can also be seen with
other infections such as tuberculosis or brucellosis. Congenital neutropenias
occur in several syndromes such as reticular dysgenesis. Kostmann syndrome is
defined as a congenital agranulocytosis. The pancreatic insufficiency and growth
retardation associated with Schwachmann-Diamond syndrome often presents
with neutropenia and frequent infections. Mutations in the ELA-2 gene encoding
neutrophil elastase were identified in about half of cases with severe congenital
neutropenia (SCN). In rare cases, a mutation of the zinc finger transcriptional
repressor Gfi1 was identified. It was proposed that mutations of the ELA-2 gene
lead to a mistrafficking of neutrophil elastase. A long-term follow-up of patients
with SCN and Schwachmann-Diamond syndrome has shown that 5–10% develop
myelodysplastic syndrome or acute myeloid leukemias. The transition to acute
leukemias is associated with monosomy 7, ras mutations, and mutations of the
G-CSF receptor. Further rare genetic diseases associated with neutropenia are:
Hermansky-Pudlak syndrome (mutation of the AP3B1 gene), Chediak-Higashi
syndrome (mutation of the LYST gene), Barth syndrome (mutation of the TAZ
gene), and Cohen syndrome (mutation of the COH1 gene). The disease entity of
cyclic neutropenia is discussed later. Autoimmune disorders like lupus erythe-
matosus frequently have neutropenia due to granulocyte antibodies. The Felty
syndrome (rheumatoid arthritis, leukopenia, and splenomegaly) also has an auto-
immune etiology. Leukopenia is often found in glycogen storage disorders.
Myelokathexis, a rare disorder with morphological aberrations of neutrophils,
also manifests as neutropenia. Finally, T-γδ-lymphocytosis, which was recently
classified as T-cell large granular lymphocyte leukemia (T-LGL), is often asso-
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ciated with a chronic neutropenia. The lymphocytes in T-LGL are clonal as can
be shown with T-cell receptor rearrangement. The characteristic immunophenotype
is CD3+, CD16+, and CD57+. Clinically, the patients with T-LGL have frequent
infections, occasional splenomegaly, and, rarely, hepatomegaly. Enlarged lymph
nodes are uncommon in T-LGL. Sometimes, an isolated neutropenia is of auto-
immune origin or is idiopathic. For patients with congenital, idiopathic, and
cyclic neutropenias, the clinical course and the treatment are documented in an
international registry.
Alloimmune neonatal neutropenia is observed in less than 0.3% of pregnan-
cies and caused by the transplacental transfer of immunoglobulin (Ig)G antibod-
ies to neutrophils. This type of neutropenia is often severe, causing neonatal
infections. However, with supportive care including antibiotics, the prognosis is
good. The neutropenia resolves by 6–8 wk after delivery.
The differential diagnosis of a newly diagnosed neutropenia includes a wide
spectrum of other hematological disorders, including aplastic anemias, leuke-
mias, myelodysplastic syndromes, pernicious anemias, malignancies with bone
marrow infiltration, and hypersplenism. These cases almost always have a bicyto-
or pancytopenia and other signs and symptoms (e.g., lymph node swelling, dys-
plastic changes). Further diagnostic work-up includes bone marrow studies with
cytology, histology, and immunological and molecular studies.
Treatment depends on the severity of the neutropenia. For a patient on a
medication known to be associated with neutropenia, discontinuation of the
medication should be the first measure. For a slight neutropenia, it is sufficient
to control the white cell count at regular intervals. The etiology of severe neutro-
penia should be investigated thoroughly. If the patients have frequent infections
and if no other etiology of the neutropenia can be found, a treatment with G-CSF
(filgrastim, see Chapter 2) should be started. Almost all patients with chronic
neutropenias or Kostmann syndrome respond to G-CSF and normalize their
white cell count. The rare cases of Kostmann syndrome that fail to normalize
their white cell counts are candidates for a bone marrow transplant. Leukopenias
during the course of autoimmune disorders often respond favorably to an immu-
nosuppressive treatment.
4. DRUG-INDUCED NEUTROPENIA (AGRANULOCYTOSIS)
Agranulocytosis has been described as a potentially severe side effect of a
number of drugs, including antithyroid drugs, phenothiazines, and antiarrythmic
drugs (incidence 0.01–2% per treatment course). A list of certain drugs associ-
ated with a risk of agranulocytosis is given in Table 1
As pathomechanisms, toxic and/or allergic reactions against myeloid pro-
genitors and granulocytes have been recognized. In a proportion of patients,
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serum antibodies reacting with the drug or with metabolites can be demonstrated.
Some cases of agranulocytosis occur without a preceding leukopenia (idiosyn-
cratic reaction). In many cases, a dose dependency was shown. For example,
penicillin-related agranulocytosis is more frequent after prolonged and high-
dose therapy. Renal failure or folic acid deficiency predispose, at least for some
drugs, to agranulocytosis.
In most cases, the clinical signs of agranulocytosis start as an acute infectious
episode, with high fever, sore throat, and mouth or gingival ulcers. The lymph
nodes of the neck are often enlarged and painful. The spleen may be enlarged or
of normal size. In the blood smear, the granulocytes are severely reduced or absent,
the absolute number of monocytes and lymphocytes may be decreased or is
normal. The red blood cells and platelets are normal. The bone marrow aspirate
shows a normal erythropoiesis and megakaryopoiesis. The myelopoiesis is se-
verely reduced, showing a typical block of maturation at the promyelocyte stage.
Bacterial infections often derive from the oropharyngeal cavity. After prolonged
neutropenia, fungal infections are also possible. The laboratory investigations
often show an increased sedimentation rate, C-reactive protein, and other mark-
ers of infection.
The first therapeutic measure is to discontinue all potentially offending drugs.
The patient should be hospitalized and kept in a germ-reduced environment. A
selective decontamination of the gastrointestinal tract is recommended. All
Table 1
Some Drugs Reported to Cause Neutropenia and/or Agranulocytosis
Antiarrhythmic and other cardiovascular drugs:
Procainamide, chinidin, aprindin, captopril
Antibiotics and antiviral drugs:
Penicillins, cephalosporins, sulfonamides, vancomycin, chloroquin, co-trimoxazole,
sulphasalazine, ganciclovir, zidovudin, dapsone
Anti-inflammatory and antirheumatic drugs:
Gold compounds, penicillamin, aminopyrine, phenylbutazone, diclofenac
Cytostatic and immunosuppressive drugs:
Most compounds of this group
 Antithyroid drugs:
Carbimazole, thiamazole, thiouracil
Psychotropic drugs:
Imipramine, clozapine, mianserine, chlorpromazine, thioridazine
Anticonvulsants:
Carbamazepine, valproic acid
Miscellaneous:
Ticlopidine, thiazide diuretics, cimetidine
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infections should be carefully investigated and treated without delay. Chapter 3
gives details about the treatment of infections in neutropenic patients. In most
cases of drug-induced agranulocytosis, a spontaneous regeneration of the myeloid
cells occurs after 5–9 d. In a few cases the recovery is delayed for up to 20 d. Often,
the patients develop a leukocytosis with a left shift which subsides after a few
days. Corticosteroids are not indicated in the treatment of the usual drug-induced
agranulocytosis. The hematopoietic growth factors (G-CSF, GM-CSF) hasten
the recovery of neutrophils and should be given in cases of protracted leucopenia
(for details, see Chapter 2). A renewed exposure to the incriminated drug should
be avoided.
As far as the prophylaxis of drug-induced agranulocytosis is concerned, any
drug treatment should be critically evaluated. Blood counts should be controlled
at regular intervals after the administration of drugs with a known risk of agranu-
locytosis (e.g., clozapine, but also antithyroid drugs). The prognosis of drug-
induced agranulocytosis is generally good, but older patients with co-incident
morbidity are at risk from sepsis.
5. CYCLIC NEUTROPENIA
In this rare disorder, infectious episodes occur in 19- to 23-d cycles. The
common infections, most often accompanied by high fever, are bacterial skin
infections, cellulitis, septicemias, and tonsillitis. Immediately before the fever
begins, the circulating neutrophils decrease to values below 200/µL; they gen-
erally recover after 4–5 d. Some cases have dominant inheritance, whereas in
some cases a new mutation is observed. The diagnosis is usually made in early
childhood; however, some cases become manifest only at the adult age. The
pathophysiological basis of cyclic neutropenia is a defect of the hematopoietic
stem cell. In many cases, germline mutations of the ELA-2 gene (different from
mutations seen in SCN) were identified. Some patients also have cyclic varia-
tions of platelets and reticulocytes. The treatment of cyclic neutropenia has much
improved since G-CSF was introduced into clinical practice more than 10 yr ago.
Subcutaneous G-CSF normalizes the neutrophil count of patients with cyclic neu-
tropenia; however, cyclic variations persist. The recommended dose of G-CSF is
approx 3–5 µg/kg; however, some patients need much lower doses or only an
intermittent treatment to normalize the neutrophil counts. The treatment with
G-CSF is indicated if the patient has frequent or severe infections. As in other
cases of neutropenia, the prophylaxis and treatment of infections is essential.
6. DIFFERENTIAL DIAGNOSIS OF EOSINOPHILIA
An eosinophilia (relative number of eosinophils 5%, absolute number >500/µL)
is a frequent sign of allergic reactions, asthma, skin disorders, angioedema, and
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parasitoses such as trichinosis and ascariasis. Many tropical disorders (e.g., filari-
asis) have an eosinophilia of 20–30%. Further disorders with eosinophilia are IgA
deficiency, Addison’s disease, disorders of autoimmunity, vasculitis (especially
Churg-Strauss syndrome), and eosinophilic gastroenteritis. The pathophysiol-
ogy of eosinophilia is the production of interleukin (IL)-5 mediated by activated
T-lymphocytes. Patients treated with the cytokines GM-CSF, IL-2, and IL-3
often develop eosinophilia. A paraneoplastic eosinophilia is sometimes observed
in Hodgkin’s lymphomas and some leukemias and lymphomas (especially of the
T-cell phenotype). The malignant clone of some myeloproliferative disorders
may also differentiate into eosinophils.
Idiopathic hypereosinophilic syndrome (IHES) is by definition an unexplained
eosinophilia of more than 1500/µL that lasts longer than 6 mo. This rare disorder
predisposes to organ complications which are due to the infiltration or degranu-
lation of eosinophils in various tissues. IHES is observed almost exclusively in
men and, if left untreated, has a poor prognosis. Complications such as intracavitary
thrombosis, endocardial fibrosis, and pulmonary and neurological disturbancies are
seen. Treatment should be started if the number of eosinophils increases rapidly
or if organ complications are imminent. Recently, a specific chromosomal (sub-
microscopic) deletion was identified in at least half of patients with IHES. This
deletion on chromosome 4 (del(4)(q12q12) creates the FIP1L1-PDGFR α fusion
gene. Because clonality is proven in such patients, they should be reclassified as
having chronic eosinophilic leukemia. Interestingly, patients with the fusion
gene respond well to low doses of the tyrosine kinase inhibitor imatinib. Most
patients treated so far have reached a molecular remission, but similarly to chronic
myelogenous leukemia, resistance to imatinib may develop during treatment.
Patients without the fusion gene generally have a transient or incomplete response
to imatinib. Patients who fail imatinib may control their eosinophil counts with
prednisone or hydroxyurea. Case reports have shown the efficacy of α-interferon,
2 chlorodeoxyadenosine, and cyclosporine A. As supportive treatment,
antihistaminics should be given.
The eosinophilia-myalgia syndrome is a multisystem disorder that was
reported several years ago and which was found to be caused by contaminants
in some L-tryptophan preparations used as nutritional supplements. The clinical
signs of the eosinophilia-myalgia syndrome were contractures of the skeletal
muscles, scleroderma-like skin lesions, and damage to the heart and lung.
7. DIFFERENTIAL DIAGNOSIS OF BASOPHILIA
A basophilia (>50 basophils/µL) can occur during many infections, in allergic
reactions, as a sign of thyrotoxicosis, in systemic mastocytosis, and in myelopro-
liferative syndromes. A clear basophilia in chronic myelogenous leukemia is a
sign of acceleration or impending blast crisis.
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8. DIFFERENTIAL DIAGNOSIS OF MONOCYTOSIS
A monocytosis (>1000/µL) is observed during some infections like tubercu-
losis, kala-azar, subacute bacterial endocarditis, disorders of autoimmunity, and
some malignancies. A relative monocytosis is common during recovery from
cytostatic therapies and after bone marrow transplantation. If monocytes are
increased to a larger extent, a differential diagnosis to some leukemias must be
made (especially acute monoblastic leukemias and chronic myelomonocytic
leukemia). In these cases, special stains and bone marrow and cytogenetic stud-
ies must be performed.
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1. INTRODUCTION
The myeloproliferative syndromes encompass four major clinical entities:
chronic myelogenous leukemia (CML), polycythemia vera (PV), essential throm-
bocythemia (ET), and idiopathic myelofibrosis (IM). These disorders are clonal
myeloid stem cell disorders characterized by the autonomous proliferation of the
clone, which results in the overproduction of one or more hematopoietic cell
lineages. The clinical presentation and natural history of each disorder is distinct,
but the features of the disorders often overlap (e.g., CML with myelo-fibrosis or
PV with thrombocytosis).
2. CHRONIC MYELOGENOUS LEUKEMIA
CML occurs predominantly in adults with a median age of approx 50 yr. It has
an incidence of 1–2 per 100,000 people in the West but it is less common in Asia.
Unlike the other myeloproliferative disorders, CML is a malignant process with
a well characterized cytogenetic abnormality.
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2.1. Basic Biology
CML is a clonal stem cell disorder with a classic cytogenetic abnormality, the
Philadelphia chromosome (Ph1), which results from a reciprocal translocation
between chromosomes 9 and 22 (Fig. 8.1). At the molecular level, this translo-
cation fuses the BCR gene to the ABL gene on chromosome 9, resulting in a
chimeric gene that encodes a unique fusion protein (usually 210 kD) with en-
hanced tyrosine kinase activity. Rarely, patients with CML have a variant trans-
location resulting in a smaller BCR-ABL protein (190 kD). This BCR-ABL
species is typically found in Ph1-positive acute lymphoblastic leukemia. Ap-
proximately 90% of patients with CML are found to have the Philadelphia chro-
mosome by routine cytogenetics. In most of the remaining patients, the Ph1
chromosome is absent but the BCR-ABL translocation can be detected by
flourescent in situ hybridization (FISH) or by reverse-transcription (RT)-PCR.
Disease progression in CML is associated with the acquisition of one or more
additional copies of the Ph1, or additonal cytogenetic abnormalities such as
trisomy 8. The BCR-ABL protein and its constitutive tyrosine kinase activity is
central to CML pathogenesis, as it affects numerous signaling cascades that
activate cell growth, inhibit apoptosis, and downregulate the expression of genes
encoding adhesion molecules.
Fig. 8.1. Chronic myelogenous leukemia. Karyotype showing t(9;22).
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2.2. Clinical Manifestations
There is usually an insidious onset of symptoms due to CML, usually occur-
ring over several months. Alternatively, the diagnosis may be made after a rou-
tine blood test for unrelated reasons. Symptoms may relate to the hypermetabolic
state associated with a large tumor burden, such as fevers and night sweats. Sple-
nomegaly may cause a feeling of upper abdominal fullness or early satiety. Splenic
infarcts may cause pain in the left lateral abdomen. Marked hyperleukocytosis
(white blood cell [WBC] >100,000/µL) can cause neurological symptoms (such
as decreased alertness, confusion, or seizures), visual changes, or, in rare cases,
painful erection (priapism). On physical examination, splenomegaly is common,
and the spleen may be massively enlarged. Less commonly, there can be
hepatomegaly. The presence of lymphadenopathy suggests extramedullary dis-
ease progression to the acute phase (blast crisis). Patients in blast crisis often have
systemic symptoms with fever, night sweats, fatigue, and bone pain. The clinical
manifestations of blast crisis are similar to those of acute leukemia.
2.3. Laboratory Abnormalities
In patients with chronic phase CML, the WBC count is invariably increased
and may be higher than 200,000/µL. The platelet count is frequently increased;
thrombocytopenia suggests accelerated or blast phase CML. The hemoglobin
concentration is usually normal. The peripheral blood smear is consistent with
the diagnosis of CML when the differential includes the spectrum of myeloid
cells including metamyelocytes, myelocytes, promyelocytes, and occasional
blasts, in addition to segmented neutrophils and band forms. In the bone marrow,
the cellularity is typically 90–100% and it demonstrates marked myeloid hyper-
plasia with a myeloid:erythroid ratio of 20:1 or higher. The number of blast cells
in the bone marrow may be increased, but is below 15%. The leukocyte alkaline
phosphatase (LAP) test result is characteristically low in CML, in contrast to
leukemoid reactions, for which there is an elevated LAP score. As a consequence
of the increased cell turnover, the lactate dehydrogenase (LDH) and uric acid are
often increased.
The accelerated phase of CML is associated with increasing numbers of im-
mature cells (promyelocytes and blasts) in the peripheral blood and bone marrow
and decreasing platelet count. The WBC count may rise and splenomegaly may
worsen on a previously effective dose of medication. The percentage of baso-
phils in the blood may increase to more than 20%. In the bone marrow, the
number of blast cells and promyelocytes increases to more than 20% but less than
30%. The criteria used to define the chronic, accelerated, and blast phase of CML
are listed in Table 1.
140 Paquette, Hiller, and Munker
Although blast crisis most commonly progresses from chronic-phase CML,
patients may present in this stage of disease. Similarly, blast-crisis CML may
rapidly evolve from chronic-phase disease without progressing through the
accelerated phase. Blast-crisis CML is similar clinically to acute leukemia,
with greater than 30% blasts in the blood or bone marrow, anemia, and throm-
bocytopenia. Extramedullary blast crisis may occur in the lymph nodes or other
soft tissues. The blast cells have a myeloid phenotype in 80% of cases and a
lymphoid phenotype approx 20% of the time. It is quite common for the flow
cytometry to reveal biphenotypic features. Additional cytogenetic abnormalities
may be present in addition to the Philadelphia chromosome (e.g., a duplication
of the Phl chromosome, an isochromosome 17q, or trisomy 8).
2.4. Treatment
There are two prinicpal therapeutic options available: medical therapy with
imatinib and allogeneic stem cell transplantation (SCT). Because of the issues
discussed as follows, guidelines regarding the timing of transplantation in patients
with CML are controversial at this time. Any newly diagnosed CML patient who
is a potential transplant recipient should be referred to a transplant center to
discuss this issue in detail. Imatinib mesylate is the first “targeted therapy” for
leukemia. The drug was initially selected for study in CML because it was found
to compete with adenosine triphosphate (ATP) for binding to the tyrosine kinase
domain of the BCR-ABL protein. When imatinib occupies the ATP-binding site
of BCR-ABL, it cannot bind ATP, it maintains an inactive conformation, and it
has no tyrosine kinase activity. Imatinib was initially evaluated in patients who
were not responding to interferon (IFN)-α, the most effective medical therapy
for CML at the time. The study demonstrated that imatinib 400 mg/d was remark-
ably effective in this patient population that otherwise had a poor prognosis.
Normalization of the peripheral blood counts (complete hematological response)
was observed in 95% of patients. Half of the patients required less than 1 mo to
Table 1
Diagnostic Criteria for Stages of Chronic Myelogenous Leukemia
Feature Chronic Accelerated Blast
Blasts in BM or blood <15% 15–29% 30%
Blasts + promyelocytes in BM or blood <30% 30%
Basophils in blood <20% 20%
Platelet count (unrelated to treatment) >100,000 <100,000
BM, bone marrow.
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achieve a complete hematological response and 86% reached this endpoint within
3 mo. Approximately 60% of patients had a greater than 65% reduction in the
number of Ph1 chromosome-positive cells in the bone marrow (major cytoge-
netic response) and 40% had no Ph1 positive cells in the bone marrow (complete
cytogenetic response) after 1 yr of therapy. As a result, in May 2001 imatinib was
approved by the Food and Drug Administration (FDA) for the treatment of CML
that was unresponsive to IFN therapy. A randomized trial of imatinib vs IFN-α
plus cytarabine (standard therapy at the time) for newly diagnosed CML patients
demonstrated markedly superior results for imatinib, with 85% of patients achiev-
ing a major cytogenetic response and 74% a complete cytogenetic response at 1 yr
compared with 22% and 8%, respectively, for IFN-α plus cytarabine. Virtually
all imatinib-treated patients who achieved a major cytogenetic response with
imatinib did so within the first year of treatment. The risk of disease progression
to accelerated or blast phase was approx 3% for the imatinib arm vs 8% for the
combination arm after 18 mo of treatment. Therefore, imatinib has emerged as
the medical treatment of choice for CML. Although the randomized study used
an imatinib dose of 400 mg/d, it may not be the most effective dose. A single-arm
study administering 400 mg of imatinib twice daily to newly diagnosed CML
patients demonstrated a major cytogenetic response rate of 96% and a complete
cytogenetic response rate of 90%. A randomized trial will be required to defini-
tively identify the optimal imatinib dose. Despite these excellent results, limited
clinical information as well as laboratory data suggest that imatinib is not cura-
tive. Only rarely have patients been taken off drug, even in cases of a complete
cytogenetic response. Prolonged follow-up will be required to determine the
durability of response to imatinib.
Depth of response to imatinib is an important prognostic variable. Several
response landmarks have been identified by the clinical trials performed to date.
The first chronological landmark after the initiation of imatinib is the achieve-
ment of a complete hematological response (normalization of peripheral blood
counts). Most newly diagnosed patients will reach this endpoint within the first
month of treatment, and virtually all patients who will respond do so within the
first 3 mo. The next important landmark is the achievement of a major cytoge-
netic response. Approximately 70% of major cytogenetic responders reach this
endpoint within 3 mo, and 90% do so by 6 mo. The third endpoint is the achieve-
ment of a complete cytogenetic response. At least 90% of patients who reach this
endpoint do so within the first year of treatment. Although cytogenetic response
is important, standard chromosomal analysis evaluates only 20 cells. FISH for
the BCR-ABL translocation typically evaluates 200 cells. The quantitative PCR
(Q-PCR) assay for the BCR-ABL translocation can detect up to a 4.5-log reduc-
tion in transcript levels. This assay is typically performed on peripheral blood
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and is much more sensitive than standard cytogenetic studies to assess disease
response. Among CML patients who achieved a complete cytogenetic response,
those who also had a 3-log or greater reduction in BCR-ABL transcript copy by
Q-PCR number by 1 yr had 0% risk of disease progression after one additional
year of follow-up compared with a 5% risk if less than a 3-log reduction was
achieved; patients without a complete cytogenetic response had a 15% risk of
disease progression. These data have helped to define the methods of following
imatinib-treated patients and identifying those individuals with an inadequate
response to therapy and, hence, increased risk of disease progression. Peripheral
blood FISH and Q-PCR for BCR-ABL should be performed every 3 mo for
imatinib-treated patients. Patients who fail to achieve a complete hematological
response by 3 mo, a major cytogenetic response by 6 mo, or a complete cytoge-
netic response by 1 yr should be considered for alternative therapy, especially
allogeneic SCT, when appropriate clinically. When a complete cytogenetic re-
sponse is achieved, Q-PCR is the only method of measuring the size of the
leukemic clone. A greater than twofold increase in Q-PCR levels unrelated to
imatinib dose modification is suggestive of acquired imatinib resistance and
early disease progression.
Acquired resistance to imatinib is often due to point mutation of BCR-ABL
that results in an amino acid subtitution in the kinase domain of the encoded
protein. The various amino acid substitutions identified to date interfere with the
ability of imatinib to interact with the ATP-binding site and induce BCR-ABL
into an inactive structural conformation. Imatinib resistance is manifested clini-
cally as progressive loss of hematological or cytogenetic response that is unre-
lated to drug dosing. Because the degree of residual imatinib sensitivity varies
between mutants, some resistance can be overcome by imatinib dose escalation.
However, the benefit of imatinib dose escalation may be only transient. Second-
generation tyrosine kinase inhibitors are currently being evaluated in clinical
trials. These compounds have activity against most of the mutant BCR-ABL pro-
teins that are resistant to the effects of imatinib. Alternative treatment approaches
including allogeneic SCT should be considered for patients with de novo or
acquired imatinib resistance. Recently, a new class of SRC-ABL inhibitors was
developed. These molecules are pyrido[2,3-d] pyrimidines and bind both to the
SRC kinase and the ATP-binding site in ABL. Such molecules are also active in
most imatinib-resistant CML cell clones. One such compound (dasatinib) has
oral bioavailability and has 2-log increased activity as an ABL kinase inhibitor
compared with imatinib. More importantly, the activity is retained in 14 of 15
imatinib-resistant BCR-ABL mutants. This activity was confirmed in a mouse
model of imatinib-resistant CML and in preliminary clinical studies.
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The principal toxicity of imatinib is hematological, which is actually a reflec-
tion of its therapeutic efficacy. Neutropenia and thrombocytopenia are com-
monly observed after imatinib is initiated because the drug reduces the leukemic
clone that produces all of the neutrophils, red cells, and platelets. The blood
counts are gradually restored as the leukemic clone is reduced and normal
hematopoietic cells grow in the bone marrow. Treatment should be transiently
interrupted if severe peripheral blood cytopenias occur (neutrophil count <1000/
µL, platelet count <50,000/µL) and re-instituted when the blood counts improve
(neutrophil count >1500/µL, platelet count >75,000/µL). Fluid retention is a
common side effect, but it is rarely severe. Skin rash can be managed with
antihistamines and topical steroids in most cases. In rare cases, a systemic rash
can be severe enough to require drug discontinuation and systemic steroids. The
drug can usually be re-introduced at a lower dose once the rash has resolved.
Transaminase elevations can be severe in rare cases and co-administration of
acetaminophen may exacerbate this toxicity. Liver function tests should be
monitored routinely, and treatment should be withheld if they exceed five times
the upper limit of normal. Although dose reduction for toxicity is occasionally
required, attempts should be made to re-escalate dosing after resolution of side
effects because response to treatment appears to be dose-dependent.
Allogeneic SCT offers the only chance of cure for CML. Approximately 60–
65% of the patients undergoing related-sibling SCT survive at least 5 yr. Survival
is approx 50–55% if an unrelated donor is used. The results of SCT are best when
the recipient is younger and when the transplant is performed within 12 mo of
diagnosis. The effectiveness of SCT in eradicating CML depends to a large
extent on a potent antileukemic activity mediated by the donor T-lymphocytes
present in the stem cell product (graft-vs-leukemia [GVL] effect). Because the
GVL effect occurs in the setting of chronic graft-vs-host disease (cGVHD),
patients with cGVHD have a lower risk of disease relapse. If CML relapses after
allogeneic SCT, a remission can be effectively re-induced by infusing additional
lymphocytes collected from the original stem cell donor. The use of less inten-
sive (nonmyeloablative) conditioning prior to allogeneic SCT is a promising
method of reducing the toxicity of the transplant procedure for older patients with
CML. Transplantation is discussed in more detail in Chapter 4.
The dramatic success of imatinib therapy has affected the clinical decision-
making regarding the timing of allogeneic SCT. Imatinib offers a high rate of
complete cytogenetic response with minimal toxicity, but it is not a cure and its
long-term efficacy is unknown. Allogeneic SCT is a cure, but it carries with it the
chance of early morbidity and mortality. It is not known if a trial of imatinib prior
to allogeneic SCT will adversely affect the outcome of the transplant procedure.
Because these issues are complex and are progressively evolving, any potential
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transplant candidate should be referred to a transplant center to discuss the thera-
peutic options in detail at the time of diagnosis. Potential transplant recipients
who opt for an initial trial of imatinib rather than SCT must be monitored closely
for response to treatment, as discussed previously, to identify those patients who
are unlikely to benefit from imatinib therapy and thus should be transplanted
instead. Indicators of inadequate imatinib response include failure to achieve a
complete hematological response by 3 mo, a major cytogenetic response by 6 mo,
or a complete cytogenetic response by 1 yr. Another indication for transplanta-
tion would be loss of complete cytogenetic response. For treatment algorithm,
see Fig. 8.2.
The preceding discussions regarding the timing of allogeneic SCT and use of
imatinib therapy for chronic-phase CML may also be applicable for patients with
accelerated-phase disease. Blast-crisis patients are generally not transplanted
unless they can be converted back into chronic phase disease because they almost
invariably relapse in spite of the transplant. Patients who present with acceler-
ated or blast phase of CML can benefit from imatinib therapy, but the response
rates are lower and long-term disease control is less likely. Survival is superior
for accelerated phase patients who are initially treated with imatinib 600 mg/d
compared to 400 mg/d. The dose of 800 mg/d was not evaluated for this patient
population, but extrapolation of preliminary data from chronic phase patients
suggests this dose may be preferable for patients with accelerated phase disease.
Blast-crisis patients should also initially receive 800 mg/d in divided doses.
These patients frequently develop severe peripheral blood cytopenias on imatinib.
The development of severe neutropenia or thrombocytopenia should be evalu-
ated by bone marrow biopsy. Imatinib should only be held if the marrow is
hypocellular without evidence of residual blasts, otherwise the cytopenias are
usually attributable to the underlying disease and treatment should continue.
The potential benefit of combining imatinib with chemotherapy for blast-crisis
patients has not been carefully evaluated to date. Ideally, blast-crisis patients
should be enrolled in clinical trials that address this issue. Blast-crisis patients
who are potential candidates for allogeneic SCT should be treated to maximum
response and then transplanted promptly. Because relapse occurs rapidly, espe-
cially for lymphoid blast-crisis patients, donor evaluation should be intiated at
the time of diagnosis.
3. POLYCYTHEMIA VERA
PCV is a clonal, acquired disorder of the pluripotent hemopoietic stem cell.
All three lineages of hemopoiesis are involved; however, the major manifesta-
tion is seen in erythropoiesis. Many cases of PCV also have an increased number
of granulocytes or platelets.
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Fig. 8.2. Proposed treatment algorithm for chronic-phase chronic myelogenous leukemia.
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3.1. Basic Biology
In PCV, the erythroid progenitors proliferate in the absence of erythropoietin.
The serum levels of erythropoietin are low in patients with PCV, whereas in
patients with secondary polycythemias (e.g., with pulmonary disease or con-
genital heart disease), the erythropoietin levels are high. A defective expression
of the thrombopoietin receptor by platelets from PCV was described. This trans-
lated into a defective signal transduction by JAK2 and STAT5 and may be a cause
for the unregulated proliferation of megakaryocytes in PCV. The majority of
patients with PCV do not have cytogenetic abnormalities. Interestingly, the increased
expression of a gene named PRV-1 or CD177 was found on granulocytes (not
progenitor cells) of patients with PCV compared with normal persons. Recently,
a recurrent somatic missense mutation (JAK2V617F) was identified in granulo-
cyte DNA samples in 121 of 164 patients with PCV. Of these 121 patients, 41
were homozygous and 80 had heterozygous mutations. Similar mutations were
also found in some patients with ET or IM, but not in normal persons. An in vitro
analysis showed that JAK2V617F is a constitutionally active tyrosine kinase.
Incubation with a small molecular inhibitor leads to reduced proliferation of
progenitor cells from patients with PCV, ET, and IM, implying that the JAK2
tyrosine kinase is a potential target for treatment in such patients.
3.2. Clinical Manifestations
PCV is a rare disorder with an estimated incidence of 0.5–0.8 new cases per
year per 100,000 people. The disease is most common in the medium and older
age groups. PCV is often asymptomatic in the beginning and may be discovered
as an incidental finding (increased hemoglobin or hematocrit values). When
symptoms are present, they are usually related to an increased blood volume and
increased blood viscosity. The skin and visible mucous membranes are plethoric
(dark red) and the lips and the tips of the fingers appear cyanotic. Some patients
experience a burning pain in the fingers and toes (erythromelalgia). Many have
bothersome pruritus, especially after a hot bath. At least half of the patients
present with splenomegaly. The enlarged spleen may cause discomfort in the
upper left abdomen and, in some cases, splenic infarctions cause severe pain. The
increased blood viscosity reduces the oxygen supply to the brain resulting in
vertigo, headaches, and even visual disturbances. Vascular changes can also be
recognized in the fundus (purple color with dilated vessels). Patients with PCV
often develop an arterial hypertension. A serious complication is the formation
of arterial or venous thromboses, or bleeding episodes, especially when platelets
are elevated. Apoplexia, angina pectoris, deep venous thrombosis, and pulmo-
nary emboli may complicate this disorder. The vascular complications are respon-
sible for the increased morbidity and mortality in PCV. Rare but disastrous
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complications include thrombosis of the splenic or portal veins, the Budd-Chiari
syndrome, and mesenteric infarctions. The bleeding tendency (hematomas,
bleeding of the skin and mucous membranes) in PCV is caused by functional
defects of the platelets together with the increased blood viscosity. Patients with
PCV also are prone to gastric ulcers, which may lead to massive gastrointestinal
bleeding.
3.3. Diagnosis
In addition to an elevated hemoglobin and hematocrit, patients with PCV
often have an increased platelet count, neutrophil count, and an increased LAP
score. The serum vitamin B12 levels are usually increased as a result of the
increased neutrophils, which produce increased levels of vitamin B12-binding
protein. An increased red blood cell mass is invariably present. In this study,
blood is drawn from the patient, red cells are quantitated and labeled with 51Cr,
then reinjected. Blood is later redrawn, and the extent to which the labeled red
cells were diluted by those in the circulation permits the calculation of the red
blood cell mass. Among patients with a red blood cell mass, PCV must be dis-
tinguished from causes of secondary polycythemia.
The bone marrow cytology shows an increased cellularity with a predomi-
nance of erythropoiesis. Megakaryocytic hyperplasia is often present and may
appear dysplastic. The bone marrow biopsy often shows fibrosis, which increases
during the course of the disease. Iron studies often detect a decrease in iron stores
even at diagnosis because of the increased production of red cells. Below are the
diagnostic criteria for PCV (criteria of the Polycythemia Vera Study Group).
• Major criteria
Al. Raised red cell mass (>125% of normal)
A2. Absence of secondary polycythemia
A3. Palpable splenomegaly
A4. Marker of clonality (e.g., del {20q})
• Minor Criteria
B1. Thrombocytosis
B2. Neutrophil leukocytosisB3. Splenomegaly demonstrated by ultrasound or
isotope study
B4. Independent BFU-E-growth, or low serum erythropoietin
The diagnosis of PCV can be made if A1, A2, and A3 or A4 are present or if
A1 + A2 + two B criteria are present.
3.4. Differential Diagnosis
A secondary polycythemia or erythrocytosis is generally due to the increased
production of the hormone erythropoietin. This happens in disorders with tissue
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hypoxia in which the kidneys are stimulated to produce erythropoetin. The effect
of erythropoietin is mediated by the hypoxia-inducible factor (HIF)-1. Other
genes turned on by hypoxia are angiotensin-II and insulin-like growth factor
(IGF)-I binding proteins.
Diseases with hypoxia are chronic lung disorders, sleep apnea syndromes,
cyanotic heart disease, and certain hemoglobinopathies with altered oxygen
affinity of the hemoglobin molecule. Persons living at high altitudes also develop
a reactive erythrocytosis due to the chronic hypoxia. The causes of tissue hypoxia
are usually evident or can be diagnosed with pulmonary function studies, blood
gas analysis, or cardiac imaging studies.
A paraneoplastic polycythemia (associated with ectopic production of erythro-
poietin) is observed in certain kidney tumors, hepatomas, uterine myomas, cer-
ebellar hemangiomas, and other rare tumors. Some nonmalignant kidney lesions
(e.g., polycystic kidney disease) also stimulate the production of erythropoietin.
As a diagnosis of exclusion, in rare instances no cause for the increased red cell
production can be found (idiopathic erythrocytosis). Rarely, familial or congeni-
tal polycythemias are observed. In some but not all families, a gain-of-function
truncation of the erythropoietic receptor is responsible. In the Chuvash poly-
cythemia (observed in some ethic groups in Russia), a mutation of the VHL
protein leads to impaired interaction with HIF-1, which results in defective oxy-
gen sensing.
Some individuals have spurious erythrocytosis (Gaisböck’s syndrome) due to
a decreased plasma volume. This abnormality has been observed in hypertensive
smokers. It is distinguished from PCV and secondary causes of polycythemia by
a normal red blood cell mass study. There is no indication for treatment, although
in extreme cases low-dose aspirin may prevent thromboembolic complications.
3.5. Treatment
The standard treatment for PCV is phlebotomy. The goal of phlebotomy is to
reduce the hematocrit and blood viscosity in order to prevent thrombotic com-
plications. In a patient with a newly diagnosed PCV, phlebotomies (450 mL
each) should be made two or three times weekly until the hematocrit is in the
range of 40–45%. When this value is reached, phlebotomies should be made as
necessary to maintain the hematocrit in this range. This may be once a month or
once every 3 mo. Repeated phlebotomies result in iron deficiency, which may
cause symptoms like angular cheilosis. A recent randomized, placebo-controlled
study demonstrated that aspirin 100 mg daily significantly decreased the com-
bined incidence of cardiovascular events including myocardial infarction, stroke,
deep venous thrombosis, and pulmonary embolism in PCV patients who were
receiving standard phlebotomy. There was no significant increase in bleeding
events associated with aspirin adminstration. Therefore, low-dose aspirin should
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be administered to PCV patients without a clinical contraindication to such
therapy.
A second treatment option for patients with PCV is a cytotoxic treatment with
hydroxyurea. Hydroxyurea is indicated if phlebotomies fail to control the increase
in red cell volume or if an excessive thrombocytosis (>700,000/µL) occurs. The
usual dose for hydroxyurea is 1–2 g/d. Subcutaneous IFN-α has been shown to
be effective in the control of PCV and may be indicated for patients who do not
tolerate hydroxyurea or in younger patients who fear a possible mutagenic risk
of hydroxurea. The use of radioactive phosphorus or alkylating agents for PCV
have been abandoned because of the high risk of leukemic transformation induced
by these agents. Patients with PCV should avoid dehydration or other conditions
that predispose to vascular complications. Patients with thrombocytosis
(>700,000/µL) should receive a low-dose platelet anti-aggregating agent if there
is no hemorrhagic tendency. If present, a hyperuricernia should be treated with
allopurinol. Anagrelide is an effective drug for the treatment of thrombocytosis
in PCV (see “Essential Thrombocythemia”). Selected younger patients with
poor prognosis PCV are candidates for a human leukocyte antigen (HLA)-
matched allogeneic SCT.
4. ESSENTIAL THROMBOCYTHEMIA
Thrombocythemia is present if the platelets are constantly elevated to more
than 600,000/µL. A reactive thrombocytosis is, in most cases, self-limited and
occurs after a major blood loss, after surgery, after splenectomy, or it may be
paraneoplastic in some cases. Thrombocythemia can occur as part of other
myeloproliferative syndromes (e.g., PCV, chronic myelogenous leukemia, or
osteomyelofibrosis [OMF]) or may occur as the only manifestation of a myelo-
proliferative syndrome (ET). ET is the rarest entity among the myeloprolifera-
tive syndromes (incidence about 0.1 cases/100,000). Because the life expectancy
of patients with ET is close to normal, the prevalence of ET is several-fold higher
than the annual incidence.
4.1. Basic Biology
The etiology of the sustained thrombocytosis and megakaryocytic hyper-
proliferation characteristic of ET is unknown. No specific cytogenetic abnor-
malities or molecular markers have been associated with the disorder, and its
diagnosis is one of exclusion. In ET, about half the patients have a clonal prolif-
eration of hematopoietic progenitors, similarly to the other myeloproliferative
disorders. In vitro, these patients show a spontaneous proliferation of early eryth-
roid and/or megakaryocytic progenitors (burst-forming units-erythroid [BFU-E],
colony-forming unit-megakaryocyte [CFU-Meg]). In contrast to the normal DNA
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content found in reactive thrombocytosis, the DNA content (ploidy) of the mega-
karyocytic progenitors is increased in ET.
4.2. Clinical Manifestations
ET may be asymptomatic and discovered when a routine blood count is per-
formed. Bleeding manifestations and a predisposition to thromboembolic events
are the main clinical findings. However, the incidence of these complications,
and especially the incidence of major thrombotic events, remains controversial
in ET. Recurrent gastrointestinal bleeding and epistaxis are the most common
bleeding manifestations. Thrombotic complications are more common in elderly
patients and are rare in young patients, even when platelet counts are quite high.
Both venous and arterial thrombosis may develop, and vessels in unusual sites
may be involved (e.g., the hepatic veins, mensenteric vessels, the veins of the
penis resulting in priapism, and the splenic vein). The digital vessels of the
fingers and toes may be occluded by a disturbed microcirculation, especially if
the number of platelets is excessive. In the majority of cases, however, a benign
course over a period of years can be documented despite high platelet counts. The
same patients may have an arterial or venous thrombosis months or years later.
Splenomegaly is found in a number of patients. Thrombotic events appear more
frequent in patients with clonal hematopoiesis.
4.3. Diagnosis
Platelet count in ET is consistently increased above 600,000/µL (in many
cases >106/µL). By definition, another myeloproliferative syndrome or a reac-
tive thrombocytosis are excluded. The Philadelphia chromosome is not present
in ET, and the red cell mass is normal. Bone marrow aspiration often results in
a dry tap as a result of secondary fibrosis, and the bone marrow biopsy shows a
megakaryocyte hyperplasia. There is no evidence for myelodysplastic syndrome.
The serum interleukin (IL)-6 levels are normal in most cases, whereas in reactive
thrombocytosis, an increase is frequently seen. This high platelet count can cause
“pseudohyperkalemia” as a result of potassium released from platelets in vitro
during the process of coagulation. This can be prevented by measuring potassium
in an anticoagulated blood sample.
4.4. Treatment
ET is treated to prevent thromboembolic complications. In younger patients
without a history of bleeding and without an excessive increase in platelets, low-
dose acetyl salicylic acid (100 mg daily) is an adequate treatment. In other cases,
after a complication, or with platelets above 900,000/µL, the platelet count should
be controlled with hydroxyurea, IFN, or anagrelide. Hydroxyurea is given orally
(0.5–1.5 g daily). IFN is injected subcutaneously (3–5 × 106 U three times
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weekly). IFN is particularly useful when managing ET during pregnancy.
Anagrelide acts as a specific antagonist of megakaryocyte production and is also
active for thrombocytosis occurring in other myeloproliferative syndromes. The
drug (1–2 mg daily po) is generally well tolerated. Side effects usually associated
with higher doses include fluid retention, tachycardia, or headache. Recently,
data from a large study in Great Britain comparing anagrelide and hydroxyurea
as treatment for high-risk ET were presented. Both treatment arms received low-
dose aspirin. The study was stopped after 7 yr because patients in the anagrelide
arm developed more complications (arterial thrombosis, major bleeding, and
transient ischemic attacks). The incidence of leukemogenesis was similar in both
treatment arms. Therefore, hydroxyurea should be considered as standard treat-
ment for ET with anagrelide being reserved as second-line treatment. Platelet
pheresis is a treatment that rapidly lowers excessive platelet counts in emergen-
cies but it should not be used without other treatment modalities.
4.5. Prognosis
The prognosis of treated ET is mostly favorable with a median survival of 8–
15 yr. The disease in some patients transforms into other myeloproliferative
syndromes such as OMF or PCV but rarely into acute leukemia.
5. IDIOPATHIC MYELOFIBROSIS
IM (or agnogenic myeloid metaplasia) is characterized by fibrosis and scle-
rosis of the bone marrow. Extramedullary hematopoiesis takes place in the spleen
resulting in splenomegaly, which may become massively enlarged. IM is a rare
disorder occuring predominantly in persons over the age of 60 yr. Findings
similar to those in IM can be observed during the progression of the other my-
eloproliferative syndromes (especially PCV and ET).
5.1. Basic Biology
IM is a clonal stem cell disorder. Several cytokines (e.g., platelet-derived
growth factor and transforming growth factor-β) are produced excessively by
megakaryocytes, induce the proliferation of the mesenchymal cells, and stimu-
late the deposition of collagen, laminin, and fibronectin in the bone marrow.
Extramedullary hematopoiesis develops as a secondary phenomenon. Cytoge-
netic abnormalities [trisomy 8, trisomy 9, del (12p), del (13q), and others] are
found in at least one-third of the cases of IM at diagnosis. At later stages, espe-
cially if a transformation or acceleration has occurred, the frequency of clonal
cytogenetic aberrations is higher. In the peripheral blood of patients with IM,
high numbers of circulating myeloid progenitor cells have been observed. This
may correlate with an earlier transformation into acute myeloid leukemia.
Angiogenesis is considered to be increased in IM.
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5.2. Clinical Manifestations
Myelofibrosis may be present months or years before the diagnosis is made.
Symptoms are often caused by a progressive enlargement of the spleen that lead
to pain or upper abdominal fullness. In advanced cases of IM, the spleen may be
felt down to the pelvis. Most patients develop anemia and complain of fatigue
and general weakness. Progressive marrow fibrosis and splenomegaly often
leads to worsening anemia and thrombocytopenia, and occasionally neutrope-
nia. Patients often become transfusion dependent. Progressive weight loss is
common because of early satiety. The course of the disease is inexorably progres-
sive. Occasionally, IM evolves into acute myeloid leukemia.
5.3. Diagnosis
Typical findings for IM are a substantial bone marrow fibrosis, marked sple-
nomegaly, and leukoerythroblastic blood smear due to presence of immature
WBCs and nucleated red cells in the circulation. Anisocytosis, poikilocytosis,
and teardrop-shaped erythroid cells are seen on the blood smear. Most patients
are anemic because of ineffective erythropoiesis and hypersplenism. Patients
initially have elevated platelet counts, which decline over time. Almost all
patients have leukocytosis. A bleeding diathesis may be present as a result of
functional abnormalities of the platelets.
5.4. Differential Diagnosis
Other myeloproliferative disorders, especially PCV and ET commonly evolve
into IM. Patients with chronic myelogenous leukemia often develop some degree
of marrow fibrosis. Myelodysplastic syndrome may be accompanied by myelofi-
brosis. Marrow fibrosis also may be present in Hodgkin’s lymphoma, hairy cell
leukemia, metastatic carcinoma, and tuberculosis. Rarely, myelofibrosis indis-
tinguishable from IM may be associated with a positive antinuclear antibody
(ANA) test. These patients may not fulfill adequate clinical criteria for a diag-
nosis of systemic lupus erythematosus, but the myelofibrosis can respond dra-
matically to glucocorticoids. For this reason an ANA should be checked to
exclude this possibility. Acute megakaryocytic leukemia is a cause of “acute
myelofibrosis” accompanied by pancytopenia, but not splenomegaly.
5.5. Treatment
Treatment of IM is mainly supportive. Anemic patients may require transfu-
sions. Occasionally androgens may benefit anemic patients. Hydroxyurea may
be useful to reduce the white blood count, platelet count, and spleen size, but it
may induce or exacerbate anemia. Anagrelide can be used to manage isolated
thrombocytosis. Thalidomide plus prednisone can occasionally improve sple-
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nomegaly. Etanercept (a soluble tumor necrosis factor [TNF]-α receptor) was
found to palliate constitutional symptoms in patients with IM. A splenectomy
may be beneficial if refractory anemia, thrombocytopenia, or intractable symp-
toms are due to massive splenic enlargement. Because it is not possible to predict
how much a patient’s hematopoiesis is being carried out in the spleen preopera-
tively, peripheral blood counts may worsen after splenectomy if the spleen is the
primary site of blood cell production. The surgical risk may be considerable in
patients with IM, particularly in those who are elderly. Splenic irradiation is
typically of minimal and transient benefit. Patients with hyperuricemia should
receive allopurinol to prevent symptomatic gout. Allogeneic SCT may be con-
sidered in young patients who have an HLA-matched sibling or unrelated donor.
Because patients can survive for many years with minimal intervention, guide-
lines governing the timing of transplantation for IM have not been defined. In the
future, reduced-intensity transplants may offer a chance for cure with less acute
complications than full-intensity allogeneic transplants.
6. OTHER MYELOPROLIFERATIVE SYNDROMES
Several rare syndromes have features of the aforementioned entities, but do
not fit exactly into one or the other disease categories.
Juvenile myelomonocytic leukemia (JMML) occurs in children and is nega-
tive for the Philadelphia chromosome. Instead, mutations of several genes have
been identified that lead to constitutive activation of the RAS signaling pathway,
which is normally activated in response to growth factors. Mutations affecting
the PTPN11 gene that encodes the Src homology 2 domain-containing protein
phosphatase (SHP-2) occur in approximately one-third of cases. Activating
mutations of a RAS gene occur in approximately one-fourth of patients. The NF1
gene, which encodes a protein that negatively regulates RAS activity, has inac-
tivating mutations in an additional minority of patients. Because mutations of
these three genes have similar effects on the cell, the mutations are mutually
exclusive. Clinically, the patients have hepatomegaly, splenomegaly, and lym-
phadenopathy in most cases. The myeloid progenitors in the bone marrow grow
in culture without added growth factors. JMML responds poorly to cytotoxic
drugs but retinoids have some activity. Cure can only be achieved with allogeneic
SCT.
Chronic neutrophilic leukemia is a rare myeloproliferative syndrome, where only
mature granulocytes are increased. The Philadelphia chromosome is negative.
Chronic myelomonocytic leukemia also has features of the myeloprolifera-
tive syndromes but is categorized (according to the French-American-British
classification) among the myelodysplastic syndromes.
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1. INTRODUCTION
Acute myelogenous leukemias (AMLs) are aggressive hematological neo-
plasms that require, in most cases, urgent treatment. Despite intensive treatment
with cytostatic drugs, only a minority of patients can be cured at present. In
adults, about 80% of all acute leukemias belong to the group of AML. The term
“acute nonlymphocytic leukemia” is often used interchangeably for AML. The
incidence of AML is about three to four new cases per 100,000 persons. AML
is rare in children and young adults; the incidence of AML increases with advanc-
ing age, the median age being between 60 and 70 yr.
2. ETIOLOGY, BIOLOGY, AND PATHOPHYSIOLOGY OF AML
In most cases of AML, no etiological agent can be identified, but for some
patients a genetic or acquired predisposition to develop AML is likely or proven.
For example, some constitutional cytogenetic aberrations have been linked to the
development of AML. A 10-fold increase in the incidence of AML has been
observed in children with Down syndrome. Patients with Fanconi anemias,
Bloom syndrome, and ataxia telangiectasia have an elevated risk of developing
AML. Splenectomy increases the risk of subsequent leukemia in Hodgkin’s
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lymphoma. Exposure to benzene or ionizing radiation increases the risk of AML.
Both myelodysplastic and myeloproliferative disorders often terminate in AML
(“blastic transformation”). Approximately 15% of all AML cases are treatment-
related, and can present in two different ways. The more common form of treat-
ment-related AML results from exposure to alkylating agents. This type of AML
has a medium latency period of 3–6 yr and usually proceeds through a
myelodysplastic phase. Cytogenetics usually reveals a deletion of all, or of the
long arm, of chromosomes 5 or 7. A second, less common type of therapy-related
AML is associated with exposure to etoposide or other topoisomerase II inhibi-
tors. This form of AML has a shorter latency period and does not have a
myelodysplastic phase. Molecular markers of these cases involve a rearrange-
ment of the MLL/ALL-1 gene located on chromosome 11q23.
In AML, a myeloid stem cell (or an early progenitor cell) is transformed. This
stem cell expands and proliferates in the blood and bone marrow and suppresses
normal hematopoiesis. A characteristic finding in AML is the leukemic bulge
(the appearance of immature leukemic cells in blood and bone marrow without
terminal maturation). Blasts of myeloid leukemias proliferate under the influ-
ence of myeloid growth factors, some of which are produced by the leukemic
cells themselves (autocrine growth of tumor cells).
Consistent with the clonal transformation of myeloid stem cells, AML blasts
express cytogenetic abnormalities in 50–70% of cases (by classic cytogenetics).
AML cells harboring specific cytogenetic abnormalities may demonstrate unique
biological and clinical manifestations. Common cytogenetic abnormalities and
their prognostic impact are discussed later. Segments from two different genes
are fused and give rise to a chimeric gene consisting of the 5' end of one gene and
the 3' end of the other gene. From these genes, a new leukemia-associated mes-
senger RNA is transcribed and a new protein is synthesized. For example, vir-
tually all cases of acute promyelocytic leukemia harbor a translocation between
chromosomes 15 and 17. Cells with t(15;17) have a fusion of retinoic acid recep-
tor (RAR)D and PML genes. The encoded fusion protein is a dominant negative
inhibitor of the normal RARD protein and thereby causes the arrest of myeloid
maturation at the promyelocyte stage. The inhibition of terminal differentiation
is mediated by the association of the fusion protein with the nuclear co-repres-
sor–histone deacetylase complex. Other common cytogenetic aberrations giving
rise to fusion genes are t(8;21) and inversion 16 [inv(16)]. The t(8;21) results in
the fusion of the AML1 gene (which encodes the subunit D of the core-binding
factor) on chromosome 21 with the ETO gene on chromosome 8. The novel
chimeric gene produces a transcript that can be detected by reverse-transcription
(RT)-PCR. The protein product of this gene is important in maintaining the
leukemic phenotype. A schematic drawing of t(8;21) that involves the subunit D
of the core-binding factor is reproduced in Fig. 9.1. t(8;21) is considered a good-
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risk translocation. Interestingly, granulocytic sarcomas (chloromas) are some-
what more common in patients with t(8;21). The AML1 gene is also involved in
the t(3;21)(q26;q22) associated with therapy-related myelodysplastic syndome
(MDS). As a consequence, AML1 is fused with EVI1, EAP, or MDS1 genes. In
these cases, the AML1 promoter drives the expression of a fusion transcript that
contains the AML1 DNA-binding domain but lacks the transactivation domain.
Inv(16)(p13;q22) results in the fusion of the core-binding factorE (CBFE) sub-
unit at 16 q22 to the smooth-muscle myosin heavy-chain gene at 16p13. CBFE is
the heterodimeric partner of the human AML1 gene involved in t(8;21). Together,
they form the transcription factor designated as core-binding factor. In addition
to translocation events, mutations of cellular proto-oncogenes, especially N-ras,
also play a role in the pathogenesis of AML. Patients with normal cytogenetics
still constitute a large group of all patients with AML. Recently, rearrangements
and mutations of several genes were identified that are common in this group of
patients and that can even be used prognostically. The FLT3 gene encodes mem-
brane receptor protein tyrosine kinase, which is involved in the regulation of
proliferation, differentiation, and apoptosis of hematopoietic stem and progeni-
tor cells. It was found that an internal tandem duplication of this gene occurs in
approx 30–40% of patients with normal cytogenetics AML. This internal tandem
duplication spans exons 14 and 15 and creates an in-frame transcript that is
translated into a constitutively activated protein. In addition, mutations and
overexpression of the FLT3 gene have been reported as potentially leukemogenic
pathways. Most clinical studies have shown that internal tandem duplications of
Fig. 9.1. The translocation t(8;21) involves the subunit D of core-binding factor.
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the FLT3 gene in patients with normal cytogenetics are a marker of poor prog-
nosis, resulting in early relapse and/or death from leukemia. The MLL gene is the
human homolog of the Drosophila trithorax gene, located at chromosome band
11q23. It was recently found that submicroscopic rearrangements of MLL can be
found in patients with normal cytogenetics AML. These rearrangements were
shown to result from partial tandem duplications spanning exons 5–11 or 12.
These tandem duplications are found in 5–20% of cases, may co-exist with other
submicroscopic mutations, and correlate with a short remission duration. The
CCAAT enhancer-binding protein D (CEBPA) gene is, in its normal state, involved
in myeloid differentiation. Mutations of this gene can be detected in 4–15 % of
patients with AML, more commonly in subtypes M1 and M2. Interestingly,
mutations of CEBPA seem to confer a better prognosis. The brain and acute
leukemia cytoplasmic (BAALC) gene is located on the chromosome segment
8q22.3 and encodes a protein with no known homology to any other known
protein. The overexpression of BAALC appears to confer a poor prognosis.
These recent advances in understanding the molecular biology of AML have
already led to a more accurate classification of AML and will lead to improved
treatment.
In addition to morphology, immune markers, cytogenetic, and molecular
markers, gene expression profiling has been found to be a useful research tool in
delineating subtypes of AML and making prognostic predictions. Gene expres-
sion profiles in supervised cluster analysis recognize the established prognostic
subsets, such as cases with t(8;21), inv(16), or 11q23 abnormalities. Novel classes
of genes or signatures can be recognized within the established subgroups.
Patients with normal cytogenetics or high-risk, good cytogenetic markers espe-
cially will benefit from a more accurate risk assessment. For example, gene
expression profiling permits recognition of CEBPA mutations in several differ-
ent subgroups of AML. The findings of gene expression profiling in different
platforms (which may not be be translated in other array systems) depend on
uniform sample processing, and the prognostic value of many subsets must be
confirmed in patients from different ethnic backgrounds. However, because new
treatments for AML are being developed, it appears possible to target treatments
for AML on individual genetic profiles. An example for a gene expression profile
of 285 cases of AML is given in Fig. 9.2.
3. CLINICAL MANIFESTATIONS
In de novo AML, the onset of symptoms usually occcurs within days or weeks
of presentation. The patients suffer from fatigue, shortness of breath, fever, and,
in some cases, bone pain. About 30% of patients have major infection at diagno-
sis (cellulitis, pneumonia, or septicemia). The clinical examination reveals the
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signs of failing hematopoiesis: the patients are often anemic and consequently
are pale and have dyspnea on exertion. The patients are often neutropenic and
virtually all are thrombocytopenic, presenting with petechial bleeding, gum
bleeding, or other signs of bleeding or easy bruising. About 10% of patients have
skin infiltrates (flat elevated plaques or nodules), and some patients develop
extramedullary tumors (chloromas). In cases of AML with monocytic differen-
tiation, the gingiva is often hyperplastic. Many patients have a moderate sple-
nomegaly. In contrast to acute lymphoblastic leukemias (ALLs), enlarged lymph
nodes are an infrequent feature of AML and the CNS (meningeosis) is rarely
involved. Further complications such as acute renal failure are seen in cases with
high white cell count at diagnosis (leukostasis, hyperuricemia, tubular damage).
Cases with leukostasis (leukemic thrombi in the microcirculation) also may
develop pulmonary infiltrates or CNS ischemia. Some forms of AML, such as
acute promyelocytic leukemias (APLs), are especially prone to bleeding compli-
cations.
4. DIAGNOSIS AND CLASSIFICATION OF AML
The diagnosis of AML is apparent when the white cell count is increased
(sometimes in excess of 100,000 cells/PL) and only abnormal myeloid blasts are
found in the peripheral blood. These blasts are generally large, have ample cyto-
plasm, and few to numerous azurophilic granules. In some cases of AML, the white
cell count at diagnosis is normal or decreased (leukopenia). In all cases of AML,
by definition, more than 20% of leukemic blasts can be found in the bone marrow
aspirate. Morphological evaluation of Wright-stained blood and bone marrow
cells is the first step for the diagnosis of acute leukemias, followed by cytochemi-
cal, immunological, cytogenetic, and molecular studies. Cyto-chemical stains permit
the distinction of myeloid and lymphoid leukemias and are the basis of the French-
American-British (FAB) classification of acute myeloid leukemias. AML blasts
are reactive to stains for peroxidase, Sudan black, and nonspecific esterase. The
blasts of ALLs are negative for these stains, but show a coarse positivity for
periodic acid-Schiff reagent. The distinction of acute myeloid and ALL is impor-
tant because of the different prognosis and different treatment. A pathognomonic
sign for AML is the presence of Auer rods in leukemic blasts. Auer rods derive
from pathological lysosomes and are frequent in the AML subtypes M2, M3, and
M4. Figure 9.3 (see also Color Plate 4) shows typical blasts of APL (FAB-type
M3) with numerous cytoplasmic granules and Auer rods. In Fig. 9.4 (see also
Color Plate 5), a peroxidase stain of AML blasts is shown. Figure 9.5 (see also
Color Plate 6) shows a fluorescence in situ hybridization (FISH) with painting
probes for chromosomes 5 and 17 in a case of APL (molecular cytogenetics). A
bone marrow biopsy has the advantage of quantifying the density and pattern of
160
M
unker
Fig. 9.2
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infiltration by leukemic blasts. Some, but not all, surface markers can also be
studied on biopsy specimens. In some cases, a bone marrow aspiration does not
give a sufficient sample of the leukemic blasts. This may occur in hypoplastic
leukemias or with myelofibrosis. In these cases, a bone marrow biopsy will
provide an adequate diagnostic sample. A brief description of the subtypes of
AML according to the FAB classification is given in Table 1. The World Health
Organization has recently established a new classification, which incorporates
cytogenetic risk profiles (Table 2).
Surface markers as defined by the cluster designation (CD) nomenclature
generally confirm the diagnosis of AML. AML blasts generally express HLA-
DR, CD13, CD14, and CD33 and are negative for most lymphoid markers. CD14
is positive in AML with monocytic differentiation. The minimally differentiated
blasts of AML M0 (and some other leukemias) express the progenitor antigen
CD34, which has a negative prognostic impact. If a broad panel of monoclonal
antibodies is used, lineage infidelity with aberrant marker combinations can be
observed in up to 50% of cases. The expression of the lymphoid marker CD7 in
AML is considered as a sign of poor prognosis. Leukemias that express both bona
fide myeloid and lymphoid markers (mixed lineage leukemias) are rare and have
a poor prognosis. The MDR1 (multi-drug resistant phenotype) gene catalyze the
efflux of cytostatic drugs like anthracyclines and vinca alkaloids. Leukemias
overexpressing MDR1 respond poorly to chemotherapy.
As mentioned, the molecular correlates of many cytogenetic aberrations are
known, thus permitting studies of minimal residual disease with PCR.
4.1. Differential Diagnosis of AML
In most cases, the diagnosis of AML is clear-cut. In MDS and myeloprolifera-
tive syndromes, an increase of blasts can occur, but the number of blasts in the
bone marrow is, by definition, below 20%.
4.2. Laboratory Features of AML
and Further Laboratory Investigations
As a result of high cell turnover, lactate dehydrogenase and uric acid values
are often increased. Besides thrombocytopenia, the plasmatic coagulation may
Fig. 9.2. (opposite page) Example of a gene expression profile of 285 cases of acute
myelogenous leukemia using 2856 probe sets. In the left part, the expression of 40 top
genes is correlated with each of 16 individual gene expression clusters. In the right part,
all patients are correlated with gene expression signature and morphological, cytoge-
netic, and molecular markers. (Reproduced from Valk PJ, Verhaak RG, Beijen MA, et
al. Prognostically useful gene expression profiles in acute myloid leukemia. N. Eng J Med
2004;350:1617–1628, with permission.)
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Fig. 9.3. Acute promyelocytic leukemia. Myeloid blasts with numerous cytoplasmic
granules and Auer rods (acute myelogenous leukemia, French-American-British classi-
fication type M3).
Fig. 9.4. Acute myelogenous leukemia. Peroxidase stain of myeloblasts.
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be disturbed. In patients with myelomonocytic and monoblastic leukemias, the
lysozyme in serum and urine may be increased. All patients with acute leukemias
should be examined for clinical and laboratory signs of infection (see Chapter 3).
Because many patients with acute leukemias are candidates for bone marrow or
stem cell transplantation (SCT), the human leukocyte antigen (HLA)-type should
be determined as early as possible and potential donors should be sought.
5. PROGNOSTIC FACTORS IN AML
Unfavorable prognostic features are: unfavorable cytogenetics (Table 3), age
greater than 60 yr, poor performance status, major infections at diagnosis, leu-
kocyte count greater than 50 000/PL, FAB-types M0, M5, M6, or M7, a distur-
bance of the plasmatic coagulation, and secondary leukemias.
Favorable prognostic features are: favorable cytogenetics, younger age, Auer
rods, normal growth pattern in bone marrow cultures, and complete remission
after one cycle of induction chemotherapy. More prognostic factors based on
molecular markers and gene expression patterns are currently being delineated.
An example of a new marker is the internal tandem duplication of the FLT3 gene.
Fig. 9.5. Acute myelogenous leukemia. Blasts stained with painting probes for chromo-
somes 5 and 17, red-green cell with t(5;17).
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Table 1
French-American-British (FAB) Classification of Acute Meylogenous Leukemia
FAB-type Morphological features POX ANAE Frequency
M0 Undifferentiated 0 0 <5%
Lymphoid markers negative,
reactive with some myeloid markers
(CD33, CD13), ultrastructural
 peroxidase
M1 Myeloid, no maturation
Poorly differentiated blasts with rare r 0 15–20%
 azurophilic granules
M2 Myeloid with maturation  0 25–30%
Myeloblasts, promyelocytes,
occasionally eosinophils and
basophils, often Auer rods
M3 Promyelocytic  0 10%
Two variants: hypergranular (90%)
and atypical microgranular (10%)
M4 Myelomonocytic   15%
Leukemic myeloblasts and mono-
blasts, variant: M4Eo with abnormal
eosinophils
M5 Monoblastic 0  2–9%
Leukemic monoblasts (two variants:
M5a, M5b)
M6 Erythroleukemia 0 0 <5%
More than 50% abnormal
erythropoietic cells, >30% myelo-
blasts among all nonerythroid cells
M7 Megakaryoblastic 0 0 2–10%
Usually associated with myelo-
fibrosis, platelet markers present
POX, peroxidase; ANAE, D-naphthyl acetate esterase
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Table 2
World Health Organization Classification of Acute Myelogenous Leukemia (AML)
1. AML with recurrent cytogenetic translocations
AML with t(8;21)(q22;q22)
AML with abnormal bone marrow eosinophils: inv(16)(p13;q22) or t(16;16)(p13;q11)
Acute promyelocytic leukemia: t(15;17)(q22;q11) and variants
AML with 11q23 (MLL) abnormalities
2. AML with multilineage dysplasia
With/without a prior myelodysplastic syndrome
3. AML and myelodysplastic syndromes, therapy related
Alkylating agent-related
Topoisomerase type II inhibitor-related
Other types
4. AML not otherwise categorized
Includes most AMLs categorized in the French-American-British classification,
excludes AMLs in groups 1–3
Acute panmyelosis with myelofibrosis
5. Acute biphenotypic leukemias
Table 3
Common Cytogenetic Abnormalities in Acute Myelogenous Leukemia (AML) and
Their Prognostic Impact
Cytogenetic marker Association with FAB-type Prognostic impact
t(8;21) AML M2 Good
Inv(16) AML M4 Eo Good
t(15;17) AML M3 Good
Normal karyotype Various Intermediate
–Y, +6, del(12p), t(9;11) Various Intermediate
11q23 AML M4, M5 Poor
Trisomy 8 Various Poor
Inv(3) AML M1, M4 Poor
Del5/5q– or 7/7q– Various Poor
Multiple aberrations Various Poor
FAB, French-American-British classification.
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Table 4
Treatment Protocols for Acute Myelogenous Leukemia
Drug combinations Dosage Schedule
3  7 Protocol
Daunorubicin 45–60 mg/m2 d 1–3 , i.v.
Cytosine arabinoside 200 mg/m2 d 1–7 , i.v.
Induction for APL (AIDA, GIMENA)
All-trans-retinoic acid 45 mg/m2 d1–30, orally
Idarubicin 12 mg/m2 d 2, 4, 6, 8, i.v.
High-dose Ara-C-
Anthracycline
Daunorubicin 45 mg/m2 d 7–9, i.v.
Cytosine-arabinoside 3000 mg/m2 (every12 h) d 1–6, i.v.
High-dose Ara-C-(consolidation)
Cytosine-arabinoside 3000 mg/m2 (every12 h) d 1,3,5, i.v.
AMSA-Ara-C
Cytosine-arabinoside 2 g/m2 d 1–6, i.v.
Amsacrine 120 mg/m2 d 5–7, i.v.
Gemtuzumab-ozogamicin 9 mg/m2 d 1, 14, i.v.
ICE, Interluekin-1E-converting enzyme; EORTC, European Organisation for Research and
Treatment of Cancer; AIDA, ATRA plus idarubicin; GIMEMA, Gruppo Italiano Malattie
Ematologiche dell’Adulto; APL, acute promyelocytic leukemia; AMSA, acridinylamine
methanesulfon-m-anisidide.
6. TREATMENT STRATEGIES
6.1. Induction Treatment
The first aim of treatment in acute leukemias is to induce a complete remis-
sion. The standard induction protocol is the combination of an anthracycline with
cytosine arabinoside (3  7 protocol; see Table 4). With minor variations, this
protocol has been the basis for the treatment of AML for the last 25 yr and has
been able to induce remission in 60–80% of patients with newly diagnosed AML.
Because of comorbidity or reduced performance status, not all patients qualify
for full-dose treatment; therefore, the overall complete remission rate of
unselected patients is closer to 50–60%. In patients who do not reach complete
remission, or who show an insufficient early effect on bone marrow blasts, the
induction should be repeated. The criteria for a complete remission are defined
as less than 5% blasts in the bone marrow, no blasts in the peripheral blood,
adequate granulocyte (>1500/PL) and platelet (>100,000/PL) counts. After the
induction of complete remission, a consolidation treatment should follow. Using
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this strategy, a median duration of remission of 12–15 mo can be expected.
Depending on the biological characteristics of the leukemic cells and patient
selection, between 10% and more than 50% of patients in complete remission
will survive 5 yr or longer. In the past, other drugs (e.g., 6-thioguanine, vinca
alkaloids, or etoposide) were added to the 3  7 protocol without an improved
outcome. Approximately half of patients who fail the induction regime fail because
of resistant disease; the other half fail because of major complications (e.g.,
infection, hemorrhage, multi-organ failure). Some studies indicate that idarubicin
instead of doxorubicin may improve the outcome of induction chemotherapy.
More recently, high-dose cytosine arabinoside was tested in the setting of induc-
tion treatment. Although the percentage of complete remissions or the overall
survival did not improve with high-dose cytosine arabinoside, the duration of
complete remissions was improved. This approach has toxic complications,
especially in older patients, and cannot be considered as a standard approach.
6.2. Complications of Treatment
After the induction treatment, the patients remain granulocytopenic for at
least 15–20 d and are susceptible to bacterial, fungal, and viral infections (see
Chapter 3). The disturbances of coagulation and the thrombocytopenia predis-
pose the patients to bleeding and need support with platelet concentrates and
other blood products. It was shown that myeloid growth factors (granulocyte
colony-stimulating factor [G-CSF] or granulocyte/macrophage colony-stimu-
lating factor [GM-CSF]) given after chemotherapy shorten the period of neutro-
penia, especially in older patients, without decreasing the rate of complete
remissions. Because the use of myeloid growth factors in AML does not improve
the overall prognosis, however, a selective approach should be taken, giving
growth factors to older patients with a high risk of neutropenia-related infections.
6.3. Consolidation Treatment
A consolidation treatment is administered to patients who have reached com-
plete remission. Two (to four) courses of consolidation are considered as stan-
dard. Depending on the risk factors for AML, 20–25% of the patients will survive
for more than 4 yr. The fraction of patients who become long-term survivors
increases with intensive consolidation treatment. In a randomized study, high-
dose cytosine arabinoside (3 g/m2) was compared with standard-dose cytosine
arabinoside (100–400 mg/m2). In patients 60 yr old or younger, 44% remained
in complete remission in the high-dose treatment group vs 24–29% in the stan-
dard dose group. Neurological toxicity precludes the use of high-dose cytosine
arabinoside in older patients. The effect of high-dose cytarabine is especially
marked in patients with favorable cytogenetic features. In a long-term follow-up
of these patients, 78% were in continuous remission when treated with high-dose
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cytarabine. Patients treated with intermediate- or standard-dose cytarabine had
57 and 16% continuous complete remissions, respectively. In the other cyto-
genetic groups, no major influence of the cytarabine dose on the long-term rate
of complete remissions (approx 20%) could be demonstrated.
6.4. Role of Allogeneic Bone Marrow Transplantation
Allogeneic bone marrow transplantation (BMT) or allogeneic SCT is a treat-
ment with curative potential in AML. The antileukemic effect of transplantation
is mediated by the conditioning regimen and by the antileukemic effect of donor
cells. The long-term disease-free survival depends on the timing of transplanta-
tion: more than 50% of patients transplanted in first complete remission can
expect cure, vs 25–35% in second remission. Even in refractory AML, 15–20%
of patients will enter remission. The pool of donors for allogeneic BMT has
increased as unrelated, but histocompatible, donors can also be used with suc-
cess. At present, the searched for appropriate donors for patients with AML
should first include family members. If no match can be found, the registries
should be searched for matched unrelated donors. A further alternative is cord
blood registries (see Chapter 4). For standard-risk patients who have a donor and
do not have a contra-indication to an allogeneic transplant, the transplantation
should be performed in first complete remission. In patients with good risk
features [e.g., APL, leukemias with t(8;21)], the transplantation should be
deferred until the second remission. Patients with refractory leukemia should
also be referred for a donor search, because these patients have a chance (5–8%)
of long-term survival free of disease. Patients in first remission who do not have
an allogeneic donor, or who are reluctant to undergo an allogeneic transplant
should undergo intensive consolidation or autologous transplantation (see fol-
lowing section).
6.5. Role of Autologous Transplantation
Remission bone marrow or stem cells can be harvested, preserved in liquid
nitrogen, and reinfused into the patient after further chemotherapy. Autologous
transplantation eliminates the complications and toxicities of allogeneic trans-
plantation, but relapse is inevitable because of the presence of leukemic stem
cells in the graft. There is hope that in vitro manipulation of the graft (“purging”)
may eliminate clonogenic leukemic cells. In one multi-center study, autologous
transplantation was compared with allogeneic transplantation and intensive
consolidation treatment. The results of autologous transplantation were nearly
comparable with those of allogeneic transplantation and were better than inten-
sive consolidation treatment. The projected rate of disease-free survival at 4 yr
was 55% for allogeneic transplantation, 48% for autologous transplantation, and
30% for intensive chemotherapy. The relapse rate was highest in the intensive-
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chemotherapy group and lowest in the allogeneic transplant group, whereas the
rate of early deaths was highest after allogeneic transplantion and lowest after
intensive chemotherapy. However, at 4 yr, the overall survival after complete
remission was comparable in all three groups (59% yr for allogeneic, 56% for
autologous transplantation, and 46% for intensive chemotherapy) because of the
rescue of relapses after chemotherapy by autologous transplantion. Autologous
transplantation can also be performed in patients up to the age of 65 yr. These
favorable results of autologous transplantation may not be generalizable for all
adult patients with AML who lack an HLA-identical donor. In a randomized
comparison, a postinduction course of high-dose cytarabine provided equivalent
disease-free survival and slightly better overall survival when it was compared
with autologous marrow transplantation. In any case, intensive consolidation
treatment (given as high-dose chemotherapy or autologous transplantation) pro-
vides a chance for long-term survival in AML. Autologous transplantation gen-
erally has a shorter cytopenia than high-dose cytarabine. With optimal supportive
treatment, autologous SCT is a well tolerated procedure, but it does not provide
the graft-vs-leukemia effect offered by allogeneic transplantation.
6.6. Treatment of Relapsed or Refractory AML
In relapsed AML, a re-induction treatment with the original protocol can be
considered if the duration of the first remission is more than 9 or 12 mo. In other
cases and in primary refractory AML, second-line protocols that incorporate
high-dose cytosine arabinoside, anthracycline, and other drugs are recommended.
A second complete remission that is generally of short duration can be achieved
in 30–50% of patients with these protocols. If an allogeneic donor has been
found, the patients should be referred for BMT without delay.
6.7. Treatment of APL
Following the observation that APL responds to retinoids, the prognosis and
the treatment of APL has changed dramatically. Earlier studied showed that even
refractory cases of APL obtained complete remission with oral all-trans-retinoic
acid (ATRA). The treatment of APL is the first example for a differentiation
treatment of human cancer. At present, the optimal treatment for patients with
APL is to combine retinoids with induction chemotherapy. In a randomized
study it was shown that the inclusion of retinoic acid improved both disease-free
and overall survival in patients with APL (disease-free survival at 4 yr around
70%). Retinoic acid has changed the prognosis of APL by reducing the likelihood
of relapse. The standard dose of ATRA is 45 mg/m2 per day (given orally). About
20–30% of patients treated with retinoic acid develop “retinoic acid syndrome”
(unexplained fever, weight gain, pleural and pericardial effusions, interstitial
pulmonary infiltrates). In this case, retinoic acid should be stopped and treatment
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with cytostatic drugs must be started. Steroids may also be necessary. Different
from other types of AML, the prognosis of APL is improved if the patient
receives maintenance chemotherapy. The optimal maintenance therapy is cur-
rently investigated in studies, but generally includes retinoic acid. Another agent
with activity in APL is arsenic trioxide (>80% responses, many complete remis-
sions) in patients who relapsed after chemotherapy and/or ATRA). Currently, the
effect of arsenic incorporated into induction regimens for APL is being investi-
gated. In APL, the disappearance of the PML/RAR a gene product corresponds
to a stable remission, whereas the reappearance (tested by a sensitive PCR)
heralds relapse in many cases. Patients who reach a second remission should be
investigated for a SCT or BMT. It was found recently that patients who have a
second molecular remission and who are able to mobilize PCR-negative stem
cells actually have a better outcome (especially older patients) than patients who
undergo an allogeneic transplant.
6.8. Treatment of Secondary Leukemias
Patients with secondary leukemias have little chance of obtaining a complete
remission with current chemotherapy protocols. Therefore, these patients should
undergo allogeneic BMT early, if they have a histocompatible donor. The trans-
plantation may be done without further chemotherapy or after one cycle of che-
motherapy for cytoreduction to decrease the risk of relapse after transplantation.
6.9. Treatment of AML in Older Patients, Antibody Conjugates
Older patients often have unfavorable cytogenetics and, as a result of co-
morbidity, may not be able to tolerate a full-dose induction chemotherapy. In
older patients, AML is more often secondary to MDS. Patients in good perfor-
mance status can and should be treated with intensive chemotherapy. However,
even when older patients are treated with standard doses of chemotherapy, their
rates of complete remission and of long-term survival are lower than those in
younger patients. In most patients older than 65 yr with AML, the treatment goals
are palliative. Patients should be treated for complications and infections and
receive blood transfusions. Some older patients have a prolonged survival on
supportive treatment. Selected patients may be candidates for a reduced-inten-
sity allogeneic SCT. Patients with CD33-positive AMLs who are not candidates
for aggressive chemotherapy or who have relapsed after a short remission may
benefit from gemtuzumab-ozogamicin. This drug consists of a humanized mono-
clonal antibody directed against CD33 coupled to an antitumor antibiotic. Most
myeloid leukemias are positive for CD33. Complete or partial remissions can be
expected in about 30% of older patients with relapsed AML. Toxicities are more
severe if patients with high white cell counts are treated. Therefore, in cases with
high white cell counts, a pretreatment with oral chemotherapy or leukapheresis
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is recommended. Common side effects include acute infusion reactions, neutro-
penia, increases in bilirubin, and transaminases. Occuring less frequently is veno-
occlusive disease. Patients who later undergo an allogeneic transplantation are
at an increased risk of veno-occlusive disease. CD33 antibodies can also be
conjugated to radioactive isotopes and other toxins. These conjugates have not
yet been developed commercially. Older patients may be candidates for the
treatment with new molecules like farnesyl transferase inhibitors, which do not
have the side effects of traditional chemotherapy and may be lead to a clearance
of blasts in selected cases.
6.10. New Treatment Strategies and Outlook
New treatment strategies based on the molecular aberrations found in most
AML are currently under development. Farnesyl transferase inhibitors have
shown activity in refractory AML. Inhibitors of histone deacetylases induce
differentiation of AML blasts and are currently in clinical trials. As mentioned,
activating mutations of the FLT3-receptor tyrosine kinase occur in about 30% of
AMLs. Currently, four inhibitors of FLT3 are in clinical trials. Further approaches
that are in the early stages of clinical testing involve new agents that reverse
MDR, tumor vaccines, immunotoxins directed against myeloid differentiation
antigens, and monoclonal antibodies conjugated to radioisotopes.
Immunotherapy for AML offers the theoretical benefit of antileukemic response
mediated by T-lymphocytes or natural killer cells without the complications and
morbidity of graft-vs-host disease. As the cures observed after allogeneic trans-
plantation underscore, the human immune system is definitely able to recognize
and eliminate the blasts of AML. However, the immunotherapeutic approach
needs development. Several groups have developed vaccines, based on peptides,
proteins, and direct cell-mediated antigen-recognition.
The Wilms tumor antigen (WT1) is overexpressed in many cases of AML.
Several groups have developed vaccines from WT1 peptides. Early clinical
responses were seen in patients with low tumor loads. The clinical responses
correlated with the activity or frequency of WT1-specific cytotoxic T-lympho-
cytes after vaccination. Further targets expressed on myeloid blasts and used as
potential targets for immunotherapy are proteinase-3, PR-1, and MY4. Selected
patients with refractory AML vaccinated against tumor-associated AML reached
even molecular remissions.
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1. INTRODUCTION
Acute lymphoblastic leukemias (ALLs) are a group of hematological
neoplasias defined by cytomorphology, cytochemistry, immunological markers,
and more recently, molecular markers. The prognosis of ALL has much improved
in the last 30 yr, especially in the age group between 2 and 10 yr, where most
patients can be cured by chemotherapy. The incidence of ALL is lower than for
acute myelogenous leukemia (AML) (~1–2 cases per 100,000 inhabitants in
Western countries per year). In contrast to AML, a bimodal age peak is found in
ALL: most cases occur in children (with a peak incidence of 10 per 100,000 at
3 yr) and young adults followed by a second age peak beyond 60 yr. The peak
is more pronounced in whites, higher socioeconomic strata, and industrialized
nations in the Western hemisphere, and is mainly due to early pre-B-cell ALL.
Although recent studies in the United States, the United Kingdom, and Italy seem
to implicate an increased incidence of early pre-B-cell ALL as being responsible
for an increase in incidence of B-lineage ALL, a very large study in Nordic
countries did not mirror this finding. It could be partially explained by a concomi-
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tant decrease in incidence of undifferentiated ALL due to improved methods of
diagnosis. ALL is four times as common as AML in children. In the United
States, about 3000–4000 new cases of ALL are diagnosed each year; of these,
about 2500 are children.
2. MOLECULAR BIOLOGY OF ALL
The earliest event in ALL is the transformation and clonal proliferation of a
lymphoid stem cell. The phenotype of ALL blasts is determined by the cell of
origin and the degree of differentiation of this stem cell. In a number of cases, an
aberrant gene expression leads to an incomplete or inadequate expression of
differentiation markers. Similarly to AML, the blasts of ALL are incapable of
terminal differentiation.
With sensitive cytogenetic analysis, most cases of ALL have cytogenetic
aberrations (e.g., translocations, deletions, inversions), some of which are
prognostically relevant (discussed later). With the techniques of molecular biol-
ogy, most breakpoints involved in the cytogenetic aberrations have been cloned,
and in some patients, submicroscopic lesions in the DNA of leukemic cells have
been detected. Taken together, molecular studies have revealed a large hetero-
geneity of ALL. However, despite the advances of molecular biology, the mecha-
nisms of leukemogenesis are only beginning to be understood.
Among B-lineage ALL, t(8;14) is pathognomonic for the surface immunoglo-
bulin (Ig)-positive B-ALL with L3 morphology (this is considered to be the
leukemic form of Burkitt’s lymphoma). In some cases, other chromosomes (chro-
mosome 2, chromosome 22) are fused with chromosome 8. Leukemias with
these aberrations often present with an involvement of the CNS and/or abdomi-
nal lymph nodes. In B-ALL, the c-myc proto-oncogene is juxtaposed with Ig loci
(IgH, IgK, or IgL), thereby expressing a dysregulated c-myc protein. In B-pre-
cursor ALL, several cytogenetic lesions are known. The t(1;19) fuses the E2A
and PBX-1 genes and produces a fusion protein that activates transcription
through the E2A transactivation domain. About 2–5% of children and up to 20%
of adult cases with ALL have the Philadelphia chromosome (Phl, t9;22). As in
chronic myelogenous leukemia (CML), the c-abl proto-oncogene on chromo-
some 9 is fused with the bcr gene on chromosome 22. In contrast to CML, a fusion
transcript of 6.5 kb and a fusion protein of 190 kDa are produced in most cases
of Ph1-positive ALL. Ph1 positivity has a negative prognostic impact in ALL.
Some B-precursor ALLs have abnormalities of the long arm of chromosome 11
(11q23). In these cases, the MLL gene is rearranged. The function of the MLL
protein (synthesized in cases with MLL rearrangement) is to maintain the expres-
sion of particular members of the HOX family. Mutated MLL proteins have a
dominant gain of function effect and disrupt the normal expression of HOX
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proteins. Altered expression of HOX family members has also been found to
induce leukemia in other model systems. In some cases of ALL, the tumor sup-
pressor genes p15 and p16 are homogeneously deleted. Almost half of pediatric
patients with early pre-B-cell ALL (25% of all pediatric ALL) have a unique
chromosomal rearrangement, t(12;21)(p13;q22), which was identified by fluo-
rescent in situ hybridization (FISH) in 1994. It was missed earlier because it
involves rearrangement of chromosomal segments with an essentially identical
banding pattern. This abnormality results from the fusion of TEL (now called
ETV6) and AML1 (CBFA2).
In T-lineage ALL, a number of chromosomal aberrations are also found.
Examples are t(1;14), t(11;14), and t(7;9). In t(1;14) the SCL (or TAL-1) gene is
dysregulated. In such cases, the T-cell antigen receptor alpha/delta is juxtaposed
with either the TTG1 or TTG2 loci. Transgenic mice that overexpress the TTG1
or TTG2 genes develop T-cell lymphomas. In leukemic cells with t(7;9), a trun-
cated form of the TAN-1 protein is expressed. The TEL-AML1 transcription
factor gene results from the translocation t(12;21). The TEL-AML1 fusion pro-
tein inhibits the transcription, which is normally initiated when AML1 binds to
a core-enhanced sequence. The resulting protein complex regulates transcrip-
tion. Like the normal AML1, the abnormal TEL-AML1 fusion protein can bind
to the core-enhanced sequence, where instead of activating transcription, this
results in closure of chromatin structure, which inhibits transcription. The major
cytogenetic abnormalities encountered in ALL and the fusion genes caused by
these genetic changes are described in Table 1.
Depending on whether the malignant cells are derived from early T- or B-
cells, the genes for the T-cell receptor and Ig are rearranged in ALL. These
rearrangements however, are not specific for a certain type of leukemia, as about
10% of T-ALLs and occasionally AMLs have rearranged Ig genes. The etiology
of ALL is unknown in the vast majority of cases. In Down syndrome (DS) and
other rare genetic syndromes, especially chromosomal breakage syndromes like
Fanconi anemia, ataxia telangectasia, and Bloom syndrome, the incidence of
ALL (as of other malignancies) is increased. A large study in Scandinavia during
1984–2001 involving 3494 children with acute leukemia revealed that 2.1% of
the children with ALL had DS, the most common syndrome that causes a 10- to
20-fold increased incidence of ALL. All inherited/genetic causes combined are
responsible for less than 5% of all cases of ALL. Patients with DS had similar age
and sex distribution and no major differences in blood counts compared with
non-DS children with ALL. None of the DS patients had T-cell leukemia. Out-
come was inferior to that of non-DS children (in contrast to AML in DS) and
treatment results did not improve over time. Recently, a syndrome similar to T-
ALL was observed in 2 out of 11 children who underwent gene therapy for severe
combined X-linked immunodeficiency. It was found that the retroviral vector
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Table 1
Important Chromosomal Aberrations in Acute Lymphoblastic Leukemia
Translocation Genes involved Function Frequency
t(9:22) BCR  Unknown Adults 20–30%
(q34;q11) ABL Tyrosine kinase Children 5%
t(1;19) E2A bHLH transcription factor Adults 2%
(q23;pl3) PBX1 Homeotic Children 5%
t(11;v) MLL  Trithorax-like 3–7% (75% in
infants
(q23;v) Variable Variable
t(12;21) TEL  Ets-like transcription factor Adults 3%
(p13;q22) AML1 Runt-like transcription factor Children 25%
t(17;19) E2A bHLH transcription factor <1%
(q22;p13) HLF bZIP transcription factor
t(8;14) MYC bHLH transcription factor 2–5%
(q24;q32) IgH Immunoglobulin enhancer
t(8;14) MYC  bHLH transcription factor <1%
(q24;ql1) TCRα T-cell receptor enhancer
t(1;14) TAL1/SCL  bHLH transcription factor <1%
(p32;q11) TCRδ T-cell receptor enhancer
t(11;14) TTG2  LIM protein 1%
(p15;q11) TCRδ T-cell receptor enhancer
t(7;9) TAN1 Notch-like <1%
(q34;q34) TCRβ T-cell receptor enhancer
, Prognostically favorable; , prognostically unfavorable.
bHLH, basic helix-loop-helix; bZIP, basic leucine zipper.
Modified from Sallan et al. Educational brochure, American Society of Hematology, 1997.
had integrated near the promoter of the LMO2 gene, leading to aberrant transcrip-
tion and expression. Indeed, LMO2 is one of genes activated in T-ALL. As a
secondary event, one of these cases had acquired a mutation of the TAL1 gene in
the leukemic blasts.
A very simple classification of ALL is based on DNA histograms (hyperdip-
loid [25% of pediatric patients, 7% of adult patients], pseudodiploid, and, rarely,
hypodiploid) and is a prognostic indicator in pediatric studies of ALL, with
worsening prognosis in hyperdiploid cases. The major cytogenetic categories
observed in different age groups are schematically depicted in Fig. 10.1.
The acute T-cell leukemia caused by human T-lymphotropic virus (HTLV)-
1 is a special case of ALL (see also Chapter 22). In these leukemias, HTLV-1 is
integrated into the genome of T-cells and encodes transforming proteins like rex
and tax.
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2.1. Concept of Minimal Residual Disease
Many patients in complete remission relapse as a result of a low number of
leukemic cells in the bone marrow or other sanctuary sites that cannot be recog-
nized by the usual morphological methods (minimal residual disease). These
leukemic cells, however, can be recognized by methods like flow cytometry or
PCR.
Although the surface markers on leukemic cells are not leukemia-specific,
some leukemias have aberrant marker combinations that are suitable for the
analysis of minimal residual disease. It is evident that further improvements in
the treatment of ALL will depend on the ability to influence or eliminate minimal
residual disease. The sensitivity of immunological studies can be enhanced by
combining these studies with genotypic analysis (e.g., FISH). More recently,
studies using PCR also attempt to quantify the number of leukemic cells express-
ing leukemia-associated transcripts. PCR reactions can be established not only
for the leukemia-associated translocations encountered in ALL or AML but also
for clonotypic changes in individual patients with ALL. Examples are the gene
for IgH in leukemias of B-cell derivation and the gene for the T-cell receptor in
blasts of T-lineage.
Fig. 10.1. Relative incidence of cytogenetic respectively molecular features in acute
lymphoblastic leukemia with major prognostic and therapeutic significance in different
age groups (see text). (Reproduced from Greaves, M. Childhood leukaemia. BMJ
2002;324:283–287, with permission.)
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3. CLINICAL MANIFESTATIONS
As for all acute leukemias, the signs and symptoms of ALL result from the
infiltration of the bone marrow and other organs by malignant blasts. Conse-
quently, anemia, neutropenia, and thrombocytopenia result. The signs of anemia
are pale skin and mucous membranes, and easy fatigability; signs of neutropenia
are infections, especially abscesses and pneumonias. Thrombocytopenia is indi-
cated by gum bleeding, petechial bleeding, sometimes retinal bleeding, and easy
bruising. Hematomas are less frequent. Children often have bone and joint pain,
and sometimes a painful enlargement of the spleen. In comparison with AML,
the cytopenias in ALL are often less steep and extramedullary manifestations are
more frequent. Characteristic signs of ALL are enlarged lymph nodes and a
swelling of the spleen or liver. In many cases, ALL of the T-phenotype presents
with an enlarged mediastinum. The mediastinal tumor may cause such symp-
toms as venous engorgement or compression of the airways. About 5–10% of
patients with ALL already have an involvement of the CNS at diagnosis. Char-
acteristic signs are headaches, meningeal irritation, or a paralysis of the cranial
nerves due to infiltration and somnolence, or stroke due to increased blood vis-
cosity leading to ischemia. Other organ manifestations like infiltration of skin,
testes, or kidneys are less frequent.
4. DIAGNOSIS AND CLASSIFICATION OF ALL
Diagnosing ALL is easy if the white cell count is increased with immature
lymphoid blasts in the peripheral blood and if platelets and neutrophils are de-
creased. The blasts of ALL have large, rounded, and indented nuclei and scant,
darker blue cytoplasm. In contrast to the blasts found in AML, no cytoplasmic
granules or Auer rods are present. (Fig. 10.2, Color Plate 7; a typical ALL lym-
phoblast is shown.) The blasts of B-ALL are larger and often vacuolated (Fig.
10.3, see Color Plate 8). Some patients with ALL have a normal or decreased
white cell count, but if the blood smear is carefully inspected, there are always
blasts. The next essential step in the diagnosis of an acute leukemia is a bone
marrow biopsy with aspiration, which is usually performed at the iliac crest. The
cytochemical profile of ALL blasts is shown in Table 2: the blasts of ALL are
negative for peroxidase, Sudan black, or chloroacetate esterase; approx 80% are
positive for the periodic acid-Schiff (PAS) stain (often large cytoplasmic aggre-
gates of PAS). Acid phosphatase may also be positive.
In many cases, the bone marrow aspiration shows a dense infiltration with
leukemic blasts (>50–90%). In a few cases, the infiltrate of leukemic cells is so
dense that no aspiration is possible (dry tap). In such cases, a bone marrow biopsy
will establish the diagnosis of acute leukemia. The differentiated immunological
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Fig. 10.2. Acute lymphoblastic leukemia (French-American-British [FAB]-type L2).
Fig. 10.3. Acute B-lymphoblastic leukemia. Large lymphoblasts with basophilic cyto-
plasm and vacuoles.
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and cytochemical differentiation of the blasts can be performed from blood. It is
of special importance to differentiate between ALL and AML, because the treat-
ments and prognoses are different. Leukemic blasts should always be phenotyped
for the expression of differentiation antigens (B, T, natural killer [NK], and
myelomonocytic markers) using a panel of monoclonal antibodies. In addition,
ALL subtypes are defined by immunological markers. Certain cytoplasmic
markers are also helpful to differentiate ALL, including cytoplasmic Ig for early
B-ALL, cytoplasmic CD3 for T-ALL, and the enzyme terminal transferase (TdT)
reactive in most ALL. TdT is expressed in all cases of ALL with the exception
of B-ALL (Table 3); however, it can also be found in some cases of typical AML.
Occasionally, the bone marrow shows less then 25% blasts with ALL morphol-
ogy, despite extramedullary manifestations such as enlarged lymph nodes and a
mediastinal mass. These cases are classified as lymphoblastic lymphomas with
bone marrow involvement. Because of the diagnostic and prognostic relevance
of cytogenetics (as mentioned), ALL blasts should always be examined in a
cytogenetic laboratory. Some cooperative groups base treatment strategies in
ALL on the presence or absence of certain molecular markers. Therefore, the
DNA and RNA of leukemic cells should be isolated at diagnosis.
When a case of ALL is newly diagnosed, a chest X-ray should be performed
in order to recognize a mediastinal tumor (typical of T-ALL) and to exclude
pneumonic infiltrates. If the chest X-ray shows an enlarged mediastinum, a
computed axial tomography (CAT) scan (or a magnetic resonance tomography
[MRT] scan) of the mediastinum should also be requested to measure the exact
dimensions of the mediastinal tumor. As mentioned in Chapters 3 and 8, possible
Table 2
French-American-British (FAB) Classification of Acute Lymphoblastic Leukemias
FAB type Morphological features POX PAS Acid phosphatase
L1 Small homogeneous with scanty 0 +/++ 0/+
cytoplasm, moderate basophilia,
inconspicuous nuclei
L2 Larger, heterogeneous cells, 0 +/++ 0/+
variable cytoplasm, basophilia,
prominent nucleoli
L3 Larger, homogeneous cells 0 +/++ 0/+
with dark basophilic cytoplasm,
prominent vacuoles, prominent
nucleoli
POX, peroxidase; PAS, periodic acid-Schiff.
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Table 3
Immunological Classification of Acute Lymphoblastic Leukemias (ALLs)
Frequency
Type of ALL HLA-DR TdT CD10 CD19a CyIg SIg CD7 CyCD3 Adults Children
Pro-B-ALL + + 0 + 0 0 0 0 4–10% 7%
Common ALL + + + + 0 0 0 0 50–60% 70%
Pre-B-ALL + + + + + 0 0 0 ≈10% ≈15%
B-ALL + 0 +/– + +/– ++ 0 0 3–4% 2–3%
Early T-ALL 0 + 0/+ 0 0 0 + + 7–10% ≈l%
T-ALLb 0 + 0/+ 0 0 0 + + 15–20% ≈10%
(+CD1a, CD2,
CD3)
CD, cluster of differentiation (see Appendix 2); CyIg, cytoplasmic immunoglobulin; SIg, surface immunoglobulin; CyCD3, cytoplasmic
CD3.
aAs accessory markers for B-lineage, CD79a and/or CD22 are useful.
bThe subtype of thymic (cortical) ALL is characterized by the CD1a and has a better prognosis in adult patients
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infections should be investigated in a patient with acute leukemia before the
chemotherapy is started.
Patients with ALL should have a lumbar puncture to exclude or confirm an
involvement of the CNS with leukemia. The sediment should be carefully
screened for the presence of leukemic blasts. All treatment protocols for ALL
include a prophylaxis to the CNS by administering drugs (e.g., methotrexate) to
the intrathecal space. In case of a thrombocytopenia (<50,000/µL), a platelet
concentrate should be transfused before the lumbar puncture.
4.1. Laboratory Features of ALL
The blood and bone marrow findings were mentioned previously. Signs of
increased cell turnover are increased uric acid, lactate dehydrogenase, and, less
frequently, a hypercalcemia. Evidence of disseminated intravascular coagula-
tion is rare in ALL.
4.1.1. THE FRENCH-AMERICAN-BRITISH CLASSIFICATION OF ALL
The French-American-British (FAB) group distinguishes three categories of
ALL according to morphological criteria (Table 2). With the exception of the
type L3, which correlates with the immunological type of B-ALL and which can
be considered as a leukemic form of Burkitt’s lymphoma, the FAB types of ALL
furnish little prognostic information. Type L1 is more frequent in children with
ALL, whereas L2 is more frequent in adults.
According to immunological criteria, at least six categories of ALL can be
distinguished (Table 3). A positive reaction is scored if more than 10–15% of the
blasts bear the antigen investigated. None of the markers as defined by the cluster
of differentiation (CD) nomenclature is leukemia-specific. Some or all can be
found on proliferating cells or regenerating bone marrow. Some combinations
are leukemia-associated. However, the diagnosis of ALL or of acute leukemia in
general should only be made if the population of leukemic cells can also be
identified by cytomorphology.
Gene expression profiling was found helpful to subdivide cases of ALL
according to the phenotypes, genotypes, and the oncogenic pathways involved.
For example, cases involving the HOX11L2, LYL1, and HOX11 genes are char-
acterized by high levels of MYC expression and the loss of p16INK4a and p14ARF,
whereas cases involving LYL1 are characterized by high levels of N-MYC
expression and the deletion of other as-yet unidentified genes. Gene expression
profiles on their own may have prognostic significance in ALL, but prospective
studies must be performed in order to understand whether certain markers will
mandate different treatments. Gene expression profiling has already identified
novel leukemia-associated genes, which can be monitored in blood or bone
marrow while the patient receives treatment.
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The most frequent form of ALL is designated as Common-ALL (in adults 50–
60% of all patients with ALL, in the pediatric age group more than 70%). The
second most frequent form of ALL bears markers of T-cell lineage (T-ALL, 10–
30% of all patients). A very immature form of B-lineage ALL is designated as
early pre-B-ALL, whereas B-ALL has a more mature immunophenotype with
the expression of surface Ig. The so-called acute undifferentiated leukemia has
become rare. At present, more than 98% of all acute leukemias can be either
classified as lymphoid or myeloid. With more sensitive typing methods, an
increasing number of acute leukemias have been found to bear both lymphoid
and myeloid markers (“leukemias of mixed lineage”). This phenomenon is also
described as “lineage infidelity” and is related to the leukemic transformation. At
least in the pediatric age group, mixed lineage leukemias appear to have an
unfavorable prognosis. Some bona fide ALLs express myeloid markers (e.g.,
CD33) without being positive for myeloperoxidase (a specific myeloid marker).
This phenomenon does not appear to have clinical relevance. In Fig. 10.4, the
combined findings in a case of ALL (immunophenotype, karyotype, and geno-
type) are shown.
In Japan and the Caribbean, a form of acute T-cell leukemia associated with
a human retrovirus (HTLV-1) is endemic. This acute T-cell leukemia (ATL)
manifests itself with lymph node swelling, hypercalcemia, skin lesions, and a
hepatosplenomegaly. Most cases have an aggressive clinical course (see Fig. 15.5
and Color Plate 19).
5. PROGNOSTIC FACTORS AND COMPLICATIONS IN ALL
Unfavorable prognostic features are leukocyte count greater than 50,000/µL,
age less than 1 yr or greater than 40 yr, male sex (at least for children), meningeal
involvement at diagnosis, slow remission induction (indicating drug resistance),
and certain cytogenetic and molecular aberrations (BCR/ABL translocation, MLL
rearrangement).
At present and as a result of the chemosensitivity of pediatric ALL, treatment
intensity is, at least in children, among the most powerful positive prognostic factors.
Hyperdiploidy (increased number of chromosomes) is a favorable prognostic
factor, at least in children. The presence of the TEL/AML1 fusion gene in the
leukemic cell population also has a favorable prognostic impact. The L3 type of
ALL (which corresponds to B-ALL) used to have the worst prognosis but has
improved in recent years. In the present era of intensive induction and reinduction
treatments, the pre-B- and T-phenotypes are less prognostically different. Early
pre-B-ALL contributes to the bulk of pediatric patients, and a distinct category
comprised of common ALL antigen (cALLa, CD10)-positive leukemias that are
too immature to synthesize cytoplasmic Igs contribute to about 60% of all pedi-
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atric ALL. Although biologically diverse, they are more likely to have favorable
prognostic characteristics such as hyperploidy and have excellent prognosis,
resulting in a cure rate of about 90%, prompting therapeutic trials with less
intensive chemotherapy for this group of patients.
Despite the prophylaxis administered to all patients with ALL, up to 10%
develop a meningeal involvement. Risk factors are a high initial blast count and
the immunophenotypes B-ALL and T-ALL. If the diagnosis of meningeal leuke-
mia is unclear, suspicious cells in the cerebrospinal fluid (CSF) should be
immunophenotyped. In some cases, meningeal leukemia is associated with
the formation of blastic tumors in the CNS; therefore, a CAT scan or MRT of the
brain should be obtained. See Fig. 10.4 for a case example.
Up to 15% of boys with ALL develop an isolated testicular relapse. Testicular
relapses should be treated with a bilateral irradiation and the reinduction of
chemotherapy.
6. TREATMENT STRATEGIES
Marked improvement in survival, from 30% in 1970 to more than 80% in
pediatric ALL at present, has been achieved mainly by intelligent yet empiric
intensive multi-agent chemotherapy with universal CNS prophylaxis. This re-
markable success story (brought about by multi-center randomized clinical trials
without new drugs) has served as a paradigm for treatment of other cancers. A
finding in many studies, however, is that in the United States, non-white children
have significantly lower cure rates (especially in 1- to 9-yr age group)—72–74%
compared with 82% in white children.
6.1. Induction Treatment
This phase aims at rapidly lowering the leukemic burden and decreasing the
incidence of emergence of resistance to chemotherapy. A minimum of three
drugs is required to achieve durable long-term remission. The present treatment
protocols for induction combine corticosteroids, vincristine, and asparaginase or
anthracyclines. Addition of antimetabolites (such as methotrexate and cytosine-
arabinoside), epipodophyllotoxins, and alkylators (e.g., cyclophosphamide) to
the four drugs benefits patients with high-risk ALL, albeit with higher short-term
morbidity and no significant increase in mortality. The protocols induce a com-
plete remission in more than 95% of pediatric patients and in 70–80% of adults
with ALL. The induction treatment is generally given over 2 mo.
6.2. Consolidation Treatment
If a remission is reached with the induction treatment, a consolidation treat-
ment is given. Consolidation employs multiple cytostatic drugs, including drugs
not used in the induction (e.g., methotrexate or epipodophyllotoxins plus
cytarabine). The rationale of the consolidation treatment is to reduce minimal
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Fig. 10.4. Diagnostic findings in acute lymphoblastic leukemia: combination of
immunophenotype, karyotype, and genotype in a case of CD10– ALL.
residual disease as much as possible. Many study groups vary the treatment
according to the risk of relapse. In patients in the low-risk category, the treatment
intensity is decreased. This avoids an unnecessary toxicity. Many protocols
also include a reinduction treatment, repeating a modified induction protocol
after 5 or 6 mo. Patients with special risk features (e.g., a high white cell count),
receive an intensified consolidation treatment. Their regimens would consist of
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intensified chemotherapy immediately after induction (early intensification),
followed by intensified chemotherapy following a short less-intensive phase
(delayed intensification). The UK ALL group has shown improved results in
high-risk children by using a third round of intensified chemotherapy in between
the phases of early and delayed intensification. Children with BCR-ABL and
infants have a worse prognosis and Ph1-positive patients are candidates for an
allogeneic stem cell transplantation (SCT) or bone marrow transplantation
(BMT) after reaching remission.
6.3. Continuation or Maintenance Treatment
ALL generally requires a prolonged maintenance treatment for cure. Many
protocols administer monthly vincristine, and prednisone or dexamethasone,
methotrexate weekly, and daily mercaptopurine. In pediatric protocols, mainte-
nance is given for 2 yr in females and 3 yr in males (mainly to prevent testicular
relapse) counted from the end of induction. In rare individuals with a deficiency
of thiopurine S-methyltransferase (the enzyme that inactivates mercaptopurine)
the drug causes a severe cytopenia, but can be safely given at lower doses. Hence
many protocols either monitor drug metabolite levels and/or tailor drug dosage
to peripheral leukocyte and platelet counts. Examples for standard-risk protocols
for adults with ALL are shown in Table 4.
Table 4
Treatment Protocols for Adult Acute Lymphoblastic Leukemia (ALL)
I. GMALL Protocol for ALLa
A. Induction Chemotherapy
Part 1 Predniso(lo)ne 3 × 20 mg/m2 (days 1–28)
Vincristine 2 mg (days 1, 8, 15, 22)
Daunorubicin 45 mg/m2 (days 1, 8, 15, 22)
L-Asparaginase 5000 U/m2 (days 15–28 every other
day)
Part 2 Cyclophosphamide 1000 mg/m2 (days 29, 43, 57)
Cytosine-arabinoside 75 mg/rn2 (days 31–34, 38–41,
45–48, 52–55)
6 Mercaptopurine 60 mg/m2 (days 29–57)
Intrathecal prophylaxis 15 mg methotrexate (d 0, 31, 38, 45, 52)
Prophylactic irradiation of CNS  if complete remission is reached after d 28
B. Consolidation Treatment
If complete remission after (A) and adequate regeneration of hematopoiesis
Week 13 and week 17 (+ further CNS prophylaxis)
C. Reinduction Chemotherapy (weeks 21–26)
Part 1 Prednisolone 3 × 20 mg/m2 (d 1–28)
Vincristine 2 mg (days 1, 8, 15, 22)
Doxorubicin 25 mg/m2 (days 1, 8, 15, 22)
(continued)
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Part 2 Cyclophosphamide 1000 mg/m2 (day 29)
Cytosine arabinoside 75 mg/m2 (days 31–34, 38–41)
Thioguanine 60 mg/m2 (days 29–42)
Further CNS prophylaxis (methotrexate, cytosine arabinoside, and dexamethasone)
D. Second Consolidation Chemotherapy (after week 29)
Two alternating cycles of cyclophosphamide/cytosine arabinoside and teniposide/arabinoside
E. Maintenance Therapy (until month 30)
Oral 6-mercaptopurine (daily) and methotrexate (weekly), further CNS prophylaxis
(methotrexate, cytosine arabinoside, and dexamethasone, every 2 mo)
II. HyperCVAD Protocol for Adult ALL
Part 1 Cyclophosphamide 300 mg/m2 i.v. over 3 h every 12 h for six doses on days 1–3,
mesna, vincristine 2 mg i.v. on days 4 and 11, doxorubicin 50 mg/m2 i.v. on day 4,
dexamethasone 40 mg/d on days 1–4 and 11–14
Part 2 Methotrexate 200 mg/m2 over followed by 800 mg/m2 i.v. by continuous infusion over
24 h, leucovorin 15 mg starting 24 h after completion of MTX infusion and given every
6 h for eight doses (until MTX levels are less than 0.1 µM), cytarabine 3 g/m2 i.v. over 2
h every 12 h for four doses on day 2 and 3, methylprednisolone 50 mg i.v. twice daily on
days 1–3 (a total of eight alternating cycles is given; for details on CNS prophylaxis and
maintenance treatment see original literature)
III. CALGB Induction Regimen
Induction regimen: cyclophosphamide 1200 mg/m2, daunorubicin 45 mg/m2 for 3 d i.v. on
days 1–3, vincristine 2 mg iv. on days 1,8,15, and 22, Prednisone 60 mg/m2 d p.o. on d 1–
21, l-asparaginase 6000 U/m2 i.v. on d 5,8,11,15,18, and 22
(For consolidation, CNS prophylaxis, and late intensification see original protocol description,
a maintenance is given with vincristine, prednisone, and 6-mercaptopurine, total treatment
lasts 24 mo.)
IV. Example for a Pediatric Protocol (POG 9905 for standard-risk ALL, shortened
version)
• Induction: all regimens (weeks 1–5)
• Dexamethasone, vincristine, L-asparaginase, intrathecal methotrexate
• Consolidation: regimens A and B (weeks 5–24) for low-risk patients (risk determined
by age, white blood cell count at diagnosis, molecular markers, DNA index, and
response to therapy)
• Intravenous methotrexate, intrathecal methotrexate, 6-mercaptopurine, dexameth-
asone, vincristine
•  Consolidation: regimens C and D (weeks 5–32) for high-risk patients
Intravenous methotrexate, L-asparaginase, intrathecal methotrexate, 6-mercaptopurine,
dexamethasone, vincristine, daunomycin, cyclophosphamide, cytosine arabinoside, 6-
thioguanine
•  Intensive continuation: all regimens
HD-MTX, 6-mercaptopurine, intrathecal methotrexate, vincristine, dexamethasone
• Continuation: all regimens
Methotrexate p.o., 6-mercaptopurine, intrathecal methotrexate, vincristine, dexamethasone
(total duration of 2.5 yr in complete remission)
aLow-risk category, modified from German multi-center adult ALL study group. MTX, methotrexate;
CALGB, Cancer and Leukemia Group B.
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6.4. Prophylaxis of Meningeal Leukemia
CNS prophylaxis of leukemia is an integral part of all protocols for pediatric
and adult ALL. Systemic therapy plays an integral role in prevention of relapse
in CNS. High-dose systemic therapy, especially corticosteroids, cytarabine, and
methotrexate, when given in conjunction with intrathecal chemotherapy,
helps decrease intensity of CNS radiation, especially in high-risk pediatric
ALL (T-cell, presence of high white blood cell [WBC] counts, age >10 yr, or
overt CNS leukemia at diagnosis), who contribute about 40% of the cases. This
strategy eliminates need for CNS irradiation in low-risk pediatric patients if
additional intrathecal injections are added during consolidation and maintenance.
CNS radiation may be responsible for poor intellectual development, multiple
neuroendocrine abnormalities, and second malignancies. Systemic L-asparagi-
nase also decreases CSF asparagine levels and may help control CNS disease.
Generally, intrathecal methotrexate is administered at diagnosis and at differ-
ent times (12–15 injections, up to 23 injections in pediatric patients depending
on intensity of systemic therapy and type of disease) during the consolidation and
maintenance therapy. Some protocols also give irradiation to the brain (12–18 Gy
depending on the age group especially those with high-risk features). The treat-
ment of meningeal leukemia consists of two or three weekly intrathecal injections
of 15 mg methotrexate, 40 mg cytosine arabinoside, and 4 mg dexamethasone (in
adults) or 24 mg hydrocortisone (in children). When no more blasts can be seen
in the CSF, five more intrathecal injections should be given. Intraventricular
injections via an Ommaya port are an alternative treatment to intrathecal injec-
tions. Ommaya devices are implanted by neurosurgeons. All intrathecal injec-
tions have to be performed under absolute sterility. For the definitive treatment,
a consolidation by irradiation (24 Gy to the whole brain and the neuraxis) is
recommended.
6.5. Supportive Treatment and Prevention of Early Complications
Patients with ALL, as with other acute leukemias, need an intensive sup-
portive treatment. Infections should be investigated and treated aggressively.
Patients with ALL are at risk for pneumocystis pneumonia infections; therefore,
most centers give a prophylaxis with oral trimethoprim-sulfamethoxazole (TMP-
SMX, 2 or 3 d/wk, orally). Patients who do not tolerate TMP/SMX can be treated
with aerosolized pentamidine or dapsone. ALL blasts are very sensitive to che-
motherapy and steroids. Therefore, the possibility of a tumor lysis syndrome
should always be considered during the induction chemotherapy. The laboratory
features of a tumor lysis syndrome are an increase in uric acid, potassium, phos-
phate, and decreased calcium. If no prophylaxis is made, tumor lysis syndrome
may lead to acute renal failure. The prophylaxis consists of an adequate hydra-
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tion (at 2000 mL/m2 in children or 3 L/d isotonic fluids in adults). Electrolytes
should be balanced and allopurinol should be given. The urine should be alka-
lized with sodium bicarbonate to maintain urine pH between 7.0 and 7.5, as uric
acid precipitates at pH less than 5.0, and phosphate precipitates at a pH greater
than 7.5. Hyperkalemia, hypocalcemia, and hyperphosphatemia due to electro-
lyte release from dying leukemic cells can be life-threatening. Uric acid stones
can precipitate renal failure. Recombinant fungal urate oxidase (Rasburicase)
acts more rapidly against hyperuricemia than allopurinol, but can cause hemoly-
sis or methemoglobinemia in patients with glucose-6-phosphate dehydrogenase
deficiency. Acute renal failure is treated by hemodialysis. Extreme leukocytosis
(leukocytes >200,000/L) should be ameliorated rapidly by leukapheresis to pre-
vent or treat CNS complications. Adding cytokines (e.g., granulocyte colony-
stimulating factor) has ameliorated the short-term complications of neutropenia
during ALL treatment, but has by itself no major prognostic impact in ALL.
Fever and presumed or diagnosed infections necessitate starting broad-spectrum
antibiotics including addition of antifungal therapy for continued fever until
definitive therapy can be instituted. Complications of thrombocytopenia and
anemia are prevented by prophylactic transfusions of irradiated (to prevent graft-
vs-host disease) and filtered blood products. Administration of filtered blood
products lowers risk of allosensitization, cytomegalovirus (CMV) infections,
and febrile and possibly allergic reactions.
6.6. Cure Rates and Late Complications in ALL
With the strategies outlined, about 80% of pediatric patients appear to be
cured. In the adult patient group, the cure rate is lower (about 20–40% long-term,
relapse-free survivors). Along with the relatively good prognosis of pediatric
ALL, the problem of late effects has emerged. A retrospective analysis found an
incidence of second malignancies of 1.5% 10 yr after diagnosis. Children who
had irradiation to the brain had an increased risk of CNS tumors, endocrine
abnormalities, and significant intellectual handicaps; hence, some newer proto-
cols have eliminated CNS irradiation in all cases except CNS ALL. In the total
group of patients with ALL, non-Hodgkin’s lymphomas and other cancers were
found. Patients treated with inhibitors of topoisomerase II are at a risk of devel-
oping secondary myeloid leukemias (mean latency period 3 yr). Other late effects
are endocrine disturbances, obesity, short stature, and osteoporosis. The admin-
istration of growth hormone ameliorates the growth deficit. Some children with
ALL who had cranial irradiation develop neuropsychological problems, usually
1–3 yr or more after chemotherapy. The administration of anthracyclines, espe-
cially at high cumulative doses, may lead to a cardiomyopathy. Cardio-protec-
tive substances (e.g., dexrazoxane) are under development.
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6.7. Treatment of Relapsed or Refractory
ALL and Indications for BMT
The prognosis of refractory ALL is poor. Clofarabine, a purine nucleoside
antimetabolite is now approved by the Food and Drug Administration for
relapsed or refractory pediatric ALL after at least two prior regimens. The rec-
ommended dose is 52 mg/m2 daily for 5 d. It inhibits synthesis and repair of DNA,
and thus acts on multiplying and quiescent leukemic cells. Alternative protocols
with high-dose cytosine arabinoside or monoclonal antibodies targeted against
T- or B-cell differentiation antigens have some clinical efficacy. The strategies
for relapses depend on the time of relapse. Relapses that occur early after the
maintenance is discontinued should be treated with alternative protocols. Re-
lapses occurring several years after the end of the maintenance phase should be
treated with the initial regime and then consolidated with a different protocol. All
patients with ALL who relapse are candidates for BMT or SCT. Therefore, the
search for a histocompatible donor should begin early. Certain high-risk patients
(e.g., those with a high likelihood of relapse, a high WBC count, Ph1-positivity,
or an MLL rearrangement) should be referred for BMT (if a donor is found) after
they have entered complete remission. In an international study in patients with
ALL aged 15–45 yr, allogeneic transplantation was compared with intensive
chemoconsolidation. The 5-yr, relapse-free survival was 38% in the chemo-
therapy group and 44% in the transplant group (not statistically different). In the
chemotherapy group, almost all deaths were caused by relapses; in the transplant
group the main cause of death was transplant-related complications. Allogeneic
transplants are recommended for all patients in second remission who have a
matched donor, as these patients have a low likelihood of cure. For children with
relapsed ALL, the transplantation of cord blood stem cells also appears feasible.
Children that relapse during therapy or within 6 mo of completion of chemo-
therapy are less likely to respond to chemotherapy and hence are clearly ben-
efited by an SCT, especially if a matched sibling donor is available. The earlier
the relapse during chemotherapy, the worse the prognosis. It is therefore logical
that failure to induce a remission probably carries the worst prognosis in pediatric
ALL. Autologous transplantation does not have a clear indication in the treat-
ment of ALL. Even if the autologous graft is incubated with monoclonal antibod-
ies or toxins, most patients treated with this approach so far have relapsed.
6.8. Treatment of B-ALL
Patients with B-ALL (FAB group L3) do not enter into the standard ALL
protocols, but are treated with special protocols that feature high-dose cyclo-
phosphamide and high-dose methotrexate and omit a longer maintenance treat-
ment. The response and cure rates of B-ALL have improved in recent years (the
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rates of complete remissions are about 70% and the long-term, leukemia-free
survival approaches 50%). Some studies have added ifosfamide or etoposide to
the drugs given for B-ALL.
6.9. Treatment of ALL in Older Patients
Patients with ALL who are older than 50 to 65 yr generally have a poor
outcome. This is due to comorbidities, but also due to the biological character-
istics of the leukemic cells, with a higher percentage of patients having poor
prognosis karyotypes. In published case series, a remission rate of 43–58% and
an early death rate of 16–24% were reported. The overall survival for these patients
was only in the range of 7–12 mo. Patients who are in good performance status
benefit from intensive chemotherapy, but it is unclear which maintenance che-
motherapy is best at prolonging remission. To improve the prognosis for
older patients, new approaches are needed. Successful examples for targeted
therapies are imatinib for bcr/abl-positive leukemias and rituximab for CD20-
positive leukemias.
6.10. Use of Monoclonal Antibodies in the Treatment of ALL
Recently, monoclonal antibodies have become available for clinical use and are
widely used in the treatment of non-Hodgkin’s lymphomas. In mature B-ALL and
Burkitt’s lymphomas, the initial results of the combination of chemotherapy and
a CD20 antibody (rituximab) are promising. Longer follow-up will determine if
such antibodies have also activity in other types of B-lineage ALL and if they will
improve the long-term cure rates. Other antibodies (directed against CD19,
CD22, CD25, and CD52) are currently under development or in clinical trials.
Occasional patients with B-lineage ALL co-express the myeloid marker CD33.
Such patients are candidates for a treatment with antibodies or toxins directed
against CD33.
6.11. Current Treatment Approaches for Ph+ (BCR/ABL+) ALL
Imatinib was found to have single agent activity in relapsed or refractory Ph+
ALL. At a dose of 400–800 mg p.o., at least half of patients had a clinical response
that lasted on average 2–3 mo. In many patients, blasts in the peripheral blood
cleared, although no major response was seen in bone marrow blasts. Imatinib
induced responses even in patients who relapsed after an allogeneic transplant.
Based on these encouraging results, clinical trials were started for newly diag-
nosed patients with Ph1+ ALL, combining imatinib given orally with standard
chemotherapy. Preliminary results from these studies show that this combination
is safe and highly effective, at least at short-term follow-up. Historically, Ph1+
ALL has a chance of complete remission with aggressive chemotherapy of only
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50–60%. The preliminary results of the combination of chemotherapy with
imatinib show complete remission rates of 80–90%. Some of these patients may
then undergo an allogeneic SCT with a chance for cure.
6.12. Future Perspectives
As ALL is a rare disease, the achievement of excellent cure rate makes it
increasingly difficult, statistically and even ethically, to test the effectiveness of
newer strategies and modalities for treatment. Extensive cooperation within large
research groups across continents is needed to generate sufficient data to appre-
ciate subtle improvements in outcome measures.
Multiple new drugs, inhibitors of signaling cascades, targeting surface recep-
tors, oncogenes, angiogenesis, and apoptotic pathways are presently under devel-
opment. The successful use of imatinib has encouraged similar new treatment
approaches. Because many breakpoints of leukemia-associated genes have been
cloned, a specific genetic therapy with antisense constructs, small interfering
RNAs, and ribozymes is a logical approach. An alternative path of research
directs the immune system against the leukemic cells, making the leukemic cells
a target for autologous or allogeneic killer cells. In good-risk pediatric patients,
the treatment intensity has already been curtailed to minimize long-term toxici-
ties. Pharmacogenetics, pharmacogenomics, gene arrays, and proteomics will be
used to tailor the treatment intensity in individual patients and help discover
novel proteins that would target and modulate hitherto unreachable molecular
targets to render resistant cells susceptible to chemotherapy. Genes that are
already known to influence the outcome and treatment intensity in ALL are
thiopurine methyltransferases and thymidylate synthase. Study of presence or
absence of mutations in these and other enzymes that are critical for metabolism
of certain drugs may help individualize the intensity of chemotherapy.
Gene expression profiling has identified specific subgroups of patients who
have increased sensitivity (such as L-asparaginase sensitivity in TEL-AML1
subtype and hyperdiploidy), or resistance to chemotherapeutic agents (such as
methotrexate in T-cell ALL due to lesser expression of folylpolyglutamate syn-
thetase). This method is easier than the in vitro drug sensitivity testing. Although
it is unlikely that gene expression profiling will replace the established risk
stratification methods base on age, sex, counts, and cytogenetics, it will soon
complement it.
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1. DEFINITION
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal dis-
orders characterized by one or more peripheral blood cytopenias and dysplasia
of at least one lineage (classically three lineages) in the bone marrow. The approxi-
mate incidence is two to four cases for a population of 100,000 annually.
2. ETIOLOGY
In the elderly population in which MDS typically occurs, its etiology is poorly
understood. MDS occurs infrequently before the age of 50 but its incidence
increases rapidly thereafter. Prior exposure to chemotherapeutic agents, ionizing
radiation, or benzene are well established risk factors in a minority of cases.
Alkylating agents and etoposide are the drugs that most frequently cause MDS,
and the risk is proportional to the duration of exposure. MDS also can arise in
patients with pre-existing Fanconi anemia or aplastic anemia.
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3. PATHOPHYSIOLOGY
The vast majority of MDS cases are acquired. The development of MDS is due
to accumulated DNA damage in the hematopoietic stem cell. This damage may
take the form of chromosomal gains or losses, translocations, or point mutations.
The most common cytogenetic abnormalities observed in MDS are shown in
Table 1. Most single cytogenetic abnormalities, with the exception of monosomy
5 or 7 or the deletion of 7q, are not associated with an adverse prognosis. These
cytogenetic changes are frequently observed as a complication of prior alkylat-
ing chemotherapy. Cases of MDS harboring 11q23 translocations can be observed
as early as 2 yr following exposure to etoposide, and are associated with a high risk
of disease progression to acute myelogenous leukemia (AML).
The critical genes affected by most of the cytogenetic abnormalities are
unknown at present. An exception is the p53 gene, which is a tumor suppressor
gene residing on the short arm of chromosome 17. The p53 protein prevents entry
of a cell into S phase or triggers programmed cell death (apoptosis) in response
to DNA damage. In the absence of functional p53, cells can continue to prolif-
erate even with extensive DNA damage, leading to the accumulation of addi-
tional chromosomal abnormalities. Alterations of p53 are observed in 5–10% of
Table 1
Cytogenetic Abnormalities in Myelodysplastic Syndromes
Alteration Prognostic significancea
5q−b Favorable
−5, −7, or 7q− Adverse
+8 Adverse
20q− Neutral
11q− Neutral
−Y Neutral
−17 or 17p− Adverse
Translocation of 3q26 Adverse
Translocation of 11q23 Adverse
Multiple Adverse
aCompared with a normal karyotype.
bAs sole abnormality.
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MDS cases. MDS patients with monosomy 17 or a deletion of 17p often have an
inactivating mutation of the remaining p53 gene, and thus have no functional
p53. The MLL oncogene resides on 11q23, the chromosomal region that is rear-
ranged in MDS patients with a history of etoposide exposure. The functions of
the normal MLL protein and the fusion proteins encoded by the genes resulting
from MLL translocations are unknown. One form of refractory anemia with
ringed sideroblasts (RARS) is inherited as an X-linked disorder. It results from
mutation of the erythroid-specific 5-aminolevulinate synthase gene, which
impairs the activity of the encoded enzyme.
The most common molecular abnormalities in MDS are point mutations of the
Ras genes. The H-, K-, and N-Ras genes encode signal transducing proteins that
act downstream of growth factor receptors. The RAS proteins have the ability to
bind and hydrolyze guanosine triphosphate (GTP). When the RAS proteins bind
GTP, they signal cells to proliferate; after they hydrolyze the GTP to guanosine
diphosphate (GDP), the RAS proteins become inactive. The GTPase activating
protein (GAP) increases the GTPase activity of the RAS protein. Mutations of
the Ras genes diminish the intrinsic GTPase activity of the encoded RAS pro-
teins, and decrease their sensitivity to GAP, causing RAS to be in a constitutively
active state. In this way, Ras mutations lead to increased levels of cell prolifera-
tion. In MDS, these point mutations predominantly affect the N- and K-Ras
genes. Mutations of other genes that affect the RAS signaling pathway have been
described in MDS. The neurofibromatosis type 1 (NF1) gene encodes a GAP
protein. The NF1 mutations diminish the ability the encoded protein to activate
GTPase activity, thus increasing the amount of time that the RAS proteins are
GTP-bound and active.
In addition to abnormalities in DNA integrity, alterations in DNA methylation
may also be present in MDS. These epigenetic changes can affect gene expres-
sion. The cumulative effect of genetic and epigenetic abnormalities is to alter cell
cycle regulation, programmed cell death (apoptosis), and growth factor signaling
pathways. The manner in which these cellular processes are altered differs depend-
ing on the stage of MDS. In MDS subtypes with fewer than 5% myeloblasts, there
is a high frequency of cells undergoing apoptosis. Hematopoiesis is ineffective
because of the increased rate of cells dying in the bone marrow. In MDS subtypes
with increased numbers of myeloblasts, the rate of apoptosis is decreased and
hematopoiesis is ineffective as a result of impaired differentiation of the blasts
into mature blood cells. These differences in biology between MDS subtypes
suggest that the therapeutic approach should be different depending on the nature
of problem. Anti-apoptotic agents would theoretically benefit low-risk MDS,
whereas cytotoxic therapy would be more appropriate when increased blasts are
present.
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4. CLINICAL AND LABORATORY MANIFESTATIONS
The symptoms experienced by patients with MDS are related to the type and
severity of the peripheral blood cytopenias. Patients commonly present with
symptoms of fatigue and decreased exercise tolerance due to anemia. Less often,
patients will have bleeding, easy bruisability, or recurrent bacterial infections as
an initial complaint.
Physical examination may reveal pallor, peripheral edema, and if the anemia is
severe, evidence of heart failure. Petechiae may be present on the lower extremities
or the buccal mucosa if severe thrombocytopenia is present (i.e., the platelet count
is less than 20,000/µL); ecchymoses may be observed. Splenomegaly may be
present, especially in patients with chronic myelomonocytic leukemia (CMML).
Laboratory tests may reveal an isolated decrease of one peripheral blood count
or multiple cytopenias. The anemia may be microcytic, normocytic, or macro-
cytic, but it is typically reticulocytopenic (corrected reticulocyte count <1%).
Leukopenia due to a decrease in the absolute neutrophil count may be present.
Occasionally, the white blood count may be elevated with a left-shifted myeloid
series and nucleated red blood cells may be present in the peripheral blood
(leukoerythroblastic picture). An absolute monocytosis (monocytes >1000/µL)
is present in CMML. Thrombocytopenia may be present, although the platelet
count may be elevated in patients with refractory anemia (RA) and an isolated
5q− abnormality, or in some cases of RARS.
The peripheral blood smear often demonstrates cellular morphological
abnormalites. The neutrophils may be hypogranular, and the nucleus may have
a bilobed appearance (pseudo-Pelger-Huet abnormality). Myeloblasts may be
present in the peripheral blood, and they may contain Auer rods. Leukoerythro-
blastic abnormalities, including a left-shifted myeloid series (with circulating
metamyelocytes, myelocytes, promyelocytes, and myeloblasts), nucleated red
blood cells, and giant platelets may be present. The red cells may be microcytic
or macrocytic, and teardrop forms may be present. Chemistry tests typically are
normal except the lactate dehydrogenase, which is elevated as a result of increased
rate of cell death in the bone marrow.
The bone marrow biopsy usually is hypercellular for the age of the patient.
However, approx 15% of patients have a hypocellular marrow (cellularity <25%).
The presence of peripheral blood cytopenias in spite of bone marrow hyper-
cellularity reflects the high rate of intramedullary cell death and ineffective
hematopoiesis. The hallmark of MDS is the presence of tri-lineage dysplasia in
the marrow. The erythroid series usually is megaloblastic in appearance, with
prominent nuclear-cytoplasmic asynchrony. The erythroid cells may have addi-
tional abnormalities including bi-nuclearity or nuclear budding. Figure 11.1 (see
Color Plate 9) gives an example for the dysplastic changes in erythropoiesis.
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Ringed sideroblasts, erythroid precursors with iron-laden mitochondria sur-
rounding the nucleus, may be increased and they exceed 15% of the nucleated
bone marrow cells in patients with RARS. An example of ringed sideroblasts in
a case of MDS is shown in Fig. 11.2 (see Color Plate 10). Megakaryocytes
frequently are small (micromegakaryocytes) with decreased nuclear ploidy
(mono- or binucleated). The myeloid series usually is left-shifted and increased
myeloblasts are present in more advance stages.
Patients with MDS have been categorized into five types based on the blood
and bone marrow abnormalities discussed previously, and the percentage of
myeloblasts present in the bone marrow (Table 2).
Because of the variability of the clinical presentation of MDS, the differential
diagnosis depends on the laboratory abnormalities present. If pancytopenia is
present, the differential diagnosis is as shown in Table 1. Vitamin B12 or folate
deficiency should be ruled out if the patient presents with a macrocytic anemia
or the bone marrow has a megaloblastic appearance. The differential diagnosis
of microcytic anemia should be considered if the patient instead has low red
blood cell indices. Chronic myelomonocytic leukemia must be differentiated from
other causes of monocytosis such as tuberculosis, subacute bacterial endocarditis,
systemic lupus erythematosus, rheumatoid arthritis, Hodgkin’s lymphoma, or
other malignancies. Monocytosis can also be observed in the M4 or M5 subtypes
of acute AML, Philadelphia chromosome-negative (atypical) chronic myeloid
Fig. 11.1. Myelodysplastic syndrome. Dysplastic changes in erythropoiesis.
200 Paquette and Munker
leukemia (CML), and other myeloproliferative disorders. CMML can be differ-
entiated from atypical CML by a higher frequency of circulating immature
myeloid cells (10–20% of the leukocytes) and more profound granulocytic dys-
plasia in the bone marrow of the latter entity.
5. PROGNOSIS
The most important variables associated with the survival and risk of devel-
oping AML are the percentage of bone marrow myeloblasts and the number and
types of cytogenetic abnormalities present. The number of peripheral blood
cytopenias is of secondary prognostic importance. An International Prognostic
Scoring System (IPSS) has been devised to estimate the clinical course of patients
with MDS (see Tables 3 and 4).
6. MDS IN CHILDREN AND YOUNG ADULTS
Myelodysplasia is uncommon in the pediatric age group. In about one-third
of children, a predisposing condition like Schwachman-Diamond syndrome,
Fanconi anemia, or neurofibromatosis is found. Juvenile myelomonocytic leu-
kemia (JMML) occurs only in infants and young children, and is associated with
aberrant Ras signaling and an abnormal sensitivity of the blasts to granulocyte-
macrophage colony-stimulating factor (GM-CSF). In most cases, mutations of
Fig. 11.2. Myelodysplastic syndrome. Ringed sideroblasts (coarse perinuclear iron staining).
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Table 2
Classification of Myelodysplastic Syndromes:
A. FAB Classification of Myelodysplastic Syndromes
Subtype Blood myeloblasts BM myeloblasts Other features
RA <1% <5%
RA with RS <1% <5% RS > 15% BM cells
RAEB <5% 5–20%
CMML < 5% < 20% AMC > 1000/mL
B. WHO Classification of Myelodysplastic Syndromes
Myelodysplastic syndromes
RA with or without RS Erythroid-only dysplasia (<5% blasts)
Refractory cytopenia with multi- Two or three lineage dysplasia (<5% blasts)
lineage dysplasia
RAEB-1 Blasts 5–9%
RAEB-2 Blasts 10–19%
5q− syndrome <5% blasts
Myelodysplastic syndromes, Dysplasia, not meeting above criteria
unclassifiable
Myelodysplastic/myeloproliferative syndromes
CMML
Atypical chronic myelogenous leukemia
JMML
FAB, French-American-British; BM, bone marrow; RA, refractory anemia; RS, ringed
sideroblasts; RAEB, refractory anemia with excess blasts; CMML, chronic myelomonocytic
leukemia; AMC, absolute monocyte count; WHO, World Health Organization; JMML, juvenile
myelomonocytic leukemia.
PTPN11, RAS, or NF1 can be identified. A high proportion of children with
MDS have bone marrow cytogenetic aberrations, and the most common is mono-
somy 7. Unfavorable prognostic factors are a low platelet count, elevated hemo-
globin F, and complex cytogenetic aberrations. JMML has shown transient
responses to multi-agent chemotherapy, clofarabine, and cis-retinoic acid, but,
as in all cases of pediatric MDS an allogeneic stem cell transplant is the treatment
with the best long-term outcome.
7. TREATMENT
Because the majority of patients with MDS are elderly, supportive care is the
treatment of choice for many patients. The objective is to maintain the quality of
life for the patient. Blood transfusions frequently are required for symptomatic
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Table 3
International Prognostic Scoring System for Myelodysplastic Syndromes
Score value
Prognostic variable 0 0.5 1.0 1.5 2.0
BM blasts (%) <5 5–10 — 11–20 21–30
Karyotype Good Intermediate Poor — —
Cytopenias 0/1 2/3 — — —
Karyotypes: Good = normal, -Y, 5q-, 20q-; Poor = complex (3;three abnormalities) or
chomosome 7 abnormalities; Intermediate = other abnormalities.
BM, bone marrow. Adapted from Greenberg et al., 1997.
Table 4
Survival and Risk of Leukemia for International Prognostic Scoring System (IPSS)
Risk Groups
Risk group Scorea Median survival (yr) Risk of leukemia
Low 0 5.7 19%
INT-1 0.5–1.0 3.5 30%
INT-2 1.5–2.0 1.2 33%
High > 2.0 0.4 45%
a
see Table 3 for IPSS score values.
anemia and antibiotics are administered for bacterial infections. Chronic red
blood cell transfusions lead to iron overload. In patients who will require ongoing
transfusional support, iron chelation should be considered after 20 U of packed
red cells have been administered or when the serum ferritin level exceeds 1000
ng/mL. Desferoximine by subcutaneous or intravenous infusion has traditionally
been used for this purpose. Recently, deferasirox (Exjade®) was approved for
transfusion-associated iron overload. It is administered orally, at a dose of 20 mg/
kg/d. Renal and hepatic function should be monitored closely. Platelet transfu-
sions typically are reserved for individuals who are actively bleeding or those
who have experienced life-threatening bleeding below a certain platelet count.
Hematopoietic growth factors may benefit a minority of patients with MDS.
A trial of erythropoietin administration may be useful in treating anemia in
approx 20–40% of patients with MDS. Erythropoietin is most likely to benefit
individuals who are not transfusion-dependent and who have a serum erythropoi-
etin level of less than 200 U/L. Erythropoietin has been administered in a variety
Chapter 11 / Myelodysplastic Syndromes 203
of doses and schedules, but 10,000 U three times a week or 40,000 U once a week
by subcutaneous injection are often used. Darbepoietin is a recombinant eryth-
ropoietin with a larger half-life due to the addition of two glycosylation sites. It
has efficacy similar to that of erythropoietin but can be given less frequently (200
µg weekly or 500 µg every 2 wk). Administration of granulocyte colony-stimu-
lating factor (G-CSF) in doses capable of normalizing or doubling the neutrophil
count (beginning at 1 µg/[kg · d] by subcutaneous injection) in combination with
erythropoietin may improve the chances of an erythroid response. However, the
impact of G-CSF on survival has not been evaluated.
Although neutropenia predisposes many patients with MDS to the risk of
serious bacterial infections, the chronic use of myeloid growth factors including
G-CSF or GM-CSF has not been shown to improve survival or prevent infections
in patients with MDS. Therefore, long-term administration of myeloid growth
factors is not recommended. The use of G-CSF or GM-CSF in a neutropenic
MDS patient with an active infection may be of benefit, but this has not been
demonstrated in a clinical trial.
The drug 5-azacytidine (Vidaza®) was recently approved by the Food and
Drug Administration (FDA) for the treatment of MDS. 5-azacytidine is a
hypomethylating agent that may reactivate tumor suppressor or cell cycle regu-
latory genes that are turned off in the MDS clone as a result of methylation of
regulatory regions upstream of the genes. 5-Azacytidine also has cytotoxic
activity. In a randomized, controlled trial 5-azacytidine dosed 75 mg/(m2 · d)
subcutaneously for 7 d every 28 d was compared with supportive care in patients
with >5% bone marrow loss, transfusion-dependent anemia, or severe peripheral
blood cytopenia.  Clinical improvement (at least a 50% reduction in transfusion
requirements) was observed in 60% of patients receiving 5-azacytidine com-
pared with 5% of patients receiving supportive care after 4 mo. Several of the 5-
azacytidine-treated patients (7%) achieved a complete response. The risk of
leukemic transformation or death was significantly reduced. The major side
effects of 5-azacytidine, nausea and vomiting, were controlled by pretreatment
with a serotonin receptor antagonist. Neutropenia was also a common toxicity.
A related hypomethylating agent, 5-aza-2'-deoxycytidine (decitabine), has orphan
drug status in Europe. It is administered intravenously at a dose of 15 mg/(m2 · d)
for 3 d every 6 wk. It has been reported to induce responses in approx 20% of
patients with MDS, but it can cause severe and delayed myelosuppression. As a
result, its use is primarily being evaluated in advanced MDS (e.g., MDS-refractory
anemia with excess blasts [RAEB], RAEB in transformation [RAEB-T]).
Other novel therapies have been studied recently for MDS. The drug thalido-
mide, which can suppress the production of proapoptotic cytokines, has been
reported to improve anemia in approx 20% of patients with MDS. However, the
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drug is not well tolerated by elderly patients with MDS because it frequently
causes fatigue, sedation, constipation, fluid retention, dizziness, and peripheral
neuropathy and more potently inhibits TNF-α. A structurally related compound
that lacks the neurotoxicity of thalidomide is lenalidomide (formerly CC5013).
This oral drug has produced encouraging results in clinical trials and was recently
approved by the FDA for treatment of MDS patients with 5q– cytogenetic abnor-
mality. Transfusion-dependent, low- and intermediate-risk patients with MDS
with 5q– abnormality were treated on a phase II trial of lenalidomide therapy 10
µg daily for 21 or 28 days per 28-day cycle. Approximately 67% of the patients
became transfusion-independent with lenalidomide. In addition, cytogenetic re-
sponses were observed in 74% of patients; 44% had a complete cytogenetic
response. These remarkable results were very stable with chronic drug adminis-
tration. Myelosuppression was the most common and severe toxicity, and most
patients required dose reduction during the course of the trial. Arsenic trioxide
(Trisenox®) is a drug that is FDA approved to treat acute promyelocytic leuke-
mia. Trials demonstrated that approx 25% of MDS patients with anemia will
experience improvement in hemoglobin levels with arsenic. Antithymocyte
globulin, which is routinely used to treat aplastic anemia, was reported to render
approximately one-third of patients with MDS red blood cell transfusion-inde-
pendent. Platelet and neutrophil responses also were observed. Responses oc-
curred in patients with RA and RAEB subtypes, but not in those with RARS.
Other clinical features that were associated with a higher likelihood of response
were younger age and the presence of thrombocytopenia.
Chemotherapy with AML treatment regimens has been explored in MDS.
Although complete remissions have been achieved in 40–60% of selected
patients, the risk of treatment-related mortality can be high in the elderly and
remission durations typically are short. The impact of aggressive chemotherapy
on survival in MDS has not been investigated. Unlike AML, chemotherapy is not
curative for MDS. Patients with a high risk of developing AML may be consid-
ered for aggressive chemotherapy, but it has not been demonstrated that with-
holding treatment until AML develops is worse than treating those patients early.
Therefore, it is unclear which, if any, subgroups of patients with MDS may
benefit from this approach to treatment.
Allogeneic stem cell transplantation (SCT) is the only curative modality for
MDS, but because the vast majority of patients are elderly, most are not eligible
for this form of treatment. The major risks of SCT in patients with MDS are
treatment-related toxicity, acute graft-vs-host disease, and disease relapse. Early
transplant-related mortality following an allogeneic SCT is approx 40% and
disease-free survival is 30–40% for patients with MDS. Patients who have
increased numbers of myeloblasts in the bone marrow (RAEB or RAEB-T)
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have a very high risk of disease relapse (50–70%) following SCT, whereas those
without increased blasts (RA or RARS) have a low risk of relapse (<5%).
Attempts to reduce the risk of relapse in high-risk patients by administering
AML induction chemotherapy prior to performing the SCT have not resulted in
improved survival. Therefore, patients with MDS who potentially could do well
for several years with supportive care alone are most likely to be cured following
SCT, but they may be subjected to a high risk of early morbidity and mortality
with the transplant. In contrast, patients with MDS who are at greatest risk from
dying from their disease also are most likely to have a poor outcome following
SCT. Retrospective analyses have failed to demonstrate a survival benefit for
SCT in patients with low and Int-1 IPSS scores because of the early excess
mortality from the procedure.
One approach to reduce the morbidity and mortality from allogeneic SCT has
been to administer less-intensive chemotherapy in doses that are not capable of
eliminating all of the recipient’s bone marrow (nonmyeloablative transplant). In
this approach, the drugs used prior to transplant in the conditioning regimen are
potently immunosuppressive to permit the transplanted donor cells to engraft
and, over time, to replace the recipient’s hematopoietic cells. This approach
relies on the potential ability of the donor immune system, rather than the condi-
tioning chemotherapy, to eradicate the MDS clone. Although nonmyeloablative
SCT is a promising approach for patients with MDS, there currently are inadequate
data to determine the indications for the use of this treatment.
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1. DEFINITION
The aplastic anemias are characterized by peripheral blood pancytopenia,
bone marrow hypocellularity, and absence of a clonal hematological process.
They have an incidence of approximately two patients per million population in
the West and four per million in Asia.
2. ETIOLOGY
Aplastic anemia can be either inherited or acquired (see Table 1). The majority
of the congenital aplastic anemias have an autosomal recessive inheritance pat-
tern. Patients with inherited bone marrow failure states often have associated
physical and developmental abnormalities including growth retardation, skeletal
malformations, and skin pigmentary changes. Because of the variability of the
clinical manifestations, these disorders may be diagnosed at any time from birth
to adulthood.
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Table 1
Etiology of Aplastic Anemia
Inherited
Fanconi anemia
Diamond-Blackfan anemia
Dyskeratosis congenita
Kostmann’s syndrome
Shwachman-Diamond syndrome
Thrombocytopenia absent radius syndrome
Acquired
Idiopathic
Drugs
Chloramphenicol
Nonsteroidal anti-inflammatory agents
Sulfonamides
Sulfonylureas
Antithyroid drugs
Anticonvulsants
Gold salts
Penicillamine
Allopurinol
Hepatitis
Benzene
Ionizing radiation
Cytotoxic chemotherapy
The etiology of most cases of acquired aplastic anemia usually cannot be
determined, and therefore is considered idiopathic. At least two-thirds of patients
have no clear antecedent precipitating cause. Drugs, as a group, are the most
frequently implicated as a cause of aplastic anemia. Many drugs have been
associated with at least one case of aplastic anemia. However, because aplastic
anemia is rare, an etiological association between any drug and this disorder is
difficult to establish. Only a few classes of drugs have been shown to be statis-
tically associated with the development of aplastic anemia in epidemiological
studies. Chloramphenicol, an antibiotic now rarely used in the West, can cause
either dose-dependent bone marrow suppression or idiosyncratic aplastic ane-
mia. Although the nonsteroidal anti-inflammatory agents (NSAIDS) indometha-
cin, diclofenac, and phenylbutazone have an association with the development
of aplastic anemia, most NSAIDS have not been reported to cause this disorder.
Sulfa derivatives including the sulfa antibiotics, the sulfonylureas, and furo-
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semide all have been associated with aplastic anemia. Two drugs used to treat
rheumatoid arthritis, gold and penicillamine, have been statistically associated
with aplastic anemia. The antiseizure medication carbamazepine also has been
implicated in this etiology of this disorder.
Approximately 2–5% of patients with aplastic anemia have a history of hepa-
titis occurring within several months prior to the development of pancytopenia.
Typically, the hepatitis is resolving when patients present with abnormal blood
counts. None of the hepatitis viruses identified so far, including hepatitis A, B,
C, E, or G (GVB-C), have been shown to be causally associated with the devel-
opment of aplastic anemia.
Benzene, an organic solvent with a variety of industrial uses, causes dose-
dependent bone marrow failure. Occupational safety regulations have been en-
acted that strictly limit exposure to this compound. As a result, cases of aplastic
anemia due to benzene exposure have progressively declined in the last few
decades.
Radiation and cytotoxic chemotherapy are iatrogenic causes of bone marrow
failure. In contrast, accidental exposure to ionizing radiation is a rare cause of
aplastic anemia. Approximately 100–200 cGy of total body irradiation given as
a single dose can cause pancytopenia, whereas 400–800 cGy can induce irrevers-
ible bone marrow failure.
3. PATHOPHYSIOLOGY
There are at least three mechanisms for the development of aplastic anemia.
The inherited forms of aplastic anemia, especially Fanconi anemia, are caused
by DNA instability. Some acquired forms of aplastic anemia are due to direct
injury of hematopoietic stem cells by a toxic insult, such as ionizing radiation.
The pathogenesis of the majority of acquired cases involves an autoimmune
reaction against the stem cells.
Fanconi anemia is perhaps the most common of the inherited forms of aplastic
anemia, all of which are rare. At least seven different genetic abnormalities can
produce a Fanconi anemia phenotype. Cells from all types of the disease share
a sensitivity to drugs that cross-link DNA. As a result of this sensitivity to DNA
damage, patients with Fanconi anemia have a high risk of evolving myelodysplastic
syndrome (MDS) and acute myelogenous leukemia (AML) following the initial
aplasia. DNA damage activates a complex consisting of Fanconi proteins A, C,
G, and F. This in turn leads to the modification of the FANCD2 protein. This
protein interacts, for example, with the breast cancer susceptibility gene BRCA1.
The exact sequence of how patients with Fanconi anemia develop aplastic ane-
mia from mutagen sensitivity and DNA damage is still unknown.
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Direct toxic injury to hematopoietic stem cells can be induced by exposure to
ionizing radiation, cytotoxic chemotherapy, or benzene. These agents can cross-
link DNA and induce DNA strand breaks leading to inhibition of DNA and RNA
synthesis.
Immune-mediated destruction of hematopoietic stem cells probably is the
major pathophysiological mechanism of aplastic anemia. Although the inciting
events are unknown, it appears that cytotoxic T-lymphocytes are responsible for
inhibiting stem cell proliferation and inducing stem cell death. Direct killing of
the stem cells has been hypothesized to occur via interations between Fas ligand
expressed on the T-cells and Fas (CD95) present on the stem cells, which triggers
programmed cell death (apoptosis). T-lymphocytes also may suppress stem cell
proliferation by elaborating soluble factors including interferon-γ.
4. CLINICAL MANIFESTATIONS
Symptoms at presentation in patients with aplastic anemia are due to pancy-
topenia. Moderate to severe anemia is manifested as fatigue and dyspnea on
exertion. Neutropenia is associated with the development of bacterial or fungal
infections. Bleeding or bruising due to thrombocytopenia also commonly occur.
Physical examination may reveal pallor, mucosal bleeding, ecchymoses, or pete-
chiae. The presence of hepatomegaly, splenomegaly, or lymphadenopathy sug-
gests another diagnosis.
5. DIAGNOSIS AND CLASSIFICATION
The differential diagnosis of aplastic anemia includes causes of pancytopenia
(Table 2). Aspiration and biopsy of the bone marrow are performed to obtain
samples for routine histochemical stains, flow cytometry, and cytogenetic analy-
sis. Depending upon the clinical setting (especially if splenomegaly is present),
a tartrate-resistant alkaline phosphatase stain (to exclude hairy cell leukemia) or
a reticulin stain (to exclude myelofibrosis) also should be considered. The bone
marrow aspirate typically contains acellular or hypocellular spicules when aplas-
tic anemia is present. Cellular elements may include a minimal number of
residual myeloid or erythroid cells. Plasma cells and lymphocytes may be
relatively increased in numbers but they do not represent clonal populations. The
cellularity of the bone marrow biopsy usually has less than or equal to 10%
cellularity. Figure 12.1 (Color Plate 11) shows the bone marrow findings in a case
of severe aplastic anemia. For comparison, a normal bone marrow section is
shown in Fig. 12.2 (Color Plate 12). Paroxysmal nocturnal hemoglobinuria
(PNH), MDS, and AML also can present with a hypocellular marrow. The latter
two disorders should be rigorously excluded with the use of flow cytometric
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studies, immunohistochemical stains, and cytogenetic analysis. PNH may co-exist
with aplastic anemia as an overlap syndrome in up to 20% of patients, but the
clinical behavior of this entity is similar to that of aplastic anemia. The peripheral
blood granulocytes should be analyzed for the surface expression of phosphati-
dyl-inositolglycan (PIG)-linked molecumles (CD55 and CD59, see Appendix 2);
red blood cells from untransfused patients should also be analyzed for these
markers. Children and young adults, especially those with suggestive physical
findings, should have a blood sample sent for chromosome breakage analysis in
order to exclude Fanconi anemia. Fanconi anemia is the most common of the rare
inherited bone marrow failure syndromes (see above and Table 1). Fanconi anemia
has autosomal recessive inheritance, presents with pancytopenia associated with
Table 2
Differential Diagnosis of Pancytopenia
Aplastic anemia
Paroxysmal nocturnal hemoglobinuria (PNH)
Myelodysplastic syndromes (MDS)
Acute leukemia
Acute myelogenous leukemia
Acute lymphoblastic leukemia
Blast crisis of chronic myelogenous leukemia
Lymphoproliferative disorders
Hodgkin’s lymphoma
Non-Hodgkin’s lymphoma
Multiple myeloma
Hairy cell leukemia
Metastatic carcinoma
Myelofibrosis
Vitamin B12 or folic acid deficiency
Hypersplenism
Gaucher’s disease or other storage pool diseases
Sepsis (especially pneumococcal)
Granulomatous disease involving the bone marrow
Coccidiodomycosis
Histoplasmosis
Mycobacterium avium intracellularae
Mycobacterium tuberculosis
Human immunodeficiency virus
Rheumatological disorders
Rheumatoid arthritis
Systemic lupus erythematosus
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Fig. 12.1. Aplastic anemia, histological section.
Fig. 12.2. Normal bone marrow, histological section.
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physical abnormalities (skin pigmentation, malformations such as thumb aplasia
and microcephaly, and hypogonadism). The age group when Fanconi anemia is
usually discovered is in childhood, but occasionally young adults present with
the stigmata of Fanconi anemia or have a positive chromosome breakage assay
without the physical signs of Fanconi anemia. The pancytopenia of Fanconi
anemia progresses in more than 90% of cases to full-blown aplastic anemia.
Patients with Fanconi anemia are also prone to develop malignancies (AML,
some solid tumors).
The classification of aplastic anemia is based on the severity of the peripheral
blood abnormalities. Severe disease is characterized by any two of the following:
absolute neutrophil count (ANC) less than 500/µL, corrected reticulocyte count
less than 1% (or reticulocyte count <20,000/µL), and platelet count less than
20,000/µL. Very severe disease has the same criteria as severe disease except the
ANC is less than 200/µL. Patients are considered to have moderate disease if they
have a hypocellular bone marrow, do not fulfill severe disease criteria, and have
at least two of the following: ANC less than or equal to l200/µL, platelet count
less than or equal to 70,000/µL, and hemoglobin less than or equal to 8.5 g/dL
with an absolute reticulocyte count less than or equal to 60,000/µL.
6. TREATMENT
Acutely ill patients must first be stabilized by administering empiric broad-
spectrum antibiotics for neutropenia fevers, or transfusing platelets for active
bleeding. A critical early decision is whether or not the patient is eligible for
allogeneic bone marrow transplantation (BMT). This is important because such
patients have a lower risk of graft rejection if transfusion with blood products is
minimized prior to transplantation. Urgent referral of such patients to a trans-
plant center is essential. Unless transplantation is excluded as an option, all
patients should be given cytomegalovirus (CMV) seronegative blood products
until their CMV immune status is known. Seronegative transplant candidates
should continue to receive CMV seronegative blood. This is done because CMV
can cause serious infections following BMT. All blood products must be leuko-
cyte reduced and irradiated in potential BMT recipients to minimize allosensitization
and eliminate the potential risk of transfusion-related graft-vs-host disease (GVHD).
Related allogeneic BMT is the therapy of choice for Fanconi anemia and
severe or very severe aplastic anemia in children and young adults. The upper age
for which transplantation is the best initial option is controversial, and may range
from 25 to 45 yr depending on the transplant center. The risk of mortality from
GVHD increases with age, but delaying transplantation to treat with immuno-
suppression first increases exposure to blood products and subjects patients to
risk of infection or bleeding. If transplantation is an option, patients and their
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siblings should have human leukocyte antigen (HLA)-typing performed as rap-
idly as possible. It is preferable to use bone marrow rather than peripheral blood
progenitor cells (PBPCs) as the source of stem cells for transplantation in aplastic
anemia. This is because PBPCs have a much higher T-lymphocyte dose and a
higher risk of GVHD than bone marrow. Cyclophosphamide and antithymocyte
globulin (ATG) are used to condition aplastic anemia patients prior to transplan-
tation of related-donor bone marrow. Radiation therapy (total body irradiation)
must be added to the conditioning regimen when using unrelated-donor bone
marrow because of the increased risk of graft rejection. In contrast, reduced-
intensity conditioning must be used for patients with Fanconi anemia because of
their increased risk of toxic side effects (often with fludarabine and ATG). The
goal of the conditioning therapy is to suppress the recipient’s immune system in
order to permit engraftment of the donor cells. Long-term survival following
allogeneic BMT for severe aplastic anemia is approx 65–75% when related-
donor bone marrow is used and 30–55% with unrelated-donor bone marrow. The
most important favorable prognostic variables affecting survival are patient age
less than 20 yr, time between diagnosis and transplant of less than1 yr, and use
of a related donor.
Immunosuppressive therapy is the initial treatment of choice for patients
with moderate disease, patients without an HLA-identical sibling, and “older”
patients. Immunosuppressive therapy consists of ATG or antilymphocyte globu-
lin (ALG) plus cyclosporine. One standard ATG and cyclosporine regimen is
provided in Table 3. A test dose of ATG is given subcutaneously prior to full
dosing to exclude patients with anaphylaxis. High doses of glucocorticoids must
be administered with the ATG/ALG to prevent the development of serum sick-
ness, which usually occurs 10–14 d after starting ATG. Steroids should be tapered
off within 3–4 wk after starting ATG as they do not improve the response rate and
are associated with an increased infection risk. Cyclosporine should be contin-
ued until maximal response, then tapered very slowly over many months (to
minimize relapse). Combined immunosuppressive therapy with ATG or ALG
and cyclosporine yields a response rate of 65–80%. Cyclosporine as a single
agent can be a useful treatment for aplastic anemia. As initial therapy,
cyclosporine induces fewer remissions than ATG in patients with severe disease,
but it can be useful when reinstituted in early relapse to prevent the need for
retreatment with ATG. Cyclosporine may also be considered as initial therapy in
patients without severe cytopenias. Because aplastic anemia is a rare disease,
referral to a tertiary center for enrollment in active clinical trials is encouraged.
Hematopoietic growth factors, including granulocyte colony-stimulating fac-
tor, granulocyte-macrophage colony-stimulating factor, and erythropoietin should
play only an adjunctive role in the treatment of acquired aplastic anemia. Although
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these growth factors can improve the peripheral blood counts in some aplastic
anemia patients, they have not been shown to induce disease remission. In gen-
eral, the likelihood of response to a hematopoietic growth factor is inversely
related to the severity of the peripheral blood cytopenia for which it is being
administered. The precise roles of these medications in the treatment of aplastic
anemia have not yet been clearly defined. The most clear-cut indication for the
use of the myeloid growth factors is in neutropenic patients with active infection.
Patients who fail to respond to an initial course of ATG/ALG plus cyclosporine
should be given a second treatment with immunosuppression. Approximately
20–50% of such patients may respond to a second course of treatment.
7. LATE COMPLICATIONS
Patients with aplastic anemia who respond to immunosuppressive therapy
face two major risks: disease relapse and the development of clonal hematopoi-
etic disorders. Relapse of aplastic anemia most frequently occurs within the first
2 yr after immunosuppressive treatment; however, it may occur at any time.
Between 10 and 40% of patients suffer a disease relapse. Relapse has been
defined as a decrease of peripheral blood counts to levels that are less than half
of those at the time of stable response, to levels that meet the criteria for severe
disease, or to levels requiring reinstitution of transfusion support. Fortunately,
most relapsed patients respond to reinstitution of cyclosporine or administration
Table 3
Antithymocyte Globulin (ATG) Protocol for Aplastic Anemia
ATG test dose:
ATG 1:1000 dilution in saline 0.1 cc intradermally (i.d.) with control saline 0.1 cc i.d.
in other arm. If no anaphylaxis occurs, ATG can subsequently be given.
Premedications for ATG (given 30 min prior to ATG):
Acetaminophen 650 mg p.o.
Diphenhydramine 50 mg p.o. or IVPB
Hydrocortisone 50 mg IVPB
ATG Therapy:
ATG 40 mg/kg in 1000 cc NS over 8–12 h daily for 4 d
Concomitant Medications:
Prednisone 100 mg/m2 p.o. q.d. beginning with ATG and continuing for 10–14 d;
then, if no serum sickness develops, taper the dose over 2 wk.
Cyclosporine 5 mg/(kg · d) p.o. divided BID until maximal response then taper by 1 mg/
(kg ·mo), or more slowly. Patients aged 50 or older should receive 4 mg/(kg · d). Dose
should be decreased for deterioration in renal function or elevated liver enzymes
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of another ATG course. A more ominous complication is the development of a
clonal hematological process including MDS, and AML. There is a 12–15% risk
of developing MDS or AML after 10 yr. Therefore, a patient with aplastic anemia
who experiences falling blood counts after an initial response to immunosup-
pressive treatment must be evaluated for the latter two possibilities by perform-
ing bone marrow studies with cytogenetic analysis. The treatment of either of
these disorders in the setting of previous aplastic anemia is similar to that of the
de novo conditions.
A clonal population of granulocytes deficient in glycosyl phosphatidylinos-
itol-linked proteins can be detected in approximately one-third of patients with
aplastic anemia who have received immunosuppressive therapy. However,
hemolytic anemia and clinically evident PNH occurs in perhaps 10% of these
patients. Performing flow cytometry of granulocytes for CD55 and CD59 can be
used to monitor the evolution of a PNH clone over time. The presence of a PNH
clone in patients who fulfill the criteria for aplastic anemia does not alter the
approach to treatment. However, if a large PNH clone develops (>50% of granu-
locytes are deficient for CD55 and CD59), and the platelet count is over 100,000/
µL, coumadin should be initiated (target INR 2–3) to reduce the risk of throm-
bosis in this disorder. At this time, there is no standard treatment for hemolytic
PNH, but recent clinical trial results of a monoclonal antibody targeting the C5-
complement component holds promise for future therapy.
SUGGESTED READING
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1. INTRODUCTION AND DEFINITIONS
Enlarged lymph nodes or an increase in the size of the spleen (splenomegaly)
are seen during many infections, but can also be symptoms of many blood dis-
eases. A lymphocytosis is present if the lymphocyte count in peripheral blood is
increased to more than 4000/µL; a lymphopenia is present if the lymphocytes are
decreased to less than 1000/µL. In general, a palpable spleen must be considered
enlarged (splenomegaly). In order to measure the size of the spleen accurately,
the spleen should be examined with ultrasound. The maximum normal size is
approx 12 × 10 × 5 cm, as determined by ultrasonic evaluation. It is also possible,
using ultrasound, to recognize infiltrates of malignant lymphomas or splenic
infarcts. High-resolution computed tomography (CT) is also able to determine
the spleen size accurately. Lymphadenopathy is a term for enlarged and/or patho-
logical lymph nodes. Lymph nodes must be considered enlarged or pathological
if they present as chain of multiple lymph nodes or their size measures more than
1 cm. Other commonly used methods are CT and magnetic resonance imaging.
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2. DIFFERENTIAL DIAGNOSIS OF A LYMPHOCYTOSIS
A reactive lymphocytosis is observed during many bacterial infections; for
example, during pertussis (whooping cough), rickettsiosis, brucellosis, tubercu-
losis, and shigellosis, as well as during certain viral infections such as varicella,
Herpes zoster, cytomegalovirus (CMV) infections, infectious mononucleosis,
hepatitis, coxsackie virus, and adenovirus infections, rubella, and mumps. Chil-
dren with pertussis frequently have a lymphocyte count of up to 40,000/µL. This
is due to the action of pertussis toxin, which blocks the migration of lymphocytes
through the capillaries. Infectious mononucleosis is characteristically accompa-
nied by an increase of CD8+ lymphocytes and is described separately (see Chap-
ter 18). Lymphocytosis is commonly seen in children with exanthema subitum,
a rash caused by human herpesvirus-6. Some patients with congenital immune
deficiencies develop a reactive lymphocytosis. HIV-infected patients having an
increased number of CD8+-positive lymphocytes appear to have a better prog-
nosis and somewhat fewer opportunistic infections. Patients who are treated with
the cytokine interleukin (IL)-2 develop an increase in the number of lymphocytes
as a result of the proliferation of CD16+ natural killer cells. A lymphocytosis with
predominantly mature appearing small lymphoid cells observed in elderly patients
is most frequently due to a B-chronic lymphocytic leukemia (see Chapter 18).
Other malignant lymphomas like hairy cell leukemia or Sezary syndrome have
circulating lymphoid cells in the blood, which usually have a characteristic
morphology (for details, see Chapter 15).
In order to differentiate between a neoplastic or a nonmalignant-reactive lym-
phocytosis, immunological and molecular studies are often necessary. In the
former case, only one type of immunoglobulin light chain and a monoclonal
rearrangement of the immunoglobulin genes or of the T-cell receptor genes are
detected. Persistent polyclonal B-lymphocytosis with circulating binucleated
lymphoid cells and an increase of serum immunoglobin M is a rare condition
observed in smokers and is generally benign. The T-gamma lympho-prolifera-
tive disorder is characterized by a monoclonal proliferation of CD8+ and CD16+
lymphoid cells, morphologically described as “large granular lymphocytes.”
These patients often have anemia and are neutropenic. The disease is indolent in
most cases and infections are related to the degree of neutropenia. Some cases,
however, show a rapidly progressive course.
3. DIFFERENTIAL DIAGNOSIS OF LYMPHOCYTOPENIA
A decrease of lymphocytes in the peripheral blood (lymphocytopenia or lym-
phopenia) is seen in certain immune deficiency syndromes (e.g., ataxia
telangiectatica and others; see Chapter 17), in disseminated malignancies,
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Hodgkin’s lymphoma, active sarcoidosis, and in autoimmune disorders like lu-
pus erythematodes and myasthenia gravis. Some cases of advanced AIDS and of
severe aplastic anemia are accompanied by lymphopenia. Lymphopenia is fre-
quently a secondary reaction to treatment with corticosteroids, extended field
irradiation, or treatment with cytotoxic drugs. A rare cause of lymphopenia is the
loss of lymph in intestinal lymphangiectasia and in disorders like Whipple’s
disease.
4. DIFFERENTIAL DIAGNOSIS OF LYMPHADENOPATHY
A reactive lymph node swelling (lymphadenopathy) is a frequent sign of a
bacterial or viral infection. A pharyngitis or middle ear infection is often accom-
panied by a prominent lymphadenopathy, especially in children. Patients with
erysipelas frequently develop enlarged lymph nodes in the draining lymphatic
area. Infectious lymphadenopathies are often painful or sensitive to palpation,
whereas neoplastic lymphadenopathies are indolent in most cases. An exception
is syphilis in the secondary stage, which characteristically presents with a pain-
less lymph node swelling. Lymph nodes tend to form fistulas in tuberculosis and
actinomycosis. Further bacterial infections producing enlarged or sometimes
painful lymph nodes are brucellosis, cat scratch disease, and tularemia. Lym-
phogranuloma inguinale is a venereal infection with a soft swelling of inguinal
lymph nodes. Toxoplasmosis is caused by the protozoan toxoplasma gondii and
can present with a generalized lymphadenopathy (for details, see Chapter 17,
“Hematological Aspects of AIDS”). The so-called lymphadenopathy syndrome
is an early stage of HIV infection. By definition, two or more extrainguinal
lymph nodes are enlarged for more than 3 mo. During the later stages of HIV
infection (AIDS, AIDS-related complex) multiple lymph nodes can also be
enlarged. Infectious mononucleosis is characterized by an acute swelling of
several lymph nodes and high fever (for details, see Chapter 18, “Infectious
Mononucleosis and Other Epstein-Barr Virus Syndromes”). Rheumatic and
autoimmune diseases, sarcoidosis, and some allergic reactions are also accom-
panied by enlarged lymph nodes.
Pseudolymphomas are, by definition, benign or nonmalignant; however, they
have a tendency to transform into a non-Hodgkin’s lymphoma in some cases.
Castleman’s disease is an example of a pseudolymphoma. Kikuchi-Fujimoto
disease is a rare and self-limited disease characterized by lymph node swelling,
fever, splenomegaly, and leucopenia. Histologically, the enlarged lymph nodes
show patchy irregular areas of necrosis. The etiology of Kikuchi-Fujimoto dis-
ease is unclear.
The diagnostic procedures for enlarged lymph nodes depend on the clinical
circumstances. First of all, all lymph node areas should be inspected and palpated
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carefully. The next step is to measure the exact dimensions of all lymph nodes
by means of ultrasound and to document these findings. Figure 13.1 shows
ultrasound findings in a patient who was found to have a large-cell lymphoma.
Serologically, antibodies against HIV, Epstein-Barr virus (EBV), CMV, toxo-
plasmosis, and other infectious agents should be investigated. If the cause of the
enlarged lymph nodes cannot be found within 2–4 wk, or if other signs of a
malignant tumor are present, a lymph node should be biopsied and examined by
a pathologist.
Because inguinal lymph nodes often have nonspecific reactive changes, an
axillary or cervical lymph node should preferably be biopsied. Fresh unfixed
material should also be sent to the pathologist for further immunophenotyping
in case of a malignant lymphoma. If a malignant lymphoma is confirmed or
strongly suspected, staging should be performed (including CT scans of thorax
and abdomen [see Chapters 14 and 15], Hodgkin’s lymphoma, and non-
Hodgkin’s lymphomas). Enlarged lymph nodes can also be secondary to meta-
static carcinomas. Examples are nasopharyngeal tumors, breast cancer, and
gastrointestinal cancers. The lymph node metastases of epithelial cancers are
generally indurated and attached to the surrounding tissues. If a malignant tumor
is suspected, but the histology of the lymph node biopsy shows only reactive
changes, a second biopsy should be made in a different lymph node area.
Fig. 13.1. Ultrasound image of mesenteric lymph nodes (bulky disease, patient with a
large-cell lymphoma; arrows point to lymph nodes, transverse section).
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5. DIFFERENTIAL DIAGNOSIS OF SPLENOMEGALY
An enlargement of the spleen (splenomegaly) is a common physical finding
in such hematological neoplasias as leukemias, myeloproliferative syndromes,
and lymphomas. In osteomyelofibrosis, a huge and indurated spleen is often
observed. Patients with acquired and inherited hemolytic anemias often present
with a splenomegaly due to the increased destruction and sequestration of red
blood cells. During certain severe infections such as endocarditis, hepatitis,
infectious mononucleosis, septicemia, toxoplasmosis, malaria, and fungal
infections, the spleen also enlarges and can be felt in the left upper abdomen. In
tropical countries, splenomegaly is a frequent symptom due to malaria, leishma-
niasis, or schistosomiasis or chronic hemolytic anemias. In disorders like sarcoi-
dosis, lupus erythematosus, or rheumatoid arthritis (Felty’s syndrome),
splenomegaly can be observed. Splenomegaly is also associated with portal
hypertension (liver cirrhosis, chronic heart failure, portal vein thrombosis, portal
vein aneurysm, or Budd-Chiari syndrome), and accumulative disorders like
Gaucher’s disease, amyloidosis, or splenic cysts. Patients who are treated with
cytokines like IL-2 often develop a transient splenomegaly. A moderate sple-
nomegaly is commonly found in patients with AIDS. As mentioned, ultrasound
is a reliable method to measure spleen size and detect changes of splenic texture.
Figure 13.2 shows the infiltration of the spleen with a low-grade non-Hodgkin’s
lymphoma.
The term hypersplenism means that patients who have an enlarged spleen
often develop a thrombocytopenia, in many cases also a neutropenia and/or
anemia due to the splenomegaly itself. Hypersplenism is related to the seques-
tration, and, in many cases, enhanced destruction of platelets, red cells, and
granulocytes.
Splenectomy may be indicated in cases of certain symptomatic hemolytic anemias
like hereditary spherocytosis, and refractory autoimmune thrombocytopenias; in
some cases of hairy cell leukemia or other lymphomas; in cases of isolated
splenic vein thrombosis; and rarely in other conditions. Rarely, enlarged spleen
can be the only disease manifestation of a non-Hodgkin’s lymphoma. In most
cases, the surgical risk of splenectomy is small (0.1–1%) but may be considerable
in advanced cases of osteomyelofibrosis or portal hypertension. For most non-
malignant disorders, a laparoscopic splenectomy is preferable over a splenec-
tomy by laparotomy. For experienced surgeons, laparoscopic splenectomies have
fewer complications, need less pain medication and have a shorter stay in the
hospital. Immediately after a splenectomy, leukocytosis and thrombocytosis
develop, which normalize however within 5–10 d. Following splenectomy,
Howell-Jolly bodies, which are red cells with DNA remnants (see Fig. 13.3 and
Color Plate 13) usually removed by an intact spleen, can be seen in the peripheral
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Fig. 13.2. Ultrasound image of the spleen (nodular infiltration in a patient with chronic
lyrnphocytic leukemia).
Fig13.3. Howell-Jolly bodies. Cytoplasmic remnant of nucleus, observed after splenectomy.
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blood smear. Patients who are splenectomized have a small, but significant, risk
of fulminant bacterial infections (overwhelming postsplenectomy infection
[OPSI] syndrome). The pathogens seen in OPSI syndrome are pneumococci and
meningococci, pathogens that are otherwise phagocytized by an intact spleen.
Patients who undergo splenectomy should be vaccinated against pneumococci
with a polyvalent vaccine if possible 1 or 2 wk prior to the splenectomy. This
vaccination should be repeated every 5 yr. Children should not be splenecto-
mized before the age of 5 yr and should be treated prophylactically with an
antibiotic for 1–2 yr or lifelong, depending on the underlying disease. Adults who
are splenectomized should receive antibiotic treatment for any febrile infection.
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1. INTRODUCTION
Hodgkin’s lymphoma (HL) was first described by Thomas Hodgkin in 1832.
Carl Sternberg and Dorothy Reed reported on the typical multinuclear giant cells
and their relationship to the mononuclear Hodgkin cell. For more than a century,
this disease was regarded as a chronic inflammatory disorder, which is reflected
by the old term lymphogranulomatosis. However, because aneuploidy and
monoclonality were detected in the cells, Hodgkin’s disease, or in terms of the
World Health Organization (WHO) classification of malignant lymphomas, HL,
today is considered a malignant tumor.
HL, together with testicular cancer, has become a prototype for curable neo-
plasms. Up to 80% of the cases diagnosed in adults and an even higher percentage
in children can expect long-term, disease-free survival and cure. The advances
in treatment have been brought about by improvements in histopathological
diagnosis, by careful staging techniques, and by the combined application of
radiation and chemotherapy including stem cell transplantation (SCT).
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2. EPIDEMIOLOGY
In the United States, approximately three to four new cases of HL are diag-
nosed in 100,000 people each year. The age distribution frequency is bimodal,
with one peak occurring at 15–30 yr, followed by a second peak in older patients.
The incidence of HL has increased in recent years. There is a slight male pre-
dominance and, in addition, an increased risk of the disease is associated with
higher socioeconomic status.
3. PATHOGENESIS AND ETIOLOGY
HL combines signs of inflammatory reactions as well as signs of a malignant
disorder. The etiology of HL remains unknown, and there has been a long debate
as to whether the changes seen are of malignant or infectious origin. It has been
speculated that a viral infection occurring sometime during young adulthood
may trigger the proliferation of premalignant lymphoid cells in certain individu-
als. A candidate virus is the Epstein-Barr virus (EBV). Indeed, in up to 50% of
the cases in North America, this virus has been found to be integrated in the
malignant cells. Nevertheless, because not all cases are positive for EBV, EBV
is most likely not the only agent or virus implicated in the etiology of HL, but
possibly only a co-factor for a yet-unknown agent. The clinical features of pa-
tients who are positive for EBV do not differ from those who are not. It has been
proposed that EBV promotes genetic instability in susceptible patients. We know
today that Hodgkin and the giant Reed-Sternberg cells are pathognomonic for
HL, and that these cells are derived from a germinal B-cell in most cases. The
cellular progeny of Hodgkin and Reed-Sternberg cells was determined when
clonal rearranged immunoglobulin genes were amplified from single Hodgkin
and Reed-Sternberg cells that had been micromanipulated from primary HL
biopsy specimens. This proved the malignant character of HL by showing the
clonality of the pathognomonic Hodgkin and Reed-Sternberg cells. Addition-
ally, the detection of somatic mutations within the rearranged immunoglobulin
genes implied a germinal center or postgerminal-center B-cell to be the precursor
of Hodgkin and Reed-Sternberg cells, because mutations are introduced into
immunoglobulin genes during this particular development stage of the B-cell.
Patients with untreated HL typically have a defect in cellular immunity. The
clinical manifestations—for example, B-symptoms and the histological pic-
ture—are determined by cytokines secreted in large amounts by Sternberg-Reed
cells. Interleukin-1, a cytokine that might explain the fever and night sweats
associated with HL, has been demonstrated in HL-derived cell lines. Tumor
necrosis factor (TNF)-α and TNF-β; have also been shown to to be produced by
such cell lines and like interleukin-1 may cause B symptoms. Recently, trans-
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forming growth factor (TGF)-β has been characterized as the major immunosup-
pressive cytokine in HL.
4. CLINICAL FEATURES
The typical presentation of HL is an indolent enlargement of a lymph node or
of several lymph nodes, most often at the neck and less frequently at the axillae.
Although any lymphatic region can be affected, inguinal or femoral lymph nodes
are involved in less than 10% of the cases as the only disease localization. A
typical manifestation of the disease is a mediastinal enlargement that may cause
dyspnea or no symptoms, which is only discovered on a routine chest X-ray.
Abdominal lymph nodes and the spleen may be enlarged, causing abdominal
discomfort, or may be discovered only during staging procedures. Solid organs
like the lung or the liver may be involved, generally indicating disseminated
disease, but may also be infiltrated by direct extension from a lymphatic mass.
This situation has a better prognosis and may still be curable by local treatment.
The bone marrow is involved in less than 5% of unselected patients. Involvement
of the central nervous system is rare at the time of diagnosis and usually occurs
only in late progressive disease. Patients may have B-symptoms, especially in
advanced stages (night sweats and unexplained fever, which may be of the Pel-
Ebstein type, and weight loss of >10% within 6 mo). An unusual (<2% of cases)
but typical symptom is pain in the enlarged lymph nodes or involved tissues felt
after the ingestion of alcohol. More often (in about 10% of cases), patients
experience nonspecific pruritus. The typical pattern of disease progression is
lymphogenous and per continuitatem . In its early stages, the disease may progress
slowly, and occasionally, enlarged lymph nodes may regress for some time. The
lymphatic areas which may become involved by HL and two commonly used
radiotherapy fields (mantle field and inverted Y) are shown in Fig. 14.1.
5. DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS, STAGING OF HL
If a suspicious lymph node is larger than 2 cm in diameter or smaller lymph
nodes persist for more than 4–6 wk, or if B-symptoms or other signs suggest
malignant lymphoma, the lymph node should be biopsied without delay. If no
clear diagnosis can be made, the biopsy should be repeated, whenever possible,
on a peripheral node. The differential diagnoses are other tumors, the group of
non-HLs, and reactive processes, such as toxoplasmosis or pseudolymphomas.
If the diagnosis is HL, then the exact stage has to be determined (staging) (see
Table 1).
Other staging procedures may also be useful. For example, magnetic reso-
nance tomographies may also detect an enlarged spleen or abdominal lymph
nodes. Lymphography is a sensitive, but invasive, method to detect abdominal
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Fig. 14.1. Lymphatic areas and radiotherapy fields (mantle field, left, and inverted Y with
spleen, right).
Table 1
Staging Procedures for Hodgkin’s Lymphoma
Clinical examination
Complete laboratory status (including lactate dehydrogenase, complete blood count,
sedimentation rate, C-reactive protein, alkaline phosphatase)
Chest X-ray
Computed tomography scans of thorax, abdomen, and neck
Ultrasound of abdomen
Positron emission tomography imaging (in selected circumstances)
Bone marrow biopsy
Liver biopsy (if liver involvement is suspected)
lymph nodes and has been abandoned by most centers. In some situations,
positron emission tomography (PET) using fluorodeoxyglucose has been found
useful for the staging and follow-up of patients with HL. PET is sensitive and,
in most instances, specific enough to detect involvement by HL. In untreated
patients, a higher stage is found in at least 20% of cases using PET imaging as
compared with conventional imaging. However, the clinical relevance of this
change in stage is not clear in all instances and must be studied in a prospective
trial. PET may also be used in patients with residual tumor masses to discriminate
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between active disease and residual fibronecrotic tissue. PET imaging can give
further useful information to assess early response to chemotherapy and to prog-
nosticate the outcome of autologous SCT.
The need for staging laparotomies has been controversial for many years. The
original observation that up to 40% of patients with HL had a change in their stage
of disease led to the introduction of surgical staging; however, as a result of more
sensitive imaging techniques, positive staging laparotomies (detecting a change
in the stage) have decreased to below 20%. Today, staging laparotomies are no
longer performed routinely because of the delay in treatment, late immunologi-
cal consequences, and the ability of chemotherapy to treat occult abdominal
disease.
Table 14.2 describes the clinical stages of HL.
The histopathology of HL is rather distinctive. The Reed-Sternberg cells (large
lobulated, multinucleated cells with prominent nucleoli) are generally consid-
ered to be a part of the tumor cell population found in the affected tissues along
with stroma cells, reactive lymphoid cells, eosinophils, and neutrophils. A sec-
tion of a lymph node involved by HL is shown in Fig. 14.2 (see Color Plate 14).
As already mentioned, Reed-Sternberg cells belong in most cases to the B-cell
lineage. Marker analysis reveals them to be positive for CD30, frequently posi-
tive for CD15 and for CD25, and negative in most cases for CD45 and for CD20.
In addition, these cells bear markers of dendritic cells. The reactivity with anti-
bodies against CD30 is typical of Hodgkin’s disease, but not specific, as acti-
Table 2
Clinical Stages of Hodgkin’s Lymphoma
(Ann Arbor Classification 1971, Cotswold Modification 1990)
I Involvement of one lymphatic area on one side of the diaphragm or of a single
extralymphatic site (IE)
II Involvement of two or more lymphatic areas on one side of the diaphragm
III Lymphatic involvement on both sides of the diaphragm
III1 1: Lymph nodes in upper abdomen
III2 2: Para-aortic, mesenteric, or pelvic lymph nodes enlarged
IV Diffuse involvement of solid organs(s) or bone marrow and/or lymphatic
involvement
A or B is indicated for all stages: A,  no general symptoms; B, general symptoms (night sweats,
fever, weight loss of >10%; E, localized extranodal involvement of a solid organ. X indicates a
mass of >10 cm in diameter or a mediastinal mass less than one-third of the thoracic diameter is
present.
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vated lymphoid cells and anaplastic lymphomas are also positive. Nodular lym-
phocyte-predominant HL has a different immunophenotype, being CD15 and
CD30 negative, and CD20 and leukocyte common antigen (LCA)-positive.
The new WHO classification distinguishes only two groups—the nodular
lymphocyte-predominant HL and the classical HL. The latter is subdivided in
four forms as depicted below.
Nodular lymphocyte-predominant HL   5%
Classical HL:
1. Lymphocyte-rich HL 5–8%
2. Nodular-sclerosis HL 35–55%
3. Mixed-cellularity HL 20–35%
4. Lymphocytic-depletion HL 3–4%
The frequency of these subtypes differs in different parts of the world. At present,
with effective treatments for HL, the subtypes are no longer prognostically rel-
evant. However, some of these types have particular clinical features: nodular
sclerosis is more frequent in young women with a large mediastinal mass. The
lymphocyte-predominant HL resembles a low-grade, B-cell lymphoma, and can
be treated with limited irradiation at least in early stages. Prognostic factors in
HL are age, sex, stage, and some serum markers such as sedimentation rate and
Fig. 14.2. Hodgkin’s lymphoma. Lymph node with CD30-positive Hodgkin cells and
binucleated Reed-Stemberg cells.
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soluble CD25. Recently, a prognostic score was established for advanced HL.
This score, into which seven unfavorable clinical and laboratory parameters
enter, predicts treatment failure (low serum albumin, anemia, male sex, age  45
yr, stage IV, leukocytosis, and lymphocytopenia).
6. TREATMENT OPTIONS AND RESULTS
6.1.Treatment
For the choice of treatment, stage, and systemic B-symptoms are the two
major components for stratifying patients with HL. Bulky disease (<10 cm) has
emerged as a third prognostic factor in the treatment concept. In the United
States, most centers treat patients according to the classifications of early stages
(IA–IIA or IIB) and advanced stages (III–IVA or B; I–IIB with bulky disease).
In Europe, the European Organisation for Research and Treatment of Cancer
(EORTC) and the German Hodgkin’s Lymphoma Study Group (GHSG) have
defined stage I–II as unfavorable or intermediate if certain adverse factors (large
mediastinal mass, age >50 yr, elevated erythrocyte sedimentation rate, >3 involved
regions) are present. Most patients who die of HL today present with stage IIIB or
IV disease, or are of older age (>60 yr) at the time of diagnosis. Thus, in advanced
disease, there is a need for more effective therapy, whereas in early stages, which
have an excellent prognosis, a reduction of the treatment-related toxicity is
needed. Treatment options for diagnosed HL are radiation, chemotherapy, and
the combination of both (combined modality). Because the prognosis of HL is
generally good, and because relapses may be salvaged by high-dose chemo-
therapy, different treatment options may be offered to some patients.
6.1.2. EARLY-STAGE DISEASE (CLINICAL STAGE I AND II)
Until a few years ago, early-stage (favorable) HL was treated in most centers
with extended-field radiation without chemotherapy. However, a high incidence
of relapse (about 25%) was observed, indicating that rescue therapy was neces-
sary, which led to a very good overall survival of nearly 95% after 10 yr. But
extended-field radiation therapy plus rescue therapy administered to about 25%
of the patients caused an increased toxicity, such as secondary neoplasm, cardiac
toxicity, infertility, and others. For this reason, extended-field radiotherapy has
been replaced in favor of combined modality treatment consisting of a short-
duration chemotherapy (e.g., two to four cycles of ABVD [Adriamycin® (doxo-
rubicin), bleomycin, vinblastine, and dacarbazine]) followed by involved-field
radiotherapy (20–30 Gy). Although a further improvement of overall survival
could not to be achieved, the long-term treatment complications could thus be
reduced considerably. Whether chemotherapy alone is sufficient to control dis-
ease has yet to be determined.
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6.1.3. EARLY-STAGE UNFAVORABLE DISEASE
In the past, patients with clinical stage I and II with risk factors who underwent
extended-field irradiation had a poor 10-yr relapse-free survival in the 50%
range. Therefore, it is generally accepted today that these patients qualify for
combined modality therapy. In many institutions, four cycles of ABVD followed
by involved-field irradiation has become the standard regimen for unfavorable
stage I–II disease. Because 5% of those patients progress and 15% relapse early,
more intense regimens are evaluated in clinical studies (Stanford V, BEACOPP
[bleomycin, etoposide, Adriamycin (doxorubicin), cyclophosphamide, Oncovin®
(vincristine), procarbazine, and prednisone]) in combination with involved-field
radiotherapy. For patients not included in clinical studies, at the present time four
cycles of ABVD followed by involved-field irradiation can be considered the
treatment of choice. Involved-field radiation is sufficient to control occult dis-
ease when combined with chemotherapy.
6.1.4. ADVANCED STAGE (CLINICAL STAGES III AND IV)
Advanced-stage HL consists of patients with lymph node involvement above
and below the diaphragm, and those in stage IV with additional involvement of
extralymphatic manifestations (lung, liver, bone, bone marrow). Until the early
1960s, patients with advanced-stage disease were uncurable. The report of De
Vita and colleagues of the effectiveness of MOPP (mechlorethamine, vincris-
tine, procarbazine, and prednisone) with a 50% cure rate remains a landmark in
the success story of treatment in HL. Later, it became clear that alternating the
regimes MOPP and ABVD was superior to MOPP alone. After 15 yr, the overall
survival is around 65%. ABVD alone seems to be as effective as the alternating
MOPP/ABVD protocol. The main advantage of ABVD alone is the relatively
low incidence of long-term toxic effects as compared with alkylating agents-
based regimens.
To address the still considerable rate of treatment failure in advanced disease
with conventional regimens, clinical trials with escalation of dose and introduc-
tion of etoposide as a novel chemotherapeutic agent were investigated in clinical
studies. Stanford V is a seven-drug (mechlorethamine, doxorubicin, vinblastine,
vincristine, bleomycin, etoposide, and granulocyte colony-stimulating factor
[G-CSF]) regimen that was given weekly for a total of 12 wk in combination with
consolidation radiotherapy to sites of initial bulky disease. In a phase-II study of
142 patients, a 5-yr freedom from progression of 89% and an overall survival of
96% at a median of 5.4 yr was achieved. The escalated BEACOPP regimen
proposed by a German study group (cyclophosphamide, doxorubicin, etoposide,
procarbazine, prednisone, vincristine, and bleomycin; Table 3) administered
every 3 wk with G-CSF achieved an 87% freedom from progression and a 91%
overall survival after 5 yr. Both schemes are toxic and therefore should only be
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Table 3
Chemotherapy Protocols for Treating Hodgkin’s Lymphoma
Drugs Dose (mg/m2) Route Days
MOPP
Nitrogen mustard 6 i.v. 1, 8
Vincristine 1.4 i.v. 1, 8
Procarbazine 100 Oral 1–14
Prednisone 40 Oral 1–14
ABVD
Doxorubicin 25 i.v. 1, 15
Bleomycin 10 i.v. 1, 15
Vinblastine 6 i.v. 1, 15
Dacarbazine 375 i.v. 1, 15
Stanford V
Doxorubicin 25 i.v. 1, 15, 29, 43, 57, 71
Vinblastine 6 i.v. 1, 15, 29, 43, 57, 71
Nitrogen mustard 6 i.v. 1, 29, 57
Vincristine 1.4 i.v. 8, 22, 36, 50, 64, 78
Bleomycin 5 i.v. 8, 22, 36, 50, 64, 78
Etoposide 60 i.v. 15, 43, 71
Prednisone 40 Oral for 12 wk
BEACOPP-baseline
Bleomycin 10 i.v. 8
Etoposide 100 i.v. 1–3
Doxorubicin 25 i.v. I
Cyclophosphamide 650 i.v. I
Vincristine 1.4 i.v. 8
Procarbazine 100 p.o. 1–7
Prednisone 40 p.o. 1–14
BEACOPP-escalated
Bleomycin 10 i.v. 8
Etoposide 200 i.v. 1–3
Doxorubicin 35 i.v. 1
Cyclophosphamide 1200 i.v. 1
Vincristine 1.4 i.v. 1
Procarbazin 100 p.o. 1–8
Prednisone 40 p.o. 1–14
BEACOPP is repeated on day 22.
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administered in larger centers with much experience and within clinical trials.
The occurrence of nine cases of acute leukemia after increased-dose BEACOPP
is a reason for concern; however, this complication must be weighed against the
lower rate of early progression and higher rates of failure-free survival and
overall survival rates at 5 yr. Outside clinical trials at present, four double cycles
of MOPP/ABVD or eight cycles of ABVD may still be considered as a standard
treatment.
Through the years, a number of groups have addressed the added benefit of
radiotherapy in advanced HL. A number of these studies were underpowered to
demonstrate a significant clinical benefit. In a recent multi-center study of the
EORTC on 739 patients, involved-field radiotherapy did not improve the out-
come in patients with advanced-stage HL who had a complete remission after
MOPP/ABV chemotherapy. However, it was concluded that the only patients
who benefit from radiotherapy are those in partial remission after chemotherapy.
6.1.5. LYMPHOCYTE-PREDOMINANT HL
Nodular lymphocyte-predominant HL is a rare subtype that accounts for less
than 5% of all cases of HL. Mostly peripheral lymph nodes are involved, 75% of
the patients have stage IA disease, and organ involvement rarely occurs. The
clinical course is indolent with frequent relapses, but responsive to treatment.
Patients in stage I–IIA disease should be treated with involved-field radiation
(30 Gy). Patients in a higher stage should probably be treated more aggres-
sively by chemotherapy because they show a substantially worse progression-free
survival and overall survival than patients with early-stage lymphocyte-predomi-
nant disease. Recently, the anti-CD20 antibody rituximab was used for treatment
at first diagnosis or relapse. Remission rates of 80% were observed but there are
no data as yet for long-term follow-up.
6.2. Prognosis
The prognosis for patients with various stages of HL is as follows:
1. In early stages, 5-yr survival is about 95%. Because of combined modality
treatment (i.e., a short-duration chemotherapy prior to involved-field radio-
therapy), the freedom from progress comes close to the survival rate after 5 yr.
2. In intermediate stages, the 5-yr survival is 90%, and 75–80% survive without
relapse.
3. In advanced stages, the 5-yr survival is decreased to 75–80% and freedom from
treatment failure is in the range of 60% with COPP/ABVD (earlier data from GHSG).
With the modern dose-intensified chemotherapy regimens (e.g., BEACOPP) the
rates of freedom from treatment failure at 5 yr are significantly better and were 76%
for the baseline BEACOPP and 87% for the escalated BEACOPP. Beyond 5 yr,
relapses are rare and most patients can be considered as cured.
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4. The ultimate prognosis for patients depends not only on relapse-free survival
and early treatment complications, but also on long-term complications and
comorbid conditions. In patients with early-stage HL, it was shown that after 13 yr,
deaths from other conditions (i.e., late treatment-related conditions) exceeded death
from relapsed HL.
7. TREATING RELAPSED HL
The clinical diagnosis of a relapse must be established with a biopsy. Gener-
ally, a relapse of HL is prognostically unfavorable and justifies aggressive treat-
ment. The therapeutic options for recurrences within 1 yr or progressive disease
include high-dose chemotherapy followed by autologous SCT. High-dose che-
motherapy is generally given following four cycles of salvage chemotherapy
with protocols such as ESHAP (etoposide, solu-medrol, high-dose ara-C, and
cis-platinum), ICE (ifosfamide, carboplatin, and etoposide), or DHAP (dexam-
ethasone, high-dose cytarabine, and cisplatin). Negative prognostic factors for
an autologous transplant are: B-symptoms at relapse, duration of complete re-
mission of less than 1 yr, extranodal disease at relapse, and persistent PET posi-
tivity. A different approach exists if a localized relapse occurs after radiotherapy
alone, in which case conventional dose chemotherapy (plus additional irradia-
tion if necessary) may still be curative. Similarly, if a localized nodal relapse
occurs after chemotherapy alone, radiotherapy (plus further chemotherapy) may
result in a durable remission in some situations. The current treatment of choice
for HL relapsing, however, is high-dose chemotherapy. If possible, an adjuvant
irradiation following high-dose therapy should be considered. The results of
allogeneic transplantation for relapsed HL compared unfavorably with autolo-
gous transplantation. More recently, promising results were observed with re-
duced-intensity transplants and might be proposed to young patients with a fully
matched donor.
8. LATE EFFECTS OF TREATMENT
Of patients receiving mantle radiotherapy, 20–50% develop some degree of
hypothyroidism, which may require substitution by thyroid hormones. These
patients are also at a higher risk of developing cardiovascular disease. Shortly
after receiving mantle-field irradiation, less than 5% of patients develop a radia-
tion pneumonitis and less than 2% develop pericarditis. Late effects may be lung
fibrosis from radiation plus bleomycin. The dose-intensified chemotherapy regi-
mens are associated with a high risk of sterility (80%). A rare (<0.5%) but serious
late effect of splenectomy was septicemia caused by pneumococci. This may be
prevented to a large extent by immunizing such patients against pneumococci
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prior to splenectomy. A significant problem emerging in recent years is the
appearance of other malignant tumors in patients cured of HL. These second
neoplasms have been called the “price of success” and can be observed in about
20% of patients after 20-yr follow-up. Compared with the general population, the
risk of second malignancy is about three- to fivefold elevated. The major types of
second cancers are acute myelogenous leukemias (increased risk within 3–8 yr),
myelodysplastic syndromes, NHLs, and various solid tumors. Some types of
second tumors are associated with special treatment features and appear prevent-
able (e.g., the risk of breast cancer is increased only in young women treated with
radiation, and smokers have a higher risk of developing second lung cancers).
Despite the generally good prognosis, the late complications of treatment man-
date a lifelong follow-up of patients treated for HL.
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1. INTRODUCTION
Non-Hodgkin’s lymphomas (NHLs) are malignant proliferations of the lymphoid
tissues that can be distinguished from Hodgkin’s lymphoma (see Chapter 14) by a
variety of clinical and histological features. NHLs are a disease of predominantly
elderly persons, with a median age around 50–70 yr, are more heterogeneous in
their behavior, and often have an extranodal involvement. The classification of
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NHLs continues to evolve. Recently, a new World Health Organization (WHO)
classification scheme was introduced, which is based on the revised European
American Lymphoma (REAL) classification and incorporates some of the
progress in immunology and molecular biology (see “Classification”). Consid-
erations that enter into these classifications are the lymphocyte lineage (B- vs T-
cell type), and maturation status (precursor vs mature cell type), additional
immunophenotypic markers, and characteristic molecular alterations. Based on
these criteria, the clinical course and biology of each distinct lymphoma subtype
may be more accurately predicted. About 90% of the NHLs are derived from a
malignant B-cell, the remaining cases from T-cells, natural killer (NK) cells, or
undifferentiated cells. In recent years, the incidence of NHL has steadily in-
creased. NHLs are more frequent than Hodgkin’s lymphoma and have an annual
incidence of about 15–20 new cases per 100,000 people.
2. ETIOLOGY OF NHLs
The etiology of NHLs cannot be determined in most cases. There is some
evidence that chronic antigenic stimulation by viral or bacterial infections
increases the likelihood of NHLs. This is true for patients infected with HIV who
have a high risk of developing NHLs (most of aggressive histology), as well as
for children in Central Africa who develop Burkitt’s lymphomas. The genome
of the Epstein-Barr virus (EBV) is integrated into the tumor cells of classic
Burkitt’s lymphomas. As with normal B-lymphocytes transformed by EBV, a
number of transformation-associated genes are expressed in the tumor cells.
Serologically, patients with Burkitt’s lymphoma show an immune response
against viral capsid antigens of EBV. Lymphomas in Europe and North America
with similar histology (Burkitt’s-like lymphomas) do not have a clear correlation
with EBV; therefore, other factors play a role in these lymphomas. An increased
risk for NHL exists in cases of congenital immunodeficiency syndromes (e.g.,
ataxia telangiectasia). A human retrovirus (HTLV-1) that is endemic in Japan
and in the Caribbean is associated with the development of acute T-cell leuke-
mias or lymphomas. HTLV-1 is found to be clonally integrated into the tumor
cells; however, as only a small fraction of the infected individuals develops lym-
phoma, this retrovirus is considered to be only a co-factor in lymphomagenesis.
Another important example is the association between infection of the stomach
by Helicobacter pylori and mucosa-associated lymphoid tissue (MALT)-type
gastric lymphomas. The eradication of the bacterial infection with antibiotics in
an early stage results in the regression of the lymphoma. More recently, it was
shown that a new human herpesvirus (HHV8) is associated with a rare type of
undifferentiated lymphoma (primary effusion lymphomas). Chronic infection
with the hepatitis C virus has been associated with the development of NHL
predominantly of the marginal zone type. Infections with Borrelia burgdorferi,
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the etiological agent of Lyme disease, are associated with some forms of cuta-
neous lymphomas.
The distinct lymphoma subtypes are reflected by characteristic chromosomal
translocations detectable in the majority of cases. Several types of lymphomas
have such cytogenetic markers. An example is the translocation t(14;18)(q32;q21)
in 80–90% of follicular lymphomas. Translocation t(14;18) leads to an over
expression of the bcl-2 gene thereby immortalizing the tumor cells by suppres-
sion of the programmed cell death (apoptosis). However, this translocation can
also be found in the peripheral blood of some normal individuals. Thus, the
expression of certain oncogenes or antiapoptotic genes is only one factor in the
multi-step pathogenesis of lymphomas. Accordingly, bcl-2-transgenic mice also
do not regularly develop follicular lymphomas. Another example is the translo-
cation t(8;14)(q24;q32) or related translocations, which are present in virtually
all cases of Burkitt’s lymphoma and lead to an activation of the Myc oncogene.
Table 1 lists important cytogenetic and molecular changes in NHL.
3. CLASSIFICATION
As mentioned previously, the current WHO classification is accepted world-
wide and takes into account clinical, immunological, and molecular observa-
tions. Compared with the previous Working Formulation, several additional
entities with distinct features are now included (e.g., mantle cell lymphomas,
MALT lymphomas, and mediastinal B-cell lymphomas). In the clinical section
of this chapter, the clinical features and treatment of the major and some rare
categories are discussed. A simplified version of the WHO classification is listed
in Table 2. The WHO classification also incorporated some chronic leukemias
(chronic lymphocytic leukemias [CLL], hairy cell leukemia [HCL]). Likewise,
Hodgkin’s lymphoma and multiple myeloma are included in the WHO classifica-
tion of lymphoid neoplasms, but in this book are described in separate chapters.
Table 1
Cytogenetic and Molecular Markers in Non-Hodgkin’s Lymphomas
Follicular lymphoma t(14;18)\Bcl-2
Mantle cell lymphoma t(11;14)
Bcl-1/cyclin D1
B-cell chronic lymphocytic leukemia Trisomy 12, other markers
Burkitt’s lymphoma t(8;14)(q24;q32), c-myc
t(2;8)(p12;q24)
t(8;22)(q24;q11)
Anaplastic large-cell lymphoma t(2;5)
Alk
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Table 2
World Health Organization Lymphoma Classification
B-Cell neoplasms
Precursor B-cell neoplasms
Precursor B-lymphoblastic leukemia/lymphoma
Peripheral B-Cell neoplasms
Small lymphocytic lymphoma (B-Cell chronic lymphocytic leukemia)
Prolymphocytic leukemia
Lymphoplasmacytic lymphoma/immunocytoma (including M. Waldenström)
Hairy cell leukemia
Follicular lymphoma
Marginal zone B-cell lymphoma (extranodal, MALT-type, nodal, splenic marginal zone)
Mantle cell lymphoma
(grade I–III)
Diffuse large B-cell lymphoma
Subtype: Primary mediastinal (thymic) B-cell lymphoma
Burkitt’s lymphoma
T-Cell neoplasms
Precursor T-cell neoplasms
Precursor T-lymphoblastic leukemia/lymphoma
Peripheral T-Cell and natural killer (NK)-cell neoplasms
T-Cell chronic lymphocytic leukemia
T-Cell Prolymphocytic leukemia
Large granular lymphocytic leukemia
Mycosis fungoides
Sezary syndrome
Anaplastic large cell lymphoma, CD30 positive, T- and null-cell types
Peripheral T-cell lymphomas (not otherwise specified): Extranodal NK-/T-cell
lymphoma (nasal type
Angioimmunoblastic T-cell lymphoma Enteropathy-type T-cell lymphoma
Hepatosplenic T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
Adult T-cell lymphoma/leukemia
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4. CLINICAL FEATURES AND DIAGNOSTIC STRATEGIES
Patients with lymphoma present most frequently with lymph node swelling
(lymphadenopathy) that may be either peripheral (e.g., axillary, cervical, inguinal)
or involve central locations (e.g., mediastinal tumor, abdominal lymph nodes).
In most cases, the enlarged lymph nodes are painless. The lymph nodes may
enlarge very slowly, as is the case in most low-grade or indolent lymphomas, or
show an aggressive growth pattern. Abdominal lymph nodes may sometimes
enlarge considerably before clinical symptoms occur. Especially marginal zone
lymphoma, but also other lymphoma subtypes, may have an extranodal spread:
the gastrointestinal tract or solid organs such as the liver; rarely, the CNS can be
involved. In such cases, the clinical symptoms may be different. For example, the
first symptoms of gastric lymphoma may be dyspepsia or discomfort in the upper
abdomen. When the bone marrow is involved, the patient may present with
anemia, leukopenia, or thrombocytopenia. Similarly to patients with Hodgkin’s
lymphoma, patients with NHL may also have systemic or B-symptoms (fever,
night sweats, or weight loss).
The clinical staging of NHL is based on the Ann Arbor classification, which
recognizes four clinical stages (I–IV), the presence or absence of systemic symp-
toms, and/or the presence of extranodal localized disease. The Ann Arbor clas-
sification was originally developed for Hodgkin’s lymphoma and is described in
Chapter 14, Table 2.
If a malignant lymphoma is suspected, a lymph node biopsy should be per-
formed without delay. Biopsies should also be performed on other tissues (e.g.,
gastric mucosa, solid organs) if clinical or radiological evidence suggests that
these systems are involved. A lymph node aspiration may yield some diagnostic
information, but is usually insufficient to make the proper classification of
malignant lymphoma. The diagnosis of malignant lymphoma is generally made
on fixed, paraffin-embedded tissue. For some immunochemical and molecular
studies, unfixed tissue is necessary. An accurate diagnosis of malignant lympho-
mas is important, as the prognosis and the treatment of the different categories
of NHL differ considerably.
The diagnostic strategies for NHL are described in Table 3.
The different categories of NHL can be divided into two major groups:
1. Low-grade (indolent) NHL: these lymphomas have an indolent course, do not
always need treatment, but cannot be cured by most present approaches. Examples
are the follicular lymphomas and CLL.
2. High-grade (aggressive) NHL: these lymphomas have an aggressive clinical
course and, if untreated, are rapidly fatal. In a fraction of these NHL, cure is
achieved with chemotherapy. Examples are Burkitt’s lymphomas and diffuse
large B-cell lymphomas (DLBCLs).
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Table 3
Diagnostic Strategies for the Non-Hodgkin’s Lymphomas
History and clinical examination Ask for B symptoms and palpate all lymph nodes,
liver, and spleen
Lymph node biopsy Biopsy, if possible, a peripheral lymph node,
obtain immunohistochemistry and molecular
studies (bcl-2, myc, cyclin-D1, others)
Laboratory studies Obtain complete laboratory status, including
blood counts, sedimentation rate, white cell
differential, clotting tests, lactate
dehydrogenase, β2-microglobulin, total
protein, serum electrophoresis, quantitative
immunoglobulins, immunoelectrophoresis if
a monoclonal protein is suspected, creatinine,
urea, uric acid, GOT, GPT, γ-GT, alkaline
phosphatase; if hemolysis is suspected:
haptoglobin, Coombs’ test; if risk category:
HIV serology
Chest radiograph (in two planes) CT scan of the thorax
CT scans of the abdomen Ultrasound of the abdomen and the neck
FDG-PET scan
Bone marrow biopsy Bone marrow aspiration (with
immunophenotyping to detect lymphoma
infiltration) (if leukemic presentation,
immunophenotyping can be done from blood)
EKG, cardiac ultrasound,
or MUGA scan
Further studies (dependent on ENT examination, endoscopy, liver biopsy,
clinical situation and type of skeletal X-rays, bone scan, magnetic
lymphoma) resonance imaging, lumbar puncture
GOT, glutamic-oxaloacetic transaminase; GPT, glutamic-pyruvic transaminase; γ-GT, γ-glutamyl
transpeptidase; CT, computed tomography; FDG-PET, fluorodeoxyglucose-positron emission
tomography; MUGA, multiple-gated acquisition; ENT, ear–nose–throat.
The major categories of NHL are described in the following seven sections,
based on the WHO classification. Some special forms or presentations of NHLs
are described in “Special Forms of NHL.”
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5. DIFFUSE LARGE B-CELL LYMPHOMA
This is the most frequently occurring NHL. It includes lymphomas predomi-
nantly classified in the former Working Formulation as diffuse large-cell, diffuse
mixed-cell, or immunoblastic, and lymphomas classified as diffuse centroblastic,
diffuse centroblastic/centrocytic, and immunoblastic in the Kiel classification.
Histopathologically, a diffuse proliferation of large, transformed lymphoid
cells is found. The nuclei have a vesicular chromatin, prominent nucleoli, baso-
philic cytoplasm, and a moderate to high proliferation fraction. Figure 15.1 is an
example of an involved lymph node at high magnification (see Color Plate 15).
Cytogenetically, about 50% of patients with diffuse large-cell lymphomas have
abnormalities of the chromosome region 3q27–29. These abnormalities corre-
late with the presence of a rearrangement of the Bcl-6 oncogene. Other oncogenes
or antiapoptotic genes like bcl-2 are also involved in some diffuse large-cell
lymphomas. Cases that overexpress Bcl-2 have a worse prognosis. By marker
analysis, most diffuse large-cell lymphomas are positive for B-cell antigens like
CD19, CD20, and CD22.
Fig. 15.1. Diffuse large B-cell lymphoma. Lymph node structure destroyed by large
neoplastic lymphatic cells, numerous mitoses, Giemsa stain, high-power magnification.
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5.1. Prognostic Factors in High-Grade NHL
The prognosis in NHL is more heterogeneous than in Hodgkin’s lymphoma
and the Ann Arbor stage is not a good prognostic indicator for all cases. Recently,
an International Index was described and was found to permit a better estimation
of remission rate and survival. Factors (each contributing one point) that enter
into this International Index are age greater than 60 yr, reduced performance
status, clinical stage III or IV, increased lactate dehydrogenase (LDH), and
extranodal manifestation in two or more locations.
Based on these criteria, four categories are defined (Table 4).
Additional adverse prognostic factors for response to treatment and survival
of patients with aggressive lymphomas include the presence of p53 mutations,
lack of class II antigens, some karyotypic abnormalities, deletion of the tumor
suppressor genes p15 and p16, and bcl-6 rearrangements.
5.2. Gene Expression Profiling in Diffuse Large B-Cell Lymphoma
Using clinical prognostic models such as the International Prognostic Index
alone cannot identify the molecular basis of clinical heterogeneity of diffuse
large B-cell lymphoma. Recent development of DNA microarrays has allowed
scientists to take a genome-wide approach towards furthering insights into the
disease, predicting the treatment outcomes, and developing novel targeted treat-
ments. Several studies have demonstrated that there are at least two subtypes of
diffuse large B-cell lymphoma: germinal center B-cell type and activated B-cell
type (see Table 5). The gene-based predictor is independent from the interna-
tional prognostic index. More recently, these findings were confirmed by tissue
microarray. This suggests that the findings from gene expression profiling can
be translated into clinical application at the level of routine immunohistochem-
istry. The molecular classification based on gene expression profiling not only
shows distinct clinical features in the two subtypes, but also suggests different
lymphomagenic mechanisms. Activated B-cell lymphoma cells cannot survive
without constitutive activation of nuclear factor (NF)-κB, which may give a
potential target for treatment.
Table 4
International Index for Aggressive Non-Hodgkin’s Lymphomas
Number of Rate of 5-yr Survival
Risk group risk factors complete remissions Relapse-free Total
Low 0–1 87% 61% 73%
Low-intermediate 2 67% 34% 51%
High-intermediate 3 55% 27% 43%
High 4–5 44% 18% 26%
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Primary mediastinal large B-cell lymphoma, a subtype of diffuse large B-cell
lymphoma by the WHO classification, serves as another example of the power
of this new technology. Gene expression profiling studies have shown that this
specific subtype of lymphoma does not belong to either germinal B-cell type or
activated B-cell type. Rather, it shares many clinical and molecular features with
classical Hodgkin’s lymphoma.
5.3. Treatment
The treatment of large-cell lymphomas depends on the stage of disease.
Patients with disseminated disease (generally stages III and IV) are given six
to eight cycles of CHOP (cyclophosphamide, hydroxydaunomycin, Oncovin®
[vincristine], and prednisone) or a comparable regimen (seeTable 6). In patients
with a B-lineage phenotype, the chimeric monoclonal antibody rituximab should
be added to CHOP. With this approach, about 60–70% of the patients obtain a
complete remission and approx 35% are cured. The advantage of adding
rituximab to CHOP chemotherapy has mainly been demonstrated in older
patients, but promising results indicate that both overall survival and relapse-
free survival are improved in younger patients when treated with a combined
approach. Patients with localized disease (stages I or II) are treated with a shorter
course of chemotherapy (three to four cycles) and involved-field radiation. Again,
the prognosis seems to be improved when immunotherapy with rituximab is
added to chemotherapy. At present, the 5-yr freedom from progression is around
70–85% and the overall survival around 80–85%. High-dose therapy with stem
cell or bone marrow support is indicated for certain high-risk patients with large-
cell lymphomas. In a French study, four cycles of standard chemotherapy were
given followed by either high-dose therapy or further conventional treatment.
The total group of patients did not benefit from high-dose therapy, but patients
who had more than one risk factor in the International Index had a longer sur-
Table 5
Gene Expression Profile in Diffuse Large B-Cell Lymphoma
Germinal center B-cell-type Activated B-cell-type
Frequency 50% 30%
Genes expressed CD10, BCL-6, LMO2 PKCb1, CND2,
MUM1, CD44
Oncogenic events BCL-2 translocation Nuclear factor-κB activation
REL amplification
5-yr survival 60% 35%
Median survival 10 yr 2 yr
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vival. Gene expression profiling may further delineate risk factors and treatment
choices. More studies are necessary to define exactly the indications for an initial
high-dose treatment. Patients who relapse or who do not achieve a complete
response have a poor prognosis. All such patients are candidates for high-dose
treatment if the disease is still sensitive to chemotherapy. Common salvage regi-
mens for patients with relapsed diffuse large B-cell NHL are ICE (ifosfamide,
carboplatin, and etoposide), which can be combined with rituximab (see Table 6),
DHAP (dexamethasone, high-dose cytarabine, and cisplatin), or ESHAP
(etoposide, solumedrol, high-dose ara-C, and platinol). In an Italian study, 84%
of patients with relapsed diffuse large-cell NHL achieved a complete response
with high-dose treatment and 46% survived after more than 5 yr vs 44 and 12%
in the conventional treatment arm. At present, there is limited experience with
allogeneic transplantation for large-cell lymphomas. If a high-dose treatment is
not indicated because of age, previous treatment, or co-morbidity, a good pallia-
tion may be reached with various protocols including ESHAP and MINE
(mitoxantrone, ifosfamide, and etoposide). In selected cases, radiotherapy can
Table 6
Chemotherapy Protocols for the Treatment of Non-Hodgkin’s Lymphomas
1. CHOP protocol (repeat on day 21)
Cyclophosphamide 750 mg/m2 i.v., day 1
Adriamycin 50 mg/m2 i.v., day 1
Vincristine Vincristine 2 mg, day 1
Prednisone 100 mg p.o., days 1—5
2. CHOP Rituximab Protocol ( repeat on day 21)
(Same as 1, addition of Rituximab 375 mg/m2 i.v. on day1)
3. CVP protocol (repeat on day 21)
Cyclophosphamide 400 mg/m2, intravenous, days 1–5 (modified at some centers)
Vincristine Vincristine 1.4 mg /m2 (maximum 2 mg), day 1
Prednisone 100 mg p.o., days 1–5
4. ESHAP protocol (repeat on day 21)
Etoposide 60 mg/m2 i.v., days 1–4 Methylprednisolone 500 mg i.v.,
days 1–4
Cytarabine 2 g/m2 i.v., day 5
Cisplatin 25 mg/m2 continuous infusion, days 1–4
(continued)
Chapter 15 / Non-Hodgkin’s Lymphomas 247
Table 6 (Continued)
5. MINE protocol (repeat on day 21)
Mitoxantrone 8 mg/m2 i.v., day 1
Ifosfamide 1.33 g/m2 i.v., days 1—3 (together with Mesna, 1.33 g/m2)
Etoposide 65 mg/m2 i.v., days 1-3
6. Rituximab-ICE
Rituximab 375 mg/m2 i.v. 48 h prior to cycle 1 and on day 1 of cycles 1–3
Etoposide 100 mg/m2 i.v. days 1–3
Carboplatin AUC5 (capped at 800 mg i.v. on d 4)
Ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna (as
continuous infusion for 24 h on day 4)
7. Oral chlorambucil
Chlorambucil 0.08 mg/kg p.o. or 2–4 (8) mg absolute dose (continuous
treatment, until toxicity is reached or not effective)
Alternatively 0.4 mg/kg p.o., day 1 (increase dose, if no major
toxicity, repeat after 2 wk)
8. Fludarabine protocol (repeat on day 29)
Fludarabine 25 mg/m2 i.v., days 1–5
9. FCM Protocol (repeat on day 29)
Fludarabine 25 mg/m2 i.v., days 1–3
Cyclophosphamide 200 mg/m2 i.v., days 1–3
Mitoxantrone 8 mg/m2 i.v., day 1
10. FCR Protocol (repeat on day 29/after recovery from toxicity)
Fludarabine 25 mg/m2 i.v., days 2–4
Cyclophosphamide 250 mg/m2 i.v., days 2–4
Rituximab 375 mg/m2 i.v., day 1 (cycles 2+: dose of 500 mg/m2)
11. Cladribine protocol (in hairy cell leukemia: repeat on day 29, if no complete remission)
Cladribine (2 CdA) 0.1 m/kg i.v., days 1–7
12. CVB protocol (protocol for autologous transplantation)
Cyclophosphamide 4.8–7.2 g/m2 i.v., over 4 d
Etoposide 750–2,400 mg/m2 i.v., over 4 d
Carmustine (BCNU) 300–600 mg/m2 i.v., over 4 d
Stem cell infusion Day 7 (at least 1 × 108 cells/kg for marrow or 2 × 106 CD34+
cells/kg for peripheral blood stem cells)
13. Total body irradiation with cyclophosphamide (protocol for autologous transplantation)
Total body irradiation: 12 Gy total dose (days 6–4)
Cyclophosphamide 60 mg/kg (day 3 to -2)
Stem cell infusion: day 0
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also give a palliation for refractory lymphomas. Besides autologous stem cell
transplantation (SCT), dose-intense therapy is a further way to improve the
prognosis of patient with diffuse large-cell lymphoma. Patients with bulky lym-
phomas (lymph node diameter in excess of 5 or 10 cm) are generally excluded
from the approach followed in localized disease and should be treated as for
advanced stages.
The subtype of primary mediastinal B-cell lymphoma typically occurs in
young adults who have a rapidly enlarging mediastinal mass. As with other
B-cell lymphomas, the markers CD19 and CD20 are positive. Histologically,
sclerosis and monocytoid lymphoid cells are typical. The recommended treat-
ment at present is an aggressive chemotherapy consolidated by radiotherapy.
The prognosis is relatively good.
Primary testicular lymphoma is a rare form of diffuse large B-cell lymphoma
(1–2% of all NHL). Despite being initially localized, primary testicular lym-
phoma commonly relapses in extranodal sites (CNS, lung, pleural, soft tissues).
6. FOLLICULAR LYMPHOMA
The combined group of follicular lymphomas or follicle center lymphomas
makes up the second most frequent type of NHL (approx 20–30% of all cases of
NHLs). In many countries, an increased incidence of follicular lymphomas has
been observed.
Pathologically, the follicular lymphomas have a characteristic picture that
resembles normal germinal centers. Centrocytes are mixed with centroblasts and
form a neoplastic germinal center. The growth pattern is usually follicular (see
Fig. 15.2 and Color Plate 16), but may be diffuse in rare cases.
According to number of blasts per high power field, grade I (<5), II (5 to 15
blasts) and III (>15 blasts) may be differentiated. Recently, the latter type was
further subclassified in grade IIIa (mixture of centrocytes and blasts) and IIIb
(diffuse sheets of blasts). Clinically, grades I–II appear more indolent with a
relapsing course whereas grade III lymphomas are more aggressive and should
be treated according to the guidelines of diffuse large-cell lymphoma.
At the molecular level, about 90% of patients with follicular lymphomas have
the t(14;18) (q32;q21) translocation. Translocation t(14;18) leads to an
overexpression of the bcl-2 protein. The immunophenotype of follicular lym-
phomas (as determined on tissue sections or in cell suspensions) is CD19+,
CD20+, CD10+ in most cases, CD3—, and CD5—.
6.1. Clinical Symptoms
The clinical course of follicular lymphomas is indolent in most cases. The
median age of patients with follicular lymphomas is around 50–60 yr. The dis-
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ease most often begins with peripheral lymphadenopathy, and the mediastinum
is rarely enlarged. Less than one-fifth of the patients have B-symptoms. The bone
marrow is involved in about half of the patients, typically showing nodular
infiltration. The clinical symptoms are often subtle and caused by the enlarged
lymph nodes; para-aortic lymph nodes or an enlarged spleen may cause abdomi-
nal fullness or other local symptoms. An extranodal manifestation is observed in
about 10% of the patients (gastrointestinal tract, rarely in the skin).
6.2. Prognosis
Generally, newly diagnosed follicular lymphomas respond well to treatment
(radiation or chemotherapy). In contrast to high-grade lymphomas, however,
follicular lymphomas cannot be cured by the conventional treatment strategies
available. A possible exception is the early stages of follicular lymphomas.
Taking into account all stages, people with newly diagnosed follicular lympho-
mas can expect to live an average of 8–10 yr. Risk factors for an adverse prog-
nosis are male sex, older age, systemic symptoms or reduced performance status,
a large tumor mass, bone marrow infiltration, and among laboratory criteria, an
increased LDH, or increased β2-microglobulin. The relevance of the Interna-
tional Index established for high-grade lymphomas is limited in low-grade
NHL. Recently, a more specific Follicular Lymphoma International Prognostic
Index (FLIPI) has been proposed. FLIPI distinguishes three groups of patients
Fig. 15.2. Follicle center lymphoma. Lymph node structure replaced by follicular infil-
trate, Giemsa stain, low-power magnification.
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according to the number of adverse prognostic factors. In the good prognostic
group (0–1 adverse prognostic factors), a 10-yr survival of 70% can be ex-
pected. An intermediate group with two adverse prognostic factors has a 10-yr
survival of 50%. A poor prognostic group (at least three adverse prognostic
factors) has a 10-yr survival of only 35%. Despite the initially good prognosis,
up to 40% of follicular lymphomas finally transform into high-grade NHL,
which then require more aggressive treatment strategies such as chemotherapy.
Gene expression profiling was studied in patients with follicular lymphoma.
Interestingly, survival correlates could be established not with genes expressed
in tumor cells but with genes expressed in infiltrating immune lymphocytes.
6.3. Treatment
At present, several therapeutic strategies can be considered for the follicular
lymphomas: observation, radiation therapy, standard chemotherapy, and high-
dose therapy with autologous transplantation.
6.3.1. OBSERVATION (WATCH-AND-WAIT STRATEGY)
Observation is indicated for asymptomatic patients with advanced disease
(stage III–IV) who do not have B-symptoms or other complications caused by the
lymphoma. Clinical examination, laboratory and ultrasound studies, and, if nec-
essary, computed tomographies should be performed at regular intervals (e.g.,
quarterly) to estimate the disease activity and behavior. If there is rapidly progres-
sive disease (e.g., B-symptoms, a major increase in the size of the lymph nodes,
or if signs of bone marrow failure develop), chemotherapy should be started.
6.3.2. RADIOTHERAPY
Radiotherapy is indicated in stages I and II without bulk (usually as involved-
or extended-field radiation with 30–40 Gy). This strategy can induce prolonged
remissions and possibly cures especially in stage I whereas in stage II with high
tumor load, the majority of patients will finally relapse. The rate of complete
remissions is 90–95% after radiotherapy and the survival free from relapse is 60–
70% after 5 yr. An initial treatment with combined modality (chemotherapy plus
radiation) may induce longer remissions in patients with follicular lymphomas,
but the total survival is comparable to that observed with radiotherapy alone.
Thus, combined modality treatment cannot be considered as standard treatment
in the early stages of follicular lymphomas.
6.3.3. SYSTEMIC CHEMOTHERAPY
Chemotherapy is indicated in all advanced stages if the disease causes symp-
toms or if the disease progresses after an observation period. Basically, a
monotherapy with an alkylating agent (e.g., chlorambucil) is effective but, because
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of a slow response, is only appropriate for selected patients with contraindications
to more aggressive options. Various combination treatments (e.g., CVP [cyclo-
phosphamide, vincristine, and prednisone], CHOP) can achieve a faster (and
usually longer) response (see Table 6). Four to six cycles of such protocol should
be given and, after a satisfactory response, the patient should be observed again.
In recent years, good responses to a treatment with fludarabine combinations
(e.g., FCM [fludarabine, cyclophosphamide, mitoxantrone]) have been reported.
For treatment of relapses, the same protocol as used initially can be repeated if
the remission has lasted several years. If the relapse occurs earlier, a more inten-
sive protocol (e.g., the CHOP or a related protocol) should be used. According
to a recent meta-analysis a maintenance treatment with interferon (IFN)-α pro-
longs the relapse-free survival. However, side effects are more frequently observed.
Younger patients with follicular lymphomas have an unfavorable long-term
prognosis, despite the initial good response. Therefore, these patients are candi-
dates for novel treatment strategies, especially if risk factors like B-symptoms or
large lymph node masses are present. Such an approach is myeloablative chemo-
consolidation with subsequent autologous SCT and results in prolonged progres-
sion-free survival (>60% risk of relapse). However, consistent data on overall
survival are still lacking, and late side effects (secondary malignancies) represent
an inherent risk of this approach. Recent studies attempt to remove malignant
cells with immunomagnetic purging or combine high-dose chemotherapy with
in vivo purging.
6.3.4. ANTIBODIES/COMBINED IMMUNO-CHEMOTHERAPY
The monoclonal anti-CD20-antibody rituximab destroys lymphoma cells via
complement- and antibody-mediated cellular cytotoxicity. Side effects of
rituximab are mainly fever and a depletion of normal B-cells; however, no major
myelotoxicity has been observed. In a phase II study, a response rate of 50% was
observed in patients with relapsed follicular lymphomas, but progression-free
survival was rather short (12–18 mo). In recent clinical trials, rituximab given in
combination with conventional chemotherapy (R-CHOP, R-CVP, or R-FCM)
resulted in a prolonged progression-free survival (up to a median of >7 yr)
comparable to the effect of myeloablative consolidation. Currently, different
antibody maintenance schedules are being evaluated.
Because of the curative approach with local radiation in early stages of dis-
ease, radioactively labeled antibodies represent another promising approach.
Recent phase II studies indicate very favorable remission durations especially in
patients who are in complete remission.
6.3.5. ALLOGENEIC TRANSPLANTATION
Allogeneic transplantation with either conventional myeloablative or reduced-
intensity conditioning remains the only curative treatment approach in advanced
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stages, but has a substantial treatment-related morbidity and thus remains reserved
for relapsed disease.
6.4. Novel Strategies
Molecular approaches (bcl-2 antisense, proteasome inhibitors) and vaccina-
tion strategies as well adoptive immunotherapy approaches are currently evalu-
ated in clinical studies.
7. MANTLE CELL LYMPHOMA
7.1. Definition and Incidence
Mantle cell lymphoma accounts for about 5–8% of all cases of NHL and is
characterized by an aggressive clinical course despite its apparently “non-blas-
tic” morphological features. As with other forms of NHL, the incidence of mantle
cell lymphomas increases with age, the median age being 60–70 yr. There is a
striking predominance of males (70%). The mantle cell lymphomas have a spe-
cific cytogenetic marker, the t(11;14) translocation, which involves a rearrangement
of the bcl-1 gene with subsequent overexpression of cyclin-D1. Histopathologi-
cally, a monomorphic proliferation of small- to medium-sized cells is found
mixed with follicular dendritic reticulum cells. The immunological phenotype of
mantle cell lymphomas is CD3-, CD5+, CD10-, CD20+, CD23-, and cyclin-D1+.
7.2. Clinical Symptoms
The major symptom of mantle cell lymphomas is the enlargement of lymph
nodes. About 80% of patients at diagnosis are already at an advanced stage (III
or IV). About 30% of patients have B-symptoms. Almost two-thirds of the
patients have an enlarged spleen. The bone marrow is involved in two thirds of
the cases, and in some patients a leukemic dissemination can be found already
at diagnosis. In about 10% of patients the gastrointestinal tract is involved; for
example, as multiple gastrointestinal polyposis.
7.3. Prognosis
Compared with the follicular lymphomas, the mantle cell lymphomas have a
rather unfavorable prognosis related to the relative resistance of the neoplastic
cells to cytotoxic treatments. The average survival is about 3–4 yr. A high num-
ber of mitoses or a blastic transformation in the lymph node section and a leuke-
mic dissemination are unfavorable prognostic signs.
7.4. Treatment
The optimal chemotherapy (CHOP, CVAD [hyper-cyclophosphamide, vinc-
ristine, Adriamycin®, and dexamethasone]) has not yet been well established. In
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recent studies, a combined immuno-chemotherapy (R-CHOP) achieved superior
remission rates greater than 90%, but remission duration remained limited, thus
effective consolidation strategies are urgently warranted. Myeloablative
radiochemotherapy results in a significantly superior progression-free survival
and a trend to prolonged overall survival in patients up to 65 yr. Although the
majority of patients relapse even after such multi-modal approach, allogeneic
transplantation still has to be considered as an experimental approach and remains
reserved for relapsed disease. Molecular approaches (especially proteasome inhibi-
tors and rapamycine derivatives) show promising results in current phase I/II
studies and may become a part of future treatment strategies. In rare cases with
localized disease I/II and low tumor burden, external radiation may achieve long-
lasting remissions.
8. CHRONIC LYMPHOCYTIC LEUKEMIA
CLL is typically a leukemia of elderly people and accounts for about 20% of
all NHLs. In Western countries, CLL is the most frequent type of leukemia,
whereas in Asia, the typical CLL is much rarer. CLL has a clear male predomi-
nance and characterized by the monoclonal accumulation of small, mature-appear-
ing lymphoid cells. The morphology of CLL cells is depicted in Fig. 15.3 (see also
Color Plate 17). The typical immunophenotype is CD3-, CD5+, CD10-, CD19+,
CD20+, and CD23+ (in contrast to mantle cell lymphoma). As in other malignant
lymphomas, surface immunoglobulins are light-chain restricted (generally with
a weak expressed). The typical CLL belongs to the entity of peripheral B-cell
neoplasms, whereas about 5% of all CLLs have a T-cell phenotype. With a
sensitive cytogenetic analysis, most cases of CLL have chromosome aberrations.
Frequent markers are trisomy 12, aberrations of chromosome 13q, as well as the
deletions of chromosomes 11q and 17p (location of the p53 tumor suppressor
gene p53). Both latter alterations usually predict clinical unresponsiveness.
Another important risk factor is the immunoglobulin mutation status, which may
be substituted by the fluorescence-activated cell sorting analysis of the closely
associated expression of the adhesion molecule zeta chain-associated protein
(ZAP)-70. Expression of ZAP-70, as well as unmutated status of the immunoglo-
bulin heavy chain genes confers a poorer prognosis.
8.1. Clinical Features
Most patients present with enlarged lymph nodes. In early stages, the patients
are asymptomatic and have a leukocytosis as the only sign of disease. In later
stages, anemia, splenomegaly, and hepatomegaly develop. Some patients also
have bruising due to thrombocytopenia, and frequent infections due to neutrope-
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nia and hypogammaglobulinemia. Some patients develop erythroderma (skin
infiltration with CLL cells). Two common classification schemes of CLL based
on clinical and laboratory features are shown in Table 7.
8.2. Laboratory Features
A lymphocytosis that may be as low as 5000 or higher than 200,000/µL is
constantly found in CLL. In advanced stages, anemia and/or thrombocytopenia
are present. The anemia may also be due to autoimmune hemolysis. Bone mar-
row aspiration shows infiltration of the bone marrow with CLL cells (at least 25%
of the aspirate, but in many cases as high as 90%). Bone marrow biopsy shows
a nodular, diffuse, or mixed infiltration. The bone marrow trephine biopsy may
not be necessary in all cases of CLL, as a nodular infiltration has been not
confirmed as independent prognostic factor. In many, and especially in advanced,
cases, the serum immunoglobulins are decreased (hypogammaglobulinemia). A
monoclonal para-protein is rarely present in CLL. About 5% of patients termi-
nally transform into an aggressive NHL (Richter syndrome).
Lymphocytic lymphomas resemble B-CLL cytomorphologically, but there is
no leukemic dissemination or infiltration of the bone marrow. Lymphocytic
lymphomas are rare (<2% of all NHL). The treatment is oriented at the principles
outlined for other indolent lymphomas.
Fig. 15.3. Chronic lymphocytic leukemia. Small, mature-appearing lymphoid cells with
a thin cytoplasmic rim.
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8.3. Prognosis
The prognosis of B-CLL depends on clinical and molecular laboratory fea-
tures. In early stages, the survival is more than 12 yr (Binet A); some patients with
early CLL (about one third of patients in Binet stage A) do not progress for many
years and do not have a reduced life expectancy (smoldering CLL). In contrast,
in advanced stages (Binet C, Rai IV) the median survival is less than 2 yr.
Mutations of p53, deletions of chromosome 11q, and a lymphocyte doubling
time of less than 12 mo have a negative impact on prognosis. More recently, it
was found that overexpression of the Syk tyrosine kinase ZAP-70 (important in
T cell development) confers a poor prognosis in B-CLL.
8.4. Treatment
The conventional treatment of CLL aims at the palliation of symptoms, not at
a cure. In the early stages (Rai 0–II or Binet A or B) the disease may be stable for
several years; therefore, no treatment is indicated. If the disease progresses rap-
idly, if B-symptoms develop, or if the disease leads to complications such as
frequent infections or an autoimmune hemolytic anemia, treatment with alkylat-
ing agents or fludarabine is indicated in later stages. A symptomatic autoimmune
hemolytic anemia needs an emergency treatment (high-dose steroids, 1–2 mg/kg
prednisone or cyclophosphamide, or both).
Supportive therapy plays a major role in the management of patients with
CLL. Infections need prompt treatment. Patients with hypogammaglobulinemia
and frequent infections may benefit from prophylactic antibiotics or the admin-
istration of polyvalent immunoglobulins in case of life-threatening infections.
Table 7
Chronic Lymphocytic Leukemias Classification Schemes
Rai classification Binet classification
Stage 0 Lymphocytosis 5000–15000/µL Stage A 0, 1, or 2 lymphatic areas
enlarged
Stage I Lymphocytosis + Stage B 3, 4, or 5 areas enlarged
lymphadenopathy
Stage II As 0 + hepato- and/or Hb >10 g/dL, Platelets
splenomegaly > 100000/µL
Stage III As 0 + anemia (Hb <11 g/dL) Stage C Any lymphatic involvement
Stage IV As 0 + thrombocytopenia Hb <10, and/or platelets
(platelets <100000/µL) <100,000
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8.4.1. SINGLE-AGENT CHEMOTHERAPY
Chlorambucil is still a commonly used alkylating agent for the first-line treat-
ment of CLL. It can be given as a pulse treatment (18 mg/m2 on day 1, repeat after
2 or 3 wk, increase dose if no major toxicity is seen) or as a continuous treatment
(0.1–0.2 mg/kg for 14 d, then repeat on day 28). The treatment should be continued
for 6–12 mo until a maximum response is seen or until the disease is progressive.
8.4.2. FLUDARABINE
The purine analog fludarabine is the most active single-agent drug in the
treatment of CLL. In the second-line treatment, 30–70% of patients obtain partial
and complete remissions. Fludarabine is given at the dose of 25 mg/m2 i.v. for
5 d; this is repeated after 28 d. A side effect of the treatment with fludarabine is
a long-lasting immunosuppression and an increase in the incidence of opportu-
nistic infections. Fludarabine must be discontinued if an autoimmune hemolytic
anemia develops. Cladribine (another purine analogue) is also active in CLL
(about 80% responses in previously untreated patients). Based on the superior
remission rates and progression-free survival, purine analogs represent the pre-
ferred first-line treatment in younger patients.
8.4.3. COMBINED IMMUNO-CHEMOTHERAPY
Multi-agent chemotherapy is indicated for patients whose disease progresses
after the first- and second-line treatment, or who present with a very aggressive
form. For these patients, protocols such as COP (cyclophosphamide, Oncovin,
and prednisone), CHOP, or combinations with fludarabine are currently in use.
Similarly, first studies suggest a superiority of fludarabine combinations (FC) in
comparison to fludarabine alone.
Recently, monoclonal antibodies directed against B- or T-cell antigens
(rituximab, alemtuzumab) have been introduced. Rituximab monotherapy has
only limited effect as a result of, the low CD20 expression on CLL cells whereas
the combination of fludarabine, cyclophosphamide, and rituximab (FCR) has
shown considerable activity in relapsed and refractory CLL. FCR is currently
tested in newly diagnosed CLL. Especially in refractory cases (frequently asso-
ciated with p53 deletions), anti-CD52 antibody alemtuzumab (Campath®) shows
high efficacy either as consolidation or in combination with chemotherapy
(FluCam) but is hampered by its serious immunosuppressive effect on B- and T-
cells.
8.4.4. EXPERIMENTAL STRATEGIES
Younger patients with an aggressive clinical course may benefit from an
autologous SCT. Patients less than 50 yr of age who have a human leukocyte
antigen-identical donor may also be candidates for an allogeneic SCT or bone
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marrow transplantation, but such treatments should be performed within con-
trolled clinical trials
For selected patients, splenic irradiation or splenectomy may be indicated
(large spleen with hypersplenism).
8.5. Special Forms of CLL
8.5.1. PROLYMPHOCYTIC LEUKEMIA
In prolymphocytic leukemia (PLL), the leukemic cells are larger than in clas-
sical CLL, appear to be immature, and have a prominent nucleolus (see Fig. 15.4
and Color Plate 18). Most cases of PLL have a B-phenotype (strong expression
of surface immunoglobulin and negative for CD5), but some cases are derived
from T-cells. In T-cell prolymphocytic leukemia, alterations of chromosome 11
and the ATM gene are frequent. Patients generally present with a huge spleen and
a high leukocyte count and do not respond well to the usual treatment for CLL.
The median survival of patients with PLL is shorter than for CLL (2–3 yr). For
this reason, an intensive chemotherapy (with CHOP-type regimens), or a treat-
ment with purine analogues or monoclonal antibodies should be considered
early.
Fig. 15.4. Prolymphocytic leukemia. Large lymphoid cells with a large nucleus and a
prominent nucleolus.
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8.5.2. SMOLDERING CLL
Some patients with early CLL (about one-third of patients in Binet stage A)
do not progress for many years and do not have a reduced life expectancy (smol-
dering CLL). By definition, the lymphocyte doubling time is longer than 12 mo
in such cases.
8.5.3. T-CHRONIC LYMPHOCYTIC LEUKEMIA
A T-cell phenotype is rare in CLL (about 3% of all cases). These patients are
younger, often have cutaneous involvement, and respond poorly to therapy.
Although these cases are usually derived from CD3+, CD4-, and CD8- T-cells, an
indolent (CD8+) variant is probably derived from immature NK cells.
Some T-cell leukemias and lymphomas are associated with the retrovirus
HTLV-1. Figure 15.5 (Color Plate 19; see also “Etiology of NHLs”) depicts the
neoplastic cells of a patient with a HTLV-1-associated lymphoma.
9. LYMPHOPLASMACYTOID/-IC LYMPHOMA/
IMMUNOCYTOMA (INCLUDING WALDENSTRÖM’S DISEASE)
The lymphoplasmacytoid lymphoma or immunocytoma has been grouped as
CLL variant in the WHO classification. Lymphplasmocytic immunocytomas
Fig, 15.5. Neoplastic cells of a patient with adult T-cell leukemia/lymphoma (small- to
medium-sized lymphoid cells with a highly irregular nucleus, “flower cells”).
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also include Waldenström’s disease with an immunoglobulin (Ig)M paraprotein
and a typical bone marrow morphology.
The clinical signs and symptoms of immunocytomas are comparable to those
of other low-grade NHLs. About 80–90% of patients have advanced disease at
diagnosis. A special form of immunocytomas involves the eye or the skin; occa-
sionally, an enlarged spleen is the main manifestation of an immunocytoma.
Immunocytoma cells bear the B-lymphoid antigens CD19, CD20, and CD22.
In contrast to the typical B-CLL, immunocytoma cells are negative for CD5 and
CD23.
The prognosis of immunocytomas is somewhat inferior to that of classical
CLL depending on the patient risk profile. The median survival in Waldenström’s
disease is about 5 yr. As far as the treatment is concerned, radiation is only
indicated in the rare localized forms. If immunocytomas are disseminated or
leukemic, the treatment is oriented at the principles outlined for CLL or follicular
lymphomas.
Waldenström’s macroglobulinemia is a special form of immunocytoma with
particular features. The bone marrow is involved in virtually all cases, showing
a dense infiltrate with small basophilic lymphoid cells and plasma cells. The
patients are frequently anemic as a result of bone marrow infiltration. The spleen
or lymph nodes are enlarged in about 20–40% of cases. A common feature is
an increased number of mast cells. The presence of a typical IgM paraprotein
(>30 g/L) can lead to a hyperviscosity syndrome with vertigo, visual distur-
bances, and mucous membrane bleeding. Further complications are hemolytic
anemia with cold agglutinins, peripheral neuropathy, amyloidosis, and renal
failure.
If urgent treatment is indicated, a hyperviscosity syndrome can be ameliorated
rapidly by plasmapheresis. In general, the treatment indications for Waldenström’s
macroglobulinemia are similar to those in CLL. Patients who are treated with
chlorambucil respond in 50–70% of the cases with a reduction of the paraprotein
and the lymphadenopathy. However, fludarabine and other purine analogues
represent the preferred treatment option with up to 80% response rate. Whereas
only an extended schedule of antibody monotherapy (eight cycles) has some
effect, a recent randomized study confirmed the superiority of a combined
immuno-chemotherapy. Recent data show a considerable role for autologous
SCT in relapsed Waldenström’s disease.
10. BURKITT’S LYMPHOMAS, BURKITT-LIKE LYMPHOMAS,
AND LYMPHOBLASTIC LYMPHOMAS
In Africa, Burkitt’s lymphoma is a disease of children; in Europe and North
America, Burkitt-like lymphomas typically occur in young adults. The disease
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often has an extranodal and abdominal manifestation. Lymphomas of the jaws,
kidneys, and retroperitoneum are typical for the African variety (endemic
Burkitt’s lymphoma).
Histopathologically, a monomorphic infiltration of medium-sized cells with
round nuclei containing multiple basophilic nucleoli is typically found. The
cytoplasm is deeply basophilic. A starry sky pattern in Burkitt’s lymphoma
reflects macrophages that have ingested apoptoptic lymphoma cells. The pri-
mary genetic abnormality in Burkitt’s lymphoma is the translocation t(8;14) or
variations thereof, with rearrangements of the Myc oncogene. The immuno-
phenotype of Burkitt’s lymphomas indicates expression of CD19, CD20, CD22,
CD79a, CD10, and CD43 and absence of surface IgM, CD5, CD23, and Bcl-2.
Burkitt’s lymphoma is aggressive and urgently requires treatment. Using in-
tensive protocols that include high-dose cyclophosphamide and a prophylaxis
for CNS involvement, about 30–50% of patients (especially children) can expect
cure. Examples for dose-intense protocols used in Burkitt’s lymphomas are the
Hyper-CVAD and the CODOX-M (cyclophosphamide, Oncovin, doxorubicin,
high-dose methotrexate)/IVAC (ifosfamide, etoposide, and high-dose cytarabine)
protocols.
Lymphoblastic lymphomas are rare in adults, but somewhat more frequent in
children and adolescents. The WHO classification distinguishes B- and T-pre-
cursor lymphoblastic lymphomas. T-lymphoblastic lymphomas often present
with a mediastinal mass. If the bone marrow is involved in lymphoblastic lym-
phoma and more than 25% of lymphoma cells are found, the disease is classified
by definition as acute lymphoblastic leukemia (ALL). Most cases of lympho-
blastic lymphomas are treated with protocols developed for ALL (including a
prophylaxis for CNS involvement).
11. MYCOSIS FUNGOIDES (CUTANEOUS T-CELL LYMPHOMA)
AND SÉZARY SYNDROME
Mycosis fungoides is a clonal proliferation of neoplastic helper (CD4+) lym-
phocytes that manifests in the skin. Mycosis fungoides, or cutaneous T-cell
lymphoma, often has a protracted course over many years. The WHO classifica-
tion includes mycosis fungoides in the group of mature (peripheral) T-cell neo-
plasms. The tumor cells are atypical lymphocytes with hyperconvoluted
cerebriform nuclei. Mycosis fungoides has three clinical stages: premycotic and
patch stage, infiltrative and plaque stage, and the tumor stage.
Other staging systems are used for clinical studies, and include the presence
or absence of lymph node and visceral manifestations (bone marrow or other
organs). The median survival of patients with cutaneous T-cell lymphomas var-
ies between 2 and 15 yr depending on the stage of the disease. In Sézary syn-
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drome, a leukemic dissemination of the neoplastic cells has occurred (about 5%
of all patients with mycosis fungoides present with Sézary syndrome) and the
patients have a generalized erythroderma.
The treatment of mycosis fungoides is mainly supportive and aims at pallia-
tion. Skin care and the treatment of infections are important during all stages.
In the plaque stage, topical alkylating agents (nitrogen mustard or carmustin)
are effective in 60–80% of cases. An alternative treatment is photosensitizer with
UVA irradiation (PUVA) photochemotherapy. For this treatment, oral meth-
oxypsoralen is combined with UVA irradiation. Remissions last for approx 11–
13 mo. PUVA can also be given as an extracorporeal photophoresis, which is
especially effective in Sézary syndrome. Retinoids and IFN also have some
efficacy in mycosis fungoides. In the tumor stage, an external irradiation with
electron beams (30–36 Gy over 8–10 wk) is indicated and controls the disease
for several months. A systemic chemotherapy (analogous to high-grade NHL),
in some cases also steroids, fludarabine, and other agents such as 2-chloro-
deoxyadenosine are also effective for disease control or palliation in the tumor
stage and with visceral manifestations. Rarely, cutaneous lymphomas are de-
rived from B-cells, which often have an indolent clinical behavior.
12. SPECIAL FORMS OF NHL
12.1. Hairy Cell Leukemia
HCL is an uncommon B-cell lymphoproliferative disorder that was originally
referred to as “leukemic reticuloendotheliosis.” Because of the presence of promi-
nent and characteristic thin cytoplasmic projections, its name was changed to
hairy cell leukemia several decades ago. It is currently thought of as a low-grade
or indolent NHL. If counted among the leukemias, HCL makes up about 2–4%
of all leukemias. It is mainly a disease of men, with a male to female ratio of about
four to one. The median age of onset is in the mid 50s, with a range of 40–70 yr.
The pathogenesis of HCL is not known.
The malignant cells of HCL are B-lymphocytes, which have the previously
mentioned fine cytoplasmic projections (see Fig. 15.6 and Color Plate 20). These
cells express features that are consistent with late stages of B-cell development.
They are often characterized by:
• Tartrate-resistant acid phosphatase (TRAP) positivity.
• The expression of B-cell surface antigen markers (CD19, CD20, CD22) and an
early plasma cell marker (PCA-1).
• The expression of surface antigen markers that are not routinely identified on B-
cells such as CD11c, CD103, and CD25. The presence of CD103, in the presence
of other pan-B-cell markers, is highly suggestive of HCL.
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• No consistent or specific chromosomal mutations (although a partial loss of 7q
as well as other abnormalities have been reported).
• The expression of clonal immunoglobulin light- and heavy-chain gene rear-
rangement as well as monoclonal surface immunoglobulins.
• The production of cytokines like tumor necrosis factor (TNF)-α, fibroblast
growth factors (bFGF, FGF-2) and interleukin (IL)-1. In untreated patients,
increased serum levels of soluble IL-2 receptors are found. Some of these
cytokines may be etiological in the marrow inhibition and fibrosis sometimes
seen in HCL.
Clinically, the spleen is enlarged in most patients and is responsible for the
presenting symptom of abdominal fullness or discomfort in many. Others may
present with constitutional symptoms such as fatigue, malaise, and weight loss.
Night sweats are not common, although some will present with fevers due to
frequent infections. These infections may be life-threatening as a result of dis-
ease-related neutropenia and monocytopenia. Similarly, some patients will
present with excessive bleeding and bruising due to disease-related thrombocy-
topenia. Enlarged lymph nodes and other clinical manifestations are rather infre-
quent, and approx 25% of patients will be asymptomatic at the time of diagnosis.
The diagnosis of HCL in these patients is frequently made during the evaluation
of incidentally noted splenomegaly or mild cytopenias.
The typical blood picture most commonly reveals pancytopenia. The majority
of patients will present with anemia, neutropenia, monocytopenia, and thromb-
Fig. 15.6. Hairy cell leukemia. Peripheral blood smear with two hairy cells (lymphoid
cells with cytoplasmic protrusions).
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ocytopenia. Despite being called a “leukemia,” only about 20% of patients will
present with a leukocytosis greater than 10,000/µL.
Most patients have a “dry tap” when the bone marrow is aspirated. Staining
of the marrow core for reticulin frequently reveals a moderate to marked increase
in reticulin fibrosis. The peripheral blood should be analyzed by flow cytometry
and the blood and bone marrow subjected to TRAP staining. Histological inves-
tigation of the bone marrow shows a dense infiltration of the bone marrow with
hairy cells in virtually all patients and some degree of fibrosis is also typically
found. In addition, many patients also have circulating hairy cells. In about 20%
of the patients, a frank leukemic blood picture develops. Rarely however is there
an extreme leukocytosis.
12.1.1. TREATMENT
Treatment of the patient with HCL is most often indicated in the setting of
symptomatic splenomegaly and/or worsening cytopenias. Recurrent infections
or leukocytosis (>20,000/µL) are often indications for treatment as well. Some
patients with HCL are asymptomatic and can be observed for months or even
years without treatment. Once a decision to treat has been made, the patient with
symptomatic HCL may have several options. These include purine analog-based
chemotherapy, IFN, and splenectomy.
Prior to the early 1980s, splenectomy was the treatment of choice for symp-
tomatic patients. It did relieve symptoms that were directly related to splenom-
egaly and often resulted in improvement of the cytopenias. It did not affect the
underlying disease, however, and is now reserved for the rare patient who has
disease that is refractory to pharmacological therapy.
IFN-α has also been very effective in HCL. There is an overall response rate
of approx 80%, but complete responses are rare. The majority of patients achieve
only partial remissions (defined as normalization of all peripheral blood counts.)
Even if IFN does not induce a complete remission, the number of hairy cells in
the blood and bone marrow are reduced and the cytopenias are improved. IFN-α
is generally given at a dosage of 2–3 × 106 units three times a week subcutaneously.
In order to achieve a maximal response, IFN-α must be given for 12 to 18 mo. The
side effects of IFN-α are described elsewhere in this volume.
The therapeutic arsenal has much improved since the introduction of the purine
analogs 2-deoxycoformycin (DCF, pentostatin) and 2-chloro-deoxy-
adenosine (2-CDA, cladribine). Both drugs induce long-term remission in HCL.
After one cycle of 2-CDA, 85% of patients reach a complete remission, which
increases to 95% after two treatment cycles. These remissions last for many
years. Acute side effects of 2-CDA are fever, a transient bone marrow suppres-
sion, fatigue, headache, and some nausea (see Table 5 for dose of cladribine).
Pentostatin is also very effective in the treatment of HCL (rate of 80–90% com-
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plete remissions), but more patients suffer relapses. Pentostatin is also given as
monotherapy. Generally three to five cycles are needed to reach a complete
response, that is, the disappearance of all hairy cells from blood and bone mar-
row. The acute side effects of pentostatin are comparable with those of cladribine.
Both drugs also induce a long-lasting depression of cellular immunity. In patients
with relapsed or refractory HCL, interesting clinical activity was found for the
monoclonal antibody rituximab and the immunotoxin BL-22 (a CD22 antibody
fused to pseudomonas exotoxin).
12.2. Gastric and MALT Lymphomas
Lymphoma deriving from the MALT was first described as a distinct patho-
logical entity in 1983. Under the current WHO classification, it is classified as
extranodal marginal zone lymphoma MALT type, and comprises 8% of all NHL.
MALT lymphoma has characteristic features such as homing in epithelial tissue,
lymphoepithelial destruction, and an indolent clinical course. They arise in epi-
thelial tissues normally devoid of lymphatic cells, where the lymphatic tissue
was acquired after, for instance, a chronic infection. The best example here is the
association of gastric MALT lymphoma and the infection of the stomach with
H. pylori. Gastric MALT lymphoma also exemplifies the translation of bio-
logical knowledge of a disease towards improved clinical practice. Rarely,
MALT lymphomas arise in tissues other than the stomach (salivary glands, where
they are associated with Sjogren’s syndrome or lungs). MALT lymphomas of the
ileum are also rare and have a less favorable prognosis.
12.2.1. ASSOCIATION WITH H. PYLORI AND PATHOGENESIS
Multiple lines of evidence indicate a causative role of H. pylori infection in the
gastric MALT lymphoma. MALT of the stomach is always a sequela of H. pylori
infection. Acquired MALT is the precondition for the potential development of
a MALT lymphoma. Prior H. pylori infection is therefore a pre-MALT lym-
phoma condition. In more than 90% of cases, MALT lymphoma is associated
with H. pylori infection. In animal experiments MALT lymphomas can be
induced by H. pylori infection. H. pylori eradication alone can lead to complete
remission of the MALT lymphoma. Besides the classical association with gastric
MALT lymphomas, there have been reports in which an association between
H. pylori and DLBCL has been observed as well. Consequently, cure of H. pylori
infection resulted in remission induction not only in gastric MALT lymphomas,
but also in some patients with limited stages of DLBCL of the stomach.
In addition to the association with H. pylori, progress has been made with
regard to MALT lymphoma biology. Three translocations, t(11;18)(q21;q21),
t(1;14)(p22;q32), and t(14;18)(q32;q21) are specifically associated with MALT
lymphoma and the genes involved have been identified. t(11;18) results in a
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chimeric fusion between the API2 and MALT1 genes and is specifically associated
with gastric MALT lymphomas that do not respond to eradication of H. pylori.
t(1;14) and t(14;18) deregulate BCL10 and MALT1 expression, respectively.
These seemingly irrelevant chromosomal translocations share common onco-
genic properties by targeting the same NF-κB oncogenic pathway. These genetic
events seem specific in that they have been observed only in MALT lymphomas.
Once present, at least the more frequently observed translocation t(11;18) ren-
ders cells resistant to cure of H. pylori infection. The result is H. pylori-indepen-
dent growth and a unique clinical picture characterized by a more advanced
presentation and unresponsiveness to H. pylori eradication therapy. Although
more likely to require cytotoxic therapy, this subtype is paradoxically less likely
to undergo large-cell transformation.
12.2.2. CLINICAL FEATURES AND STAGING
The median age of the presentation is 63 yr, with a similar proportion of male
and female patients. The majority of patients have insidious onset of disease and
a very indolent course. The most common presenting symptoms are nonspecific
dyspepsia and epigastric discomfort. Classical B-symptoms are extremely rare.
The most common gastric location is the antrum, although multi-focal disease is
seen in approximately one-third of cases. At endoscopy, erythema, erosions, or
ulcerations are commonly seen whereas masses are rare. MALT lymphomas
have characteristic histopathological features. Reactive B-cell follicles sur-
rounded by tumor cells (centrocyte-like cells) are found. The centrocyte-like
cells are small- to medium-sized lymphoid cells with an irregular nuclear shape,
which selectively penetrate epithelial structures and form lymphoepithelial
lesions. The immunophenotyping is that of typical marginal zone B-cells with
CD20+, CD21+, CD5–, CD10–, IgM+, IgD–, and cyclin D-. In light of their signifi-
cance in biology and clinical characteristics, the chromosome translocations,
especially t(11;18) should be searched for, and can be done by either fluorescent
in situ hybridization or reverse-transcription polymerase chain reaction. For
staging, either the Ann Arbor system or the Lugano system for gastrointestinal
lymphoma (Table 8) can be used.
12.2.3.TREATMENT
Optimal treatment for gastric MALT lymphoma depends upon H. pylori sta-
tus, disease stage, the presence of translocation like t(11;18), and evidence of
large cell transformation. H. pylori eradication therapy is a worthy goal in all
cases, and is probably the only therapy required in a majority (75–80%). A
common protocol for the eradication of H. pylori is the combination of
omeprazole (20 mg twice a day [bid]), clarithromycin (500 mg bid), and
amoxicillin (1 g bid) for 10–14 d. For patients who are allergic to penicillin,
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metronidazole (500 mg bid) can be used instead of amoxicillin. Eradication can
be achieved in 85% of patients with both regimens. If the lymphoma does not
regress after the eradication of H. pylori, a local irradiation (of 30 Gy) can lead
to prolonged remissions. Patients with advanced stages of disease should be
treated like other indolent lymphoma. Options include watchful waiting, chemo-
therapy, and antibody-based (e.g., rituximab) approaches. The discovery that
these cases have constitutive activation of NF-κB suggests a role of novel tar-
geted therapy such as proteasome inhibition.
12.3. Angioimmunoblastic T-Cell Lymphoma
The angioimmunoblastic lymphoma (previously angioimmunoblastic lymph-
adenopathy) is a rare clonal proliferation of T-cells. Patients present with enlarged
lymph nodes, fever, a rash, and an enlarged spleen. The disease is almost always
disseminated and shows multiple biochemical abnormalities. There is no stan-
dard treatment, but most patients respond well to steroids and alkylating agents.
Remissions are usually incomplete and of short duration. High-dose chemo-
therapy with SCT should be considered as a therapeutic option.
12.4. Anaplastic Large-Cell Lymphoma
About 2–8% of all NHL fit into the category of anaplastic large-cell lympho-
mas (ALCL). ALCL are characterized by a proliferation of pleomorphic large
lymphoid cells that are strongly CD30+ and typically spread into the lymphoid
sinuses. Previously, ALCL were diagnosed as malignant histiocytoses or other
entities. Clinically, patients with ALCL are younger than patients with other
forms of NHL, frequently male and often present with B-symptoms. ALCL have
a cytogenetic marker, t(2;5), which is rarely found in other lymphomas. The
molecular product of t(2;5) is the fusion gene NPM-ALK, which has transforming
properties in vitro. Most cases of ALCL have a CD8-positive phenotype, some
Table 8
Lugano Staging of Gastrointestinal Lymphomas
Stage I Tumor confined to the gastrointestinal tract
Stage II Tumor extending into the abdomen from the primary site
IIı: Local node involvement (perigastric or perimesenteric)
II2: Para-aortic or paracaval node involvement
IIE: Penetration of serosa to involve adjacent organs or tissue
Stage IV Disseminated disease or supradiaphragmatic lymph node involvement
No stage III defined.
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express no distinct markers (null phenotype). In the WHO classification, ALCL
belong to the mature (peripheral) T-cell neoplasms. Of all patients with high-
grade lymphomas, those with ALCL generally respond best to treatment, 70%
achieving a 5-yr survival.
12.5. Lymphomas in Children
The clinical presentation of NHL in children is aggressive, and in 90% of the
cases they have a high-grade histology (large cell, lymphoblastic, Burkitt type).
Despite these unfavorable features, children with NHL respond well if treatment
is started without delay. At present, 70% of children with NHL can expect cure.
The treatment protocols for pediatric NHL are tailored to the type of lymphoma
and the individual risk situation. In children with large abdominal masses, the
risk of a tumor lysis syndrome has to be considered. In pediatric Burkitt’s lympho-
mas risk-adapted treatments are given, which incorporate high-dose methotrexate
and high-dose cytosine arabinoside in addition to vincristine, doxorubicine, pred-
nisone, and cyclophosphamide.
12.6. Lymphomas in HIV-Infected Individuals
NHLs are an AIDS-defining illness in HIV-infected individuals. Of all pa-
tients with AIDS, 3–8% have NHL as the first manifestation of their disease. The
incidence of AIDS-related lymphomas has recently decreased since the intro-
duction of high-active antiretroviral therapy. These lymphomas most often have
an aggressive presentation, intermediate- to high-grade histology and frequently
have an extranodal spread (e.g., gastrointestinal tract, CNS). The prognosis of
AIDS-associated NHL (mostly B-cell NHLs) is unfavorable but has recently
improved (see also Chapter 17, Table 5). Cerebral lymphomas generally arise in
the context of advanced immunosuppression with low CD4 counts. All patients
with AIDS-related lymphomas, especially if they have CD counts less than 200/µL
and B-symptoms, should be investigated for opportunistic infections like cytomega-
lovirus, toxoplasmosis, and cryptococcosis. EBV is integrated into the genome
of lymphoma cells of HIV-infected individuals in about half of the cases of
AIDS-related lymphomas. In AIDS-related CNS lymphomas, EBV is found in
approx 100% of cases. Patients with a good performance status should be treated
with full-dose CHOP-type chemotherapy. Most studies show that antiretroviral
therapy can safely be combined with chemotherapy and actually restores the
immune competence. The addition of the monoclonal antibody rituximab to
chemotherapy has not improved the response to chemotherapy and may even
worsen the prognosis of AIDS-related lymphomas. In advanced cases or an
extranodal presentation of AIDS-related lymphomas, a CNS prophylaxis is
indicated. In selected cases of relapsed AIDS-related lymphomas, autologous
SCT was performed successfully.
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12.7. Cerebral Lymphomas
Most primary cerebral lymphomas are of high-grade histology. The symp-
toms relate to the location and are comparable with those of a brain tumor. CNS
lymphomas have increased in incidence and currently represent 4% of all CNS
malignancies. Disturbances of motor and sensory function, intellectual alter-
ations, and other symptoms are found. The diagnosis of cerebral lymphoma can
be suspected if computed tomography and nuclear magnetic resonance imaging
shows typical findings (see Fig. 15.7). If a meningeal dissemination has oc-
curred, lymphoma cells and an increased protein content are found in the cere-
brospinal fluid. If a primary CNS lymphoma is suspected, a histological diagnosis
should be obtained by stereotactic (or open) biopsy. Classically, primary cere-
bral lymphomas were treated with corticosteroids and irradiation with 40 Gy.
Fig. 15.7. High-grade brain lymphoma (magnetic resonance image with contrast
enhancement).
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This treatment induced remissions for 12–18 mo and less than 5% of patients
survived more than 5 yr. More recently, multi-modal concepts were introduced
for CNS lymphomas (e.g., intrathecal chemotherapy, irradiation, and systemic
chemotherapy including high-dose methotrexate). In a study published by de
Angelis and colleagues, five cycles of systemic methotrexate were combined
with vincristine and procarbazine. Most patients subsequently received whole-
brain radiotherapy and high-dose cytarabine. Of all patients, 94% responded and
approx 50% reached a complete remission. In the entire group, the median sur-
vival was 3 yr. The major adverse side effect was neurotoxicity (due to the whole-
brain radiation).
12.8. Splenic Marginal Zone Lymphoma
This rare entity is the most indolent of the low-grade lymphomas. A large
spleen may or may not be associated with villous lymphocytes in the peripheral
blood. Following splenectomy, prolonged remissions have been observed. Alter-
natively, fludarabine and/or antibody may be administered.
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1. INTRODUCTION
Multiple myeloma (MM) is a complex clonal malignancy of plasma cells in
which the malignant cell has synergistic and complex interactions with the
stroma. The first description of the disease was in the 1840s. The patient, Thomas
Alexander McBean, was a carpenter born in 1800. He went to his family physi-
cian Dr. Thomas Watson in 1844 with sternal pain, which was treated with a
plaster cast. The pain recurred 1 yr later and was treated with cupping and then
steel and quinine. With relapse in August 1845, the patient was referred to Wil-
liam MacIntyre, a Harley Street physician, who personally examined both the
urine and the patient. He noted that with boiling, the urine became opaque, and
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that on cooling, a precipitate formed that clarified on reheating. Henry Bence
Jones, physician at St. George’s Hospital, confirmed the finding and, by chemi-
cal analysis, determined the substance to be a protein different from albumin. Mr.
Bean died on New Year’s Day 1846. John Dalrymple performed the autopsy and,
noting bony abnormalities, coined the term “mollities and fragilitas ossium.”
Subsequently, Bence Jones presented a paper “On a new substance occurring in
the urine of a patient with ‘mollities ossium’,” and 2 years later, MacIntyre
described the patient in a paper “Case of mollities and fragilitas ossium accom-
panied with urine strongly charged with animal matter.”
Other early historic landmarks include the description in 1873 by Rustizky,
who performed an autopsy on a patient with eight separate tumors of the marrow
and designated them MMs. In 1889, Kahler rediscovered Bence Jones’ protein
and described the clinical problems of loss of stature and kyphosis from
osteoporosis in MM. In 1900, Wright made the connection between plasma cell
proliferation, MM, and Bence Jones protein in the urine.
2. EPIDEMIOLOG  Y OF MM
The incidence of MM in the United States is about 4 cases per 100,000 of the
population. In 2004, there were an estimated 15,000 new cases of MM in the
United States. The nearly 12,000 deaths from MM in 2004 accounted for about
2% of cancer deaths, with the death-to-new-case ratio of 3:4 being among the
worst for all new malignancies. Although the disease is usually characterized as
a disease of the elderly, the mean age at diagnosis in men is 62 yr, with 35% of
the cases occurring in men under 60 yr of age. In women, the mean age at
diagnosis is 61 yr, with 41% of the cases diagnosed in women under 60 yr of age.
The incidence is twofold higher in African-Americans and in males in all popu-
lations. A map of mortality rates from myeloma shows a several-fold difference
across the United States, with a trend toward higher mortality rates in the north-
ern tier of states.
3. PLASMA CELL DYSCRASIAS
The gamut of plasma cell disorders run from the malignant precursor condi-
tion monoclonal gammopathy of undetermined significance (MGUS), to a vari-
ety of malignant monoclonal gammopathies. MGUS occurs in about 1% of adults
and in nearly 10% of the population over 90 yr old. The malignant entities
encompass variants of MM and other plasma cell malignancies as noted in Table 1.
The median time for progression of smoldering myeloma to symptomatic
myeloma is about 23 yr. Currently, patients with MM have a median survival
of about 33 mo. Plasma cell leukemia is an uncommon event and can occur either
as a primary entity or a secondary event during the progression of myeloma. In
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either case, the prognosis is poor, with a mean survival of several months.
Although most patients with myeloma have an M-component demonstrable in
serum or urine, about 1% of patients will have a nonsecretory disease without
synthesis of any portion of a clonal immunoglobulin (Ig). Osteosclerotic myeloma
is a rare form of myeloma with an interesting complex of signs and symptoms
known as POEMS syndrome: polyneuropathy, osteosclerosis, endocrinopathy,
myeloma, and skin lesions. MM can present as solitary growths or plasmacyto-
mas involving the bone or as extramedulary plasmacytomas. Plasmacytomas of
the bone have a high frequency of converting to a systemic MM, whereas
extramedullary plasmacytomas, especially those that occur in the upper respi-
ratory tract, have a greater tendency to remain localized.
The diagnostic criteria for MGUS are: the concentration of the monoclonal
serum protein is below 30 g/L; the levels of the normal (polyclonal) Igs are not
decreased; the bone marrow aspirate contains less than 10% plasma cells; a
Bence Jones protein cannot be detected; and other malignancies (e.g., malignant
lymphoma, MM, solid tumors) have been excluded. Patients with MGUS are
generally asymptomatic.
Waldenström’s macroglobulinemia is a distinct plasmalymphocytic mono-
clonal proliferation of B-lymphocytes and plasma cells that produce an IgM
monoclonal protein. The morphology of the malignant cells and the clinical
progression of Waldenström’s macroglobulinemia (described in detail in Chap-
ter 15) are distinct from myeloma. Macroglobulinemia can also occur in other
Table 1
Types of Multiple Myeloma and Other Plasma Cell Dyscrasias
Multiple myeloma
Smoldering multiple myeloma
Symptomatic multiple myeloma
Plasma cell leukemia
Primary
Secondary
Nonsecretory myeloma
Osteosclerotic myeloma (POEMS)
Plasmacytoma
Solitary plasmacytoma of bone
Extramedullary plasmacytoma
Waldenström’s macroglobulinemia
Heavy chain diseases
Primary amyloidosis
Monoclonal gammopathy of unknown significance (MGUS)
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proliferative lymphocytic disorders including MGUS, chronic lymphocytic leu-
kemia (CLL), lymphomas, and primary amyloidosis.
Heavy chain disease (HCD) refers to monoclonal lymphocytic proliferations
with the elaboration of only an Ig heavy chain. These entities have distinct
clinical-pathological correlates. For example, alpha HCD, which is also known
as immunoproliferative small intestinal disease (IPSID), Mediterranean lym-
phoma, or diffuse small intestinal lymphoma, is a subtype of the indolent
mucosa-associated lymphoid tissue (MALT) lymphomas. D-HCD occurs pri-
marily in the Middle East and is characterized by the synthesis of an alpha heavy
chain paraprotein and constitutes a form of small intestinal lymphoma called
IPSID. In P-HCD, a monoclonal band is found in the minority of cases and
hypogammaglobulinemia is a prominent feature.
Primary amyloidosis is also uncommon. The light chain synthesized by the
malignant plasma cell clone diffuses into numerous tissues and stimulates pro-
duction of amyloid protein. Often, the light chain is so potent in the incitement
of amyloid that the amyloid depositions are detected well before it is possible to
detect the presence of myeloma.
4. BIOLOGY OF MM
MM is a clonal B-cell malignancy with the myeloma cells derived from post-
germinal center bone marrow plasmablasts. In the progression to plasma cells,
the B-cells undergo a variety of DNA breaks necessary for variable diversity
joining recombinations, somatic mutations, and isotype switching. It is assumed
that this inherent genetic instability makes the plasma cell more prone to malig-
nant transformation. Conventional karyotyping reveals abnormalities in only
about 20% of patients presenting with stage I disease, increasing to 60% in stage
III. By interphase fluorescence in situ hybridization (FISH), at least one chromo-
somal abnormality can be demonstrated in about 90% of cases of myeloma and
4050% of cases of MGUS. The disparity of karyotyping and FISH analysis may
be explained by the low labeling index in the malignant plasma cells and, hence,
the difficulty in obtaining metaphases for analysis. FISH analysis demonstrates
genetic abnormalities involving the Ig heavy-chain (IGH) gene at 14q32 occur-
ring in about 75% of cases. The more common of the translocation partners
include 11q13 (CCND1), 4p16.3 (FGFR-3 and MMSET), 6p21 (CCND3), 16q23
(c-Maf), and 20q11 (mafB). In addition, deletions of chromosome 13 occur in
nearly 50% of patients and, during the evolution and course of the disease,
mutations affecting nRAS, kRAS, cMyc, and p53 are frequently seen.
The traditional hypothesis for the evolution of myeloma is that somatic mu-
tations involving IGH at 14q32 lead to MGUS, which has an approx 1% per year
conversion rate to myeloma or related B-cell malignancies. Subsequent translo-
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cations of 14q32 lead to progression to myeloma either as smoldering myeloma
or solitary plasmacytomas. Additional mutations of N-RAS, K-RAS, P53, and/or
13q14 deletions allow for progression to clinically significant myeloma. At odds
with this hypothesis for progression is that the mean age at diagnosis of MGUS
is far greater than that of myeloma.
Most of the translocations that involve the five recurrent translocation part-
ners seem to be primary event translocations that occur from errors in IgH switch
recombination during B-cell development in germinal centers. However, some
other translocations may take place as a secondary event after the development
of MGUS or MM. For example, c-myc translocations appear to be late secondary
events that do not involve B-cellspecific recombination mechanisms. The preva-
lence of occurrence of c-myc translocations increase as the disease advances to
late stages. In addition, p16 methylation occurs both as early change and some-
times later in progression. Activating mutations of N- and K-RAS appear to mark,
if not cause, the MGUS to MM transition in some tumors, but can also occur as
later progression events. Other late oncogenic changes include inactivation of
p18 and p53.
Altered gene expression in MM has also been analyzed by the use of gene
array. Several studies have now demonstrated distinct differences between gene
expression in plasma cells from bone marrow of patients with MM versus MGUS
and nonmalignant plasma cells. As it is not yet practical to assay gene expression
by array analysis for every patient, studies have tried to select genes whose
expression best correlates with outcome. For example, after adjusting for the
presence of chromosome 13 deletions detected by FISH and for the presence of
other chromosomal abnormalities three genes—RAN, ZHX-2, and CHC1L—
have correlated with early relapse. RAN, which maps to 6p21, is a member of the
Ras family of GTPase proteins and has a number of functions including transport
into and out of the nucleus, regulation of chromosome condensation, and cell-
cycle progression. The CHC1L gene (CHromosome Condensation 1-Like), maps
to 13q14.3, a region that has been suspected of harboring a tumor suppressor gene
for myeloma. ZHX-2 is a negative regulator of the transcription factor, nuclear
factor (NF)-NB, which is a transcriptional regulator of many genes involved in
cell cycle control. Increased expression of RAN predicted a high probability of
early relapse, especially with decreased expression of either ZHX-2 or CHC1L,
whereas increased expression of ZHX-2 and CHC1L predicted longer event-free
survivals. Recently, high-resolution genomic profiles were established for sub-
groups of multiple myeloma patients. In this analysis, 87 discrete minimal com-
mon regions were defined within recurrent and focal copy number alterations.
The chromosomal abnormalities in MM may have an impact on prognosis and
may predict response to therapy. An unfavorable outcome of MM has been
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associated with increased plasma cell labeling index, hypodiploid cytogenetics
compared with hyperdiploid states, monosomy and deletions of chromosome 13,
monosomy of chromosome 17, and altered cyclin D1 expression. Activating
mutations of K-Ras (but not N-Ras) also represent an adverse prognostic factor.
Specific IgH translocations also have a profound prognostic significance, with
shortened survival being seen with t(4;14) and with t(14;16) translocations
regardless of standard or high-dose therapy. On the other hand, patients with
MM who have a t(11;14) translocation appear to have a marginally better sur-
vival following conventional chemotherapy and to have a markedly better sur-
vival following intense therapy. Deletions of 13 q correlate with an increase of
proliferation and stage. Plasma cells in patients with 13q14 have increased ex-
pression of Ki67. At least 70% of patients with Stage III myeloma have 13q14
deletions compared with approx 50% of patients with Stage II, and have a lower
likelihood of being chemotherapy responsive (41% vs 78%) and a shortened
median survival (24 mo vs >60 mo).
Cyclins D1, D2, or D3 interact with cdk4 and/or cdk6 to regulate phosphory-
lation of retinoblastoma (Rb), facilitating the G1/S cell cycle transition. Recent
studies using gene array analysis of plasma cells from patients with myeloma
demonstrate that a substantial fraction of of cases of MM express increased
CCND1 in the absence of a t(11;14) translocation and that about 40% of MM
tumors bi-allelically express CCND1 mRNA. Therefore, a novel mechanism that
bi-allelically dysregulates CCND1 is a frequent oncogenic event in MM. Cyclin
D1 is expressed in most proliferating tissues, but with little or no expression of
CCND1 in lymphoid tissues or tumors. Presumably, biallelic expression of
CCND1 must be controlled by trans-acting factors, but the candidate factors that
increase cyclin D1 expression have not been identified. The expression levels of
cyclin D1, cyclin D2, or cyclin D3 mRNA in MM and MGUS cells are distinctly
higher than in normal plasma cells. The occurrence of Ig translocations that
dysregulate cyclin D1 or cyclin D3 contributes to about 20% of MM tumors.
Cyclin D1 is overexpressed in almost all tumors with t(11;14) translocation.
Additionally, cyclin D1 is overexpressed in nearly 40% of tumors lacking a
t(11;14) translocation, whereas cyclin D2 levels are overexpressed in most of the
remaining tumors. Therefore, it seems apparent that almost all MM tumors
dysregulate at least one of the cyclin D genes.
The dysregulation of one of the three cyclin D genes may render the cells more
susceptible to proliferative stimuli, resulting in selective expansion owing to
interaction with bone marrow stromal cells (BMSCs) that produce interleukin
(IL)-6 and other cytokines. In addition to the dysregulation of a cyclin D gene,
which appears to be a nearly universal event in early pathogenesis, there is
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evidence that the Rb pathway is further disrupted by p16INK4a methylation and
inactivation in a substantial fraction of MGUS and MM tumors. Further disrup-
tion of the Rb pathway by inactivation of Rb or p18INK4c can also occur at a
lower frequency and mostly as a late progression event. The frequency and
timing of other events, such as inactivation of phosphatase and tensin homolog
(PTEN), remain to be determined.
Genetic and growth-factor driven events that lead to myeloma occur not only
in the malignant plasma cell but also affect the bone marrow microenvironment.
During the evolution of myeloma, there is a subtle interaction of malignant
plasma cells with stroma, with various paracrine factors being generated by
the stroma that affect plasma cell function and various factors generated by the
plasma cells that affect the stroma. For example, under the influence of the
malignant clone of plasma cells, in particular the secretion of vascular endothe-
lial growth factor (VEGF), BMSCs secrete IL-6, insulin-like growth factor
(IGF)1, IL-1E, transforming growth factor (TGF)-E, and tumor necrosis factor
(TNF)-D. The secretion of IL-6 in turn increases release of VEGF by MM cells.
IL-6 is a major growth and survival factor for myeloma cells. IL-6 triggers signal
transduction through the mitogen-activated protein kinase cascade. IL-6 also
promotes survival of myeloma cells by upregulation of antiapoptotic molecules
such as BCL-x and c-Myc. Finally, IL-6 induction of VEGF has an adverse affect
on dendritic cell function and leads to the generalized decrease of Igs, which
characterizes myeloma and puts patients at risk for infection. The generalized
osteolytic activity that is observed in myeloma derives from the activation by
osteoblasts of the receptor activator of NF-N% ligand (RANKL) with a reduction
of the decoy receptor osteoprotegerin. As a consequence of the increased ratio
of RANKL to osteoprotegerin, osteoclast activity is increased and bone reab-
sorption occurs. In addition, IGF-1 is elaborated by stromal cells in response to
VEGF and other factors from the myeloma cells, and IGF-1 acts on the myeloma
cells through activation of Ras, stimulation of the PI3K and Akt pathways, and
inhibition of apoptosis by affecting phosphorylation of BCL2 family members.
5. DIAGNOSIS AND STAGING OF MM
The diagnosis of myeloma requires that the clinician be attuned to the present-
ing symptoms and signs of bone pain, anemia, infections, renal failure, and/or
hypercalcemia. The laboratory should be attuned to certain abnormalities on the
peripheral smear, namely rouleaux formation and the presence of a “bluish”
precipitate on the background staining of a blood smear. The radiologist should
be attuned to the classic “punched out” lesions in the skull (Fig. 16.1) and long
bones or diffuse osteoporosis that afflicts many patients with myeloma.
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The workup of a person suspected of having MM is summarized in Table 2.
This table also indicates parameters that are useful in following response to
therapy and/or relapse.
The bone marrow aspiration and biopsy is usually diagnostic with sheets or
syncitia of plasma cells (see Figs. 16.2 and 16.3). However, as the disease may
present with multiple plasmacytomas, the aspiration or biopsy of the marrow
between plasmacytomas may, on occasion, allow the marrow to appear normal.
Immunohistochemistry often is helpful with the identification of CD38- and 138-
positive cells that may be difficult to see on routine Wright stain. In addition, in
some patients, it may be of diagnostic importance to obtain flow cytometry,
examining for CD38 and 138 (syndecan) and plasma cell labeling index in
particular. Other markers that are helpful in diagnosis include CD10, which is
expressed in a subset of patients, in contrast to CD19 and CD20, which are
rarely expressed. CD28 and CD86 often occur with progressive disease. CD34
is not expressed and CD56 (N-CAM) is expressed in MGUS and plasma cell
leukemia but not in all cases of MM.
Fig. 16.1. Multiple myeloma with osteolytic bone lesions (lateral radiograph of the skull).
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The characteristic finding in patients with MM is a monoclonal protein in the
serum and/or urine, which in most (but not all) cases results in a spike in the
conventional serum electrophoresis (see Fig. 16.4). A clue to the presence of a
monoclonal gammopathy is an elevated total protein.
The clinician at all times must contemplate areas of possible complications of
the disease and the signs that these complications may cause. For example,
hypercalcemia may appear both at the time of diagnosis or as a sign of failure to
respond to therapy. The patient with hypercalcemia may present with polyuria,
polydypsia, and constipation; also, the sensorium may be muddled in these
patients, and end-organ failure, especially of renal function, may occur. Mul-
tiple causes of renal failure occur in myeloma and are often present at the time
of diagnosis. The precipitants of renal failure include hypercalcemia, hyper-
uricemia, infiltration of the kidneys with myeloma, precipitation of Igs in the
renal tubules, tubular dysfunction from light chain production, and amyloidosis.
Table 2
Workup of Suspected Multiple Myeloma
Parameter Rationale
History and physical examination Diagnosis, stage, determination of performance
status
CBC, differential count, platelelets Diagnosis, monitoring
BUN/creatinine, electrolytes Diagnosis, monitoring
including Ca++ and uric acid
SPEP and immunofixation Diagnosis, monitoring
Quantitative immunoglobulins Diagnosis, monitoring
24-h urine PEP and immunofixation Diagnosis, monitoring
Radiological skeletal survey Indicates possible need for local intervention
MRI Possible need for local intervention
PET imaging Staging, extent of disease (experimental)
Bone marrow aspirate and biopsy Diagnostic evaluation
(unilateral)
Cytogenetics including FISH Prognostic significance
E2-Microglobulin Parameter of response
C-reactive protein Parameter of response
LDH Parameter of response
Serum viscosity Parameter of response
CBC, complete blood count; BUN, blood urea nitrogen; SPEP, serum protein electrophoresis;
PEP, protein electrophoresis; MRI, magnetic resonance imaging; PET, positron emission
tomography; FISH, fluorescence in situ hybridization; LDH, lactate dehydrogenase.
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Fig. 16.2. Multiple myeloma. Dense infiltrate of neoplastic plasma cells.
Fig. 16.3. Multiple myeloma. Histological section of the bone marrow.
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Additionally, in some patients it may necessary to obtain an MRI for suspected
cord lesions or to identify a solitary plasmacytoma of the bone. MRI is more
sensitive than classic radiography to detect bone involvement of MM. An
example of an MRI of the thoracic spine involved with MM is shown in Fig. 16.5.
Recently, positron emission tomography (PET) imaging has been introduced
into clinical medicine for the staging of tumors. In MM, only a few cases have
been imaged by fluorodeoxyglucose (FDG)-PET, but it appears this imaging
technique is especially sensitive for highly proliferative myelomas. Hypervis-
cosity is usually seen with Waldenström’s macroglobulinemia; however, pa-
tients with high levels of IgG can present with symptoms of hyperviscosity
(altered state of consciousness, headaches, visual disturbances) and may respond
to vigorous plasmapheresis.
In assessing the workup of the patient with suspected myeloma, it is necessary
to distinguish between smoldering (asymptomatic) myeloma and symptomatic
myeloma. Smoldering myeloma is usually considered if the monoclonal protein
in the serum is greater than or equal to 3.0 g/dL and/or the bone marrow demon-
strates clonal plasma cells greater than or equal to 10% with no symptoms and
no related organ damage including absence of bone lesions.
Fig. 16.4. Multiple myeloma. Serum electrophoresis showing a monoclonal peak (para-
protein).
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The criteria generally used for diagnosis of symptomatic myeloma are noted
in Table 3.
Many years ago, Durie and Salmon determined three stages of MM based on
radiographic and clinical chemistry findings (see Table 4). This staging system
makes an estimate of the total body plasma cell mass and is widely used. Because
this classification relies on conventional bone radiographs which may be insen-
sitive for major bone disease and may not detect aggressive early disease, re-
cently an international study group proposed a new International Staging System.
A simple, three-stage classification was developed based on serum E2-
microglobulin (SE2m) and serum albumin (SA). Stage I is defined as SE2m less
than 3.5 mg/L and SA greater than or equal to 3.5 g/dL. Stage III is defined as
SE2m greater than or equal to 5.5 mg/L. The intermediate stage II applies to all
patients who are neither stage I or III. In the international survey of more than
10,000 newly diagnosed patients, the median survival in stage I was 62 mo, in
stage II 44 mo, and stage III 29 mo.
Fig. 16.5. Multiple myeloma. Magnetic resonance imaging (STIR) showing infiltration
of the upper thoracic spine.
Chapter 16 / MM and Related Paraproteinemias 283
Table 3
Diagnostic Criteria for Multiple Myeloma
Major criteria 1) Plasmacytomas
2) Bone marrow >30% plasma cells
3) Monoclonal Ig (IgG > 3.5 g/L or IgA > 2 g/L)
or N or O > 1 g/d in urine/24 h
Minor criteria 1) 1030% plasmacytosis
2) monoclonal Ig spike less than above
3) lytic bone lesions
4) normal IgM < 50 mg/dL, IgA < 100 mg/dL, or IgG < 600 mg/dL
Diagnosis Any two major criteria
Major criterion 1 plus minor 2, 3, or 4
Major criterion 3 plus minor criterion 1 or 3
Minor criteria 1, 2, and 3 or 1, 2, and 4
Table 4
Staging of Multiple Myeloma (According to Durie and Salmon)
Tumor cell burden
Stage Criteria (u1012/m2)
I All of the following: <0.6 (low)
Hgb >10 g/dL
Normal Ca++
Radiologically normal or only osteolytic lesions
Low concentrations of monoclonal protein
IgG < 5g/dL
IgA < 3 g/dL
Light chains in urine < 4 g/24 h
II Neither stage I or III 0.61.2 (intermediate)
III At least one of the following: >1.2 (high)
Hgb < 8.5 g/dL
Elevated Ca++
Advanced osteolytic bone lesions
High monoclonal protein levels
IgG > 7 g/dL
IgA > 5 g/dL
Light chains > 12 g/24 h
All stages are appended by A (renal function normal or slightly impaired) or B (renal function
impaired, creatinine > 2 mg/ dL). Hgb, hemoglobin.
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6. THERAPY OF MM
6.1. Stem Cell Transplantation
The decision to treat patients is based on the accuracy of the diagnosis, the
staging of the patient, and the presence of complications of the disease. There is
no evidence that treatment of asymptomatic smoldering myeloma is beneficial.
The median time to progression from smoldering to symptomatic myeloma is
about 23 yr. However, as there is a wide range as to when the disease will require
treatment, each patient requires an individual approach that involves monitoring
various laboratory parameters as well as patient symptoms. Because of the proven
efficacy of high-dose chemotherapy with subsequent autologous stem cell
transplantation (SCT), the approach to treatment can be divided between those
patients who are eligible for transplantation and those who are not (see Table 5 for
transplantation eligibility criteria).
High-dose therapy (HDT) with autologous SCT represents a significant
improvement in the treatment of myeloma. The mortality rate for autologous
SCT is about 12%, with the most widely used preparative regimen being
melphalan at a dose of 200 mg/m2. Most studies demonstrate a survival advan-
tage in individuals who undergo intensive therapy with rescue with autologous
SCT compared with those who undergo chemotherapy alone. Tandem (double)
autologous SCT allows for a second planned transplantation after recovery from
the first. Long-term event-free survival (EFS) is about 40% increased for those
who underwent a second transplantation compared with patients who underwent
a single procedure. The role of allogeneic transplantation in myeloma remains
experimental. Considering the age of patients on presentation, the availability of
human leukocyte antigen (HLA)-matched siblings, and end-organ failure, only
a minority of patients are candidates for allogeneic transplantation. The graft-vs-
myeloma effect of allogeneic transplantation was established without doubt, for
example in patients who relapsed with myeloma after a reduced-intensity trans-
plant and then were treated with donor lymphocyte infusions. Currently, pro-
tocols incorporating a full-intensity autologous and a reduced-intensity
allotransplant are under development. Another interesting idea is to immunize
Table 5
Transplantation Eligibility Criteria
Age <65 yr
Performance status 02
Concomitant diseases Normal cardiac and pulmonary function
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healthy donors with the isotype of the myeloma and then stimulate the immune
system further after an allogeneic transplant done in remission.
If patients with myeloma are eligible for (autologous) transplantation, a now
commonly used approach is to treat with thalidomide and dexamethasone before
stem cell harvesting (induction). The underlying assumption in this approach
is that stem cell function is not adversely affected and that the rate of response
is sufficient to allow most patients to undergo intense chemotherapy with stem
cell rescue. This approach spares potential damage to the stem cell. Four cycles
of treatment are usually given with doses of thalidomide 200 mg/d and 40 mg
dexamethasone per day on days 14, 912, and 1720 on odd cycles and days
14 on even cycles. Stem cells are harvested after the fourth cycle. With this
program, major responses (prior to high-dose chemotherapy and SCT, defined as
greater than or equal to 50% reduction in serum and urine M-protein) of over 60%
have been reported. The most common grade 3/4 toxicities include deep vein
thrombosis, constipation, rash, and infections.
The outcome of HDT has been evaluated in several ways. Complete remission
(CR) has been defined as true CR by negative immunofixation and as near CR
by the less-sensitive negative electrophoresis. In most series, CRs are signifi-
cantly more frequent after HDT than after chemotherapy (17–44% vs 515%).
The median EFS are always longer with HDT compared with chemotherapy (25
42 mo vs 1634 mo). It is more difficult to evaluate the effect of HDT on overall
survival (OS), as OS will be influenced by salvage therapies. However, signifi-
cantly increased OSs have been demonstrated in several trials, including the
British Medical Research Council (MRC) trial in which the OS was 54 mo after
HDT compared with 42 mo after chemotherapy alone. In all HDT studies, the
mortality rates were less than 5% and not significantly different from chemo-
therapy. The data strongly suggest that HDT is now the standard of care of
patients up to the age of 65 yr with newly diagnosed MM.
There are several prognostic variables that the clinician should keep in mind
when planning HDT. With both HDT and chemotherapy, standard biological
markers are important predictors of outcome. These include high levels of E2m,
C-reactive protein, or lactate dehydrogenase (LDH) and low levels of albumin,
all of which are associated with poorer outcome. Genetic abnormalities, as evalu-
ated either by conventional cytogenetics or by molecular biology techniques, are
also prognostic markers. Hypodiploid states, chromosome 13 deletions, and
14q32 translocations are all poor prognostic markers, with short EFS and OS.
6.2. Cytotoxic Drugs and Other Therapies
For patients who are not candidates for HDT or as alternative treatment pro-
grams to thalidomide and dexamethasone, a variety of chemotherapeutic regi-
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mens are available including VAD chemotherapy (vincristine, Adriamycin®
[doxorubicin], and dexamethasone) or melphalan and prednisone. Numerous
other treatment programs have been proposed. It is possible that no chemo-
therapy regimen is superior to melphalan and prednisone if SCT cannot be accom-
plished. In stage IIIB disease and with more aggressive-appearing myeloma, VAD
and VBMCP (Vincristine, BCNU [carmustine], melphalan, cyclophosphamide,
prednisone) are often used. Newer programs have also incorporated liposomal
doxorubicin (Doxil®), as this drug may have a lower incidence of myocardial
toxicity. The more common therapies are listed in Table 6.
Patients need to be carefully monitored for toxicity and efficacy of the chemo-
therapy and for evidence of complications of the myeloma. At a minimum the
monitoring must include the parameters of response listed in Table 2. If there is
no response to therapy when these parameters are reviewed every two cycles it
may be worth considering an alternate therapeutic intervention, bearing in mind
that the number of approaches is relatively limited. The treatment plan may have
to be changed because of drug toxicities. For example, severe neuropathy may
dictate modification of the dose of vincristine whereas psychiatric symptoms or
the appearance of difficult-to-control diabetes may dictate that dexamethasone
is eliminated. The clinician must be astute to the clinical manifestations of
Table 6
Treatment Regimens for Multiple Myeloma
Regimen Doses
Melphalan and prednisone Every 6 wk,
Melphalan 810 mg p.o. d 1–7
Prednisone 60 mg d 1–7
VBMCP Every 5 wk
Vincristine
Carmustine
Melphalan
Cyclophosphamide
Prednisone
VAD Every 4 wk
Vincristine
Doxorubicin
Dexamethasone
Second-line therapy
Bortezomib 1.3 mg/m2 on d 1, 4, 8, 11 every 21 d
Thalidomide 100200 mg p.o. for maintenance
300400 mg p.o. for refractory or relapsed myeloma
(if tolerated)
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hypercalcemia (hyperdypsia, polyuria, and constipation) and treat hypercalce-
mia aggressively with bisphosphonates such as zoledronic acid. However, as in
most patients, zoledronic acid is used prophylactically (see “Bone Diseases and
Bone Pain”) to prevent bone fractures and pain, and the occurrence of hypercal-
cemia is not as frequent as previously seen. The major cause of death in myeloma
is infection (see below) and all febrile episodes must be investigated and appro-
priately treated.
A number of agents for the treatment of myeloma are now available that are
not typical chemotherapeutic drugs. These novel therapies include thalidomide
(Thal) and more potent analogs, the proteasome inhibitor bortezomib (Velcade®),
and arsenic trioxide (As2O3). Thal was proposed as a potential therapy for my-
eloma because of its known antiangiogenic activity and the demonstration of
increased angiogenesis in the involved bone marrow of patients with myeloma.
Thal and its analogs such as lenalidomide have other actions including the induc-
tion of G1 growth arrest of myeloma cells, the prevention of adhesion of myeloma
cells to BMSCs, and the enhancement of natural killer (NK) cell number and
activity against myeloma cells. The net result of these actions is decreased pro-
duction by the bone marrow stroma of IL-6 and VEGF with a resulting decreased
stimulation of myeloma cells and of neo-angiogenesis. Hence, Thal acts in part
as an immunomodulator and in part as an anticytokine and has been observed to
generate a significant response rate either as first-line or second-line therapy.
Analogs of Thal, such as lenalidomide, are far more potent stimulators of NK cell
and T-cell co-stimulatory activity as well as stimulators of IL-2 and interferon
(IFN) production, and may prove to be more efficacious than Thal. Thal is being
explored in combination with other agents such as melphalan and preliminary
studies in elderly patients suggest a high level of activity. Thal has activity in
advanced and refractory myeloma. In a recent randomized, long-term study,
Thal was added to high-dose therapy. The frequency of complete responses was
increased and the event-free survival was extended, but the overall survival was
not improved. In addition, more than 20% of patients on Thal had adverse events
such as thrombosis or neuropathy.
Bortezomib (Velcade®) is a proteasome inhibitor and represents a novel class
of therapeutic agents that also target the myelomaBMSC interaction. NF-NB is
a transcription factor whose activity is important in stimulating IL-6 production
both in the myeloma cell and in the bone marrow stroma. IL-6 production stimu-
lates the growth and survival of myeloma cells. Cellular levels of NF-NB are
controlled by the binding of inhibiting factor (IF)-NB, the levels of which are in
turn controlled by catabolism via the proteosome. By inhibiting the proteasome,
IF-NB remains bound to NF-NB and NF-NB remains inactive. Bortezomib has
been shown to induce apoptosis of myeloma cells resistant to known conven-
tional therapies and is synergistic in the antimyeloma effects of dexamethasone.
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The net effects of bortezomib are to prevent the binding of myeloma cells to the
BMSCs, inhibit the expression of IL-6 that is triggered by myelomastromal
interactions, and reduce angiogenesis. These clinically relevant actions result
from downregulation of growth/survival signaling pathways and upregulation of
apoptotic pathways as well as upregulation of the proteasome pathway. The
efficacy of bortezomib as a single agent was shown in heavily pretreated patients
with myeloma, with about 10% achieving CR and an OS of 35%. Based on
preclinical studies, dexamethasone was added, with considerable additional
benefit. Responding patients were noted to have improved hemoglobin levels
and renal function, decreased blood transfusion requirements, and an increase in
the levels of the uninvolved Igs. The major toxicities of bortezomib are signifi-
cant thrombocytopenia and neuropathy. A number of trials are being conducted
with bortezomib in newly diagnosed myeloma patients or using bortezomib as
a second-line agent either alone or in combination with other agents, such as
pegylated liposomal doxorubicin, melphalan, and Thal.
As2O3 also targets the myeloma cellbone marrow stroma interaction. As2O3
induces apoptosis, adds to the efficacy of dexamethasone, and inhibits the
antiapoptotic actions of IL-6. In addition, As2O3 decreases binding of myeloma
cells to the bone marrow stroma and inhibits the secretion of IL-6 and VEGF
induced by the adhesion of myeloma cells.
6.3. Maintenance Therapy
The decision to initiate maintenance therapy depends in part on how long
induction therapy is continued. With melphalan and prednisone, therapy is con-
tinued until there is a plateau of the monoclonal protein that is being monitored.
In general, this means that patients are treated from 6 to 12 mo. For the more
aggressive therapies such as VAD, assessment of response should be done after
two cycles. There are few data to support the use of VAD beyond four cycles. It
is extremely important to monitor responses, and if minimal headway is made
either in symptoms (e.g., bone pain), signs (e.g., anemia, neutropenia, and/or
thrombocytopenia), or in the monoclonal protein, then therapy must be reas-
sessed and changed. There is an insufficient database from which to gauge the
appropriate length of treatment with new agents such as bortezomib, Thal, or
As2O3. In trials with bortezomib, the drug was used for a total of 29 wk. Thal has
been used continuously, with the drug stopped for toxicity or disease relapse.
Although a plateau phase can be achieved with chemotherapy, this apparent
quiescent state is unlike that of MGUS or smoldering MM in that virtually all
patients with MM will relapse. There is no evidence that continued chemo-
therapy is of benefit in preventing relapse. There are data suggesting that contin-
ued exposure to chemotherapy will increase resistance and may lead to the
development of myelodysplasia and/or acute leukemia.
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There have been trials of IFN-D and prednisone for maintenance therapy. A
meta-analysis of trials comparing IFN with no maintenance treatment demon-
strated delay of time to progression of 6 mo, with an estimated overall increase
in median survival of approx 4 mo. This efficacy must be balanced by the con-
siderable toxicity of the IFN, which is used at an initial dose of five million units
subcutaneously three times per week, with the dose reduced for side effects. Over
50% of patients reduce the dose because of toxicity.
The efficacy of prednisone for maintenance therapy has been evaluated in a
randomized trial of patients who received and responded to induction therapy
with VAD. Maintenance treatment with 50 mg of prednisone p.o. every other day
compared with 10 mg p.o. every other day resulted in beneficial effects both in
progression-free survival (14 vs 5 mo) and OS (37 vs 26 mo) for the higher-dose
regimen. As all of the patients responded to a regimen containing a glucocorti-
coid, it is not known if responders to other chemotherapies would also benefit
from prednisone maintenance.
7. COMPLICATIONS OF MM
7.1. Renal Failure
There are two major categories of causes of renal failure: one related to the
metabolic consequences of myeloma and the other directly related to the Ig
products of the myeloma cells. The metabolic causes of renal failure include
hypercalcemia and hyperuricemia. It is not unusual for patients to present with
elevated serum calcium or for elevated calcium to be an early sign of disease
progression. Hence, serum calcium must be part of the initial workup and
included in the routine surveillance of patients. As the serum albumin will
decrease with an increase in tumor load, patients who present with high-stage
myeloma or who have relapsed will be hypoalbuminemic, and the serum calcium
levels will have to be adjusted. Hypercalcemia leads to renal failure by producing
renal vasoconstriction and by direct intratubular calcium deposition. Elevated
filtered calcium may also potentiate the toxicity of filtered light chains. The
clinician must also be cognizant of symptoms caused by hypercalcium (namely,
polyuria and polydypsia, which result from nephrogenic diabetes insipidus),
constipation, and an altered sensorium. The renal failure induced by hypercalce-
mia is generally reversible. Immediate treatment is directed at lowering the
serum calcium, and should include isotonic saline with a loop diuretic and
bisphosphonates. The underlying disease must also be treated. If renal failue is
severe, placing the patient in a poor performance status, the patient can be treated
with high-dose decadron and more definitive therapy instituted as the perfor-
mance status improves. The cell turnover in myeloma, especially with high-stage
disease, can lead to production of large amounts of uric acid and result in the
deposition of urate crystals in the kidney.
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Renal failure may also be the result of direct infiltration of the kidney with
myeloma cells. But far more commonly, renal disease in MM results from the
toxicity of the Igs being synthesized by the myeloma cells, especially the over-
production of monoclonal Ig light chains, which can lead to cast nephropathy,
primary amyloidosis, and light chain deposition disease (LCDD). Detection of
light chains in the urine is an essential part of the initial workup of a patient
suspected of having a plasma cell dyscrasia. Light chains cannot be detected by
the common urinary dipsticks, which detect albumin, but should be quantitated
with immunoelectrophoresis and immunofixation techniques. The kidney has a
large capacity for catabolism of light chains. However, some light chains have
properties that make them nephrotoxic. In vitro, light chains from patients with
renal failure aggregate to form high-molecular-weight complexes, and it is
hypothesized that these aggregates lead to tubule cast formation. Other prop-
erties of light chains are important. Most patients with primary amyloidosis have
O light chains, whereas individuals with LCDD usually have N light chains. Light
chains filtered into the tubules can produce renal failure either by intratubular
cast formation or direct tubular toxicity. Precipitated light chains lead to
intratubular cast formation with obstruction, especially in the distal and collect-
ing tubules. The cast formation may be accelerated by the binding of the light
chains to the Tamm-Horsfall mucoprotein, a protein excreted by the tubules, and
which is commonly found in the casts of patients with myeloma kidney. In other
patients, light chains are absorbed by the renal tubule cells and are not catabo-
lized by lysozymes, but instead crystallize in the tubule cell, causing tubular
dysfunction and renal failure. Renal failure can also occur either from LCDD or,
less commonly, from heavy chain deposition disease (HCDD). In these cases,
light chains or, occasionally, fragments of heavy chains are deposited on the
basement membrane of the tubules, Bowman’s capsule, and glomeruli.
7.2. Bone Disease and Bone Pain
Patients with MM commonly present with bone pain in association with ane-
mia. The interaction of the myeloma cells with the bone marrow stroma results
in the activation of osteoclasts and the inhibition of osteoblasts by many mecha-
nisms. The net result of the increased osteoclastic activity is that most patients
have significant osteoporosis. Skeletal surveys done at the time of diagnosis
demonstrate that osteoporosis is present in nearly 80% of patients and that focal
lytic lesions can be found in about half of the patients, with pathological frac-
tures, including compression fractures of the spine, in about one-fith of the cases.
The increase in bone resorption is the result of an increase in the number and
activity of osteoclasts combined with inhibition of osteoblastic activity. A
number of factors are involved in these processes, including IL-1, TNF-D, IL-6,
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IL-1E, lymphotoxin, TNF, IL-3, vascular cell adhesion molecule-1, receptor
activator of NF-NB (RANK), and RANKL (also known as osteoclast differentia-
tion factor and osteoprotegerin ligand). In addition to diffuse osteoporosis, at the
site of plasmacytomas within the bone marrow the presumed high concentration
of these factors locally gives rise to the classic “punched out” or lytic lesions of
myeloma. The interactions between myeloma cell and stroma that result in
increased bone resorption also provide a microenvironment that is conducive
to the proliferation and survival of myeloma cells. For example, the IL-6 and
osteopontin as well as the other factors will promote myeloma cell growth.
The result of these processes is that patients are at risk for small cortical
fractures from the diffuse osteoporosis and significant fractures from the larger
osteolytic lesions. The approach to the treatment of the ensuing pain from either
type of lesion has been to first insure that a critical bone, for example a femoral
head, is not imminently going to fracture, in which case prophylactic treatment
must be instituted. Patients should be started on primary therapy for the myeloma,
and one measure of response will be a decrease in the degree of pain. Simulta-
neously, appropriate analgesia should be instituted, and a decrease in dose with
time serves as another good measure of the efficacy of primary therapy. If pain
persists or if a lesion seems to pose the threat of imminent fracture, then radiation
therapy should be instituted. It is imperative that the painful areas be well circum-
scribed so that the radiation ports are delimited. Such an approach will limit
radiation to bone marrow-bearing sites and prevent bone marrow compromise,
which could lead to a limited tolerance for future chemotherapy. It is wise to
consult with the orthopedic surgeon at this point to determine whether concurrent
stabilization of the bone is required.
A marked change in the handling of bone disease has occurred with the use of
bisphosphonates for the treatment and prevention of osteoporosis in MM as well
as other malignancies, such as breast cancer and prostate cancer, in which bone
disease plays a major role in morbidity. The use of bisphosphonates prevents
skeletal complications and is extremely useful both in breast cancer and prostate
cancer in the prevention of treatment-related bone loss, and possibly in delaying
skeletal progression. Randomized controlled trials have demonstrated that oral
clodronate and intravenous pamidronate and zoledronic acid are superior to
placebo in reducing skeletal complications, with a reduction also seen in verte-
bral fractures. The mechanism of action of the bisphosphonates in myeloma is
not clear. Pamidronate has been shown to decrease bone resorption, and this
effect correlates with improvement in pain. The American Society of Clinical
Oncology has published guidelines on the use of bisphosphonates. The recom-
mendation is to use intravenous pamidronate or zoledronic acid, as these two
agents have been demonstrated to delay the time to first skeletal event, and as
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clodronate is not available in the United States. The choice between pamidronate
or zoledronic acid is made based on convenience (pamidronate has a 90-min infu-
sion time vs 15 min for zoledronic acid) and cost (pamidronate is less expensive).
7.3. Infectious Complications
Patients with myeloma are highly susceptible to bacterial infections, which
are a leading cause of morbidity and mortality in this disease. The most common
sites of infections are the lungs and kidneys, with the most common pathogens
being Streptococcus pneumoniae, Staphylococcus aureus, and Klebsiella
pneumoniae in the lungs and Escherichia coli and other Gram-negative organ-
isms in the urinary tract. The etiology of the increase in infections is multifold.
First, all patients with myeloma have a progressive decrease of normal Igs and,
hence, decreased titers of opsonins. Interestingly, with treatment with nonclas-
sical drugs such as thalidomide, restoration of normal Igs may be seen. In addi-
tion, patients may be neutropenic because of the myelophthisic effect of the
myeloma in the marrow, suppressing normal myeloid differentiation. Finally,
patients may be neutropenic from chemotherapy. A reasonable approach in newly
diagnosed patients or after patients have had one infectious episode is to vacci-
nate patients with pneumococcal and influenza vaccines. Prophylactic antibiot-
ics may also be used. Certainly, after a single or recurrent pneumococcal infection,
daily oral penicillin would be of benefit. Prophylactic use of thrice-weekly oral
trimethoprim/sulfamethoxazole may also be helpful. Intravenous Ig (IVIg) may
be given if IgG levels minus the monoclonal protein are less than 500 mg/dL,
with the intent of infusing IVIg often enough to maintain the IgG levels at more
than 500 mg/dL. J-Globulins may be beneficial for patients with recurrent infec-
tions, but the administration is inconvenient and expensive.
7.4. Anemia
Anemia is commonly observed in myeloma and has several causes. Clearly,
marrow infiltration will decrease erythropoiesis. In addition, cytotoxic drugs
will further impede marrow function and renal failure will decrease erythropoi-
etin production. Several studies have demonstrated the efficacy of administering
erythropoietin, both in its ability to increase the hemoglobin and also in the
resultant improvement in the quality of life. The patient should be evaluated to
determine other possible causes of anemia, including iron levels. A common
approach is to use erythropoietin 40,000 units weekly, escalating the dose if no
response is seen. If iron stores appear low, then oral iron supplementation or
ferrous gluconate can be given intravenously. The clinician should aim to main-
tain a hemoglobin level of about 1012 g/dL.
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8. AMYLOIDOSIS
Amyloidosis is a multisystem disorder that frequently involves the heart,
kidneys, liver, skin, subcutaneous tissues, nerves, and other organs. Amyloidosis
is characterized by the deposition of amyloid fibrils. All forms of amyloid are
derived from a particular folding of a protein, have green birefringence under
polarized light, and stain positive with Congo red. The most common form,
amyloid L (AL) or light chain amyloidosis, is derived from the deposition of
monoclonal light chains. Less common is secondary amyloidosis (or amyloid A
amyloidosis), which is observed in chronic infectious or inflammatory disorders.
Light chain amyloidosis is associated in only about 10% of cases with frank MM.
Rare forms of amyloidosis are heredofamilial forms of amyloidosis, localized
amyloidosis, and amyloidosis associated with certain neurodegenerative disor-
ders. Systemic amyloidosis should be suspected in nephrotic range proteinuria,
unexplained heart failure, peripheral neuropathy in patients without diabetes,
unclear hepatomegaly, or a combination of these findings. If AL amyloidosis is
a possible diagnosis, the serum and urine should be screened for monoclonal
light chains by immunofixation and free lights should be measured by the free
light chain assay. Interestingly, O light chains are a more frequent cause of AL
amyloidosis than N light chains. A tissue biopsy for amyloid can be obtained from
many organs, but a bone marrow biopsy and a biopsy of subcutaneous fat are
recommended, as these have both a low risk and a high diagnostic yield. The
clinical manifestations of amyloidosis are multiple and protean. Most patients
suffer from fatigue. Kidney disease, often with massive proteinuria, is present in
most patients. Many patients develop congestive heart failure. Echocardiography
shows a biventricular thickening and hypokinesia. A typical finding in advanced
cases is “granular sparkling” of the interventricular septum. Other clinical find-
ings are hepatomegaly, orthostatic hypotension, macroglossia, peripheral neur-
opathy, thickening of muscles (“shoulder pad” sign), and malabsorption. The
prognosis of AL amyloidosis was poor in most cases until now. Heart failure
especially is a sign of poor prognosis (median survival 6 mo or less). Serum
troponin and brain natriuretic peptide are serum markers of cardiac failure and
portend a poor prognosis if elevated. More recently, it was shown that high-dose,
melphalan-based chemotherapy with stem cell rescue improves the prognosis of
patients with early amyloidosis. Major complications, including death from trans-
plantation, occurred mainly in older patients and in patients with advanced heart
failure or the involvement of multiple organs. In good- to average-risk patients,
a transplant-related mortality of 1015% was observed. At least 50% of patients
had a clonal response to high-dose chemotherapy, including complete responses.
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All patients with amyloidosis need symptomatic treatment of heart failure, kid-
ney failure, and gastrointestinal complications. Patients with progressive renal
failure need dialysis. Selected patients with end-stage renal disease may benefit
from kidney transplantation. An alternative to high-dose therapy may be dexam-
ethasone pulses. Patients in poor performance status may stabilize when treated
with melphalan-prednisone pulses. Experimental therapies for amyloidosis in-
clude proteasome inhibitors, thalidomide analogs, and inhibitors of TNF-D.
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1. INTRODUCTION
The development of the immune system and its function are outlined in Chap-
ter 1. Congenital immunodeficiencies are rare; more details can be found in
pediatric textbooks. Here, only the most important entities are discussed. Acquired
immunodeficiencies are observed in many lymphoproliferative disorders and
during treatment with steroids or chemotherapy with cytostatic drugs. The defi-
ciency of cellular immunity induced by HIV infection is a common problem in
many countries. In this chapter, we describe only some hematological conse-
quences of HIV infection.
The following are common tests of immune defense or immune status of an
organism. These tests are indicated if a patient has frequent infections—bacte-
rial, fungal, viral, or protozoan. Which tests are used depends on the clinical
situation and the type of particular immune defect suspected.
1. Blood count with white cell differential count, flow cytometry: this permits
exclusion of morphological abnormalities (e.g., a granulation defect of granu-
locytes). Full blood counts of lymphocyte, neutrophil, and eosinophil numbers
are helpful. The mononuclear cell populations can be further differentiated and
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analyzed with monoclonal antibodies (see Appendix 2, “CD Nomenclature”).
This can be done both with flow cytometry or immunocytochemistry.
2. Functional studies of granulocytes and monocytes: chemotaxis (Boyden
chamber), phagocytosis, bactericidal capacity, nitroblue of tetrazolium reduc-
tion, myeloperoxidase activity, CD18 expression.
3. Studies of humoral immunity: serum immunoglobulins (Igs) (IgG, IgA, IgM,
IgE, IgG, subclasses), isohemagglutinins (not helpful in blood type AB patients),
complement levels, components of the complement cascade, levels of specific
antibodies, e.g., IgG antivaccine levels: pneumococcus, tetanus, and diphtheria
(depends on immunization history). In vivo studies can be done by immunizing
with specific antigens (e.g., tetanus toxoid). Ig synthesis is tested in vitro by
incubating B-lymphocytes with certain mitogens.
4. Studies of cellular immunity (lymphocyte subpopulations, see Item 1).
– In vitro: stimulation of lymphocytes with mitogens and antigens, production
of cytokines such as interleukin (IL)-2 or granulocyte-macrophage colony-
stimulating factor, cytotoxic activity of T-cells, activity of natural killer (NK)
cells, antibody-dependent cellular cytotoxicity activity. Measurements of T-
cell effector cytokine production.
– In vivo: skin tests (purified protein derivative [PPD], tetanus, streptokinase,
Candida, and other antigens). Sensitization with dinitrochlorobenzol.
5. Further studies: sedimentation rate, total serum protein, serum electrophoresis,
complement factors (total complement, CH50), classical and alternate pathway,
global tests of complement (if complement defect is suspected).
2. CONGENITAL IMMUNODEFICIENCIES
Congenital immunodeficiencies are subdivided into the following:
• Defects of the phagocytic system (see Table 1).
• Defects of combined immunodeficiencies (see Table 2).
• Defects of humoral immunity (Ig synthesis) (see Table 3).
• Defects of cellular immunity (see Table 4).
• Defects of complement components (see Table 5).
Most congenital immunodeficiencies manifest themselves within the first 2
months of life. A defect of humoral immunity often becomes apparent several
months later when Igs transferred via the placenta disappear. Tables 1–4 also
indicate the clinical features and the treatment of these immunodeficiency states.
The group of complement deficiencies (C1–C9) has autosomal-recessive inher-
itance and, in some cases, is associated with frequent infections. Some patients
with complement defects suffer from autoimmune disorders. The majority of the
congenital immunodeficiencies have autosomal- or X-linked-recessive inherit-
ance. Only four congenital immunodeficiencies appear to have dominant inher-
itance: isolated congenital asplenia, hyper-IgE syndrome, isolated chronic
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Table 1
Congenital Defects of the Phagocytic System
Disease Defect Symptoms Treatment
Chronic granulomatous Defect of bactericidal Abscess forming infections Symptomatic, interferon γ
 disease capacity (oxidative metabolism)
Defect of Enzyme defect Asymptomatic or frequent No treatment or antimycotic
myeloperoxidase infections with Candida
Defect of adhesion Chemotaxis, phagocytosis Frequent bacterial infections, Symptomatic
molecules  sepsis
Chediak-Higashi Giant granules in neutrophils, Severe bacterial infections Symptomatic or bone
syndrome functional defect marrow transplant (BMT)
Hyper-IgE syndrome Chemotaxis Cutaneous infections, Symptomatic
(multisystem disorder) candidiasis
Reticular dysgenesis Defect of hematopoietic stem cell Lethal within first 3 mo BMT (?)
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Table 2
Congenital Defects of the B- and T-Cell Systems (Combined Immunodeficiency)
Disease Defect Symptoms Treatment
Severe combined immunodeficiency B- and T-cells Severe intestinal and BMT, infusions of ADA
pulmonary infections (gene therapy; see also
Chapter 2)
Hyper-IgM syndrome CD40-ligand defective Pyogenic infections, Symptomatic
lymphoproliferative
syndrome
Defect of major histocompatibility Transcription Severe infections BMT
complex expression
Ataxia telangiectasia Cellular immunity Neurological disturbances, Symptomatic
(IgA, IgE deficiency)  lymphatic malignancies
(defective ATM gene,
cell cycle regulation,
and DNA repair defective)
BMT, bone marrow transplantation; ADA, adenosine deaminase; Ig, immunoglobulin.
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Table 3
Congenital Defects of Humoral Immunity
Disease Defect Symptoms Treatment
X-linked agammaglobulinemia No mature B-cells present, Relapsing infections of sinuses Immunoglobulins (Igs)
(type Bruton) T-cell defect and bronchi, diarrhea
Common variable Heterogeneous, usually Pyogenic infections, autoimmune Igs
immunodeficiencies in B-cells  disorders, malignancies
(manifestation often after
puberty)
Transient immunoglobulin Delayed synthesis Infections Symptomatic
deficiency of newborns
IgA deficiency IgA synthesis defective Gastrointestinal disturbances, Symptomatic
anaphylactic reactions to
transfusions
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Table 4
Congenital Defects of Cellular Immunity (T-Cell System)
Disease Defect Symptoms Treatment
Di George syndrome Cellular immunity Abscess forming infections, Transplantation of fetal thymus,
(thymic hypoplasia,  hypocalcemia, malignancies bone marrow transplant (BMT)
cardiac malformations,
impaired development
Purine nucleoside Cellular immunity Variable, infections (symptoms BMT, enzyme replacement
phosphorylase deficiency start between 3 and 18 mo)
Wiskott–Aldrich syndrome Cellular immunity Infections, thrombocytopenia, BMT
eczema, low immunoglobulin M
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Table 5
Congenital Defects of Complement Components
Disease Inheritance/Defect Presentation Laboratory findings
C1 deficiency Autosomal recessive, Pyogenic (neisserial) infections, Abnormal total hemolytic
nonfunctional, or SLE-like syndromes complement
absent protein/1p36.3,
12p13
C1 inhibitor deficiency Autosomal dominant/11q11 Physical trauma-induced Nonfunctional or diminished C1
hereditary angioedema inhibitor levels
Factor I, H, D, Autosomal recessive Pyogenic (neisserial infections, Abnormal TH50, AH50, properdin
properdin deficiency (properdin is X-linked)/ urticaria, immune complex  levels
factor I-4q25, H-1q32,  disease; H: hemolytic uremic
D-?, Properdin-Xp11.4  syndrome)
C2 deficiency 6p21.3 50% asymptomatic; pyogenic
infections, vasculitides
(SLE, HSP)
C3 deficiency Autosomal recessive/ 19p13.3 Pyogenic (neisserial infections, Low C3 levels
urticaria, immune complex
disease)
C4 deficiency Autosomal recessive/ 6p21.3 SLE, CVID, IgA deficiency, Low C4 levels
auto-immune disease
SLE, systemic lupus erythematosus; HSP, Henoch-Schonlein purpura; CVID, common variable immunodeficiency; IgA, immunoglobulin A.
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mucocutaneous candidiasis, and Di George syndrome (DGS; which is associated
with deletions on chromosome 22q11.2 and may involve several genes). Several
newly described immunodeficiency syndromes have autosomal-dominant in-
heritance. The pathogenesis of these and other syndromes was elucidated re-
cently. Isolated congenital asplenia is often asymptomatic in early childhood and
manifests itself by sudden overwhelming infections. The diagnosis of asplenia
can be made by ultrasound showing the absence of a spleen and peripheral blood
smears showing Howell-Jolly bodies. In the WHIM syndrome (warts, hypo-
gamma-globulinemia, infections, and myelokathexis), patients have an abnor-
mality of the chemokine receptor CXCR4. Patients with WHIM syndrome suffer
from common bacterial infections and display a defect in the maintenance of
memory B-cells. Both in the partial interferon gamma receptor 1 (IFNγR1) de-
ficiency and in the partial signal transducer and activator (STAT)1 deficiency,
patients suffer from infections by mycobacteria and Salmonella. Deletions or
missense mutations of the respective genes lead to abnormal signal transduction.
Anhydrotic ectodermal dysplasia with immunodeficiency has X-linked inherit-
ance in most cases. Patients with this condition suffer from severe infections with
Gram-positive bacteria. Recently, the responsible gene was identified as NEMO/
IKKγ, which leads to impaired NF-κB activation in response to various recep-
tors. As described in Table 3, in Bruton’s agammaglobulinemia, no mature B-
cells are present. Bruton’s agammaglobulinemia is caused by mutations in the
gene encoding Bruton tyrosine kinase.
2.1. Severe Combined Immunodeficiencies
Patients with severe combined immunodeficiencies (SCIDs) exhibit profound
disturbance in function of both T- and B-cells (see Table 2). They develop recur-
rent, severe, life-threatening infections (bacterial, viral, fungal), intractable
diarrhea, and failure to thrive in early infancy. Opportunistic infections are
common. Approximately 20 defective genes have now been identified as asso-
ciated with SCIDs, classified according to the specific mutation present, the
associated lymphocyte phenotype, and type of inheritance. Early diagnosis and
immune reconstitution by stem cell transplant (SCT) is critical.
X-linked form (termed X-linked SCID or XSCID), which is due to a mutation
in the IL2RG gene, is the most common form of SCID. It is present in 44–50%
of cases in the United States. This mutation leads to an abnormality in the “com-
mon” gamma chain (γc) receptor shared by several cytokine receptors (including
interleukin [IL]-2, IL-4, IL-7, IL-9, IL-15, and IL-21). The lack of γc leads to
early arrest of T-cell and natural killer (NK)-cell development and to the produc-
tion of immature B-cells. The lymphoid tissue and thymus develop poorly. SCT
without myeloablation is indicated because the disease is lethal without therapy.
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Gene therapy for XSCID is currently on hold, as a result of leukemia developing
in two of these patients (see Chapter 2). Patients with an autosomal recessive
mutation in the α-chain of the IL-7 receptor also have severe immunodeficiency;
however, both NK- and B-cell numbers are normal in these patients. An auto-
somal recessive mutation in the JAK3 enzyme, a tyrosine kinase associated
with γc required for signal transduction, lead to a similar phenotype in 8% of
patients with SCID.
Adenosine deaminase (ADA) deficiency is the most common form of SCID
with autosomal recessive inheritance, seen in approx 15% of patients with SCID
(see Table 3). This and another milder and very rare disorder, purine nucleoside
phosphorylase (PNP) deficiency, are the only disorders of nucleotide synthesis
resulting in immunodeficiency. These purine salvage pathway defects lead to
increasing lymphopenia due to metabolic self-poisoning of these cells by
byproducts (5'-triphosphates) of deoxyadenosine and deoxyguanosine, usually
within the first few months of life, and about 15% are symptomatic later in
childhood. ADA activity of less than 2% of control or mutations in both alleles
of ADA must be present in order to diagnose this condition. Skeletal abnormali-
ties (cupping and flaring of the costochondral junctions) are seen in 50% of
patients with ADA deficiency, and there may also be associated hepatic, renal,
and neurological abnormalities. Enzyme replacement therapy with percutaneous
endoscopic gastrostomy (PEG)–bovine ADA can lead to partial immune recon-
stitution. Red blood cell (RBC) transfusions help patients with ADA deficiency
(and not with PNP deficiency), as RBCs are rich in ADA. Gene therapy has been
successful.
Defects in the recombinase-activating genes, RAG1 and RAG2 leads to an early
arrest of lymphocyte development. Thirty percent of SCID patients manifesting
RAG1 or RAG2 mutations account for the majority of patients with autosomal
recessive type T(–)B(–)NK(+) SCID. During the process of Ig and T-cell receptor
gene recombination in differentiating lymphocytes, the RAG proteins introduce
DNA double-stranded breaks, which are repaired via nonhomologous end join-
ing. Clinical manifestations are similar to those seen in XSCID. Omenn syndrome
(OS) is caused by a partial loss of function in RAG1 or RAG2, and has an early
onset associated with severe infections, diarrhea, erythroderma, lymphadenopa-
thy, and hepatosplenomegaly. T-cell function is markedly defective in OS; how-
ever, increased IgE levels and eosinophilia are characteristic of this syndrome.
2.2. Antibody Deficiencies
2.2.1. DEFECTS OF B-CELL MATURATION
Abnormalities in B-cell maturation and function result in impaired Ig produc-
tion and antibody deficiency. This leads to recurrent bacterial infections in the
first year of life, including otitis, sinusitis, and pneumonia, and these may mani-
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fest soon after the loss of maternal IgG antibodies. The respiratory tract, skin, and
gastrointestinal tract are the common sites of infection. Patients with significant
defects in B-cell development require Ig replacement and sometimes prophylac-
tic antibiotics.
2.2.2. X-LINKED AGAMMAGLOBULINEMIA
X-linked agammaglobulinemia (XLA) is the most severe of the antibody
deficiency syndromes (see Table 3) and is due to a mutation in the gene for a
cytoplasmic (Bruton’s) tyrosine kinase (BTK). It was described in 1993. Muta-
tions of BTK impair B-cell receptor signaling and lead to the maturational arrest
of B-cells. More than 400 different mutations in BTK have been described, most
resulting in absent BTK protein due to unstable BTK mRNA or protein; 30% of
these mutations are sporadic. Most patients with XLA have profoundly decreased
peripheral B-cells, virtually undetectable serum Ig, and hypoplastic or absent
lymphoid tissue. T-cell numbers and function in XLA are normal, although
severe viral infections, such as with enteroviruses, may result in meningoen-
cephalitis. Patients with XLA are exempt from autoantibody-driven autoim-
mune disease. The median age at presentation for patients with sporadic XLA
was 26 mo in a recent study, whereas the age at presentation in patients with
familial disease is more variable. Male patients have less than 2% CD19+ B-cells
and at least one of the following criteria is required for definitive diagnosis: (1)
mutation in the BTK gene; (2) absent BTK mRNA on Northern blot analysis of
neutrophils or monocytes; (3) absent BTK protein in monocytes or platelets; (4)
maternal cousins, uncles, or nephews with less than 2% CD19+ B-cells.
2.3. B-Cell Defects of Unknown Cause
2.3.1. COMMON VARIABLE IMMUNODEFICIENCY
Common variable immunodeficiency (CVID) is a heterogeneous group of
distinctly separate disorders resulting in hypogammaglobulinemia with sporadic
inheritance in most cases (see Table 3). The prevalence is approx 1 in 30,000 to
50,000 individuals. Diagnosis of CVID requires decreased Ig of at least two
isotypes (serum IgG, IgA, and/or IgM reduced by two or more standard devia-
tions from the normal mean) with impaired specific antibody formation. Multiple
defects in B-cell maturation and differentiation as well as T-cell abnormalities
have been associated with CVID. However, lymphocyte subsets are usually
preserved. The mean age at diagnosis is 29 yr for males and 33 yr for females,
although symptoms start 5 to 10 yr prior to diagnosis. It is a diagnosis of exclu-
sion. Patients present like XLA, with recurrent bacterial infections, most notably
sinopulmonary; 78% experience at least one pneumonia prior to diagnosis.
Chronic enteroviral infections are also seen. Autoimmune disease (particularly
idiopathic thrombocytopenia and autoimmune hemolytic anemia) and malig-
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nancy (most frequently lymphoreticular) are increased, with frequencies of 22
and 8%, respectively. Chronic inflammatory diseases (e.g., chronic lung disease,
hepatitis, granulomas, inflammatory bowel disease), malabsorption, and autoim-
mune syndrome may also occur in a significant percentage of patients.
2.3.2. IGA DEFICIENCY
Isolated IgA deficiency (IGAD) (see Table 3) is the most common primary
immunodeficiency of humans, with both IgA1 and IgA2 subclasses being equally
affected. The rate of prevalence varies from 1:400 to 1:3000 with some studies.
Prevalence of 1:700 in whites and 1:18,500 in Japanese in one study suggests
population genetics differences. It results from unknown defects causing the
failure of B-cells to differentiate into IgA-secreting plasma cells and is defined
by a serum IgA of less than 7 mg/dL with normal serum IgG and IgM in a patient
older than 4 yr of age. Specific antibody production following immunization is
normal. The majority of patients are asymptomatic; however, some have increased
susceptibility to sinopulmonary infections. Those with severe infections are more
likely to have an associated IgG subclass deficiency (IGGSD), particularly IgG2
and IgG4. Gastrointestinal diseases (especially giardiasis and celiac disease),
atopic diseases, and a number of autoimmune diseases occur with increased
frequency in patients with IGAD. Unless significant IgG antibody defects are
found, Ig replacement is not necessary; prophylactic antibiotics may be helpful.
The specific defects leading to the development of IGGSD, transient
hypogammaglobulinemia of infancy (THI), and specific antibody deficiency
with normal immunoglobulins (SADNI) remain unknown. These may result in
recurrent bacterial infections of the upper and lower respiratory tracts. In
IGGSD, especially in IgG2-deficient patients, there is an increased risk of
infection from encapsulated bacteria (e.g., Streptococcus pneumoniae or Hemo-
philus influenzae). Infants with THI have a delay in the onset of Ig synthesis;
however, spontaneous recovery occurs between 18 and 36 mo of age. In SADNI,
specific antibody production following immunization with protein vaccines or,
more commonly, to unconjugated polysaccharide-based vaccines is impaired
even though serum Igs and IgG subclass concentrations are normal. Immuniza-
tion with newer protein-conjugate vaccines may help in reducing infections in all
of these disorders. The use of prophylactic antibiotics and Ig replacement may
also be required in IGGSD but more rarely, as a temporary measure, in THI.
2.4. Cellular Deficiencies
2.4.1. T-CELL ACTIVATION DEFECTS—DEFECTS OF THE T-CELL ANTIGEN
RECEPTOR
Several mutations have also been associated with defects in signaling through
the T-cell antigen receptor (TCR). CD45 is a transmembrane tyrosine phos-
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phatase critical for both T- and B-cell antigen receptor transduction. Deficiency
in this surface protein results in a phenotype similar to that of most other patients
with SCID. CD3 deficiencies (due to mutations in the γ and ε chains) result in
defective expression of the TCR–CD3 complex, and have clinical manifestations
that may range from mild to severe. Patients with zeta chain-associated protein
(ZAP)-70 (tyrosine kinase) deficiency have profound CD8+ lymphocytopenia;
although CD4+/CD8+-double positive cells are present in the thymic cortex of
these patients, only CD4, and not CD8, single-positive cells appear in the thymic
medulla, suggesting a selective block of positive selection of CD8+ cells. As a
consequence of the signaling defect, there are normal or elevated numbers of
CD4+ cells that are defective and fail to differentiate.
2.4.2. CYTOKINE AND SIGNALING DEFECTS LEADING TO MYCOBACTERIAL
INFECTIONS
Mutations in five genes (IFNGR1, IFNGR2, STAT1, IL12B, and IL12RB1)
cause Mendelian susceptibility to mycobacterial infection (MSMD), a rare clini-
cal syndrome that leads to increased susceptibility to nontuberculous mycobac-
teria in the first few years of life. These patients also develop disseminated
disease following vaccination with bacillus Calmette–Guerin, and increased rate
of infections with nontyphoid Salmonella. In familial cases, an autosomal reces-
sive inheritance is observed. All of these defects affect the cytokine pathway
involved with IL-12 and IFN-γ production, and granuloma formation appears
impaired. Antimycobacterial prophylaxis is required, and in the more severe forms
of MSMD, bone marrow transplant (BMT) or SCT may be necessary.
2.5. Field Defects That Lead to T-Cell Dysfunction
2.5.1. DI GEORGE SYNDROME
Deletions in chromosome 22q11.2 are seen in most patients with DGS (dele-
tions of 10p13 reported in some patients); it is associated with abnormal devel-
opment of the third and fourth pharyngeal pouches during embryogenesis (see
Table 4). Conotruncal cardiac defects (in 50% of patients with DGS), thymic
aplasia (or hypoplasia), and hypoparathyroidism are common. Other clinical
features include dysmorphic facies, cleft lip/palate, neurodevelopmental delay,
and autoimmunity. Complete aplasia of the thymus is associated with a SCID-
like phenotype, although varied severity of hypoplasia of the thymus and par-
athyroids is more common (partial DGS). Increased susceptibility to viral or
opportunistic infections is seen with T-lymphocytopenia, and immune function
may often improve in time. Fluorescence in situ hybridization (FISH) analysis
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is used to diagnose DGS. Supportive care is usually adequate enough for those
patients with mild immunodeficiency; however, severe cases (complete DGS)
have required BMT or thymic transplants.
2.6. Combined Deficiencies
2.6.1. WISKOTT–ALDRICH SYNDROME
The classic triad of eczema, thrombocytopenia, and immunodeficiency mani-
fests in the first year of life with bloody diarrhea as the presenting feature (see
Table 4). Autoimmunity, vasculitis, and risk of lymphoreticular (Epstein-Barr
virus [EBV]-induced) malignancy are significantly increased. The platelets are
small and dysfunctional, resultant excessive bleeding can lead to significant
morbidity and mortality in Wiskott–Aldrich syndrome (WAS). This X-linked
disorder is due to a defect in the WAS protein (WASP). Mutations in WASP have
also been found in patients with X-linked thrombocytopenia (XLT) and X-linked
neutropenia. Patients with XLT also have thrombocytopenia with small plate-
lets, but they do not share the other clinical findings that are observed in classic
WAS. Patients with WAS often have poor specific antibody production and
progressive lymphopenia. Hematopoietic SCT is the only cure for classic WAS
and is the treatment of choice in presence of a matched sibling donor. Ig replace-
ment and prophylactic antibiotics may suffice in more mild cases. Splenectomy
may be required for uncontrollable bleeding and by itself can prolong lifespan
from 5 to 25 yr. IL-2 infusions have been helpful in some cases.
2.7. Defects in Pathways of T-Cell Death and Regulation
2.7.1. AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME
The autoimmune lymphoproliferative syndrome (ALPS) is due to abnormal
survival of lymphocytes leading to massive proliferation of these cells as a result
of a defect in the Fas–Fas ligand cell death pathway. There is an autosomal
dominant inheritance pattern in most families with mutations found in the Fas-
encoding gene (TNFRSF6, or tumor necrosis factor receptor superfamily mem-
ber 6). Altered lymphocyte apoptosis leads to massive lymphadenopathy and
splenomegaly in infants and children that may regress over time. Unusual or
severe infections are unlikely, but autoimmunity and lymphoreticular malignan-
cies are encountered. Diagnosis of ALPS necessitates all of the following: (1)
chronic accumulation of nonmalignant lymphoid cells; (2) defective lymphocyte
apoptosis in vitro; and (3) the presence of 1% or more double-negative T-cells
in peripheral blood or the presence of double-negative T-cells in lymphoid tissue.
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Immunosuppressive treatment is required for autoimmune manifestations in
ALPS, and BMT has been successful in patients with severe disease.
2.7.2. X-LINKED LYMPHOPROLIFERATIVE DISEASE
XLP was first reported in 1975 in male members of a large kindred who died
following primary EBV infection due to an abnormal and uncontrolled immune
response. The clinical manifestations that characterize most patients with XLP
include fulminant infectious mononucleosis, malignant lymphoma, and
dysgammaglobulinemia. In the first two forms, XLP is generally fatal in the first
decade of life. Lymphocyte function is generally normal in patients with XLP
prior to EBV infection. Aggressive treatment of EBV infection and related com-
plications is necessary, but definitive treatment requires SCT before develop-
ment of typical XLP manifestations (see also Chapter 18).
2.8. Defects of T-Cell Regulation
2.8.1. AUTOIMMUNE POLYENDOCRINOPATHY–CANDIDIASIS–ECTODERMAL
DYSTROPHY
Multiple autoimmune endocrinopathies, severe and recurrent chronic muco-
cutaneous candidiasis, and ectodermal dystrophies occur in this disorder and
symptoms often start in early childhood. This disorder is also referred to as
autoimmune polyglandular syndrome type 1 (APS-1). Autosomal recessive
inheritance is found in autoimmune polyendocrinopathy–candidiasis–ectodermal
dystrophy (APECED) with a defect in the autoimmune regulator (AIRE) gene.
Autoantibody-induced polyendocrinopathy include hypothyroidism, adrenal
failure, hypoparathyroidism, insulin-dependent diabetes mellitus, and gonadal
failure. Ectodermal dystrophies include alopecia, vitiligo, and keratopathy. Anti-
fungal prophylaxis and management of associated autoimmune complications are
important in treatment.
2.9. Defects of DNA Repair
2.9.1. ATAXIA TELANGIECTASIA
This autosomal-recessive disorder (see Table 2) includes progressive ataxia
followed by oculocutaneous telangiectasias, sensitivity of cells to radiation dam-
age being the hallmark of this disease. The ataxia is usually evident in the second
year of life after the child begins to walk. Recurrent sinopulmonary infections are
seen ultimately leading to early death and a median life span of 20 yr, although
in some cases the immunodeficiency may be mild. Patients with ataxia telangi-
ectasia (AT) have an increased incidence (1% per year) of malignancy (85% are
lymphoreticular), which is frequently fatal. Additional features of AT are hypo-
gonadism, insulin-resistant diabetes mellitus, and skin abnormalities (atrophy and
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pigmentary changes). The AT-mutated (ATM) gene product was first identified
as the cause of this disorder in 1995, and more than 400 mutations have subse-
quently been identified. This protein is important in the detection of double-
stranded breaks in DNA, and the failure to correctly repair breaks in DNA and
delayed induction of p53 (a protein that halts cell cycle until DNA damage is
repaired) leads to dysregulated recombination, cell division in cells (with
unrepaired DNA), and apoptosis. As a result, absence of the ATM gene leads to
abnormalities in both lymphocyte function and development. Progressive lym-
phopenia is common (with selective CD4+ lymphopenia), with decreased serum
IgA, IgG2, and IgE levels noted in many patients. Serum α-fetoprotein (AFP)
levels are also elevated. Supportive care and antibiotic therapy are recommended,
as is close monitoring for the development of malignancy. Patients with AT
respond poorly to treatment regimens that include ionizing radiation and certain
chemotherapies (e.g., topoisomerase inhibitors), so modification of standard
protocols is required.
2.9.2. NIJMEGEN BREAKAGE SYNDROME
Similarly to patients with AT, patients with Nijmegen breakage syndrome
(NBS) have chromosome fragility. It is transmitted with autosomal-recessive
inheritance. Patients with NBS are also immunodeficient and radiosensitive, and
have an increased risk of malignancy (particularly lymphoma). This disorder is
associated with short stature, microcephaly, and mental retardation, and is more
common in eastern Europeans. The immunological and laboratory manifestations
of this disorder are also similar to those seen in AT; however, AFP levels are
normal in NBS.
2.10. Congenital Defects of Complement Components
The complement system has 20 serum proteins, 5 complement receptors, and
has varied distribution among leukocytes and most cell membranes. The mani-
festations of their defects is briefly discussed in Table 5.
3. ACQUIRED OR SECONDARY IMMUNODEFICIENCIES
Acquired immunodeficiencies are seen not only in HIV infection, but also
during many hematological disorders. The Ig synthesis is decreased in low-grade
malignant lymphomas, especially in chronic lymphocytic leukemia and in mul-
tiple myeloma resulting in hypogammaglobulinemia and frequent infections. In
patients with a paraprotein, as, for example, in multiple myeloma, the synthesis
of normal polyclonal Igs is inhibited. The normal T- and B-cell immunity is
defective or delayed for some time after the transplantation of bone marrow or
stem cells. Nonhematological causes of secondary immunodeficiency are mal-
nutrition, protein-losing enteropathy, diabetes, and alcoholism. A disturbance of
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cellular and humoral immunity is a frequent side effect of the treatment with
corticosteroids, immunosuppressive drugs like cyclosporine A, tacrolimus, and
a number of cytostatic drugs. The immunity is also transiently defective during
radiation therapy and some viral infections.
At present, there are only limited possibilities of stimulating the immune
system to fight malignancies or bacterial or viral infections. An exception is the
treatment with Ig preparations of patients with hypogammaglobulinemia. Patients
with leukemias or lymphomas, or who had SCT or BMT, should not be immunized
with live vaccines because of the risk of a disseminated infection. Although it has
been shown in healthy persons that the efficacy of inactivated vaccines is
decreased, these vaccines should be given to immunosuppressed individuals if
the clinical situation makes it necessary.
4. HEMATOLOGICAL ASPECTS OF AIDS
AIDS is caused by HIV, a human retrovirus. Worldwide, at least 60 million
people are infected with HIV. Despite public health education, in the United
States, currently 40,000 new cases of HIV infection are observed annually. There
are two subtypes of HIV: HIV-1 is the most common type, HIV-2 is less common
and is observed in some cases in Africa and Europe. The infection with HIV
proceeds in three stages (I–III) and categories (A–C): the initial primary infec-
tion may be mononucleosis-like; later, the infection is commonly asymptomatic
(category A). These patients may also present with lymphadenopathy. In cat-
egory B, patients have symptoms with AIDS-defining illnesses (see Table 5). In
category C, AIDS-defining illnesses are observed (a list of 23 such diseases as
defined by the Centers for Disease Control and Prevention [CDC] is listed in
Table 5). The interval between categories A and C may be months to many years.
Because of the effective treatment with antiretroviral drugs, some patients will
never progress from category A to B or C. For epidemiological purposes, three
stages of HIV infection have been defined. CD4 counts also enter into this defi-
nition of stages. HIV is transmitted by homosexual and heterosexual intercourse,
by needle-sharing among drug addicts, by occupational exposure (in the case of
medical personnel), and perinatally; in the past, the virus was also transmitted by
contaminated blood products. Prognosis of the HIV infection has improved in
recent years as a result of a combination treatments with inhibitors of reverse
transcriptase and proteases.
The HIV virus is a retrovirus, with RNA encoding three groups of structural
genes (gag, pol, and env). HIV infects CD4+ helper lymphocytes through a cell
surface receptor. There is a specific interaction of gp120 envelope glycoprotein
with the CD4 molecule and members of the chemokine receptor family (usually
CCR5 or CXR4). Some cells are lysed on infection, whereas in other cells, the
virus remains latent until the cells are activated. The long-term consequence of
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HIV infection is a progressive depletion of CD4+ cells, although other cells, such
as antigen-presenting cells, neural cells, and hematopoietic progenitor cells, may
also become infected with HIV. During HIV infection, the cellular immune
defense is progressively and irreversibly lost. Chronic B-cell stimulation often
leads to a polyclonal hyper-gammaglobulinemia. The absolute number of CD4
cells (per µL blood) is an established prognostic factor for the complications and
progression of HIV infection. The diagnosis of an HIV infection is made by
demonstrating antibodies against HIV antigens. The screening test is done with
ELISA techniques.
Positive or unclear results are confirmed by Western blot, which detects spe-
cific antibodies against viral proteins (e.g., p24, p41 or p120/160). ELISA results
become positive 4–8 wk after the initial infection. Other tests (p24 antigen,
Table 6
Clinical Categories and Stages of the HIV Infectiona
CD4 category
(counts/µL) Clinical category A Clinical category B Clinical category C
Laboratory and Clinical Categories
1. 500 Al B1 Cl
2. 200–499 A2 B2 C2
3. <200 A3 B3 C3
Stages
1. 500 Stage  I Stage I Stage III
2. 200–499 Stage  I Stage II Stage III
3. <200 Stage II Stage II Stage III
aAccording to the 1993 revised classification of the Centers for Disease Control.
Definitions of clinical categories: A: Asymptomatic HIV infection, persistent generalized
lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute
HIV infection. B: Symptomatic conditions, not included in category C, that are related to HIV
infection and a defect in cell-mediated immunity or conditions that are complicated by HIV
infection. Examples are bacillary angiomatosis, oropharyngeal candidiasis, persistent vulvovaginal
candidiasis, cervical dysplasia or carcinoma in situ, constitutional symptoms, oral hairy
leukoplakia, Herpes zoster in two dermatomes, or relapsed, idiopathic thrombocytopenic purpura,
listeriosis, pelvic inflammatory disease, peripheral neuropathy. C: Pneumocystis carinii
pneumonia, toxoplasma encephalitis, candida infection of esophagus, lungs, trachea, chronic H.
simplex ulcers, bronchitis, pneumonia, esophagitis, cytomegalovirus retinitis, relapsing salmonella
septicemias, relapsing pneumonias, extrapulmonary cryptoccocal infections, chronic intestinal
cryptosporidiasis, chronic intestinal infection with isospora belli, coccidiomycosis, disseminated
or extrapulmonary histoplasmosis, tuberculosis, infections by Mycobacterium avium or M. kansasii
(disseminated or extrapulmonary), Kaposi sarcomas, malignant lymphomas, invasive cervix
carcinoma, HIV encephalopathy, progressive multifocal leukencephalopathy, wasting syndrome.
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polymerase chain reaction, or viral culture) may be positive somewhat earlier or
later.
The signs and symptoms of HIV infection according to the category of the
disease are described in Table 6. Many patients with HIV infection have hema-
tological manifestations. During the acute infection, a mononucleosis-like syn-
drome is often found. At this stage, fever, which lasts a few days or weeks, lymph
node swelling, anorexia, and lethargy are typical. Other patients have a mild
meningoencephalitis or are asymptomatic. An atypical lymphocytosis in the
peripheral blood can be seen in about half the patients.
A thrombocytopenia is frequent in HIV-infected patients (3–8% in early
stages, 30–50% in AIDS). Pathogenic factors are a decrease in production and
an increase in platelet destruction, due in some cases to antiplatelet antibodies.
In severe symptomatic cases, steroids or high-dose Ig are as effective as in
idiopathic thrombocytopenic purpura without HIV infection. Steroids, however,
may further decrease cellular immunity. A splenectomy may be indicated in
some refractory cases. Some patients improve with antiviral treatment. A throm-
botic-thrombocytopenic purpura developing in some HIV-infected patients can
be treated similarly as that diagnosed in non-HIV-infected patients (plasma
infusions or plasma exchange).
Many patients with HIV infection are leukopenic (granulocytopenia and/or
lymphopenia). This may be due to the infection itself but may also be due to drugs
used to treat HIV-infected patients. Examples are zidovudine, cotrimoxazole,
gancyclovir, and pentamidine, among others. The leukopenia of HIV-infected
patients responds well to colony-stimulating factors, such as granulocyte colony-
stimulating factor.
In advanced stages of HIV infection, anemia is frequent. It may be due to
disturbed maturation of erythroblasts, but is also caused by drugs like zidovudine.
Especially in cases of low serum erythropoietin levels (<500 IU/L), the anemia
of patients with AIDS responds well to erythropoietin. Some rare cases have
anemia due to a persistent infection with parvovirus B19.
HIV-associated lymphomas are a consequence of the depressed immunity
and belong (according to the CDC classification) to the AIDS-defining ill-
nesses. These non-Hodgkin’s lymphomas (NHLs) are often extranodal (about
25% with bone marrow involvement) and aggressive. Histologically, most NHLs
in patients with AIDS are high-grade (Burkitt’s lymphomas, Burkitt-like lym-
phomas, diffuse-large cell lymphomas) and have a B-cell phenotype. The inci-
dence of NHLs in patients with AIDS has increased (up to 25% of all NHLs in
the United States are HIV-related). A reason is the longer life expectancy of
HIV-infected patients due to better antiviral treatment and improved treatment
of opportunistic infections.
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Those lymphoma patients in good general condition should undergo combi-
nation chemotherapy while continuing antiretroviral therapy. This approach has
dramatically improved the complete remission rate and survival of patients with
HIV-related NHLs (see Chapter 15). Hodgkin’s lymphoma is not mentioned in
the original definition of AIDS-related conditions, but is also observed more
frequently in HIV-infected patients.
The bone marrow in HIV-infected patients often shows megaloblastic and
myelodysplastic features. The cellularity is often increased. Common bone
marrow findings are megakaryocyte abnormalities with bare megakaryocyte
nuclei, giant metamyelocytes, detached nuclear fragments in granulocytes, and
gelatinous degeneration (especially in late stages). In the peripheral blood, the
granulocytes often show detached nuclear fragments. These changes are reactive
and cannot be considered as preleukemic. In some cases, a fibrosis or polymor-
phic lymphocellular infiltrates are evident. In other cases, pathogens such as
mycobacteria, cryptococci, or histoplasma can be demonstrated. A common
finding in bone aspirates is a polyclonal plasmacytosis, which is related to the
B-cell hyperactivity in HIV-infected patients.
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1. INTRODUCTION
In this chapter, several infections are discussed that occur particularly in
hematological patients. It is important to recognize these infections, as some
of them elicit special changes in hematological parameters. Some viruses have
transforming properties. Other infections belong to the group of opportunistic
infections common in immunosuppressed patients. The vast group of infections
caused by bacteria and fungi is not discussed here, but is covered in Chapter 3
(supportive therapy).
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2. INFECTIOUS MONONUCLEOSIS
AND OTHER EPSTEIN-BARR VIRUS SYNDROMES
Infectious mononucleosis is characterized by fever, lymph node swelling,
splenomegaly, and pharyngitis and is caused by the Epstein-Barr virus (EBV).
In most parts of the world, more than 80% of the adult population has become
infected with EBV: in children, the infection is often subclinical, whereas in
young adults, the typical signs and symptoms of “glandular fever” or “kissing
fever” appear. EBV is a double-stranded DNA virus belonging to the group of
herpesviruses that mainly infects B-lymphocytes and epithelial cells. The recep-
tor for EBV on B-lymphocytes was characterized as complement receptor type
2 and has been assigned CD21 in the CD nomenclature. After an infection, EBV
persists indefinitely in a small percentage of B-lymphocytes.
EBV-associated malignomas are Burkitt’s lymphoma in the tropics and in
HIV-infected patients, nasopharyngeal carcinoma, and some cases of Hodgkin’s
lymphoma and of T-/natural killer (NK) cell lymphoma. In the last few years, an
increasing number of EBV-associated lymphomas have been observed in immu-
nosuppressed patients (patients with AIDS and recipients of organ transplants).
The incubation time of infectious mononucleosis is around 4–8 wk; the trans-
mission commonly occurs through the saliva of persons with a latent infection.
After a prodromal stage of several days, the disease manifests itself acutely with
a generalized, painful lymph node swelling and an exudative pharyngitis or
tonsillitis. About 10% of patients have an exanthema; in about half of the pa-
tients, an enlarged spleen can be felt. A hepatomegaly, sometimes associated
with jaundice, can also be observed. More severe complications can be expected
in 1–5% of adults: an acute obstruction of the upper airways can occur as a
complication of tonsillitis; encephalitis, meningoencephalitis, or Guillain-Barré
syndrome can occur as complications of the CNS; in addition, hepatitis, myo-
carditis, and, on rare occasions, splenic rupture are possible complications.
A leukocytosis of 10,000–30,000 white blood cells/µL is a characteristic
change in the blood parameters observed after the second week. The differential
count shows more than 70% atypical cells with a large nucleus, rough chromatin,
and basophilic cytoplasm, sometimes with azure granulations (see Fig. 18.1 and
Color Plate 23). These cells correspond to a reactive proliferation of CD8 T-
lymphocytes and contribute to the elimination of infected B-lymphocytes. Oc-
casionally, these cells are misdiagnosed as blasts of an acute leukemia.
A specific diagnosis is possible with the demonstration of antibodies to EBV.
Antibodies against capsid antigens (VCA) become positive within the first dis-
ease phase. Immunoglobulin (Ig)M antibodies decrease in titer after 4–6 wk,
whereas IgG antibodies remain positive indefinitely. Antibodies against early
antigens (EA) and Epstein-Barr nuclear antigens (EBNA) become positive some-
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what later and also remain positive permanently. High-titer antibodies are often
produced within a few days in adults, whereas in children the serology becomes
positive only after a certain delay. Several fast reactions take advantage of
heterophilic antibodies (e.g., directed against horse erythrocytes) that are formed
in the context of a nonspecific immune stimulation. Heterophilic antibodies are
seen in 80–90% of adults with infectious mononucleosis and are specific in more
than 95% of cases. Besides the atypical lymphoid proliferation, a neutropenia or
a thrombocytopenia is occasionally observed. A mild hemolysis is only rarely
seen in infectious mononucleosis.
Infectious mononucleosis generally heals within 1 or 2 wk after the start of
acute symptoms without leaving sequelae. In some cases, weakness persists for
a few weeks. In complicated cases, steroids are recommended. The value of a
virostatic treatment with acyclovir has not been proven.
The differential diagnosis of the disease caused by EBV includes syndromes
resembling infectious mononucleosis, which are caused by other agents such as
cytomegalovirus (CMV), HIV, or other viruses and Toxoplasma gondii.
Rarely, EBV causes atypical lymphoid proliferation, for example, in children
with an X-linked lymphoproliferative syndrome (XLPS). In these children, an
Fig. 18.1. Infectious mononucleosis. Large lymphoid cells with an irregular nucleus and
clear cytoplasm.
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uncontrolled proliferation of lymphoid cells develops in the context of immune
deficiency and leads to death as a result of multiorgan failure. This condition is
generally fatal and happens when male offspring of female carriers of the XLPS
mutation are infected with EBV. The underlying defect is the functional absence
of the serum alkaline phosphatase (SAP) molecule. In patients with AIDS or in
recipients of organ or stem cell transplants, polyclonal and oligoclonal lymphoid
proliferation can occur, which are caused by EBV and frequently progress into
malignant lymphomas. This condition has also been named EBV-associated B-cell
lymphoproliferative disease or posttransplant lymphoproliferative disease.
Regression could be achieved by a reduction of the immune suppression.
Some complete responses were observed using the monoclonal antibody
rituximab. EBV-specific cytotoxic T-lymphocytes from stem cell donors show
promise for the treatment of posttransplant lymphoproliferative disease after
allogeneic transplants. Anecdotal reports show some activity of acyclovir. A
further rare condition is chronic active EBV infection. Vaccines are currently
under development for EBV-associated disorders and malignancies. There is a
low risk of transmitting EBV by blood transfusion; however, at present, there are
insufficient data as to whether this risk can be further reduced by depleting
leukocytes from blood products with special filters (see Chapter 22).
3. CMV INFECTIONS
CMV belongs to a group of herpesviruses and can cause a clinical picture
similar to infectious mononucleosis in immunocompetent patients: lymph node
swelling, fever, and changes in the white cell differential count. Serologically,
40–80% of the adult population has antibodies against CMV as a sign of a
previous infection. Most infections have a subclinical course, but occasionally
immunocompetent persons may develop a pneumonia, myocarditis, or encepha-
litis caused by CMV. In most cases, the restitution is faster compared with EBV-
mononucleosis. When the acute infection has subsided, the virus persists
indefinitely in leukocytes. CMV may cause life-threatening complications in
immunosuppressed individuals, for example, in patients with AIDS and after
organ transplants (especially lung and bone marrow transplants [BMT]).
Approximately 20–50% of patients transplanted with allogeneic bone marrow
develop a CMV infection or reactivation, which manifests itself in most cases
between 30 and 80 d after transplantation. Risk factors are graft-vs-host reac-
tions, total body irradiation, and the transfer of CMV-positive bone marrow,
stem cells, or blood products into a CMV-negative recipient. The infection may
remain clinically unapparent or manifest itself as gastroenteritis, unclear fever,
or hepatitis. Interstitial pneumonias are the most feared complication of CMV
infection and still have a lethality of up to 80%.
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The presence of a CMV infection can be proved in biopsates by histological,
immunological, and molecular methods. A likely diagnosis can be made if sero-
logically the virus titers increase or if the virus can be isolated from urine or from
throat washings.
Therapeutically, the virostatic drug gancyclovir (7.5 mg/kg body weight daily)
is given for a 14-d treatment course and may be combined with hyperimmune
globulins. Major side effects of gancyclovir are leukocytopenia and thrombocy-
topenia. After a course of gancyclovir, the drug should be continued at a lower
dose for several weeks. An alternative drug is foscarnet, which has a different
toxicity profile (renal toxicity, hypocalcemia, neuropathy). Cidofovir is a new
antiviral drug with a mechanism of action similar to gancyclovir but that does not
require viral enzymes for activation. Cidofovir is administered once weekly as
an intravenous infusion for two doses (5 mg/kg) and then as maintenance treat-
ment once every 2 wk. Cidofovir may be active against resistant CMV strains.
Common side effects are neutropenia and nephrotoxicity. After allogeneic trans-
plantation involving CMV-seropositive donors or recipients, regular monitoring
by an antigen assay or molecular monitoring is indicated. If the patient develops
antigenemia, a pre-emptive treatment should be given. This strategy has reduced
the transplant-related mortality in CMV-positive patients to that observed in
CMV-negative patients, at least for matched related allogeneic transplantation.
In some patients treated with this strategy, late relapses (beyond day 100 after
transplantation) of CMV antigenemia and disease are observed. The transfusion
of CMV-specific cytotoxic T-lymphocytes is an elegant strategy for the prophy-
laxis or treatment of CMV disease. However, this adoptive immunotherapy is not
universally available.
For the prophylaxis of CMV infections, the transfusion of CMV-negative
blood products is recommended in CMV-negative transplant recipients. If these
are not available, leukocyte-depleted blood products might offer some degree of
protection. Ganciclovir has also been shown to be active in the prophylaxis of
CMV infections.
4. PARVOVIRUS B19 INFECTIONS
Parvovirus B19 was originally discovered serologically by screening healthy
blood donors. The majority of the US population is immune to parvovirus. In
children, the virus causes erythema infectiosum (fifth disease). In adults, the
infection is often unapparent or causes arthralgias. Parvovirus infections may
also be a rare cause of hydrops fetalis. The main hematological relevance of
parvovirus infections is that hematopoietic (erythroid) precursor cells may
become infected thus leading to transient aplastic crises in patients with hemolytic
anemias (examples are thalassemias and sickle cell anemias, but also autoimmune
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hemolytic anemias). The cellular receptor for parvovirus is globoside, a neutral
glycolipid. Globoside is also known as the erythrocyte P antigen. Therefore, rare
individuals lacking P are not susceptible to an infection with parvovirus B19. A
chronically compensated hemolysis decompensates when the patient becomes
infected with parvovirus. From time to time, an aplastic crisis due to parvovirus
may be the first sign to reveal a chronic hemolytic anemia. Infections with
parvovirus B19 manifest themselves particularly in patients with immune de-
fects (among them, BMT recipients and HIV-infected individuals). Occasion-
ally, these infections cause an isolated erythroblastopenic anemia (persistent
parvovirus infections). In this situation, antibodies to parvovirus are usually
absent; however the virus can be readily detected in the circulation, often at
extremely high levels (>1012 genome copies per mL).
The genome of parvovirus B19 has approx 5600 nucleotides. The genome
encodes only three proteins of known function: the nonstructural protein NS1
and the capsid proteins VP1 and VP2. Folding of the proteins creates α-helical
loops that appear on the surface of the assembled capsids, where the host immune
system can recognize them.
The diagnosis can be made serologically by demonstrating IgM antibodies
(which is unreliable in immunosuppressed patients) or by detecting viral DNA
in serum or bone marrow by molecular methods. As far as bone marrow cytomor-
phology is concerned, giant pronormoblasts are considered as pathognomonic.
Occasionally, the infection may also be accompanied by neutropenia and/or
thrombocytopenia. DNA assays are required to diagnose persistent infection,
because antibody production is absent or minimal. Parvovirus DNA can be found
early in the course of an aplastic crisis. DNA direct hybridization is reliable for
detecting viral titers of 106 copy numbers or higher. DNA amplification tech-
niques are more sensitive but may detect low-level viremia in normal persons
without clinical relevance.
The treatment of parvovirus B19 infections with hematological manifesta-
tions consists of administering commercially available Ig preparations (a dosage
of 0.4 g/kg body weight for 5 successive days has been suggested). Patients who
present with an aplastic crisis during hemolytic anemias or who are immunodefi-
cient and develop a persistent anemia with decreased erythroblasts should
always be screened for an infection with parvovirus.
5. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
The disease called progressive multifocal leukoencephalopathy (PML) is
caused by an infection of the CNS with human polyomavirus JC (JCV). During
the course of AIDS up to 3% of patients may develop PML; in patients with
hematological diseases, the risk is much lower. Factors that increase the risk are
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irradiation of the CNS, intrathecal application of methotrexate, and severe
immunosuppression. In healthy individuals, the JCV is latent in the organism.
When immunosurveillance is lacking, the virus can cause demyelinization, begin-
ning in the deeper structures of the brain and progressing rapidly. This damage can
be depicted as an area of high signal density with nuclear magnetic resonance
imaging.
The clinical signs and symptoms of PML are fatigue, disorientation, dementia,
depression, seizures, hemiparalysis, and other focal neurological signs. An increase
in titer of antibodies to the JCV can raise the suspicion of PML; an accurate
diagnosis may be made when the virus is demonstrated in brain tissue with
immunological or molecular methods. In most cases, the disease has a fatal
course within weeks or months. In singular cases, remissions were described
following a treatment with cytosine-arabinoside.
6. TOXOPLASMOSIS
Toxoplasmosis can manifest itself in otherwise healthy persons as a lymph
node swelling, hepatosplenomegaly, and changes in the white cell differential
count, similarly to infectious mononucleosis. Quite often, however, toxoplasmo-
sis remains clinically inapparent. A large segment of the population is immune
against T. gondii. Transmission occurs by means of insufficiently cooked meat
and by contact with domestic animals. Toxoplasmosis may also be transmitted
via blood transfusions. If the prime infection occurs during pregnancy, the fetus
may become infected via the placenta.
The diagnosis of an acute infection can be made serologically by demonstrat-
ing IgM antibodies and an increase in titer of IgG antibodies (by indirect immu-
nofluorescence or complement binding reactions). A histological diagnosis from
lymph nodes can be made showing toxoplasma parasites or cysts.
Immunosuppressed patients (especially in cases of AIDS, also after organ
transplants, rarely after BMT) can experience a life-threatening disseminated
form of toxoplasmosis. Disseminated toxoplasmosis leads to a generalized lymph
node enlargement or involves the brain, the eyes, or the myocardium. A cerebral
toxoplasmosis shows pleocytosis in the spinal fluid. In computed tomography
(CT) scans, focal lesions are visualized, which typically show enhancement after
intravenous contrast agents.
Patients with intact immune function generally do not need a specific
treatment. In patients with immune deficiency, a combination treatment with
pyrimethamine (oral daily dose 25–50 mg) and sulfadiazine (daily dose 100 mg/
kg body weight, orally [p.o.] or intravenously [i.v.]) is recommended. Because
pyrimethamine is an antagonist of folate, folinic acid (10 mg daily p.o. i.v.) should
be administered. Side effects of the combination treatment are myelodepression,
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gastrointestinal disturbances, exanthemas, and, in rare cases, seizures. As alter-
native treatment, clindamycin (daily dose 1.2–2.4 g p.o. or i.v.), often in combi-
nation with pyrimethamine, has been recommended.
7. PNEUMOCYSTIS CARINII PNEUMONIAS
The pathogen Pneumocystis carinii has been classified as protozoan, and most
likely persists in the lungs of healthy individuals at a latent stage. During states
of immunosuppression, pneumocystis may cause life-threatening interstitial
pneumonias. In patients with AIDS, P. carinii pneumonias are the most frequent
opportunistic infection. In hematological patients not infected with HIV, the risk
of contracting pneumocystis pneumonias has been estimated to be between 0.1
and 1%. At risk are recipients of BMT, patients with acute lymphoblastic leuke-
mias, and those treated with high-dose steroids. Untreated, pneumocystis
pneumonias lead to a rapidly worsening respiratory failure.The first signs are
cough, an increased respiratory rate, fever, and, in the chest X-ray, interstitial
infiltrates that may be absent in a radiograph taken during the first hours of
worsening respiratory distress. A diagnosis can be made by invasive means,
demonstrating the etiological agent in the sediment of bronchial lavage or in a
biopsate (staining with methenamine silver or toluidine blue).
The standard treatment of pneumocystis pneumonias consists of high-dose
trimethoprim-sulfamethoxazole (TMP/SMX, daily dose 20 mg/kg trimethoprim
and 100 mg/kg sulfamethoxazole, given in three to four single doses). The duration
of treatment should be 3–4 wk, and during the initial phase the addition of corti-
costeroids (3 × 40 mg prednisone equivalent) has been proved to be beneficial.
Similarly to patients with AIDS, pentamidine (4 mg/kg i.v. once daily) can be
administered. The lethality of pneumocystis infections in patients with hemato-
logical disorders is still in the range of up to 40%, especially if the diagnosis is
delayed. If bronchoscopy or an open-lung biopsy are considered to be hazardous
because of impending respiratory failure, an empiric treatment is justified. Most
BMT centers give a prophylactic treatment against pneumocystis until day 100
after transplant. Such a prophylaxis is also recommended in patients who recov-
ered from a pneumocystis pneumonia. A common regime is to administer oral
TMP/SMX twice weekly (e.g., Mondays and Thursdays). Possible side effects
of TMP/SMX are myelosuppression, renal toxicity, rash, and fever. Another pro-
phylactic regime consists of pentamidine inhalations (once monthly, 300 mg).
Recently oral dapsone (50 mg/m2) was proposed as pneumocystis prophylaxis
for persons intolerant to TMP/SMX. Because pneumocystis pneumonias are
generally responsive to treatment, the possibility of this opportunistic infection
should be considered early in hematological patients with unclear interstitial
infiltrates. A prophylaxis is indicated in high-risk cases.
Chapter 18 / Infections Relevant to Hematology 323
8. INFECTIONS CAUSED BY HUMAN HERPESVIRUS-6
Human herpesvirus (HHV)-6 is a herpesvirus discovered in the 1980s and has
two variants. HHV-6 causes exanthema subitum in children. In individuals under-
going stem cell transplantation or BMT, HHV-6 can cause a skin rash, marrow
suppression, encephalitis, or pneumonitis and exacerbate graft-vs-host disease.
HHV-6 as detected by PCR is found in 50–70% of BMT recipients. Because the
virus is ubiquitous in mononuclear cells, it is recommended serum or cerebrospi-
nal fluid be used for diagnostic purposes. Using sensitive techniques, an infec-
tion is generally detectable 2–4 wk after transplantation. HHV-6 can also
reactivate other herpesviruses. HHV-6 infections are due to exogenous transmis-
sion from the donor, an endogenous reactivation, or a transmission from other
sources. As to treatment, gancyclovir or foscarnet are recommended.
9. INFECTIONS CAUSED BY HUMAN HERPESVIRUS-8
9.1. Introduction
HHV-8 is a newly discovered herpesvirus associated with Kaposi’s sarcoma
(KS) and rare lymphoproliferative disorders. Together with non-Hodgkin’s
lymphomas, KS is the most frequently found neoplasm in patients with AIDS.
Patients with AIDS and KS most often come from the high-risk group of male
homosexuals. KS tumors not associated with AIDS are rare, although they were
observed long before the current AIDS epidemic. An endemic increase has been
reported in central Africa and in parts of the Mediterranean countries. In addition,
KS is occasionally associated with patients who are immunosuppressed because
of organ transplants.
According to the epidemiological evidence, an infectious etiology has been
suspected for many years. Finally, a new herpesvirus (HHV-8) was discovered
in the tumor tissue of KS by representational display analysis, a new PCR tech-
nique.
9.2. Biology of HHV-8
According to sequence homology, HHV-8 (also known as KS-associated
herpesvirus [KSHV]), belongs to the subfamily of γ-herpesviruses, similar to
EBV and herpesvirus saimiri. The genome of HHV-8 consists of approx 140,000
base pairs and is flanked by several repetitive sequences (size ≈ 800 base pairs).
HHV-8 has several similarities with EBV:
1. The structure of the genome is very similar.
2. HHV-8 infects B-lymphocytes.
3. HHV-8 is also considered as a possible tumor virus.
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Several genes of HIV-8 play a role in its transforming potency. HHV-8 encodes
the genes for cytokines and related molecules. The pathogenesis of HHV-8-asso-
ciated disorders is multifactorial, with HHV-8, immunosuppression, cytokines,
and other factors playing a role.
Because of the relationship with EBV, malignant lymphomas were initially
screened for HHV-8 sequences. However, most cases turned out to be negative,
and only a rare group of malignant lymphomas, primary effusion lymphomas
(PEL), was found to be consistently infected with HHV-8. Similar to KS, PEL
occur in HIV-infected and noninfected patients.
PEL proliferate as ascites and pleural or pericardial effusions—they do not
form tumors; they are often coinfected with EBV; and they have the phenotype
of immature B-cell tumors. In addition, HHV-8 can be found in some atypical
lymphoproliferative disorders like Castleman’s disease or angioimmunoblastic
lymphadenopathy. Some cytokines, such as interleukin-6, are involved in the
pathogenesis of these diseases as they are in KS. In other disorders, the detection
of HHV-8 sequences is not confirmed or universally accepted. The diseases and
disorders associated with HHV-8 are summarized in Table 1.
9.3. Diagnosis and Epidemiology of HHV-8 Infections
Initially, it was shown that HHV-8 is specifically detected in KS and rare
lymphoproliferative disorders. In patients with KS, HHV-8 could also be de-
tected in CD 19+ cells, which points toward B-lymphocytes as a possible sanc-
tuary of virus. Later, HHV-8 was also found in blood and other tissues of
HIV-negative immunosuppressed individuals. HHV-8 sequences have also been
found in rare cases in the blood of otherwise healthy normal individuals. In some
studies, the detection of HHV-8 in the peripheral blood correlates with disease
activity (as far as KS and Castleman’s disease are concerned).
Table 1
Diseases and Disorders Associated With HHV-8
Kaposi’s sarcomas (all varieties, patients ± HIV infection)
Primary effusion lymphomas
Castleman’s disease (especially multicentric variety)
Angioimmunoblastic lymphadenopathy
Mycosis fungoidesa
Angiosarcomaa
Multiple myeloma and Waldenström’s diseasea
Sarcoidosisa
Encephalitis in HIV-infected patientsa
aUnconfirmed or controversial. HHV, human herpes virus
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Patients with KS and other HHV-8-associated disorders develop antibodies to
the virus. In normal persons in Europe and the United States, a low prevalence
of HHV-8 is detected serologically. In some regions of Africa, a high prevalence
of HHV-8 that correlates with the incidence of KS is observed.
9.4. Treatment of HHV-8-Associated Disorders
Currently, only retrospective data point to some efficacy of antiviral drugs
against HHV-8-associated diseases, especially KS. Prospective studies are being
undertaken. In established KS, the treatment depends on the stage of the disease
and currently ranges from local measures such as surgery or irradiation to sys-
temic treatments such vinblastine, doxorubicin, or interferon-α. The discovery
of HHV-8 may also open perspectives for immunotherapy against KS and related
disorders.
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1. NORMAL HEMOSTATIC MECHANISMS
The hemostatic system consists of blood vessels, platelets, and the plasma
coagulation system including the fibrinolytic factors and their inhibitors. When
a blood vessel is injured, three mechanisms operate locally at the site of injury
to control bleeding: (1) vessel wall contraction, (2) platelet adhesion and aggre-
gation (platelet plug formation), and (3) plasmatic coagulation to form a fibrin
clot. All three mechanisms are essential for normal hemostasis. Abnormal bleed-
ing usually results from defects in one or more of these three mechanisms. For
a better understanding of the pathogenesis of pathological bleeding, it is custom-
ary to divide hemostasis into two stages (i.e., primary and secondary hemosta-
sis). Primary hemostasis is the term used for the instantaneous plug formation
upon injury of the vessel wall, which is achieved by vasoconstriction, platelet
adhesion, and aggregation. The fibrin formation is not required for hemostasis
at this stage. Primary hemostasis is, however, only temporarily effective. Hem-
orrhage may start again unless the secondary hemostasis reinforces the platelet
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plug by formation of a stable fibrin clot. Finally, mechanisms within the fibrin-
olytic system lead to a dissolution of the fibrin clot and to a restoration of normal
blood flow.
2. ENDOTHELIUM AND THE VASCULAR SYSTEM
Normal, intact endothelium does not initiate or support platelet adhesion and
blood coagulation. Endothelial thromboresistance is caused by a number of
antiplatelet and anticoagulant substances produced by the endothelial cells.
Important vasodilators and inhibitors of platelet function are prostacyclin (pros-
taglandin I2, PgI2) and nitrite oxide (NO), formerly called endothelium-derived
relaxing factor (EDRF). The thrombin-binding protein thrombomodulin and hep-
arin-like glycosaminoglycans exert anticoagulant properties. Thrombomodulin not
only binds thrombin, but also activates protein C as a thrombin–thrombomodulin
complex. Endothelial cells also synthesize and secrete tissue factor pathway
inhibitor (TFPI), which is the inhibitor of the extrinsic pathway of blood coagu-
lation. In addition, tissue plasminogen activator (t-PA) and its inhibitor plasmi-
nogen activator inhibitor-1 (PAI-1), which modulate fibrinolysis, are secreted by
endothelial cells. Endothelial cells also possess some procoagulant properties by
synthesizing and secreting von Willebrand factor (VWF) and PAI-1. Following
injury, these procoagulant factors and tissue factor (TF) activity are induced.
This leads to adhesion and activation of platelets and local thrombin generation.
The hemostatic properties of the endothelial cells are modulated by cytokines
such as endotoxin, interleukin (IL)-1, and tumor necrosis factor (TNF), resulting
in an increased TF activity and downregulated thrombomodulin.
Small blood vessels comprise arterioles, capillaries, and venules. Only arte-
rioles have muscular walls, which allow changes of the arteriolar caliber. Upon
contraction, arterioles contribute to hemostasis, thus temporarily preventing
extravasation of blood. Platelet secretion of thromboxane A2, serotonin, and
epinephrine promotes vasoconstriction during hemostasis.
3. THE ROLE OF PLATELETS
Platelets are anuclear cells released from megakaryocytes in the bone marrow.
Their life span in the peripheral blood is approx 9 d. The average platelet count
in peripheral blood ranges from 150,000 to 400,000 per microliter. The mecha-
nism for their production, release, and aging is described in Chapter 1 under the
heading “Megakaryopoiesis.” The exterior coat of platelets is comprised of sev-
eral glycoproteins, including integrins and leucine-rich glycoproteins. They
mediate platelet adhesion and aggregation as receptors for agonists such as adenos-
ine diphsophate (ADP), arachidonic acid, and other molecules. Electron micro-
scopic examination shows the presence of many cytoplasmatic bodies such as
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α-granules and dense bodies (see Fig. 19.1). α-Granules are the storage site of
β-thromboglobulin, platelet factor (PF) 4, platelet-derived growth factor (PDGF),
VWF, fibrinogen, factor V, PAI-1, and thrombospondin. Dense bodies contain
ADP, ATP, calcium, and serotonin. Platelets also contain actin filaments and a
circumferential band of microtubules, which are involved in maintaining the
shape of the platelets. The open canicular system has its role in the exchange of
substances from the plasma to the platelets and vice versa.
Whereas normal platelets circulate in the blood and do not adhere to normal
vasculature, activation of platelets causes a number of changes resulting in pro-
motion of hemostasis by two major mechanisms:
1. Formation of the hemostatic plug at the site of injury (primary hemostasis).
2. Provision of phospholipids as a procoagulant surface for plasmatic coagulation.
The formation of the initial platelet plug can be divided into separate steps,
which are very closely interrelated in vivo: platelet adhesion, shape change, the
release reaction, and platelet aggregation (see Fig. 19.2). Within seconds after
endothelial injury, platelets attach to adhesive proteins, such as collagen, via
specific glycoprotein surface receptors (platelet adhesion). In this context, VWF
serves as a bridge that first adheres to collagen fibers and then changes its con-
Fig. 19.1. Ultrastructure of a platelet.
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firmation. This is followed by the binding of platelets to VWF via the platelet
membrane glycoproteins (GP) Ib and IX (see Fig. 19.3).
Two congenital bleeding disorders, von Willebrand disease and Bernard-
Soulier syndrome, are characterized by the absence of VWF and GP Ib/IX and
thus by defective adhesion, which causes a life-long bleeding tendency. Follow-
ing adhesion, platelets undergo a shape change from a disc shape to a spherical
shape and extend pseudopods. Almost simultaneously the release reaction oc-
curs by which a number of biologically active compounds stored in the platelet
granules are secreted to the outside. These released substances, which include
ADP, serotonin, Thromboxane A2 (TxA2), βTG, PF4, and VWF, accelerate the
reaction of plug formation and also initiate platelet aggregation, i.e., the adhesion
of platelets to each other. As a result of platelet aggregation, the platelet plug
increases in size and a further release of granular contents is initiated in order to
induce more platelets to aggregate. The prostaglandins play an additional role in
mediating the platelet-release reaction and aggregation. Thromboxane A2 is a
very potent inducer of platelet secretion and aggregation. It is formed from
arachidonic acid by the enzyme cyclooxygenase. Arachidonic acid is liberated
Fig. 19.2. Platelet adhesion, shape change with secretion, and platelet aggregation fol-
lowing activation.
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from the platelet membrane by phospholipases following activation of the plate-
lets by collagen and epinephrine. At the end of the aggregation process, the
hemostatic plug consists of closely packed degranulated platelets. Fibrinogen is
required for platelet aggregation binding to specific glycoprotein receptors (GP
IIb/IIIa) (see Fig. 19.4). In Glanzmann’s thrombasthenia, a disease characterized
by the absence of these receptors, the bleeding time is markedly prolonged,
platelet aggregation is absent, and clinically a life-long bleeding tendency is
present.
4. THE ROLE OF BLOOD COAGULATION
The fibrin clot is the end product of a multiplicity of complex reactions of
plasma proteins called coagulation or clotting factors. Most of the clotting fac-
tors are zymogens of serine proteases and are converted to active enzymes during
the process of blood coagulation. The six serine proteases are the activated forms
of the clotting factors II, VII, IX, X, XI, and XII. The letter “a” accompanying
a Roman numeral (e.g., factor Xa) indicates that the factor is in its activated form.
Factors V and VIII are not enzymes but co-factors, which, after activation, modify
the speed of the coagulation reaction. The reactions of the coagulation factors
take place on the surface of phospholipids. Following platelet activation, certain
phospholipids (i.e., phosphatidyl ethanolamine, phosphatidyl serine, and
phophatidyl choline) that were not present on the surface of the resting platelet
become exposed on the platelet surface. These newly exposed phospholipids
Fig. 19.3. von Willebrand factor as a bridge between the injured vessel wall (collagen
fibers) and platelet.
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provide the appropriate phopholipid surface upon which reactions of the coagu-
lation factors take place (Fig. 19.5).
The plasmatic coagulation traditionally has been divided into two different
pathways—the intrinsic and extrinsic pathway. This understanding of coagula-
tion has been built on studies of clotting in a relatively cell-free plasma system
in vitro. However, such a division does not really occur in vivo because factor
VIIa-TF complex is a potent activator of factor IX as well as factor X. The
principal initiating pathway of in vivo blood coagulation is the extrinsic system.
The critical component is TF, an intrinsic membrane component expressed by
cells in most extravascular tissues. The nomenclature “extrinsic” continues to be
used today, despite being somewhat outdated. TF is not always extrinsic to the
circulatory system, but it is expressed also on the surface of the endothelial cells
and leukocytes under certain pathological conditions. TF functions as a co-factor
of the major plasma component of the extrinsic pathway, factor VII. A complex
of these two proteins leads to the activation of factor VII to factor VIIa, which
then converts factor X to factor Xa, the identical product as formed by the intrin-
sic pathway. As mentioned previously, factor VIIa-TF complex also activates
factor IX to factor IXa. As factor Xa levels increase, however, factor VIIa-TF
complex is subject to inhibition by factor Xa-dependent TFPI.
Fig. 19.4. Scheme of platelet adhesion and aggregation. Surface glycoprotein (GP) Ib and
IX interact with von Willebrand factor to adhere to subendothelial tissue. Aggregation
involves the GP Iib/IIIa receptor and fibrinogen as essential co-factors.
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The early part of the intrinsic pathway is called contact phase. This phase is
carried out by factor XII (contact factor), prekallikrein, and high-molecular-
weight (HMW) kininogen. In vitro contact phase is initiated by the binding of
factor XII to negatively charged surfaces, such as glass or kaolin. This leads to
the formation of the enzyme factors XIIa and kallikrein, and the release of brady-
kinin from HMW kininogen. Factor XIIa then activates factor XI. The resulting
factor XIa converts factor IX to factor IXa, a reaction that requires the presence
of calcium. Factor IXa then forms a complex with its co-factor protein factor
VIIIa on a negatively charged membrane surface. This enzymatic complex, also
referred to as tenase complex, converts factor X to factor Xa.
After both the extrinsic and intrinsic pathways have resulted in the formation
of factor Xa, the ensuing reactions of the coagulation pathway are the same and
are referred to as the common pathway.
Based on the discovery that the factor VIIa-TF complex also activates factor
IX to factor IXa, which appears to be the favored reaction, a new revised concept
of coagulation was suggested in which factor VIIa-TF complex is thought to be
the main initiator of coagulation, whereas the intrinsic pathway is considered
necessary to sustain the coagulation response.
Fig. 19.5. Exposed phospholipids on the surface of platelets providing surface for coagu-
lation reactions.
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4.1. Formation of Fibrin
Fibrinogen is a large plasma protein with a molecular weight (MW) of 340 kDa.
It is synthesized in the liver and its concentration in normal individuals is in the
range of 200 to 400 mg/dL. The half-life of fibrinogen is about 4 to 5 d. It is a
dimeric protein of extremely low solubility composed of two pairs of three
nonidentical polypeptide chains, designated as A-α, B-β, and γ (A-α-2, B-β-2,
γ-2). The chains are covalently linked together by disulfide bonds. The conver-
sion of fibrinogen to fibrin proceeds in three stages. In the first step, thrombin
cleaves four small peptides—the fibrinopeptides A (FPA) and fibrinopeptides B
(FPB)—from the fibrinogen molecule, resulting in the formation of a new mol-
ecule called fibrin monomer. The release of these fibrinopeptides exposes sites
on the A-α and the B-β chains that seem to be essential for the polymerization
of the fibrin. In the second step, polymerization occurs spontaneously by
noncovalent end-to-end and side-to-side associations to form fibrin polymers.
These polymers are easily dissolved in denaturating agents such as urea or
monochloroacetic acid. In the third step, a resistent and stable fibrin molecule is
formed by the action of factor XIII (fibrin-stabilizing factor) and calcium ions.
Factor XIII must first be activated by thrombin before it becomes a transglutamase
capable of crosslinking fibrin polymers by forming covalent bonds (γ-glutamyl/
epsilon-lysil). The fibrin gel is now stabilized and insoluble in urea or
monochloroacetic acid.
5. INHIBITORS OF THE PLASMATIC COAGULATION SYSTEM
Human plasma contains a number of antiproteases that inhibit the activity of
most of the activated coagulation factors and fibrinolytic enzymes. These inhibi-
tors include antithrombin (AT), protein C and S, TFPI, and PAI, among others.
All belong to the serine protease inhibitors (SERPINs). Their task is to limit
thrombosis on the one side and fibrinolysis on the other side. A defect or decrease
of activity of these inhibitors can thus lead to thrombosis or hyperfibrinolysis.
5.1. Antithrombin
This glycoprotein with an MW of 65 kDa is synthesized in the liver, is com-
posed of a single polypeptide chain, and migrates with the α2-globulins. The
normal concentration of AT in plasma is in the range of 18 to 30 mg/dL. It is the
major inhibitor of thrombin, but it also inhibits the factors XIIa, XIa, Xa, IXa,
VIIa, plasmin, and plasma kallikrein. It inhibits thrombin as the other serine
proteases by forming a stable 1:1 complex between an arginine residue of AT and
the serine-active site of thrombin or the other clotting factors. The presence of
heparin greatly accelerates the reaction by inducing a conformational change in
AT, which renders arginine at the reactive site more readily available for the
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binding of thrombin (see Fig. 19.6). A congenital deficiency of AT may lead to
the occurrence of repeated episodes of venous thrombosis.
5.2. Protein C and Protein S
Protein C is the zymogen of a serine protease with an MW of 56 kDa and a plasma
concentration of about 0.4 mg/dL. Protein S (MW 69 kDa) serves as a co-factor for
activated Protein C and like protein C is a vitamin K-dependent protein. Its
plasma concentration is about 2.5 mg/dL. Protein S exists in plasma either in a
free form or bound to the C4b-binding protein, a component of the complement
system. Only the free form of protein S can serve as a co-factor for activated
protein C. When thrombin escapes the localized area of vascular injury, it must
be kept from freely circulating in blood. This is accomplished by the upregulation
of thrombomodulin on the cell surface of the vascular endothelium, primarily in
the microcirculation. Thrombomodulin binds thrombin, thus switching off the
procoagulant activity of thrombin. Thrombin in this bound form changes its
substrate specificity from fibrinogen to protein C. The thrombomodulin/throm-
bin-complex activates protein C. Following activation, activated protein C forms
Fig. 19.6. Antithrombin inhibits thrombin and other serine proteases. This reaction is
greatly accelerated in the presence of heparin.
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a complex with protein S. This complex degrades factor Va and factor VIIIa by
limited proteolysis, dramatically reducing the local generation of thrombin.
Activated protein C also increases fibrinolysis by inactivating PAI-1. The
downregulation of thrombin generation and the role of protein C and protein S
are shown in Fig. 19.7. The physiological significance of the protein C-
thrombomodulin pathway in the control of thrombin generation is emphasized
by the increased incidence of thrombosis in individuals with hereditary deficien-
cies of protein C or protein S. Recent studies revealed that in addition to a
deficiency state, an inherited poor anticoagulant response to activated protein C
also exists in patients with a point mutation in the factor V gene (Factor V
Leiden). Because this mutation involves the cleavage site of factor V by activated
protein C, the activated factor V in these individuals is resistant to cleavage and
thus to the ability of activated protein C to control thrombin generation (see
Chapter 21 ).
6. ROLE OF FIBRINOLYSIS
The fibrinolytic system is essential for removal of excess fibrin deposits in
order to preserve vascular patency. Figure 19.8 depicts its individual compo-
nents. The circulating proenzyme plasminogen is a single-chain glycoprotein
with an MW of 90 kDa. Cleavage of the Arg560–Val561 bond converts plasmino-
gen to an active two-chain plasmin molecule. Plasmin digests a number of plasma
proteins including fibrin, fibrinogen, and factors V and VIII . Conversion of
plasminogen to plasmin is achieved by a variety of plasminogen activators that
include physiological substances such as urokinase and tissue plasminogen
activator, as well as streptokinase, a compound derived from streptococcus
Lancefield group C. The most important circulating plasminogen activator in
humans is t-PA, which is a serine protease existing either in a single-chain or two-
chain form. Both t-PA and plasminogen bind to the fibrin gel and are incorpo-
rated into the developing thrombus. The stage is set for dissolution of the fibrin
clot from its inception. t-PA is not only present in human vascular endothelial
cells but is also found in other human tissues and cell lines. The control of
plasmin generation is as important as the previously described control of throm-
bin. The strongest inhibitor of plasmin is α2-antiplasmin, a single-chain protein
that forms a 1:1 complex with plasmin so rapidly that under normal circum-
stances free plasmin is never detectable. Other inhibitors of minor significance
are α2-macroglobulin and α1-antitrypsin. The most important inhibitor of t-PA
is the PAI-1, which not only inhibits t-PA but also urokinase plasminogen acti-
vator (u-PA). PAI-1 circulates in plasma in a free, noncomplexed form of 48 kDa
and as a complex with t-PA of 110 kDa. In normal human plasma, most of the
t-PA is complexed. Plasma-PAI-1 behaves as an acute-phase reactant, rising in
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Fig. 19.7. Thrombin is inactivated by endothelial thrombomodulin. The thrombin/thrombomodulin complex thereafter activates
protein C.
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a variety of pathological conditions and occuring in relatively large quantities in
platelets. A second inhibitor, known as PAI-2, has been identified in the placenta
and in plasma samples of pregnant women.
7. CLINICAL EVALUATION OF HEMORRHAGIC DISORDERS
7.1. The Bleeding History
The initial evaluation of a patient with hemorrhagic problems involves obtain-
ing a detailed history of bleeding symptoms and inspecting any current lesions.
The bleeding history forms the basis of the laboratory tests and therapy. Asking
patients if they are bleeders is not always helpful, as patients with mild to mod-
erate bleeding abnormalities may not admit that their bleeding episodes are
significant. Questioning must be specific and designed to ascertain whether
bleeding occurs in response to mild trauma. The diagnostic value of any single
hemorrhagic symptom varies with the different disorders. Valuable information
may be obtained if a patient has undergone major surgery; however, if this is not
the case, inquiries as to minor surgical procedures, such as dental extractions and
tonsillectomy, should be made. It is important to get information on the duration
of bleeding, the type of bleeding and what procedure was necessary to stop the
bleeding (blood transfusion?).
Fig. 19.8. Fibrinolytic system with the components of activation and inhibition.
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7.2. Physical Examination
The clinical examination of a patient is important to evaluate the nature and
extent of any current hemorrhage. Several clinical as well as laboratory features
help differentiate clinical disorders associated with qualitative and quantitative
platelet defects and abnormalities of the blood vessel wall (diseases of primary
hemostasis) from those associated with disorders of the coagulation factors.
Diseases of primary hemostasis have also been referred to as “purpuric syn-
dromes.” Purpuric syndromes are characterized by capillary hemorrhages occur-
ring chiefly in the skin and mucous membranes. The usual lesions encountered
are spontaneous petechiae and ecchymoses, which result from a breakdown of
the anatomic and physiological integrity of small vessel walls. Petechiae are
pinpoint to small areas of skin bleeding, which characteristically appear as crops
of lesions in dependent portions of the microvasculature. Larger accumulations
of skin lesions are usually called ecchymoses. It is often difficult to differentiate
petechiae secondary to a platelet disorder from purpura caused by a defect of the
blood vessel wall. The latter can only be proven by the absence of defects in
number and function of platelets. Gastrointestinal and genitourinary bleeding
may occur spontaneously with abnormalities of platelets and/or coagulation
factors. Deep hematomas, areas of palpable skin or soft tissue bleeding, and
hemarthroses are most often associated with coagulation factor deficiencies or
abnormalities. It is important to note the relationship of excessive bleeding to
antecedent trauma or surgery, such as tooth extraction, tonsillectomy, or circum-
cision. Recurrent bleeding for several days usually indicates an underlying bleed-
ing disorder. In women, a careful and thorough history of their menstrual bleeding
pattern gives valuable information about the nature of their hemostatic mecha-
nism.
8. LABORATORY EVALUATION OF HEMOSTATIC DISORDERS
Understanding of the physiology of primary and secondary hemostasis is
important for the interpretation of diagnostic laboratory tests and for the subse-
quent management of patients with hemostatic disorders. The type of bleeding
may be of significant help in designing the program of hemostatic laboratory
tests. Patients who have a severe hemostatic defect usually present no problems
in either clinical recognition or laboratory diagnosis. Unfortunately, difficult
diagnostic problems frequently arise because most patients who present for
evaluation show only mild or equivocal bleeding symptoms and the results of the
screening tests often turn out to be normal.
Familiarity with a number of laboratory procedures will enable one to place
a hemostatic defect in one of several broad categories, i.e., a disorder of the
platelets or a disorder of the plasma coagulation factors. More specialized tests
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are subsequently employed to establish a definite diagnosis. Thus, when evalu-
ating a bleeding disorder, the first task is to establish whether the disorder is
attributable to damage to the microvasculature (vasculitis), to an inadequate
number or function of platelets, or to impairment of the reactions leading to
thrombin generation and fibrin clot formation. This is accomplished by perform-
ing a platelet count, a bleeding time, an activated partial thromboplastin time
(aPTT) and a prothrombin time (PT), and a thorough review of the patient’s
peripheral blood smear.
8.1. Screening Tests
The platelet count is performed to detect thrombocytopenia, which is defined
as a platelet count of less than 150,000/µL. The test is usually performed as part
of an automated blood cell profile and can be considered as reliable down to a
platelet count of 30,000/µL. The finding of an unexpected thrombocytopenia
should be confirmed by a review of the peripheral blood smear. The possibility
of the existence of red blood cell fragments or of a pseudothrombocytopenia may
provide clues for further evaluation of the patient.
The bleeding time is defined as the time between the infliction of a small
standard cut and the moment the bleeding stops. Although the test is quite simple,
bleeding time has many variables and is difficult to standardize. Bleeding time
measures the interactions of the platelets with the vessel wall and the subsequent
formation of the primary hemostatic plug. A long bleeding time will be recorded
either when the number of platelets is decreased, their function is abnormal, or
there is defect of the vessel wall. The bleeding time may also be prolonged when
there is a decrease of plasmatic factors, especially the VWF or fibrinogen. The
various methods for performing the bleeding time are basically modifications of
two techniques: the bleeding time according to Duke, in which a puncture is
made in the earlobe, or the bleeding time according to Mielke, in which an
incision is made in the forearm while the capillaries are under increased constant
pressure from an inflated blood pressure cuff. The depth, width, and position of
the skin incision are difficult to standardize and thus the diagnostic usefulness is
of limited value as an individual test. Evaluation of the closure time (“in vitro
bleeding time”) with PFA-100™ (Platelet Function Analyzer) allows a rapid and
simple determination of VWF-dependent platelet function. This high shear stress
system was demonstrated to be sensitive and reproducible for the screening of
von Willebrand disease.
The prothrombin time (PT) is performed by adding a crude preparation of TF
(usually an extract of brain) to citrate-anticoagulated plasma, recalcification of
the plasma, and measurement of the clotting time. Both thromboplastin and
CaCl2 are usually added in a single step. The prothrombin time may be prolonged
because of a deficiency of a factor(s) of the extrinsic coagulation pathway, i.e,
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factors II, V, VII, X, and/or fibrinogen. A circulating anticoagulant directed
against on or more of these factors may also cause a prolongation of the PT. The
assay of coagulation factor deficiencies depends on the type of thromboplastin
used because each thromboplastin has a different sensitivity. Therefore, the
World Health Organization has proposed that thromboplastins be calibrated
against an international reference preparation to derive an international sensivity
index (ISI). Once the ISI of the thromboplastin is assigned, the results can be
reported as the international normalized ratio (INR). The INR has two major
advantages: it allows comparison between results obtained from different labo-
ratories, and it allows investigators to standardize anticoagulant therapy in clini-
cal trials and scientific publications.
The aPTT is performed by adding a surface activating agent, such as kaolin or
ellagic acid, and phospholipid to citrate-anticoagulated plasma. After a standard-
ized incubation time to allow optimal activation of the contact factors, the plasma
is recalcified and the clotting time recorded. In the old “cascade” theory of
coagulation, the aPTT involves factors of both the intrinsic and common path-
way (see Fig. 19.9). The aPTT may be prolonged as a result of a deficiency of one
or more of these factors or of the presence of inhibitors that affect the functions
of the factor(s) or the phopholipid reagents. A decrease in factor levels to less
than 30% of normal are usually required to prolong the aPTT. The aPTT will not
detect deficiencies of factors VII and XIII, the factor that crosslinks fibrin. In
some instances it may be helpful to perform a thrombin time (TT) as part of the
screening procedures. The test consists of adding a diluted solution of thrombin
to anticoagulated plasma and performing a clotting time. The thrombin time will
be prolonged when the levels of plasma fibrinogen are very low, and when
fibrinolytic split products, abnormal fibrinogen (dysfibrinogenemia), and/or
heparin are present. The presence of an inhibitor is identified when a mixture of
patient and normal plasma fails to correct the prolonged clotting time of the test
in question.
8.2. Interpretation the Screening Tests of Hemostasis
Discrimination of the majority of the inherited and acquired hemostatic dis-
orders is possible by looking at the results of the three screening tests: aPTT, PT,
and TT.
Patients with a prolonged aPTT and normal PT have abnormal activities of
factors in the first stage (intrinsic) of the coagulation mechanism (i.e., factors
VIII, IX, XI, and XII). Deficiencies of prekallikrein and HMW kininogen are
possible. Whereas deficiencies of factor XII, prekallikrein, and HMW kininogen
are not associated with bleeding, deficiencies of factors VIII, IX, and XI will
cause bleeding. A prolonged PT and a normal aPTT and TT may indicate a factor
VII deficiency. Inherited or acquired deficiencies of factors II, V, VII, and X have
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to be considered if a prolonged PT and aPTT and a normal thrombin time are
found. A prolongation of aPTT, PT, and thrombin time may reflect fibrinogen
deficiency or dysfibrinogenemia. Most congenital deficiencies are single,
whereas acquired abnormalities caused by vitamin K deficiency, liver disease,
disseminated intravascular coagulation (DIC), or anticoagulant therapy cause
multiple coagulation defects. A prolonged bleeding time in the presence of a
normal platelet count usually is a sign of an abnormality of platelet–blood vessel
interaction (e.g., von Willebrand disease). The proper interpretation of the screen-
ing tests of hemostasis will be time- and cost-effective with regard to determining
which coagulation factor assays are necessary to clearly identify the specific
factor deficiency and its level in patient plasma.
Fig. 19.9. The coagulation cascade.
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8.3. Specific Assays of Coagulation
Factors II, V, VII, and X are usually assayed by determining the ability of
various dilutions of the patient’s plasma to correct the PT of a plasma congeni-
tally deficient in the factor to be assayed. The degree of correction is compared
to that produced by equivalent dilutions of normal pooled plasma. Factors VIII,
IX, XI, and XII are determined in a similar manner except that the specific factor
assays are based on the aPTT.
A number of procedures for the determination of fibrinogen have been devised.
In most laboratories, however, the assays are based on the original method of
Clauss. This procedure involves an initial (10-fold) dilution of the plasma sample
to ensure that fibrinogen is rate limiting for clotting and the subsequent measure-
ment of the clotting time by the addition of an excess of thrombin to the sample.
The length of the clotting time is inversely related to the concentration of fibrino-
gen. The presence of inhibitors of fibrin polymerization, such as degradation
products of fibrinogen or fibrin produced by plasmin (DIC, fibrinolytic therapy)
may, however result in an underestimation of the actual fibrinogen concentration
in this assay.
The screening test for factor XIII is based on the ability of monochloric acid
to dissolve a fibrin clot in the presence of a severe factor XIII deficiency. Quan-
titative assays depend on factor XIII transamidase properties (i.e., the incorpo-
ration of monodansylcadaverine into casein). Chromogenic assays are also
commercially available.
Although a prolonged bleeding time is the hallmark of von Willebrand dis-
ease, this laboratory finding is not specific. Thus, the diagnosis has to be estab-
lished by additional laboratory tests. These usually include measurements of the
amount of von Willebrand antigen present in the plasma, the functional activity
of the VWF, and the procoagulant activity of the associated factor VIII molecule.
Analysis of the multimeric structure of VWF is useful in some special settings.
The VWF protein is quantitated by ELISA. In most patients with von Willebrand
disease the antigenic level of the VWF protein will be reduced. The mean VWF
antigenic level in individuals with blood group 0 is approx 25% lower than that
found in individuals with other blood types. The functional activity of VWF is
assessed by measurement of the ristocetin co-factor activity of the patient’s
plasma. In this assay, the ability of VWF in the plasma to agglutinate a standard-
ized suspension of fixed normal platelets in the presence of ristocetin is deter-
mined from either the rate or the extent of platelet agglutination.
Clinical platelet function tests measure platelet adhesion (retention) and
aggregation, the release reaction, and coagulant activity. These tests must be
meticulously performed and are usually available only in specialized laborato-
ries. Platelet aggregation is monitored by the increase in light transmission
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through a suspension of platelet-rich plasma as aggregation occurs. A sample
platelet aggregation curve is depicted in Fig. 19.10. Collagen, ADP, epinephrine,
arachidonic acid, and ristocetin are the agonists usually used in the hematological
laboratory. Platelet aggregation is affected by many drugs. In recent years flow
cytometry of platelets has become a most valuable tool to assess platelet function
in the specialized coagulation laboratory. This technique offers a number of
advantages, such as the examination of full blood samples, a multiparamter
examination (expression of glycoproteins, size of platelets, granularity of plate-
lets), and the chance to identify asymptomatic heterozygotes of rare platelet
disorders such as Glanzmann’s disease.
8.4. Tests of Hypercoagulability and Fibrinolysis
Failure of the coagulation mechanisms may cause bleeding, but failure of the
control mechanisms may give rise to thrombosis. These modulators of coagula-
tion include AT, protein C, and protein S. AT can be measured by immunological
and functional techniques. The functional assays that use chromogenic substrates
measure AT as a heparin co-factor. Heparin is added to form an AT–heparin
complex. This step is followed by adding an excess of thrombin, some of which
is neutralized by the AT–heparin complex. A chromogenic substrate is used to
measure the excess, uninhibited thrombin, which is inversely proportional to the
concentration of AT.
Fig. 19.10. Curve of ADP-induced platelet aggregation. The “second peak” is caused by
secretion of platelet granule contents, such as intrinsic ADP.
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For protein C, a number of functional assays exist that are based on the pro-
longation of the aPTT due to the inactivation of factors V and VIII by activated
protein C. Determination of protein S is complicated by the existence of a free
protein S and a complex of protein S with C4b-binding protein. Only the free
protein S serves as cofactor of activated protein C. A functional assay for protein
S is available using protein S-deficient plasma and activated protein C. The
anticoagulant effect of activated protein C is proportional to the amount of pro-
tein S added to the deficient plasma.
In the past, the fibrin/fibrinogen degradation products were measured by a
variety of methods. In most laboratories today, only the D-dimer, a cross-linked
fragment of fibrin not produced by the digestion of fibrinogen, is measured as a
diagnostic parameter for DIC and other thrombotic events. A monoclonal anti-
body has been produced that can detect the fibrin D-dimer in plasma. The fact that
the antibody does not react with fibrinogen allows the test to be performed in
plasma.
For the evaluation of hypercoagulability in the scientific laboratory, pro-
thrombin fragment 1 and 2 (F1 + 2), thrombin-antithrombincomplex (TAT), β-
thromboglobulin, and PF 4 can all be measured by ELISA. However, these
assays are usually not applied for evaluation of a bleeding patient or a patient with
thrombotic disorders.
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1. VASCULAR DISORDERS ASSOCIATED WITH BLEEDING
Vascular disorders of bleeding are classified into congenital disorders and
acquired disorders. Congenital disorders are caused by either vascular malfor-
mations (telangiectasias, hemangiomas) or disorders of connective tissue. Acquired
disorders usually present with purpura. The different vascular causes of bleeding are
classified in Table 1.
1.1. Hereditary Vascular Malformations
1.1.1. HEREDITARY HEMORRHAGIC TELANGIECTASIA
(OSLER-WEBER-RENDU DISEASE)
Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease) is the
most common inherited vascular bleeding disorder, with an autosomal-dominant
transmission and a positive family bleeding history in both sexes. Bleeding
occurs spontaneously or after minor trauma from teleangiectases (i.e., malfor-
mations of dilated small vessels in the skin and mucosa). These abnormal, small
vessels have very thin walls lacking smooth muscle. They rupture easily and do
not contract effectively, causing prolonged bleeding. The lesions have a diameter
of 2–4 mm, appear dark red, and are frequently localized on the face, the lips, the
348 Hiller
mucous membranes of the mouth or nose, and the fingertips. Bleeding becomes
more common in adulthood as the number of lesions increases. Recurrent epistaxis
and gastrointestinal hemorrhage are the most common bleeding patterns, and can
lead to iron deficiency anemia. Arteriovenous malformations may develop in the
lungs and can cause shunting of blood between the right and left heart.
Coagulation studies are normal. A causative treatment does not exist, and
treatment is symptomatic. Acute epistaxis must be treated by local measures
(compression, topical hemostatic drugs). In some instances, antifibrinolytic
therapy with tranexamic acid may be beneficial. Recurrent gastrointestinal bleed-
ing and recurrent pulmonary bleeding must be treated by surgical means. The
other hereditary vascular disorders listed in Table 1 are very rare. They are caused
by defects of the connective tissue or elastic fibers. The most important diseases
are Ehlers-Danlos syndrome, osteogenesis imperfecta, and pseudoxanthoma
elasticum. In all three diseases, the inborn defects of connective tissue lead to a
largely augmented vessel fragility and pathological changes of the skin and
skeletal system.
1.2. Acquired Vascular Disorders
The most frequent and important acquired vascular disorders are purpura
simplex, senile purpura, Henoch-Schönlein purpura, scurvy, and purpura due to
corticosteroids.
Table 1
Vascular Causes of Bleeding
Congenital disorders Hereditary hemorrhagic telangiectasia (Osler)
Cavernous hemangioma (Kasabach-Merritt)
Ataxia telangiectasia
Connective tissue disorders
Ehlers-Danlos syndrome
Osteogenesis imperfecta
Pseudoxanthoma elasticum
Marfan syndrome
Acquired disorders Purpura simplex
Purpura senilis
Purpura due to infections
Purpura due to chemicals or drugs
Henoch-Schönlein purpura (vasculitis)
Miscellaneous Amyloid
Excess corticosteroids
Paraproteinemia
Vitamin C deficiency (scurvy)
 Cushing syndrome
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1.2.1. PURPURA SIMPLEX (IDIOPATHIC PURPURA)
Spontaneous easy bruising of the trunk and the lower extremities, especially
during the reproductive period without any abnormality of platelet number and
function, is a relatively common problem. Sometimes, the patients report a minor
trauma with a painful event probably due to a rupture of small vessels. The cause
of purpura simplex is unclear, but is probably due to an increased fragility of skin
vessels. It is one of the most frequent reasons why patients come for evaluation
of their coagulation parameters. From a practical point of view, easy bruising is
a cosmetic problem. If the investigation does not reveal an underlying disease,
the patient has to be reassured and advised to avoid taking aspirin.
1.2.2. SENILE PURPURA
Progressive loss of collagen in the dermis and vascular wall may lead to
characteristic lesions of old age, senile purpura. The purpura usually occurs on
the dorsal side of the hands and wrists and on forearms. The lesions may be quite
large and are well demarcated. The skin is very thin, the dorsal veins have fragile
walls, and venipuncture may result in rapidly spreading purpura. The lesions
resolve slowly. No specific treatment exists. Prolonged pressure should be applied
after venipuncture in elderly patients.
1.2.3. PURPURA DUE TO INFECTIONS
Infections may cause purpura of the skin and mucous membranes (internal
bleeding) by a number of mechanisms, such as direct vessel damage by micro-
organisms or toxins, vasculitis, thrombocytopenia, or disseminated intravascu-
lar coagulation (DIC). There is usually an acute onset of fever, which may be
followed by renal failure, rapidly spreading purpura with skin necrosis, and
circulatory failure. The treatment of choice is to treat the underlying disorder.
1.2.4. HENOCH-SCHÖNLEIN PURPURA (ALLERGIC OR ANAPHYLACTOID PURPURA)
Henoch-Schönlein Purpura (allergic or anaphylactoid purpura) is a hypersen-
sitivity or acute necrotizing vasculitis involving the skin, kidneys, gut, and joints.
Increased permeability of the vessel wall leads to exudation and hemorrhage into
the tissue. Streptococcal bacteria have been suspected as offending agents, because
the clinical manifestations of the disease often occur 1–3 wk after an upper respi-
ratory tract infection. Drugs such as penicillin and sulfonamides have also been
implicated. There is an acute onset of fever with a macular–papular exanthema
on the buttocks, legs, and arms. The rash rapidly becomes purpuric and crops of
lesions are common. Internal organs (kidneys, gut, joints) are involved in about
half of the patients affected. In one half of the patients a cause of the disease
cannot be found. Clinical manifestations persist for up to 3 mo. Treatment is
symptomatic. Precipitating factors have to be excluded. Corticosteroids may be
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necessary and are often effective when systemic symptoms are marked. Relapses
occur frequently.
1.2.5. MISCELLANEOUS DISORDERS
Purpura due to damage of the vessel wall of the terminal vessels are seen in
a number of metabolic disorders such as diabetes mellitus, vitamin C deficiency
(scurvy), Cushing syndrome, and uremia, as well as following corticosteroid
therapy. Paraproteinemias and amyloidosis may also lead to purpura.
2. PLATELET DISORDERS
Although platelets are classified as cells, they are actually cytoplasmatic frag-
ments derived from megakaryocytes in the bone marrow. Platelet formation and
release probably occur through the sinus endothelial cells; however, others pos-
tulate that megakaryocytes undergo cytoplasmatic fragmentation in the pulmo-
nary capillary bed. Production and release of platelets from the bone marrow is
controlled by thrombopoietin. Platelets remain in the circulation for approx 8–
10 d. The normal platelet count ranges from 150,000/µL to 400,000/µL. The
diameter of normal platelets is 1–4 µm. At a given point, 70% of the platelets are
in the circulation and 30% are in the spleen (splenic pool). The daily platelet
production of 40,000/µL can be increased eightfold.
2.1. Quantitative Disorders of Platelets
Thrombocytopenia, by definition, exists when the platelet count drops below
150,000/µL, although bleeding attributable to thrombocytopenia usually never
occurs when the platelet count is above 100,000/µL. Spontaneous bleeding usu-
ally occurs with platelet counts less than 20,000/µL. Thrombocytopenia is due
either to decreased bone marrow production of platelets or increased destruction
and sequestration of the platelets from the circulation, or both. A diagnostic ap-
proach toward the etiology of thrombocytopenia is shown in Table 2.
2.2. Investigation of Thrombocytopenia
If either bleeding symptoms or an incidentally documented low platelet count
lead to the diagnosis of thrombocytopenia, a blood smear must be obtained to rule
out the possibility of a pseudothrombocytopenia caused by EDTA (platelet
clumps) or a hematological disorder such as acute leukemia. The size of platelets
may also give a diagnostic clue, because platelets may be enlarged in hereditary
conditions. A drug history must be taken and the patient questioned about symp-
toms of viral illness. If a hematological systemic disease is suspected, a bone
marrow examination will be necessary. Assays for detecting platelet antibodies
are quite unspecific and insensitive.
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2.3. Thrombocytopenia Due to Decreased Platelet Production
Thrombocytopenia due to decreased platelet production means that the bone
marrow is unable to keep up with normal platelet requirements. Table 2 depicts
the causes of thrombocytopenia due to underproduction of platelets (e.g., aplas-
tic anemia, leukemia, myelodysplastic syndromes). Thrombocytopenia fre-
quently occurs in patients with underlying malignancies who have received
chemotherapy or radiotherapy that destroy the hematological stem cells. These
patients require supportive therapy including platelet transfusions if they are
bleeding. A permanent normalization of the platelet count is only possible with
a successful therapy of the underlying disease. Megaloblastic anemias, including
vitamin B12  and folic acid deficiencies, can present as isolated thrombocyto-
penia, although usually, all cell lines are affected. Many patients with acute and
Table 2
Classification of Thrombocytopenias
Decreased platelet production
• Marrow failure (e.g., aplastic anemia)
• Marrow infiltration (e.g., leukemia, MDS)
• Marrow depression—cytotoxic drugs, radiation
• Selective megakaryocyte depression—drugs, ethanol, viruses, chemicals
• Nutritional deficiency—megaloblastic anemia
• Hereditary causes (rare)—Fanconi syndrome, amegakaryocytic hypoplasia, absent
radii syndrome, Wiskott-Aldrich syndrome
Increased platelet destruction
• Immune
– Idiopathic thrombocytopenic purpura
– Other autoimmune states—SLE, CLL, lymphoma
– Drug-induced: heparin, quinidine, quinine, gold, penicilline, cimetidine
– Infectious—HIV, other viruses, malaria
– Posttransfusion purpura
– Neonatal purpura
• Nonimmune
– DIC
– Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome
– Cavernous hemangioma
– Cardiopulmonary bypass
– Hypersplenism
MDS, myelodysplastic syndrome; SLE, systemic lupus erythematosus; CLL, chronic
lymphocytic leukemia; DIC, disseminated intravascular coagulation.
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chronic disorders of alcohol abuse have thrombocytopenia. Hypersplenism can
contribute to the thrombocytopenia if cirrhosis of the liver is present as well.
However, for most patients the thrombocytopenia is due to acute alcohol-
induced marrow supression. The hereditary causes of thrombocytopenia are
quite rare. In amegakaryocytic thrombocytopenia, the platelets are normal to
small in size, the platelet life span is normal or only slightly reduced, and the bone
marrow biopsy shows a marked reduction in the number of megakaryocytes.
2.4. Thrombocytopenia Due to Increased Platelet Destruction
Isolated thrombocytopenia is, in most instances, caused by increased platelet
destruction. In these patients, the rate of platelet destruction cannot be compen-
sated by the bone marrow with increased platelet production. The causes of
increased platelet destruction are shown in Table 2. These patients have isolated
thrombocytopenia, and the number of megakaryocytes in the bone marrow is
normal or increased. The platelet life span is shortened.
2.5. Immune Thrombocytopenia
Immune thrombocytopenia is an increase of platelet destruction caused by
immunological mechanisms. The sensitization of platelets by immunoglobulin
G (IgG) and IgM antibodies reacting with antigenic sites (usually glycoprotein
[GP]IIb/IIIa in idiopathic thrombocytopenic purpura [ITP], platelet alloantigens
in post-transfusion purpura, and neonatal isoimmune purpura) on the platelet
membrane is the main cause of platelet destruction.
2.6. Idiopathic Thrombocytopenic Purpura
ITP occurs in both children and adults. Acute ITP in children is equally com-
mon in boys and girls, has its peak incidence at age 2 to 4 yr, and frequently
follows a viral infection. More than 80% of these children have a spontaneous
remission of their illness in 2 to 4 wk. Serious morbidity or mortality is rare
(approx 1%), but the recovery of the platelets can be hastened by the administra-
tion of high doses of intravenous IgG (discussed later). The use of corticosteroids
without a bone marrow examination is controversial.
The peak incidence of ITP in adults is at 20 to 40 yr of age, and the disease is
much more common in women than in men (5:1). A number of patients will seek
medical attention because of petechiae, purpura, epistaxis, or menorrhagia. In
some patients, the hemostatic disorder is unmasked after taking a medication that
interferes with platelet function, such as aspirin. However, asymptomatic throm-
bocytopenia is discovered in a substantial number of patients during routine
blood testing. Except for clinical signs of bleeding (petechiae), the physical
examination is usually unremarkable. An enlarged spleen usually suggests a
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disorder other than ITP. In addition to the platelet count, a white blood cell count
and hemoglobin level should be measured in adult patients. ITP has normal white
blood cells and hemoglobin, unless chronic bleeding would have caused an iron
deficiency anemia. A bone marrow study may be useful to exclude other hema-
tological disorders, especially if a splenectomy is planned; however, in a consen-
sus recommendation, it was not generally recommended (1). If it is done, one
usually will find megakaryocytes in normal or increased number. As stated ear-
lier, assays for antiplatelet antibodies can no longer be recommended because of
the lack of sensitivity and specificity. Other tests may be performed because
certain autoimmune diseases are associated with ITP. These tests include those
to detect the presence of antinuclear antibodies and rheumatoid factor, thyroid
function tests, and serological tests for HIV.
ITP is caused by an autoantibody—almost always IgG—that binds to specific
platelet glycoproteins, especially GP IIb, IIIa. These antibodies attached to the
platelet membranes may bind complement and cause accelerated platelet destruc-
tion through phagocytosis by the reticuloendothelial cells in the spleen and the
liver. A compensatory increase in bone-marrow megakaryopoiesis usually occurs,
which may initially prevent or delay the development of more severe thrombocy-
topenia. In a few cases, the measurement of the platelet life-span may be helpful.
On rare occasions, platelets of patients with apparent ITP have a nearly normal
life-span. The cause of the thrombocytopenia in these patients is unclear, an early
myelodysplastic syndrome should be ruled out.
2.7. Treatment in Adults
The first issue is to decide whether a patient requires any specific treatment or
not. Patients with moderate thrombocytopenia (platelets >40,000/µL) with no
history or signs of bleeding do not require therapy and should just be observed.
In contrast, patients with clinical signs of bleeding or very low platelet counts,
usually less than 20,000/µL, require therapy. Initial therapy consists of corticos-
teroids (prednisone or prednisolone 1–2 mg/[kg · d]), which usually will raise the
platelet count to safe levels in 70–80 % of the patients within 1 to 2 wk. When
the platelet count has risen above 100,000/µL, one can begin to taper the dose of
corticosteroids down to 10–15 mg/d. Only a few patients (10–20 %) will have
long-lasting remissions following treatment with corticosteroids. Unfortunately,
the platelet count of most adults with ITP will fall as the dose of corticosteroids
is reduced. Splenectomy is indicated in patients who become unresponsive to
corticosteroids or require prohibitively high doses to maintain the platelet count
at an acceptable level. Splenectomy will not only remove the major site of plate-
let destruction but also a source of platelet autoantibody production. Approxi-
mately 70–80% of patients will sustain a long-term remission after splenectomy,
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and in 60% of patients the platelet count will return to normal. Prior to splenec-
tomy, a vaccination with pneumococcal vaccines is strongly recommended to pre-
vent a life-threatening pneumococcal infection (overwhelming postsplenectomy
infection syndrome [OPSI]) that may occur many years after a splenectomy.
Splenectomy fails to correct the platelet count in about 25% of adults with ITP.
In patients with an initial response to splenectomy followed by a relapse, the
possibility of an accessory spleen should be ruled out. Because subsequent treat-
ments pose increased risks to the patients, it should be decided whether treatment
in failing patients is absolutely necessary. Treatment options for failing patients
include “pulse-dose” dexamethasone (40 mg/d for days 1–4, every 4 wk),
azothioprine, cyclophosphamide, vinca alkaloids, cyclosporine A, and danazole.
The drugs may be effective in a few patients, but they have both considerable
acute and long-term side effects. High doses of intravenous IgG (0.4 g/kg for 2–
5 d or 1 g/kg day 1 [for 1–2 d]) raise the platelet count in about 60–70 % of patients
with ITP. For patients with life-threatening bleeding or preoperatively, if corti-
costeroids have failed, IgG is the treatment of choice. However, the platelet rise
is of short duration usually lasting only 1–3 wk. The costs of treatment are very
high. For this reason, treatment with intravenous IgG can only be justified in
emergency situations. The anti-D immunoglobulin is effective only in Rh D-
positive nonsplenectomized patients, in whom the antibody binds to the eryth-
rocyte D antigen. The mechanism of action involves immune-mediated clearance
of the opsonized erythrocytes via the Fc receptors of the reticuloendothelial
system, thereby minimizing removal of antibody-coated platelets. Anti-D
(WinRho SDF™) can be administered by intravenous injection over a few min-
utes. The response rate was 70% in one series, and the increase of platelets lasted
more than 3 wk in 50% of the responders. The standard dosage of 50–75 µg/kg
per day of intravenous anti-D requires 72 h to produce a clinically significant
platelet increase. The great majority of patients who respond to anti-D require
periodic retreatments. Several small studies have investigated the use of
rituximab, a monoclonal antibody directed against the B-cell antigen CD20. The
results were variable, but overall the response rate was about 50%, with 25–30%
sustained responses over 6 mo.
Because antiplatelet IgG traverses the placenta, about 25% of infants born to
mothers with active ITP will develop this disorder. In some cases, neonatal ITP
also occurs in infants born to women with only a history of a previous ITP.
Prenatal treatment with corticosteroids (prednisone 20–40 mg/d for 10–14 d) is
associated with reduced frequency and severity of thrombocytopenia in the in-
fants. For active ITP associated with bleeding, a cesarean section is recom-
mended. If a fetal scalp sampling reveals a normal or moderately reduced platelet
count of the infant, a spontaneous delivery should be allowed.
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2.8. Other Autoimmune Conditions
Immune-mediated thrombocytopenia with elevated levels of platelet-associ-
ated IgG occurs as a complication in a number of systemic disorders. It is usually
indistinguishable from classic ITP. The association of an immune thrombocy-
topenia with malignant lymphomas, systemic lupus erythematosus, thyrotoxico-
sis, infectious mononucleosis, and other severe infections is well known. Also,
the thrombocytopenia seen after bone marrow or renal transplantation may be
immune mediated. In autoimmune hemolytic anemia, a thrombocytopenia may
develop as a parallel event (Evan’s syndrome). The secondary thrombocytopenia
in these disorders may improve with the treatment of the underlying disease.
2.9. Drug-Induced Thrombocytopenia
A large number of drugs can induce thrombocytopenic purpura. In most cases,
isolated thrombocytopenia is caused by immune mechanisms, although few drugs
cause direct marrow toxicity in the absence of immune mechanisms. The drugs
that commonly cause thrombocytopenia include quinine and quinidine, heparin,
H2-antagonists (cimetidine, ranitidine), gold salts, valproic acid, and certain
antibiotics, especially the penicillins and sulfonamides. Clinically, drug-induced
thrombocytopenic purpuras are acute in onset, occurring within hours to days
after ingesting the offending drug. Chills and fever may precede purpuric and
petechial hemorrhage. Historically, the drug-induced thrombocytopenia due to
quinine or quinidine has been studied most extensively. The external platelet
surface is capable of nonspecifically absorbing certain antibody–drug complexes,
which then lead to platelet damage by an “innocent bystander” effect. The admin-
istered drug binds as a hapten to a plasma protein or “carrier” to form an antigen.
Antibodies stimulated by the immunogen bind to the drug, and these immune
complexes secondarily interact with the platelet membrane, leading to cellular
damage. Specific metabolic products of certain drugs rather than the primary
agent may interact as the offending immunogen. In recent years, heparin has
become the most thoroughly studied drug, because it may lead, in up to 5% of
patients, to an immune-mediated thrombocytopenia (see heparin). In drug-
induced thrombocytopenia, all drugs should be discontinued. If absolutely nec-
essary, these compounds should be replaced by pharmacologically equivalent
but chemically different preparations. Corticosteroids may be given; their value,
however, is disputable. In life-threatening bleeding complications, platelet trans-
fusions should be used.
2.10. Posttransfusion Purpura
The posttransfusion purpura syndrome occurs 1 wk after transfusion of blood
or blood products that contain or are contaminated with platelets. In this disorder,
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platelet-specific alloantigens have been implicated. The PIA1 antigen is present
in 98% of the population. The other 2% are at risk for the development of
posttransfusion purpura if they receive blood products that express PIA1. Thus,
the disorder will develop in those patients who have been previously sensitized
through blood transfusion or pregnancy. Most cases have developed in multi-
parous women without prior blood transfusions. The clinical picture resembles
that of acute ITP with platelet counts as low as 1000/µL. The diagnosis can be
confirmed by demonstrating a platelet-specific antibody from the patient that
reacts with PIA1. The antibody will disappear within 1 to 5 wk and the patient
usually recovers spontaneously.
2.11. Neonatal Purpura
Neonatal thrombocytopenia may develop due to isoimmunization of the
mother against fetal platelets with subsequent transplacental transfer. The inci-
dence of alloimmune neonatal purpura is 1 in 5000 deliveries. The most com-
monly involved antigen is PIA1, an antigen that is present on platelets of 98% of
the population. The infant shows generalized purpura at delivery, and platelet
counts are usually below 30,000/µL. Intracranial hemorrhage is a severe compli-
cation that occurs in about 10% of affected infants.
2.12. Nonimmune Thrombocytopenia
2.12.1. DISSEMINATED INTRAVASCULAR COAGULATION
This group of disorders is discussed in Chapter 21. It is generally associated
with significant thrombocytopenia. The platelets are “consumed” secondary to
the generation of excessive amounts of thrombin into the circulation.
2.13. Thrombotic Thrombocytopenic Purpura (Moschcowitz’s
Disease) and Hemolytic-Uremic Syndrome (Gasser’s Syndrome)
In both thrombotic thrombocytopenic purpura (TTP; Moschcowitz disease)
and hemolytic-uremic syndrom (HUS; Gasser syndrome), schistocytes (frag-
mented red blood cells, helmet cells) and low platelets are found. TTP is an acute
disease which presents a clinical spectrum, including thrombocytopenic pur-
pura, microangiopathic hemolytic anemia, renal disease, transient fluctuating
neurological symptoms, and fever. Neurological symptoms range from transi-
tory bizarre behavioral disturbances with sensorimotor deficits to seizures and
coma. The diagnosis is made on clinical grounds and by excluding other causes
of schistocytic hemolytic anemia and thrombocytopenia. HUS is a triad of throm-
bocytopenia, acute renal failure, and intravascular hemolysis with schistocyto-
sis. It is observed mainly in pediatric patients. There is a close clinical,
pathophysiological, and therapeutic relationship between TTP and HUS because
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of similarities of the thrombotic microangiopathy. Clinically, the neurological
symptoms of TTP are not present in HUS, whereas the severe renal dysfunction
characteristic of HUS is generally not as extreme in TTP. Because the throm-
bocytopenia is not caused by thrombin, most clotting tests are normal. However,
a number of studies have demonstrated abnormalities of the von Willebrand
factor (VWF) in patients with TTP. Pathologically, arterioles and capillaries in
multiple organs are occluded by hyaline thrombi. This material represents throm-
bin-induced dense platelet aggregates surrounded by thin layers of fibrin. The
exact pathogenesis of the platelet microthrombi has never been clearly eluci-
dated. TTP has been linked to a history of antecedent respiratory tract infections
and to the ingestion of certain drugs (antibiotics, oral contraceptives), as well as
to the postoperative state, pregnancy, meningococcal and mycoplasma infec-
tions, and vaccines. It is speculated that TTP and HUS are the consequence of the
intrusion into the circulation of one or more platelet-aggregating agents. The
aggregating agent has variously been reported to be a protein(s) with a molecular
weight of 37,000 or 59,000 Daltons. This may include a calcium-activated pro-
tease (calpain) that has the capacity to cleave VWF multimers into fragments
with increased platelet-binding capacity. Also, unusually large VWF multimers
that bind to platelet GP Ib-IX and IIb/IIIa with induction of aggregation may be
involved. In addition, there is evidence of a VWF depolymerase that reduces the
size of the unusually large VWF multimers that are synthesized. Recently it was
reported that the VWF-cleaving protease was purified and identified as a new
member of the ADAMTS (a disintegrin and metalloprotease with thrombospondin
motifs) family of metalloproteinases (ADAMTS13). The gene encoding this
protease is located on chromosome 9q34. Autoantibodies to this enzyme were
described. These antibodies apparently prevent the formation of small fragments
of VWF. During the acute episode, most patients with a single episode of TTP
have ultra-large multimers of VWF in plasma, probably because of systemic
endothelial cell injury. Serial studies of plasma samples from patients during
these episodes have shown that the ultra-large VWF multimers and also the large
forms of the multimers disappear as the TTP episode continues and worsens. This
is probably due to attachment of the ultra-large VWF multimers to the platelets
during intravascular aggregation. There is an increase in large multimers follow-
ing recovery or between relapses. For confirmation of the diagnosis, biopsies of
the gingiva, the bone marrow, skin, or muscle are recommended. These may
show hyaline thrombi in 50–60% of patients. In rare cases, familial and chronic
relapsing TTP is observed. Such patients have very low levels of ADAMTS13
plasma activity as a result of mutations of the ADAMTS13 gene. In the more
frequent cases of acquired idiopathic TTP, autoantibodies against ADAMTS13
are found. Clinically useful assays to measure ADAMTS13 activity are currently
under development.
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The treatment of TTP is a hematological emergency. Untreated TTP was fatal
in up to 90% of patients. Currently, plasma therapy brings the disease into remis-
sion in 80–90% of patients, although relapses occur frequently. The treatment of
choice is plasmapheresis and plasma exchange of 3–4 L/d. The rationale behind
this treatment is the replacement of platelet-aggregating factors, such as ultra-
large VWF multimers and other factors by normal blood components such as the
deficient depolymerase. Plasmapheresis and plasma exchange must be contin-
ued in some refractory or relapsing patients for up to 4 wk. If plasmapheresis or
plasma exchange is not available, the transfusion of larger amounts of fresh
frozen plasma may also be effective. This has often been successfully employed
with the chronic relapsing form of TTP. Although no sound scientific evidence
exists, many clinicians feel that patients with TTP may profit from additional
corticosteroid therapy. Plasma exchange with cryoprecipitate supernatant (from
which VWF-rich cryoprecipitate has been removed) has been successful in a
number of unresponsive patients. Some patients have also improved following
intravenous injections of vincristine. There is no evidence that aspirin or
dipyridamol are effective, and heparin is probably not only ineffective but also
dangerous.
In HUS, a disorder observed mainly in infants and young children, aggressive
therapy has reduced mortality to about 5%, although 20–25 % of the patients may
suffer permanent renal damage. When anuria is present for less than 24 h, fluid
and electrolyte therapy will usually be sufficient. If the HUS is more severe,
dialysis is required. This should be started early to prevent permanent renal
damage. As yet, it is unclear whether plasma therapy as employed in TTP plays
a role in disease management.
2.14. Cavernous Hemangioma (Kasabach-Meritt Syndrome)
Giant cavernous hemangioma is generally detected at birth and is due to
abnormal proliferation of capillaries (angiomatoid malformation) that may grow
during the first year of life but regress slowly in ensuing years. Thrombocytope-
nia, which may be severe, results from excessive sequestration and consumption
of platelets within the relatively static blood in the vascular network of the tumor.
Intravascular coagulation takes place within the tumor. Thrombocytopenia is the
most prominent feature of the generalized coagulation disorder. Surgical exci-
sion of the tumor, if possible, and radiation therapy have been used successfully
in therapy.
2.15. Cardiopulmonary Bypass
During extracorporal perfusion for cardiac surgery, a variable degree of throm-
bocytopenia almost always occurs. The mechanism of the thrombocytopenia is
multifactorial. The drop in platelet number is primarily due to hemodilution. In
Chapter 20 / Bleeding Disorders 359
addition, there is evidence of platelet activation and loss in the plastic tubing. The
drop in platelet count generally persists for several days following bypass prob-
ably due to increased clearance of damaged platelets. The bypass procedure can
also lead to abnormalities in platelet function.
2.16. Hypersplenism
Thrombocytopenia may occur in any disorder associated with an enlarged
spleen. Under normal circumstances, approximately one-third of the total body
platelet mass is found in the splenic pool, which exchanges with the freely cir-
culating platelets. In patients with splenomegaly, regardless of the cause, the
splenic platelet pool may be greatly expanded and up to 90% of the platelets can
be trapped at any one time. Thus, a redistribution of platelets will occur, resulting
in thrombocytopenia despite normal platelet production and normal platelet
survival. The thrombocytopenia secondary to splenomegaly is rarely severe
enough to produce hemorrhagic disease.
2.17. Thrombocytosis
Thrombocytosis refers to clinical situations in which the platelet count is
significantly elevated. Secondary thrombocytosis usually occurs as a temporary
event following splenectomy, or as a response to an acute or chronic inflamma-
tory disease, acute hemorrhage, iron deficiency, or exercise. Asymptomatic sec-
ondary thrombocytosis with platelet counts in the range of 600,000 to 1 million
µL may be present in a number of patients with untreated carcinoma, Hodgkin’s
and other lymphomas. The thrombocytosis may be caused by a nonspecific
megakaryocytic proliferative response to tissue necrosis. Thrombocytosis has
also been noted after the use of drugs such as vincristine, which interferes with
microtubules.
Essential thrombocythemia is a chronic myeloproliferative disorder with a
sustained increase of platelet production uncontrolled by normal regulatory pro-
cesses. Essential thrombocythemia is a clonal proliferative disorder primarily
affecting megakaryocytes (see “Myeloproliferative Disorders”). Hemorrhage
and/or thrombosis occur in about one-third of patients. Bleeding is usually from
mucosal surfaces and frequently is associated with one or more functional plate-
let abnormalities.
3. QUALITATIVE PLATELET DISORDERS
Several hemorrhagic disorders can be attributed to abnormalities in platelet
function occurring in the presence of adequate numbers of circulating platelets.
The abnormalities may result from processes involving adhesion, activation
aggregation, or a deficient release reaction. The bleeding time is probably the
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most useful in vivo test for rapid evaluation of platelet function. In vitro tests to
evaluate platelet function include the measurement of adhesiveness to glass bead
columns, platelet aggregation tests, and the most reliable system, platelet flow
cytometry.
3.1. Bernard-Soulier Syndrome (BSS)
BSS is a rare congenital bleeding disorder transmitted as an autosomal reces-
sive trait. The platelets are usually moderately decreased in number and on
review of the blood smear they are large and variable in their morphology.
Bleeding from cutaneous and mucous membranes is quite common. The major
functional abnormality in this disease is an impaired adhesion of the platelets to
the subendothelial matrix causing a markedly prolonged bleeding time. The
adhesion defect is due to a deficiency or absence of the GP Ib/IX complex, which
results in impaired interaction of platelets with VWF at the vessel wall. Thus,
BSS should be suspected when giant platelets are found on the blood smear and
when ristocetin is unable to aggregate platelets in the presence of normal VWF.
GP Ib/IX is the binding site for VWF when platelets are exposed to ristocetin. The
diagnosis is confirmed by quantitation of the GP Ib/IX complex by platelet flow
cytometry. Patients with BSS may need platelet transfusions to prevent or treat
hemorrhage. However, multiple transfusions will lead to the development of
alloantibodies that destroy donor platelets and limit the efficacy of subsequent
transfusions. Therapeutic modalities that have been employed with questionable
results include desmopressin (DDAVP), corticosteroids, and oral contraceptive
therapy to decrease menstrual bleeding. In a life-threatening bleeding complica-
tion also the recombinant factor VIIa (NovoSeven™) may be effective (see
“Hemophilias A and B”).
3.2. Thrombasthenia (Glanzmann Disease)
Glanzmann thrombasthenia is an autosomal recessive disorder characterized
by moderate to severe mucocutaneous bleeding, including menorrhagia, and
postoperative bleeding. In most patients, the bleeding diathesis is severe, although
there are exceptions. The hallmarks of the disease are a prolonged bleeding time
and an absent aggregation response to all aggregation agonists such as ADP,
collagen, epinephrine, thrombin, and arachidonate. The typical form of the dis-
ease is marked by a deficiency or absence of the platelet membrane GP IIb/IIIa
complex. As a result, the platelets cannot bind fibrinogen following platelet
activation and cannot aggregate to form the platelet plug. Thrombasthenic plate-
lets show normal secretory responses and can adhere to the vessel wall. The
diagnosis is confirmed by demonstrating the absence of agonist-induced platelet
aggregation and the absence or partial deficiency of the GP IIb/IIIa complex by
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platelet flow cytometry. Glanzmann thrombasthenia is classified into type I
patients, who completely lack GP IIb/IIIa and fibrinogen on the surface of their
platelets, and type II patients, who have a partial deficiency of GP IIb/IIIa (5–
20%) and fibrinogen on the surface of their platelets. In case of bleeding the
therapy of choice is platelet transfusions, which are successful initially but are
followed as a rule by subsequent immunization. According to recent case reports,
the recombinant F VIIa concentrate (NovoSeven™) seems to be a potential
alternative to platelet transfusion in Glanzmann’s thrombasthenia patients, par-
ticularly in those with antiplatelet antibodies and/or platelet refractoriness.
3.3. Abnormalities of Platelet Secretion
Platelet cytoplasma contains four types of granules: dense granules (contain-
ing ADP, ATP, calcium, and serotonin), α-granules (containing a variety of
proteins), lysosomes (containing acid hydrolases), and microperoxymes (con-
taining peroxidase activity). Following platelet activation, the contents of these
granules are secreted in a process called platelet secretion. Inherited disorders of
platelet secretion result from the deficiency of one or more of these types of
platelet granules or from abnormalities in the mechanism of platelet secretion
with a quantitatively normal granule population. These disorders usually cause
mild to moderate bleeding manifesting itself by easy bruising, menorrhagia, and
excessive postoperative or postpartum blood loss. Patients with a disorder of
platelet secretion usually have a moderately prolonged bleeding time, absence of
the second wave of platelet aggregation after stimulation with the agonists ADP
and epinephrine (δ-granule defect), and decreased aggregation after stimulation
with collagen. Similar laboratory patterns may be observed in acquired abnor-
malities of platelet secretion induced by drugs such as aspirin, or in systemic
diseases such as uremia and dysproteinemias.
3.4. α-Granule Deficiency
(Gray Platelet Syndrome, α-Storage Pool Disease)
The gray platelet syndrome is a rare bleeding disorder resulting from the
absence of morphologically recognizable α-granules in the platelets of affected
patients. The name derives from the large gray platelets that appear on the blood
smear. The disorder presumably results from a defect in granule formation or
packing within the megakaryocytes. α-granules contain a variety of proteins
such as platelet factor (PF)-4, β-thromboglobulin (TG), platelet-derived growth
factor (PDGF), thrombospondin, fibrinogen, VWF, and others. The lack of these
proteins can cause a life-long history of mild mucocutaneous bleeding and a
prolonged bleeding time. The number of platelets is usually decreased (60,000–
100,000/µL). Aggregation studies give conflicting results, but usually there is a
decrease or absence of collagen-induced aggregation.
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3.5. Dense Granule Deficiency (δ-Storage Pool Disease)
The diagnosis of δ-granule deficiency is usually suspected upon finding a
reduction in the amount of δ-granule substances (e.g., ADP, serotonin) in the
platelets. A defect in the platelet release reaction results in a single reversible
aggregation wave, because there are no dense body components to recruit plate-
lets for the second wave.
A hereditary deficiency in dense granules is also a feature of Hermansky-
Pudlak syndrome, which is associated with oculocutaneous albinism and a ceroid-
like pigment in marrow macrophages. Another dense granule deficiency disorder
is Chediak-Higashi syndrome (oculocutaneous albinism, chronic infections, and
hemorrhage). Platelet granule abnormalities have also been reported in Wiskott-
Aldrich syndrome (thrombocytopenia, infections, eczema). Platelets that have
normal dense granule components but are unable to release them have also
been classified as having an “aspirin-like” defect because the clinical symp-
toms resemble those following the ingestion of aspirin. Patients with δ-storage
pool disease present with a mild to moderate bleeding diathesis characteristic of
platelet secretion defects. The number of platelets and their morphology are
usually normal, whereas the bleeding time is often, but not always, prolonged.
3.5.1. THERAPY
Severe bleeding episodes may require platelet transfusions, but DDAVP
should be tried initially because it may be effective in a number of patients.
Acquired storage pool disease has been described in association with
antiplatelet antibodies, in systemic lupus erythematosus, in myeloproliferative
disorders, and following tumoricidal doses of mithramycin.
3.6. Acquired Disorders of Platelet Function
Several systemic diseases are complicated by qualitative abnormalities in
platelet function. In these systemic diseases, usually external or unphysiological
components of the plasma result in partial or complete interference with platelet
functions.
3.6.1. UREMIA
Many patients with uremia have a bleeding diathesis characterized by a pro-
longed bleeding time and abnormal platelet adhesion, aggregation, secretion,
and platelet procoagulant activity. The pathogenesis of the platelet defect is not
clear. Abnormalities in plasma VWF, reduction in GP Ib, and a decreased adhe-
sion via GP IIb/IIIa have been reported. Uremic platelets exhibit, when stimu-
lated, a reduced release of arachidonic acid from membrane phospholipids. Some
of the functional abnormalities may be due to a uremic toxin. Both dialyzable and
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nondialyzable substances found in uremic plasma can inhibit platelets in vitro at
high concentrations. The bleeding diathesis and the prolonged bleeding time in
uremia often improve with dialysis. Infusion of DDAVP (0.3 µg/kg) will improve
hemorrhage and bleeding times in more than 50% of uremic patients.
3.6.2. MYELOPROLIFERATIVE DISORDERS
Platelet dysfunctions are observed in patients with chronic myeloproliferative
disorders (essential thrombocythemia, polycythemia vera), but also in some
patients with acute leukemias and myelodysplastic syndromes. The patterns of
abnormality vary from patient to patient, and none of the functional defects
reliably predicts a potential clinical hemorrhage. In most of these disorders,
thrombocytopenia is usually a more significant cause of bleeding than platelet
dysfunction. However, in essential thrombocythemia, bleeding may occur with
elevated platelet counts, even if the bleeding time is normal. These same patients
may also experience vascular ischemic syndromes due to microvascular platelet
occlusion.
3.6.3. DYSPROTEINEMIAS
The dysproteinemias (multiple myeloma, Waldenström macroglobulinemia)
are another group of systemic disorders in which the hemorrhagic diathesis has
multiple causes. One major cause of bleeding complications is due to the block-
age of surface-connected platelet functions. Paraproteins adsorbed on platelet
and vessel surfaces result in the inhibition of GP IIb/IIIa, platelet adhesion, and
clot retraction. Platelet survival is shortened. Additional defects include throm-
bocytopenia, inhibition of coagulation factors (factor VIII), defective fibrin
polymerization, and hyperviscosity.
3.6.4. LIVER DISEASE
Disorders of hemostasis in liver disease are multifactorial. Clotting factor
deficiencies, thrombocytopenia, enhanced fibrinolysis, a mild persistent DIC,
and dysfibrinogenemia all contribute to bleeding and measurable coagulation
defects. Excess fibrinogen/fibrin degradation products that are present in liver
disease, adsorb to platelets and may interfere with platelet functions. Bleeding
time is frequently prolonged. DDAVP is effective in some patients, but in the
case of severe bleeding and platelet counts less than 50,000/µL, platelet trans-
fusions will be necessary.
3.6.5. DRUG-INDUCED PLATELET ABNORMALITIES
Many drugs affect platelet function in vitro, although relatively few of them
prolong the bleeding time. Aspirin ingestion results in abnormal platelet function
with a moderately prolonged bleeding time and a defective platelet aggregation
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due to the inhibition of the cyclooxygenase and the thromboxane synthetase (see
Chapter 19). Large doses of carbenicillin and other penicillins, as well as the
cephalosporin moxolactam, prolong the bleeding time in a dose-related fashion.
This effect begins within hours after drug administration and may last for several
days. All phases of platelet function—adhesion, aggregation, and secretion—
may be affected. In vitro, the penicillins impair the interaction of the VWF and
aggregation agonists with the platelet surface membrane. The plasma expanders
dextran and hydroxyethyl starch can prolong the bleeding time and cause abnor-
malities of platelet function comparable to those observed in dysproteinemias.
Numerous other agents used in clinical medicine adversely affect normal hemo-
stasis. Included among these are the anti-inflammatory agents (diclofenac,
indomethacine, and others).
4. INHERITED DISODERS OF BLOOD COAGULATION
Inherited disorders of blood coagulation are due to the lack of synthesis or to
the synthesis of a dysfunctional molecule of one and, in rare instances, more than
one coagulation factors. Although uncommon, theses disorders have provided a
great deal of information about the normal physiology of blood coagulation.
Factor VIII and factor IX deficiencies are inherited as a sex-linked trait. Von
Willebrand disease (VWD) is inherited in an autosomal dominant manner,
whereas all the other abnormalities of coagulation factors show an autosomal
recessive pattern of inheritance. Many of the coagulation proteins have been
cloned and their amino acid sequences are known.
4.1. Hemophilias A and B
Hemophilia A (factor VIII deficiency) is the most common hereditary disor-
der of blood coagulation. It is due to the absent or decreased function of coagu-
lation factor VIII, resulting from mutations in the factor VIII gene. The gene for
factor VIII is located near the tip of the long arm of the X chromosome (Xq2.8).
A rather large number of defects, including many deletions and different point
mutations, have been found in the factor VIII gene by mutation analysis. The
inheritance is sex-linked, but 30–40% of patients are without a positive family
history, thus in these cases, the presence of the factor VIII gene is likely the result
of spontaneous mutation. Hemophilia A occurs in approx 1 in 10,000 per-
sons. Because the gene for factor VIII is present on the X chromosome,
females are usually not affected because they carry only one defective gene. The
inheritance pattern of a case of hempohilia A is shown in Fig. 20.1. Children of
a female carrier have a 50% chance of inheriting the abnormal X chromosome.
The inheritance as well as the clinical features of hemophilia B (factor IX
deficiency, Christmas disease) are identical to those of hemophilia A. The inci-
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dence is one-fifth of that of hemophilia A. The two disorders can only be distin-
guished by coagulation factor assays. The factor IX gene is close to the gene for
factor VIII near the tip of the long arm of the X chromosome (Xq2.6). It is about
one-fifth the size of the factor VIII gene. Molecular probes have demonstrated
point mutations or deletions within the gene in a number of families.
4.1.1. CLINICAL PRESENTATION
Excess bleeding is relatively uncommon at birth. The first bleeding problems
usually start when a child starts crawling, and this may be from 9 mo to 1 yr of
age. Bleeding, however, can occur after surgery, i.e., circumcision. The first
signs that parents may notice are large skin bruises. Abnormal and recurrent
bleeding can then occur from any part of the body. A dominant feature of the
severe form of the disorder is recurrent painful bleeding into the joints (hemarthro-
sis) and into the muscles (muscle hematomas). Joint bleeding usually involves the
large joints (knees, ankles, ellbows), and the accumulation of blood in the joint
space leads to severe pain. If left untreated, the recurrence of the bleeding epi-
sodes will lead to progressive deformity and crippling in severely affected
patients (Fig. 20.2). Soft tissue and intramuscular bleeding may lead to consid-
erable blood loss, particularly in the retroperitoneum and the thigh. Repeated
subperiostal hemorrhage with bone destruction, new bone formation, and expan-
sion of the bone may result in large pseudotumors. Bleeding in the pharyngeal
area may be life-threatening because of potential airway obstruction. Minor head
traumas may cause serious CNS bleeding leading to death or permanent disabil-
ity. The severity of the bleeding manifestations depends on the remaining activ-
ity of factors VIII or IX measured in clotting assays (see Table 3).
Fig. 20.1. Sex-linked pattern of inheritance in hemophilia A and B.
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Fig. 20.2. Repeated hemarthroses result in chronic synovitis, destruction of cartilage, and
progressive flexion contractures. A and B are X-rays depicting the elbows and the knee
of a 35-yr-old patient with hemophilia.
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4.1.2. LABORATORY DIAGNOSIS
The laboratory diagnosis of the hemophilias is straightforward, as often the
family history and the clinical manifestations suggest the diagnosis. Of the screen-
ing tests, only the activated partial thromboplastin time (aPTT) is prolonged.
With the severe form of hemophilia, a prolongation in the range of 90–100 s can
be expected. Subsequent testing with a specific, factor VIII- or IX-deficient
plasma can prove the suspected diagnosis of hemophilia A or B. The bleeding
time, the prothrombin time, and also the VWF activity should be normal.
Diagnosis of carrier status with DNA analysis is more predictive if a restric-
tion-length polymorphism can be established for the affected family. Until
recently, the ratio of factor VIII to VWF was used to predict a carrier status. This
ratio is 0.5 in the carrier status as opposed to 1.0 in normal females. However, the
normal range of factor VIII is broad, which makes this method unreliable. For
antenatal diagnosis, chorionic biopsies at 8–10 wk gestation will provide suffi-
cient DNA from fetal cells for analysis using PCR technology. Caution should
be used in making a diagnosis of moderate or mild hemophilia B in the neonatal
period because normal levels of factor IX in full-term infants are not reached until
6–9 mo. Factor VIII levels, on the other hand, are in the normal adult range by
28 wk of gestation. Thus all forms of hemophila are distinguishable by assay in
both premature and full-term infants.
4.1.3. TREATMENT
Acute bleeding episodes are treated with concentrates of clotting factor VIII
in hemophilia A and clotting factor IX in hemophilia B. The plasma concentrates
are derived from the plasma donations of 10,000 or more individuals. Since the
mid-1980s, all commercial concentrates have been subjected to virucidal tech-
Table 3
Correlation of Factor VIII or IX Activity and Disease Severity
Coagulation factor activity (%) Clinical manifestations
>1 Severe disease
Recurrent spontaneous bleeding episodes
Joint deformities and crippling, if insufficiently
treated
1–5 Moderate disease
Occasional spontaneous bleeding
Postsurgical or posttraumatic bleeding
5–20 Mild disease
Postsurgical or posttraumatic bleeding
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niques to eliminate the transmission of pathogenic blood borne viruses (see
“Treatment-Related Problems”). Since the mid-1990s, recombinant factor VIII
concentrates have also been included in the treatment regimens, mainly for pre-
viously untreated persons (“PUPs”). Spontaneous bleeding (joints, muscles) is
usually controlled if the patient’s factor level is raised to 20% of the normal level.
If the hemorrhage is occurring at critical sites (CNS, nasopharyngeal area),
before major surgery, or after serious posttraumatic bleeding, the factor VIII
or IX level should be elevated to 100% and then maintained above 50% until
healing has occurred. The amount of clotting factor needed can be calculated as
follows:
1 unit of factor VIII/kg will raise the blood level by 1%
1 unit of factor IX/kg will raise the blood level by 1–2%
However, it must be taken into consideration that, in the event of acute bleed-
ing, the rise of the factor level may be only half of the amount calculated for more
stable situations.
DDAVP provides an alternative treatment for increasing the factor VIII levels
in patients with a mild form of hemophilia A. A residual factor VIII activity
(usually >10%) is required to obtain a moderate rise in the patient’s factor VIII
level following the intravenous administration of 0.3 µg/kg DDAVP.
Local supportive measures in treating hemarthrosis and hematomas include
resting the affected extremity and administration of systemic nonspecific drugs
such as antifibrinolytic agents (e.g., tranexamic acid), which may be helpful in
prevention or treatment of mucocutanous hemorrhage and after dental proce-
dures.
Most patients attend specialized hemophilia centers where they are educated
and trained on the management of bleeding complications including home treat-
ment. The coagulation factor concentrates may be stored in domestic refrigera-
tors and, at the earliest suggestion of bleeding, the affected hemophiliac can be
treated at home. This early home treatment reduces the occurrence of crippling
hemarthrosis and also saves a great number of hospital days. Treatment of hemo-
philia involves not only replacement therapy but an overall approach to the
patient and his family with regard to education, psychosocial care, and periodical
dental and orthopedic evaluation. With modern treatment, the daily life of a child
with hemophilia can be almost normal, although certain activities (body contact
sports) should be avoided.
4.1.4. TREATMENT-RELATED PROBLEMS
A serious problem in the management of hemophilia is the development of
inhibitors (usually IgG antibodies), which occur in 20% of patients with hemo-
philia A but only in 1% of patients with hemophilia B. As a result, the infusion
of the usual dose of factor VIII is no longer effective. The level of the inhibitors
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is expressed in Bethesda Units (BU). In the event of bleeding, “low responders”
(<5 BU) are usually treated with very high doses of factor VIII concentrates,
whereas for “high responders” (>5 BU) alternative treatment modalities are
required. These include certain factor IX concentrates containing activated fac-
tors that “bypass” the need for factor VIII (known as factor VIII inhibitor bypass-
ing activity or FEIBA), or a recombinant activated factor VII concentrate
(NovoSeven™).
Many hemophiliacs have features of subclinical liver disease and a few have
overt chronic hepatitis, due to the many infusions of clotting factor products that
had not been strictly subjected to virucidal techniques before the mid-1980s. A
fact is that transmission of hepatitits B or, more frequently, hepatitis C had
occurred in a great number of patients prior to 1985. This also accounts for the
transmission of AIDS, which was for a number of years the most common cause
of death in severe hemophilia. As a result of HIV in clotting concentrates infused
before 1985, more than 50% of the hemophiliacs treated in the United States or
western Europe were HIV positive. The incidence of clinical AIDS had been
steadily increasing. Fortunately, the new virucidal techniques (pasteurization,
terminal high temperature heating of lyophilized concentrates, and/or solvent/
detergent methods) have effectively eliminated new HIV transmissions and have
virtually prevented transmission of the lipid-enveloped hepatitis B, C, and D
viruses. In the 1990s, the safety has further increased by the introduction of
genetically engineered recombinant factor VIII concentrates.
4.2. Von Willebrand Disease
VWD is characterized by an abnormal platelet adhesion with or without a low
factor VIII activity. VWF promotes platelet adhesion and is also the carrier for
factor VIII, protecting the latter from premature destruction. This explains the
combination of defective platelet adhesion and reduced levels of factor VIII.
4.2.1. GENETICS
VWD is a bleeding disorder inherited in an autosomal dominant disorder. The
penetrance is high, but the expression is quite variable from family to family and
also within families. Severe type 3 VWD is inherited in an autosomal recessive
manner and is associated with very low or undetectable levels of VWF. A large
number of molecular defects have been identified in VWD, including point
mutations and major deletions.
4.2.2. PREVALENCE AND CLINICAL PRESENTATION
VWD is clearly the most common genetic bleeding disorder to be encountered
in clinical practice, although its estimated incidence varies widely from 0.1% to
as high as 1% of the general population. The most common variant, type 1 VWD,
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characterized by a moderate quantitative deficiency of functionally normal VWF,
accounts for about 70% of patients. The most common clinical features in VWD
are mucocutanous episodes, including epistaxis, easy bruising, hematomas, and
menorrhagia. Postoperative bleeding occurs after tooth extraction, tonsillec-
tomy, and, naturally, following major operative procedures. Bleeding is quite
variable in each patient and within the same family, and menstrual blood loss in
females varies widely in the same family. An unexplained observation is the
tendency of clinical symptoms to decrease after the patient enters the second
decade of life.
4.2.3. LABORATORY DIAGNOSIS
Initial diagnostic tests should include the bleeding time, a factor VIII assay,
and measurement of the levels of VWF. Bleeding time varies from abnormal in
moderately and severely affected patients to normal in patients with mild forms
of VWD. Bleeding time correlates well with the clinical symptoms. Because
bleeding time performed on the skin is quite insensitive, the automatic platelet
function analyzer (PFA-100®, Dade International) has become popular. Antico-
agulated fresh whole blood passes at a high shear rate through a capillary tube
through a membrane coated with collagen, in the presence of ADP or epineph-
rine, to an aperture. Formation of a platelet plug is signaled by a closure time
(CT). CT is more sensitive in VWD than bleeding time. Decreased factor VIII
activity will be detected only in patients with a moderate or severe form of VWD.
aPTT may be prolonged in those patients whose factor VIII activity is decreased
to less than 40% of normal. There is a defective platelet aggregation with ristocetin
in most patients with a moderate or severe form of VWD. Aggregation to the
other agonists (ADP, collagen, epinephrine) is normal. The VWF or ristocetin
co-factor assay uses washed or formalin-fixed normal platelets and compares the
rate of platelet aggregation using patient vs normal plasma in the presence of
ristocetin. This test measures the patient’s plasma VWF activity in a quantitative
manner.
Agarose gel electrophoresis allows visualization of different sizes of the VWF
multimers. This assay identifies the variant forms of VWD and helps to subdivide
the disorder into three major subtypes. Type 1 VWD refers to a partial quantita-
tive deficiency of VWF. Type 2 VWD refers to qualitative deficiency of VWF.
Type 3 VWD refers to a virtually complete deficiency of VWF. The qualitative
type 2 VWD is divided further into four variants—2A, 2B, 2M, and 2N—based
on the phenotype.
4.2.4. TREATMENT
Most patients with moderate disease (usually type 1) and mild bleeding symp-
toms or bleeding after minor surgery will respond to DDAVP (deamino-8-D-
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arginine-vasopresssin, desmopressin, Stimate®), a synthetic analog of the natu-
ral hormone vasopressin, which releases factor VIII, VWF, and plasminogen
activator from storage sites. It is given in a dosage of 0.3 µg/kg i.v. over 30 min.
DDAVP probably releases the very large VWF multimers from the endothelial
cells or platelets and thus corrects the prolonged bleeding time. The effect extends
over several hours, the response decreases if treatment is repeated over a period of
several days. It is helpful to determine the response to DDAVP at diagnosis or
before an elective procedure. The levels of factor VIII and ristocetin co-factor
activity should be determined 1 and 4 h after a test is done. DDAVP should not
be given in type 2B (may cause platelet agglutination and thrombocytopenia) and
type 3 VWD (it is ineffective). In these subtypes bleeding episodes must be
treated with plasma, cryoprecipitates, or intermediate-purity factor VIII concen-
trates, which contain VWF and factor VIII (e.g., Humate P®, licensed in the
United States for treatment of VWD). Factor VIII infusions may be associated
with sustained increases of factor VIII activity due to the fact that the infused
VWF in the factor VIII concentrate prolongs the survival of the patient’s own
factor VIII. Fibrinolytic inhibitors (tranexamic acid) have proved useful in
reducing bleeding from the mouth, nose, or uterus. In type 1 VWD, estrogens
or oral contraceptives, as well as pregnancy, increase the level of both factor VIII
and VWF. During and after delivery, care should be taken to minimize bleeding.
In types 1 and 2, factor VIII levels should be monitored for up to 2 wk. Alloan-
tibodies to VWF develop in 10–15% of patients with type 3 disease. In this
situation, very high doses of recombinant factor VIII can be infused until hemo-
stasis is obtained. Acquired von Willebrand syndrome is due to an accelerated
clearance of VWF secondary to its binding to abnormal cells or surfaces. This is
observed in lymphomas, essential thrombocythemia, and valvular heart disease.
4.3. Other Inherited Disorders of Coagulation Factors
All other inherited disorders (deficiency of fibrinogen, and factors II, V, VII,
X, XI, XII, and XIII) are very rare. In most instances the inheritance is autosomal
recessive and there is a clear correlation between the patient’s symptoms and the
severity of the coagulation factor deficiency. The conditions rarely produce
hemarthrosis and many patients with these inherited coagulation deficiencies
will not bleed unless they are exposed to surgery or trauma.
Inherited defects of fibrinogen are quantitative or qualitative. Quantitative
defects include heterozygous hypofibrinogenemia or homozygous afibrinogen-
emia. Qualitative defects—the dysfibrinogenemias—are inherited as incom-
pletely autosomal dominant traits with more than 200 reported fibrinogen
variants. Defective fibrin polymerization or fibrinopeptide release may occur.
The diagnosis should be suspected when the aPTT, the prothrombin time, and
thrombin time are prolonged.
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Deficiencies of the vitamin K-dependent factors II, VII, and X are associated
with spontaneous hemorrhages only in homozygotes, which is also true for patients
with factor V deficiency. Screening studies show a prolonged prothrombin time
in all four deficiency states, but also the aPTT may be prolonged if the factor
activity is below 30% of normal.
Factor XI deficiency is remarkable for the variability in bleeding symptoms
associated with it. Although rare in the general population, the incidence is much
higher in Ashkenazi Jews, in which as many as 5–10% have been estimated to
be heterozygotes. The diagnosis is made when a prolonged aPTT and a decreased
factor XI level are present.
Factor XIII deficiency is rare and is usually manifest clinically only in homozy-
gotes. Symptoms include delayed postoperative bleeding with abnormal scar for-
mation. The coagulation screening tests are normal, but clot solubility (e.g., in
5 mol/L urea) is not.
Deficiencies of the contact phase coagulation factors (factor XII, prekallikrein,
high-molecular-weight kininogen) are not associated with a clinical bleeding
diathesis. All three factor deficiencies may be suspected in the presence of a long
aPTT in the absence of bleeding symptoms. In factor XII (Hageman factor)
deficiency a latent hypercoagulability is probably present.
Therapeutic recommendations for the treatment of the rare autosomal-reces-
sive coagulopathies described previously are outlined in Table 4.
5. ACQUIRED COAGULATION DISORDERS
Acquired disorders of blood coagulation are much more common than the
inherited disorders and occur in a variety of clinical situations. Multiple coagu-
lation factor deficiencies are usual, which is not the case for the inherited disor-
ders. Many of these abnormalities are associated with the potential for significant
bleeding, others are associated with bleeding and/or thrombosis, and still others
are primarily laboratory phenomena. Routine screening tests of blood coagula-
tion can establish a presumptive diagnosis in most cases.
5.1. Vitamin K Deficiency
Vitamin K is a fat-soluble vitamin obtained by dietary intake of vegetables and
liver and absorbed in the small intestine, or produced by bacterial synthesis in the
small intestine. Vitamin K plays an important role in the posttranslational syn-
thesis of the vitamin K-dependent coagulation factors. Inadequate diet, malab-
sorption, or intake of drugs such as warfarin, which act as vitamin K antagonists,
can cause a deficiency of vitamin K. This in turn leads to a decrease in the
functional activity of the clotting factors II, VII, IX, and X, and the coagulation
antagonists protein C and S. Immunological methods show normal levels of
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these factors. These nonfunctional proteins are called PIVKA (proteins formed
in vitamin K absence). Conversion of the PIVKA factors to their biologically
active forms is a posttranslational event involving the insertion of carboxyl groups
at the γ carbon glutamic acid residues in the N-terminal region. γ-Carboxylated
glutamic acid plays an essential role in the binding of the zymogen to calcium—
a step that is required for the activation of these zymogens to serine proteases. In
the process of carboxylation, vitamin K is converted to vitamin K epoxide, which
is converted back to the reduced form by reductases. Oral anticoagulants are
thought to interfere with the reduction of vitamin K epoxide leading to a func-
tional vitamin K deficiency.
5.1.1. CLINICAL MANIFESTATIONS
5.1.1.1. Deficiency in the Newborn. The vitamin K-dependent factors are
low at birth and there is a further drop in breast-fed children during the first days
of life due to the immaturity of liver cells and the low quantities of these factors
in breast milk. Less than 1% of newborns may develop hemorrhages, usually
between the second and fourth day of life. The diagnosis is based on a low
prothrombin time. The therapy of choice is vitamin K (phytomenadione) at a
dosage of 1 mg given orally or intramuscularly. Children who are bleeding
should receive vitamin K every 6 h, and if the hemorrhage is more severe, fresh
frozen plasma should be given as well.
5.1.1.2. Deficiency in Adults. Because body stores are limited, dietary defi-
ciency may arise within a few weeks in patients who are not eating properly.
Systemic illnesses, parenteral nutrition, hepatic failure, malabsorption due to
small bowel disease, obstruction of bile flow, and antibiotic treatment may be
compounding factors causing vitamin K deficiency and associated with overt
bleeding. Both the prothrombin time and aPTT are prolonged and clotting factor
Table 4
Therapeutic Recommendations for Other Inherited Coagulopathies
Factor Half-life (h) Required blood level Source
II 41–72 20% Plasma, complex concentrate
V 24–36 10–15% Plasma
VII 2–5 10% Plasma, complex concentrate,
factor VII concentrate
X 20–42 20% Plasma, complex concentrate
XI 60–70 15–20% Plasma
XIII 100–120 2–3% Plasma, factor XIII concentrate
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analysis reveals low levels of factors II, VII, IX, and X in plasma. In liver disease,
additional coagulation defects are present. Most patients with mild to moderate
deficiencies do not have bleeding problems. Vitamin K, 10 mg administered
intravenously over 3–5 min, should shorten or correct the abnormal prothrombin
time within 6–8 h. Oral or parenteral treatment should be continued until the
basic disorder is corrected.
5.2. Liver Disease
Patients with liver disease may have multiple coagulation abnormalities that
predispose them to bleeding. The liver plays an important role in hemostasis
because hepatocytes synthesize coagulation factors I (fibrinogen), II, V, VII, IX,
X, XI, XII, and XIII, as well as the coagulation inhibitors antithrombin, protein
C and S, and components of the fibrinolytic system. As hepatic disease progresses,
deficiencies of some or, in severe disease, of all factors may occur. Liver disease
also leads to a reduced clearing of activated clotting factors and plasminogen
activators. Finally, as a result of very low thrombopoietin levels and splenom-
egaly, thrombocytopenia is a common feature in advanced liver disease. Biliary
obstruction can result in impaired absorption of vitamin K, causing a further drop
in factors II, VII, IX, and X due to decreased synthesis. All of these defects can
cause a multiplicity of coagulation abnormalities, making the precise mecha-
nism leading to the abnormal tests difficult to interpret. Prolongation of the
prothrombin time is usually the earliest abnormality. A prolonged aPTT,
hypofibrinongenemia, a prolonged thrombin time, and thrombocytopenia occur
as the disease progresses. The great majority of bleeding complications are sec-
ondary to preexisting anatomic lesions such as esophageal varices or gastritis and
peptic ulcers related in part to portal hypertension. Patients with overt bleeding
may be at additional risk to develop intravascular coagulation and fibrinolysis.
In general, fresh-frozen plasma containing all coagulation factors may be
useful in treating bleeding complications. Large volumes would be necessary to
correct the multiple coagulation defects. However, most patients would not be
able to tolerate large volume loads. Thus, the efficiency of fresh-frozen plasma
is of questionable benefit. Vitamin K may be of value in some patients. Prothrom-
bin concentrates, theoretically of value, carry the risk of enhancing pre-existing
intravascular coagulation and inducing thrombotic complications. Heparin may
prolong the half-life of some coagulation factors, but often increases the hemor-
rhages and should not be given.
5.3. Disseminated Intravascular Coagulation
The common denominator in DIC is the pathological generation of thrombin,
which leads to widespread intravascular deposition of fibrin and to the consump-
tion of coagulation factors and platelets (“consumption coagulopathy”). DIC is
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as such not a disease entity, but the consequence of a variety of disorders that
diffusely lead to the activation of coagulation mechanisms within the blood-
stream. The formation of thrombi in the microcirculation activates the fibri-
nolytic process as a compensatory mechanism to lyse the clots. This mechanism
generates circulating fibrin degradation products, which in concert with the
coagulation deficiencies and thrombocytopenia results in bleeding.
DIC occurs in a wide spectrum of diseases. DIC may be triggered by the
liberation and entry of procoagulant material into the circulation, which may
occur after premature separation of the placenta, in widespread metastatic car-
cinoma, or in acute promyelocytic leukemia (M3-leukemia). Another mecha-
nism potentially triggering DIC is the widespread endothelial damage occurring
in endotoxinemia, meningococcal septicemia, or following severe burns or hy-
pothermia. Vascular stasis as in circulatory shock and severe pulmonary embo-
lism can also precipitate DIC.
Table 5 lists the most common disorders associated with DIC.
Table 5
Causes of Disseminated Intravascular Coagulation
Obstetric complications
Amniotic fluid embolism
Retained dead fetus
Premature separation of placenta
Eclampsia
Malignancy
Acute promyelocytic leukemia
Pancreatic carcinoma and other neoplasms
Infections
Gram-negative septicemia
Meningicoccal septicemia
Septic abortion
Falciparum malaria
Hypersensitivity reactions
Incompatible blood transfusion
Anaphylaxis
Miscellaneous
Heat stroke
Hypothermia
Snake bites
Severe burns
Vascular malformations (Kasabach-Merritt syndrome)
Acute liver failure
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5.3.1. CLINICAL FEATURES
The most common signs of hemorrhages are petechiae, ecchymosis, oozing
from venipuncture sites and catheter sites, as well as bleeding from surgical
incisions. Thrombosis, which occurs in acute, very severe DIC, may lead to
cutaneous acrocyanosis or gangrene, oliguria, acute respiratory distress, and
neurological changes. The thrombotic changes are prominent in patients with
septicemia and hypoperfusion.
Not all patients experience severe bleeding and thrombotic complications.
Patients with a more chronic form of DIC, as commonly observed in malignancy,
have mild or no clinical symptoms at all and DIC becomes evident only by
laboratory analysis. However, these patients may become symptomatic after
stress situations such as surgery or severe infection.
5.3.2. LABORATORY FINDINGS
Because DIC is an acute emergency that may occur during the nighttime or on
weekends, the physician should have access to a simple panel of laboratory tests
that are available 24 h a day in the hospital laboratory. More sophisticated tests
are important for scientific questions. Table 6 lists a panel of tests that should be
requested if DIC is suspected.
The most common laboratory findings are thrombocytopenia, decreased fibrino-
gen level, prolonged aPTT, prothrombin time and thrombin time, elevated fibrino-
gen/fibrin split products or elevated D-dimers, and positive testing for
fibrin-monomer complexes. The inhibitors of coagulation, antithrombin, and
protein C are also likely to be depressed.
5.3.3. TREATMENT
Most important in the management of DIC is the treatment of the underlying
cause. All additional therapeutic recommendations are primarily empirical and
Table 6
Tests of Hemostasis in Suspected Disseminated Intravascular Coagulation
Plateletsa
Fibrinogena
Activated partial thromboplastin time
Prothrombin time
Thrombin time
Fibrinogen/fibrin split products (D-dimer)
Fibrin–monomer complex
Antithrombin, protein C
aImportant: Take serial measurements of platelets and fibrinogen.
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often not based on scientific evidence. Supportive therapy with fluid, blood, fresh
frozen plasma, platelet concentrates, and fibrinogen are indicated in patients with
dangerous or extensive bleeding. The use of heparin to reduce thrombin genera-
tion and interrupt the consumption of coagulation factors leading to fibrin for-
mation and microthrombi may be theoretically convincing, but is highly
controversial among experts. Many clinicians have observed that the use of
heparin has even aggravated bleeding in a number of cases. It may have its place,
however, at the very beginning of DIC in the absence of bleeding and in the more
chronic forms of DIC. Because the inhibitor antithrombin, which is consumed
during the process of DIC, acts as a direct inhibitor of thrombin, some smaller
study groups tried to evaluate antithrombin concentrates as a therapeutic agent
in the management of in acute DIC. In these small studies conducted in Europe,
it could be shown that antithrombin was able to shorten the duration of DIC, but
did not contribute to a prolonged survival of the patients studied. This may be due
to the small number of patients studied. In a large multicenter study in the United
States (KyberSept Trial), high-dose antithrombin therapy had no effect on 28-d
all-cause mortality in adult patients with severe sepsis and septic shock (usually
associated with DIC) when administered within 6 h after onset. High-dose anti-
thrombin was associated with increased risk of bleeding when administered with
heparin. There was some evidence to suggest a treatment benefit of antithrombin
in the subgroup of patients not receiving concomitant heparin (2).
Drotrecogin alfa (activated) is a recombinant human activated protein C prepa-
ration caused a reduction of the relative risk of death of 19.4% in a large double-
blind phase III sepsis study, at the cost of a slight increase in bleeding
complications. Other effects apart from coagulation inhibition seem to be involved
in the clinical benefit of this treatment. The approved indication for treatment with
drotrecogin alfa (activated) is severe sepsis associated with organ dysfunction,
independent of the presence of DIC. Patients are treated with 24 µg/kg body
weight per hour for 96 h (Tayler et al.).
5.4. Acquired Inhibitors
Acquired inhibitors of coagulation factors can result in bleeding or thrombo-
sis. Most of these inhibitors are IgG or IgM antibodies. They may develop in
response to a specific antigen exposure, as in patients with hemophilia A who are
treated with factor VIII concentrate (see“Hemophilias A and B,” and “Treat-
ment-Related Problems”). Factor VIII antibodies may also arise in a number of
other clinical settings, such as in the postpartum period, in certain immunological
disorders (lupus erythematodes, rheumatoid arthritis), following menopause,
and after exposure to certain drugs. They also may occur in healthy persons.
These inhibitors usually prolong the aPTT or the prothrombin time if they are
directed against factor II, V, VII, or X. They may be identified in vitro by the
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inability of normal plasma at a ratio of 1:1 with patient plasma to correct the
coagulation deficiency. Antibodies against VWF have also been described, usu-
ally associated with chronic myelogenous leukemia (“acquired VWD”).
If the patient is not bleeding, then no therapy is required. Clinical bleeding
requires replacement therapy. The infused coagulation factor may be ineffective
because of the rapid in vivo inactivation by the antibody. With effective treat-
ment of the underlying disease, the antibody may disappear. In postpartum or
menopausal women with acquired inhibitors and bleeding manifestations, an
immunosuppressive treatment (azothioprin, cyclophosphamide, anti-IgG-col-
umns) may be necessary.
Another inhibitor known as lupus anticoagulant interferes with phospholipid-
dependent stages in coagulation and is usually detected by a prolongation of the
aPTT. This inhibitor is detected in more than 10% of patients with systemic lupus
erythematosus and in patients with other autoimmune diseases. Frequently, the
patients also have antibodies to other lipid-containing antigens, such as cardio-
lipin. Because the lupus anticoagulant interferes with phospholipids, all tests that
depend on coagulation factor–phospholipid interactions are prolonged. The
lupus anticoagulant is not associated with a bleeding tendency, but the risk of
thrombosis and recurrent abortion is increased. Because the lupus anticoagulants
and/or antiphospholipid antibodies may be associated with a variety of clinical
presentations, therapeutic recommendations for individual patients will depend
on the predominant clinical manifestations (see Chapter 21).
5.5. Massive Transfusions
The transfusion of large amounts of blood within a few hours may lead to
severe coagulation disturbances and consequently to severe bleeding, requiring
even more transfusions. The extent of these disturbances is dependent on the
amount of transfused units of blood, the duration of storage of the blood, the
proteases derived from the leukocytes within the stored blood, the amount of
additional plasma expanders transfused, and, of course, the underlying disease
and its complications. Blood loss results in reduced levels of platelets, coagula-
tion factors, and inhibitors. Further dilution of these factors occurs during
replacement therapy with stored blood and plasma expanders. After 24–48 h
storage at 4°C, the platelet count falls progressively and the function of platelets
also deteriorates. In addition, the labile factors V and VIII lose activity because
of their short half-lives. A latent DIC may be aggravated by microaggregates of
platelets and degenerate leukocytes. Established bleeding with abnormal coagu-
lation tests (aPTT, prothrombin time) and low platelets should be treated by
administration of fresh-frozen plasma, platelet transfusions, and erythrocyte
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concentrates as needed. The value of transfusion of fresh whole blood or “warm
blood” has never been proven.
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1. THROMBOPHILIA (HYPERCOAGULABILITY)
Patients with a tendency to thrombosis are defined as having thrombophilia.
The term “inherited thrombophilia” should be used for individuals with predis-
posing genetic defects. Hypercoagulability and thrombophilia are synonymous.
Thrombophilia is usually suspected in patients with one or more of the following
clinical features: idiopathic thrombosis, thrombosis at a young age, recurrent
thrombosis, and thrombosis at an unusual site. Individuals who have laboratory
abnormalities or clinical disorders that are known to predispose to thrombosis,
but have not had an episode of thrombosis, are potentially thrombophilic. Prior
to 1993, the diagnosis of a hereditary disorder could be established in only 10–
15% of younger patients presenting with venous thromboembolism (VTE). The
only disorders known at this time were deficiencies of antithrombin (AT), pro-
tein C, and protein S. With the discovery of the factor V Leiden mutation (acti-
vated protein C [APC] resistance; see “Inherited Hypercoagulable States”) and,
more recently, the prothrombin gene mutation, it is currently possible to define
genetic risk factors in many younger patients with idiopathic venous thrombosis.
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The main acquired thrombophilic disorders are antiphospholipid antibodies and/
or lupus anticoagulant (LA), malignancy, nephrotic syndrome, myeloprolifera-
tive disorders, paroxysmal nocturnal hemoglobinuria (PNH) and induction of
cancer chemotherapy. In Table 1, patients with thromboses are placed into two
major categories. The first group has the characteristics suggesting an inherited
thrombotic disorder, whereas the second group describes acquired or secondary
hypercoagulable states arising in a heterogenous group of disorders.
1.1. Inherited Hypercoagulable States
1.1.1. FACTOR V LEIDEN MUTATION (APC RESISTANCE)
Resistance to the anticoagulant APC was first reported by Dahlbäck (1) to be
a major cause of hereditary thrombophilia. It is inherited as an autosomal trait and
associated with the disease in some 40% of thrombophilic families. The fre-
quency of APC resistance in unselected white patients with thromboembolism
has been found to be between 20 and 30%. The probability of developing a
thrombosis during lifetime is sevenfold as compared to controls. Dutch inves-
tigators from Leiden subsequently showed that a defect in factor V (i.e., the mutation
of argine 506 to glutamine 506 [Arg506Glu, Factor V Leiden]), is the cause of APC
Table 1
Inherited and Acquired Hypercoagulable States
Inherited hypercoagulable states
Activated protein C resistance due to factor V Leiden mutation
Prothrombin gene mutation
Antithrombin deficiency
Protein C deficiency
Protein S deficiency
Elevated factor VIII level
Dysfibrinogenemia (rare)
Hyperhomocysteinemia
Acquired hypercoagulable states
Antiphospholipid syndrome (Lupus anticoagulant)
Malignancy
Nephrotic syndrome
Paroxysmal nocturnal hemoglobinuria
Postoperative state
Immobilization
Old age
Pregnancy
Oral contraceptives or other estrogen use
Chapter 21 / Thrombosis and Therapy 383
resistance in 90% of the cases. This is the site at which factor Va is inactivated
by APC through the degradation of the factor Va heavy chain. The alteration
Arg506Glu makes the mutant factor Va molecule resistent to inactivation by
APC. Most patients with APC resistance are heterozygous for the factor V Leiden
mutation and are at a relatively low thrombotic risk, whereas homozygotes are
at a much higher thrombotic risk. The factor V Leiden-associated thrombotic risk
depends very much on the additional underlying clinical setting. Thus, oral con-
traceptives and pregnancy may significantly increase the risk for venous throm-
bosis in women with the mutation, whereas a statistical significant increased risk
with preexistent cancer or recent surgery could not be demonstrated (only 1.7-
fold increase). The latter may be due to the prophylactic heparin treatment given
during surgery (2). The prevalence of heterozygosity for factor V Leiden ranges
between 5 and 7% in Caucasians. The mutation is apparently not present in
African blacks, Chinese, Japanese, or native American populations.
1.1.2. PROTHROMBIN GENE MUTATION
In 1996, investigators in Leiden also reported that a G to A substitution at
nucleotide 20210 in the 3'-untranslated region of the prothrombin gene leads to
elevated plasma prothrombin levels and an increased risk of venous thrombosis.
In the Leiden Thrombophilia study, 6.2% of patients with venous thrombosis and
2.3% of matched controls had this prothrombin gene mutation. The mutation is
associated with a 2.8-fold increased risk of venous thrombosis. Among the
patients with thrombosis, 40% also carried the factor V Leiden mutation, which
supports the view of venous thrombosis as a multigene disorder. The prothrom-
bin gene mutation is the second most common genetic risk factor for venous
thrombosis.
1.1.3. AT DEFICIENCY
AT inhibits blood coagulation by inactivating thrombin and the other serine
proteases, i.e., factors XIIa, XIa, Xa, and IXa. AT deficiency is an autosomal-
dominant disorder with reduced and highly variable penetrance. Thus, between
15 and 100% of the AT-deficient members of affected families suffer from
thromboembolic disease. It is estimated that the lifetime thrombotic risk for
heterozygotes is 80–90%. Symptomatic AT deficiency has a prevalence of 0.02–
0.05% in the general population, but asymptomatic deficiency is propably up to
ten times more frequent (0.17%). The risk of developing thrombosis is low until
the age of 15, and then occurs at a rate of approx 2–4% per year. Patients with
AT deficiency are at a higher thrombotic risk to develop thrombosis than those
with other defects. A number of molecular variants has been described in differ-
ent affected families. AT concentrates are available for acute thrombotic epi-
sodes and for prophylaxis during surgery or delivery.
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1.1.4. PROTEIN C AND S DEFICIENCIES
Protein C is a vitamin K-dependent protein, which acts as inhibitor of the
activated factors V and VIII. Deficiency of protein C accounts for 3% of cases
of hereditary thombophilia. Inheritance is autosomal dominant with variable
penetrance. The rare homozygous patient presents with severe purpura fulminans
in infancy. A number of patients develop “coumarin necrosis” of the skin when
treated with oral anticoagulants, thought to be due to reduction of protein C levels
in the first two days of oral anticoagulant treatment before the reduction in the
levels of factors II, VII IX, and X. According to a large collaborative Austrian/
German study a lifetime thrombosis risk of 80% or higher was calculated for
heterozygous relatives with an annual incidence rate of 2.5%.
Protein S is a co-factor of APC in the inactivation of factors Va and VIIIa.
Protein S exists in a free form (30–40%) and in a complex with the C4b-binding
protein. Only the free form has APC co-factor activity. The inheritance of protein
S deficiency is autosomal dominant. The thrombotic risk profile of deficient
individuals is similar to those with protein C and AT deficiency. Data on the
prevalence of protein S deficiency in the general population are lacking. An
acquired decrease in protein S levels occurs in pregnancy and under oral contra-
ceptives.
1.1.5. HYPERHOMOCYSTEINEMIA
Hyperhomocysteinemia was found in one study in 10% of patients with a first
episode of venous thrombosis. In comparison with sex-matched controls, a rela-
tive risk of 2.3 was calculated, a figure which was confirmed in other studies.
Similar to venous thrombosis, hyperhomocysteinemia is also a common finding
among patients with arteriosclerosis, particularly among those who suffer from
clincal events at young age. A common genetic mutation may contribute to an eleva-
tion of plasma homocysteine. A missense mutation in methylentetrahydrofolate
reductase (MTHFR) at bp 677 that converts alanine to a valine codon was con-
firmed as a genetic risk factor for mild homocysteinemia, primarily when folate
levels are low. Additional genetic variants in MTHFR and in other enzymes of
homocysteine metabolism are being identified.
1.1.6. HIGH PLASMA CONCENTRATIONS OF FACTOR VIIIC
Studies have shown that an elevated level of factor VIII procoagulant activity
(factor VIIIc) is likely an independent, relatively prevalent risk factor for venous
thrombosis. The cause and the precise pathogenetic mechanism of the elevated
factor VIIIc, a known acute phase protein, is not understood. It is unclear whether
an increased factor VIIIc concentration is familial. It also remains unclear whether
there is a critical cut-off value of factor VIIIc plasma concentration or that there
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exists a dose-dependent relationship with the risk of thrombosis. According to
one study increased factor VIIIc levels (>175 IU/dL) may be found in approxi-
mately one-fourth of unselected patients with symptomatic VTE (3).
1.1.7. LABORATORY DIAGNOSIS OF INHERITED THROMBOPHILIA
Patients suspected of having an inherited thrombophilia should be referred to
a specialized coagulation laboratory. An important consideration in the labora-
tory evaluation of these patients is the timing of testing. Incorrect diagnoses can
be made as a result of the influence of acute thrombosis, anticoagulant treatment,
or co-morbid illnesses. Coagulation assays with high sensitivity and specificity
for the factor V Leiden mutation are now widely available. These tests are based
on the resistance of the mutant factor Va molecule to inactivation by APC. They
can not be done while a patient is under oral anticoagulant treatment. However,
testing for the factor V Leiden mutation can be performed by analyzing DNA
obtained from blood mononuclear cells regardless of whether or not the patient
is under oral anticoagulant treatment. The best screening tests for deficiencies of
AT, protein C, and protein S are functional assays that detect both quantitative
and qualitative defects. The prothrombin gene mutation can only be tested
genetically.
1.2. Acquired Hypercoagulable States
The risk of postoperative venous thrombosis has been a well-known fact for
many decades. Thrombosis is more likely to occur in the aged, obese, those with
a previous history of thrombosis, and in those in whom surgery for malignancy,
hip, or knee surgery is performed.
Venous stasis and immobility are factors responsible for the high incidence of
postoperative venous thrombosis and for venous thrombosis associated with
congestive heart failure and varicose veins.
Patients with malignancy, especially gastrointestinal carcinomas and carci-
noma of the breast, lung, and prostate have a continuous increased risk of throm-
boembolism. This is due to liberation of tissue factor from the tumor activating
the extrinsic pathway of coagulation, as well as to direct activation of factor X
by a cancer procoagulant (CP) from mucous adenocarcinomas independent of
the presence of factor VII.
Myeloproliferative disorders, such as polycythemia vera and essential
thrombocythemia, are associated with a relatively high risk of thromboembolism
and arterial thrombosis due to increased viscosity, elevated number of platelets, and
increased activity of platelets. Thromboses at atypical sites like hepatic and
cerebral veins are not uncommon. PNH and sickle cell anemia are complicated by
an increased number of venous thromboses, which also may occur at unusual sites.
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A high incidence of postoperative venous thrombosis exists for women on
high-dose estrogen therapy and full-dose estrogen-containing oral contracep-
tives. Estrogen therapy is associated with increased plasma levels of a number
of coagulation factors and decreased levels of AT and tissue-plasminogen acti-
vator (t-PA) in the vessel wall. Presently, there is controversial discussion as to
whether the new low-dose estrogen contraceptives are associated with a lower
number of thrombotic complications.
The LA, often associated with antiphospholipid antibodies (see Chapter 20),
is found in systemic lupus erythematosus, but also in other autoimmune disor-
ders, in lymphoproliferative disease, postviral infections, after certain drugs, and
for unknown reasons (postpartum, with menopause). It is often, but not neces-
sarily, identified by a prolonged activated partial thromboplastin time (aPTT).
This phenomenon is caused by an antibody that is directed against membrane
phospholipids causing a prolongation in all coagulation reactions in which phos-
pholipids are involved. Patient with LA have an increased risk to develop venous
and arterial thrombosis and pregnant women are at high risk for recurrent abor-
tion due to placental infarction.
1.3. Management of Thrombophilia
The acute management of an initial thrombosis or pulmonary embolism (PE)
in patients with hereditary or acquired thrombophilia is generally not different
from that of patients without thrombophilia (see “Thromboembolic Disease”).
Because recent data indicate that the risk of recurrence is greater in patients with
ongoing as opposed to temporary risk factors, it is reasonable to continue anti-
coagulant treatment in patients with inherited thrombophilia but no additional
exogenous risk factor (e.g., pregnancy, surgery) for at least 6 mo and no shorter
period. After 6 mo, an assessment must be made as to the relative benefit of long-
term anticoagulant therapy vs the potential side effects, inconvenience for the
patient, and costs. According to one study, testing for thrombophilia in unselected
patients who have had a first episode of VTE does not allow prediction of recur-
rent VTE in the first 2 yr after anticoagulant therapy is stopped (4).
2. THROMBOEMBOLIC DISEASE
Thrombosis can occur in either the arterial or venous system, but the thrombi
differ in their structure and clinical significance. Arterial thrombi usually form
at the site of pre-existing vascular lesions causing platelet reaction and accumu-
lation, and leading to the development of a “white” platelet thrombus. In veins,
thrombus formation is the consequence of increased thrombin formation in areas
of retarded blood flow and coagulated blood leads to the development of a “red”
thrombus.
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2.1. Venous Thrombosis
2.1.1. PATHOGENESIS
The complexity of venous thrombosis was already apparent to Virchow, who
stated in 1856 that the pathophysiology of thrombosis involved three factors: (1)
damage to the vessel wall, (2) stasis, and (3) increase in blood coagulability
(“Virchow’s triad”). None of these factors alone is usually capable of causing
thrombosis. It is the coincidence of activation of blood coagulation at the time of
surgery, the immobile leg veins, and possibly the damaged vessel wall, which
cause thrombosis. Whereas the first two components of Virchow’s triad repre-
sent acquired conditions, blood hypercoagulability is a result of both endogenous
(inherited) and exogenous (acquired) factors as outlined in the previous chapter
on thrombophilia.
2.1.2. CLINICAL MANIFESTATIONS AND DIAGNOSIS
Thrombosis in veins occurs most commonly in deep and superficial veins of
the lower extremities. Deep vein thrombosis (DVT) usually begins in the soleal
arcade of the calf muscles where they may resolve, organize, or extend. When
extension occurs, the thrombus involves the popliteal, superficial femoral, com-
mon femoral, and iliac veins; more rarely the inferior vena cava is affected. Once
extension into the major deep vessels of the leg has occurred, the patient is at
significant risk for circulatory obstruction, valve damage, and PE (see “Prophy-
laxis”). Damage to the venous valves may cause venous stasis and insufficiency;
possibly leading to chronic edema, fibrosis, pigmentation, and trophic ulceration
of the extremity. In a particularly serious form of DVT called phlegmasia cerulea
dolens, cyanosis and swelling of the extremity are associated with the disappear-
ance of the arterial pulses. The massive venous occlusion involving the deep,
superficial, and intercommunicating veins will lead to a total outflow obstruc-
tion. The leg becomes cold and without immediate surgical intervention gan-
grene and circulatory shock may follow.
Superficial thrombophlebitis usually is diagnosed clinically, because the
thrombosed vessel can be palpated beneath the skin as a tender cord. DVT is
much more difficult to diagnose, because it may or may not be accompanied by
local symptoms and signs. The most useful noninvasive technique is compres-
sion ultrasonography. The sensitivity and specificity for proximal DVT are more
than 95%. However, for isolated DVT in the calf, the sensitivity of ultrasono-
graphy is lower. Venography, though most specific, is no longer used often
clinically because of its invasive nature, its technical demands, and potential
risks, such as allergic reactions and renal dysfunction.
2.1.3. PROPHYLAXIS
Stasis should be eliminated whenever possible. This includes the wearing of
elastic stockings or a supportive hose and also intermittent pneumatic compres-
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sion. Early ambulation is encouraged after surgery or illness. Prophylactic hep-
arin therapy must be considered in high-risk groups and is mandatory for surgical
patients during the peri- and postoperative period. Heparin and its derivative,
low-molecular-weight heparin (LMWH), are the anticoagulants of choice for
prophylaxis and treatment of DVT. Both types of heparin are given in lower
doses when employed for primary prophylaxis than when used for the treatment
of DVT. Their major anticoagulatory effect is produced by activating AT. For
general surgical patients, 5000 U of standard heparin is administered subcutane-
ously two or three times daily and LMWH is administered once daily by subcu-
taneous injection in a fixed standard dose. Laboratory monitoring is not
necessary, because the low-dose heparin or LMWH used for prophylaxis usually
do not lead to a prolongation of the clotting times, such as the aPTT. In high-risk
situations, the dosage may have to be increased.
2.1.4. TREATMENT
The continous intravenous infusion of heparin has been, until recently, the
preferred mode of therapy in the treatment of DVT or PE. In adult patients with
an average weight of 70 kg, doses of 30,000–40,000 U over 24 h (1200–2000 U/
h with a loading dose of 5000 U) are usually required. Subcutaneous heparin
(e.g., 15,000 U every 12 h) can be used as an alternative to the intravenous route.
The therapy must be monitored by maintaining the aPTT between 1.8 and 2.5
times the normal time. Multicenter studies and meta-analyses have shown that
LMWH is as safe and effective as normal heparin in preventing recurrent VTE,
and causes less bleeding. LMWH must be administered in a weight-adjusted
fashion and does not require laboratory monitoring. Estimates of the number of
hospital days that would be saved by outpatient administration of initial therapy
average 5 to 6 d for each patient. Warfarin therapy can be started on day 2 after
the initiation of heparin therapy. Thus on days 5–7, one can expect that warfarin
is in the therapeutic range (international normalized ratio [INR] > 2) (see p. 341)
and heparin can be discontinued. Oral anticoagulant therapy should be continued
for at least 3 mo and longer than 3 mo when the thrombophilic state persists. In
recent studies, it was shown that long-term, low-intensity warfarin therapy was
highly effective in preventing recurrent thromboembolism (5).
The anticoagulants heparin and warfarin prevent additional thrombus forma-
tion and PE. However, after anticoagulant treatment, venous valve function and
venous pressure seldom normalize, thus predisposing to the postthrombotic
syndrome. Thrombolytic agents potentially dissolve the preformed thrombus
and restore the venous flow more promptly. In the treatment of DVT, it appears
that the early use of thrombolytic agents, such as streptokinase or urokinase,
decrease pain, swelling, and loss of venous valves; in some studies, it reduced the
incidence of the postphlebitic syndrome. However, this syndrome develops
late and is variable in its manifestation, and there are conflicting findings as to
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the long-term benefit. Because of the potentially severe bleeding complications
and the uncertain long-term benefit, thrombolytic therapy should be reserved for
selected younger patients with massive DVT involving the femoral and iliac
veins (for dosage, see “Thrombolytic Therapy”).
Inferior vena caval filter placement is recommended when there is a contrain-
dication or complication of anticoagulant therapy in a patient with or at high risk
for proximal vein thrombosis or PE. It is also recommended for recurrent embo-
lisms that occur despite adequate anticoagulation and for chronic recurrent
embolism with pulmonary hypertension.
2.2. Pulmonary Embolism
PE is a common complication of DVT that originates in the deep veins of the
leg in more than 90% of the cases. Most PEs are clinically silent. Dyspnea is the
most frequently reported symptom. Massive PE causes tachypnoe, tachycardia,
cyanosis, and hypotension. The diagnostic tests for PE include pulmonary angio-
graphy, ventilation/perfusion lung scanning, and, more recently, spiral computed
tomographic scanning. An elevated level of the D-dimer is well compatible with
a clinically suspected PE, whereas negative or normal D-dimers make a diagno-
sis of PE very unlikely.
Anticoagulants as previously outlined for treatment of DVT are definitely
effective in reducing morbidity and mortality from PE. Thrombolytic therapy
with streptokinase or recombinant tissue plasminogen activator (rt-PA) is more
effective than heparin alone in improving the angiographic defects produced by
PEs and may be better than heparin at preventing death in patients with massive
PE associated with shock. Based on these findings, thrombolytic therapy is the
treatment of choice for patients with massive PE. Massive emboli may be defined
as two lobar arteries completely obstructed with thrombus or several smaller
thrombosed vessels. The optimal treatment requires immediate start of infusion
upon diagnosis. Recent new therapeutic schedules have employed large doses of
thrombolytic agents as employed in cases of acute myocardial infarction. Thus
1.5 to 3 × 106 U of streptokinase or 100 mg of rt-PA are infused over 60 to 120
min leading frequently to prompt reperfusion of blood flow in the obstructed
vessels.
2.3. Arterial Thrombosis
Atherosclerosis is the most common underlying cause of coronary heart dis-
ease, cerebrovascular disease, and peripheral arterial disease. Arterial thrombo-
sis usually is a complication of atherosclerosis. Endothelial lesions due to
atherosclerosis of the arterial walls and plug rupture expose the blood to tissue
factor and subintimal tissue, such as collagen. This may initiate the adhesion of
platelets to the site of endothelial damage and the subsequent formation of a
platelet plug, which incorporates fibrin strands. Further aggregation is enhanced
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by the liberation of adenosine diphosphate (ADP) and thromboxane A2 (TxA2)
from the activated and damaged platelets. The platelet plug may organize and
becomes incorporated into the atherosclerotic plaque. With more marked arterial
narrowing, shear rates increase and promote more extensive platelet and fibrin
deposition, which can result in the formation of an occlusive thrombosis.
The most effective means of preventing arterial thrombosis is to prevent ath-
erosclerosis. A discussion of the risk factors and conditions and the reversal of
these conditions is beyond the scope of this chapter. At this point only the three
forms of medical therapy used in the treatment of arterial thrombosis—antiplatelet
drugs, anticoagulants, and thrombolytic agents—will be discussed shortly.
2.3.1. ANTIPLATELET DRUGS
Two antiplatelet drugs, aspirin and ticlopidine, have been shown to be effec-
tive in preventing and treating arterial thromboses. During recent years, glyco-
protein (GP) IIb/IIIa-receptor antagonists have also been introduced and show
great promise.
2.3.1.1. Aspirin. The antithrombotic effects of aspirin are attributed to its
ability to irreversibly inhibit platelet cyclooxygenase, thus reducing the synthe-
sis of TxA2, a potent inducer of platelet aggregation and vasoconstriction. The
inhibitory effects of aspirin persist for the life span of platelets, because the drug
irreversibly acetylates cyclooxygenase. The recommended oral dose is beween
100 and 300 mg daily. In a number of studies, it has been demonstrated that
aspirin has a mild to moderate benefit in reducing the incidence of further myo-
cardial infarction and sudden death in patients with coronary artery disease.
Aspirin also reduces the risk of stroke in patients with cerebral ischemia, particu-
larly in men, and decreases the risk of acute thrombosis after aortocoronary
bypass or coronary angioplasty. It may be useful in patients with thrombocytosis.
2.3.1.2. Ticlopidine and Clopidogrel. Ticlopidine and clopidrogrel inhibit
platelet aggregation induced by ADP and a variety of other agonists. Unlike
aspirin, the inhibitory effects on platelet function are delayed for 24–48 h after
administration, limiting the potential value when rapid antithrombotic action is
required. Ticlopidine has been shown to be more effective than aspirin in reduc-
ing strokes in patients who have suffered from transient cerebral ischemia (TIA)
or a minor stroke. Ticlopidine is also effective in reducing acute occlusion of
coronary bypass grafts and stents following angioplasty. In the latter setting, it
is often given in combination with aspirin. The recommended dose of ticlopidine
is 200 mg as tablets twice daily. The most serious side effect is neutropenia
occurring in 1–2%, less serious side effects are diarrhea and skin rashes. For this
reason, clopidogrel has been introduced, which has the same antithrombotic prop-
erties as ticlopidine without the side effects. The recommended dose is a 75-mg
tablet, once daily.
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2.3.1.3. GP IIb/IIIa-Receptor Antagonists. GP IIb/IIIa antagonists inhibit
platelet aggregation in response to all agonists, including collagen and thrombin,
because they block fibrinogen bridging between platelets, the final common
pathways of platelet aggregation. Three GP IIb/IIIa receptor antagonists have
been approved as adjunctive therapy to decrease the ischemic complications of
percutaneous coronary interventions (PCI) and/or unstable angina. They include
the chimeric murine/human monoclonal antibody 7E3 Fab fragment abciximab
Reopro™, eptifibatide (Integrilin™), a cyclic hexapeptide, and tirofiban
(Aggrastat™), a nonpeptidyl GPIIb/IIIa antagonist. Abciximab is administered
as an intravenous bolus of 0.25 mg/kg followed by an infusion rate of 10 µg/min
for 12 h. Abciximab is currently approved for high-risk coronary ballon
angioplasty. It has also been used with a favorable clinical experience in stent
implantation. The agents are very effective in providing both short-term and
long-term benefit after PCI. Severe thrombocytopenia is an infrequent but poten-
tially serious complication of therapy with all the agents.
2.3.2. ANTICOAGULANTS
The role of anticoagulants in the treatment of arterial thrombosis is controver-
sial. In patients with acute myocardial infarction, heparin in moderate doses
(12,500 U subcutaneously twice daily) may reduce reinfarction and death, and
will reduce the incidence of mural thrombosis. Heparin also prevents early
reocclusion of the infarct-related artery after successful thrombolysis. Oral
anticoagulants are probably effective in the long-term treatment of patients with
myocardial infarction as several studies have shown.
2.3.3. THROMBOLYTIC THERAPY
More than 80% of patients with acute myocardial infarction have thrombotic
occlusion of the infarct-related coronary artery. Thrombolytic therapy will pro-
duce rapid lysis of these thrombi in 50–75% of the cases. t-PA has been found
to be more effective than streptokinase in achieving early coronary lysis, but both
drugs improve left ventricular function and reduce mortality. In combination
with aspirin both agents reduce mortality by 40–50%. In the Global Utilization
Strategy for Thrombolysis of Occluded Arteries (GUSTO) study, an accelerated
t-PA regimen resulted in a 14% greater reduction of mortality than was achieved
with streptokinase. For dose recommendations, see the next section.
3. ANTITHROMBOTIC THERAPY
The conventional anticoagulant therapy with unfractionated heparin and oral
anticoagulants is based on indirect inhibition of coagulation factors. It is widely
used in the prophylaxis and treatment of thromboembolic disease. Its value in the
treatment of arterial thrombosis is less well established.
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3.1. Unfractionated Heparin
Unfractionated heparin (UFH) is a mucopolysaccharide from either porcine
or bovine sources with an average molecular weight (MW) of 15,000 Daltons.
The anticoagulant effect is produced by its interaction with AT. Binding of a
pentasaccharide sequence to AT causes a conformational change that accelerates
its interaction with thrombin and the other serine proteinases (i.e., factors Xa,
IXa, XIa, and XIIa). UFH can be administered by intravenous or subcutaneous
route. The biological half-life is 1–1.5 h. The bioavailability is only 30% after
subcutaneous administration. This is due to binding to a number of plasma pro-
teins, endothelial cells, von Willebrand factor, and neutralization by platelet
factor (PF) 4. For this reason the LMWH were introduced (discussed later).
The main indications for heparin are the treatment of DVT, PE, acute myocar-
dial infarction, and unstable angina pectoris. It is also used in cardiopulmonary
bypass surgery and for anticoagulation during pregnancy as it does not cross the
placenta.
For treatment of acute thromboembolic events, continuous intravenous infu-
sion with a perfusion pump has been the standard treatment for decades until the
LMWHs were introduced. For adult patients with a weight of 70 kg, doses of
30,000–40,000 U over 24 h (1200–1800 U/h) with a loading dose of 5000 U are
usually required. Subcutaneous heparin in a dose of 15,000–18,000 U every 12 h
is equally effective. Therapy is monitored by maintaining the aPTT between 1.5
and 2.5 times the normal value. It is usual to start warfarin therapy after 1–3 d of
heparin treatment and overlap with heparin until an INR in the therapeutic range
(2.5–3.5) has been reached.
In peri- and postoperative thrombosis, prophylaxis with UFH is given every
8 (high risk) or every 12 (normal risk) h in a dose of 5000 U subcutaneously. It
is not necessary to monitor the prophylactic dose.
3.2. Low-Molecular-Weight Heparins
LMWH is manufactured from UFH, usually of porcine origin, by controlled
depolymerization using either chemical or enzymatic techniques. LMWH-frac-
tions have an MW of about one-third of UFH (MW 5000). The smaller size with
its reduced negative charge causes less binding to plasma proteins and endothe-
lial cells, resulting in a much better bioavailability and more predictable anticoagu-
lant response than UFH. The longer half-life allows a single daily subcutaneous
dosage as thrombosis prophylaxis. The various LMWHs differ in mean molecu-
lar weight, aminoglycan content, and anticoagulant activity, which is usually ex-
pressed as anti-Xa activity. In contrast to UFH, LMWH have only minor anti-IIa
activity. Thus, even when used in higher therapeutic doses, the aPTT will not be
prolonged and cannot be used for monitoring. Currently, three LMWH prepara-
tions, enoxaparin (Lovenox®), dalteparin (Fragmin®), and ardeparin (Normiflo®)
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have been approved in the United States, and probably additional LMWH prepa-
rations—as is the case in Europe—will be approved in the near future. Because
evidence is accumulating that LMWHs have fewer serious complications than
UFH, such as bleeding, heparin-induced immune thrombocytopenia (HIT), and
osteoporosis, UFH has been replaced by LMWH in thrombosis prophylaxis in
many institutions. Recent randomized trials have shown that LMWHs are also
safe and effective in the treatment of uncomplicated DVT and even PE at home
as compared to intravenous UFH in the hospital. The rates of recurrent throm-
boembolism and major bleeding did not differ in the two treatment approaches.
The dose is weight-adjusted and laboratory monitoring is not required. The
positive results of a number of studies and one or two daily doses of LMWH
required will likely lead to the use of LMWHs in outpatient treatment of uncom-
plicated VTE in the majority of patients.
3.3. Complications of Heparin Therapy
The main adverse effects of UFH include bleeding, thrombocytopenia, and
osteoporosis after prolonged therapy. Patients predisposed to bleeding (peptic
ulcer, malignancy, liver disease, postoperatively) must be carefully monitored
and the dose of heparin reduced, unless a life-threatening clinical event (serious
PE) justifies a full heparin dose in spite of a high bleeding risk. If life-threatening
hemorrhage occurs, the effects of heparin can be reversed quickly by intravenous
infusion of protamine sulfate. The usual dose of protamine sulfate is 1 mg/100
U of heparin. The drug can be also used to reverse some of the action of LMWH.
Heparin-induced immune thrombocytopenia (HIT) is a quite frequently rec-
ognized complication of heparin therapy that usually occurs within 5–10 d after
initiation of heparin treatment. Of patients who receive UFH, 0.1 to 1% develop
immune thrombocytopenia mediated by immunoglobulin (Ig)G antibody di-
rected against a complex of PF 4 and heparin. This may be accompanied by
arterial or venous thrombosis (“white clot syndrome”) with potentially serious
complications, such as limb amputation, cerebral infarction, or death. For this
reason platelet counts determined two to three times weekly are required during
the first 3 wk of treatment. When HIT is diagnosed, heparin in all forms must be
discontinued immediately. For patients requiring ongoing anticoagulation, two
alternatives are possible:
1. Danaparoid (Orgaran, N.V. Organon Oss, The Netherlands)
2. Hirudin or argatroban, both are direct thrombin inhibitors (see following)
LMWHs may also cause HIT, but as compared with UFH, the incidence of
HIT is definitely lower.
Osteoporosis and fractures of vertebral bodies have been observed in patients
who have been treated with daily UFH doses of 20,000 U or more over a period
of several months. It is believed that this complication does not occur with LMWH.
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3.4. Oral Anticoagulants
Oral anticoagulants produce an anticoagulant effect by inhibiting the vitamin
K-dependent γ-carboxylation of coagulation factors II, VII, IX, and X. This leads
to biological inactive forms of these coagulation proteins (see Chapter 19). By
the same mechanism, synthesis of the inhibitors proteins C and S is impaired.
Currently, the following compounds, all 4-hydroxy coumarins, are in use: warfarin
(Coumadin®) mostly used in the United States, Canada, and Scandinavia;
phenprocoumon (Marcumar®), acenocoumarol (Sintrom®), and bishydroxy-
coumarol (dicoumarol), used in other European countries. Oral anticoagulants
have a very good bioavailability. Once absorbed from the intestinal tract, they are
bound to plasma proteins (97–99%), primarily to albumin. Therefore, interac-
tions with other drugs capable of displacing these agents from binding sites must
be taken into consideration. Changes in blood coagulability do not occur before
12 h after administration. It takes several days until the 4-hydroxy coumarins are
clinically fully effective and heparin can be discontinued. Laboratory monitor-
ing is mandatory throughout the course of treatment. Most commonly the pro-
thrombin time (PT) is used. It is sensitive to reduced activity of factors II, VII,
and X, but insensitive to a reduced factor IX. To standardize the monitoring of
oral anticoagulant therapy, the World Health Organization has developed an
international reference thromboplastin from human brain tissue and has recom-
mended that the PT ratio be expressed as the INR (see Chapter 19). The thera-
peutic range corresponds to an INR of 2–3.5. It is usual to start warfarin treatment
with 10 mg on days 1 and 2, 5 mg on day 3, and then alter the dose according the
results of the PT. The usual maintenance dose of warfarin is 3–9 mg daily, but
individual responses vary greatly.
3.5. Complications and Interactions
Bleeding complications are observed in 10–20% of patients treated with oral
anticoagulants. Half of these complications occur because the therapeutic range
of the PT or INR has been exceeded. Most bleeding complications are mild
(epistaxis, hematuria), but more serious bleeding, such as retroperitoneal hemato-
mas, gastrointestinal bleeding, or even cerebral bleeding, may occur. In keeping
within the therapeutic INR range of 2.0 and 3.0 for most indications, the hemor-
rhagic complications have decreased. Patients with life-threatening hemorrhage
or overdosage (error, suicidal) require immediate correction of the PT. The ad-
ministration of prothrombin complex preparations simultaneously with vitamin
K is necessary.
Drug interactions that affect the albumin-binding or excretion of oral anti-
coagulants, or those that decrease the absorption of vitamin K interfere with the
control of therapy and may either increase the risk of bleeding or render the
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treatment ineffective because of an insufficient anticoagulation. Table 2 lists a
number of drugs that either potentiate or depress the effects of oral anticoagu-
lants.
Warfarin-induced skin necrosis is a rare complication. During initiation of
warfarin therapy, usually between days 2 and 7, the patient develops a bluish
purple lesion on the buttock, breast, or thigh. Over several days this lesion
becomes increasingly necrotic while the surrounding tissue becomes erythema-
tous and inflamed. Thrombi in the microvascualture can be demonstrated histo-
logically. This skin necrosis is often due to a hereditary protein C deficiency.
After the onset of warfarin therapy, the activity of protein C, which has a short
half-life, drops to low levels before the other vitamin K-dependent coagulation
factors reach an anticoagulant level. Thus, protein C, already at a reduced level
due to the hereditary deficiency, is inappropriately low for 1–2 d following the
onset of warfarin therapy. For this reason, heparin must be simultaneously given
during the first 5 d.
Table 2
Drugs and Other Factors That Interfere With the Control of Anticoagulant Therapy
Potentiation of oral anticoagulants
Reduced coumarin binding to albumin
Phenylbutazone
Sulfonamides
Inhibition of microsomal degradation
Allopurinol
Metronidazole
Cimetidine
Tricyclic antidepressants
Alteration of hepatic receptor site
Quinidine
Thyroxin
Diminished vitamin K uptake
Malabsorption
Antibiotic therapy (moxalactam)
Depression of the effects of oral anticoagulants
Acceleration of microsomal degradation
Barbiturates
Rifampicin
Increased synthesis of clotting factors
Estrogen
Oral contraceptives
Pregnancy
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Teratogenic effects have been described with coumarin derivatives. Fetal
exposure during the first trimester may result in embryopathies (nasal hypopla-
sia, epiphyseal abnormalities). Oral anticoagulants are therefore contraindicated
in the first trimester of pregnancy. LMWH is recommended throughout the preg-
nancy, if anticoagulation is mandatory.
3.6. Direct Thrombin Inhibitors (Hirudin)
In contrast to UFH and LMWH, direct thrombin inhibitors inactivate not only
free thrombin, but also thrombin bound to fibrin. Hirudin (Desirudin, Lepidurin),
a polypeptide obtained by recombinant technology, and its synthetic derivative
hirulog interact with both the active site of thrombin and the substrate recognition
site. From a theoretical point of view, the direct thrombin inhibitors should be
superior to heparin, which is an indirect thrombin inhibitor. However, random-
ized controlled trials conducted in patients with acute coronary syndromes
reported no significant evidence for a superiority of the direct thrombin inhibi-
tors (desirudin) over UFH.
Lepirudin was extensively studied in heparin-induced thrombocytopenia,
and appears effective and safe, allowing platelet count recovery and providing
adequate anticoagulation.
In a study in patients undergoing hip replacement, desirudin significantly
reduced the frequency of postoperatice DVT compared with LMWH therapy
without an increased incidence of bleeding.
aPTT is largely used to monitor therapy with direct thrombin inhibitors.
However, aPTT is insensitive at plasma levels higher than 0.6 mg/L of hirudin,
so that overdoses may be missed despite monitoring. Therefore, therapy with
direct thrombin inhibitors should be monitored with the ecarin clotting time.
Renal insufficiency causes accumulation of the blood levels of hirudin and a high
risk of bleeding because the drug is exclusively excreted by the kidney.
3.7. New Antithrombotic Drugs
Two new antithrombotic drugs have been investigated in a number in large-
scale clinical studies and have the potential of improving the treatment of throm-
botic disorders. One of them, fondaparinux, has already been introduced in
Europe.
3.7.1. FONDAPARINUX (ARIXTRA®)
Fondaparinux is a pentasaccharide and is a synthetic antithrombotic agent. To
inhibit thrombin, UFH must bind not only to AT but also to thrombin itself,
whereas fondaparinux binds only to AT and is therefore a specific inhibitor of
factor Xa. Its pharmacokinetic properties allow for a simple, fixed-dose, once-
daily regimen of subcutanous injection without the need for monitoring. In a
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dosage of 2.5 mg s.c. once daily, it was found to be superior to enoxaparin in
thrombosis prophylaxis in high-risk patients undergoing orthopedic surgery for
hip and knee replacement. Also, in a dose-ranging trial involving patients with
symptomatic proximal DVT, 7.5 mg of fondaparinux appeared to have efficacy
and safety similar to those of LMWH (dalteparin). In a clinical trial of initial
antithrombotic therapy for acute symptomatic PE, therapy with fondaparinux
was equal to therapy with UFH. It probably does not cause HIT.
3.7.2. NEW DIRECT THROMBIN INHIBITORS (ARGATROBAN, XIMELAGATRAN)
As a result of better understanding the interaction of hirudin with thrombin,
other direct thrombin inhibitors such as argatroban and melagatran, both of which
can neutralize clot-bound thrombin, have been developed. Argatroban is is ap-
proved in the United States and Canada for both prophylaxis and treatment of
thrombosis in patients with HIT and in the United States as an antithrombotic agent
during percutaneous coronary interventions in patients with HIT or a history of
HIT. The therapeutic half-life is 46 ± 10 min. Treatment is initiated at a dose of 2
µg/kg/min. The aPTT is checked 2 h later, and the dose is adjusted to prolong the
aPTT one-and-a-half to three times the baseline (maximum 100 s). There is no
antidote for bleeding. Melagatran is poorly absorbed, but has been chemically
modified and, in the form of ximelagatran, is the first new oral anticoagulant since
warfarin. Ximelagatran is metabolized to melagatran and, like fondaparinux, does
not require laboratory monitoring. It has been tested in a number of major clinical
trials and was equal and in some trials even superior to the conventional
antithrombotic drugs such as heparin and warfarin. In a study for the prevention
of VTE after total hip- and knee-replacement surgery, two daily oral doses of 36
mg were superior to enoxaparin. In prevention of arterial thromboembolism in
atrial fibrillation, ximelagatran was as effective as oral anticoagulation with war-
farin. Ximelagatran is not approved by the US Food and Drug Administration and
suspended in Europe in 2006 as a result of liver toxicity.
3.8. Fibrinolytic Therapy
Fibrinolytic agents, in contrast to anticoagulants, digest and dissolve arterial
and venous thrombi and emboli and thus reinstitute blood flow distal to the site
of obstruction. They have been used systemically for patients with acute major
PE, ileofemoral DVT, acute myocardial infarction, and locally in patients with
acute peripheral arterial occlusion.
To date, four different fibrinolytic agents have been approved for clinical use:
streptokinase , urokinase , rt-PA, and acylated plasminogen-streptokinase acti-
vator complex (APSAC). Fibrinolytic agents are administered by intravenous
systemic infusion and by local intravenous or intraarterial perfusion. Throm-
bolytic therapy should be initiated as early after diagnosis as possible. However,
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certain clinical situations or complications exclude the use of thrombolytic agents
(see Table 3).
For most indications, administration of standardized dosage regimens of the
thrombolytic agents is common practice. Studies comparing mortality reduc-
tions between various thrombolytic agents in coronary thrombolysis have gen-
erally shown no significant differences.
3.8.1. STREPTOKINASE
Derived from β-hemolytic streptococci; indirect plasminogen activator; dose
for acute myocardial infarction and massive PE: 1.5  × 106 U over 60 min, for
DVT: 250,000 U (30 min), maintenance dose 100,000 U/h, duration 24–72 h;
alternative dose schedule (in Europe) 9 × 106 U/6 h, to be repeated every 24 h two
to five times. Pyrogenic reactions are the main side effect of streptokinase.
3.8.2. UROKINASE
Direct plasminogen activator; for acute myocardial infarction 1.5 to 3 × 106
U over 60 to 90 min; for PE and DVT 4000 U/(kg · h), 12–48 h, with loading dose
(30 min); for severe PE also 1.5 to 3 × 106 U over 60–90 min.
3.8.3. RT-PA (ALTEPLASE)
Has particularly high affinity for fibrin, less systemic activation of fibrinoly-
sis. In acute myocardial infarction as in severe PE, 100 mg over 90 min;
“frontloaded” regime (GUSTO Study): 15 mg 1–3 min, 50 mg over 30 min, 35 mg
Table 3
Contraindications to Fibrinolytic Therapy
Absolute contraindications
Established hemorrhage
Cerebrovascular accident, head injury in the past 2 mo
Neurosurgery during past 2 mo
Intracranial aneurysm or neoplasm
Aortic dissection
Proliferative diabetic retinopathy
Relative contraindications
Surgery during past 10 d
Arterial puncture previous 7 d
Prior organ biopsy
Recent obstetric delivery
Past history of gastrointestinal bleeding
Severe hypertension (systolic > 200 mmHg, diastolic > 110 mmHg)
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over 60 min. At present, rt-PA can not be recommended for the treatment of DVT
(high costs, no advantage).
3.9. Antiplatelet Drugs
The antiplatelet drugs, such as aspirin, ticlopidine, and GP IIb/IIIa antago-
nists, are discussed under “Arterial Thrombosis.”
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1. INTRODUCTION
Blood transfusion is essential and vital in the successful treatment of many
malignant and nonmalignant hematological disorders. Children with thalassemia,
adults with myelodysplastic syndromes, and patients with autoimmune hemolytic
anemias, leukemias, or aplastic anemias become chronically dependent on blood
transfusions. Modern treatment procedures such as high-dose chemotherapy and
progenitor cell transplantation require intensive support with blood components
and products. The serological basis of blood transfusion, the available blood
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components and products, and adverse effects of blood transfusion with special
emphasis on infectious disease transmission are discussed in this chapter.
2. RED CELL SEROLOGY
2.1. The ABO, Hh, and Sese Systems
Genes for three different blood group systems (ABO, Hh, and Sese) indirectly
control the expression of the A, B, and O antigens because antigenic activity is
determined by sugars linked to either polypeptides (forming glycoproteins) or
lipids (forming glycolipids). Each of the A, B, and H genes code for a specific
enzyme (glycosyltransferase) that adds a different sugar on a polypeptide or lipid
to form the ABH antigens.
The ABO system is the most important system in red cell serology and involves
three allelic genes (A, B, and O) in chromosome a. The A and B genes encode
glycosyltransferases (enzymes) that produce the A and B antigens, respectively.
The O gene is considered to be nonfunctional because it determines no detectable
blood group antigen. The expression of the O gene results in loss of production
of a functional protein or enzyme; consequently, no product is formed. The red
cells of a group O individual lack A and B antigens, but have an abundant amount
of H antigen. The precursor H enzyme (fucosyltransferase) specifically adds
fucose to a terminal galactose, thus giving H antigenic expression. If the
glycosyltransferase adds N-acetyl-D-galactosamine to the terminal D-galactose
of an H antigen, then the red cells will have the A antigen on their surface.
Correspondingly, if the glycosyltransferase adds D-galactose, a B antigen is
formed. ABO specificity is dependent on both ABO and Hh genes. Table 1 shows
the incidence of the four main phenotypes of the ABO system.
The A blood group has two main subgroups: A1 and A2, which could be
distinguished using the Dolichos biflorus lectin reagent. A1 individuals have
more
 
A antigen sites than A2 individuals. The A2 gene differs from the A1 gene
by one base pair. Variability in genes causes variable reactivity as well add after
“as well.” Subgroups of B are very rare and less frequent than A subgroups.
 
In the ABO system, naturally occurring antibodies (isoagglutins) are present
against A or B antigens. Individuals with the blood group A have isoagglutinins
against B red cells and vice versa (see Table 1). These antibodies invariably are
immunoglobulin (Ig)M that activate complement and cause immediate intravas-
cular hemolysis resulting in severe acute hemolytic transfusion reactions (HTR).
They are absent at birth and develop within 3–6 mo of age, when the immune
system is exposed to ABH antigenic determinants present in our environment
(i.e., bacteria, plants, dust, and food). Antibodies are naturally developed against
the ABH antigens absent in the individual. Generally, the antibody titer increases
until the age of 10 yr and progressively falls with increasing age in adults. In
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acquired immunodeficiency states (e.g., leukemias and lymphomas) the levels
may be significantly low.
The ABH antigens present in red cells have been demonstrated in most tissues
of the body, including platelets and leukocytes. The ability to secrete soluble
ABH antigens is controlled by the secretor (Se) gene that is separate from the
ABH system. About 80% of the population have the dominant secretor (Se) gene
that controls one’s ability to secrete soluble ABH antigens. These individuals
(secretors) distinctly have soluble ABH substances in their plasma and secre-
tions (i.e., saliva, semen, and sweat).
2.2. The Rhesus System
The Rhesus (Rh) system is the second most clinically important and complex
blood group system. It consists of some 50 different antigens, but only 5 anti-
gens—D, C, c, E, and e—are inherited in various combinations and account for
most of the Rh-related problems encountered in practice. The Rh antigen with the
strongest antigenicity is the Rh (D) antigen. As a simple rule, it can be noted that
persons whose red cells express the D antigen are Rh (D) positive and individuals
whose red cells lack the D antigen are Rh (D) negative. The different genotypes,
their Rh status, and the frequency of these genotypes in Caucasians are shown in
Table 2. About 85% of North American Caucasians are Rh (D) positive.
After the discovery of the Rh system in 1940, various theories were postulated
to explain the mode of inheritance and different nomenclatures were proposed.
The Wiener system proposed that the gene product was a single entity with
multiple serological specificities. The Fisher-Race system postulated three sets
of closely linked genes and gene products (C and c, D and d, and E and e).
Rosenfield proposed a third nomenclature system based on serological reactions,
which assigns a number for each Rh antigen. The World Health Organization in
Table 1
ABO Antigens and Antibodies (Isoagglutinins)
Incidence (%)a
Phenotype Genotype Antigens Antibodies Whites Blacks
O OO (H) Anti-A Anti-B 45 49
A (A1 or A2) AA or AO A (A1 or A2) and (H) Anti-B 40 27
B BB or BO B and (H) Anti-A 11 20
AB (A1B or A2B) AB A, B, and (H) None 4 4
aIncidence (%) in the United States among whites and blacks.
 From Brecher ME, ed. American Association of Blood Banks Technical Manual (14th. ed.). Bethesda,
MD: AABB Publications, 2002:p. 272.
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1977 recommended the CDE nomenclature of Fisher-Race as it easily fits with
the serological reactions. Cde or [R1] and cde or [r] are the most common hap-
lotypes in Caucasians. cDe or [R0] is most common in blacks.
Genomic studies have revealed the presence of two closely linked genes (RHD
and RHCE) with considerable homology that refutes both Wiener and Fisher-
Race postulates. The RHD gene controls the production of the D antigen and is
absent in Rh (D)-negative individuals and explains the absence of the “d” anti-
gen. The RHCE gene encodes for Cc and Ee antigens. The D and CE polypeptides
differ in only 36 amino acids, the C and c polypeptides differ in four amino acids,
and E and e differ in only one amino acid. The approximate molecular weight of
a nonglycosylated Rh protein is 30 kDa. Recently, a D protein (a mixture of Rh
[c] and [e]) has been isolated from Rh (D)-negative red cells that differ from the
D protein of Rh (D)-positive cells. Genetic polymorphism may account for the
difference.
Individuals whose red cells give weaker reactions with anti-D reagents are
classified as quantitative weak D (red cells that require additional steps to dem-
onstrate D were formerly classified as D variant or Du). The D antigen has more
than 37 epitopes, and if a significant number of epitopes are absent, then the
individual is known to have partial D antigen (formerly classified “D mosaic”
or “D variant”) and can produce an antibody to the portion of the D antigen they
lack. Partial D phenotypes arise from nucleotide interchange between the RHCE
and the RHD genes or from single mutations. Gene interaction also depends on
the position of the genes that ultimately affect the expression of the D antigen.
A weak D antigen can also result from the suppressive effect of C in trans position
to a D on the opposite chromosome exemplified by CDe/Cde. A weak D indi-
vidual because of gene interaction has the entire D antigen and can receive D-
Table 2
Rhesus Genotype Frequencies and Their Rh Status
Genotype Rhesus status Frequencya
CDe/cde or R1 r Positive 32%
CDe/CDe or R1R1 Positive 16%
CDe/cDE or R1R2 Positive 11%
cDE/cde or R2r Positive 11%
Other genotypes with D Positive <13%
cde/ cde or rr Negative 15%
Weaker variants of D or C Positive for donors, <1%
negative for recipients
Rh-null Null Extremely rare
aIn Caucasians.
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positive blood. In contrast, weak D individuals who have partial absence of the
D should only be transfused with D-negative blood because they can produce
anti-D antibodies. The American Association of Blood Banks (AABB) requires
that blood donors be screened for weak expression of the D antigen and to be
labeled as Rh (D)-positive if the test is positive; however, recipients need not be
tested for weak D.
On very rare occasions, red cells may lack the expected Rh antigens (e.g., −D−,
−De, cD−). In Rh-null individuals, the Rh antigens are completely absent. This can
arise from the absence of the gene that regulates Rh antigen expression or  the
presence of an amorphic gene at the Rh locus. Rh-null individuals have a compensated
hemolytic anemia and abnormal red cell morphology (stomatocytosis). If transfused,
they will produce antibodies against the different Rh antigens; therefore, Rh null
individuals should be transfused only with Rh-null cells from the rare donor reg-
istry or with autologous red cells.
Rh antibodies can be acquired during pregnancy or a blood transfusion. The
most common Rh antibody is anti-D. Rhesus immunization during pregnancy or
delivery may occur when an Rh (D)-negative woman has an Rh (D)-positive
child. This can be prevented by the prophylactic injection of anti-D Igs (RhIg).
Rh antibodies are predominantly IgG and react at 37°C. They do not fix comple-
ment effectively, but can cause hemolytic disease of newborn (HDN; see Chapter
6) and hemolytic transfusion reaction (HTR). Extravascular hemolysis occurs
through the mononuclear phagocyte system.
2.3. Other Red Cell Systems
Red cells bear antigens of many other blood group systems besides the ABO
and Rh systems (Kell, Duffy, Lewis, I, P, MN, Lutheran, Kidd, and others).
These red cell antigens are not routinely typed and generally are rare causes of
HDN. The Kell and Duffy systems are briefly discussed. For more comprehen-
sive information on the other red cell antigen systems, the reader is referred to
reference texts. (see “suggested reading”).
The Kell blood group system is clinically important, as the K antigen follows
the D antigen in immunogenicity and its antibodies can cause HDN and HTR.
Currently, this system includes 24 alloantigens, the most common being the K,
k, Kp(a), Kp(b), Js(a), and Js(b) antigens. A defective and weak expression of
Kell antigens (also lack Kx) is observed in individuals with the McLeod pheno-
type. These individuals have a chronic compensated hemolytic anemia and abnor-
mal red cell morphology (acanthocytosis). Individuals with McLeod red cells also
have neuromuscular and cardiovascular abnormalities (myopathy, areflexia, and
cardiomyopathy). Rarely, the McLeod phenotype is associated with chronic
granulomatous disease and arises from the deletion of the X chromosome that
includes both XK and X-CGD loci.
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The Duffy system is unusual in that the antigen frequency varies in different
racial groups. The Duffy glycoprotein is the receptor for the malarial parasite and
serves as an erythrocyte receptor for a number of cytokines, notably interleukin
(IL)-8. Duffy glycoproteins also serve as a sponge for excess chemokines with-
out any adverse effect on the red cell. This system has six antigens; two of these
are important and deserve mention. Both Fya and Fyb antigens have low inci-
dence in Africans. In West Africa, most probably by natural selection, both
antigens are absent in the majority of blacks [Fy (a−b−)]. Their red cells exhibit
resistance to infection by Plasmodium vivax and P. knowlesi. Anti-Fya antibody
may cause mild HDN and rare but severe HTR. Infrequently, Anti-Fyb is asso-
ciated with either HDN or HTR; other antibodies of this system have not been
implicated at all.
2.4. Diagnostic Methods in Blood Group Serology
Prior to any blood transfusion, the red cell ABO and Rh(D) blood group (blood
type) of the recipient is determined, and the serum is screened for any unexpected
red cell antibodies (usually IgM and IgG antibodies). Thereafter, a cross-match
is carried out between the donor’s red cells and the recipient’s serum. Blood
group antigens or antibodies are determined with agglutination methods. The
IgM antibodies (i.e., anti-A or anti-B) are usually detected by saline techniques,
whereas enzyme, albumin, or antiglobulin methods are employed for the IgG
antibody detection. Low ionic strength solution (LISS) is widely used in blood
group serology as it shortens the incubation period and is helpful with emergency
blood requests. The antiglobulin (Coombs’) test detects antibodies coated on the
red cells. The direct antiglobulin test (DAT) detects antibodies that are already
bound to red cells in vivo, whereas the indirect antiglobulin test (IAT) detects
antibodies present in the serum. The direct antiglobulin test may be positive in:
(1) autoimmune hemolytic anemias (seen in lymphomas, system lupus erythe-
matosus, cold agglutinin syndrome, and paroxysmal cold hemoglobinuria); (2)
alloimmune hemolytic anemias (HDN and HTR); and (3) drug-induced
hemolytic anemia. Figure 22.1 schematically outlines the determination of the
ABO blood group with agglutination methods, whereas Fig. 22.2 shows the
principles of both DAT and IAT.
3. LEUKOCYTE ANTIGENS
Human leukocytes bear two types of surface antigens: the human tissue or
cell-specific antigens and individual type-specific antigens.
The first group is described in the cluster designation (CD) nomenclature.
These antigens characterize the lineage, function, or activation state of the indi-
vidual type of leukocyte (e.g., CD3 for mature T-cells). A list of the most current
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Fig. 22.1. Agglutination of red cells.
Fig. 22.2. Direct and indirect Coombs’ test (antiglobulin test).
CD markers is given in Appendix 2. The second group, the family of human
leukocyte antigens (HLAs) (Class I, II, and III antigens), is encoded by the major
histocompatibility complex (MHC) genes on the short arm of chromosome 6.
Class I and II antigens are the classic transplantation antigens that define tissue
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tolerance or rejection and are important for organ transplantation, but their pri-
mary role is in immune response regulation. Class III antigens (i.e., complement
C2 and C4 or tumor necrosis factor [TNF]-α) may be directly or indirectly
involved with MHC function.
The HLA system is expressed on many tissues. The Class I antigens (HLA-A,
-B, and -C molecules) are present on all nucleated cells and platelets. Class II
antigens (HLA-D molecules) are expressed on B-lymphocytes, antigen-present-
ing cells (monocytes, macrophages, and dendritic and Langerhans cells), and ac-
tivated T-lymphocytes. HLA Class I and Class II antigens differ in immunological
function. Class I antigens interact with CD8+ lymphocytes, which recognize endo-
genous antigens. Class II molecules on the surface of antigen-presenting cells
bring exogenous antigens in contact with CD4+ lymphocytes.
Class I molecules consist of two glycosylated heavy chains of 44–45 kDa and
a noncovalently bound 12 kDa molecule (β2-microglobulin). The class I heavy
chain has three extracellular domains, a transmembrane region, and an intracy-
toplasmic domain. Each of the class II molecules (HLA-DR, DQ, and DP) con-
sists of two transmembrane noncovalently associated glycosylated polypeptide
chains. The α-chain has a molecular weight of about 30–34 kDa; the β-chain has
a molecular weight of about 26–29 kDa.
The inheritance of the HLA genes is closely linked, and the entire MHC is
inherited as an HLA haplotype (half of the genotype) in a Mendelian fashion
from each parent. For example, a haplotype of A3, B7, Cw7, and DR2 may come
from the father and the other haplotype of A9, B27, Cw1, and DR7 may come
from the mother. Distances between loci may permit some chance of recombi-
nation within the HLA system, but this occurs only infrequently (<1%) and
usually between DP and DQ loci. Statistically, siblings have a 25% chance of
inheriting the same pairs of HLA molecules from the parents (i.e., being HLA
identical).
The HLA system is the most polymorphic human antigen system, thereby
showing an enormous number of different HLA haplotype combinations. The
HLA antigen pattern varies among different ethnic groups. Because of linkage
disequilibrium, some haplotypes occur more frequently in certain populations.
For example, HLA-A1, B8, DR3 is the most common HLA haplotype among
Caucasians with a 5% frequency.
The HLA complex is divided into three regions indicating the locations of loci.
Serological and DNA techniques differ in the number of alleles that they can
identify for each locus. HLA-A, HLA-C, and HLA-B loci have 20, 8, and 30
serologically defined alleles but have 309, 167, and 563 alleles detected by DNA
analysis. Among the Class II antigens, the HLA-DR, HLA-DP, and HLA-DQ
molecules expressed on the cell membranes are most important with 442, 81, and
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127 alleles defined by DNA techniques. The allelic variations of DQ-A, DP-A,
and DP-B can only be defined by DNA methods.
Two HLA nomenclatures are currently in use. The older list of specificities is
based on detection of epitopes by immunological techniques (serology or mixed
leukocyte culture reactions) and the newer molecular nomenclature is based on
specific nucleotide sequences of alleles using DNA-based methods, now a com-
monly used technique in HLA-typing laboratories. Peripheral blood lympho-
cytes express class I antigens and are used for the serological typing of HLA-A,
HLA-B, and HLA-C. Class II antigens are typed using B-lymphocytes. Classic
serology uses lymphocyte microcytotoxicity tests (by Terasaki) utilizing sera
from multiparous women who have been immunized against certain HLA anti-
gens. Clinical molecular techniques have revealed the complexities of both class
I and II antigens. For example, the identities of class II antigens can be shown by
the mixed lymphocyte reaction but HLA–D identical pairs remain nonreactive
using this method. However, molecular typing is able to distinguish serologi-
cally indistinguishable but functionally discrete HLA alleles.
All current DNA-based HLA typing assays utilize PCR to amplify the genes
of interest. There are three commonly used procedures: sequence–specific prim-
ers (PCR–SSP), sequence specific oligonucleotide probes (PCR–SSOP), and
sequence-based typing (PCR–SBT). DNA typing is specific (no batch-to-batch
variation in specificity) and flexible (new reagents can be designed as new alleles
or new nucleotide sequences are identified). It is highly reproducible (with SSOP)
and more robust than other techniques because it does not require viable lympho-
cytes nor is it influenced by the patient’s health. DNA based methods have the
added advantage of HLA-typing large numbers of volunteers for donor regis-
tries. Furthermore, it can detect the full range of HLA diversity. HLA alleles can
specify the HLA proteins that are indistinguishable by serology. For example,
DRB1*0401 and DRB1*0412 are allele splits identified by DNA typing that
belong to the broad specificity DR4 serological type.
In addition to the major histocompatibility antigens just described, minor
histocompatibility antigens (mHags) have been defined by both Class I and II
MHC-restricted T-cells and may affect the outcome of progenitor stem cell and
solid organ transplantation. The mHags are immunogenetic peptides bound to
Class I molecules that stimulate T-cell responses. They are also inherited and the
number of minor histocompatibility loci is probably high. To date, the range of
polymorphism of these antigens is not well characterized. The disparity of mHags
can be associated with graft-vs-host disease (GVHD) in HLA-identical trans-
plants (i.e., H–Y antigen in a male recipient and a female donor immunized by
pregnancy). The frequency of allelic forms, immunogenicity of peptides and
tissue-specific expression of proteins will determine the role of mHag disparity
in either GVHD or graft rejection.
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3.1. Applications of HLA Testing
HLA testing is used in progenitor stem cell and organ transplantation, disease
susceptibility studies, and parentage testing. HLA identity is the sine qua non of
allogeneic bone marrow transplantation. Despite full HLA-identical progenitor
cell grafts, a substantial number of patients develop graft-vs-host mHag reactiv-
ity (details about allogeneic progenitor stem cell and bone marrow transplanta-
tion are described in Chapter 4). The HLA antigens are also important for solid
organ transplantation (i.e., kidney or liver). HLA-A, HLA-B, and HLA-DR are
considered to be the major transplantation antigens, whereas HLA-C, HLA-DP,
and HLA-DQ are generally of minor importance. In kidney transplantation, HLA
matching between donor and recipient is done routinely. HLA-matched kidney
grafts have better outcomes than unmatched grafts. In contrast to bone marrow
transplantation, solid organ transplantation requires ABO-compatible grafts. For
logistic reasons, other solid organs (heart, liver, lung, and pancreas) are not
routinely matched for HLA-antigens. HLA antibodies play a major role in graft
survival and chronic rejection. The presence of cytotoxic HLA antibodies in the
serum of transplant recipients reactive against a panel of cells (expressed as panel
reactive antibodies or [PRA]) lowers the graft survival rates and may be a con-
traindication for kidney transplantation. The PRA effect is greater among recipi-
ents of a second transplant.
Multiparous women and patients who receive multiple blood transfusions are
frequently alloimmunized to HLA antigens. These HLA antibodies are broadly
reactive. Post-transfusion HLA alloimmunization is variable and dependent on
the patient’s diagnosis and therapy. Patients with leukemia have lower detectable
antibodies (25 to 30%) than patients with aplastic anemia (80%) because they are
usually immunosuppressed from intensive chemotherapy when the transfusions
are given. Leukocyte reduction of blood components to less than 5 × 106 has
significantly reduced the development of primary HLA alloimmunization. This
can be achieved by the use of third-generation leukocyte filters for red blood cells
(RBCs) and platelets or by inline leukoreduction systems of blood cell separators
used to collect pheresis blood components. As will be discussed later in the
chapter, HLA antibodies have been implicated in febrile nonhemolytic transfu-
sion reactions and transfusion-related acute lung injury.
Immunological refractoriness to platelet transfusions results from immune
destruction of transfused platelets more often by HLA antibodies (Class I antigens
are expressed on platelets) than by platelet-specific antibodies. Nonimmune causes
of platelet refractoriness need to be ruled out such as splenomegaly, disseminated
intravascular coagulation (DIC), bleeding, infection, marrow transplantation, and
antibiotics (amphotericin B, vancomycin, ciprofloxacin). Detection of HLA- or
platelet-specific antibodies is usually done by solid phase red cell adherence assay
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(SPRCA), flow cytometry, ELISA, monoclonal antibody specific immobilization of
platelet antigen assay, or mixed passive hemagglutination assay.
Once immune refractoriness is established, special platelet products are indi-
cated. These patients can receive HLA-matched platelets, or platelet crossmatching
can be done using SPRCA or flow cytometry. Both methods of crossmatching
will detect platelet antibodies against Class I and platelet-specific antigens. The
efficacy of crossmatched platelets may be as good as HLA-matched platelets.
Platelet-crossmatched units have the additional advantage of being readily avail-
able for transfusion. Crossmatching is not always practical because alloimmunized
patients may have HLA antibodies that react to more than 90% of the random
population. These patients may also have few broadly reactive antibodies against
public epitopes of Class I molecules, which will make it harder for a blood center
to provide a product because the best HLA-matched platelet unit can still have
some incompatibility.
Numerous diseases have a more or less strong association with certain HLA
antigens. Well-known examples are ankylosing spondylitis associated with HLA-
B27, narcolepsy associated with HLA-DR2, hemochromatosis associated with
HLA-A3, celiac disease with HLA-DQB1*02, and type I diabetes mellitus with
DR-3 and -4 heterozygotes. The HLA-A1, B8, DR3 haplotype is frequently in-
volved in autoimmune disorders. These disease associations indicate the central
role of the major histocompatibility complex in determining the susceptibility to
disease and immune responsiveness.
The HLA system is used in parentage testing because of its polymorphism
with a low recombination rate and Mendelian inheritance. There is a decreasing
use of HLA typing because it does not provide a high exclusion probability when
a case involves a paternal haplotype common in one particular ethnic group.
Thus, molecular techniques using non-HLA genetic systems are widely favored.
4. BLOOD PRODUCTS AND INDICATIONS
FOR BLOOD TRANSFUSION
4.1. Whole Blood
The use of whole blood is limited and is indicated in massive blood loss to
replace the loss of both RBC mass and blood volume. Many trauma centers have
abandoned the transfusion of whole blood in favor of intravenous solutions in
conjunction with RBCs and other blood components. Currently, whole blood
units serve as source material for blood components and plasma products.
4.2. Red Blood Cells
RBCs are indicated for replacement of red cell mass in patients who require
increased oxygen-carrying capacity to prevent tissue hypoxia. The hemoglobin
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or hematocrit value, at which a transfusion is given, depends on the clinical
circumstances. Current information supports a “restrictive strategy.” Transfu-
sions are indicated when hemoglobin concentration falls below 7 g/dL. The
hemoglobin concentration should be maintained between 7 and 9 g/dL. Note: In
younger patients, it may be necessary to transfuse if the hemoglobin concentra-
tion drops below 6 g/dL. In elderly anemic patients with cardiovascular disease
(acute myocardial infarction and unstable ischemic syndromes), the threshold
for transfusion may be 9 or 10 g/dL. To avoid volume overload, transfusions
should be given slowly. In recent years, the recommended hemoglobin value for
transfusion during surgery has been lowered from 10 to 7 g/dL. In a typical 70-kg
(155-lb) patient, each unit of transfused RBCs is expected to raise the hemoglobin 1
to 1.5 g/dL and the hematocrit by 3 to 5%.
4.3. Platelets
Two types of platelet components are available for transfusion: “Pheresed
Platelets,” derived from single donors using an automated cell separator, and
“Pooled Platelets,” derived from whole blood donation and multiple donors.
Automated cell separators effectively collect platelets (3 to 4 × 1011/U) from
donors.
The major goal of prescribing platelet transfusions is to effectively and safely
prevent and/or treat bleeding in thrombocytopenic patients. Platelets may be
given prophylactically in severely thrombocytopenic patients who have a hem-
orrhagic tendency or to patients on intensive myelosuppressive chemotherapy to
keep the platelet count above 10 × 109/L. The success of modern chemotherapy in
patients with hematological disorders (i.e., acute leukemias and myelodysplastic
syndromes) and progenitor cell transplantation (bone marrow or stem cell trans-
plantation) is largely dependent on effective platelet transfusions. Platelet counts
for those at risk for spontaneous bleeding (patients with fever, infection, im-
paired platelet function from drugs, or hepatic or renal failure) should be kept
above 15 to 20 ×109/L. Platelets are also indicated in other thrombocytopenic
states: consumption coagulopathy, massive transfusion, GVHD, von Willebrand
disease, and congenital and acquired platelet defects. Invasive procedures (i.e.,
lumbar puncture and liver biopsy) can be performed safely when the platelet
count is at least 50 × 109/L. Counts of 100 ×  109/L should be maintained if
excessive bleeding cannot be tolerated (i.e., CNS or retinal procedures). In au-
toimmune thrombocytopenia, hypertransfusions of platelets are only indicated
in cases of major hemorrhage. Platelets are not useful in most other instances, as
the autoantibody shortens the survival of both transfused and patient’s own
platelets.
To investigate the mechanism of a poor response to a platelet transfusion, a
platelet count is usually obtained within 1 h of the transfusion and the corrected
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count increment (CCI) or percent recovery is calculated. Patients who are refrac-
tory to platelet transfusions (CCI < 7.5 × 109/L or percent recovery of <15 or
20%) may have a better response if transfused with a sufficient dose of apheresis
platelets. For those who become immunologically refractory, HLA-matched or
crossmatched compatible platelets may offer satisfactory results. However,
patients refractory to all available platelet concentrates may benefit from intra-
venous immunoglobulin (IVIg), plasma exchange, massive ABO-identical plate-
let transfusions, and acid-treated platelets (stripped of HLA antigens).
Platelets are stored at 20–22°C (room temperature) with agitation for no more
than 5 d. More recently (April 2005), the Food and Drug Administration (FDA)
extended the shelf-life of apheresis platelets to 7 d only if collected by the Trima®
COBE Spectra™ blood separator in conjunction with 100% testing by bacterial
culture system, bioMerieux BactT/ALERT Microbial Detection System Release
Test®, to monitor for any bacterial contamination.
4.4. Granulocytes
Current blood separators can collect granulocytes at high yields (20 to 30 × 109
granulocytes) from donors stimulated with recombinant granulocyte colony-
stimulating factor (G-CSF) and steroids; however, granulocyte transfusions lost
popularity between 1985 and 1995 because of reported adverse pulmonary reac-
tions and marginal clinical results. The unimpressive clinical efficacy may be
attributed to rapid postcollection neutrophil apoptosis and inadequate doses (be-
cause previous donors did not undergo any stimulation/mobilization). Renewed
interest in granulocyte transfusion stems from the availability of G-CSF that not
only increases the yield of granulocyte collections but also inhibits neutrophil
apoptosis. Currently, granulocyte transfusion has limited indications that
include refractory fungal or bacterial infections in neutropenic patients and
those with qualitative neutrophil defects. Granulocyte transfusions may also be
beneficial to newborns with sepsis, neutrophil counts of less than 3000/µL or a
defective marrow response. Granulocytes have no defined regulatory specifica-
tions because the FDA does not license them. However, the American Associa-
tion of Blood Banks (AABB) requires that each unit contain at least 1.0 × 1010
granulocytes (Note: value intended as a goal for adequate collection but not as
an adequate clinical dose). At least four consecutive transfusions of 1.0 × 1010
granulocytes are recommended. The use of additional transfusions is based on
the patient’s response or clinical course and the clinician’s judgment. Granulo-
cyte units are suspended in 200 to 400 mL plasma and contain significant num-
bers of platelets (1 to 6 × 1011 platelets, equivalent to an apheresis platelet unit),
RBCs, and viable lymphocytes. Thus, they must be ABO and Rh compatible with
the recipient and irradiated to prevent transfusion-associated (TA)-GVHD.
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Granulocytes have to be transfused as soon as possible and, if necessary, stored
without agitation at 20–24°C for no more than 24 h.
4.5. Fresh-Frozen Plasma
Fresh-frozen plasma (FFP) is a single-donor unit of plasma that has been
separated from one unit of whole blood or collected by apheresis and frozen at
–18°C or lower within 6 to 8 h of collection. It contains coagulation factor levels
at 1 U/mL (or 100% activity) and is indicated to treat global or multiple coagu-
lation factor deficiencies (i.e., liver failure and dilutional coagulopathy in mas-
sively transfused patients). Other uses for FFP include emergent reversal of
warfarin therapy (when time does not allow the use of vitamin K) and plasma
exchanges in thrombotic thrombocytopenic purpura and hemolytic uremic syn-
drome. The timing and dose are important. Correction of a markedly abnormal
prothrombin time and activated partial thromboplastin time requires FFP trans-
fusions immediately before surgery because several of the coagulation factors
have very short half-lives (particularly factor VII with a biological half-life of 3
to 6 h). The dose is based on the patient’s weight  at 10 to 20 mL/kg. FFP contains
ABO antibodies and therefore must be compatible with the recipient’s red cells.
4.6. Cryoprecipitated Antihemophilic Factor
Cryoprecipitated antihemophilic factor (CRYO) is the cold insoluble portion
of plasma processed from FFP by cold precipitation. The precipitate is formed
as FFP is thawed at 1 to 6°C. The stability of the coagulation factors is maintained
for up to 1 yr at –18°C storage. It is a plasma-derived product that contains the
highest concentration of fibrinogen (250 mg, primarily used in acquired
hypofibrinogenemia of DIC), factor VIII (80–120 U/concentrate), and a variable
percentage of the original plasma concentration of von Willebrand factor (40–
70%) and factor XIII (30%). It is indicated for the treatment of hemorrhagic
disorders resulting from either quantitative or qualitative defects of these factors.
However, the availability of factor concentrates and recombinant factors have
contributed to its diminished usage. CRYO is also used as a source of fibrinogen
to form a fibrin glue or sealant (when added to thrombin) and is also indicated
to ameliorate the platelet dysfunction in uremia. Like FFP, it contains ABO
antibodies, requiring consideration of recipient red cell compatibility.
4.7. Immunoglobulins
Parenteral Igs are manufactured from pooled human plasma and are used in
primary or acquired hypogammaglobulinemia to protect against viral and bac-
terial infections. They consist of all subclasses and allotypes of IgG with only
trace amounts of IgM and IgA. Polyvalent/multispecific immunoglobulins offer
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protection against many infections, whereas hyperimmune/specific immuno-
globulins are obtained from actively immunized donors and contain high titers of
disease-specific antibodies (i.e., hepatitis B virus [HBV]), Varicella zoster, rabies,
or cell-specific [RhIg]). Rigorous donor screening and modified Cohn fraction-
ation have made immunoglobulin preparations relatively safe.
Immunoglobulins can either be administered intravenously (IVIg) or intra-
muscularly (immune serum globulins) and are generally well tolerated. Adverse
effects are rare (<1%) and include headache, nausea, vomiting, chills, volume
overload, and allergic and pulmonary reactions that can be prevented by slow
infusion and pretreating with diphenhydramine and/or hydrocortisone. True ana-
phylactic reactions are very rare and are seen in common variable immune defi-
ciency and IgA deficiency. IgA deficient products are recommended in these
cases.
Polyvalent immunoglobulins are indicated in hypogammaglobulinemias (con-
genital or acquired) and for immunomodulation in certain disorders. Note: the
plasma half-life of IgG (the major human immune globulin) is 21–23 d, but
longer in hypogammaglobulinemia. In hypogammaglobulinemia, a dose of 0.4–
0.6 g/kg body weight is given every month to maintain serum IgG levels. In
acquired hypogammaglobulinemia (e.g., multiple myeloma), immunoglobulins
are recommended in patients with frequent infections. Established indications
for immunoglobulin replacement or prophylaxis are parvovirus B19 infections
(among immunosuppressed patients) and recurrent life-threatening infections
(among HIV-infected children). The use of prophylactic IVIg in adults with
advanced HIV infection has shown equivocal results.
High-dose polyvalent immunoglobulins achieve immunomodulatory effects
through multiple mechanisms: (1) by suppressing antibody production directly
through its effect on B-lymphocytes, (2) by interfering in the interaction between
autoantibodies and cellular targets through its anti-idiotypic antibodies, and (3)
by blocking the Fc-receptors on macrophages. Higher doses of IVIg (e.g., 0.4 g/
kg × 5 d) are recommended for immunomodulation in Kawasaki syndrome (a
mucocutaneous lymph node syndrome in children) and idiopathic thrombocy-
topenic purpura.
5. ADVERSE REACTIONS TO BLOOD TRANSFUSION
5.1. Acute Hemolytic Transfusion Reactions
Acute hemolytic transfusion reactions (AHTR) involves rapid destruction of
blood cells immediately or within 24 h of a transfusion, commonly of RBCs or
whole blood. It has a low rate of occurrence but is the most dangerous compli-
cation with a high mortality. Mortality depends on the amount of incompatible
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blood infused (25 to 44 % with infusion of less than or more than 1000 mL,
respectively). ABO incompatibility is the most common cause of immune AHTR
and accounts for 74% of all fatal reactions. AHTR is due to preformed antibodies,
often IgM (commonly anti-A), that bind complement and cause red cell lysis.
Nonimmune causes of hemolysis mimic immune mediated hemolysis and have
to be excluded. Chemical, mechanical, thermal, and physical damage of red cells
may result from bacterial contamination, mechanical trauma during infusion,
thermal hemolysis (from overheating or freezing a unit), and osmotic hemolysis
(use of hypotonic reconstituting solutions and co-administration of drugs during
transfusions)
The patients commonly experience fever and chills, hypotension, and chest
pain. Other signs and symptoms include low back pain, flushing, dyspnea, hemo-
globinuria, gastrointestinal symptoms (abdominal pain, diarrhea, and vomiting),
and unexpected bleeding from DIC. In patients under anesthesia, no immediate
reactions may be recognized. Changes in blood pressure, diffuse bleeding, and
hemoglobinuria may be the only signs. AHTR may cause oliguria and acute renal
failure.
The classic laboratory changes include a drop in hemoglobin and hematocrit,
hemoglobinemia (free hemoglobin can be demonstrated in serum or plasma),
hemoglobinuria, reduced serum haptoglobin, and positive DAT. Elevations of
unconjugated bilirubin, methemalbumin, and lactate dehydrogenase, and an
unexpected red cell antibody may be present.
The signs and symptoms of an IgM-type acute hemolysis result from comple-
ment-mediated lysis of red cells and the release of cytokines. Binding of comple-
ment to the red cell surface is a major factor in cytokine production. The symptoms
of IgG-type hemolysis also involve several cytokines (IL-1, IL-6, IL-8, and
TNF). Coagulopathy, frequently seen in hemolytic transfusion reactions, espe-
cially due to IgM antibodies, results from several mechanisms. The coagulation
cascade is activated by (1) antigen–antibody complexes (activates Hageman
factor); (2) thromboplastic substances of the red cell stroma; (3) platelet factor
3 released by activated platelets; and (4) tissue factor release secondary to hy-
potension.
In order to minimize AHTRs, all transfusions should have clearly defined
indications. If an AHTR is suspected, the transfusion must be stopped and im-
mediate steps taken to confirm or exclude this possibility. Management of AHTR
is dependent on the clinical status of the patient and may include cardiopulmo-
nary support, prevention of renal failure (i.e., fluid resuscitation, vasopressors,
and diuretics), and treatment of DIC. Severe bleeding in DIC requires platelets,
replacement of procoagulant factors and fibrinogen (FFP and CRYO transfu-
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sions), and administration of low-dose heparin. Heparin limits both hemolysis
(by its direct anticomplement activity) and inappropriate activation of procoagu-
lant activity (by enhancing antithrombin III-neutralizing serine proteases).
5.2. Delayed Hemolytic Transfusion Reaction
Delayed hemolytic transfusion reaction (DHTR) represents an anamnestic
response to a red cell antigen to which the patient has been previously sensitized
by pregnancy or previous transfusions. It occurs in patients without identifiable
antibody detected in the pretransfusion compatibility testing who experience
accelerated red cell destruction of the transfused red cells after an interval of 3
to 10 d from transfusion. Such reactions are due to weaker antigen–antibody
reactions and may develop over days. Because of the low titer of reactivity, the
implicated antibody is not detectable at the time of screening or compatibility
testing. The sensitivity of the antibody-screening test is important in preventing
DHTRs because insensitive tests will miss weak-reacting antibodies. Note: these
weak-reacting antibodies commonly include Rh antibodies (against CEce) and
other antibodies in the Kell (anti-K), Kidd (anti-JKa), and Duffy (anti-Fya) blood
group systems.
DHTRs often remain asymptomatic and have milder symptoms than AHTRs,
including unexplained anemia, jaundice, and fever. In patients with sickle cell
disease, DHTRs may precipitate a sickle cell crisis. Laboratory findings are
similar to those of AHTR, except for the identification of a new alloantibody in
the patient’s RBC eluate or serum or both. The degree of hyperbilirubinemia will
depend on the rate and amount of hemolysis and the patient’s liver function.
Hemolysis is usually extravascular but intravascular hemolysis can occur. Both
AHTRs and DHTRs can demonstrate a positive, mixed-field, or negative DAT.
A mixed-field reaction will show a mixture of agglutinated transfused donor
cells along with unagglutinated patient’s cells. The DAT can be negative if all the
incompatible transfused donor cells are immediately destroyed.
There is a need to differentiate DHTR from delayed serological transfusion
reactions (DSTRs), in which only serological incompatibility is evident without
clinical evidence of hemolysis. DSTRs are more common than DHTRs in the
multiply transfused patient as more sensitive screening methods are employed
and the length of stay for in-patients increases.
DHTRs are tolerated well by many patients and may only require close moni-
toring. Typically, fluid loading and diuresis are not indicated unless active intra-
vascular hemolysis is present. Complications, such as renal failure and sickle cell
crisis, should be treated accordingly. A red cell exchange is indicated if there is
a large burden of antigen-positive cells. IVIg may be useful because extravascu-
lar hemolysis is similar to acute immune hemolytic anemia. Transfusion should
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be avoided until the causative antibody is identified and antigen-negative units
are available. Withholding transfusions because of the lack of serologically
compatible blood in patients with severe anemia is associated with significant
morbidity. This can be avoided by good communication between the clinician
and transfusion service.
5.3. Febrile Nonhemolytic Transfusion Reactions
Febrile nonhemolytic transfusion reactions (FNHTR) are defined as a tem-
perature rise of at least 1°C in association with a transfusion or up to 4 h after that
may be accompanied by chills or rigors. Such reactions are due to acquired
antibodies to donor leukocyte antigens or pyrogenic cytokines (IL-1, IL-6, IL-
8, and TNF-α) elaborated by leukocytes present in the blood components or
products. FNHTRs are less frequent with prestorage leukocyte-depleted blood
components. They occur in 0.5–1.4% of all transfusions. The fever is self-limited
and resolves after 4–6 h. Antipyretics are effective as symptomatic treatment.
Meperidine can be useful for treating rigors. Among patients who have experi-
enced a FNHTR, there is a 15% recurrence rate.
5.4. Allergic Reactions
Allergic reactions are probably the most frequent, occurring in 1–2% of all
transfusion reactions. The symptoms range from local or diffuse pruritus, urti-
caria, erythema, and cutaneous flushing to anaphylactic allergic reactions occur-
ring within minutes of the transfusion. Anaphylactoid reactions fall in between
the two ends of the spectrum.
Allergic disorders afflict 30% of donors, and passive transfer of IgE antibod-
ies may be involved. Uncomplicated allergic reactions are associated with in-
creased histamine (increased during storage), cytokines, mast cell activators
(i.e., leukotrienes), and other vasoactive substances (C3a and C5a) produced by
donor leukocytes during storage. Some allergic reactions only have pulmonary
signs and symptoms without cutaneous involvement (10%).
Severe anaphylactic reactions may occur after infusion of a very small volume
(<10 mL) in patients with IgA deficiency and are due to preformed, class specific,
recipient anti-IgA antibodies against infused donor IgA proteins. Additionally,
they may be due to antibodies against complement C4 and haptoglobin. Patients
with Chido (Ch) and Rogers (Rg) antibodies (against the Ch/Rg blood group
antigens carried by complement C4d of the classic complement pathway) also
exhibit anaphylactoid reactions following plasma product transfusions. Hapto-
globin deficiency is rare in North American populations but more common than
IgA deficiency among Japanese patients experiencing anaphylactic reactions.
Anaphylactoid reactions are typically associated with subclass, allotypic, or
specific anti-IgA in patients with normal or demonstrable levels of IgA. These
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reactions may be seen in other transfused products, such as peanut allergen
transfused to patients with peanut allergy.
Mild uncomplicated allergic reactions involving hives (without other symp-
toms) respond to antihistamines (such as diphenhydramine). The transfusion
may be restarted after treatment if there is no recurrence or progression of symp-
toms. Restarting a transfusion is not advisable with more serious reactions; in
particular, pulmonary symptoms with airway involvement. Treatment of severe
anaphylactic reactions is the same as for any anaphylactic reaction and requires
immediate cessation of the transfusion, epinephrine, and other supportive care.
Prevention of anaphylaxis in IgA-deficient individuals requires avoidance of all
plasma containing products unless collected from a known IgA-deficient donor
and washing of all red cell and platelet products.
6. DISEASES TRANSMITTED BY BLOOD TRANSFUSION
The major concern is to make all blood transfusions as safe and effective as
possible. Several infectious agents, viruses, bacteria, and parasites are transmis-
sible by transfusion of whole blood, blood components, or products. Attention
will focus on those transfusion-transmissible diseases (TTD) that present risks
of chronic infection in the recipient.
Major strategies available to reduce transmission include: stringent donor
selection and laboratory testing; use of autologous blood, pharmacological sub-
stitutes, or new transfusion strategies; inactivation of residual infectious agents
in the units to be transfused, and limiting the number of donor exposures and
allogeneic transfusions.
Blood donor screening is one of the more important steps in protecting the
safety of the blood supply. Nonremunerated, voluntary donors with low infec-
tious risks are encouraged and recruited to become blood donors. The scarcity of
the blood supply in many countries has spurred the use of paid donors. Direct
interviews, miniphysical examinations and laboratory testing of all blood collec-
tions help to exclude donors who have exposure to transmissible infections or
who have the risk factors for TTD.
The blood supply is screened or tested for bacterial and viral infections (includ-
ing tick borne infections), parasites (i.e., malaria, babesia, Chagas’ disease, and
microfilariasis).
Blood intended for autologous (only if transfused outside the collection facil-
ity) and allogeneic use require tests for syphilis (STS), HBV (HBV surface
antigen [HBsAg] and antibodies to the hepatitis core antigen [anti-HBc]), hepati-
tis C virus (HCV, anti-HCV, and HCV RNA), HIV (antibodies to HIV-1/HIV-2
and HIV-1 RNA), and human T-cell lymphotropic virus (anti-HTLV-I and II).
Other infectious agents can be tested or excluded based on the epidemiology of
the infectious agent, geographic area, and intended use of the blood product. In
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countries with endemic malaria, testing for malaria parasites is mandatory. The
general safety of the blood supply will be enhanced if these concerns are addressed;
however, minimal risks still remain because very recent infections are not detected
by recommended/standard laboratory tests (see Table 3).
6.1. Bacterial Infections Transmitted by Blood Transfusion
Bacterial contamination resulting in transfusion-associated bacterial sepsis is
now believed to be the most common infectious source of morbidity and the most
frequently reported cause of transfusion-related fatalities in the United States
(accounting for 16% of transfusion fatalities). Bacteria are believed to originate
from the donor either from the venipuncture site or unsuspected bacteremia.
Excluding donors with chronic diseases or recent febrile infections and scrupu-
lous disinfection of the skin reduces the risk of bacterial transmission. Both
Gram-positive and -negative bacteria have been implicated.
Bacterial multiplication is more likely in components stored at room tempera-
ture (i.e., platelets) than refrigerated components (i.e., RBCs) or frozen compo-
nents (FFP and CRYO). Bacterial contamination of platelet transfusion is one of
the most common infectious risks of transfusion, causing life-threatening sepsis
in 1 in 100,000 recipients and immediate fatal outcome in 1 in 500,000 recipients.
Despite limiting platelet storage to 5 d, various pathogens have been implicated
(Staphylococcus, Enterobacteriaceae, Streptococcus, Bacillus, and Pseudomo-
nas).
Table 3
Risk Estimates of Transfusion-Transmitted
Infections in the United Statesa
Infection Risk estimate (per unit transfused)
Hepatitis B 1/205,000
Hepatitis C 1/1,935,000
HTLV 1/2,993,000
HIV 1/2,135,000
aEstimates of residual risk in donations from repeat donors
of the American Red Cross blood donor population from
1995 to 2001 (after NAT testing for HIV and HCV).
From Dodd RY, Notari EP 4th, Stramer SL.Current
prevalence and incidence of infectious disease markers and
estimated window-period risk in the American Red Cross
blood donor population. Transfusion 2002;42(8):975–979.
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The low incidence of platelet-associated sepsis may be due to underreporting
because (1) they typically occur several hours after transfusion and are not as
catastrophic as RBC-associated sepsis; and (2) sepsis is attributed to other causes
because platelets are commonly transfused to immunocompromised patients
with other complex problems.
Psychrophilic Gram-negative bacteria can multiply in refrigerated blood and
components. RBC contamination is primarily from Yersinia enterocolitica and
Serratia liquifaciens. Y. enterocolitica proliferates and produces an endotoxin in
refrigerated anticoagulated blood because it can grow at temperatures below
37°C in a calcium-free medium even after a long lag period. Any bacterial con-
tamination of blood products is potentially serious.
P. cepacia and P. aeruginosa are environmental organisms that grow opti-
mally at 30°C and have been isolated from cryoprecipitate and plasma thawed in
contaminated water baths.
Syphilis transmission by blood transfusion is possible but its occurrence is
extremely rare because the phase of spirochetemia is short and the infective
organism, Treponema pallidum, does not survive refrigerated storage for more
than 96–120 h. Seroconversion occurs after the phase of spirochetemia so testing
donor blood by standard STS does not effectively prevent transmission. How-
ever, most positive STS results are demonstrated by donors with inadequately
treated noninfectious syphilis, or are biological false positives (may be positive
for hepatitis, mononucleosis, measles, chickenpox, immunizations, rheumatoid
arthritis, and pregnancy). There have only been two cases of transfusion-trans-
mitted syphilis reported in the English literature. Another spirochete, Borrelia
burgdorferi, causing Lyme disease (transmitted by the Ixodes deer tick) can
survive routine storage of RBCs and FFP. However, transfusion-related trans-
mission has not been reported at this time. The phase of spirochetemia is asso-
ciated with clinical symptoms that would render potential donors ineligible for
donation. Donors diagnosed with Lyme disease are accepted provided they have
completed antibiotic therapy and are completely asymptomatic.
6.2. Viral Diseases Transmitted by Blood Transfusion
6.2.1. HEPATITIS
Before the 1980s, the transmission of hepatitis was the major transfusion-
related viral infection. The absolute number of hepatitis infections post-transfu-
sion has decreased significantly, because reliable tests for HBV and HCV were
introduced. In the past, donors having elevated alanine aminotransferases were
rejected. This surrogate marker is no longer used with the availability of more
specific tests for anti-HCV and HCV RNA. Anti-HBc testing has been retained
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because it may still detect a few donors with infectious HBV who are negative
for HBsAg.
Hepatitis A (HAV), an RNA virus, is generally transmitted by the oral-fecal
route and very rarely transmitted by transfusion. The main concern of HAV (and
parvovirus B19 as well) is transmission by plasma derivatives (particularly hu-
man source factor VIII concentrates) because it does not have a lipid envelope
and is not inactivated during the manufacturing process. Nucleic acid testing
(NAT) is available and is done only for source plasma (plasma intended for
manufacture of blood derivatives/products). NAT testing for this virus is cur-
rently considered an “in-process control” by the FDA so donor notification (for
positive tests) is not required. In contrast to persons infected with HBV, persons
who are exposed to HAV do not develop a chronic carrier state. Blood donors are
not routinely screened for HAV because of the rarity of transfusion transmissible
HAV and the absence of HAV antibody at the time of viremia. The risk for HAV
is estimated at 1 per 10 million units.
HBV, a DNA virus, is primarily transmitted by the parenteral route. It can be
transmitted within the first 100 d after infection when viremia is present and no
protective immunity has yet developed, or in the chronic carrier state. Donor
screening to detect HBV infection includes assays for the HBsAg and for anti-
HBc. Most infections are asymptomatic and HBsAg positivity occurs 2 to 6 wk
before the onset of symptoms; thus, an apparently healthy but infectious donor
will be eligible for donation.
A “window period” for any transfusion-transmissible agent is defined as the
period of time that an individual is potentially infectious but demonstrates nega-
tive serological tests (without detectable antibodies). A licensed NAT test is not
available for HBV because of low levels of viremia during the “window phase”
resulting from a slow viral doubling time. However, a recent publication reported
that the “window period” can be reduced by 25–36 d using single donor NAT
(SDNAT), further reduced by 9–11 d using minipool NAT (MPNAT) and reduced
by 2–9 d using a new and more sensitive HBsAg assay. Disagreement exists as
to whether HBV-NAT will be cost effective to further reduce the risk of trans-
fusion-transmissible HBV.
HCV, an RNA virus, was discovered in 1989 and was linked with most cases
of non-A, non-B hepatitis in the past. HCV infections are mild and generally
(80%) asymptomatic. The long-term effects are far more serious in that the
majority of HCV infected patients develop chronic liver disease with 20% devel-
oping cirrhosis. In addition, those with HCV cirrhosis develop hepatocellular
carcinoma. It was estimated that the elimination of hepatitis C by anti-HCV
antibody testing prevented 40,000–50,000 new cases of post-transfusion hepa-
titis per year (an additional 10,000–13,000 cases may have been prevented by
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newer versions of the test). The risks of transfusion-transmissible HCV has
further been reduced by HCV-NAT. Prior to HCV-NAT, the window period
because of a slower doubling time was 70 d. The newly developed HCV-NAT
(MPNAT/SDNAT) has further closed the window phase to 10 d, so that the
transfusion-transmissible risk for HCV is reduced to 1:1,935,000 per unit trans-
fused from 1:276,000 in the past (see Table 3).
Hepatitis D (or δ), another RNA virus, exists as a co-infection in patients
chronically infected with HBV because the “delta agent” cannot multiply in the
absence of HBV. Testing for HBV markers eliminates hepatitis D-positive do-
nors.
The hepatitis G virus (HGV, also known as GBV-C), a newly discovered RNA
virus, is potentially transmitted by blood products. Among normal donors, the
reactivity is 1–4% by PCR techniques. Currently, HGV has not been associated
with a specific disease entity and its designation as a “hepatitis” virus may have
been premature. Thus, no routine donor testing is performed.
Two other hepatitis viruses, hepatitis E virus (HEV) and SEN virus, are appar-
ently transmitted by transfusion. HEV does not occur in the United States but is
endemic in other parts of the world, although its true incidence remains unknown.
SEN virus is the latest virus postulated to cause the remaining non A–E transfu-
sion-transmitted hepatitis. At present, the biological role of SEN virus has not
been clearly defined.
Lastly, TT virus, a DNA virus, first described by a Japanese group was origi-
nally postulated to cause non-A–E hepatitis. This virus is prevalent in many
countries and is currently not associated with hepatitis.
6.2.2. RETROVIRUSES
Retroviral infections transmitted by blood transfusion include HIV-1 and
HIV-2 and human lymphotropic virus (HTLV-I and HTLV-II). HIV is transmit-
ted by both cellular blood components and plasma; however, both types of HTLV
are highly cell-associated and require viable lymphocytes for transfusion trans-
mission.
HIV is a cytopathic retrovirus that preferentially infects CD4-positive T-
lymphocytes. The infection begins as a viremia of cell-free virions that may be
clinically manifested by an acute nonspecific flu-like illness. Viremia is detect-
able in the plasma 10 d to 3 wk after infection. As HIV antibodies appear, the
disease enters a clinically latent phase. Viral replication and dissemination con-
tinues and the virus can be transmitted by blood or genital secretions.
HIV-2 causes endemic infection in West Africa and has apparently spread
with population movements. It is indistinguishable from HIV-1 in disease spec-
trum although HIV-2 has a longer incubation period and is less efficiently trans-
mitted than HIV-1.
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The AIDS epidemic in the early 1980s had a catastrophic impact on the safety
of blood transfusions but triggered a major impetus for improvement in blood
safety. The risk of HIV transmission through blood components/products dramati-
cally decreased with more stringent donor history screening and improvement of
donor testing (see Table 3). Combination HIV-1/HIV-2 tests implemented in the
United States in 1992 have identified to date three HIV-2 infected donors, none
appear to have been infected in the United States.
Prior to 1992, the window period for HIV averaged 45 d. More sensitive HIV-
antibody screening tests closed this window to 22 d. In 1996, HIV antigen (p24
antigen) testing reduced this infectious window by an estimated 6 d; such that
circulating cell-free virions could be detected as early as 16 d following infec-
tion. With the newly developed PCR-based NAT, this window period was further
reduced to about 10 d. Although SDNAT has a detection sensitivity of less than
50 viral copies/mL, its higher cost prompted many blood centers into using
MPNAT with 14–16 donors per pool. An estimate of residual risk of HIV infec-
tion from repeat donors after NAT is 1 per 2,135,000 (per unit transfused).
Currently, many blood centers have implemented NAT and discontinued p24
antigen testing following the FDA’s licensure of the HIV-NAT assay.
HTLV-I and II are human retroviruses that can be transmitted by blood, sexual
contact (predominantly male-to-female), and through breast milk. It circulates as
a provirus that is incorporated into the DNA of lymphocytes. No cases of trans-
fusion-transmitted HTLV have been reported with noncellular blood compo-
nents. Prolonged storage for more than 10 to 14 d (refrigeration inactivates the
lymphocytes) also reduces transmission risk. Compared to other viruses, HTLV-
I and -II transfusion transmission is less efficient because exposure invariably
does not result in infection. Look-back studies have shown that one in three
HTLV-contaminated units transmitted the virus.
Risk factors for HTLV-1 infection are birth or sexual contact in areas where
the disease is endemic (Japan and certain Pacific Islands, Caribbean basin, sub-
Saharan Africa, Central and South America). The natural epidemiology of
HTLV-II is not fully known, although a high prevalence is seen in some Native
American populations. HTLV-II is presumably associated with parenteral trans-
mission with risk factors of intravenous drug use (1 to 20% seroprevalence) and
sexual contact with an IV drug user.
An excess of infectious syndromes (i.e., bronchitis, pneumonia, and urinary
infections) is seen among blood donors infected with HTLV-I or -II. However,
most HTLV-1-positive individuals remain asymptomatic donors with an
extremely long latency period (decades) and a 2–5% life-long risk of developing
adult T-cell lymphoma/leukemia or HTLV-associated myelopathy/tropical spas-
tic paresis in areas of high endemicity. Enzyme immunoassay (EIA) for both
HTLV-I and -II is used to screen donors, and EIA-reactive donors are indefinitely
Chapter 22 / Transfusion 425
deferred regardless of investigational supplemental tests since there is no li-
censed confirmatory test.
The risk of transfusion-transmissible HTLV with the same “51-d window
period” has decreased from 1:514,000 (in 1998–1999) to 1:2,993,000 (in 2000–
2001). Such a dramatic risk reduction may be partly attributed to the implemen-
tation of universal leukocyte reduction. Viral load reduction by removal of
infected leukocytes remains controversial.
6.2.3. HUMAN HERPESVIRUSES
Leukocytotropic human herpesvirus (HHV) may contaminate blood compo-
nents. Cytomegalovirus (CMV or HHV-5) and Epstein-Barr virus (EBV or
HHV-4) have the greatest clinical relevance to transfusion medicine.
CMV is transmitted by transfusion in the latent, noninfectious state in the
genome of leukocytes present in cellular blood components. Seropositivity in the
general population, United States ranges from 20 to 80%, but only a small frac-
tion of these individuals have circulating virion. Exposure and host factors de-
termine symptomatology. Among immunocompetent individuals, CMV causes
a mononucleosis-like syndrome or an asymptomatic infection and remains latent
in tissues and leukocytes.
Symptomatic CMV infections develop in immunosuppressed, seronegative
hosts. Human progenitor cell transplant (HPCT) recipients (develop CMV pneu-
monitis), low birth weight neonates (<1500 g) of seronegative/seropositive
mothers and HIV-infected patients (develop CMV chorioretinitis, encephalitis,
and enteritis) are particularly at risk. Among seropositive HPCT recipients, viral
reactivation is the most common cause of CMV infection (up to 69% in one
study). Generally, the donor organ is the source among transplant recipients.
Additionally, the risk of transfusion-transmitted CMV is high in heavily trans-
fused recipients (liver, heart-lung, and pancreas transplants).
“CMV-reduced-risk blood components” are recommended to reduce CMV
transmission. Leukoreduced cellular blood components are comparable to se-
ronegative cellular blood components. Nonetheless, there remains a small risk of
transmission with either type of component. Most centers in the United States,
Canada, Australia, and Europe recommend transfusion of CMV-negative blood
components to CMV-negative pregnant women and for intrauterine transfusions
(to prevent transplacental infection), and to CMV-negative immunosuppressed
individuals (i.e., HPCT recipients, HIV-positive with AIDS, and other immuno-
suppressed individuals). It is also prudent to extend this consideration to CMV-
negative candidates for HPCT. Despite transfusions of “CMV-reduced-risk blood
components,” a few marrow transplant patients (1 to 4%) still develop primary
CMV infection.
EBV targets B-lymphocytes causing polyclonal proliferation with T-lympho-
cyte response and demonstration of “atypical lymphocytes.” It causes infectious
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mononucleosis, the endemic form of Burkitt’s lymphoma in Africa and nasopha-
ryngeal carcinoma. EBV can be transmitted by blood transfusion, but is a rare
cause of significant disease in immunocompetent individuals. Transfusion-trans-
mitted EBV is usually asymptomatic. Rarely, EBV causes posttransfusion hepa-
titis and “postperfusion syndrome.” The latter is characterized as a viral-like
illness following massive transfusion of fresh blood during cardiac surgery.
EBV contributes to the development of lymphoproliferative disorders among
immunosuppressed HPCT and organ transplant recipients from a reactivation of
a latent infection. The high seropositivity rate (90%) among blood donors and the
low risk of acquiring clinical disease among immunocompetent recipients make
blood donor screening and laboratory testing less beneficial.
6.2.4. OTHER VIRUSES AND UNCONVENTIONAL INFECTIOUS AGENTS (PRIONS)
Parvovirus B19 is the etiological agent of erythema infectiosum (“fifth dis-
ease”) in children, arthritis in adults, and hypoplastic anemias in HIV-infected
individuals. More ominously, it causes an aplastic crisis among patients with
chronic hemolytic anemias who rely on active erythropoiesis to offset the short-
ened red cell survival. The red cell P antigen is the cellular receptor for parvovirus
B19 so those who do not possess the antigen are naturally resistant to infection.
The presence of parvovirus B19 antibodies (30 to 60% prevalence) and the brief
viremia in blood donors make viral transmission uncommon (ranging from 1 in
3300 to 1 in 50,000). The rarity of clinically significant disease or viral transmis-
sion has not made donor screening and testing imperative. There are reports of
parvovirus B19 transmission by solvent-detergent plasma (solvent detergent
viral inactivation is ineffective because the virus lacks a lipid envelop), cellular
blood components, and clotting factor concentrates. There are no reports of
transmission from IVIg and albumin. NAT screening has been implemented only
for in-process manufacturing control of plasma derivatives.
West Nile virus (WNV), a flavivirus, is transmitted through mosquito bites (an
arthropod-borne-virus), blood transfusions (first reported during the 2002 epi-
demic), and organ transplants to humans causing encephalitis, meningitis, and
very rarely asymmetrical flaccid paralysis. Immunocompromised and elderly
individuals are at risk of developing severe disease. Viremia occurs 1 to 3 d
following an infecting mosquito bite and lasts from 1 to 11 d.
WNV transfusion-transmission risk (per 10,000 donations) ranges from 1.46
to 12.33 for selected metropolitan areas and from 2.12 to 4.76 for six high-
incidence states. Serological tests are ineffective in donor screening as viremia
disappears by the time IgM antibodies are detected by ELISA tests. The seasonal
increase in 2003 prompted MPNAT under a clinical protocol in the United States.
Likewise, donor history questionnaires have been implemented to reduce the risk
of WNV transmission. During periods of high endemicity, frozen products have
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been withdrawn voluntarily from the supply, as cessation of donor collection is
not feasible. Other blood derivatives do not appear to be at risk for transmission
as the WNV is inactivated by heat or solvent-detergent treatment.
The severe acute respiratory syndrome (SARS) virus that first appeared in
Guangdong, China is spread by close person-to-person contact and is believed
caused by a corona virus that causes the common cold and/or probably a paramyx-
ovirus. Its spread to other countries was linked to airline travel, often by health
care workers in contact with SARS patients. The virus has been isolated from the
blood of an infected individual but its risk of transmission through blood trans-
fusion remains unknown. However, because of its highly contagious nature,
transfusion transmission is possible if blood collection coincides with the viremic
phase of the disease. The FDA recommends deferral of at-risk donors for 14 d
after a possible exposure and at least a 28-d deferral after resolution of symptoms.
Likewise, deferral is extended to donors with a history of travel or residence in
SARS-affected areas.
Transmissible spongiform encephalopathies (TSEs) are rare, fatal degenera-
tive neurological disorders caused by infectious agents classified as prions or
proteinaceous infectious particles that lack nucleic acid. A prion is an abnormal
isoform (PrPSC) of a normal cellular protein (PrPC) that is resistant to inactivation
by alcohol, formalin, ionizing radiation, proteases, and nucleases; but is dis-
rupted by autoclaving, phenols, detergents, and extremes in pH. TSEs have long
incubation periods (years to decades).
Two such TSEs, classic Creutzfeld-Jakob disease (CJD) and variant
Creutzfeld-Jakob disease (vCJD) are important from the transfusion medicine
perspective. Unlike classic CJD, which presents in older patients, vCJD is ob-
served in young adults and has an acute course with rapid progression to death
in 2 yr.
The majority of classic CJD is sporadic (80%). Familial cases (10–15%) are
caused by mutations and the rest (10%) arise from iatrogenic transmission
(administration of growth hormone and gonadotropic hormone derived from
pooled human pituitary tissue, allografts of dura mater and cornea, and reuse of
intracerebral electroencephalographic electrodes from such patients). To date,
transfusion transmission of CJD has been reported in experimental rodent mod-
els, but not in humans. Although theoretically possible, there is growing consen-
sus that CJD transmission by blood or its components is unlikely.
Variant CJD (vCJD), first reported in the United Kingdom in 1996, is caused
by the same prion responsible for bovine spongiform encephalopathy (BSE) but
might be entirely different. Its potential for transmission by blood and blood
components is heightened by the fact that vCJD can spread from cattle to humans
(presumably by ingestion) and from human to humans (a recipient developed
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symptoms 6.5 yr after a red cell transfusion). In December of 2003, a potential
case of vCJD associated with blood transfusion was reported in the United King-
dom. Its presence in lymphoreticular tissue of vCJD patients, determined by
animal studies and its association with B-lymphocytes, suggests possible trans-
mission through blood transfusions. As a safety measure, several European coun-
tries and Canada implemented universal leukocyte reduction for all blood
products to prevent lymphocytes from transmitting vCJD. However, the efficacy
of such intervention remains uncertain.
Expanded donor deferral criteria have been implemented to reduce the risk of
transmission of both TSEs. This includes deferral of donors at risk of exposure
due to travel or residency in areas with BSE epidemics, deferral of donors who
received bovine insulin and pituitary-derived human growth hormone or dura
transplants since 1980, and deferral of donors with blood relatives diagnosed
with CJD.
6.3. Parasites Transmitted by Blood Transfusion
Malaria is caused by several species of the intraerythrocytic protozoan Plasmo-
dium and can be transmitted by transfusion of parasitemic blood. Malarial para-
sites survive for at least 1 wk in blood components stored at room temperature
(i.e., platelets) or at 4°C. They can survive cryopreservation with glycerol. Any
blood component that contains red cells can transmit infection via the asexual
form of the parasite. It is frequently transmitted by red cell transfusions, rarely
by platelet transfusions, and is absent in plasma products. It is recognized as a
global health problem, but is very rare in the United States. However, it is the
most commonly recognized parasitic complication of transfusion and occurs as
at an estimated rate of 0.25 cases per 1 million blood units collected. Asymptom-
atic carriers are the general source of transfusion acquired infections. At present,
there are no practical serological tests to screen asymptomatic carriers. Preven-
tion of malaria transmission is possible by deferral of prospective donors with
increased risk of infectivity based on medical and travel history. In Western
Europe and the United States, blood donors are deferred for 12 mo after travel
to malaria-endemic areas. Individuals born in areas endemic for malaria gener-
ally are excluded from blood donation for 3 yr after leaving the area.
Chagas’ disease (American Trypanosomiasis) endemic in South and Central
America is caused by another protozoan parasite, Trypanosoma cruzi, transmit-
ted by reduviid bugs (cone-nosed or “kissing” bugs). Infection occurs from fecal
contamination of the reduviid bug bite wound by the infectious trypomastigote.
Acute infections are mild to asymptomatic and 20–40% of infected individuals
enter a chronic phase of intermittent parasitemia manifested by “megasyndromes”
(cardiomegaly, megaesophagus, and megacolon). Blood transfusion is a major
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source of infection in South America, where parasite reduction using chemicals
(like gentian violet) on donated blood pose additional risks. Six cases of trans-
fusion-transmitted Chagas’ disease have been reported in the United States (New
York, Los Angeles, Texas, and Florida) and Canada, involving platelet concen-
trates in at least four cases. Currently, there is a 0.1 to 0.2% seroprevalence in
areas with high immigrant populations from Central and South America. To date,
no tests are licensed by the FDA for screening, but highly specific confirmatory
tests (i.e., Western blot assays) are available. Close monitoring is needed to define
the risk of transfusion transmitted Chagas’ disease.
7. OTHER ADVERSE EFFECTS OF BLOOD TRANSFUSION
7.1. Iron Overload
Patients who are transfusion-dependent for aplastic anemias or chronic
hemolytic anemias (sickle cell anemia and thalassemias) such as genetic hemo-
chromatosis may develop iron overload (hemosiderosis), which may result in
organ failure, primarily of the heart, liver, and pancreas. Every milliliter of
transfused RBCs contains approx 1 mg of elemental iron. Signs of clinical
toxicity become evident when total body iron reaches 400 to 1000 mg/kg of
body weight. Patients who develop iron overload on chronic transfusion are
candidates for chelation therapy with parenteral deferoxamine or oral iron
chelators (see Chapter 23). Transfusion of RBC units enriched with a younger
cell population or “neocytes” (reticulocytes), advocated by some investiga-
tors, potentially increases transfusion intervals and intravascular survival of
RBCs (41%). However, its value in reducing hemosiderosis has not yet been
established.
7.2. Transfusion-Associated GVHD
A transfusion recipient’s ability to mount an immune response and inability
to reject transfused (donor) T-lymphocytes in cellular blood components is fun-
damental to the pathogenesis of TA-GVHD. Only whole blood and its cellular
components (RBCs, granulocytes, and platelets) containing sufficient, viable,
cytotoxic T-lymphocytes can meditate TA-GVHD. No cases have been reported
following FFP transfusions. This disease has been reported in immunosuppressed
patients with hematological and solid malignancies. Rarely, it occurs after organ
and HPCT and in patients receiving myeloablative therapy. Immunocompetent
transfusion recipients at risk of TA-GVHD share a haplotype with related or
unrelated HLA homozygous donors (HLA haploidentical). TA-GVHD typically
appears 2 to 50 d after transfusion. The development of marrow aplasia and
progressive pancytopenia distinguishes TA-GVHD from GVHD following
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HPCT. These patients may develop a skin rash, diarrhea, fever, and abnormal
liver function accompanied by extensive hepatocellular damage.
Most cases (>90%) of TA-GVHD are fatal. Treatment with immunosuppres-
sive regimens (steroids, cytoxan, and antithymocyte globulin, including OKT3)
has been ineffective. As a consequence, immunosuppressed patients (with con-
genital immunodeficiency syndromes, hematological malignancies undergoing
myeloablative therapy, allogeneic or autologous HPCT) premature neonates
(<1200 g), intrauterine transfusions, recipients of blood from biological rela-
tives and HLA-matched platelets should receive only irradiated blood. Solid
organ transplant recipients receiving immunosuppressive therapy or those un-
dergoing chemotherapy/radiation therapy for solid tumors do not require irradi-
ated blood componenets.  Interestingly, TA-GVHD has not been reported in
patients with AIDS. Gamma irradiation with 25–30 gy inactivates all immunore-
active lymphoid cells and prevents TA-GVHD. Leukocyte reduction is insuffi-
cient to prevent TA-GVHD.
7.3. Transfusion-Related Acute Lung Injury
The transfusion-related acute lung injury (TRALI) reaction is rare (1:2000 to
1:5000 units) and occurs during or within the 4–6 h after a transfusion. Patients
suddenly develop shortness of breath with severe hypoxemia, chills, fever, cough,
and tachycardia. Noncardiogenic pulmonary edema recognized on chest X-ray
as bilateral diffuse interstitial infiltrates results from leukocytic activation and
aggregation in the pulmonary bed causing “capillary leak.” The pathophysiology
of this reaction is thought to be immune-mediated, typically resulting from (1)
donor antibodies (granulocytic or lymphocytotoxic antibodies) directed against
white blood cell antigens, (2) HLA Class I and II antibodies, and (3) lipid acti-
vators of neutrophils in donor plasma. In very rare cases, these antibodies may
be present in the recipient.
Most donors associated with TRALI are multiparous females or donors with
multiple exposures to varying HLA types. Treatment is supportive; however,
ventilatory and pressor support may be necessary. Resolution occurs within 3 to
7 d in 81% of cases but is fatal in a small proportion of cases. TRALI is the third
leading cause of transfusion-related deaths, accounting for 13% of all transfusion
fatalities.
8. AUTOLOGOUS BLOOD TRANSFUSION
An autologous donor donates blood for his or her own future use. For  practical
reasons, the transfusion of autologous RBCs is an attractive option for patients
undergoing elective surgery. Autologous blood can be collected from a patient
in advance of anticipated need (preoperative collection) or at the start of surgery
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(acute normovolemic hemodilution); additionally, shed blood can be recovered
for reinfusion during surgery (intraoperative collection) or during the postopera-
tive period from drainage devices (postoperative collection). Clinicians should
be aware that recovered blood does not provide platelets or coagulation factors.
Autologous blood transfusion avoids the small risk of transfusion-transmitted
infectious agents, red cell alloimmunization, adverse reactions resulting from
antibody-mediated hemolysis, and leukocyte-associated febrile reactions. In a
larger perspective, autologous transfusion supplements and preserves the blood
supply for other patients who acutely or chronically need allogeneic transfusions.
Autologous donors undergoing preoperative collection should be in satisfac-
tory or good health without major cardiac problems or anemia. The predonation
hemoglobin requirement is lower (11 g/dL) for autologous donation than for
allogeneic donation (12.5 g/dL). Autologous donors can donate as often as every
72 h before the scheduled surgery. Ideally, supplemental iron is prescribed before
the first collection because iron-restricted erythropoiesis is one of the limiting
factors in collecting multiple units of blood over a short period of time. Oral or
parenteral iron supplement enhances recovery of hematopoiesis. Rarely, recom-
binant human erythropoietin must be administered to donors who have insuffi-
cient erythropoietic response.
In order to justify the cost effectiveness of autologous collections, there should
be a high likelihood that at least two units of blood will be used during surgery.
Hospitals must establish guidelines regarding indications for autologous blood.
During a 4–5 wk collection period, 2–4 units of RBCs can be collected. The
storage time of autologous blood is comparable to blood from other donors (up
to 42 d with additive solutions). Unused autologous blood may be discarded or
may be used for allogeneic transfusions in facilities that allow “crossover” only
after infectious disease testing. Only 30% of collections are typically eligible for
allogeneic use. Many institutions choose not to “crossover” autologous units
because of the cost, complexity, and error risks associated with the process.
Freezing and long-term storage of RBCs is indicated for patients with rare blood
group antibodies, making it difficult to find compatible blood (see p.439).
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1. GAUCHER DISEASE
1.1. Definition
Gaucher disease is characterized by the accumulation of glycosphingolipids
(glycosylceramide) in lysosomes due to a defect in acid-β-glucosidase. The gene
for acid-β-glucosidase is located on the long arm of chromosome 1. More than
200 mutations of the gene are known to date. Gaucher disease is inherited in an
autosomal-recessive pattern. Three types of Gaucher disease have been described
based on clinical characteristics. Type 1 is the most common variant and will be
described in detail in this chapter. Type 1 Gaucher disease results in hepatosple-
nomegaly, cytopenias, and progressive bone disease and has a highly variable
clinical course. Type 2 Gaucher disease is rare and leads to death early in life as
a result of severe CNS disease. Type 3 Gaucher disease also is rare, has a variable
course, and combines CNS disease with visceral manifestations. The incidence
of Gaucher disease varies between 1:40,000 in Western countries and 1:2000 in
Israel.
1.2. Etiology and Pathogenesis
Because of defective acid-β-glucosidase, lipid-laden macrophages accumu-
late in the reticuloendothelial system of various organs like liver, spleen, bone
marrow, and the CNS and lead to an enlargement of these organs and/or func-
tional disturbances.
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1.3. Diagnosis
The diagnosis of Gaucher disease is established by measuring acid-β-glucosi-
dase in leukocytes (0–15% of normal values is considered as pathological). A
bone marrow biopsy (which is rarely necessary for the diagnosis of Gaucher
disease) shows the presence of lipid-laden macrophages (Gaucher cells). The
diagnosis should be supported by a molecular analysis of the acid-β-glucosidase
gene. If the mutation is known, heterozygotes can be detected by PCR. Certain
mutations have ethnic and clinical correlations. Data from the Gaucher registry
show that the most common alleles are N370S (53%), L444P (18%), 84 GG
(7%), and IVS2+1 (2%). Homozygotes for N370S often have a more benign clini-
cal course than other genotypes and never develop CNS disease. Homozygotism
for L444P is associated with early symptomatic disease and CNS manifestations
(types 2 and 3). Biochemical markers for active Gaucher disease are increases in
chitotriosidase (which can be used to monitor enzyme replacement), angiotensin-
converting enzyme, tartrate-resistant acid phosphatase, lysozyme, and the
chemokine CCL18. Typical radiological manifestations are Erlenmeyer flask
deformity, osteolytic lesions, osteopenia, and avascular necrosis. Most patients
with bone disease have multiple manifestations. The extent of marrow infiltra-
tion can best be quantitated by magnetic resonance imaging (MRI).
1.4. Clinical Manifestations
A common manifestation of type 1 Gaucher disease is hepatosplenomegaly
and anemia, thrombocytopenia, and/or leukopenia. Thrombocytopenia may
result in bleeding. The disease becomes symptomatic around 10 to 25 yr;
however, in some cases the diagnosis is made earlier or much later in adulthood.
Children with Gaucher disease have growth retardation. Adults with Gaucher
disease are commonly fatigued. Bone disease manifests itself often later in life
with bone pain or frank fractures including collapse of vertebrae. The degree of
hepatosplenomegaly is variable. Liver failure develops rarely. Splenic infarcts
may occur in massively enlarged spleens. All bones of the axial skeleton and
extremities can be involved. Patients with bone disease often experience pain
crises. Rarely, other organs are involved in Gaucher disease: skin, kidneys, and
lungs. Patients with CNS manifestations may have a supranuclear gaze palsy,
myoclonus, and often develop progressive dementia.
1.5. Treatment
The treatment of choice in symptomatic patients with type 1 Gaucher disease is
enzyme replacement. Acid-β-glucosidase is available in two forms. Alglucerase
(Ceredase®) is isolated from placenta. Imiglucerase (Cerezyme®) is recombinant
mannose-terminated (macrophage-targeted) acid-β-glucosidase. The initial
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recommended dose is 60 IU/kg for children and for adults with severe bone
disease or massive hepatosplenomegaly. Both forms are given by intravenous
infusion over 2 h at 2-wk intervals and are generally well tolerated. In adults with
less severe disease manifestations or in children after clinical improvement, a
lower dose (20–40 IU/kg) may be given. This treatment has to be continued
indefinitely as maintenance. Enzyme replacement is expensive, but effectively
reduces hepatosplenomegaly, and improves cytopenias and bone or bone marrow
involvement by Gaucher disease. Cytopenias and pain generally improve within
a few months. It may take several years before radiological improvement can be
seen. Supportive treatment (e.g., joint replacement) or treatment of severe
cytopenias is necessary in patients with long-standing Gaucher disease. Splenec-
tomy, for example for the treatment of hypersplenism, is rarely necessary since
enzyme replacement became available and may actually worsen bone disease. In
Gaucher disease, the proof of principle for an effective somatic gene transfer has
been made, but has not found clinical application. For patients with less severe
forms of Gaucher disease (type 1) who cannot tolerate enzyme replacement,
recently miglustat (Zavesca®) has become available. Miglustat is taken orally,
inhibits glucosyl ceramide synthase and thereby reduces the accumulation of
glucocerebrosides. This “substrate reduction therapy” also leads to clinical
improvement but the follow-up is shorter than for enzyme replacement. Com-
mon side effects of miglustat are diarrhea and weight loss.
2. HEREDITARY HEMOCHROMATOSIS
2.1. Definition
Hereditary hemochromatosis is a common genetic disease in Caucasians char-
acterized by acquired iron overload, autosomal recessive inheritance, and (in the
vast majority of cases) by the presence of two mutated copies of the HFE gene
(type 1 hemochromatosis).
2.2. Etiology and Pathogenesis
In classic hereditary hemochromatosis, the HFE gene located on chromosome
6 is mutated. The most common mutation is an amino acid substitution at position
282 (C282Y). Homozygosity for this mutation is observed in up to 0.5% of
persons of Scandinavian descent. Less common mutations are H63D and S65C.
Most homozygotes for C282Y develop a progressive expansion of the plasma
iron compartment, which is subsequent to increased intestinal iron absorption.
This is explained by two models. In the crypt-programming model, the presence
of mutated HFE, which is unable to interact with transferrin receptor-1, leads to
iron-deficient crypt cells, which give rise to iron-deficient daughter cells. These
cells are programmed to absorb iron continuously from the intestinal lumen, even
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if all iron stores are saturated. In the hepcidin model, macrophages and their
interaction with enterocytes play a major role. In the normal state, high iron levels
lead to a diminished production of hepcidin, thereby modulating the release of iron
into the circulation. In hereditary hemochromatosis, a mutant HFE gene interacts
with the signaling pathway for hepcidin and leads to uncontrolled release of iron
from macrophages and enterocytes.
2.3. Diagnosis
The diagnosis of hereditary hemochromatosis today is often made at an
asymptomatic or presymptomatic stage. Suggestive evidence is elevated fer-
ritin and an elevated transferrin saturation (>45%). The diagnosis is established
by the presence of an HFE mutation. A liver biopsy is no longer mandatory, but
is helpful to rule out or confirm liver cirrhosis. The typical HFE mutations are
not present in all patients with hereditary hemochromatosis. Especially, in per-
sons of southern European origin, other mutations may be observed. In certain
patients (negative for HFE mutations but having a typical presentation) a liver
biopsy can be used to calculate the hepatic iron index (hepatic iron concentration
divided by age). Values of 1.9 or higher are considered as pathognomonic for
hereditary hemochromatosis. The extent of iron deposition in the liver can be
estimated semiquantitatively by MRI.
2.4. Clinical Manifestations
Patients with hemochromatosis may be asymptomatic, but the classical mani-
festations are cutaneous hyperpigmentation, diabetes mellitus, and hepatome-
galy. As a result of iron loss from menstruation and other factors, women develop
symptomatic hemochromatosis less frequently and later than men. Patients with
symptomatic disease often feel weak, lose weight, and are lethargic. Patients
with hepatomegaly commonly have abnormal liver function tests and experience
pain in the right upper quadrant. Liver cirrhosis develops in long-standing hemo-
chromatosis and up to 30% of patients with liver cirrhosis develop hepatocellular
carcinoma. Endocrine disturbances (due to iron deposition) are common in symp-
tomatic patients: diabetes mellitus, hypogonadism (in men loss of libido, testicu-
lar atrophy, in women amenorrhea), hypothyroidism. Joint disease is common
(arthralgias, arthritis, often beginning in metacarpophalangeal joints). Conges-
tive heart failure is common, as well as ventricular and supraventricular atopias,
as well as different degrees of heart block.
2.5. Treatment
The treatment of hereditary hemochromatosis consists of regular phleboto-
mies removing the excess iron stored in the body. Phlebotomies can prevent or
ameliorate most complications of the disease, including endocrine dysfunction
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and liver function abnormalities. Advanced hypogonadism, arthralgias, and liver
cirrhosis (including the risk of hepatocellular carcinoma) are not influenced by
phlebotomies. Therefore, the diagnosis and the treatment of hereditary hemo-
chromatosis should be made as early as possible. A common regimen of phle-
botomy is to remove one unit of blood weekly until the serum ferritin drops to
50 ng/mL. The serum transferrin saturation should drop below 30%. Then,
maintenance phlebotomy should be started to keep serum in the range of 50–100
ng/mL. This is generally accomplished by phlebotomizing once every 3–4 mo.
2.6. Other Forms of Hereditary Iron Overload
Rarely, other genetic diseases cause iron overload. In juvenile hereditary
hemochromatosis (type 2 of hereditary hemochromatosis), severe disease mani-
festations occur at an early age. Juvenile hereditary hemochromatosis is caused
by mutated hemojuvelin or hepcidin genes. In type 3 hereditary hemochromato-
sis, a mutated transferrin receptor 2 was found. Both type 2 and 3 hereditary
hemochromatosis have autosomal recessive inheritance and have an excellent
response to phlebotomy. Type 4 hereditary hemochromatosis has autosomal
dominant inheritance and is caused by a mutation of ferroportin. In type 4 hemo-
chromatosis, iron is mainly deposited in reticuloendothelial tissues of liver and
spleen. The response to phlebotomy is only partial and patients often develop
anemia during aggressive phlebotomy.
3. SECONDARY IRON OVERLOAD
Secondary hemochromatosis can arise in many hematological disorders when
chronic blood transfusions are needed. These disorders may be acquired or con-
genital. Examples for hereditary disorders are the hemoglobinopathies, red cell
enzyme deficiencies, membrane defects, and sideroblastic or dyserythropoietic
anemias. Any hematological disorder, for example acute leukemias and
myelodysplastic syndromes, necessitating frequent blood transfusions will result,
over time, in iron overload. Diseases with ineffective erythropoiesis and a pro-
longed clinical course, for example sideroblastic anemias, are especially prone
to develop iron overload. As a rule of thumb, one unit of red blood cells contains
200 to 250 mg of iron. Clinical symptoms of iron overload often develop after
the transfusion of 50 units and, in most cases, after the transfusion of 100 units
of red blood cell concentrates. For the diagnosis of secondary iron overload, a
liver biopsy is rarely necessary. The hepatic iron content can be estimated by
MRI. A simple measurement for the estimation of transfusion-related hemochro-
matosis is serum ferritin. Serum ferritin correlates more with reticuloendothelial
iron than with hepatic iron storage, but was found useful for the diagnosis and
follow-up of secondary iron overload. Because patients with secondary iron
overload are almost always anemic, phlebotomy is rarely feasible for the treat-
438 Munker
ment of secondary iron overload. Instead, iron chelation therapy should be insti-
tuted in all patients who need chronic blood transfusions or have developed iron
overload as a result of ineffective erythropoiesis. The longest clinical experience
is available for the iron chelator deferoxamine, which has to be administered by
subcutaneous infusion. More recently, oral chelators (deferiprone and deferasirox
[ICL 670]) were introduced.
• Deferoxamine (DFO) is hexadentate (one molecule binding one atom of iron).
DFO prevents most symptoms of iron overload (liver disease, heart failure,
endocrine disturbances). It is administered by subcutaneous infusion over 8–12 h,
5–7 d per week. The standard dose is 20–40 mg/kg in children and 2 g in adults.
Early treatment is recommended, in children after 10–20 blood transfusions, and
in adults when long-term transfusions are needed and organ complications can
be foreseen. A serum ferritin level greater than 900 µg/L is sometimes used as
indicator of iron overload. Vitamin C, 200 mg given orally with DFO, increases
the urinary excretion of iron. Side effects are observed in 5–10% of patients on
intensive chelation therapy (high-tone hearing loss, growth delay, cartilage
damage, retinal changes). Continued monitoring is required.
• Deferiprone is bidentate, is rapidly absorbed and has a peak plasma level after
45–60 min. The standard oral dose 75 mg/kg fractionated in three doses per day.
Arthropathy, agranulocytosis, gastrointestinal disturbances, and zinc deficien-
cies were described as side effects. At present, the indication for deferiprone is
the intolerance of or the inability to receive deferoxamine. Several studies com-
pared both chelators. DFO may be equivalent or superior to mobilize hepatic
iron. Deferiprone may be superior to prevent cardiac hemosiderosis. More recently,
combination studies of both drugs (2 d of DFO with 7 d of deferiprone) were
published. If the positive effects of the combination treatment are confirmed, the
side effects of either drug will be reduced and the compliance of patients with
chelation will increase.
• Deferasirox (ICL 670 or tridentate) is also rapidly absorbed and is highly selec-
tive for iron. The therapeutic dose is 20 mg/kg given once daily orally.
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APPENDIX 1
Glossary of Cytostatic Drugs
and Targeted Therapies
Michael Cockerham, PharmD
and Reinhold Munker, MD
A number of antimetabolites or cytostatic agents are employed in treating
leukemias and lymphomas. These drugs act through different mechanisms and
their correct use requires special knowledge and expertise. We have listed them
as follows in alphabetical order. Brief descriptions of the various routes of admin-
istration, the mechanisms of action, and the common side effects are provided.
Details about the dosage of the cytostatic drugs are given in the treatment pro-
tocols and product information.
Arsenic Trioxide (Trisonex)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Antineoplastic and antiangiogenic
MECHANISM OF ACTION: Causes morphological changes and DNA fragmenta-
tion characteristic of apoptosis in NB4 human promyelocytic leukemia cells in
vitro. Arsenic trioxide also causes damage or degradation of the fusion protein
PML-RARα
INDICATIONS: Induction of remission and consolidation in patients with acute
promyelocytic leukemia (APL) who are refractory to, or have relapsed from,
retinoid and anthracycline chemotherapy, and whose APL is characterized by the
presence of the t(15;17) translocation or PML/RAR a gene expression.
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SIDE EFFECTS: Leukocytosis (up to 50%), tachycardia (55%), nausea/vomiting/
diarrhea, abdominal pain (58%), fatigue, edema, hyperglycemia, dyspnea, cough,
rash or itching, headaches, dizziness, QT prolongation
COMMENT: In clinical trials these side effects did not always require interrup-
tion of therapy, nor have they been observed to be permanent or irreversible.
Electrocardiograph (EKG) monitoring recommended, electrolyte abnormalities
should be corrected
Asparaginase (Elspar, Erwinar)
Route of administration: Intravenous injection
DRUG CLASS: Enzyme
MECHANISM OF ACTION: Depletes cells of L-asparagine
INDICATIONS: Acute lymphoblastic leukemia
SIDE EFFECTS: Hypersensitivity and anaphylactic reactions, fever, broncho-
spasm, reduced synthesis of coagulation factors, increase in liver enzymes,
hyperglycemia, rarely pancreatitis, CNS toxicity (25–50%)
COMMENT: During treatment, a substitution of fresh frozen plasma or fibrino-
gen and antithrombin III may become necessary. Because of anaphylactic reac-
tions, a test dose should be given first. In case of intolerance, an alternative
preparation of asparaginase should be used (e.g., erwinia asparaginase).
Azacitidine (Vidaza)
ROUTE OF ADMINISTRATION: Subcutaneous injection
DRUG CLASS: Antimetabolite, pyrimidine nucleoside analog
MECHANISM OF ACTION: Hypomethylation of DNA and exerting direct cyto-
toxic in abnormal hematopoietic cells in the bone marrow
INDICATIONS: Myelodysplastic syndromes
SIDE EFFECTS: Thrombocytopenia, neutropenia, nausea/vomiting, anorexia,
arthralgias, injection site erythema, injection site pain
Bleomycin (Blenoxane)
ROUTE OF ADMINISTRATION: Intravenous injection, in some cases also intracavi-
tary, topical, intra-arterial
DRUG CLASS: Antibiotic
MECHANISM OF ACTION: Intercalates DNA, induces DNA breaks
INDICATIONS: Lymphomas, other malignant tumors
SIDE EFFECTS: Fever, myalgias, anorexia, skin pigmentation, rash, mucositis,
alopecia, pneumonitis (may progress to lung fibrosis), occasionally hypersensi-
tivity reactions, minor myelosuppression
Appendix 1 / Cytostatic Drugs 443
COMMENT: Pulmonary toxicity may be severe in older patients, in patients with
chronic lung disorders, or after thoracic irradiation. If higher dose therapy is
planned, lung function should be controlled regularly.
Bortezomib (Velcade)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Proteasome inhibitor
MECHANISM OF ACTION: Reversibly inhibits chymotrypsin-like activity at the
26S proteasome leading to cell-cycle arrest and apoptosis.
INDICATIONS: Multiple myeloma patients who have received at least one prior
therapy, some non-Hodgkin’s lymphomas (NHLs)
SIDE EFFECTS: Asthenia, nausea/vomiting/diarrhea, appetite decreased, consti-
pation, thrombocytopenia, peripheral neuropathy, pyrexia, anemia, headache,
insomnia, edema
Busulfan (Myleran, Busulfex)
ROUTE OF ADMINISTRATION: Intravenous injection, oral
DRUG CLASS: Alkylating agent
MECHANISM OF ACTION: Alkylates DNA, RNA, induces DNA breaks
INDICATIONS: Chronic myelogenous leukemia (CML), transplantation
SIDE EFFECTS: Severe pancytopenia, skin hyperpigmentation, nausea/vomiting/
diarrhea
Carmustine (BCNU)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Nitrosurea alkylating agent
MECHANISM OF ACTION: Bifunctional alkylating agent, induces DNA breaks
INDICATIONS: Lymphomas, solid tumors
SIDE EFFECTS: Prolonged myelosuppression, cumulative lung toxicity, nausea,
vomiting, in some cases hepatic and renal toxicity, in some cases neurotoxicity
Chlorambucil (Leukeran)
ROUTE OF ADMINISTRATION: Oral
DRUG CLASS: Alkylating agent
MECHANISM OF ACTION: Alkylates DNA, RNA, induces DNA breaks
INDICATIONS: Chronic lymphocytic leukemia (CLL), other low-grade lymphomas
SIDE EFFECTS: Leukopenia, minor gastrointestinal discomfort, rarely neurotox-
icity, sterility at high doses, pulmonary toxicity
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Cladribine (Leustatin, 2-CDA)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Antimetabolite
MECHANISM OF ACTION: Purine nucleoside analogue, DNA strand breaks
INDICATIONS: Hairy cell leukemia, CLL, CML, other low-grade lymphomas
SIDE EFFECTS: Fever (70%), leukopenia, anemia, fatigue, edema, rash
Clofarabine (Clolar)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Antimetabolite
MECHANISM OF ACTION: Purine nucleoside analog, interfering with DNA repli-
cation, disrupts the integrity of the mitochondrial membrane, releasing
proapoptotic mitochondrial proteins, cytochrome C, and apoptosis-inducing
factor, activating pathways of programmed cell death
INDICATIONS: Acute lymphoblastic leukemia (pediatric)
SIDE EFFECTS: Febrile neutropenia, Systemic Inflammatory Response Syndrome
(SIRS), nausea/vomiting/diarrhea, pyrexia, rigors, abdominal pain, fatigue, tachy-
cardia, anorexia
Cyclophosphamide (Cytoxan, CTX)
ROUTE OF ADMINISTRATION: Intravenous injection, oral
DRUG CLASS: Alkylating agent
MECHANISM OF ACTION: Alkylates DNA and RNA, induces DNA breaks
INDICATIONS: Lymphomas, leukemias, solid tumors, immunosuppression, con-
ditioning for bone marrow transplantation
SIDE EFFECTS: Myelosuppression, thrombocytopenia, nausea, vomiting, mucosi-
tis, fever, hemorrhagic cystitis, tubular nephropathy
COMMENT: Hemorrhagic cystitis can be prevented if adequate hydration (>200
mL/h) and Mesna are given. Mesna should always be given when cyclophospha-
mide is administered at greater than 400 mg/(m2 · d). If renal function is compro-
mised, the dosage of cyclophosphamide has to be adapted accordingly,
Cytosine-Arabinoside (Cytarabine, ARA-C)
ROUTE OF ADMINISTRATION: Intravenous, subcutaneous, intrathecal injection
DRUG CLASS: Antimetabolite, analogue of deoxycytidine
MECHANISM OF ACTION: Incorporates into DNA, inhibits DNA polymerases,
S-phase-specific
INDICATIONS: Acute and chronic leukemias, malignant lymphomas
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SIDE EFFECTS: Myelosuppression, gastrointestinal toxicity (nausea, vomiting,
rarely pancreatitis), pulmonary toxicity at high doses, alopecia, keratoconjunc-
tivitis, rash, neurotoxicity (at higher doses and in older patients’ severe cerebellar
syndrome, other neurologic disturbances)
COMMENTS: Also available as a liposomal preparation (DepoCyt) for lym-
phomatous meningitis.
Dacarbazine (DTIC-Dome, DTIC)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Alkylating agent
MECHANISM OF ACTION: Methylates DNA causing cross-linking
INDICATIONS: Lymphomas, other malignancies
SIDE EFFECTS: Severe nausea/vomiting, myelosuppression, alopecia, less fre-
quent: hepatotoxicity, diarrhea, and thrombophlebitis
Daunorubicin (Cerubidine)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Anthracycline antibiotic
MECHANISM OF ACTION: Intercalates DNA, forms free oxygen radicals, inhibits
topoisomerase II
INDICATIONS: Acute leukemias, lymphomas, solid tumors
SIDE EFFECTS: Myelosuppression, acute and chronic cardiotoxicity, mucositis,
nausea, alopecia, severe tissue necrosis in case of extravasation
COMMENT: The cumulative cardiotoxicity (dilative cardiomyopathy) limits the
total dose to 450–550 mg/m2. Risk factors are mediastinal irradiation, previous
cardiac disease. Do not administer if left ventricular ejection fraction is less than
40–45%.
Decitabine (Dacogen)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Antimetabolite
MECHANISM OF ACTION: Hypomethylating agent
INDICATIONS: Myelodysplastic syndromes
SIDE EFFECTS: nausea, vomiting, neutropenia, headaches
COMMENTS: Investigational
Denileukin Diftitox (Ontak)
ROUTE OF ADMINISTRATION: Intravenous injection
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DRUG CLASS: Fusion protein
MECHANISM OF ACTION: Fusion protein of interleukin-2 and diphtheria toxin deliv-
ers diphtheria toxin to targeted cells inhibiting intracellular protein synthesis.
INDICATIONS: Lymphomas
SIDE EFFECTS: Infusion related hypersensitivity (69%), vascular leak syndrome,
fever/chills (81%), asthenia, infection, nausea/vomiting, edema, hypotension,
rash, hypoalbuminemia, increased transaminases, and lymphopenia.
COMMENTS: Side effects diminish after first two treatment courses.
Doxorubicin (Adriamycin)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Anthracycline antibiotic
MECHANISM OF ACTION: Intercalates DNA, forms free oxygen radicals, inhibits
topoisomerase II
INDICATIONS: Lymphomas, solid tumors
SIDE EFFECTS: Myelosuppression, acute and chronic cardiotoxicity, mucositis,
nausea, alopecia, severe tissue necrosis in case of extravasation
COMMENT: The cumulative cardiotoxicity (dilative cardiomyopathy) limits the total
dose to 450–550 mg/m2. Risk factors are mediastinal irradiation, previous cardiac
disease. Do not administer if left ventricular ejection fraction is less than 40–45%.
Epirubicin (Ellence)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Anthracycline antibiotic
MECHANISM OF ACTION: Intercalates DNA, forms free oxygen radicals, inhibits
topoisomerase II
INDICATIONS: Lymphomas, solid tumors
SIDE EFFECTS: Myelosuppression, acute and chronic cardiotoxicity, mucositis,
nausea, alopecia, severe tissue necrosis in case of extravasation
COMMENT: Risk of cardiotoxicity increases sharply above 900 mg/m2.
Etoposide (VePesid, VP-16)
ROUTE OF ADMINISTRATION: Intravenous injection, oral
DRUG CLASS: Mitotic inhibitor
MECHANISM OF ACTION: Complexes with topoisomerase II induces DNA breaks
INDICATIONS: Leukemias, lymphomas, solid tumors
SIDE EFFECTS: Bone marrow depression, especially neutropenia, alopecia, some
nausea, some patients experience allergic or anaphylactic reactions, hypotension
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Fludarabine (Fludara)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Antimetabolite (purine analogue)
MECHANISM OF ACTION: inhibits enzymes of DNA synthesis
INDICATIONS: B-cell CLL, lymphomas, leukemias
SIDE EFFECTS: Myelosuppression, some nausea, neurotoxicity (encephalopa-
thy at high doses), protracted immunosuppression, fatigue, and somnolence.
Gemtuzumab ozogamicin (Mylotarg)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Monoclonal antibody
MECHANISM OF ACTION: Binding to CD33 antigen results in the formation of a
complex that is internalized, the calicheamicin derivative is released inside the
lysosomes of the myeloid cell, calicheamicin derivative binds to DNA resulting
in DNA double strand breaks and cell death.
INDICATIONS: Treatment of CD33-positive AML in first relapse in patients 60
yr of age or older
SIDE EFFECTS: Peripheral edema, chills, fever, nausea/vomiting, headache, rash,
hypotension, hypertension, hypoxia, dyspnea, hyperglycemia
Hydroxyurea (Hydrea, Droxia)
ROUTE OF ADMINISTRATION: Oral
DRUG CLASS: Antimetabolite
MECHANISM OF ACTION: Inhibits ribonucleotide reductase
INDICATIONS: CML, other myeloproliferative syndromes, sickle cell anemia
SIDE EFFECTS: Short-acting myelosuppression; some gastrointestinal toxicity;
rarely pigmentation; renal, hepatic, and neurologic side effects (dose adjustment
in renal failure necessary)
Idarubicin (Idamycin)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Anthracycline antibiotic
MECHANISM OF ACTION: Intercalates DNA, forms free oxygen radicals, inhibits
topoisomerase II
INDICATIONS: Acute leukemias, lymphomas
SIDE EFFECTS: Myelosuppression, acute and chronic cardiotoxicity, mucositis,
nausea, alopecia, severe tissue necrosis in case of extravasation
448 Cockerham and Munker
Ifosfamide (Ifex)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Alkylating agent (derivative of cyclophosphamide with a par-
ticular toxicity profile)
MECHANISM OF ACTION: Alkylates DNA and RNA, induces DNA breaks
INDICATIONS: Lymphomas, other malignancies
SIDE EFFECTS: Myelosuppression, nausea/vomiting/diarrhea, mucositis, hem-
orrhagic cystitis, alopecia, acute CNS toxicity (encephalopathy, cerebellar syn-
drome, ataxia, seizures; especially in older patients and higher dosage)
COMMENT: Hemorrhagic cystitis can be prevented if adequate hydration (>200
mL/h) and Mesna are given. If renal function is compromised, the dosage of
ifosfamide has to be adapted accordingly. The infusion of Na bicarbonate is
recommended for the prophylaxis of CNS toxicity.
Imatinib (Gleevec)
ROUTE OF ADMINISTRATION: Oral
DRUG CLASS: Tyrosine kinase inhibitor
MECHANISM OF ACTION: Inhibition of BCR-ABL tyrosine kinase induces
apoptosis
INDICATIONS: CML, gastrointestinal stromal tumors (GIST)
SIDE EFFECTS: Nausea/vomiting/diarrhea, fluid retention, muscle cramps, hem-
orrhage, musculoskeletal pain, skin rash, headache, fatigue.
Ibritumomab tiuxetan (Zevalin)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Monoclonal antibody/radioisotope
MECHANISM OF ACTION: Antibody linked to the radioactive isotope yttrium-90,
monoclonal antibody targets the CD20 antigen, and cytotoxic radiation is deliv-
ered directly to malignant cells.
INDICATIONS: Relapsed or refractory low-grade, follicular, or transformed
B-cell NHL
SIDE EFFECTS: Nausea/vomiting/diarrhea, anorexia, thrombocytopenia, neu-
tropenia, anemia, arthralgias, dizziness, dyspnea, increased cough
Lenalidomide (Revlimid)
ROUTE OF ADMINISTRATION: Oral
DRUG CLASS: Immunomodulatory agent
MECHANISM OF ACTION: Inhibits secretion of pro-inflammatory cytokines, in-
hibits expression of Cox-2
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INDICATIONS: Myelodysplastic syndromes (MDS) with 5q deletion
SIDE EFFECTS: Neutropenia, thrombocytopenia, pruritus, nausea, diarrhea,
fatigue
COMMENT: Due to teratogenic risk, patient must be registered in distribution
monitoring program
Lomustine (CeeNU, CCNU)
ROUTE OF ADMINISTRATION: Oral
DRUG CLASS: Alkylating agent (nitrosurea derivative)
MECHANISM OF ACTION: Alkylates DNA and RNA
INDICATIONS: Hodgkin’s lymphoma, solid tumors
SIDE EFFECTS: Nausea, stomatitis, alopecia, delayed myelotoxicity, less fre-
quent renal and hepatic toxicity
Mechlorethamine (Mustargen, Nitrogen Mustard)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Alkylating agent (nitrogen mustard)
MECHANISM OF ACTION: Bifunctional alkylating agent, induces DNA breaks
INDICATIONS: Lymphomas, solid tumors
SIDE EFFECTS: Alopecia, nausea/vomiting, myelosuppression, vesicant
Melphalan (Alkeran)
ROUTE OF ADMINISTRATION: Intravenous, oral
DRUG CLASS: Alkylating agent
MECHANISM OF ACTION: Crosslinks DNA
INDICATIONS: Multiple myeloma, solid tumors
SIDE EFFECTS: Nausea, protracted myelosuppression, rarely skin rash, pulmo-
nary toxicity, alopecia
6-Mercaptopurine (Purinethol, 6-MP)
ROUTE OF ADMINISTRATION: Oral
DRUG CLASS: Antimetabolite
MECHANISM OF ACTION: Inhibits purine synthesis
INDICATIONS: Acute leukemias, NHL
SIDE EFFECTS: Nausea, myelosuppression, liver toxicity (cholestasis), fever,
skin rash
COMMENT: If concomitant allopurinol is given, the dose has to be reduced by
65–75%.
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Methotrexate (Folex, Abitrexate, MTX)
ROUTE OF ADMINISTRATION: Intravenous injection, oral, intrathecal
DRUG CLASS: Antimetabolite
MECHANISM OF ACTION: Inhibits dihydrofolate reductase, inhibiting purine syn-
thesis
INDICATIONS: Leukemias, lymphomas, other malignancies
SIDE EFFECTS: Myelosuppression, severe mucositis (dose dependent), nausea,
diarrhea, hepatic, renal and pulmonary toxicity, skin rash, acute encephalopathy,
arachnoiditis with intrathecal administration,
COMMENT: At high doses of methotrexate, measurement of plasma levels and
“rescue” with folinic acid (leucovorin) are important.
Mitoxantrone (Novantrone)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Anthracycline antibiotic (Anthracenedione)
MECHANISM OF ACTION: Intercalates DNA, forms free oxygen radicals, inhibits
topoisomerase II
INDICATIONS: Acute leukemia, NHL
SIDE EFFECTS: Myelosuppression, acute and chronic cardiotoxicity, mucositis,
nausea, alopecia, severe tissue necrosis in case of extravasation, discoloration of
urine
COMMENTS: Cumulative dose greater than 160 mg/m2 may cause congestive
heart failure.
Nelarabine (Arranon)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Antimetabolite, deoxyguanosine analog
MECHANISM OF ACTION: Disrupts DNA synthesis, induces apoptosis
INDICATION: Relapsed or refractory T-cell acute lymphoblastic leukemia and
lymphoma
SIDE EFFECTS: Pancytopenia, anemia, hepatic enzyme elevations, nausea, vom-
iting, electrolyte disturbance, infection, cough, fatigue, dyspnea, headache, som-
nolence, neuropathy, leukencephalopathy
Pentostatin (Nipent, Desoxycoformine)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Antimetabolite
MECHANISM OF ACTION: Purine analogue, inhibits adenosine deaminase
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INDICATIONS: Hairy cell leukemia, other low-grade NHLs
SIDE EFFECTS: Myelosuppression, infection, nausea, hepatic and renal toxicity,
rash
Procarbazine (Matulane)
ROUTE OF ADMINISTRATION: Oral
DRUG CLASS: Alkylating agent
MECHANISM OF ACTION: Alkylates DNA, methylates nucleic acids
INDICATIONS: Lymphomas, multiple myeloma
SIDE EFFECTS: Myelosuppression, nausea, vomiting, skin toxicity, secondary
malignancies, CNS depression (synergistic with other depressants)
Rituximab (Rituxan)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Monoclonal antibody
MECHANISM OF ACTION: Antibody directed against CD20 antigen, which arrests
cell cycle initiation, compliment dependent cytotoxicity.
INDICATIONS: Refractory B-cell lymphoma, in combination for other CD20-
positive NHLs
SIDE EFFECTS: Headache, chills, rigors, nausea, hypotension, rash
Teniposide (Vumon)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Mitotic inhibitor
MECHANISM OF ACTION: Topoisomerase II inhibitor, DNA strand breaks
INDICATIONS: Acute lymphoblastic leukemia, lymphoma
SIDE EFFECTS: Mucositis, nausea/vomiting/diarrhea, myelosuppression
Thalidomide (Thalomid)
ROUTE OF ADMINISTRATION: Oral
DRUG CLASS: Immunomodulatory agent
MECHANISM OF ACTION: Suppress excess tumor necrosis factor-α and vascular
endothelial growth factor-inhibiting angiogenesis.
INDICATIONS: Multiple myeloma, myelodysplastic syndrome
SIDE EFFECTS: Somnolence, rash, headache, neutropenia
COMMENT: Because of teratogenic risk, patient must be registered in distribu-
tion monitoring program.
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Thioguanine (6-Thioguanine, 6-TG)
ROUTE OF ADMINISTRATION: Oral
DRUG CLASS: Antimetabolite
MECHANISM OF ACTION: Inhibits purine synthesis, incorporated into DNA
INDICATIONS: AML
SIDE EFFECTS: Myelosuppression, some nausea, diarrhea, cholestasis
Thiotepa (Thioplex)
ROUTE OF ADMINISTRATION: Intravenous and intrathecal injection
DRUG CLASS: Alkylating agent
MECHANISM OF ACTION: Polyfunctional agent, DNA crosslinking
INDICATIONS: Lymphomas, CNS leukemias (intrathecal), solid tumors
SIDE EFFECTS: Myelosuppression, pain at injection site
Tositumomab (Bexxar)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Monoclonal antibody/radioisotope
MECHANISM OF ACTION: Antibody linked to the radioactive isotope iodine 131,
monoclonal antibody targets the CD20 antigen, and cytotoxic radiation is deliv-
ered directly to malignant cells.
INDICATIONS: CD20-positive, follicular NHL, with and without transforma-
tion, whose disease is refractory to rituximab and has relapsed following chemo-
therapy
SIDE EFFECTS: Infection, myelosuppression, allergic reaction, anaphylactoid
reaction, gastrointestinal symptoms, fever, nausea, sweating, hypotension, as-
thenia
Tretinoin (Vesanoid, all-trans  retinoic acid, ATRA)
ROUTE OF ADMINISTRATION: Oral
DRUG CLASS: Vitamin A derivative
MECHANISM OF ACTION: Inhibits clonal proliferation and/or granulocyte differ-
entiation
INDICATIONS: APL
SIDE EFFECTS: Arrhythmia, hypotension, peripheral edema, headache, fever, rash,
nausea/vomiting, abdominal pain, retinoic acid syndrome, myelosuppression, dia-
phoresis
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Vinblastine (Velban, Velsar)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Vinca alkaloids
MECHANISM OF ACTION: Inhibit function of microtubules, inhibit DNA-depen-
dent RNA polymerases
INDICATIONS: Lymphomas, leukemias, other malignancies
SIDE EFFECTS: Nausea/vomiting, myelosuppression, diarrhea, constipation, sto-
matitis, mouth ulcers, neurotoxicity (cumulative, dose limiting: peripheral neur-
opathy, paresthesias, autonomous neuropathy, rarely ataxia, seizures)
COMMENTS: Vinblastine less likely to produce severe neurotoxicity compared to
other
vinca alkaloids
Vincristine (Oncovin, Vincasar)
ROUTE OF ADMINISTRATION: Intravenous injection
DRUG CLASS: Vinca alkaloids
MECHANISM OF ACTION: Inhibit function of microtubules, inhibit DNA-depen-
dent RNA polymerases
INDICATIONS: Lymphomas, leukemias, other malignancies
SIDE EFFECTS: Mild nausea/vomiting, pulmonary toxicity, diarrhea, constipa-
tion, stomatitis, mouth ulcers, major neurotoxicity (cumulative, dose limiting:
peripheral neuropathy, paresthesias, autonomous neuropathy, rarely ataxia, sei-
zures), alopecia, syndrome of inappropriate antidiuretic hormone secretion
COMMENTS: Myelosuppression minor with vincristine
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APPENDIX 2
CD Nomenclature
for Human Leukocyte Antigens
Reinhold Munker, MD
Designation Cellular distribution Function, comments
CD1 Cortical thymocytes, dendritic Role in antigen presentation
cells (four subtypes)
CD2 Pan T-cell, NK cells Receptor for sheep red blood cells,
interaction with CD48 and CD58
CD3 Pan T-cell Signal transduction from T-cell
receptor
CD4 T-helper subset Binds to class II MHC antigen
CD5 Pan T-, B-cell subset Marker for B-CLL
CD6 T-cell subset Binds to CD166
CD7 Early T-cell marker Expressed on T-ALL
CD8 T suppressor cells Co-receptor in antigen recognition
CD9 Broad (platelets, lymphoid Belongs to tetraspanin family of
progenitors, activated active proteins
lymphocytes)
CD10 Immature, some mature B-cells CALLA-antigen, expressed in pre-
B-ALL, some lymphomas,
kidney, intestine, brain
CD11a Leukocytes Adhesion
CD11b Granulocytes, monocytes, Adhesion
NK cells
CD11c Granulocytes, monocytes, Adhesion
macrophages, NK cells
CD12 Monocytes, granulocytes
(continued)
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CD Nomenclature for HLA (continued)
Designation Cellular distribution Function, comments
CD13 Monocytes, granulocytes Membrane metalloprotease
CD14 Monocytes Receptor for lipopolysaccharide
CD15 Granulocytes, monocytes Lewis x antigen
CD16 NK cells, granulocytes, mast Fc gamma receptor type III
cells
CD17 Granulocytes, monocytes, Lactosylceramide
platelets
CD18 Leukocytes Integrin β2 subunit (adhesion)
CD19 B-cells Regulates B-cell antigen receptor
signal transduction
CD20 B-cells
CD21 Mature B-cells Receptor for EBV, complement
type 2, C3d
CD22 B-cells
CD23 Activated B-cells, macrophages, Regulates IgE synthesis
follicular dendritic cells
CD24 B-cells, granulocytes, some Mucin-like adhesion molecule
tumors
CD25 Activated T-cells, B-cells, Receptor for interleukin-2 (α-chain)
macrophages
CD26 Thymocytes, activated T-cells, Membrane-bound protease
tumors, other cells
CD27 T-cells, other cells Member of TNF receptor
superfamily
CD28 T-cells, plasma cells T-cell, B-cell interactions
CD29 Most cells Adhesion (integrin β1 subunit)
CD30 Activated T- and B-cells Member of TNF receptor
superfamily (present on anaplastic
large lymphomas, Reed-Sternberg
cells)
CD31 Monocytes, platelets, PECAM-1, mediates adhesion
granulocyte, lymphocyte
subset, endothelial cells
CD32 Monocytes, platelets, other cells Fc γRII (Fc receptor for
aggregated IgG)
CD33 Monocytes, immature myeloid cells Member of sialoadhesin family
CD34 Hematopoietic progenitors,
endothelial cells
CD35 Red cells, B-cells, subset of T-cells, Complement receptor type I (binds
granulocytes, other cells C3b, C4b)
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CD36 Platelets, monocytes, other cells Multifunctional glycoprotein
CD37 Mature B-cells, some other cells
CD38 Immature B- and T-cells, plasma Multifunctional
cells, some other cells
CD39 Activated B-cells, some other cells
CD40 Mature B-cells Member of TNF receptor superfamily,
interacts with CD 154
CD41 Platelets, megakaryocytes Integrin αIIb subunit, interacts with
glycoprotein IIIa. Defect in
Glanzmann thrombasthenia
CD42a,b Platelets, megakaryocytes Platelet adhesion, binds to VWF,
defect in Bernard-Soulier syndrome
CD43 Leukocytes, mast cells Leukosialin
CD44 Widely expressed on hematopoietic Several isoforms, adhesion of
and nonhematopoietic cells leukocytes to endothelial cells,
stroma, and extracellular matrix
CD45 Leukocytes Leukocyte common antigen, several
epitopes with differential
expression
CD46 Leukocytes, endothelial, epithelial cells Regulates complement activation
CD47 Broad tissue expression Integrin-associated protein, absent on
Rhnull erythrocytes
CD48 Hematopoietic cells
CD49a Monocytes, activated T-cells Subunit of α1-integrin (VLA-1α)
CD49b Monocytes, platelets, T- and B-cells Subunit of integrin-α2
CD49c Cultured adherent cell lines Subunit of integrin-α3
CD49d Most leukocytes Subunit of integrin-α4
CD49e T cells, monocytes, platelets, Subunit of integrin-α5
activated B-cells
CD49f T-cells, monocytes, nonlymphoid Subunit of integrin-α6
tissues
CD50 Leukocytes ICAM-3, mediates adhesion
CD51 Platelets, endothelial and other cells Alpha subunit of vitronectin receptor
CD52 Lymphocytes, monocytes
CD53 Leukocytes and other cells
CD54 Hematopoietic and ICAM-1, mediates adhesion, T-cell
nonhematopoietic cells activation
CD55 Broad expression Decay-accelerating factor
CD56 NK cells, T-cell subpopulation, Isoform of NCAM, cell–cell
neural tissue interactions
CD57 Subset of NK cells and T-cells
CD58 Most hematopoietic cells, other LFA-3 adhesion ligand for CD2
cells
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Designation Cellular distribution Function, comments
CD59 Many cells Complement protectin (via GPI
anchor)
CD60 T-cell subset, platelets
CD61 Platelets, monocytes, Integrin β subunit (combines with
megakaryocytes, endothelial cells CD41 and with CD51)
CD62E Endothelial cells E-selectin (adhesion of leukocytes)
CD62L Most hematopoietic cells L-selectin (homing of lymphocytes)
CD62P Megakaryocytes, activated P-selectin (adhesion)
endothelial cells and platelets
CD63 Widely distributed
CD64 Monocytes, macrophages High-affinity Fc γ-receptor
CD65 Granulocytes
CD66 Granulocytes Cell adhesion (belongs to CEA family)
CD68 Monocytes, macrophages, other cells Belongs to family of
lysosomal-associated membrane
proteins
CD69 Activated T-cells, B-cells. NK cells Signal transduction
CD70 Activated B-cells, some activated Member of TNF receptor superfamily,
T-cells co-stimulation of T-cell
proliferation
CD71 Proliferating cells Transferrin receptor
CD72 B-cells B-cell co-receptor
CD73 Subsets of mature lymphocytes Ecto-5'-nucleotidase
CD74 B-cells, monocytes MHC class II-associated invariant
chain
Cdw75 Mature B-cells
CD76 Mature peripheral B-cells, mantle
zone B-cells, activated cells
CD77 Subset of germinal center B-cells Marker for Burkitt’s lymphomas
CD79 (a,b) B-lymphocytes, B-cell neoplasms B-cell antigen receptor complex
CD80 Activated T-cells, B-cells, monocytes Co-stimulatory signal for T-cells
(B7-1)
CD81 Broad expression Receptor for hepatitis C virus envelope
(TAPA1) E2 glycoprotein
CD82 Broad expression Suppresses metastasis in tumor cells
(KAI-1)
CD83 Dendritic cells
Cdw84 Macrophages and platelets
CD85 Plasma cells, monocytes, other cells
CD86 Monocytes, dendritic cells, Co-stimulatory signal for T-cells
activated cells (B7-2)
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CD87 Monocytes, granulocytes, large Receptor for urokinase plasminogen
granular lymphocytes activator
CD88 Myeloid and other cells Receptor for C5a (G protein-coupled
receptor)
CD89 Most phagocytic cells, other cells Receptor for IgA
CD90 Prothymocytes, brain Thy-1
CD91 Phagocytes of liver, lung, lymphoid Binds protease-inhibitor complexes
tissues
Cdw92 Myeloid cells
CD93 Granulocytes, monocytes,
endothelial cells
CD94 NK cells, subset of T-cells Receptor for HLA-E
CD95 Activated lymphocytes, monocytes, Member of TNF receptor superfamily
fibroblasts, cell lines (induces apoptosis)
CD96 Activated T-cells, NK cells, T-cell NK cell recognition
lines
CD97 Granulocytes, monocytes, activated
T- and B-cells
CD98 Monocytes, some other cells
CD99 Pan leukocyte
CD100 B-cells, T-cells, NK cells, most Class 4 semaphorin
myeloid cells, neurons
CD101 Monocytes, granulocytes, mucosal
T-cells
CD102 Most leukocytes, vascular ICAM-2, major LFA-1 ligand on
endothelium endothelial cells
CD103 Intraepithelial lymphocytes Integrin α E subunit
CD104 Desmosomes of epithelia Integrin β 4 subunit
CD105 Endothelial cells Endoglin (receptor for TGFβ)
CD106 Vascular endothelium, dendritic VCAM-1
cells, some other cells
CD107 Granulocytes, T-cells, other cells Lysosome-associated membrane
protein
Cdw108 Some lymphoid and other cells
CD109 Platelets, activated T-cells, umbilical Gova/b alloantigen
vein endothelial cells
CD116 Myeloid cells Receptor for granulocyte/macrophage
colony-stimulating factor
CD117 Hematopoietic progenitors, mast c-kit
cells, some AMLs, some solid
tumors
CD120a,b Low-level expression on many cells TNF receptors (type I and II)
CD133 Early hematopoietic cells, endothelial cells
(continued)
460 Munker
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Designation Cellular distribution Function, comments
CD134 Activated T-cells Member of TNF receptor family,
co-stimulates T-cell proliferation
CD135 Hematopoietic stem cells FLT-3, receptor for FLT-3/flk-2 ligand
Cdw137 Activated T-, B-cells, monocytes Co-stimulation of T-cell growth
CD138 Immature B-cells, plasma cells Syndecan- I
CD147 Activated cells, tumor cells Extracellular matrix metalloproteinase
inducer
CD148 Broad expression Transmembrane tyrosine phosphatase
Cdw150 Immature thymocytes, some B-cells Signaling lymphocyte activation
molecule, receptor for measles
virus
CD151 Platelets, megakaryocytes, Member of tetraspanin family
monocytes, keratinocytes
CD152 Activated T-lymphocytes Binds CD80, CD86
CD153 Activated T-cells CD30 ligand
CD 154 Activated T-cells CD40 ligand
CD155 Various types of cells Receptor for polio virus
CD157 Neutrophils GPI-anchored protein
CD158 NK cells Killer cell Ig-like receptor
CD160 NK cells Receptor for HLA-C
CD161 Natural killer cells, some T-cells
CD162 Granulocytes, monocytes, most Ligand for selectins
lymphocytes
CD163 Monocytes, macrophages Hemoglobin scavenger
CD164 Early hematopoietic progenitors Sialomucin
CD166 Broad expression Activated leukocyte cell adhesion
molecule
CD170 Myeloid cells Siglec-5
CD171 Neurons, certain tumors L1 adhesion molecule
CD172 Monocytes, dendritic cells Signal regulatory phosphatase
CD177 Neutrophils Polymorphic
CD178 Various cell types Ligand for CD95
CD180 B-cells Belongs to toll-like receptor family
CD184 Various cell types Chemokine receptor CXCR-4
CD200 Broad distribution OX2 (interacts with CD200R on
myeloid cells)
CD204 Macrophages Class A scavenger receptor
CD206 Macrophages, dendritic cells Mannose receptor
CD208 Activated dendritic cells Member of LAMP family
CD209 Dendritic cells DC-SIGN
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CD222 Many cells Multifunctional receptor
CD226 Hematopoietic cells, epithelial cells, tumors MUC1
CD229 B- and T-lymphocytes Ly9 (cell surface receptor)
CD244 NK cells, monocytes, basophils, some T-cells 2B4 (NK receptor)
The list is not complete, and additional surface markers do not yet have a CD designation.
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APPENDIX 3
Laboratory Values
Parameter Normal range
Hemoglobin Males: 13.5–17.5 g/dL
Females: 11.5–15.5 g/dL
Red cell number Males: 4.5–6.5 × 109/L
Females: 3.9–5.6 × 109/L
Hematocrit Males: 40–52%
Females: 36–48%
MCV 80–95 fL
MCHC 30–35 g/dL
Reticulocytes 0.5–2.5% or 50–100,000 × 109/L
Leukocytes (white cells) 4000–10,500/µL
Neutrophils 2500–7500/µL
Lymphocytes 1500–4000/µL
Monocytes 200–800/µL
Eosinophils 40–500/µL
Basophils 0–100/µL
Platelets 150,000–440,000/µL
LDH (lactate dehydrogenase) 100–240 IU/L
Haptoglobin 0.3–2 g/L
Serum alkaline phosphatase 30–120 U/L
Serum bilirubin (total) <10 mg/L or 17 µmol/L
Serum bilirubin (indirect) <7 mg/L or 7 µmol/L
Serum transferrin receptors 4–9 µg/L
Serum iron Males: 80–150 µg/dL or 14–27 µmol/L
Females: 60–140 µg/dL or 11–25 µmol/L
Serum ferritin Males: 40–350 µg/L
Females: 20–250 µg/L
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Laboratory Values (continued)
Parameter Normal range
Serum vitamin B12 160–900 ng/L
Serum folate 3.1–15 µg/L
C-reactive protein 0.08–3.1 mg/L
Serum β2-microglobulin 1.2–2.8 mg/L
Total protein 60–80 g/L
IgG (adults) 6–16.0 g/L
IgA (adults) 0.8–4.0 g/L
IgM (adults ) 0.5–3.3 g/L
IgD (adults ) <0.14 g/L
Serum viscosity 1.4–1.8 relative units
IgE 20–150 U/mL
Fibrinogen 2–4 g/L
Activated PTT 22.1–35.1 s
Prothrombin time 11.1–13.1 s
Thrombin time ± 3 s of control
D-dimer <0.5 mg/L
All laboratory values depend on the methods used and may vary in different age and ethnic
groups. The values in the table can only he considered as an approximate range.
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APPENDIX 4
Program Requirements for Residency
Education in Hematology
Reinhold Munker, MD
RECOMMENDATIONS OF THE ACCREDITATION COUNCIL
FOR GRADUATE MEDICAL EDUCATION (ACGME)
The ACGME has published the requirements for graduate specialty training
in the United States in hematology/oncology (duration 3 yr) and hematology
(duration 2 yr). Details are available at www.acgme.org.
In these guidelines (version of July 2005) specific program contents, and
requirements for faculty, facilities, resources, and procedures are described.
The Hematology and Oncology and the Hematology Curriculum list a variety
of topics (specific program content).
The subspecialty examination in Hematology is administered by the Ameri-
can Board of Internal Medicine (ABIM). Details are available at www.abim.org.
The minimum training required for the examination is 24 mo in an accredited
program, 12 of which have to be clinical training. The special procedures required
are:
Participation for a minimum one-half day per week in a continuity outpatient clinic;
bone marrow aspiration and biopsy, including preparation, staining, examination, and
interpretation of blood smears, bone marrow aspirates, and touch preparations of bone
marrow biopsies; measurement of complete blood count, including platelets and white
cell differential, using automated or manual techniques with appropriate quality control;
administration of chemotherapeutic agents and biological products through all therapeu-
tic routes; and management and care of indwelling venous access catheters.
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RECOMMENDATIONS FOR TRAINING BY ASH AND ASCO
The American Society of Hematology (ASH) has developed a “Hematology
Curriculum”. Details can be found at www.hematology.org/training. This cur-
riculum gives a detailed description of the knowledge and skills expected from
a trainee in hematology. The “Hematology Curriculum” is accompanied by a
reading list with 54 chapters.
The American Society of Oncology (ASCO) has developed a subspecialty
curriculum in Medical Oncology, which includes all hematologic malignancies.
An updated version of the ASCO Core Curriculum was published in JCO in
March 2005 and can be accessed at www.asco.org.
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APPENDIX 5
Databases in Hematology
Reinhold Munker, MD and  Vishwas Sakhalkar, MD
The expansion of knowledge in the area of blood diseases and in the basic
sciences related to hematology makes the use of databases mandatory. In this
section, we list and review English-language data bases (both electronic and print
media). This list is far from complete, but an effort was made to include the most
important and readily available databases. The databases, books, and journals are
shown in alphabetical order. Textbooks of Internal Medicine and Oncology also
include sections on hematologic disorders, but are excluded from this collection
of databases. Also excluded are databases devoted to pure basic research.
I. TEXTBOOKS OF HEMATOLOGY
AND RELATED DISCIPLINES
A. MAJOR TEXTBOOKS (>1000 PAGES)
BLOOD: Principles and Practice of Hematology, 2nd Edition, 2304 pp.
Ed.: Handin RI, Lux SE, Stossel TP.
Publ.: Lippincott Williams & Wilkins, 2003
Comment: Multi-author textbook on hematology
CLINICAL BONE MARROW AND BLOOD STEM CELL TRANSPLANTA-
TION, 3rd Edition, 1968 pp.
Ed.: Atkinson K, Champlin R, Ritz J, et al.
Publ.: Cambridge University Press, 2004
Comment: Standard textbook of clinical bone marrow and stem cell transplan-
tation
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HEMATOLOGY BASIC PRINCIPLES AND PRACTICE, 4th Edition, 282 pp.
Ed.: Hoffman R, Benz EJ, Shattil SJ, et al.
Publ.: Elsevier Churchill Livingstone, 2005
Comment: Standard textbook of modern hematology including basic and clini-
cal sciences, available as electronic version
HEMATOLOGY OF INFANCY AND CHILDHOOD, 6th Edition, 2060 pp.
Ed.: Nathan DG, Orkin SH, Look AT, et al.
Publ.: WB Saunders, 2003
Comment: Standard textbook of pediatric hematology
HEMOSTASIS AND THROMBOSIS: BASIC PRINCIPLES AND CLINICAL
PRACTICE, 4th Edition, 1600 pp.
Ed.: Colman RW, Hirsh J, Marder VJ, et al.
Publ.: Lippincott Williams & Wilkins, 2001
Comment: Standard textbook of thrombosis and hemostasis
POSTGRADUATE HAEMATOLOGY, 5th Edition, 1080 pp.
Ed.: Hoffbrand AV, Tuddenham T, Catovsky D.
Publ.: Blackwell, 2005
Comment: Compendium for fellowship education and practicing physicians,
recently updated
THOMAS’ HEMATOPOIETIC CELL TRANSPLANTATION, 3rd Edition,
1563 pp.
Ed. Blume KG, Forman SJ, Appelbaum FR.
Publ. Blackwell, 2004
Comment: Standard textbook of bone marrow and stem cell transplantation
WILLIAMS HEMATOLOGY, 6th Edition, 1941 pp.
Ed.: Beutler E, Lichtman MA, Coller BS, et al.
Publ. McGraw Hill Professional, 2001
Comment: Standard textbook of hematology
WINTROBE’S CLINICAL HEMATOLOGY, 11th Edition, 2719 pp.
Ed.: Greer JP, Foerster J, Lukens JN, et al.
Publ. Lippincott Williams & Wilkins, 2004
Comment: Standard textbook of hematology
B. SMALLER COMPENDIA
AMERICAN SOCIETY OF HEMATOLOGY SELF-ASSESSMENT PRO-
GRAM, 2nd Edition, 451 pp.
Ed.: Williams ME, Kahn MJ.
Publ.: Blackwell, 2005
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Comment: Intended for fellowship education in hematology, published with
a series of board-type questions (sold separately)
BETHESDA HANDBOOK OF CLINICAL HEMATOLOGY, 1st Edition, 494
pp.
Ed.: Rodgers GP, Young NS.
Publ.: Lippincott Williams & Wilkins, 2005
Comment: Short textbook, multiple authors from one institution
BONE MARROW PATHOLOGY, 2nd Edition, 704 pp.
Ed.: Foucar K.
Publ.: ASCP, 2001
Comment: Standard text of bone marrow pathology
ESSENTIAL HAEMATOLOGY, 4th Edition, 349 pp.
Ed.: Hoffbrand AV, Pettit J, Moss P.
Publ.: Blackwell, 2001
Comment: Essential facts in hematology
HEMATOLOGY FOR MEDICAL STUDENTS, 1st Edition, 270 pp.
Ed.: Schmaier AH, Petruzzelli LM.
Publ.: Lippincott Williams & Wilkins, 2003
Comment: Introduction for students
HEMATOLOGY FOR STUDENTS, 1st Edition, 341 pp.
Ed.: MacKinney AA.
Publ.: Martin Dunitz, 2002
Comment: Introduction for students
HEMATOLOGY IN CLINICAL PRACTICE, 3rd Edition, 429 pp.
Ed.: Hillman RS, Ault KA.
Publ.: McGraw-Hill, 2002
Comment: Short clinical text of hematology
OXFORD HANDBOOK OF CLINICAL HAEMATOLOGY, 2nd Edition, 736
pp.
Ed.: Provan D, Singer CRJ, Baglin T, et al.
Publ.: Oxford University Press, 2004
Comment: Pocket text of clinical hematology, many tables and protocols
TEXTBOOK OF MALIGNANT HEMATOLOGY, 2nd Edition, 876 pp.
Ed.: Degos L, Linch DC, Löwenberg B.
Publ.: Taylor & Francis, 2005
Comment: Covers many topics in leukemia and other hematologic malignancies
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TRANSFUSION THERAPY: CLINICAL PRINCIPLES
AND PRACTICE, 2nd Edition, 690 pp.
Ed. Mintz PD.
Publ. AABB, 2005
Comment: Standard text of blood transfusion
II) PERIODICALS SPECIALIZING IN HEMATOLOGY
OR PUBLISHING MAJOR HEMATOLOGIC ARTICLES
(IMPACT FACTOR GIVEN FOR 2004)
AMERICAN JOURNAL OF CLINICAL PATHOLOGY 2.716
AMERICAN JOURNAL OF HEMATOLOGY 1.701
ANNALS OF HEMATOLOGY 1.292
ANNALS OF INTERNAL MEDICINE 13.114
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 3.278
BLOOD 9.782
BLOOD CELLS, MOLECULES & DISEASES 2.549
BLOOD REVIEWS 2.838
BONE MARROW TRANSPLANTATION 2.101
BRITISH JOURNAL OF HAEMATOLOGY 3.195
CURRENT OPINION IN HEMATOLOGY 4.513
EUROPEAN JOURNAL OF HAEMATOLOGY 1.729
EXPERIMENTAL HEMATOLOGY 4.681
HAEMATOLOGICA 4.192
HUMAN PATHOLOGY 3.369
JOURNAL OF CLINICAL ONCOLOGY 9.835
JOURNAL OF PEDIATRIC HEMATOLOGY/ ONCOLOGY 1.161
LANCET 21.713
LEUKEMIA 5.810
LEUKEMIA RESEARCH 2.244
MODERN PATHOLOGY 3.643
NEW ENGLAND JOURNAL OF MEDICINE 38.570
THROMBOSIS AND HAEMOSTASIS 3.413
TRANSFUSION 3.708
III. ELECTRONIC DATABASES AND SOURCES
OF INFORMATION
BLOODLINE
Website: www.bloodline.net
Has multiple resources, book reviews, teaching cases, news, and links to
educational resources (organized by a publisher)
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BLOODMED
Website: www.bloodmed.com
Organized into several sections with section editors (mainly British hematolo-
gists), provides news (both scientific and clinical aspects of hematology), experts
answer questions, original reviews (organized by a publisher, registration required)
CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
Website: www.nccn.org
Panel of experts gives recommendations for diagnosis and treatment. This
includes most hematologic malignancies
MDCONSULT
Website: www.mdconsult.com
Offers news, online books, databases, including some hematologic resources
MEDLINE
Website: www.ncbi.nlm.nih.gov/entrez
Database of the National Library of Medicine, complete listing of medical and
biomedical journal articles
MEDSCAPE HEMATOLOGY-ONCOLOGY
Website: www.medscape.com/hematology-oncologyhome
News in clinical hematology and oncology with some basic science content,
some full-text articles, educational resources, conference coverage, and case
discussions
ONCOLOGY & HEMATOLOGY 2003 (Available in print and online, edited
by Abeloff MD, gives review and ratings of 1600 web sites, focus on oncology,
but gives information about most hematology sites). Internet access via:
www.eMedguides.com
UPTODATE
Website: www.uptodate.com
Database for internists and subspecialists, comprehensive reviews, written
and updated by experts, has multiple references and cross-references
IV. SPECIALIZED WEBSITES AND ORGANIZATIONS
APLASTIC ANEMIA & MDS INTERNATIONAL FOUNDATION
Website: www.aamds.org or www.aplastic.org
Patient-oriented resources and information about bone marrow failure syn-
dromes, offers research grants
COOLEY’S ANEMIA FOUNDATION
Website: www.cooleysanemia.org
Patient-oriented resources and information about thalassemias
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FANCONI ANEMIA RESEARCH FUND
Website: www.fanconi.org
Patient-oriented information about Fanconi anemia, offers research support
INTERNATIONAL BONE MARROW TRANSPLANT REGISTRY
Website: www.ibmtr.org
International database on autologous and allogeneic bone marrow and stem
cell transplantation, performs outcomes research
INTERNATIONAL MYELOMA FOUNDATION
Website: www.myeloma.org
Patient-oriented resources and information about multiple myeloma and re-
lated conditions, promotes research and offers research support
LEUKEMIA & LYMPHOMA SOCIETY
Website: www.leukemia.org or www.lls.org
Patient oriented resources, support and information about different types of
leukemias and lymphomas, has several types of research grants
NATIONAL HEMOPHILIA FOUNDATION
Website: www.hemophilia.org
Information about bleeding disorders for patients and health professionals,
gives recommendations for treatment, has research grants
NATIONAL MARROW DONOR PROGRAM
Website: www.marrow.org
Information about the activities of the National Marrow Donor Program
(NMDP) facilitating matched unrelated transplantation. This information is di-
rected to potential donors, patients, and physicians. The NMDP maintains the
world’s largest volunteer donor database and performs accreditation of trans-
plant centers and outcomes research
NATIONAL ORGANIZATION FOR RARE DISORDERS
Website: www.rarediseases.org
Systematic catalog of diseases, organizations, information, and support for
many rare disorders including many hematologic disorders. Fee-based direct
access to relevant publications and journals.
SICKLE CELL DISEASE ASSOCIATION OF AMERICA
Website: www.sicklecelldisease.org
Patient-oriented resources and information about sickle cell disease
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V. PROFESSIONAL ASSOCIATIONS OF HEMATOLOGISTS
AND RELATED SPECIALISTS OR SCIENTISTS
AMERICAN ASSOCIATION FOR CANCER RESEARCH
Website: www.aacr.org
Largest scientific association for basic and translational cancer research.
Publishes research journals and organizes meetings and workshops. Has both
physicians and scientists as members.
AMERICAN CANCER SOCIETY
Website: www.cancer.org
Association of cancer professionals, has local chapters, publishes journals for
clinical research in the different types of cancer
AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION
Website: www.asbmt.org
Association of North American transplant physicians and scientists. Promotes
research and issues guidelines for blood and marrow transplantation. Website
has links to other transplant-related organizations.
AMERICAN SOCIETY OF CLINICAL ONCOLOGY
Website: www.asco.org
Association of American oncologists with many international members. Issues
practice guidelines and patient information including hematologic malignan-
cies. Promotes education and clinical and translational research
AMERICAN SOCIETY OF HEMATOLOGY
Website: www.hematology.org
The American Society of Hematology (ASH) is the world’s largest profes-
sional society concerned with causes and treatments of blood disorders. ASH has
both physicians and pure scientists as members and merges the clinical and
scientific aspects of hematology. Membership is very broad and includes hema-
tologists in the United States and virtually every country of the world. The
website has a host of information both for members, non-members and patients.
There are educational materials, grant opportunities, news releases and informa-
tion about past and future annual meetings.
AMERICAN SOCIETY OF PEDIATRIC HEMATOLOGY/ ONCOLOGY
Website: www.aspho.org
Association of pediatric hematologists and oncologists
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BRITISH SOCIETY FOR HAEMATOLOGY
Website: www.b-s-h.org.uk
Association of British hematologists
EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION
Website: www.ebmt.org
European association for research and clinical practice in bone marrow and
stem cell transplantation. Issues guidelines for transplantation. Has members in
many countries and promotes clinical research in 11 working parties
EUROPEAN HEMATOLOGY ASSOCIATION
Website : www.ehaweb.org
European organization for research and education in hematology
INTERNATIONAL SOCIETY FOR EXPERIMENTAL HEMATOLOGY
Website : www.iseh.org
International organization of basic, clinical, and translational scientists in the
area of hematology
INTERNATIONAL SOCIETY FOR HAEMATOLOGY
Website: www.ish-world.org
World organization of hematologists (organized in several divisions)
SOUTH AFRICAN SOCIETY OF HAEMATOLOGY
Website : www.sash.org.za
Organization of South African hematologists
VI. PATIENT-ORIENTED DATABASES AND SOURCES
OF INFORMATION
• List of clinical trials compiled by the U.S. National Institutes of Health and the
National Library of Medicine
Internet Address: http:// clinicaltrials.gov
• MedlinePLUS
Website: www.medlineplus.gov
Information about over 700 health-related topics (database maintained by the
U.S. National Library of Medicine and the National Institutes of Health)
• UPTODATE® Patient Information
Website: http://patients.uptodate.com
Useful information for patients, written by experts, includes some hematologic
topics
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AT, see Ataxia telangiectasia
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5-Azacytidine (Vidaza®),
mechanism, indications and side
effects, 442
myelodysplastic syndrome
management, 203
B
B-7, gene therapy, 29
Babesiosis, acquired hemolytic
anemia, 124
BAL, see Bronchoalveolar lavage
Bartonellosis, acquired hemolytic
anemia, 124
Basophil, functions, 10
Basophilia, differential diagnosis, 134
B-cell,
antibody production, 13, 14
congenital defects
common variable
immunodeficiency, 304,
305
immunoglobulin A deficiency,
305
maturation defects, 303, 304
X-linked agammaglobulinemia,
304
differentiation, 13
BCNU, see Carmustine
BCR-ABL fusion, see Chronic
myelogenous leukemia
Bernard-Soulier syndrome (BSS),
features, 330, 360
Bisphosphonates, multiple myeloma
management, 291, 292
Bleeding time, assay, 340
Bleomycin,
Hodgkin’s lymphoma
management, 231, 232
mechanism, indications and side
effects, 442, 443
Blood coagulation, see Hemostasis
Blood transfusion,
adverse reactions,
acute hemolytic transfusion
reaction, 415, 416
anaphylactic reaction, 418, 419
delayed hemolytic transfusion
reaction, 417, 418
febrile nonhemolytic
transfusion reaction, 418
graft-vs-host disease, 429, 430
iron overload, 429
transfusion-related acute lung
injury, 430
autologous blood, 430, 431
blood group systems,
ABO, 402, 403
Duffy, 406
Hh, 402, 403
Kell, 405
matching, 406
Rhesus, 402, 403
Sese, 402, 403
disease transmission,
bacterial infection, 420, 421
cytomegalovirus, 71, 425
hepatitis, 521–423
human herpesviruses, 425, 426
human immunodeficiency
virus, 369, 423, 424
overview, 419, 420
parasites, 428, 429
prion disease, 426–428
retroviruses, 423–425
human leukocyte antigen typing,
409–411
indications, 401
leukocyte antigens, 406–409
massive transfusion and bleeding
disorder, 378, 379
posttransfusion purpura, 355, 356
products and indications,
cryoprecipitated antihemophilic
factor, 414
fresh-frozen plasma, 414
granulocytes, 413
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multiple myeloma management,
287, 288
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neutropenia patients, 44
BSS, see Bernard-Soulier syndrome
BTK, X-linked agammaglobulinemia
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Burkitt’s lymphoma, features, 259, 260
Busulfan, mechanism, indications
and side effects, 443
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Campath®, see Alemtuzumab
Candidiasis, management in
neutropenia patients, 49–51, 53
Carbenicillin, platelet dysfunction,
364
Carboplatin,
diffuse large B-cell lymphoma
management, 246
Hodgkin’s lymphoma
management, 235
Cardiopulmonary bypass,
thrombocytopenia, 358, 359
Carmustine (BCNU),
mechanism, indications and side
effects, 443
multiple myeloma management,
286
Cavernous hemangioma, features,
358
CCNU, see Lomustine
CD antigens,
CD33 antibody for acute
myelogenous leukemia
immunotherapy, 170, 171
nomenclature, 406, 407, 455–461
Cellular immunity, congenital
defects, 296, 300, 305–308
Central venous catheter,
infection, 56
thrombus, 57
Cephalosporin, platelet dysfunction,
364
Cerebral lymphoma, features, 268,
269
Ceredase®, see Alglucerase
Cerezyme®, see Imiglucerase
Chagas’ disease, transfusion-
transmissible disease, 428, 429
Chemotherapy, see specific agents
Chlorambucil,
chronic lymphocytic leukemia
management, 256
follicular lymphoma management,
250
mechanism, indications and side
effects, 443
Chronic lymphocytic leukemia
(CLL),
clinical features, 253, 254
epidemiology, 253
histopathology, 253
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microRNA profiling, 24
prognosis, 255
treatment,
480 Index
chemotherapy, 256
immunotherapy, 256
prospects, 256, 257
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clinical manifestations, 139
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treatment,
algorithm, 145
imatinib, 140–144
stem cell transplantation, 143,
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Cidofovir, cytomegalovirus
management, 319
Cisplatin,
diffuse large B-cell lymphoma
management, 246
Hodgkin’s lymphoma
management, 235
CJD, see Creutzfeld-Jakob disease
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hairy cell leukemia management,
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mechanism, indications and side
effects, 444
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and side effects, 444
Clonality, see Tumor clonality
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CMV, see Cytomegalovirus
Combined immunodeficiency,
congenital defects, 296, 298, 302,
303, 307, 308
Common variable immunodeficiency
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Complement system, congenital
defects, 296, 301, 309
Computed tomography (CT),
neutropenia patients, 44, 50
non-Hodgkin’s lymphoma, 242
spleen, 217
Coumadin®, see Warfarin
Creutzfeld-Jakob disease (CJD),
transfusion-transmissible
disease, 427, 428
Cryoprecipitated antihemophilic
factor, transfusion, 414
CT, see Computed tomography
CVID, see Common variable
immunodeficiency
Cyclic neutropenia, features, 133
Cyclin D, overexpression in tumors,
276
Cyclophosphamide,
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management, 245
follicular lymphoma management,
251
mechanism, indications and side
effects, 444
Cyclophosphamide,
Hodgkin’s lymphoma
management, 232
multiple myeloma management, 28
Cyclosporine, aplastic anemia
management, 214
Cytokines, see specific cytokines
Cytomegalovirus (CMV),
antiviral therapy, 319
diagnostics, 319
epidemiology, 318
infection cycle, 318
management of infection in
neutropenia patients, 56
pneumonia, 80, 18
stem cell transplant recipients, 73,
74, 80
transfusion-transmissible disease,
71, 425
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Cytosine arabinoside (Ara-C),
diffuse large B-cell lymphoma
management, 246
Hodgkin’s lymphoma
management, 235
mechanism, indications and side
effects, 444, 445
D
Dacarbazine,
Hodgkin’s lymphoma
management, 231, 232
mechanism, indications and side
effects, 445
Darbepoietin-α, clinical use, 34
Databases, hematology, 470, 471,
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Daunorubicin, mechanism,
indications and side effects, 445
DC, see Dendritic cell
DCF, see 2-Deoxycoformycin
DDAVP, see Desmopressin
Decitabine, mechanism, indications
and side effects, 445
Deep vein thrombosis (DVT),
clinical manifestations and
diagnosis, 387
prophylaxis, 387, 388
treatment, 388, 389
Deferasirox, iron overload
management, 438
Deferiprone, iron overload
management, 438
Deferoxamine (DFO), iron overload
management, 438
Delayed hemolytic transfusion
reaction (DHTR), features and
management, 417, 418
Dendritic cell (DC), functions, 11, 12
Denileukin diftitox, mechanism,
indications and side effects, 445,
446
2-Deoxycoformycin (DCF), hairy cell
leukemia management, 263
Desidurin, indications and
mechanism, 396
Desmopressin (DDAVP),
Bernard-Soulier syndrome
management, 360
hemophilia management, 368
platelet granule deficiency
management, 362
uremia management, 363
Dexamethasone,
diffuse large B-cell lymphoma
management, 246
Hodgkin’s lymphoma
management, 235
multiple myeloma management,
286
DFHTR, see Delayed hemolytic
transfusion reaction
DFO, see Deferoxamine
DIC, see Disseminated intravascular
coagulation
Diffuse large B-cell lymphoma,
gene expression profiling, 244, 245
histopathology, 243
prognostic factors, 244
treatment, 245–248
DiGeorge syndrome, features, 306, 307
Disseminated intravascular
coagulation (DIC),
clinical features, 376
etiology, 374, 375
laboratory findings, 376
treatment, 376, 377
DNA repair, congenital defects, 308,
309
Down syndrome, leukemoid reaction
in infancy, 130
Doxorubicin (Adriamycin®),
Hodgkin’s lymphoma
management, 231, 232
mechanism, indications and side
effects, 446
multiple myeloma management,
286
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Drotecogin alfa, disseminated
intravascular coagulation
management, 377
Drug-induced neutropenia, see
Agranulocytosis
Duffy blood group system, 406
DVT, see Deep vein thrombosis
E
EBV, see Epstein-Barr virus
Emesis, antiemetic therapy, 57, 58
Eosinophil, functions, 10
Eosinophilia,
definition, 133
differential diagnosis, 133, 134
Epirubicin, mechanism, indications
and side effects, 446
EPO, see Erythropoietin
Epstein-Barr virus (EBV),
diagnostics, 316, 317
Hodgkin’s lymphoma role, 226
infectious mononucleosis, 316, 317
malignomas, 316
non-Hodgkin’s lymphoma role,
238, 267
prophylaxis, 318
transfusion-transmissible disease,
425, 426
transmission, 318
Erythropoiesis, see also Red blood cell
hemoglobin, 6, 7
iron metabolism, 7, 8
stages, 5, 6
Erythropoietin (EPO),
aplastic anemia management, 214
clinical use, 33
functions, 33
myelodysplastic syndrome
management, 202, 203
Essential thrombocythemia (ET),
clinical manifestations, 150, 359
diagnosis, 150, 151
epidemiology, 149
pathophysiology, 149, 150
prognosis, 151
Estrogen therapy, postoperative
venous thrombosis association,
386
ET, see Essential thrombocythemia
Etoposide (VP-16),
diffuse large B-cell lymphoma
management, 246
Hodgkin’s lymphoma
management, 232, 235
mechanism, indications and side
effects, 446
F
Factor V Leiden,
features, 382, 383
testing, 385
Factor VIIa, see NovoSeven™
Factor VIII,
antibodies, 377
deficiency, see Hemophilia
Factor VIIIc, elevation, 384, 385
Factor IX deficiency, see Hemophilia
Factor XI, deficiency, 372
Factor XII, deficiency, 372
Factor XIII,
assay, 343
deficiency, 372
Fanconi anemia, see Aplastic anemia
Fas ligand, functions, 38
Febrile nonhemolytic transfusion
reaction (FNHTR), features and
management, 418
Fever, neutropenia patients, 42, 47
FFP, see Fresh-frozen plasma
Fibrin,
D-dimer, 345
fibrinogen defects, 371, 372
fibrinolysis, 336, 338, 344, 345
formation, 334
Fibrinolytic therapy, agents and
dosing, 397–399
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FISH, see Fluorescence in situ
hybridization
Flow cytometry,
bone marrow aspirates, 16
immunoglobulin light-chain
restriction, 23
FLT3, therapeutic targeting, 171
Fludarabine,
chronic lymphocytic leukemia
management, 256
mechanism, indications and side
effects, 447
Fluorescence in situ hybridization
(FISH),
multiple myeloma, 274
Philadelphia chromosome
detection, 138, 142
FNHTR, see Febrile nonhemolytic
transfusion reaction
Foamy virus, gene therapy vectors, 27
Folate deficiency, see Megaloblastic
anemia
Follicular lymphoma,
clinical symptoms, 248, 249
cytogenetics, 248
epidemiology, 248
histopathology, 248
prognosis, 249, 250
treatment,
chemotherapy, 250, 251
observation, 250
prospects, 252
radiation therapy, 250
rituximab, 251
stem cell transplantation, 251,
252
Fondaparinux (Arixtra®), indications
and mechanism, 396, 397
Foscarnet, cytomegalovirus
management, 319
Fresh-frozen plasma (FFP),
transfusion, 414
FTL3 ligand, functions, 37
G
Gancyclovir, cytomegalovirus
management, 319
Gasser’s syndrome, see Hemolytic
uremic syndrome
Gastric lymphoma,
clinical features and staging, 265
Helicobacter pylori role, 238, 264,
265
treatment, 265, 266
Gaucher disease,
clinical manifestations, 434
definition, 433
diagnosis, 434
etiology and pathogenesis, 433
treatment, 434, 435
Gaucher’s disease, gene therapy, 28
G-CSF, see Granulocyte colony-
stimulating factor
Gemtuzumab ozogamicin,
mechanism, indications and
side effects, 447
Gene therapy,
applications, 25, 26
clinical protocols,
antitumor immunity, 28, 29
gene marking, 28
gene replacement, 27, 28
vectors,
adenovirus, 26, 27
foamy virus, 27
liposomes, 27
retrovirus, 26
Glanzmann disease, see
Thrombasthenia
Globulins, types, 15
Glucose phosphate isomerase
deficiency, features and
management, 107
Glucose-6-phosphate
dehydrogenase,
deficiency features and
management, 105, 106
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X-inactivation assays, 23
Glycoprotein IIb/IIIa receptor
antagonists, indications and
mechanism, 391
GM-CSF, see Granulocyte–
macrophage colony-stimulating
factor
Graft-vs-host disease (GVHD),
blood transfusion, 429, 430
stem cell transplantation
clinical presentation, 75, 76
conditioning therapy
prevention, 70
prophylaxis, 76, 77
risks, 65, 66, 70, 213
staging, 75, 76
treatment, 77, 78
α-Granule deficiency, features, 361
δ-Granule deficiency, features, 362
Granulocyte colony-stimulating
factor (G-CSF),
aplastic anemia management, 214
clinical use, 31, 32, 56
functions, 29, 30
myelodysplastic syndrome
management, 203
pegfilgastim, 32
Granulocyte, transfusion, 413
Granulocyte/macrophage colony-
stimulating factor (GM-CSF),
aplastic anemia management, 214
clinical use, 30–32, 56
functions, 29, 30
myelodysplastic syndrome
management, 203
Granulocytopenia, features, 130, 131
GVHD, see Graft-vs-host disease
H
Hairy cell leukemia (HCL),
clinical presentation, 262, 263
epidemiology, 261
histopathology, 261, 262
treatment, 263, 264
HbC disease, features and
management, 117
HbE syndromes, features and
management, 117
HCDD, see Heavy chain deposition
disease
HCL, see Hairy cell leukemia
HDN, see Hemolytic disease of the
newborn
Heavy chain deposition disease
(HCDD),
features, 274
multiple myeloma association,
290
Helicobacter pylori,
eradication, 265, 266
gastric lymphoma association, 238,
264, 265
Hematocrit, normal values, 84
Hematopoiesis,
RNA interference, 25
sites, 2
stromal cell regulation, 2
Hematopoietic stem cell (HSC),
differentiation, 2, 4
functions, 63, 64
gene expression, 4
markers, 4, 64
telomere dynamics, 4, 5
transplantation, see Stem cell
transplantation
Hemoglobin,
normal values, 84
oxygen dissociation curve, 6, 7
sickle cell anemia, see Sickle cell
disease
types, 6
Hemolytic anemia,
disseminated intravascular
coagulation, see
Disseminated intravascular
coagulation
glucose phosphate isomerase
deficiency, 107
Index 485
glucose-6-phosphate
dehydrogenase deficiency,
105, 106
HbC disease, 117
HbE syndromes, 117
hemolytic disease of the newborn,
see Hemolytic disease of the
newborn
hereditary elliptocytosis, 103
hereditary pyropoikilocytosis, 103
hereditary spherocytosis, 102–104
methemoglobinemia, 117
microangiopathic anemias, 124,
126
overview, 101
parasite induction, 123, 124
paroxysmal nocturnal
hemoglobinuria, 120, 121
pyruvate kinase deficiency, 106,
107
sickle cell anemia, see Sickle cell
disease
thalassemia, see α-Thalassemia; β-
Thalassemia; Thalassemia
intermedia
Hemolytic disease of the newborn
(HDN),
ABO incompatibility, 121, 122
Rh incompatibility, 122, 123
Hemolytic uremic syndrome (HUS),
features, 356, 358
management, 358
Hemophilia,
clinical presentation, 365
diagnosis, 367
gene mutations,
factor VIII, 364
factor IX, 364, 365
human immunodeficiency virus
transmission, 369
treatment and resistance, 367–369
Hemostasis,
blood coagulation,
cascade, 331, 332
extrinsic pathway, 332
intrinsic pathway, 333
disorders, see specific diseases
endothelium and vascular system,
329
fibrin,
fibrinolysis, 336, 338
formation, 334
inhibitors, 334–336
hemorrhagic disorder evaluation,
bleeding history, 338
laboratory evaluation, 339–345
physical examination, 339
overview, 327, 328
platelet function and defects, 328–
331
Henoch-Schönlein purpura, features,
349, 350
HEPA filtration, see High-efficiency
particulate air filtration
Heparin,
arterial thrombosis management,
391
complications of therapy, 393
low-molecular-weight heparin,
deep vein thrombosis
prophylaxis and
treatment, 388
preparations, 392, 393
unfractionated heparin, 392
Heparin, disseminated intravascular
coagulation management, 377
Hepatitis,
transfusion-transmissible disease,
421–423
virus types, 422, 423
Hereditary elliptocytosis, features
and management, 103
Hereditary hemochromatosis,
clinical manifestations, 436
definition, 435
diagnosis, 436
etiology and pathogenesis, 435,
436
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Hereditary hemorrhagic
telangiectasia, see Osler-Weber-
Rendu disease
Hereditary pyropoikilocytosis,
features and management, 103
Hereditary spherocytosis, features
and management, 102–104
Herpes simplex virus (HSV),
pneumonia, 80
stem cell transplant recipients, 74,
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Hh blood group system, 402, 403
HHV-6, see Human herpesvirus-6
HHV-8, see Human herpesvirus-8
High-efficiency particulate air
(HEPA) filtration, infection
prevention, 54
Hirudin, indications and mechanism,
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HIV, see Human immunodeficiency
virus
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HLA, see Human leukocyte antigen
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classification, 230
clinical features, 227
diagnosis, 227
epidemiology, 226
histopathology, 229, 230
pathogenesis and etiology, 226,
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prognosis, 225, 230, 231, 234, 235
staging, 227–229
treatment,
advanced stage disease, 232,
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favorable disease, 231
unfavorable disease, 232
late effects, 235, 236
lymphocyte-predominant
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relapse, 235
secondary malignancies, 26
HSC, see Hematopoietic stem cell
HSV, see Herpes simplex virus
HTLV, see Human T-lymphotropic
virus
Human herpesvirus-6 (HHV-6),
infection features, 23
Human herpesvirus-8 (HHV-8),
diagnostics, 324, 325
epidemiology, 324, 325
Kaposi’s sarcoma, 323, 325
non-Hodgkin’s lymphoma
association, 238
treatment, 325
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Human immunodeficiency virus
(HIV),
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hemophiliacs, 369
immune function testing, 295, 296
infection cycle, 310, 311
Kaposi’s sarcoma, 323
lymphadenopathy, 218
non-Hodgkin’s lymphoma, 238,
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screening, 311, 312
thrombocytopenia association,
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transfusion-transmissible disease,
369, 423, 424
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class I antigens, 408
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loci, 408
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typing, 409–411
Human T-lymphotropic virus
(HTLV),
leukemia induction, 176
minimal residual disease, 177
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association, 238
transfusion-transmissible disease,
424
Humoral immunity, congenital
defects, 296, 299, 303–305
Hurler syndrome, gene therapy, 28
HUS, see Hemolytic uremic
syndrome
Hydroxydaunomycin, diffuse large
B-cell lymphoma management,
245
Hydroxyurea,
essential thrombocythemia
management, 150, 151
mechanism, indications and side
effects, 447
polycythemia vera management,
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sickle cell disease management,
114
Hypercoagulability,
acquired hypercoagulable states,
385, 386
inherited hypercoagulable states,
382–384
management, 386
overview, 381, 382
Hyperhomocysteinemia, features,
384
Hypersplenism, thrombocytopenia,
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Ibritumomab tiuxetan, mechanism,
indications and side effects, 448
Idarubicin, mechanism, indications
and side effects, 447
Idiopathic hypereosinophilic
syndrome (IHES), features and
management, 134
Idiopathic myelofibrosis (IM),
clinical manifestations, 152
diagnosis, 152
differential diagnosis, 152
pathophysiology, 151
treatment, 152, 153
Idiopathic purpura, see Purpura
simplex
Idiopathic thrombocytopenic
purpura (ITP),
features, 352, 353
treatment, 354
IFN-α, see Interferon-α
IFN-β, see Interferon-β
IFN-γ, see Interferon-γ
Ifosfamide,
diffuse large B-cell lymphoma
management, 246
Hodgkin’s lymphoma
management, 235
mechanism, indications and side
effects, 448
IHES, see Idiopathic
hypereosinophilic syndrome
IM, see Idiopathic myelofibrosis
Imatinib,
acute lymphoblastic leukemia
management, 191, 192
chronic myelogenous leukemia
management, 140–144
idiopathic hypereosinophilic
syndrome management, 134
mechanism of action, 140
mechanism, indications and side
effects, 448
resistance, 142
response endpoints, 141, 142
toxicity, 143
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Imiglucerase (Cerezyme®), Gaucher
disease management, 434
Immune function, testing, 295, 296
Immunocytochemistry,
bone marrow aspirates, 16
immunoglobulin light-chain
restriction, 23
Immunocytoma, features, 258, 259
Immunoglobulins,
gene rearrangements, 22
immunoglobulin A deficiency, 305
light-chain restriction, 23
transfusion, 414, 415
types, 15
Infection, see also specific pathogens,
multiple myeloma, 292
neutropenia patients
diagnosis, 42–44
pathogens, 44–46
prophylaxis, 54–56
treatment,
bacterial infection, 48, 49
empirical treatment, 46–48
fungal infection, 49–51, 53, 54
purpura association, 349
stem cell transplant recipients, 72–
74, 78–80
Infectious mononucleosis, features,
316, 317
INR, see International normalized
ratio
Interferon-α (IFN-α),
clinical use, 39, 251, 263
functions, 39
Interferon-β (IFN-β),
clinical use, 39
functions, 39
Interferon-γ (IFN-γ),
clinical use, 39, 40
functions, 39
Interleukins, types and functions,
34–37
International normalized ratio
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Intravenous immunoglobulin
(IVIG),
indications, 415
thrombocytopenia management,
354
Iron deficiency anemia,
clinical features, 88
diagnosis, 88, 89
pathophysiology, 87, 88
stages of iron deficiency, 87
treatment, 89, 90
Iron overload, see also Hereditary
hemochromatosis,
blood transfusion, 429
secondary hemochromatosis, 437,
438
sickle cell disease, 112, 113
Iron, metabolism, 7, 8
ITP, see Idiopathic thrombocytopenic
purpura
IVIG, see Intravenous
immunoglobulin
J
JAK, polycythemia vera defects, 146
JC virus, see Progressive multifocal
leukoencephalopathy
JMML, see Juvenile myelomonocytic
leukemia
Juvenile myelomonocytic leukemia
(JMML), features, 153
K
Kaposi’s sarcoma, see Human
herpesvirus-8
Kasabach-Meritt syndrome, see
Cavernous hemangioma
Kell blood group system, 405
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84, 463, 464
LAP test, see Leukocyte alkaline
phosphatase test
Index 489
LCDD, see Light chain deposition
disease
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indications and side effects, 448,
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Lepirudin, indications and
mechanism, 396
Leukocyte alkaline phosphatase
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myelogenous leukemia
findings, 139
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definition, 127
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Leukopenia,
definition, 127
differential diagnosis, 130, 131
Light chain deposition disease
(LCDD), multiple myeloma
association, 290
Liposomes, gene therapy vectors, 27
Liver disease,
bleeding disorders, 374
platelet dysfunction, 363
LOH, see Loss of heterozygosity
Lomustine (CCNU), mechanism,
indications and side effects, 449
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tumors, 23
Low-molecular-weight heparin, see
Heparin
Lupus anticoagulant, bleeding
disorder, 378, 386
Lyme disease,
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association, 238, 239
transfusion-transmissible disease,
421
Lymphadenopathy,
definition, 217
differential diagnosis, 219, 220
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259, 260
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differential diagnosis, 218, 219
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definition, 217
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Lymphopoiesis,
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natural killer cells, 14, 15
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T-cells, 14
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Macrophage colony-stimulating
factor (M-CSF), functions, 29, 30
Magnetic resonance imaging (MRI),
hepatic iron content, 437
multiple myeloma, 281
spleen, 217
Malaria,
acquired hemolytic anemia, 123,
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transfusion-transmissible disease,
428
treatment and prophylaxis, 125
MALT lymphoma, see Mucosa-
associated lymphoid tissue
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Mantle cell lymphoma,
clinical symptoms, 252
definition, 252
epidemiology, 252
prognosis, 252
treatment, 252, 253
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M-CSF, see Macrophage colony-
stimulating factor
MDS, see Myelodysplastic syndrome
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effects, 449
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megaloblast features, 94
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effects, 449
multiple myeloma management,
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Methotrexate, mechanism,
indications and side effects, 450
Methylenetetrahydrofolate reductase
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Metoclopramide, antiemetic therapy,
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MGUS, see Monoclonal gammopathy
of undetermined significance
MicroRNA,
profiling in leukemia, 24
transcription, 24
Miglustat (Zavesca®), Gaucher
disease management, 435
Minimal residual disease, acute
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mechanism, indications and side
effects, 450
MM, see Multiple myeloma
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diagnosis, 273
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gene mutations, 275–277
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MRI, see Magnetic resonance imaging
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Mucosa-associated lymphoid tissue
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clinical features and staging, 265
origins, 264
pathogenesis, 264, 265
treatment, 265, 266
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complications,
anemia, 292
bone disease and pain, 290–292
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diagnosis and staging, 277–279,
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gene expression, 275
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platelet dysfunction, 363
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clinical manifestations, 198
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laboratory findings, 198–200
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overview, 9, 10
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Natural killer (NK) cell, functions, 14,
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NBS, see Nijmegen breakage
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Nelarabine, mechanism, indications
and side effects, 450
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Neutropenia,
cyclic neutropenia, 133
definition, 127
drug-induced neutropenia, see
Agranulocytosis
infection,
diagnosis, 42–44
pathogens, 44–46
prophylaxis, 54–56
treatment,
bacterial infection, 48, 49
empirical treatment, 46–48
fungal infection, 49–51, 53, 54
myeloablative therapy induction,
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NHL, see Non-Hodgkin’s lymphoma
Nijmegen breakage syndrome (NBS),
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Nitric oxide (NO), function, 328
NK cell, see Natural killer cell
NO, see Nitric oxide
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chemotherapy protocols, 246, 247
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diagnosis, 241, 242
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PAI-1, see Plasminogen activator
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Paroxysmal nocturnal
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clinical features, 319
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transfusion-transmissible disease,
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treatment, 320
PCR, see Polymerase chain reaction
PCV, see Polycythemia vera
PE, see Pulmonary embolism
Pegfilgastim, clinical use, 32
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PET, see Positron emission
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Plasminogen activator inhibitor-1
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multiple myeloma, 281
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clinical features, 321
epidemiology, 320, 321
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deficiency, 384, 395
function, 335, 336
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interpretation, 341, 342
Prothrombin, mutation, 383
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66
follicular lymphoma management,
251, 252
graft failure, 74, 75
graft-vs-host disease,
clinical presentation, 75, 76
conditioning therapy
prevention, 70
prophylaxis, 76, 77
risks, 65, 66, 70
staging, 75, 76
treatment, 77, 78
hepatic veno-occlusive disease, 80,
81
indications, 64
infection treatment in
posttransplant period, 72–74
multiple myeloma management,
284, 285
myelodysplastic syndrome
management, 204, 205
pneumonia, 78–80
principles, 64, 65
sickle cell disease management,
114
thrombotic microangiopathy, 81,
82
umbilical cord blood cells, 67, 68
Stool culture,
neutropenia patients, 43
stem cell transplant recipients, 82
Streptokinase, fibrinolytic therapy,
398
Stromal cell, hematopoiesis, 2
Sulfadiazine, toxoplasmosis
management, 321
Sulfamethoxazole (SMX),
Pneumocystis carnii pneumonia
management, 55, 322
Support organizations, hematology,
471, 472
Syphilis, transfusion-transmissible
disease, 421
T
T-cell,
congenital defects,
activation defects, 305, 306
APECED, 308
autoimmune
lymphoproliferative
syndrome, 307, 308
cytokine and signaling defects,
306
DiGeorge syndrome, 306, 307
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X-linked lymphoproliferative
disease, 308
differentiation, 14
receptor gene rearrangements, 22
types, 14
Telomere, stem cell dynamics, 4, 5
Teniposide, mechanism, indications
and side effects, 451
Textbooks, hematology, 467–470
TF, see Tissue factor
TFPI, see Tissue factor pathway
inhibitor
TGF-β, see Transforming growth
factor-β
α-Thalassemia,
autoimmune hemolytic anemia,
see Autoimmune hemolytic
anemia
features, 116
β-Thalassemia,
diagnosis, 116
treatment, 116
types, 115
Thalassemia intermedia, features,
116, 117
Thalassemia minor, features, 92
Thalidomide,
mechanism, indications and side
effects, 451
multiple myeloma management,
287
myelodysplastic syndrome
management, 203, 204
THI, see Transient
hypogammaglobulinemia of
infancy
Thioguanine, mechanism, indications
and side effects, 452
Thiotepa, mechanism, indications
and side effects, 452
Thrombasthenia, features, 360, 361
Thrombin, inhibitors, 396
Thrombin time (TT), assay, 341
Thrombocythemia, see Essential
thrombocythemia
Thrombocytopenia,
classification, 350, 351
decreased platelet production, 351,
352
definition, 350
drug induction, 355
immune thrombocytopenia, 352–
356
increased platelet production, 352
investigation, 350
nonimmune thrombocytopenia,
356–359
treatment, 353, 354
Thrombocytosis, features, 359
Thrombolytic therapy,
arterial thrombosis, 391
pulmonary embolism, 389
Thrombophilia, see
Hypercoagulability
Thrombopoietin (TPO),
clinical use, 33
functions, 32
Thrombotic microangiopathy (TM),
stem cell transplant recipients,
81, 82
Thrombotic thrombocytopenic
purpura (TTP)
features, 356, 358
management, 358
Ticlopidine, indications and
mechanism, 390
Tissue factor (TF), function, 328, 332,
333
Tissue factor pathway inhibitor
(TFPI), function, 328
Tissue plasminogen activator (t-PA)
alteplase for fibrinolytic therapy,
398, 399
function, 328, 336
TM, see Thrombotic microangiopathy
TMP, see Trimethoprim
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TNF-α, see Tumor necrosis factor-α
Tositumomab, mechanism,
indications and side effects, 452
Toxoplasmosis,
clinical features, 321
diagnosis, 321
treatment, 321, 322
t-PA, see Tissue plasminogen
activator
TPO, see Thrombopoietin
TRAIL, see Tumor necrosis factor-
related apoptosis-inducing
ligand
TRALI, see Transfusion-related acute
lung injury
Transferrin receptor, iron deficiency
anemia diagnosis, 89
Transforming growth factor-β (TGF-
β), functions, 38
Transfusion-related acute lung injury
(TRALI), features and
management, 430
Transient hypogammaglobulinemia
of infancy (THI), features, 305
Tretinoin, mechanism, indications
and side effects, 452
Trimethoprim (TMP), Pneumocystis
carnii pneumonia management,
55, 322
Trisenox®, see Arsenic trioxide
Trypanosomiasis, see Chagas’ disease
TT, see Thrombin time
TTP, see Thrombotic
thrombocytopenic purpura
Tumor clonality,
clinical significance, 20, 21
cytogenetics, 21, 22
gene rearrangements, 22
Hodgkin and Reed-Sternberg
cells, 226
immunoglobulin light-chain
restriction, 23
loss of heterozygosity, 23
microRNA analysis, 24
small interfering RNA analysis, 25
X-inactivation assays, 23
Tumor necrosis factor-α (TNF-α),
functions, 38
Tumor necrosis factor-related
apoptosis-inducing ligand
(TRAIL), functions, 38
U
Umbilical cord blood cells, see Stem
cell transplantation
Uremia, platelet dysfunction, 362,
363
Urokinase, fibrinolytic therapy, 398
V
Vancomycin-resistant enterococcus
(VRE), management, 48, 49
Varicella-zoster virus (VZV),
management of infection, 55
pneumonia, 80
stem cell transplant recipients, 74,
80
Vascular endothelial growth factor
(VEGF), multiple myeloma role,
277
VEGF, see Vascular endothelial
growth factor
Velcade®, see Bortezomib
Veno-occlusive disease (VOD), stem
cell transplant recipients, 80, 81
Venous access, complications, 56, 57
Venous thrombosis,
clinical manifestations and
diagnosis, 387
pathogenesis, 387
prophylaxis, 387, 388
treatment, 388, 38
Vidaza®, see 5-Azacytidine
Vinblastine,
Hodgkin’s lymphoma
management, 231, 232
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mechanism, indications and side
effects, 453
Vincristine (Oncovin®),
diffuse large B-cell lymphoma
management, 245
follicular lymphoma management,
251
Hodgkin’s lymphoma
management, 232
mechanism, indications and side
effects, 453
multiple myeloma management,
286
Vitamin B12 deficiency, see
Megaloblastic anemia
Vitamin K deficiency,
adults, 373, 374
etiology, 372
newborns, 373
PIVKA proteins, 373
VOD, see Veno-occlusive disease
von Willebrand disease (VWD),
acquired disease, 378
epidemiology, 369, 370
features, 330
genetics, 369
testing, 343, 370
treatment, 370, 371
von Willebrand factor (VWF),
cleavage, 357
VP-16, see Etoposide
VRE, see Vancomycin-resistant
enterococcus
VWD, see von Willebrand disease
VWF, see von Willebrand factor
VZV, see Varicella-zoster virus
W
Waldenström’s macroglobulinemia,
features, 259, 273
platelet dysfunction, 363
Warfarin (Coumadin®),
complications, 394, 395
mechanism of action, 394
monitoring, 394
teratogenicity, 396
venous thrombosis management,
388
West Nile virus (WNV), transfusion-
transmissible disease, 426
Western blot, cytogenetics, 22
WHIM syndrome, features, 302
Whole blood, transfusion, 411
WinRho SDF™, see Anti-D
Wiskott–Aldrich syndrome, features,
307
WNV, see West Nile virus
WT1, therapeutic targeting, 171
X
Ximelagatrin, indications and
mechanism, 397
X-inactivation assays, tumor
clonality, 23
X-linked agammaglobulinemia,
features, 304
X-linked lymphoproliferative disease
(XLP), features, 308, 317,
318
XLP, see X-linked
lymphoproliferative disease
Z
Zavesca®, see Miglustat
Zoledronic acid, multiple myeloma
management, 291, 292
Zometa, multiple myeloma
management, 287
